Systemic	O
toxicity	B
following	O
administration	O
of	O
sirolimus	O
(	O
formerly	O
rapamycin	O
)	O
for	O
psoriasis	B
:	O
association	O
of	O
capillary	B
leak	I
syndrome	I
with	O
apoptosis	O
of	O
lesional	O
lymphocytes	O
.	O

BACKGROUND	O
:	O
Sirolimus	O
(	O
formerly	O
rapamycin	O
)	O
is	O
an	O
immunosuppressive	O
agent	O
that	O
interferes	O
with	O
T	O
-	O
cell	O
activation	O
.	O

After	O
2	O
individuals	O
with	O
psoriasis	B
developed	O
a	O
capillary	B
leak	I
syndrome	I
following	O
treatment	O
with	O
oral	O
sirolimus	O
lesional	O
skin	O
cells	O
and	O
activated	O
peripheral	O
blood	O
cells	O
were	O
analyzed	O
for	O
induction	O
of	O
apoptosis	O
.	O

OBSERVATIONS	O
:	O
A	O
keratome	O
skin	O
specimen	O
from	O
1	O
patient	O
with	O
sirolimus	O
-	O
induced	O
capillary	B
leak	I
syndrome	I
had	O
a	O
2.3-fold	O
increase	O
in	O
percentage	O
of	O
apoptotic	O
cells	O
(	O
to	O
48	O
%	O
)	O
compared	O
with	O
an	O
unaffected	O
sirolimus	O
-	O
treated	O
patient	O
with	O
psoriasis	B
(	O
21	O
%	O
)	O
.	O

Activated	O
peripheral	O
blood	O
T	O
cells	O
from	O
patients	O
with	O
psoriasis	B
tended	O
to	O
exhibit	O
greater	O
spontaneous	O
or	O
dexamethasone	O
-	O
induced	O
apoptosis	O
than	O
did	O
normal	O
T	O
cells	O
,	O
particularly	O
in	O
the	O
presence	O
of	O
sirolimus	O
.	O

CONCLUSIONS	O
:	O
Severe	O
adverse	O
effects	O
of	O
sirolimus	O
include	O
fever	B
,	O
anemia	B
,	O
and	O
capillary	B
leak	I
syndrome	I
.	O

These	O
symptoms	O
may	O
be	O
the	O
result	O
of	O
drug	O
-	O
induced	O
apoptosis	O
of	O
lesional	O
leukocytes	O
,	O
especially	O
activated	O
T	O
lymphocytes	O
,	O
and	O
possibly	O
release	O
of	O
inflammatory	O
mediators	O
.	O

Because	O
patients	O
with	O
severe	O
psoriasis	B
may	O
develop	O
capillary	B
leak	I
from	O
various	O
systemic	O
therapies	O
,	O
clinical	O
monitoring	O
is	O
advisable	O
for	O
patients	O
with	O
inflammatory	B
diseases	I
who	O
are	O
treated	O
with	O
immune	O
modulators	O
.	O

Effect	O
of	O
lithium	O
maintenance	O
therapy	O
on	O
thyroid	O
and	O
parathyroid	O
function	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
changes	O
induced	O
by	O
lithium	O
maintenance	O
therapy	O
on	O
the	O
incidence	O
of	O
thyroid	O
,	O
parathyroid	O
and	O
ion	O
alterations	O
.	O

These	O
were	O
evaluated	O
with	O
respect	O
to	O
the	O
duration	O
of	O
lithium	O
therapy	O
,	O
age	O
,	O
sex	O
,	O
and	O
family	O
history	O
(	O
whether	O
or	O
not	O
the	O
patient	O
had	O
a	O
first	O
-	O
degree	O
relative	O
with	O
thyroid	B
disease	I
)	O
.	O

DESIGN	O
:	O
Prospective	O
study	O
.	O

SETTING	O
:	O
Affective	O
Disorders	O
Clinic	O
at	O
St.	O
Mary	O
's	O
Hospital	O
,	O
Montreal	O
.	O

PATIENTS	O
:	O
One	O
hundred	O
and	O
one	O
patients	O
(	O
28	O
men	O
and	O
73	O
women	O
)	O
with	O
bipolar	B
disorder	I
receiving	O
lithium	O
maintenance	O
therapy	O
ranging	O
from	O
1	O
year	O
's	O
to	O
32	O
years	O
'	O
duration	O
.	O

The	O
control	O
group	O
consisted	O
of	O
82	O
patients	O
with	O
no	O
psychiatric	B
or	O
endocrinological	O
diagnoses	O
from	O
the	O
hospital	O
's	O
out	O
-	O
patient	O
clinics	O
.	O

OUTCOME	O
MEASURES	O
:	O
Laboratory	O
analyses	O
of	O
calcium	O
,	O
magnesium	O
and	O
thyroid	O
-	O
stimulating	O
hormone	O
levels	O
performed	O
before	O
beginning	O
lithium	O
therapy	O
and	O
at	O
biannual	O
follow	O
-	O
up	O
.	O

RESULTS	O
:	O
Hypothyroidism	B
developed	O
in	O
40	O
patients	O
,	O
excluding	O
8	O
patients	O
who	O
were	O
hypothyroid	B
at	O
baseline	O
.	O

All	O
patients	O
having	O
first	O
-	O
degree	O
relatives	O
affected	O
by	O
thyroid	B
illness	I
had	O
accelerated	O
onset	O
of	O
hypothyroidism	B
(	O
3.7	O
years	O
after	O
onset	O
of	O
lithium	O
therapy	O
)	O
compared	O
with	O
patients	O
without	O
a	O
family	O
history	O
(	O
8.6	O
years	O
after	O
onset	O
of	O
lithium	O
therapy	O
)	O
.	O

Women	O
over	O
60	O
years	O
of	O
age	O
were	O
more	O
often	O
affected	O
by	O
hypothyroidism	B
than	O
women	O
under	O
60	O
years	O
of	O
age	O
(	O
34.6	O
%	O
versus	O
31.9	O
%	O
)	O
.	O

Magnesium	O
levels	O
in	O
patients	O
on	O
lithium	O
treatment	O
were	O
unchanged	O
from	O
baseline	O
levels	O
.	O

After	O
lithium	O
treatment	O
,	O
calcium	O
levels	O
were	O
higher	O
than	O
either	O
baseline	O
levels	O
or	O
control	O
levels	O
.	O

Thus	O
,	O
lithium	O
treatment	O
counteracted	O
the	O
decrease	O
in	O
plasma	O
calcium	O
levels	O
associated	O
with	O
aging	O
.	O

CONCLUSIONS	O
:	O
Familial	O
thyroid	B
illness	I
is	O
a	O
risk	O
factor	O
for	O
hypothyroidism	B
and	O
hypercalcemia	B
during	O
lithium	O
therapy	O
.	O

Hypomania	B
-	O
like	O
syndrome	O
induced	O
by	O
olanzapine	O
.	O

We	O
report	O
a	O
female	O
patient	O
with	O
a	O
diagnosis	O
of	O
a	O
not	O
otherwise	O
specified	O
psychotic	B
disorder	I
(	O
DSM	O
-	O
IV	O
)	O
who	O
developed	O
hypomania	B
shortly	O
after	O
the	O
introduction	O
of	O
olanzapine	O
treatment	O
.	O

Acetazolamide	O
-	O
induced	O
Gerstmann	B
syndrome	I
.	O

Acute	O
confusion	B
induced	O
by	O
acetazolamide	O
is	O
a	O
well	O
known	O
adverse	O
drug	O
reaction	O
in	O
patients	O
with	O
renal	B
impairment	I
.	O

We	O
report	O
a	O
case	O
of	O
acetazolamide	O
-	O
induced	O
Gerstmann	B
syndrome	I
in	O
a	O
patient	O
with	O
normal	O
renal	O
function	O
,	O
to	O
highlight	O
predisposing	O
factors	O
that	O
are	O
frequently	O
overlooked	O
.	O

Ocular	O
manifestations	O
of	O
juvenile	B
rheumatoid	I
arthritis	I
.	O

We	O
followed	O
210	O
cases	O
of	O
juvenile	B
rheumatoid	I
arthritis	I
closely	O
for	O
eleven	O
years	O
.	O

Thirty	O
-	O
six	O
of	O
the	O
210	O
patients	O
(	O
17.2	O
%	O
)	O
developed	O
iridocyclitis	B
.	O

Iridocyclitis	B
was	O
seen	O
most	O
frequently	O
in	O
young	O
female	O
patients	O
(	O
0	O
to	O
4	O
years	O
)	O
with	O
the	O
monoarticular	O
or	O
pauciatricular	O
form	O
of	O
the	O
arthritis	B
.	O

However	O
,	O
30	O
%	O
of	O
the	O
patients	O
developed	O
uveitis	B
after	O
16	O
years	O
of	O
age	O
.	O

Although	O
61	O
%	O
of	O
patients	O
had	O
a	O
noncontributory	O
ocular	O
history	O
on	O
entry	O
,	O
42	O
%	O
had	O
active	O
uveitis	B
on	O
entry	O
.	O

Our	O
approach	O
was	O
effective	O
in	O
detecting	O
uveitis	B
in	O
new	O
cases	O
and	O
exacerbations	O
of	O
uveitis	B
in	O
established	O
cases	O
.	O

Forty	O
-	O
four	O
percent	O
of	O
patients	O
with	O
uveitis	B
had	O
one	O
or	O
more	O
identifiable	O
signs	O
or	O
symptoms	O
,	O
such	O
as	O
red	O
eye	O
,	O
ocular	B
pain	I
,	O
decreased	B
visual	I
acuity	I
,	O
or	O
photophobia	B
,	O
in	O
order	O
of	O
decreasing	O
frequency	O
.	O

Even	O
after	O
early	O
detection	O
and	O
prompt	O
treatment	O
,	O
41	O
%	O
of	O
cases	O
of	O
uveitis	B
did	O
not	O
respond	O
to	O
more	O
than	O
six	O
months	O
of	O
intensive	O
topical	O
treatment	O
with	O
corticosteroids	O
and	O
mydriatics	O
.	O

Despite	O
this	O
,	O
there	O
was	O
a	O
dramatic	O
decrease	O
in	O
the	O
50	O
%	O
incidence	O
of	O
blinding	O
complications	O
of	O
uveitis	B
cited	O
in	O
earlier	O
studies	O
.	O

Cataract	B
and	O
band	B
keratopathy	I
occurred	O
in	O
only	O
22	O
and	O
13	O
%	O
of	O
our	O
group	O
,	O
respectively	O
.	O

We	O
used	O
chloroquine	O
or	O
hydroxychloroquine	O
in	O
173	O
of	O
210	O
cases	O
and	O
found	O
only	O
one	O
case	O
of	O
chorioretinopathy	B
attributable	O
to	O
these	O
drugs	O
.	O

Systemically	O
administered	O
corticosteroids	O
were	O
used	O
in	O
75	O
of	O
210	O
cases	O
;	O
a	O
significant	O
number	O
of	O
posterior	O
subcapsular	O
cataracts	B
was	O
found	O
.	O

Typical	O
keratoconjunctivitis	B
sicca	O
developed	O
in	O
three	O
of	O
the	O
uveitis	B
cases	O
.	O

This	O
association	O
with	O
uveitis	B
and	O
JRA	O
was	O
not	O
noted	O
previously	O
.	O

Surgical	O
treatment	O
of	O
cataracts	B
,	O
band	B
keratopathy	I
,	O
and	O
glaucoma	B
achieved	O
uniformly	O
discouraging	O
results	O
.	O

Cyclophosphamide	O
-	O
induced	O
cystitis	B
in	O
freely	O
-	O
moving	O
conscious	O
rats	O
:	O
behavioral	O
approach	O
to	O
a	O
new	O
model	O
of	O
visceral	B
pain	I
.	O

PURPOSE	O
:	O
To	O
develop	O
a	O
model	O
of	O
visceral	B
pain	I
in	O
rats	O
using	O
a	O
behavioral	O
approach	O
.	O

Cyclophosphamide	O
(	O
CP	O
)	O
,	O
an	O
antitumoral	O
agent	O
known	O
to	O
produce	O
toxic	O
effects	O
on	O
the	O
bladder	O
wall	O
through	O
its	O
main	O
toxic	O
metabolite	O
acrolein	O
,	O
was	O
used	O
to	O
induce	O
cystitis	B
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
CP	O
was	O
administered	O
at	O
doses	O
of	O
50	O
,	O
100	O
and	O
200	O
mg.	O
/	O
kg	O
.	O

i.p	O
.	O
to	O
male	O
rats	O
,	O
and	O
their	O
behavior	O
observed	O
and	O
scored	O
.	O

The	O
effects	O
of	O
morphine	O
(	O
0.5	O
to	O
4	O
mg.	O
/	O
kg	O
.	O

i.v	O
.	O
)	O
on	O
CP	O
-	O
induced	O
behavioral	O
modifications	O
were	O
tested	O
administered	O
alone	O
and	O
after	O
naloxone	O
(	O
1	O
mg.	O
/	O
kg	O
.	O

s.c	O
.	O
)	O
.	O

In	O
addition	O
,	O
90	O
minutes	O
after	O
CP	O
injection	O
,	O
that	O
is	O
,	O
at	O
the	O
time	O
of	O
administration	O
of	O
morphine	O
,	O
the	O
bladder	O
was	O
removed	O
in	O
some	O
rats	O
for	O
histological	O
examination	O
.	O

Finally	O
,	O
to	O
show	O
that	O
the	O
bladder	O
is	O
essential	O
for	O
the	O
CP	O
-	O
induced	O
behavioral	O
modifications	O
,	O
female	O
rats	O
also	O
received	O
CP	O
at	O
doses	O
of	O
200	O
mg.	O
/	O
kg	O
.	O

i.p	O
.	O
and	O
of	O
20	O
mg	O
.	O

by	O
the	O
intravesical	O
route	O
,	O
and	O
acrolein	O
at	O
doses	O
of	O
0.5	O
mg	O
.	O

by	O
the	O
intravesical	O
route	O
and	O
of	O
5	O
mg.	O
/	O
kg	O
.	O

i.v	O
.	O

RESULTS	O
:	O
CP	O
dose	O
-	O
relatedly	O
induced	O
marked	O
behavioral	O
modifications	O
in	O
male	O
rats	O
:	O
breathing	O
rate	O
decrease	O
,	O
closing	O
of	O
the	O
eyes	O
and	O
occurrence	O
of	O
specific	O
postures	O
.	O

Morphine	O
dose	O
-	O
dependently	O
reversed	O
these	O
behavioral	B
disorders	I
.	O

A	O
dose	O
of	O
0.5	O
mg.	O
/	O
kg	O
.	O
produced	O
a	O
reduction	O
of	O
almost	O
50	O
%	O
of	O
the	O
behavioral	O
score	O
induced	O
by	O
CP	O
200	O
mg.	O
/	O
kg	O
.	O

This	O
effect	O
was	O
completely	O
prevented	O
by	O
pretreatment	O
with	O
naloxone	O
.	O

At	O
the	O
time	O
of	O
administration	O
of	O
morphine	O
,	O
histological	O
modifications	O
of	O
the	O
bladder	O
wall	O
,	O
such	O
as	O
chorionic	O
and	O
muscle	O
layer	O
edema	B
,	O
were	O
observed	O
.	O

In	O
female	O
rats	O
,	O
CP	O
200	O
mg.	O
/	O
kg	O
.	O

i.p	O
.	O
produced	O
the	O
same	O
marked	O
behavioral	O
modifications	O
as	O
those	O
observed	O
in	O
male	O
rats	O
.	O

Administered	O
at	O
the	O
dose	O
of	O
20	O
mg	O
.	O

intravesically	O
,	O
CP	O
did	O
not	O
produce	O
any	O
behavioral	O
effects	O
,	O
whereas	O
acrolein	O
at	O
0.5	O
mg	O
.	O

intravesically	O
induced	O
behavioral	O
modifications	O
identical	O
to	O
those	O
under	O
CP	O
200	O
mg.	O
/	O
kg	O
.	O

i.p	O
.	O
,	O
with	O
the	O
same	O
maximal	O
levels	O
.	O

Conversely	O
,	O
acrolein	O
5	O
mg.	O
/	O
kg	O
.	O

i.v	O
.	O
did	O
not	O
produce	O
any	O
behavioral	O
effects	O
at	O
all	O
.	O

CONCLUSIONS	O
:	O
Overall	O
,	O
these	O
results	O
indicate	O
that	O
this	O
experimental	O
model	O
of	O
CP	O
-	O
induced	O
cystitis	B
may	O
be	O
an	O
interesting	O
new	O
behavioral	O
model	O
of	O
inflammatory	O
visceral	B
pain	I
,	O
allowing	O
a	O
better	O
understanding	O
of	O
these	O
painful	B
syndromes	I
and	O
thus	O
a	O
better	O
therapeutic	O
approach	O
to	O
them	O
.	O

Apomorphine	O
:	O
an	O
underutilized	O
therapy	O
for	O
Parkinson	B
's	I
disease	I
.	O

Apomorphine	O
was	O
the	O
first	O
dopaminergic	O
drug	O
ever	O
used	O
to	O
treat	O
symptoms	O
of	O
Parkinson	B
's	I
disease	I
.	O

While	O
powerful	O
antiparkinsonian	O
effects	O
had	O
been	O
observed	O
as	O
early	O
as	O
1951	O
,	O
the	O
potential	O
of	O
treating	O
fluctuating	O
Parkinson	B
's	I
disease	I
by	O
subcutaneous	O
administration	O
of	O
apomorphine	O
has	O
only	O
recently	O
become	O
the	O
subject	O
of	O
systematic	O
study	O
.	O

A	O
number	O
of	O
small	O
scale	O
clinical	O
trials	O
have	O
unequivocally	O
shown	O
that	O
intermittent	O
subcutaneous	O
apomorphine	O
injections	O
produce	O
antiparkinsonian	O
benefit	O
close	O
if	O
not	O
identical	O
to	O
that	O
seen	O
with	O
levodopa	O
and	O
that	O
apomorphine	O
rescue	O
injections	O
can	O
reliably	O
revert	O
off	O
-	O
periods	O
even	O
in	O
patients	O
with	O
complex	O
on	O
-	O
off	O
motor	O
swings	O
.	O

Continuous	O
subcutaneous	O
apomorphine	O
infusions	O
can	O
reduce	O
daily	O
off	O
-	O
time	O
by	O
more	O
than	O
50	O
%	O
in	O
this	O
group	O
of	O
patients	O
,	O
which	O
appears	O
to	O
be	O
a	O
stronger	O
effect	O
than	O
that	O
generally	O
seen	O
with	O
add	O
-	O
on	O
therapy	O
with	O
oral	O
dopamine	O
agonists	O
or	O
COMT	O
inhibitors	O
.	O

Extended	O
follow	O
-	O
up	O
studies	O
of	O
up	O
to	O
8	O
years	O
have	O
demonstrated	O
long	O
-	O
term	O
persistence	O
of	O
apomorphine	O
efficacy	O
.	O

In	O
addition	O
,	O
there	O
is	O
convincing	O
clinical	O
evidence	O
that	O
monotherapy	O
with	O
continuous	O
subcutaneous	O
apomorphine	O
infusions	O
is	O
associated	O
with	O
marked	O
reductions	O
of	O
preexisting	O
levodopa	O
-	O
induced	O
dyskinesias	B
.	O

The	O
main	O
side	O
effects	O
of	O
subcutaneous	O
apomorphine	O
treatment	O
are	O
related	O
to	O
cutaneous	O
tolerability	O
problems	O
,	O
whereas	O
sedation	O
and	O
psychiatric	B
complications	O
play	O
a	O
lesser	O
role	O
.	O

Given	O
the	O
marked	O
degree	O
of	O
efficacy	O
of	O
subcutaneous	O
apomorphine	O
treatment	O
in	O
fluctuating	O
Parkinson	B
's	I
disease	I
,	O
this	O
approach	O
seems	O
to	O
deserve	O
more	O
widespread	O
clinical	O
use	O
.	O

Probing	O
peripheral	O
and	O
central	O
cholinergic	O
system	O
responses	O
.	O

OBJECTIVE	O
:	O
The	O
pharmacological	O
response	O
to	O
drugs	O
that	O
act	O
on	O
the	O
cholinergic	O
system	O
of	O
the	O
iris	O
has	O
been	O
used	O
to	O
predict	O
deficits	O
in	O
central	O
cholinergic	O
functioning	O
due	O
to	O
diseases	O
such	O
as	O
Alzheimer	B
's	I
disease	I
,	O
yet	O
correlations	O
between	O
central	O
and	O
peripheral	O
responses	O
have	O
not	O
been	O
properly	O
studied	O
.	O

This	O
study	O
assessed	O
the	O
effect	O
of	O
normal	O
aging	O
on	O
(	O
1	O
)	O
the	O
tropicamide	O
-	O
induced	O
increase	O
in	O
pupil	O
diameter	O
,	O
and	O
(	O
2	O
)	O
the	O
reversal	O
of	O
this	O
effect	O
with	O
pilocarpine	O
.	O

Scopolamine	O
was	O
used	O
as	O
a	O
positive	O
control	O
to	O
detect	O
age	O
-	O
dependent	O
changes	O
in	O
central	O
cholinergic	O
functioning	O
in	O
the	O
elderly	O
.	O

DESIGN	O
:	O
Randomized	O
double	O
-	O
blind	O
controlled	O
trial	O
.	O

PARTICIPANTS	O
:	O
Ten	O
healthy	O
elderly	O
(	O
mean	O
age	O
70	O
)	O
and	O
9	O
young	O
(	O
mean	O
age	O
33	O
)	O
volunteers	O
.	O

INTERVENTIONS	O
:	O
Pupil	O
diameter	O
was	O
monitored	O
using	O
a	O
computerized	O
infrared	O
pupillometer	O
over	O
4	O
hours	O
.	O

The	O
study	O
involved	O
4	O
sessions	O
.	O

In	O
1	O
session	O
,	O
tropicamide	O
(	O
20	O
microL	O
,	O
0.01	O
%	O
)	O
was	O
administered	O
to	O
one	O
eye	O
and	O
placebo	O
to	O
the	O
other	O
.	O

In	O
another	O
session	O
,	O
tropicamide	O
(	O
20	O
microL	O
,	O
0.01	O
%	O
)	O
was	O
administered	O
to	O
both	O
eyes	O
,	O
followed	O
23	O
minutes	O
later	O
by	O
the	O
application	O
of	O
pilocarpine	O
(	O
20	O
microL	O
,	O
0.1	O
%	O
)	O
to	O
one	O
eye	O
and	O
placebo	O
to	O
the	O
other	O
.	O

All	O
eye	O
drops	O
were	O
given	O
in	O
a	O
randomized	O
order	O
.	O

In	O
2	O
separate	O
sessions	O
,	O
a	O
single	O
dose	O
of	O
scopolamine	O
(	O
0.5	O
mg	O
,	O
intravenously	O
)	O
or	O
placebo	O
was	O
administered	O
,	O
and	O
the	O
effects	O
on	O
word	O
recall	O
were	O
measured	O
using	O
the	O
Buschke	O
Selective	O
Reminding	O
Test	O
over	O
2	O
hours	O
.	O

OUTCOME	O
MEASURES	O
:	O
Pupil	O
size	O
at	O
time	O
points	O
after	O
administration	O
of	O
tropicamide	O
and	O
pilocarpine	O
;	O
scopolamine	O
-	O
induced	O
impairment	B
in	I
word	I
recall	I
.	O

RESULTS	O
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
elderly	O
and	O
young	O
volunteers	O
in	O
pupillary	O
response	O
to	O
tropicamide	O
at	O
any	O
time	O
point	O
(	O
p	O
>	O
0.05	O
)	O
.	O

The	O
elderly	O
group	O
had	O
a	O
significantly	O
greater	O
pilocarpine	O
-	O
induced	O
net	O
decrease	O
in	O
pupil	O
size	O
85	O
,	O
125	O
,	O
165	O
and	O
215	O
minutes	O
after	O
administration	O
,	O
compared	O
with	O
the	O
young	O
group	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Compared	O
with	O
the	O
young	O
group	O
,	O
the	O
elderly	O
group	O
had	O
greater	O
scopolamine	O
-	O
induced	O
impairment	B
in	I
word	I
recall	I
60	O
,	O
90	O
and	O
120	O
minutes	O
after	O
administration	O
(	O
p	O
<	O
0.05	O
)	O
.	O

CONCLUSION	O
:	O
There	O
is	O
an	O
age	O
-	O
related	O
pupillary	O
response	O
to	O
pilocarpine	O
that	O
is	O
not	O
found	O
with	O
tropicamide	O
.	O

Thus	O
,	O
pilocarpine	O
may	O
be	O
useful	O
to	O
assess	O
variations	O
in	O
central	O
cholinergic	O
function	O
in	O
elderly	O
patients	O
.	O

High	O
-	O
dose	O
methylprednisolone	O
may	O
do	O
more	O
harm	O
for	O
spinal	B
cord	I
injury	I
.	O

Because	O
of	O
the	O
National	O
Acute	O
Spinal	B
Cord	I
Injury	I
Studies	O
(	O
NASCIS	O
)	O
,	O
high	O
-	O
dose	O
methylprednisolone	O
became	O
the	O
standard	O
of	O
care	O
for	O
the	O
acute	O
spinal	B
cord	I
injury	I
.	O

In	O
the	O
NASCIS	O
,	O
there	O
was	O
no	O
mention	O
regarding	O
the	O
possibility	O
of	O
acute	O
corticosteroid	O
myopathy	B
that	O
high	O
-	O
dose	O
methylprednisolone	O
may	O
cause	O
.	O

The	O
dosage	O
of	O
methylprednisolone	O
recommended	O
by	O
the	O
NASCIS	O
3	O
is	O
the	O
highest	O
dose	O
of	O
steroids	O
ever	O
being	O
used	O
during	O
a	O
2-day	O
period	O
for	O
any	O
clinical	O
condition	O
.	O

We	O
hypothesize	O
that	O
it	O
may	O
cause	O
some	O
damage	B
to	I
the	I
muscle	I
of	O
spinal	B
cord	I
injury	I
patients	O
.	O

Further	O
,	O
steroid	O
myopathy	B
recovers	O
naturally	O
and	O
the	O
neurological	O
improvement	O
shown	O
in	O
the	O
NASCIS	O
may	O
be	O
just	O
a	O
recording	O
of	O
this	O
natural	O
motor	O
recovery	O
from	O
the	O
steroid	O
myopathy	B
,	O
instead	O
of	O
any	O
protection	O
that	O
methylprednisolone	O
offers	O
to	O
the	O
spinal	B
cord	I
injury	I
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
discussion	O
considering	O
the	O
possibility	O
that	O
the	O
methylprednisolone	O
recommended	O
by	O
NASCIS	O
may	O
cause	O
acute	O
corticosteroid	O
myopathy	B
.	O

Reduced	O
cardiotoxicity	B
and	O
preserved	O
antitumor	O
efficacy	O
of	O
liposome	O
-	O
encapsulated	O
doxorubicin	O
and	O
cyclophosphamide	O
compared	O
with	O
conventional	O
doxorubicin	O
and	O
cyclophosphamide	O
in	O
a	O
randomized	O
,	O
multicenter	O
trial	O
of	O
metastatic	O
breast	B
cancer	I
.	O

PURPOSE	O
:	O
To	O
determine	O
whether	O
Myocet	O
(	O
liposome	O
-	O
encapsulated	O
doxorubicin	O
;	O
The	O
Liposome	O
Company	O
,	O
Elan	O
Corporation	O
,	O
Princeton	O
,	O
NJ	O
)	O
in	O
combination	O
with	O
cyclophosphamide	O
significantly	O
reduces	O
doxorubicin	O
cardiotoxicity	B
while	O
providing	O
comparable	O
antitumor	O
efficacy	O
in	O
first	O
-	O
line	O
treatment	O
of	O
metastatic	O
breast	B
cancer	I
(	O
MBC	B
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Two	O
hundred	O
ninety	O
-	O
seven	O
patients	O
with	O
MBC	B
and	O
no	O
prior	O
chemotherapy	O
for	O
metastatic	O
disease	O
were	O
randomized	O
to	O
receive	O
either	O
60	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
Myocet	O
(	O
M	O
)	O
or	O
conventional	O
doxorubicin	O
(	O
A	O
)	O
,	O
in	O
combination	O
with	O
600	O
mg	O
/	O
m	O
(	O
2	O
)	O
of	O
cyclophosphamide	O
(	O
C	O
)	O
,	O
every	O
3	O
weeks	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	B
.	O

Cardiotoxicity	B
was	O
defined	O
by	O
reductions	O
in	O
left	O
-	O
ventricular	O
ejection	O
fraction	O
,	O
assessed	O
by	O
serial	O
multigated	O
radionuclide	O
angiography	O
scans	O
,	O
or	O
congestive	B
heart	I
failure	I
(	O
CHF	B
)	O
.	O

Antitumor	O
efficacy	O
was	O
assessed	O
by	O
objective	O
tumor	B
response	O
rates	O
(	O
World	O
Health	O
Organization	O
criteria	O
)	O
,	O
time	O
to	O
progression	O
,	O
and	O
survival	O
.	O

RESULTS	O
:	O
Six	O
percent	O
of	O
MC	O
patients	O
versus	O
21	O
%	O
(	O
including	O
five	O
cases	O
of	O
CHF	B
)	O
of	O
AC	O
patients	O
developed	O
cardiotoxicity	B
(	O
P	O
=	O
.0002	O
)	O
.	O

Median	O
cumulative	O
doxorubicin	O
dose	O
at	O
onset	O
was	O
more	O
than	O
2,220	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
MC	O
versus	O
480	O
mg	O
/	O
m	O
(	O
2	O
)	O
for	O
AC	O
(	O
P	O
=	O
.0001	O
,	O
hazard	O
ratio	O
,	O
5.04	O
)	O
.	O

MC	O
patients	O
also	O
experienced	O
less	O
grade	O
4	O
neutropenia	B
.	O

Antitumor	O
efficacy	O
of	O
MC	O
versus	O
AC	O
was	O
comparable	O
:	O
objective	O
response	O
rates	O
,	O
43	O
%	O
versus	O
43	O
%	O
;	O
median	O
time	O
to	O
progression	O
,	O
5.1	O
%	O
versus	O
5.5	O
months	O
;	O
median	O
time	O
to	O
treatment	O
failure	O
,	O
4.6	O
versus	O
4.4	O
months	O
;	O
and	O
median	O
survival	O
,	O
19	O
versus	O
16	O
months	O
.	O

CONCLUSION	O
:	O
Myocet	O
improves	O
the	O
therapeutic	O
index	O
of	O
doxorubicin	O
by	O
significantly	O
reducing	O
cardiotoxicity	B
and	O
grade	O
4	O
neutropenia	B
and	O
provides	O
comparable	O
antitumor	O
efficacy	O
,	O
when	O
used	O
in	O
combination	O
with	O
cyclophosphamide	O
as	O
first	O
-	O
line	O
therapy	O
for	O
MBC	B
.	O

Fluconazole	O
-	O
induced	O
torsade	B
de	I
pointes	I
.	O

OBJECTIVE	O
:	O
To	O
present	O
a	O
case	O
of	O
fluconazole	O
-	O
associated	O
torsade	B
de	I
pointes	I
(	O
TDP	B
)	O
and	O
discuss	O
fluconazole	O
's	O
role	O
in	O
causing	O
TDP	B
.	O

CASE	O
SUMMARY	O
:	O
A	O
68-year	O
-	O
old	O
white	O
woman	O
with	O
Candida	O
glabrata	O
isolated	O
from	O
a	O
presacral	O
abscess	O
developed	O
TDP	B
eight	O
days	O
after	O
commencing	O
oral	O
fluconazole	O
The	O
patient	O
had	O
no	O
other	O
risk	O
factors	O
for	O
TDP	B
,	O
including	O
coronary	B
artery	I
disease	I
,	O
cardiomyopathy	B
,	O
congestive	B
heart	I
failure	I
,	O
and	O
electrolyte	O
abnormalities	O
There	O
was	O
a	O
temporal	O
association	O
between	O
the	O
initiation	O
of	O
fluconazole	O
and	O
TDP	B
.	O

The	O
TDP	B
resolved	O
when	O
fluconazole	O
was	O
discontinued	O
;	O
however	O
,	O
the	O
patient	O
continued	O
to	O
have	O
premature	B
ventricular	I
contractions	I
and	O
nonsustained	O
ventricular	B
tachycardia	I
(	O
NSVT	B
)	O
until	O
six	O
days	O
after	O
drug	O
cessation	O
DISCUSSION	O
:	O
Use	O
of	O
the	O
Naranjo	O
probability	O
scale	O
indicates	O
a	O
probable	O
relationship	O
between	O
the	O
use	O
of	O
fluconazole	O
and	O
the	O
development	O
of	O
TDP	B
.	O

The	O
possible	O
mechanism	O
is	O
depression	B
of	O
rapidly	O
activating	O
delayed	O
rectifier	O
potassium	O
currents	O
.	O

In	O
our	O
patient	O
,	O
there	O
was	O
no	O
other	O
etiology	O
identified	O
that	O
could	O
explain	O
QT	B
prolongation	I
or	O
TDP	B
The	O
complete	O
disappearance	O
of	O
NSVT	B
and	O
premature	B
ventricular	I
contractions	I
followed	O
by	O
normalization	O
of	O
QT	O
interval	O
after	O
the	O
drug	O
was	O
stopped	O
strongly	O
suggests	O
fluconazole	O
as	O
the	O
etiology	O
.	O

CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
that	O
fluconazole	O
,	O
even	O
at	O
low	O
doses	O
,	O
may	O
cause	O
prolongation	B
of	I
the	I
QT	I
interval	I
,	O
leading	O
to	O
TDP	B
.	O

Serial	O
electrocardiographic	O
monitoring	O
may	O
be	O
considered	O
when	O
fluconazole	O
is	O
administered	O
in	O
patients	O
who	O
are	O
at	O
risk	O
for	O
ventricular	B
arrhythmias	I
.	O

Cutaneous	B
leucocytoclastic	I
vasculitis	I
associated	O
with	O
oxacillin	O
.	O

A	O
67-year	O
-	O
old	O
man	O
who	O
was	O
treated	O
with	O
oxacillin	O
for	O
one	O
week	O
because	O
of	O
Staphylococcus	B
aureus	I
bacteremia	I
,	O
developed	O
renal	B
failure	I
and	O
diffuse	O
,	O
symmetric	O
,	O
palpable	O
purpuric	B
lesions	I
on	O
his	O
feet	O
.	O

Necrotic	B
blisters	B
were	O
noted	O
on	O
his	O
fingers	O
.	O

Skin	O
biopsies	O
showed	O
findings	O
diagnostic	O
of	O
leucocytoclastic	B
vasculitis	I
.	O

Oxacillin	O
was	O
discontinued	O
and	O
patient	O
was	O
treated	O
with	O
corticosteroids	O
.	O

The	O
rash	B
disappeared	O
after	O
three	O
weeks	O
and	O
renal	O
function	O
returned	O
to	O
normal	O
.	O

Leucocytoclastic	B
vasculitis	I
presents	O
as	O
palpable	O
purpura	B
of	O
the	O
lower	O
extremities	O
often	O
accompanied	O
by	O
abdominal	B
pain	I
,	O
arthralgia	B
,	O
and	O
renal	B
involvement	I
.	O

Etiologic	O
factors	O
or	O
associated	O
disorders	O
include	O
infections	B
,	O
medications	O
,	O
collagen	B
vascular	I
disease	I
and	O
neoplasia	B
.	O

However	O
,	O
in	O
half	O
of	O
the	O
cases	O
no	O
etiologic	O
factor	O
is	O
identified	O
.	O

Usually	O
it	O
is	O
a	O
self	O
-	O
limited	O
disorder	O
,	O
but	O
corticosteroid	O
therapy	O
may	O
be	O
needed	O
in	O
life	O
-	O
threatening	O
cases	O
since	O
early	O
treatment	O
with	O
corticosteroids	O
in	O
severe	O
cases	O
can	O
prevent	O
complications	O
.	O

Oxacillin	O
should	O
be	O
included	O
among	O
the	O
drugs	O
that	O
can	O
cause	O
leucocytoclastic	B
vasculitis	I
.	O

Preliminary	O
efficacy	O
assessment	O
of	O
intrathecal	O
injection	O
of	O
an	O
American	O
formulation	O
of	O
adenosine	O
in	O
humans	O
.	O

BACKGROUND	O
:	O
Preclinical	O
studies	O
of	O
intrathecal	O
adenosine	O
suggest	O
it	O
may	O
be	O
effective	O
in	O
the	O
treatment	O
of	O
acute	B
and	I
chronic	I
pain	I
in	O
humans	O
,	O
and	O
preliminary	O
studies	O
in	O
volunteers	O
and	O
patients	O
with	O
a	O
Swedish	O
formulation	O
of	O
adenosine	O
suggests	O
it	O
may	O
be	O
effective	O
in	O
hypersensitivity	B
states	O
but	O
not	O
with	O
acute	O
noxious	O
stimulation	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
screen	O
for	O
efficacy	O
of	O
a	O
different	O
formulation	O
of	O
adenosine	O
marketed	O
in	O
the	O
US	O
,	O
using	O
both	O
acute	O
noxious	O
stimulation	O
and	O
capsaicin	O
-	O
evoked	O
mechanical	O
hypersensitivity	B
.	O

METHODS	O
:	O
Following	O
Food	O
and	O
Drug	O
Administration	O
and	O
institutional	O
review	O
board	O
approval	O
and	O
written	O
informed	O
consent	O
,	O
65	O
volunteers	O
were	O
studied	O
in	O
two	O
trials	O
:	O
an	O
open	O
-	O
label	O
,	O
dose	O
-	O
escalating	O
trial	O
with	O
intrathecal	O
adenosine	O
doses	O
of	O
0.25	O
-	O
2.0	O
mg	O
and	O
a	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
trial	O
of	O
adenosine	O
,	O
2	O
mg	O
.	O

Cerebrospinal	O
fluid	O
was	O
obtained	O
for	O
pharmacokinetic	O
analysis	O
,	O
and	O
pain	B
ratings	O
in	O
response	O
to	O
acute	O
heat	O
stimuli	O
and	O
areas	O
of	O
mechanical	B
hyperalgesia	I
and	O
allodynia	B
after	O
intradermal	O
capsaicin	O
injection	O
were	O
determined	O
.	O

RESULTS	O
:	O
Adenosine	O
produced	O
no	O
effect	O
on	O
pain	B
report	O
to	O
acute	O
noxious	O
thermal	O
or	O
chemical	O
stimulation	O
but	O
reduced	O
mechanical	B
hyperalgesia	I
and	O
allodynia	B
from	O
intradermal	O
capsaicin	O
injection	O
for	O
at	O
least	O
24	O
h.	O
In	O
contrast	O
,	O
residence	O
time	O
of	O
adenosine	O
in	O
cerebrospinal	O
fluid	O
was	O
short	O
(	O
<	O
4	O
h	O
)	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
show	O
selective	O
inhibition	O
by	O
intrathecal	O
adenosine	O
of	O
hypersensitivity	B
,	O
presumed	O
to	O
reflect	O
central	O
sensitization	O
in	O
humans	O
after	O
peripheral	O
capsaicin	O
injection	O
.	O

The	O
long	O
-	O
lasting	O
effect	O
is	O
consistent	O
with	O
that	O
observed	O
in	O
preliminary	O
reports	O
of	O
patients	O
with	O
chronic	O
neuropathic	B
pain	I
and	O
is	O
not	O
due	O
to	O
prolonged	O
residence	O
of	O
adenosine	O
in	O
cerebrospinal	O
fluid	O
.	O

Delayed	O
-	O
onset	O
heparin	O
-	O
induced	O
thrombocytopenia	B
.	O

BACKGROUND	O
:	O
Heparin	O
-	O
induced	O
thrombocytopenia	B
presents	O
5	O
to	O
12	O
days	O
after	O
heparin	O
exposure	O
,	O
with	O
or	O
without	O
arterial	B
or	I
venous	I
thromboemboli	I
.	O

Delayed	O
recognition	O
and	O
treatment	O
of	O
heparin	O
-	O
induced	O
thrombocytopenia	B
contribute	O
to	O
poor	O
patient	O
outcomes	O
.	O

OBJECTIVE	O
:	O
To	O
describe	O
and	O
increase	O
awareness	O
of	O
a	O
clinical	O
scenario	O
in	O
which	O
the	O
onset	O
or	O
manifestations	O
of	O
heparin	O
-	O
induced	O
thrombocytopenia	B
are	O
delayed	O
.	O

DESIGN	O
:	O
Retrospective	O
case	O
series	O
.	O

SETTING	O
:	O
Three	O
large	O
urban	O
hospitals	O
(	O
with	O
active	O
cardiovascular	O
surgery	O
programs	O
)	O
.	O

PATIENTS	O
:	O
14	O
patients	O
seen	O
over	O
a	O
3-year	O
period	O
in	O
whom	O
heparin	O
-	O
induced	O
thrombocytopenia	B
became	O
apparent	O
on	O
delayed	O
presentation	O
with	O
thromboembolic	B
complications	O
.	O

MEASUREMENTS	O
:	O
Platelet	O
counts	O
,	O
onset	O
of	O
objectively	O
determined	O
thromboembolism	B
,	O
results	O
of	O
heparin	O
-	O
induced	O
platelet	O
factor	O
4	O
antibody	O
tests	O
,	O
and	O
outcomes	O
.	O

RESULTS	O
:	O
Patients	O
went	O
home	O
after	O
hospitalizations	O
that	O
had	O
included	O
heparin	O
exposure	O
--	O
in	O
most	O
cases	O
,	O
with	O
no	O
thrombocytopenia	B
recognized	O
--	O
only	O
to	O
return	O
to	O
the	O
hospital	O
(	O
median	O
,	O
day	O
14	O
)	O
with	O
thromboembolic	B
complications	O
.	O

Thromboemboli	B
were	O
venous	O
(	O
12	O
patients	O
,	O
7	O
with	O
pulmonary	B
emboli	I
)	O
or	O
arterial	O
(	O
4	O
patients	O
)	O
or	O
both	O
.	O

Platelet	O
counts	O
were	O
mildly	O
decreased	O
in	O
all	O
but	O
2	O
patients	O
on	O
second	O
presentation	O
.	O

On	O
readmission	O
,	O
11	O
patients	O
received	O
therapeutic	O
heparin	O
,	O
which	O
worsened	O
the	O
patients	O
'	O
clinical	O
condition	O
and	O
,	O
in	O
all	O
11	O
cases	O
,	O
decreased	O
the	O
platelet	O
count	O
(	O
mean	O
at	O
readmission	O
,	O
143	O
x	O
10	O
(	O
9	O
)	O
cells	O
/	O
L	O
;	O
mean	O
nadir	O
after	O
heparin	O
re	O
-	O
exposure	O
,	O
39	O
x	O
10	O
(	O
9	O
)	O
cells	O
/	O
L	O
)	O
.	O

Results	O
of	O
serologic	O
tests	O
for	O
heparin	O
-	O
induced	O
antibodies	O
were	O
positive	O
in	O
all	O
patients	O
.	O

Subsequent	O
treatments	O
included	O
alternative	O
anticoagulants	O
(	O
11	O
patients	O
)	O
,	O
thrombolytic	O
drugs	O
(	O
3	O
patients	O
)	O
,	O
inferior	O
vena	O
cava	O
filters	O
(	O
3	O
patients	O
)	O
and	O
,	O
eventually	O
,	O
warfarin	O
(	O
11	O
patients	O
)	O
.	O

Three	O
patients	O
died	O
.	O

CONCLUSIONS	O
:	O
Delayed	O
-	O
onset	O
heparin	O
-	O
induced	O
thrombocytopenia	B
is	O
increasingly	O
being	O
recognized	O
.	O

To	O
avoid	O
disastrous	O
outcomes	O
,	O
physicians	O
must	O
consider	O
heparin	O
-	O
induced	O
thrombocytopenia	B
whenever	O
a	O
recently	O
hospitalized	O
patient	O
returns	O
with	O
thromboembolism	B
;	O
therapy	O
with	O
alternative	O
anticoagulants	O
,	O
not	O
heparin	O
,	O
should	O
be	O
initiated	O
.	O

Torsade	B
de	I
pointes	I
induced	O
by	O
metoclopramide	O
in	O
an	O
elderly	O
woman	O
with	O
preexisting	O
complete	O
left	B
bundle	I
branch	I
block	I
.	O

There	O
is	O
a	O
growing	O
list	O
of	O
drugs	O
implicated	O
in	O
acquired	O
long	B
QT	I
syndrome	I
and	O
torsade	B
de	I
pointes	I
.	O

However	O
,	O
the	O
torsadogenic	O
potential	O
of	O
metoclopramide	O
,	O
a	O
commonly	O
used	O
antiemetic	O
and	O
prokinetic	O
drug	O
,	O
has	O
not	O
been	O
reported	O
in	O
the	O
literature	O
,	O
despite	O
its	O
chemical	O
similarity	O
to	O
procainamide	O
.	O

We	O
report	O
on	O
a	O
92-year	O
-	O
old	O
woman	O
with	O
preexisting	O
complete	O
left	B
bundle	I
branch	I
block	I
who	O
developed	O
torsade	B
de	I
pointes	I
after	O
intravenous	O
and	O
oral	O
administration	O
of	O
metoclopramide	O
.	O

This	O
patient	O
also	O
developed	O
torsade	B
de	I
pointes	I
when	O
cisapride	O
and	O
erythromycin	O
were	O
given	O
simultaneously	O
.	O

These	O
two	O
episodes	O
were	O
suppressed	O
successfully	O
after	O
discontinuing	O
the	O
offending	O
drugs	O
and	O
administering	O
class	O
IB	O
drugs	O
.	O

This	O
is	O
the	O
first	O
documentation	O
that	O
metoclopramide	O
provokes	O
torsade	B
de	I
pointes	I
clinically	O
.	O

Metoclopramide	O
should	O
be	O
used	O
cautiously	O
in	O
patients	O
with	O
a	O
risk	O
of	O
torsade	B
de	I
pointes	I
.	O

Steroid	O
structure	O
and	O
pharmacological	O
properties	O
determine	O
the	O
anti	O
-	O
amnesic	B
effects	O
of	O
pregnenolone	O
sulphate	O
in	O
the	O
passive	O
avoidance	O
task	O
in	O
rats	O
.	O

Pregnenolone	O
sulphate	O
(	O
PREGS	O
)	O
has	O
generated	O
interest	O
as	O
one	O
of	O
the	O
most	O
potent	O
memory	O
-	O
enhancing	O
neurosteroids	O
to	O
be	O
examined	O
in	O
rodent	O
learning	O
studies	O
,	O
with	O
particular	O
importance	O
in	O
the	O
ageing	O
process	O
.	O

The	O
mechanism	O
by	O
which	O
this	O
endogenous	O
steroid	O
enhances	O
memory	O
formation	O
is	O
hypothesized	O
to	O
involve	O
actions	O
on	O
glutamatergic	O
and	O
GABAergic	O
systems	O
.	O

This	O
hypothesis	O
stems	O
from	O
findings	O
that	O
PREGS	O
is	O
a	O
potent	O
positive	O
modulator	O
of	O
N	O
-	O
methyl	O
-	O
d	O
-	O
aspartate	O
receptors	O
(	O
NMDARs	O
)	O
and	O
a	O
negative	O
modulator	O
of	O
gamma	O
-	O
aminobutyric	O
acid	O
(	O
A	O
)	O
receptors	O
(	O
GABA	O
(	O
A	O
)	O
Rs	O
)	O
.	O

Moreover	O
,	O
PREGS	O
is	O
able	O
to	O
reverse	O
the	O
amnesic	B
-	O
like	O
effects	O
of	O
NMDAR	O
and	O
GABA	O
(	O
A	O
)	O
R	O
ligands	O
.	O

To	O
investigate	O
this	O
hypothesis	O
,	O
the	O
present	O
study	O
in	O
rats	O
examined	O
the	O
memory	O
-	O
altering	O
abilities	O
of	O
structural	O
analogs	O
of	O
PREGS	O
,	O
which	O
differ	O
in	O
their	O
modulation	O
of	O
NMDAR	O
and/or	O
GABA	O
(	O
A	O
)	O
R	O
function	O
.	O

The	O
analogs	O
tested	O
were	O
:	O
11-ketopregnenolone	O
sulphate	O
(	O
an	O
agent	O
that	O
is	O
inactive	O
at	O
GABA	O
(	O
A	O
)	O
Rs	O
and	O
NMDARs	O
)	O
,	O
epipregnanolone	O
(	O
[	O
3beta	O
-	O
hydroxy-5beta	O
-	O
pregnan-20-one	O
]	O
sulphate	O
,	O
an	O
inhibitor	O
of	O
both	O
GABA	O
(	O
A	O
)	O
Rs	O
and	O
NMDARs	O
)	O
,	O
and	O
a	O
newly	O
synthesized	O
(	O
-	O
)	O
PREGS	O
enantiomer	O
(	O
which	O
is	O
identical	O
to	O
PREGS	O
in	O
effects	O
on	O
GABA	O
(	O
A	O
)	O
Rs	O
and	O
NMDARs	O
)	O
.	O

The	O
memory	O
-	O
enhancing	O
effects	O
of	O
PREGS	O
and	O
its	O
analogs	O
were	O
tested	O
in	O
the	O
passive	O
avoidance	O
task	O
using	O
the	O
model	O
of	O
scopolamine	O
-	O
induced	O
amnesia	B
.	O

Both	O
PREGS	O
and	O
its	O
(	O
-	O
)	O
enantiomer	O
blocked	O
the	O
effects	O
of	O
scopolamine	O
.	O

The	O
results	O
show	O
that	O
,	O
unlike	O
PREGS	O
,	O
11-ketopregnenolone	O
sulphate	O
and	O
epipregnanolone	O
sulphate	O
failed	O
to	O
block	O
the	O
effect	O
of	O
scopolamine	O
,	O
suggesting	O
that	O
altering	O
the	O
modulation	O
of	O
NMDA	O
receptors	O
diminishes	O
the	O
memory	O
-	O
enhancing	O
effects	O
of	O
PREGS	O
.	O

Moreover	O
,	O
enantioselectivity	O
was	O
demonstrated	O
by	O
the	O
ability	O
of	O
natural	O
PREGS	O
to	O
be	O
an	O
order	O
of	O
magnitude	O
more	O
effective	O
than	O
its	O
synthetic	O
enantiomer	O
in	O
reversing	O
scopolamine	O
-	O
induced	O
amnesia	B
.	O

These	O
results	O
identify	O
a	O
novel	O
neuropharmacological	O
site	O
for	O
the	O
modulation	O
of	O
memory	O
processes	O
by	O
neuroactive	O
steroids	O
.	O

Activation	O
of	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
contributes	O
to	O
development	O
of	O
doxorubicin	O
-	O
induced	O
heart	B
failure	I
.	O

Activation	O
of	O
the	O
nuclear	O
enzyme	O
poly	O
(	O
ADP	O
-	O
ribose	O
)	O
polymerase	O
(	O
PARP	O
)	O
by	O
oxidant	O
-	O
mediated	O
DNA	O
damage	O
is	O
an	O
important	O
pathway	O
of	O
cell	O
dysfunction	O
and	O
tissue	O
injury	O
in	O
conditions	O
associated	O
with	O
oxidative	O
stress	O
.	O

Increased	O
oxidative	O
stress	O
is	O
a	O
major	O
factor	O
implicated	O
in	O
the	O
cardiotoxicity	B
of	O
doxorubicin	O
(	O
DOX	O
)	O
,	O
a	O
widely	O
used	O
antitumor	O
anthracycline	O
antibiotic	O
.	O

Thus	O
,	O
we	O
hypothesized	O
that	O
the	O
activation	O
of	O
PARP	O
may	O
contribute	O
to	O
the	O
DOX	O
-	O
induced	O
cardiotoxicity	B
.	O

Using	O
a	O
dual	O
approach	O
of	O
PARP-1	O
suppression	O
,	O
by	O
genetic	O
deletion	O
or	O
pharmacological	O
inhibition	O
with	O
the	O
phenanthridinone	O
PARP	O
inhibitor	O
PJ34	O
,	O
we	O
now	O
demonstrate	O
the	O
role	O
of	O
PARP	O
in	O
the	O
development	O
of	O
cardiac	B
dysfunction	I
induced	O
by	O
DOX	O
.	O

PARP-1+	O
/	O
+	O
and	O
PARP-1-	O
/	O
-	O
mice	O
received	O
a	O
single	O
injection	O
of	O
DOX	O
(	O
25	O
mg	O
/	O
kg	O
i.p	O
)	O
.	O

Five	O
days	O
after	O
DOX	O
administration	O
,	O
left	O
ventricular	O
performance	O
was	O
significantly	O
depressed	O
in	O
PARP-1+	O
/	O
+	O
mice	O
,	O
but	O
only	O
to	O
a	O
smaller	O
extent	O
in	O
PARP-1-	O
/	O
-	O
ones	O
.	O

Similar	O
experiments	O
were	O
conducted	O
in	O
BALB	O
/	O
c	O
mice	O
treated	O
with	O
PJ34	O
or	O
vehicle	O
.	O

Treatment	O
with	O
a	O
PJ34	O
significantly	O
improved	O
cardiac	B
dysfunction	I
and	O
increased	O
the	O
survival	O
of	O
the	O
animals	O
.	O

In	O
addition	O
PJ34	O
significantly	O
reduced	O
the	O
DOX	O
-	O
induced	O
increase	O
in	O
the	O
serum	O
lactate	O
dehydrogenase	O
and	O
creatine	O
kinase	O
activities	O
but	O
not	O
metalloproteinase	O
activation	O
in	O
the	O
heart	O
.	O

Thus	O
,	O
PARP	O
activation	O
contributes	O
to	O
the	O
cardiotoxicity	B
of	O
DOX	O
.	O

PARP	O
inhibitors	O
may	O
exert	O
protective	O
effects	O
against	O
the	O
development	O
of	O
severe	O
cardiac	B
complications	I
associated	O
with	O
the	O
DOX	O
treatment	O
.	O

Nicotine	O
potentiation	O
of	O
morphine	O
-	O
induced	O
catalepsy	B
in	O
mice	O
.	O

In	O
the	O
present	O
study	O
,	O
effects	O
of	O
nicotine	O
on	O
catalepsy	B
induced	O
by	O
morphine	O
in	O
mice	O
have	O
been	O
investigated	O
.	O

Morphine	O
but	O
not	O
nicotine	O
induced	O
a	O
dose	O
-	O
dependent	O
catalepsy	B
.	O

The	O
response	O
of	O
morphine	O
was	O
potentiated	O
by	O
nicotine	O
.	O

Intraperitoneal	O
administration	O
of	O
atropine	O
,	O
naloxone	O
,	O
mecamylamine	O
,	O
and	O
hexamethonium	O
to	O
mice	O
reduced	O
catalepsy	B
induced	O
by	O
a	O
combination	O
of	O
morphine	O
with	O
nicotine	O
.	O

Intracerebroventricular	O
injection	O
of	O
atropine	O
,	O
hexamethonium	O
,	O
and	O
naloxone	O
also	O
decreased	O
catalepsy	B
induced	O
by	O
morphine	O
plus	O
nicotine	O
.	O

Intraperitoneal	O
administration	O
of	O
atropine	O
,	O
but	O
not	O
intraperitoneal	O
or	O
intracerebroventricular	O
injection	O
of	O
hexamethonium	O
,	O
decreased	O
the	O
effect	O
of	O
a	O
single	O
dose	O
of	O
morphine	O
.	O

It	O
was	O
concluded	O
that	O
morphine	O
catalepsy	B
can	O
be	O
elicited	O
by	O
opioid	O
and	O
cholinergic	O
receptors	O
,	O
and	O
the	O
potentiation	O
of	O
morphine	O
induced	O
by	O
nicotine	O
may	O
also	O
be	O
mediated	O
through	O
cholinergic	O
receptor	O
mechanisms	O
.	O

Risperidone	O
-	O
associated	O
,	O
benign	O
transient	O
visual	B
disturbances	I
in	O
schizophrenic	B
patients	O
with	O
a	O
past	O
history	O
of	O
LSD	O
abuse	O
.	O

Two	O
schizophrenic	B
patients	O
,	O
who	O
had	O
a	O
prior	O
history	O
of	O
LSD	O
abuse	O
and	O
who	O
had	O
previously	O
developed	O
EPS	B
with	O
classic	O
antipsychotics	O
,	O
were	O
successfully	O
treated	O
with	O
risperidone	O
.	O

They	O
both	O
reported	O
short	O
episodes	O
of	O
transient	O
visual	B
disturbances	I
,	O
which	O
appeared	O
immediately	O
after	O
starting	O
treatment	O
with	O
risperidone	O
.	O

This	O
imagery	O
resembled	O
visual	B
disturbances	I
previously	O
experienced	O
as	O
""""	O
flashbacks	O
""""	O
related	O
to	O
prior	O
LSD	O
consumption	O
.	O

Risperidone	O
administration	O
was	O
continued	O
and	O
the	O
visual	B
disturbances	I
gradually	O
wore	O
off	O
.	O

During	O
a	O
six	O
-	O
month	O
follow	O
-	O
up	O
period	O
,	O
there	O
was	O
no	O
recurrence	O
of	O
visual	B
disturbances	I
.	O

This	O
phenomenon	O
may	O
be	O
interpreted	O
as	O
a	O
benign	O
,	O
short	O
-	O
term	O
and	O
self	O
-	O
limiting	O
side	O
effect	O
which	O
does	O
not	O
contraindicate	O
the	O
use	O
of	O
risperidone	O
or	O
interfere	O
with	O
treatment	O
.	O

Conclusions	O
based	O
on	O
two	O
case	O
reports	O
should	O
be	O
taken	O
with	O
appropriate	O
caution	O
.	O

Ketamine	O
in	O
war	O
/	O
tropical	O
surgery	O
(	O
a	O
final	O
tribute	O
to	O
the	O
racemic	O
mixture	O
)	O
.	O

A	O
technique	O
of	O
continuous	O
intravenous	O
anaesthesia	O
with	O
ketamine	O
was	O
used	O
successfully	O
during	O
the	O
Somalia	O
civil	O
war	O
in	O
1994	O
and	O
in	O
north	O
Uganda	O
in	O
1999	O
for	O
64	O
operations	O
in	O
62	O
patients	O
,	O
aged	O
from	O
6	O
weeks	O
to	O
70	O
years	O
,	O
undergoing	O
limb	O
and	O
abdominal	O
surgery	O
including	O
caesarian	O
sections	O
and	O
interventions	O
in	O
neonates	O
.	O

Operations	O
lasting	O
up	O
to	O
2h	O
could	O
be	O
performed	O
in	O
the	O
absence	O
of	O
sophisticated	O
equipment	O
such	O
as	O
pulse	O
oximeters	O
or	O
ventilators	O
in	O
patients	O
on	O
spontaneous	O
ventilation	O
breathing	O
air	O
/	O
oxygen	O
only	O
.	O

After	O
premedication	O
with	O
diazepam	O
,	O
glycopyrrolate	O
and	O
local	O
anaesthesia	O
,	O
and	O
induction	O
with	O
standard	O
doses	O
of	O
ketamine	O
,	O
a	O
maintenance	O
dose	O
of	O
10	O
-	O
20	O
microg	O
/	O
kg	O
/	O
min	O
of	O
ketamine	O
proved	O
safe	O
and	O
effective	O
.	O

Emphasis	O
was	O
placed	O
on	O
bedside	O
clinical	O
monitoring	O
,	O
relying	O
heavily	O
on	O
the	O
heart	O
rate	O
.	O

Diazepam	O
,	O
unless	O
contraindicated	O
or	O
risky	O
,	O
remains	O
the	O
only	O
necessary	O
complementary	O
drug	O
to	O
ketamine	O
as	O
it	O
buffers	O
its	O
cardiovascular	O
response	O
and	O
decreases	O
the	O
duration	O
and	O
intensity	O
of	O
operative	O
and	O
postoperative	O
hallucinations	B
.	O

Local	O
anaesthetic	O
blocks	O
were	O
useful	O
in	O
decreasing	O
the	O
requirement	O
for	O
postoperative	O
analgesia	B
.	O

An	O
antisialogue	O
was	O
usually	O
unnecessary	O
in	O
operations	O
lasting	O
up	O
to	O
2	O
h	O
,	O
glycopyrrolate	O
being	O
the	O
best	O
choice	O
for	O
its	O
lowest	O
psychotropic	O
and	O
chronotropic	O
effects	O
,	O
especially	O
in	O
a	O
hot	O
climate	O
.	O

Experience	O
in	O
war	O
/	O
tropical	O
settings	O
suggests	O
this	O
technique	O
could	O
be	O
useful	O
in	O
civilian	O
contexts	O
such	O
as	O
outdoor	O
life	O
-	O
saving	O
emergency	O
surgery	O
or	O
in	O
mass	O
casualties	O
where	O
,	O
e.g.	O
amputation	O
and	O
rapid	O
extrication	O
were	O
required	O
.	O

Pyeloureteral	O
filling	O
defects	O
associated	O
with	O
systemic	O
anticoagulation	O
:	O
a	O
case	O
report	O
.	O

The	O
etiology	O
of	O
pyeloureteritis	B
cystica	I
has	O
long	O
been	O
attributed	O
to	O
chronic	O
infection	B
and	O
inflammation	B
.	O

A	O
case	O
is	O
presented	O
that	O
is	O
unique	O
in	O
that	O
the	O
acute	O
onset	O
and	O
the	O
rapid	O
resolution	O
of	O
pyeloureteral	O
filling	O
defects	O
in	O
this	O
patient	O
were	O
documented	O
by	O
radiography	O
.	O

There	O
is	O
no	O
evidence	O
of	O
antecedent	O
or	O
concurrent	O
infection	B
in	O
this	O
patient	O
.	O

The	O
disease	O
occurred	O
subsequent	O
to	O
the	O
initiation	O
of	O
heparin	O
therapy	O
for	O
suspected	O
pelvic	O
thrombophlebitis	B
and	O
cleared	O
rapidly	O
subsequent	O
to	O
its	O
discontinuation	O
.	O

The	O
rate	O
of	O
resolution	O
of	O
the	O
radiographic	O
findings	O
may	O
be	O
helpful	O
in	O
distinguishing	O
between	O
true	O
pyeloureteritis	B
cystica	I
and	O
submucosal	B
hemorrhage	I
.	O

Protective	O
effect	O
of	O
edaravone	O
against	O
streptomycin	O
-	O
induced	O
vestibulotoxicity	B
in	O
the	O
guinea	O
pig	O
.	O

This	O
study	O
investigated	O
alleviation	O
of	O
streptomycin	O
-	O
induced	O
vestibulotoxicity	B
by	O
edaravone	O
in	O
guinea	O
pigs	O
.	O

Edaravone	O
,	O
a	O
free	O
radical	O
scavenger	O
,	O
has	O
potent	O
free	O
radical	O
quenching	O
action	O
and	O
is	O
used	O
in	O
clinical	O
practice	O
to	O
treat	O
cerebral	B
infarction	I
.	O

Streptomycin	O
was	O
administered	O
to	O
the	O
inner	O
ear	O
by	O
osmotic	O
pump	O
for	O
24	O
h	O
,	O
and	O
edaravone	O
(	O
n=8	O
)	O
or	O
saline	O
(	O
n=6	O
)	O
was	O
intraperitoneally	O
injected	O
once	O
a	O
day	O
for	O
7	O
days	O
.	O

We	O
observed	O
horizontal	O
vestibulo	O
-	O
ocular	O
reflex	O
as	O
a	O
marker	O
of	O
postoperative	O
vestibular	O
function	O
.	O

Animals	O
injected	O
with	O
saline	O
showed	O
statistically	O
smaller	O
gains	O
than	O
those	O
injected	O
with	O
edaravone	O
.	O

These	O
results	O
suggest	O
that	O
edaravone	O
suppresses	O
streptomycin	O
-	O
induced	O
vestibulotoxicity	B
.	O

Levodopa	O
-	O
induced	O
oromandibular	O
dystonia	B
in	O
progressive	B
supranuclear	I
palsy	I
.	O

Levodopa	O
-	O
induced	O
dyskinesias	B
have	O
been	O
reported	O
in	O
Parkinson	B
's	I
disease	I
and	O
multiple	B
system	I
atrophy	I
.	O

Cranial	O
dystonias	B
are	O
rare	O
in	O
patients	O
with	O
progressive	B
supranuclear	I
palsy	I
(	O
PSP	B
)	O
.	O

In	O
this	O
report	O
we	O
describe	O
an	O
unusual	O
case	O
of	O
reversible	O
levodopa	O
-	O
induced	O
Oromandibular	B
dystonia	I
(	O
OMD	B
)	O
in	O
a	O
PSP	B
patient	O
to	O
highlight	O
the	O
importance	O
of	O
recognizing	O
this	O
drug	O
related	O
complication	O
in	O
the	O
management	O
of	O
PSP	B
,	O
and	O
discuss	O
the	O
possible	O
underlying	O
pathophysiology	O
.	O

Case	O
report	O
:	O
Dexatrim	O
(	O
Phenylpropanolamine	O
)	O
as	O
a	O
cause	O
of	O
myocardial	B
infarction	I
.	O

Phenylpropanolamine	O
(	O
PPA	O
)	O
is	O
a	O
sympathetic	O
amine	O
used	O
in	O
over	O
-	O
the	O
-	O
counter	O
cold	O
remedies	O
and	O
weight	O
-	O
control	O
preparations	O
worldwide	O
.	O

Its	O
use	O
has	O
been	O
associated	O
with	O
hypertensive	B
episodes	O
and	O
hemorrhagic	B
strokes	B
in	O
younger	O
women	O
.	O

Several	O
reports	O
have	O
linked	O
the	O
abuse	O
of	O
PPA	O
with	O
myocardial	B
injury	I
,	O
especially	O
when	O
overdose	B
is	O
involved	O
.	O

We	O
report	O
here	O
the	O
first	O
case	O
of	O
Dexatrim	O
(	O
PPA	O
)	O
-induced	O
myocardial	B
injury	I
in	O
a	O
young	O
woman	O
who	O
was	O
using	O
it	O
at	O
recommended	O
doses	O
for	O
weight	O
control	O
.	O

In	O
addition	O
,	O
we	O
review	O
the	O
7	O
other	O
cases	O
of	O
PPA	O
related	O
myocardial	B
injury	I
that	O
have	O
been	O
reported	O
so	O
far	O
.	O

Physicians	O
and	O
patients	O
should	O
be	O
alert	O
to	O
the	O
potential	O
cardiac	O
risk	O
associated	O
with	O
the	O
use	O
of	O
PPA	O
,	O
even	O
at	O
doses	O
generally	O
considered	O
to	O
be	O
safe	O
.	O

Postoperative	B
myalgia	I
after	O
succinylcholine	O
:	O
no	O
evidence	O
for	O
an	O
inflammatory	O
origin	O
.	O

A	O
common	O
side	O
effect	O
associated	O
with	O
succinylcholine	O
is	O
postoperative	B
myalgia	I
.	O

The	O
pathogenesis	O
of	O
this	O
myalgia	B
is	O
still	O
unclear	O
;	O
inflammation	B
has	O
been	O
suggested	O
but	O
without	O
convincing	O
evidence	O
.	O

We	O
designed	O
the	O
present	O
study	O
to	O
investigate	O
whether	O
an	O
inflammatory	O
reaction	O
contributes	O
to	O
this	O
myalgia	B
.	O

The	O
incidence	O
and	O
severity	O
of	O
succinylcholine	O
-	O
associated	O
myalgia	B
was	O
determined	O
in	O
64	O
patients	O
pretreated	O
with	O
saline	O
or	O
dexamethasone	O
before	O
succinylcholine	O
(	O
n	O
=	O
32	O
for	O
each	O
)	O
.	O

Incidence	O
and	O
severity	O
of	O
myalgia	B
did	O
not	O
differ	O
significantly	O
between	O
the	O
two	O
groups	O
:	O
15	O
patients	O
in	O
the	O
dexamethasone	O
group	O
complained	O
of	O
myalgia	B
compared	O
with	O
18	O
patients	O
in	O
the	O
saline	O
group	O
,	O
and	O
severe	O
myalgia	B
was	O
reported	O
by	O
five	O
patients	O
and	O
three	O
patients	O
,	O
respectively	O
(	O
not	O
significant	O
)	O
.	O

At	O
48	O
h	O
after	O
surgery	O
,	O
12	O
patients	O
in	O
both	O
groups	O
still	O
suffered	O
from	O
myalgia	B
(	O
not	O
significant	O
)	O
.	O

In	O
addition	O
,	O
interleukin-6	O
(	O
IL-6	O
)	O
as	O
an	O
early	O
marker	O
of	O
inflammation	B
was	O
assessed	O
in	O
a	O
subgroup	O
of	O
10	O
patients	O
pretreated	O
with	O
saline	O
.	O

We	O
found	O
an	O
increase	O
of	O
IL-6	O
for	O
only	O
three	O
patients	O
,	O
but	O
only	O
one	O
patient	O
reported	O
myalgia	B
;	O
no	O
relationship	O
between	O
myalgia	B
and	O
the	O
increase	O
of	O
IL-6	O
was	O
found	O
.	O

In	O
conclusion	O
,	O
there	O
is	O
no	O
evidence	O
for	O
an	O
inflammatory	O
origin	O
of	O
succinylcholine	O
-	O
associated	O
myalgia	B
.	O

IMPLICATIONS	O
:	O
Administration	O
of	O
dexamethasone	O
before	O
succinylcholine	O
was	O
not	O
effective	O
in	O
decreasing	O
the	O
incidence	O
or	O
the	O
severity	O
of	O
succinylcholine	O
-	O
induced	O
postoperative	B
myalgia	I
.	O

Furthermore	O
,	O
there	O
was	O
no	O
significant	O
relationship	O
between	O
postoperative	B
myalgia	I
and	O
time	O
course	O
of	O
interleukin-6	O
concentrations	O
,	O
a	O
marker	O
of	O
inflammation	B
.	O

Pretreatment	O
with	O
dexamethasone	O
is	O
not	O
justified	O
to	O
prevent	O
postoperative	B
myalgia	I
after	O
succinylcholine	O
.	O

Comparison	O
of	O
developmental	O
toxicology	O
of	O
aspirin	O
(	O
acetylsalicylic	O
acid	O
)	O
in	O
rats	O
using	O
selected	O
dosing	O
paradigms	O
.	O

BACKGROUND	O
:	O
Analysis	O
of	O
the	O
literature	O
for	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
suggests	O
that	O
a	O
low	O
incidence	O
of	O
developmental	B
anomalies	I
occurs	O
in	O
rats	O
given	O
NSAIDs	O
on	O
specific	O
days	O
during	O
organogenesis	O
.	O

Aspirin	O
(	O
acetylsalicylic	O
acid	O
[	O
ASA	O
]	O
)	O
,	O
an	O
irreversible	O
cyclooxygenase	O
1	O
and	O
2	O
inhibitor	O
,	O
induces	O
developmental	B
anomalies	I
when	O
administered	O
to	O
Wistar	O
rats	O
on	O
gestational	O
day	O
(	O
GD	O
)	O
9	O
,	O
10	O
,	O
or	O
11	O
(	O
Kimmel	O
CA	O
,	O
Wilson	O
JG	O
,	O
Schumacher	O
HJ	O
.	O

Teratology	O
4:15	O
-	O
24	O
,	O
1971	O
)	O
.	O

There	O
are	O
no	O
published	O
ASA	O
studies	O
using	O
the	O
multiple	O
dosing	O
paradigm	O
of	O
GDs	O
6	O
to	O
17	O
.	O

Objectives	O
of	O
the	O
current	O
study	O
were	O
to	O
compare	O
results	O
between	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
and	O
Wistar	O
strains	O
when	O
ASA	O
is	O
administered	O
on	O
GD	O
9	O
,	O
10	O
,	O
or	O
11	O
;	O
to	O
compare	O
the	O
malformation	O
patterns	O
following	O
single	O
and	O
multiple	O
dosings	O
during	O
organogenesis	O
in	O
SD	O
rats	O
;	O
and	O
to	O
test	O
the	O
hypothesis	O
that	O
maternal	O
gastrointestinal	B
toxicity	I
confounds	O
the	O
detection	O
of	O
low	O
incidence	O
malformations	B
with	O
ASA	O
when	O
a	O
multiple	O
dosing	O
paradigm	O
is	O
used	O
.	O

METHODS	O
:	O
ASA	O
was	O
administered	O
as	O
a	O
single	O
dose	O
on	O
GD	O
9	O
(	O
0	O
,	O
250	O
,	O
500	O
,	O
or	O
625	O
mg	O
/	O
kg	O
)	O
,	O
10	O
(	O
0	O
,	O
500	O
,	O
625	O
,	O
or	O
750	O
mg	O
/	O
kg	O
)	O
,	O
or	O
11	O
(	O
0	O
,	O
500	O
,	O
750	O
,	O
or	O
1000	O
mg	O
/	O
kg	O
)	O
and	O
from	O
GD	O
6	O
to	O
GD	O
17	O
(	O
0	O
,	O
50	O
,	O
125	O
,	O
or	O
250	O
mg	O
/	O
kg	O
a	O
day	O
)	O
in	O
the	O
multiple	O
dose	O
study	O
to	O
SD	O
rats	O
.	O

Animals	O
were	O
killed	O
on	O
GD	O
21	O
,	O
and	O
fetuses	O
were	O
examined	O
viscerally	O
.	O

RESULTS	O
:	O
The	O
literature	O
evaluation	O
suggested	O
that	O
NSAIDs	O
induce	O
ventricular	B
septal	I
defects	I
(	O
VSDs	B
)	O
and	O
midline	B
defects	I
(	O
MDs	B
)	O
in	O
rats	O
and	O
diaphragmatic	B
hernia	I
(	O
DH	B
)	O
,	O
MDs	B
,	O
and	O
VSDs	B
in	O
rabbits	O
(	O
Cook	O
JC	O
et	O
al.	O
,	O
2003	O
)	O
;	O
hence	O
,	O
the	O
present	O
study	O
focused	O
on	O
these	O
malformations	B
,	O
even	O
though	O
ASA	O
induces	O
several	O
other	O
low	O
-	O
incidence	O
malformations	B
.	O

In	O
single	O
dose	O
studies	O
,	O
DH	B
,	O
MD	B
,	O
and	O
VSD	B
were	O
induced	O
on	O
GDs	O
9	O
and	O
10	O
.	O

VSD	B
also	O
was	O
noted	O
following	O
treatment	O
on	O
GD	O
11	O
.	O

In	O
contrast	O
,	O
DH	B
and	O
MD	B
were	O
noted	O
in	O
the	O
multiple	O
dose	O
study	O
design	O
only	O
in	O
the	O
high	O
-	O
dose	O
group	O
,	O
and	O
VSD	B
was	O
noted	O
across	O
all	O
dose	O
groups	O
.	O

CONCLUSIONS	O
:	O
High	O
concordance	O
in	O
major	O
developmental	B
anomalies	I
between	O
Wistar	O
and	O
SD	O
rats	O
were	O
noted	O
with	O
the	O
exception	O
of	O
VSD	B
in	O
the	O
SD	O
rats	O
and	O
hydrocephalus	B
in	O
the	O
Wistar	O
rats	O
.	O

Variations	O
and	O
malformations	B
were	O
similar	O
when	O
ASA	O
was	O
administered	O
as	O
a	O
single	O
dose	O
or	O
during	O
the	O
period	O
of	O
organogenesis	O
(	O
GDs	O
6	O
to	O
17	O
)	O
.	O

It	O
was	O
also	O
evident	O
that	O
,	O
by	O
titrating	O
the	O
dose	O
to	O
achieve	O
a	O
maximum	O
tolerated	O
dose	O
,	O
malformations	B
that	O
normally	O
occur	O
at	O
low	O
incidence	O
,	O
as	O
reported	O
from	O
previous	O
single	O
dose	O
studies	O
,	O
could	O
also	O
be	O
induced	O
with	O
ASA	O
given	O
at	O
multiple	O
doses	O
.	O

Hemolytic	B
-	I
uremic	I
syndrome	I
associated	O
with	O
ingestion	O
of	O
quinine	O
.	O

Hemolytic	B
-	I
uremic	I
syndrome	I
following	O
quinine	O
ingestion	O
is	O
a	O
newly	O
described	O
phenomenon	O
,	O
with	O
just	O
two	O
previous	O
descriptions	O
of	O
4	O
cases	O
in	O
the	O
literature	O
.	O

We	O
describe	O
a	O
5th	O
case	O
.	O

The	O
reaction	O
may	O
be	O
mediated	O
by	O
the	O
presence	O
of	O
antibodies	O
reactive	O
against	O
platelets	O
in	O
the	O
presence	O
of	O
quinine	O
.	O

Treatment	O
has	O
included	O
use	O
of	O
plasma	O
exchange	O
,	O
prednisone	O
,	O
aspirin	O
,	O
and	O
dipyridamole	O
.	O

The	O
patients	O
have	O
all	O
regained	O
some	O
degree	O
of	O
renal	O
function	O
.	O

However	O
,	O
it	O
is	O
unclear	O
whether	O
pharmacological	O
treatment	O
or	O
spontaneous	O
resolution	O
is	O
responsible	O
for	O
the	O
improvement	O
.	O

Quinine	O
-	O
associated	O
hemolytic	B
-	I
uremic	I
syndrome	I
probably	O
occurs	O
more	O
often	O
than	O
is	O
recognized	O
.	O

It	O
is	O
important	O
to	O
recognize	O
this	O
reaction	O
when	O
it	O
occurs	O
and	O
to	O
avoid	O
further	O
quinine	O
exposure	O
,	O
since	O
the	O
reaction	O
seems	O
to	O
be	O
recurrent	O
.	O

All-	O
trans	O
-	O
retinoic	O
acid	O
-	O
induced	O
erythema	B
nodosum	I
in	O
patients	O
with	O
acute	B
promyelocytic	I
leukemia	I
.	O

Erythema	B
nodosum	I
associated	O
with	O
all-	O
trans	O
-	O
retinoic	O
acid	O
(	O
ATRA	O
)	O
for	O
acute	B
promyelocytic	I
leukemia	I
(	O
APL	B
)	O
is	O
very	O
rare	O
.	O

We	O
describe	O
four	O
patients	O
with	O
classic	O
APL	B
who	O
developed	O
erythema	B
nodosum	I
during	O
ATRA	O
therapy	O
.	O

Fever	B
and	O
subsequent	O
multiple	O
painful	B
erythematous	B
nodules	I
over	O
extremities	O
developed	O
on	O
D11	O
,	O
D16	O
,	O
D17	O
,	O
and	O
D19	O
,	O
respectively	O
,	O
after	O
ATRA	O
therapy	O
.	O

The	O
skin	O
biopsy	O
taken	O
from	O
each	O
patient	O
was	O
consistent	O
with	O
erythema	B
nodosum	I
.	O

All	O
patients	O
received	O
short	O
course	O
of	O
steroids	O
.	O

Fever	B
subsided	O
rapidly	O
and	O
the	O
skin	O
lesions	O
regressed	O
completely	O
.	O

All	O
patients	O
achieved	O
complete	O
remission	O
without	O
withdrawal	O
of	O
ATRA	O
.	O

ATRA	O
seemed	O
to	O
be	O
the	O
most	O
possible	O
etiology	O
of	O
erythema	B
nodosum	I
in	O
our	O
patients	O
.	O

Short	O
-	O
term	O
use	O
of	O
steroid	O
is	O
very	O
effective	O
in	O
ATRA	O
-	O
induced	O
erythema	B
nodosum	I
.	O

Pallidal	O
stimulation	O
:	O
an	O
alternative	O
to	O
pallidotomy	O
?	O

A	O
resurgence	O
of	O
interest	O
in	O
the	O
surgical	O
treatment	O
of	O
Parkinson	B
's	I
disease	I
(	O
PD	B
)	O
came	O
with	O
the	O
rediscovery	O
of	O
posteroventral	O
pallidotomy	O
by	O
Laitinen	O
in	O
1985	O
.	O

Laitinen	O
's	O
procedure	O
improved	O
most	O
symptoms	O
in	O
drug	O
-	O
resistant	O
PD	B
,	O
which	O
engendered	O
wide	O
interest	O
in	O
the	O
neurosurgical	O
community	O
.	O

Another	O
lesioning	O
procedure	O
,	O
ventrolateral	O
thalamotomy	O
,	O
has	O
become	O
a	O
powerful	O
alternative	O
to	O
stimulate	O
the	O
nucleus	O
ventralis	O
intermedius	O
,	O
producing	O
high	O
long	O
-	O
term	O
success	O
rates	O
and	O
low	O
morbidity	O
rates	O
.	O

Pallidal	O
stimulation	O
has	O
not	O
met	O
with	O
the	O
same	O
success	O
.	O

According	O
to	O
the	O
literature	O
pallidotomy	O
improves	O
the	O
""""	O
on	O
""""	O
symptoms	O
of	O
PD	B
,	O
such	O
as	O
dyskinesias	B
,	O
as	O
well	O
as	O
the	O
""""	O
off	O
""""	O
symptoms	O
,	O
such	O
as	O
rigidity	B
,	O
bradykinesia	B
,	O
and	O
on	O
-	O
off	O
fluctuations	O
.	O

Pallidal	O
stimulation	O
improves	O
bradykinesia	B
and	O
rigidity	B
to	O
a	O
minor	O
extent	O
;	O
however	O
,	O
its	O
strength	O
seems	O
to	O
be	O
in	O
improving	O
levodopa	O
-	O
induced	O
dyskinesias	B
.	O

Stimulation	O
often	O
produces	O
an	O
improvement	O
in	O
the	O
hyper-	B
or	I
dyskinetic	I
upper	O
limbs	O
,	O
but	O
increases	O
the	O
""""	O
freezing	O
""""	O
phenomenon	O
in	O
the	O
lower	O
limbs	O
at	O
the	O
same	O
time	O
.	O

Considering	O
the	O
small	O
increase	O
in	O
the	O
patient	O
's	O
independence	O
,	O
the	O
high	O
costs	O
of	O
bilateral	O
implants	O
,	O
and	O
the	O
difficulty	O
most	O
patients	O
experience	O
in	O
handling	O
the	O
devices	O
,	O
the	O
question	O
arises	O
as	O
to	O
whether	O
bilateral	O
pallidal	O
stimulation	O
is	O
a	O
real	O
alternative	O
to	O
pallidotomy	O
.	O

Hypersensitivity	B
myocarditis	B
complicating	O
hypertrophic	B
cardiomyopathy	I
heart	O
.	O

The	O
present	O
report	O
describes	O
a	O
case	O
of	O
eosinophilic	B
myocarditis	B
complicating	O
hypertrophic	B
cardiomyopathy	I
.	O

The	O
47-year	O
-	O
old	O
female	O
patient	O
,	O
known	O
to	O
have	O
hypertrophic	B
cardiomyopathy	I
,	O
was	O
admitted	O
with	O
biventricular	B
failure	I
and	O
managed	O
aggressively	O
with	O
dobutamine	O
infusion	O
and	O
other	O
drugs	O
while	O
being	O
assessed	O
for	O
heart	O
transplantation	O
.	O

On	O
transthoracic	O
echocardiogram	O
,	O
she	O
had	O
moderate	O
left	B
ventricular	I
dysfunction	I
with	O
regional	O
variability	O
and	O
moderate	O
mitral	B
regurgitation	I
.	O

The	O
recipient	O
's	O
heart	O
showed	O
the	O
features	O
of	O
apical	O
hypertrophic	B
cardiomyopathy	I
and	O
myocarditis	B
with	O
abundant	O
eosinophils	O
.	O

Myocarditis	B
is	O
rare	O
and	O
eosinophilic	B
myocarditis	B
is	O
rarer	O
.	O

It	O
is	O
likely	O
that	O
the	O
hypersensitivity	B
(	O
eosinophilic	B
)	O
myocarditis	B
was	O
related	O
to	O
dobutamine	O
infusion	O
therapy	O
.	O

Eosinophilic	B
myocarditis	B
has	O
been	O
reported	O
with	O
an	O
incidence	O
of	O
2.4	O
%	O
to	O
7.2	O
%	O
in	O
explanted	O
hearts	O
and	O
may	O
be	O
related	O
to	O
multidrug	O
therapy	O
.	O

Acute	O
low	B
back	I
pain	I
during	O
intravenous	O
administration	O
of	O
amiodarone	O
:	O
a	O
report	O
of	O
two	O
cases	O
.	O

Amiodarone	O
represents	O
an	O
effective	O
antiarrhythmic	O
drug	O
for	O
cardioversion	O
of	O
recent	O
-	O
onset	O
atrial	B
fibrillation	I
(	O
AF	B
)	O
and	O
maintenance	O
of	O
sinus	O
rhythm	O
.	O

We	O
briefly	O
describe	O
two	O
patients	O
suffering	O
from	O
recent	O
-	O
onset	O
atrial	B
fibrillation	I
,	O
who	O
experienced	O
an	O
acute	O
devastating	O
low	B
back	I
pain	I
a	O
few	O
minutes	O
after	O
initiation	O
of	O
intravenous	O
amiodarone	O
loading	O
.	O

Notably	O
,	O
this	O
side	O
effect	O
has	O
not	O
been	O
ever	O
reported	O
in	O
the	O
medical	O
literature	O
.	O

Clinicians	O
should	O
be	O
aware	O
of	O
this	O
reaction	O
since	O
prompt	O
termination	O
of	O
parenteral	O
administration	O
leads	O
to	O
complete	O
resolution	O
.	O

Dexrazoxane	O
protects	O
against	O
myelosuppression	B
from	O
the	O
DNA	O
cleavage	O
-	O
enhancing	O
drugs	O
etoposide	O
and	O
daunorubicin	O
but	O
not	O
doxorubicin	O
.	O

PURPOSE	O
:	O
The	O
anthracyclines	O
daunorubicin	O
and	O
doxorubicin	O
and	O
the	O
epipodophyllotoxin	O
etoposide	O
are	O
potent	O
DNA	O
cleavage	O
-	O
enhancing	O
drugs	O
that	O
are	O
widely	O
used	O
in	O
clinical	O
oncology	O
;	O
however	O
,	O
myelosuppression	B
and	O
cardiac	B
toxicity	I
limit	O
their	O
use	O
.	O

Dexrazoxane	O
(	O
ICRF-187	O
)	O
is	O
recommended	O
for	O
protection	O
against	O
anthracycline	O
-	O
induced	O
cardiotoxicity	B
.	O

EXPERIMENTAL	O
DESIGN	O
:	O
Because	O
of	O
their	O
widespread	O
use	O
,	O
the	O
hematologic	B
toxicity	I
following	O
coadministration	O
of	O
dexrazoxane	O
and	O
these	O
three	O
structurally	O
different	O
DNA	O
cleavage	O
enhancers	O
was	O
investigated	O
:	O
Sensitivity	O
of	O
human	O
and	O
murine	O
blood	O
progenitor	O
cells	O
to	O
etoposide	O
,	O
daunorubicin	O
,	O
and	O
doxorubicin	O
+	O
/-	O

dexrazoxane	O
was	O
determined	O
in	O
granulocyte	O
-	O
macrophage	O
colony	O
forming	O
assays	O
.	O

Likewise	O
,	O
in	O
vivo	O
,	O
B6D2F1	O
mice	O
were	O
treated	O
with	O
etoposide	O
,	O
daunorubicin	O
,	O
and	O
doxorubicin	O
,	O
with	O
or	O
without	O
dexrazoxane	O
over	O
a	O
wide	O
range	O
of	O
doses	O
:	O
posttreatment	O
,	O
a	O
full	O
hematologic	O
evaluation	O
was	O
done	O
.	O

RESULTS	O
:	O
Nontoxic	O
doses	O
of	O
dexrazoxane	O
reduced	O
myelosuppression	B
and	O
weight	B
loss	I
from	O
daunorubicin	O
and	O
etoposide	O
in	O
mice	O
and	O
antagonized	O
their	O
antiproliferative	O
effects	O
in	O
the	O
colony	O
assay	O
;	O
however	O
,	O
dexrazoxane	O
neither	O
reduced	O
myelosuppression	B
,	O
weight	B
loss	I
,	O
nor	O
the	O
in	O
vitro	O
cytotoxicity	B
from	O
doxorubicin	O
.	O

CONCLUSION	O
:	O
Although	O
our	O
findings	O
support	O
the	O
observation	O
that	O
dexrazoxane	O
reduces	O
neither	O
hematologic	O
activity	O
nor	O
antitumor	O
activity	O
from	O
doxorubicin	O
clinically	O
,	O
the	O
potent	O
antagonism	O
of	O
daunorubicin	O
activity	O
raises	O
concern	O
;	O
a	O
possible	O
interference	O
with	O
anticancer	O
efficacy	O
certainly	O
would	O
call	O
for	O
renewed	O
attention	O
.	O

Our	O
data	O
also	O
suggest	O
that	O
significant	O
etoposide	O
dose	O
escalation	O
is	O
perhaps	O
possible	O
by	O
the	O
use	O
of	O
dexrazoxane	O
.	O

Clinical	O
trials	O
in	O
patients	O
with	O
brain	O
metastases	B
combining	O
dexrazoxane	O
and	O
high	O
doses	O
of	O
etoposide	O
is	O
ongoing	O
with	O
the	O
aim	O
of	O
improving	O
efficacy	O
without	O
aggravating	O
hematologic	B
toxicity	I
.	O

If	O
successful	O
,	O
this	O
represents	O
an	O
exciting	O
mechanism	O
for	O
pharmacologic	O
regulation	O
of	O
side	O
effects	O
from	O
cytotoxic	O
chemotherapy	O
.	O

Amiodarone	O
pulmonary	B
toxicity	I
.	O

Amiodarone	O
is	O
an	O
effective	O
antiarrhythmic	O
agent	O
whose	O
utility	O
is	O
limited	O
by	O
many	O
side	O
-	O
effects	O
,	O
the	O
most	O
problematic	O
being	O
pneumonitis	B
.	O

The	O
pulmonary	B
toxicity	I
of	O
amiodarone	O
is	O
thought	O
to	O
result	O
from	O
direct	O
injury	O
related	O
to	O
the	O
intracellular	O
accumulation	O
of	O
phospholipid	O
and	O
T	O
cell	O
-	O
mediated	O
hypersensitivity	B
pneumonitis	B
.	O

The	O
clinical	O
and	O
radiographic	O
features	O
of	O
amiodarone	O
-	O
induced	O
pulmonary	B
toxicity	I
are	O
characteristic	O
but	O
nonspecific	O
.	O

The	O
diagnosis	O
depends	O
on	O
exclusion	O
of	O
other	O
entities	O
,	O
such	O
as	O
heart	B
failure	I
,	O
infection	B
,	O
and	O
malignancy	B
.	O

While	O
withdrawal	O
of	O
amiodarone	O
leads	O
to	O
clinical	O
improvement	O
in	O
majority	O
of	O
cases	O
,	O
this	O
is	O
not	O
always	O
possible	O
or	O
advisable	O
.	O

Dose	O
reduction	O
or	O
concomitant	O
steroid	O
therapy	O
may	O
have	O
a	O
role	O
in	O
selected	O
patients	O
.	O

Amisulpride	O
related	O
tic	B
-	I
like	I
symptoms	I
in	O
an	O
adolescent	O
schizophrenic	B
.	O

Tic	B
disorders	I
can	O
be	O
effectively	O
treated	O
by	O
atypical	O
antipsychotics	O
such	O
as	O
risperidone	O
,	O
olanzapine	O
and	O
ziprasidone	O
.	O

However	O
,	O
there	O
are	O
two	O
case	O
reports	O
that	O
show	O
tic	B
-	I
like	I
symptoms	I
,	O
including	O
motor	O
and	O
phonic	O
variants	O
,	O
occurring	O
during	O
treatment	O
with	O
quetiapine	O
or	O
clozapine	O
.	O

We	O
present	O
a	O
15-year	O
-	O
old	O
girl	O
schizophrenic	B
who	O
developed	O
frequent	O
involuntary	B
eye	I
-	I
blinking	I
movements	I
after	O
5	O
months	O
of	O
amisulpride	O
treatment	O
(	O
1000	O
mg	O
per	O
day	O
)	O
.	O

The	O
tic	B
-	I
like	I
symptoms	I
resolved	O
completely	O
after	O
we	O
reduced	O
the	O
dose	O
of	O
amisulpride	O
down	O
to	O
800	O
mg	O
per	O
day	O
.	O

However	O
,	O
her	O
psychosis	B
recurred	O
after	O
the	O
dose	O
reduction	O
.	O

We	O
then	O
placed	O
her	O
on	O
an	O
additional	O
100	O
mg	O
per	O
day	O
of	O
quetiapine	O
.	O

She	O
has	O
been	O
in	O
complete	O
remission	O
under	O
the	O
combined	O
medications	O
for	O
more	O
than	O
one	O
year	O
and	O
maintains	O
a	O
fair	O
role	O
function	O
.	O

No	O
more	O
tic	B
-	I
like	I
symptoms	I
or	O
other	O
side	O
effects	O
have	O
been	O
reported	O
.	O

Together	O
with	O
previously	O
reported	O
cases	O
,	O
our	O
patient	O
suggests	O
that	O
tic	B
-	I
like	I
symptoms	I
might	O
occur	O
in	O
certain	O
vulnerable	O
individuals	O
during	O
treatment	O
with	O
atypical	O
antipsychotics	O
such	O
as	O
quetiapine	O
,	O
clozapine	O
,	O
or	O
amisulpride	O
.	O

Nerve	O
growth	O
factor	O
and	O
prostaglandins	O
in	O
the	O
urine	O
of	O
female	O
patients	O
with	O
overactive	B
bladder	I
.	O

PURPOSE	O
:	O
NGF	O
and	O
PGs	O
in	O
the	O
bladder	O
can	O
be	O
affected	O
by	O
pathological	O
changes	O
in	O
the	O
bladder	O
and	O
these	O
changes	O
can	O
be	O
detected	O
in	O
urine	O
.	O

We	O
investigated	O
changes	O
in	O
urinary	O
NGF	O
and	O
PGs	O
in	O
women	O
with	O
OAB	B
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
The	O
study	O
groups	O
included	O
65	O
women	O
with	O
OAB	B
and	O
20	O
without	O
bladder	O
symptoms	O
who	O
served	O
as	O
controls	O
.	O

Evaluation	O
included	O
patient	O
history	O
,	O
urinalysis	O
,	O
a	O
voiding	O
diary	O
and	O
urodynamic	O
studies	O
.	O

Urine	O
samples	O
were	O
collected	O
.	O

NGF	O
,	O
PGE2	O
,	O
PGF2alpha	O
and	O
PGI2	O
were	O
measured	O
using	O
enzyme	O
-	O
linked	O
immunosorbent	O
assay	O
and	O
compared	O
between	O
the	O
groups	O
.	O

In	O
addition	O
,	O
correlations	O
between	O
urinary	O
NGF	O
and	O
PG	O
,	O
and	O
urodynamic	O
parameters	O
in	O
patients	O
with	O
OAB	B
were	O
examined	O
.	O

RESULTS	O
:	O
Urinary	O
NGF	O
,	O
PGE2	O
and	O
PGF2alpha	O
were	O
significantly	O
increased	O
in	O
patients	O
with	O
OAB	B
compared	O
with	O
controls	O
(	O
p	O
<	O
0.05	O
)	O
.	O

However	O
,	O
urinary	O
PGI2	O
was	O
not	O
different	O
between	O
controls	O
and	O
patients	O
with	O
OAB	B
.	O

In	O
patients	O
with	O
OAB	B
urinary	O
PGE2	O
positively	O
correlated	O
with	O
volume	O
at	O
first	O
desire	O
to	O
void	O
and	O
maximum	O
cystometric	O
capacity	O
(	O
p	O
<	O
0.05	O
)	O
.	O

Urinary	O
NGF	O
,	O
PGF2alpha	O
and	O
PGI2	O
did	O
not	O
correlate	O
with	O
urodynamic	O
parameters	O
in	O
patients	O
with	O
OAB	B
.	O

CONCLUSIONS	O
:	O
NGF	O
and	O
PGs	O
have	O
important	O
roles	O
in	O
the	O
development	O
of	O
OAB	B
symptoms	O
in	O
female	O
patients	O
.	O

Urinary	O
levels	O
of	O
these	O
factors	O
may	O
be	O
used	O
as	O
markers	O
to	O
evaluate	O
OAB	B
symptoms	O
.	O

Blockade	O
of	O
both	O
D-1	O
and	O
D-2	O
dopamine	O
receptors	O
may	O
induce	O
catalepsy	B
in	O
mice	O
.	O

1	O
.	O

The	O
catalepsy	B
induced	O
by	O
dopamine	O
antagonists	O
has	O
been	O
tested	O
and	O
the	O
possible	O
dopamine	O
subtypes	O
involved	O
in	O
catalepsy	B
was	O
determined	O
.	O

2	O
.	O

Dopamine	O
antagonist	O
fluphenazine	O
,	O
D-1	O
antagonist	O
SCH	O
23390	O
or	O
D-2	O
antagonist	O
sulpiride	O
induced	O
catalepsy	B
.	O

The	O
effect	O
of	O
fluphenazine	O
and	O
sulpiride	O
was	O
dose	O
-	O
dependent	O
.	O

Combination	O
of	O
SCH	O
23390	O
with	O
sulpiride	O
did	O
not	O
induce	O
catalepsy	B
potentiation	O
.	O

3	O
.	O
D-1	O
agonist	O
SKF	O
38393	O
or	O
D-2	O
agonist	O
quinpirole	O
decreased	O
the	O
catalepsy	B
induced	O
by	O
fluphenazine	O
,	O
SCH	O
23390	O
or	O
sulpiride	O
.	O

4	O
.	O

Combination	O
of	O
SKF	O
38393	O
with	O
quinpirole	O
did	O
not	O
cause	O
potentiated	O
inhibitory	O
effect	O
on	O
catalepsy	B
induced	O
by	O
dopamine	O
antagonists	O
.	O

5	O
.	O

The	O
data	O
may	O
indicate	O
that	O
although	O
D-2	O
receptor	O
blockade	O
is	O
involved	O
in	O
catalepsy	B
,	O
the	O
D-1	O
receptor	O
may	O
plan	O
a	O
role	O
.	O

Is	O
phenytoin	O
administration	O
safe	O
in	O
a	O
hypothermic	B
child	O
?	O

A	O
male	O
neonate	O
with	O
a	O
Chiari	B
malformation	I
and	O
a	O
leaking	O
myelomeningocoele	O
underwent	O
ventriculoperitoneal	O
shunt	O
insertion	O
followed	O
by	O
repair	O
of	O
myelomeningocoele	O
.	O

During	O
anaesthesia	O
and	O
surgery	O
,	O
he	O
inadvertently	O
became	O
moderately	O
hypothermic	B
.	O

Intravenous	O
phenytoin	O
was	O
administered	O
during	O
the	O
later	O
part	O
of	O
the	O
surgery	O
for	O
seizure	B
prophylaxis	O
.	O

Following	O
phenytoin	O
administration	O
,	O
the	O
patient	O
developed	O
acute	O
severe	O
bradycardia	B
,	O
refractory	O
to	O
atropine	O
and	O
adrenaline	O
.	O

The	O
cardiac	O
depressant	O
actions	O
of	O
phenytoin	O
and	O
hypothermia	B
can	O
be	O
additive	O
.	O

Administration	O
of	O
phenytoin	O
in	O
the	O
presence	O
of	O
hypothermia	B
may	O
lead	O
to	O
an	O
adverse	O
cardiac	O
event	O
in	O
children	O
.	O

As	O
phenytoin	O
is	O
a	O
commonly	O
used	O
drug	O
,	O
clinicians	O
need	O
to	O
be	O
aware	O
of	O
this	O
interaction	O
.	O

Delayed	O
institution	O
of	O
hypertension	B
during	O
focal	O
cerebral	B
ischemia	I
:	O
effect	O
on	O
brain	B
edema	I
.	O

The	O
effect	O
of	O
induced	O
hypertension	B
instituted	O
after	O
a	O
2-h	O
delay	O
following	O
middle	B
cerebral	I
artery	I
occlusion	I
(	O
MCAO	B
)	O
on	O
brain	B
edema	I
formation	O
and	O
histochemical	O
injury	O
was	O
studied	O
.	O

Under	O
isoflurane	O
anesthesia	O
,	O
the	O
MCA	O
of	O
14	O
spontaneously	O
hypertensive	B
rats	O
was	O
occluded	O
.	O

In	O
the	O
control	O
group	O
(	O
n	O
=	O
7	O
)	O
,	O
the	O
mean	O
arterial	O
pressure	O
(	O
MAP	O
)	O
was	O
not	O
manipulated	O
.	O

In	O
the	O
hypertensive	B
group	O
(	O
n	O
=	O
7	O
)	O
,	O
the	O
MAP	O
was	O
elevated	O
by	O
25	O
-	O
30	O
mm	O
Hg	O
beginning	O
2	O
h	O
after	O
MCAO	B
.	O

Four	O
hours	O
after	O
MCAO	B
,	O
the	O
rats	O
were	O
killed	O
and	O
the	O
brains	O
harvested	O
.	O

The	O
brains	O
were	O
sectioned	O
along	O
coronal	O
planes	O
spanning	O
the	O
distribution	O
of	O
ischemia	B
produced	O
by	O
MCAO	B
.	O

Specific	O
gravity	O
(	O
SG	O
)	O
was	O
determined	O
in	O
the	O
subcortex	O
and	O
in	O
two	O
sites	O
in	O
the	O
cortex	O
(	O
core	O
and	O
periphery	O
of	O
the	O
ischemic	B
territory	O
)	O
.	O

The	O
extent	O
of	O
neuronal	B
injury	I
was	O
determined	O
by	O
2,3,5-triphenyltetrazolium	O
staining	O
.	O

In	O
the	O
ischemic	B
core	O
,	O
there	O
was	O
no	O
difference	O
in	O
SG	O
in	O
the	O
subcortex	O
and	O
cortex	O
in	O
the	O
two	O
groups	O
.	O

In	O
the	O
periphery	O
of	O
the	O
ischemic	B
territory	O
,	O
SG	O
in	O
the	O
cortex	O
was	O
greater	O
(	O
less	O
edema	B
accumulation	O
)	O
in	O
the	O
hypertensive	B
group	O
(	O
1.041	O
+	O
/-	O

0.001	O
vs	O
1.039	O
+	O
/-	O

0.001	O
,	O
P	O
less	O
than	O
0.05	O
)	O
.	O

The	O
area	O
of	O
histochemical	O
injury	O
(	O
as	O
a	O
percent	O
of	O
the	O
cross	O
-	O
sectional	O
area	O
of	O
the	O
hemisphere	O
)	O
was	O
less	O
in	O
the	O
hypertensive	B
group	O
(	O
33	O
+	O
/-	O

3	O
%	O
vs	O
21	O
+	O
/-	O

2	O
%	O
,	O
P	O
less	O
than	O
0.05	O
)	O
.	O

The	O
data	O
indicate	O
that	O
phenylephrine	O
-	O
induced	O
hypertension	B
instituted	O
2	O
h	O
after	O
MCAO	B
does	O
not	O
aggravate	O
edema	B
in	O
the	O
ischemic	B
core	O
,	O
that	O
it	O
improves	O
edema	B
in	O
the	O
periphery	O
of	O
the	O
ischemic	B
territory	O
,	O
and	O
that	O
it	O
reduces	O
the	O
area	O
of	O
histochemical	O
neuronal	B
dysfunction	I
.	O

Intraocular	O
pressure	O
in	O
patients	O
with	O
uveitis	B
treated	O
with	O
fluocinolone	O
acetonide	O
implants	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
the	O
incidence	O
and	O
management	O
of	O
elevated	B
intraocular	I
pressure	I
(	O
IOP	O
)	O
in	O
patients	O
with	O
uveitis	B
treated	O
with	O
the	O
fluocinolone	O
acetonide	O
(	O
FA	O
)	O
intravitreal	O
implant	O
.	O

DESIGN	O
:	O
Pooled	O
data	O
from	O
3	O
multicenter	O
,	O
double	O
-	O
masked	O
,	O
randomized	O
,	O
controlled	O
,	O
phase	O
2b	O
/	O
3	O
clinical	O
trials	O
evaluating	O
the	O
safety	O
and	O
efficacy	O
of	O
the	O
0.59-mg	O
or	O
2.1-mg	O
FA	O
intravitreal	O
implant	O
or	O
standard	O
therapy	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
During	O
the	O
3-year	O
follow	O
-	O
up	O
,	O
71.0	O
%	O
of	O
implanted	O
eyes	O
had	O
an	O
IOP	O
increase	O
of	O
10	O
mm	O
Hg	O
or	O
more	O
than	O
baseline	O
and	O
55.1	O
%	O
,	O
24.7	O
%	O
,	O
and	O
6.2	O
%	O
of	O
eyes	O
reached	O
an	O
IOP	O
of	O
30	O
mm	O
Hg	O
or	O
more	O
,	O
40	O
mm	O
Hg	O
or	O
more	O
,	O
and	O
50	O
mm	O
Hg	O
or	O
more	O
,	O
respectively	O
.	O

Topical	O
IOP	O
-	O
lowering	O
medication	O
was	O
administered	O
in	O
74.8	O
%	O
of	O
implanted	O
eyes	O
,	O
and	O
IOP	O
-	O
lowering	O
surgeries	O
,	O
most	O
of	O
which	O
were	O
trabeculectomies	O
(	O
76.2	O
%	O
)	O
,	O
were	O
performed	O
on	O
36.6	O
%	O
of	O
implanted	O
eyes	O
.	O

Intraocular	O
pressure	O
-	O
lowering	O
surgeries	O
were	O
considered	O
a	O
success	O
(	O
postoperative	O
IOP	O
of	O
6	O
-	O
21	O
mm	O
Hg	O
with	O
or	O
without	O
additional	O
IOP	O
-	O
lowering	O
medication	O
)	O
in	O
85.1	O
%	O
of	O
eyes	O
at	O
1	O
year	O
.	O

The	O
rate	O
of	O
hypotony	B
(	O
IOP	O
<	O
/=	O
5	O
mm	O
Hg	O
)	O
following	O
IOP	O
-	O
lowering	O
surgery	O
(	O
42.5	O
%	O
)	O
was	O
not	O
different	O
from	O
that	O
of	O
implanted	O
eyes	O
not	O
subjected	O
to	O
surgery	O
(	O
35.4	O
%	O
)	O
(	O
P	O
=	O
.09	O
)	O
.	O

CONCLUSION	O
:	O
Elevated	O
IOP	O
is	O
a	O
significant	O
complication	O
with	O
the	O
FA	O
intravitreal	O
implant	O
but	O
may	O
be	O
controlled	O
with	O
medication	O
and	O
surgery	O
.	O

Results	O
of	O
a	O
comparative	O
,	O
phase	O
III	O
,	O
12-week	O
,	O
multicenter	O
,	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
assessment	O
of	O
the	O
efficacy	O
and	O
tolerability	O
of	O
a	O
fixed	O
-	O
dose	O
combination	O
of	O
telmisartan	O
and	O
amlodipine	O
versus	O
amlodipine	O
monotherapy	O
in	O
Indian	O
adults	O
with	O
stage	O
II	O
hypertension	B
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
the	O
efficacy	O
and	O
tolerability	O
of	O
a	O
new	O
fixed	O
-	O
dose	O
combination	O
(	O
FDC	O
)	O
of	O
telmisartan	O
40	O
mg	O
+	O
amlodipine	O
5	O
mg	O
(	O
T+A	O
)	O
compared	O
with	O
amlodipine	O
5-mg	O
monotherapy	O
(	O
A	O
)	O
in	O
adult	O
Indian	O
patients	O
with	O
stage	O
II	O
hypertension	B
.	O

METHODS	O
:	O
This	O
comparative	O
,	O
Phase	O
III	O
,	O
12-week	O
,	O
multicenter	O
,	O
prospective	O
,	O
randomized	O
,	O
double	O
-	O
blind	O
study	O
was	O
conducted	O
in	O
Indian	O
patients	O
aged	O
18	O
to	O
65	O
years	O
with	O
established	O
stage	O
II	O
hypertension	B
.	O

Patients	O
were	O
treated	O
with	O
oral	O
FDC	O
of	O
T+A	O
or	O
A	O
QD	O
before	O
breakfast	O
for	O
12	O
weeks	O
;	O
blood	O
pressure	O
(	O
BP	O
)	O
and	O
heart	O
rate	O
were	O
measured	O
in	O
the	O
sitting	O
position	O
.	O

Primary	O
efficacy	O
end	O
points	O
were	O
reduction	O
in	O
clinical	O
systolic	O
BP	O
(	O
SBP	O
)	O
/	O
diastolic	O
BP	O
(	O
DBP	O
)	O
from	O
baseline	O
to	O
study	O
end	O
and	O
number	O
of	O
responders	O
(	O
ie	O
,	O
patients	O
who	O
achieved	O
target	O
SBP	O
/	O
DBP	O
<	O
130	O
/	O
<80	O
mm	O
Hg	O
)	O
at	O
end	O
of	O
study	O
.	O

Tolerability	O
was	O
assessed	O
by	O
treatment	O
-	O
emergent	O
adverse	O
events	O
,	O
identified	O
using	O
physical	O
examination	O
,	O
laboratory	O
analysis	O
,	O
and	O
electrocardiography	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
210	O
patients	O
were	O
enrolled	O
in	O
the	O
study	O
;	O
203	O
patients	O
(	O
143	O
men	O
,	O
60	O
women	O
)	O
completed	O
the	O
study	O
while	O
7	O
were	O
lost	O
to	O
follow	O
-	O
up	O
(	O
4	O
patients	O
in	O
the	O
T+A	O
group	O
and	O
3	O
in	O
the	O
A	O
group	O
)	O
and	O
considered	O
with	O
-	O
drawn	O
.	O

At	O
study	O
end	O
,	O
statistically	O
significant	O
percentage	O
reductions	O
from	O
baseline	O
within	O
groups	O
and	O
between	O
groups	O
were	O
observed	O
in	O
SBP	O
(	O
T+A	O
[	O
-27.4	O
%	O
]	O
;	O
A	O
[	O
-16.6	O
%	O
]	O
)	O
and	O
DBP	O
(	O
T+A	O
[	O
-20.1	O
%	O
]	O
;	O
A	O
[	O
-13.3	O
%	O
]	O
)	O
(	O
all	O
,	O
P	O
<	O
0.05	O
)	O
.	O

Response	O
rates	O
were	O
87.3	O
%	O
(	O
89	O
/	O
102	O
)	O
in	O
the	O
T+A	O
group	O
and	O
69.3	O
%	O
(	O
70	O
/	O
101	O
)	O
in	O
the	O
A	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
prevalences	O
of	O
adverse	O
events	O
were	O
not	O
significantly	O
different	O
between	O
the	O
2	O
treatment	O
groups	O
(	O
T+A	O
,	O
16.0	O
%	O
[	O
17	O
/	O
106	O
]	O
;	O
A	O
,	O
15.4	O
%	O
[	O
16	O
/	O
104	O
]	O
)	O
.	O

Peripheral	O
edema	B
was	O
reported	O
in	O
8.5	O
%	O
patients	O
(	O
9	O
/	O
106	O
)	O
in	O
the	O
T+A	O
group	O
compared	O
with	O
13.5	O
%	O
(	O
14	O
/	O
104	O
)	O
in	O
the	O
A	O
group	O
,	O
and	O
cough	B
was	O
reported	O
in	O
3.8	O
%	O
patients	O
(	O
4	O
/	O
106	O
)	O
in	O
the	O
T+A	O
group	O
and	O
1.0	O
%	O
(	O
1	O
/	O
104	O
)	O
patients	O
in	O
the	O
A	O
group	O
;	O
these	O
differences	O
did	O
not	O
reach	O
statistical	O
significance	O
.	O

The	O
incidences	O
of	O
headache	B
,	O
dizziness	B
,	O
and	O
diarrhea	B
were	O
similar	O
between	O
the	O
2	O
groups	O
.	O

CONCLUSIONS	O
:	O
Among	O
these	O
Indian	O
patients	O
with	O
stage	O
II	O
hypertension	B
,	O
the	O
FDC	O
of	O
T+A	O
was	O
found	O
to	O
be	O
significantly	O
more	O
effective	O
,	O
with	O
regard	O
to	O
BP	O
reductions	O
,	O
than	O
A	O
,	O
and	O
both	O
treatments	O
were	O
well	O
tolerated	O
.	O

Exaggerated	O
expression	O
of	O
inflammatory	O
mediators	O
in	O
vasoactive	O
intestinal	O
polypeptide	O
knockout	O
(	O
VIP-	O
/	O
-	O
)	O
mice	O
with	O
cyclophosphamide	O
(	O
CYP	O
)	O
-induced	O
cystitis	B
.	O

Vasoactive	O
intestinal	O
polypeptide	O
(	O
VIP	O
)	O
is	O
an	O
immunomodulatory	O
neuropeptide	O
distributed	O
in	O
micturition	O
pathways	O
.	O

VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
exhibit	O
altered	O
bladder	O
function	O
and	O
neurochemical	O
properties	O
in	O
micturition	O
pathways	O
after	O
cyclophosphamide	O
(	O
CYP	O
)	O
-induced	O
cystitis	B
.	O

Given	O
VIP	O
's	O
role	O
as	O
an	O
anti	O
-	O
inflammatory	O
mediator	O
,	O
we	O
hypothesized	O
that	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
would	O
exhibit	O
enhanced	O
inflammatory	O
mediator	O
expression	O
after	O
cystitis	B
.	O

A	O
mouse	O
inflammatory	O
cytokine	O
and	O
receptor	O
RT2	O
profiler	O
array	O
was	O
used	O
to	O
determine	O
regulated	O
transcripts	O
in	O
the	O
urinary	O
bladder	O
of	O
wild	O
type	O
(	O
WT	O
)	O
and	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
with	O
or	O
without	O
CYP	O
-	O
induced	O
cystitis	B
(	O
150	O
mg	O
/	O
kg	O
;	O
i.p	O
.	O
;	O
48	O
h	O
)	O
.	O

Four	O
binary	O
comparisons	O
were	O
made	O
:	O
WT	O
control	O
versus	O
CYP	O
treatment	O
(	O
48	O
h	O
)	O
,	O
VIP	O
(	O
-	O
/	O
-	O
)	O
control	O
versus	O
CYP	O
treatment	O
(	O
48	O
h	O
)	O
,	O
WT	O
control	O
versus	O
VIP	O
(	O
-	O
/	O
-	O
)	O
control	O
,	O
and	O
WT	O
with	O
CYP	O
treatment	O
(	O
48	O
h	O
)	O
versus	O
VIP	O
(	O
-	O
/	O
-	O
)	O
with	O
CYP	O
treatment	O
(	O
48	O
h	O
)	O
.	O

The	O
genes	O
presented	O
represent	O
(	O
1	O
)	O
greater	O
than	O
1.5-fold	O
change	O
in	O
either	O
direction	O
and	O
(	O
2	O
)	O
the	O
p	O
value	O
is	O
less	O
than	O
0.05	O
for	O
the	O
comparison	O
being	O
made	O
.	O

Several	O
regulated	O
genes	O
were	O
validated	O
using	O
enzyme	O
-	O
linked	O
immunoassays	O
including	O
IL-1beta	O
and	O
CXCL1	O
.	O

CYP	O
treatment	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
increased	O
expression	O
of	O
CXCL1	O
and	O
IL-1beta	O
in	O
the	O
urinary	O
bladder	O
of	O
WT	O
and	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
,	O
but	O
expression	O
in	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
with	O
CYP	O
treatment	O
was	O
significantly	O
(	O
p	O
<	O
or	O
=	O
0.001	O
)	O
greater	O
(	O
4.2-	O
to	O
13-fold	O
increase	O
)	O
than	O
that	O
observed	O
in	O
WT	O
urinary	O
bladder	O
(	O
3.6-	O
to	O
5-fold	O
increase	O
)	O
.	O

The	O
data	O
suggest	O
that	O
in	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
with	O
bladder	B
inflammation	I
,	O
inflammatory	O
mediators	O
are	O
increased	O
above	O
that	O
observed	O
in	O
WT	O
with	O
CYP	O
.	O

This	O
shift	O
in	O
balance	O
may	O
contribute	O
to	O
increased	O
bladder	B
dysfunction	I
in	O
VIP	O
(	O
-	O
/	O
-	O
)	O
mice	O
with	O
bladder	B
inflammation	I
and	O
altered	O
neurochemical	O
expression	O
in	O
micturition	O
pathways	O
.	O

The	O
hemodynamics	O
of	O
oxytocin	O
and	O
other	O
vasoactive	O
agents	O
during	O
neuraxial	O
anesthesia	O
for	O
cesarean	O
delivery	O
:	O
findings	O
in	O
six	O
cases	O
.	O

Oxytocin	O
is	O
a	O
commonly	O
used	O
uterotonic	O
that	O
can	O
cause	O
significant	O
and	O
even	O
fatal	O
hypotension	B
,	O
particularly	O
when	O
given	O
as	O
a	O
bolus	O
.	O

The	O
resulting	O
hypotension	B
can	O
be	O
produced	O
by	O
a	O
decrease	O
in	O
systemic	O
vascular	O
resistance	O
or	O
cardiac	O
output	O
through	O
a	O
decrease	O
in	O
venous	O
return	O
.	O

Parturients	O
with	O
normal	O
volume	O
status	O
,	O
heart	O
valves	O
and	O
pulmonary	O
vasculature	O
most	O
often	O
respond	O
to	O
this	O
hypotension	B
with	O
a	O
compensatory	O
increase	O
in	O
heart	O
rate	O
and	O
stroke	B
volume	O
.	O

Oxytocin	O
-	O
induced	O
hypotension	B
at	O
cesarean	O
delivery	O
may	O
be	O
incorrectly	O
attributed	O
to	O
blood	B
loss	I
.	O

Pulse	O
power	O
analysis	O
(	O
also	O
called	O
""""	O
pulse	O
contour	O
analysis	O
""""	O
)	O
of	O
an	O
arterial	O
pressure	O
wave	O
form	O
allows	O
continuous	O
evaluation	O
of	O
systemic	O
vascular	O
resistance	O
and	O
cardiac	O
output	O
in	O
real	O
time	O
,	O
thereby	O
elucidating	O
the	O
causative	O
factors	O
behind	O
changes	O
in	O
blood	O
pressure	O
.	O

Pulse	O
power	O
analysis	O
was	O
conducted	O
in	O
six	O
cases	O
of	O
cesarean	O
delivery	O
performed	O
under	O
neuraxial	O
anesthesia	O
.	O

Hypotension	B
in	O
response	O
to	O
oxytocin	O
was	O
associated	O
with	O
a	O
decrease	O
in	O
systemic	O
vascular	O
resistance	O
and	O
a	O
compensatory	O
increase	O
in	O
stroke	B
volume	O
,	O
heart	O
rate	O
and	O
cardiac	O
output	O
.	O

Pulse	O
power	O
analysis	O
may	O
be	O
helpful	O
in	O
determining	O
the	O
etiology	O
of	O
and	O
treating	O
hypotension	B
during	O
cesarean	O
delivery	O
under	O
neuraxial	O
anesthesia	O
.	O

Proteinase	O
3-antineutrophil	O
cytoplasmic	O
antibody-	O
(	O
PR3-ANCA	O
)	O
positive	O
necrotizing	O
glomerulonephritis	B
after	O
restarting	O
sulphasalazine	O
treatment	O
.	O

A	O
59-year	O
-	O
old	O
woman	O
with	O
ulcerative	B
colitis	I
developed	O
red	B
eyes	I
,	O
pleural	B
effusion	I
,	O
eosinophilia	B
and	O
urinary	B
abnormalities	I
after	O
restarting	O
of	O
sulphasalazine	O
treatment	O
.	O

Light	O
microscopy	O
of	O
a	O
kidney	O
biopsy	O
revealed	O
segmental	B
necrotizing	I
glomerulonephritis	I
without	O
deposition	O
of	O
immunoglobulin	O
or	O
complement	O
.	O

Proteinase	O
3-antineutrophil	O
cytoplasmic	O
antibody	O
(	O
PR3-ANCA	O
)	O
titer	O
was	O
elevated	O
at	O
183	O
ELISA	O
units	O
(	O
EU	O
)	O
in	O
sera	O
(	O
normal	O
range	O
less	O
than	O
10	O
EU	O
)	O
,	O
myeloperoxidase	O
-	O
ANCA	O
was	O
negative	O
.	O

PR3-ANCA	O
titer	O
was	O
250	O
and	O
1,070	O
EU	O
in	O
pleural	B
effusions	I
on	O
right	O
and	O
left	O
side	O
,	O
respectively	O
.	O

Although	O
cessation	O
of	O
sulphasalazine	O
treatment	O
resulted	O
in	O
improvements	O
in	O
fever	B
,	O
red	B
eyes	I
,	O
chest	B
pain	I
,	O
titer	O
of	O
C	O
-	O
reactive	O
protein	O
and	O
volume	O
of	O
the	O
pleural	B
effusions	I
,	O
we	O
initiated	O
steroid	O
therapy	O
,	O
because	O
PR3-ANCA	O
titer	O
rose	O
to	O
320	O
EU	O
,	O
eosinophil	O
count	O
increased	O
to	O
1,100	O
cells	O
/	O
microl	O
,	O
and	O
the	O
pleural	B
effusion	I
remained	O
.	O

One	O
month	O
after	O
steroid	O
therapy	O
,	O
the	O
pleural	B
effusion	I
disappeared	O
,	O
and	O
PR3-ANCA	O
titer	O
normalized	O
3	O
months	O
later	O
.	O

This	O
case	O
suggests	O
that	O
sulphasalazine	O
can	O
induce	O
PR3-ANCA	O
-	O
positive	O
necrotizing	O
glomerulonephritis	B
.	O

DSMM	O
XI	O
study	O
:	O
dose	O
definition	O
for	O
intravenous	O
cyclophosphamide	O
in	O
combination	O
with	O
bortezomib	O
/	O
dexamethasone	O
for	O
remission	O
induction	O
in	O
patients	O
with	O
newly	O
diagnosed	O
myeloma	B
.	O

A	O
clinical	O
trial	O
was	O
initiated	O
to	O
evaluate	O
the	O
recommended	O
dose	O
of	O
cyclophosphamide	O
in	O
combination	O
with	O
bortezomib	O
and	O
dexamethasone	O
as	O
induction	O
treatment	O
before	O
stem	O
cell	O
transplantation	O
for	O
younger	O
patients	O
with	O
newly	O
diagnosed	O
multiple	B
myeloma	I
(	O
MM	B
)	O
.	O

Thirty	O
patients	O
were	O
treated	O
with	O
three	O
21-day	O
cycles	O
of	O
bortezomib	O
1.3	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
11	O
plus	O
dexamethasone	O
40	O
mg	O
on	O
the	O
day	O
of	O
bortezomib	O
injection	O
and	O
the	O
day	O
after	O
plus	O
cyclophosphamide	O
at	O
900	O
,	O
1,200	O
,	O
or	O
1,500	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
day	O
1	O
.	O

The	O
maximum	O
tolerated	O
dose	O
of	O
cyclophosphamide	O
was	O
defined	O
as	O
900	O
mg	O
/	O
m	O
(	O
2	O
)	O
.	O

At	O
this	O
dose	O
level	O
,	O
92	O
%	O
of	O
patients	O
achieved	O
at	O
least	O
a	O
partial	O
response	O
.	O

The	O
overall	O
response	O
rate	O
[	O
complete	O
response	O
(	O
CR	O
)	O
plus	O
partial	O
response	O
(	O
PR	O
)	O
]	O
across	O
all	O
dose	O
levels	O
was	O
77	O
%	O
,	O
with	O
a	O
10	O
%	O
CR	O
rate	O
.	O

No	O
patient	O
experienced	O
progressive	O
disease	O
.	O

The	O
most	O
frequent	O
adverse	O
events	O
were	O
hematological	B
and	I
gastrointestinal	I
toxicities	I
as	O
well	O
as	O
neuropathy	B
.	O

The	O
results	O
suggest	O
that	O
bortezomib	O
in	O
combination	O
with	O
cyclophosphamide	O
at	O
900	O
mg	O
/	O
m	O
(	O
2	O
)	O
and	O
dexamethasone	O
is	O
an	O
effective	O
induction	O
treatment	O
for	O
patients	O
with	O
newly	O
diagnosed	O
MM	B
that	O
warrants	O
further	O
investigation	O
.	O

Dextran	O
-	O
etodolac	O
conjugates	O
:	O
synthesis	O
,	O
in	O
vitro	O
and	O
in	O
vivo	O
evaluation	O
.	O

Etodolac	O
(	O
E	O
)	O
,	O
is	O
a	O
non	O
-	O
narcotic	O
analgesic	O
and	O
antiinflammatory	O
drug	O
.	O

A	O
biodegradable	O
polymer	O
dextran	O
has	O
been	O
utilized	O
as	O
a	O
carrier	O
for	O
synthesis	O
of	O
etodolac	O
-	O
dextran	O
conjugates	O
(	O
ED	O
)	O
to	O
improve	O
its	O
aqueous	O
solubility	O
and	O
reduce	O
gastrointestinal	O
side	O
effects	O
.	O

An	O
activated	O
moiety	O
,	O
i.e.	O
N	O
-	O
acylimidazole	O
derivative	O
of	O
etodolac	O
(	O
EAI	O
)	O
,	O
was	O
condensed	O
with	O
the	O
polysaccharide	O
polymer	O
dextran	O
of	O
different	O
molecular	O
weights	O
(	O
40000	O
,	O
60000	O
,	O
110000	O
and	O
200000	O
)	O
.	O

IR	O
spectral	O
data	O
confirmed	O
formation	O
of	O
ester	O
bonding	O
in	O
the	O
conjugates	O
.	O

Etodolac	O
contents	O
were	O
evaluated	O
by	O
UV	O
-	O
spectrophotometric	O
analysis	O
.	O

The	O
molecular	O
weights	O
were	O
determined	O
by	O
measuring	O
viscosity	O
using	O
the	O
Mark	O
-	O
Howink	O
-	O
Sakurada	O
equation	O
.	O

In	O
vitro	O
hydrolysis	O
of	O
ED	O
was	O
done	O
in	O
aqueous	O
buffers	O
(	O
pH	O
1.2	O
,	O
7.4	O
,	O
9	O
)	O
and	O
in	O
80	O
%	O
(	O
v	O
/	O
v	O
)	O
human	O
plasma	O
(	O
pH	O
7.4	O
)	O
.	O

At	O
pH	O
9	O
,	O
a	O
higher	O
rate	O
of	O
etodolac	O
release	O
from	O
ED	O
was	O
observed	O
as	O
compared	O
to	O
aqueous	O
buffer	O
of	O
pH	O
7.4	O
and	O
80	O
%	O
human	O
plasma	O
(	O
pH	O
7.4	O
)	O
,	O
following	O
first	O
-	O
order	O
kinetics	O
.	O

In	O
vivo	O
investigations	O
were	O
performed	O
in	O
animals	O
.	O

Acute	O
analgesic	O
and	O
antiinflammatory	O
activities	O
were	O
ascertained	O
using	O
acetic	O
acid	O
induced	O
writhing	B
model	O
(	O
mice	O
)	O
and	O
carrageenan	O
-	O
induced	O
rat	O
paw	O
edema	B
model	O
,	O
respectively	O
.	O

In	O
comparison	O
to	O
control	O
,	O
E	O
and	O
ED1-ED4	O
showed	O
highly	O
significant	O
analgesic	O
and	O
antiinflammatory	O
activities	O
(	O
p	O
<	O
0.001	O
)	O
.	O

Biological	O
evaluation	O
suggested	O
that	O
conjugates	O
(	O
ED1-ED4	O
)	O
retained	O
comparable	O
analgesic	O
and	O
antiinflammatory	O
activities	O
with	O
remarkably	O
reduced	O
ulcerogenicity	O
as	O
compared	O
to	O
their	O
parent	O
drug	O
--	O
etodolac	O
.	O

Dynamic	O
response	O
of	O
blood	O
vessel	O
in	O
acute	B
renal	I
failure	I
.	O

In	O
this	O
study	O
we	O
postulated	O
that	O
during	O
acute	B
renal	I
failure	I
induced	O
by	O
gentamicin	O
the	O
transient	O
or	O
dynamic	O
response	O
of	O
blood	O
vessels	O
could	O
be	O
affected	O
,	O
and	O
that	O
antioxidants	O
can	O
prevent	O
the	O
changes	O
in	O
dynamic	O
responses	O
of	O
blood	O
vessels	O
.	O

The	O
new	O
approach	O
to	O
ex	O
vivo	O
blood	O
vessel	O
experiments	O
in	O
which	O
not	O
only	O
the	O
end	O
points	O
of	O
vessels	O
response	O
within	O
the	O
time	O
interval	O
is	O
considered	O
,	O
but	O
also	O
dynamics	O
of	O
this	O
response	O
,	O
was	O
used	O
in	O
this	O
paper	O
.	O

Our	O
results	O
confirm	O
the	O
alteration	O
in	O
dynamic	O
response	O
of	O
blood	O
vessels	O
during	O
the	O
change	O
of	O
pressure	O
in	O
gentamicin	O
-	O
treated	O
animals	O
.	O

The	O
beneficial	O
effects	O
of	O
vitamin	O
C	O
administration	O
to	O
gentamicin	O
-	O
treated	O
animals	O
are	O
also	O
confirmed	O
through	O
:	O
lower	O
level	O
of	O
blood	O
urea	O
and	O
creatinine	O
and	O
higher	O
level	O
of	O
potassium	O
.	O

The	O
pressure	O
dynamic	O
responses	O
of	O
isolated	O
blood	O
vessels	O
show	O
a	O
faster	O
pressure	O
change	O
in	O
gentamicin	O
-	O
treated	O
animals	O
(	O
8.07	O
+	O
/-	O

1.7	O
s	O
vs.	O
5.64	O
+	O
/-	O

0.18	O
s	O
)	O
.	O

Vitamin	O
C	O
administration	O
induced	O
slowdown	O
of	O
pressure	O
change	O
back	O
to	O
the	O
control	O
values	O
.	O

The	O
pressure	O
dynamic	O
properties	O
,	O
quantitatively	O
defined	O
by	O
comparative	O
pressure	O
dynamic	O
and	O
total	O
pressure	O
dynamic	O
,	O
confirm	O
the	O
alteration	O
in	O
dynamic	O
response	O
of	O
blood	O
vessels	O
during	O
the	O
change	O
of	O
pressure	O
in	O
gentamicin	O
-	O
treated	O
animals	O
and	O
beneficial	O
effects	O
of	O
vitamin	O
C	O
administration	O
.	O

Fear	O
-	O
potentiated	O
startle	B
,	O
but	O
not	O
light	O
-	O
enhanced	O
startle	B
,	O
is	O
enhanced	O
by	O
anxiogenic	O
drugs	O
.	O

RATIONALE	O
AND	O
OBJECTIVES	O
:	O
The	O
light	O
-	O
enhanced	O
startle	B
paradigm	O
(	O
LES	O
)	O
is	O
suggested	O
to	O
model	O
anxiety	B
,	O
because	O
of	O
the	O
non	O
-	O
specific	O
cue	O
and	O
the	O
long	O
-	O
term	O
effect	O
.	O

In	O
contrast	O
,	O
the	O
fear	O
-	O
potentiated	O
startle	B
(	O
FPS	O
)	O
is	O
suggested	O
to	O
model	O
conditioned	O
fear	O
.	O

However	O
,	O
the	O
pharmacological	O
profiles	O
of	O
these	O
two	O
paradigms	O
are	O
very	O
similar	O
.	O

The	O
present	O
study	O
investigated	O
the	O
effects	O
of	O
putative	O
anxiogenic	O
drugs	O
on	O
LES	O
and	O
FPS	O
and	O
aimed	O
at	O
determining	O
the	O
sensitivity	O
of	O
LES	O
for	O
anxiogenic	O
drugs	O
and	O
to	O
potentially	O
showing	O
a	O
pharmacological	O
differentiation	O
between	O
these	O
two	O
paradigms	O
.	O

METHODS	O
:	O
Male	O
Wistar	O
rats	O
received	O
each	O
dose	O
of	O
the	O
alpha	O
(	O
2	O
)	O
-adrenoceptor	O
antagonist	O
yohimbine	O
(	O
0.25	O
-	O
1.0mg	O
/	O
kg	O
)	O
,	O
the	O
5-HT	O
(	O
2C	O
)	O
receptor	O
agonist	O
m	O
-	O
chlorophenylpiperazine	O
(	O
mCPP	O
,	O
0.5	O
-	O
2.0mg	O
/	O
kg	O
)	O
or	O
the	O
GABA	O
(	O
A	O
)	O
inverse	O
receptor	O
agonist	O
pentylenetetrazole	O
(	O
PTZ	O
,	O
3	O
-	O
30mg	O
/	O
kg	O
)	O
and	O
were	O
subsequently	O
tested	O
in	O
either	O
LES	O
or	O
FPS	O
.	O

RESULTS	O
:	O
None	O
of	O
the	O
drugs	O
enhanced	O
LES	O
,	O
whereas	O
mCPP	O
increased	O
percentage	O
FPS	O
and	O
yohimbine	O
increased	O
absolute	O
FPS	O
values	O
.	O

Furthermore	O
,	O
yohimbine	O
increased	O
baseline	O
startle	B
amplitude	O
in	O
the	O
LES	O
,	O
while	O
mCPP	O
suppressed	O
baseline	O
startle	B
in	O
both	O
the	O
LES	O
and	O
FPS	O
and	O
PTZ	O
suppressed	O
baseline	O
startle	B
in	O
the	O
FPS	O
.	O

CONCLUSIONS	O
:	O
In	O
contrast	O
to	O
findings	O
in	O
the	O
FPS	O
paradigm	O
,	O
none	O
of	O
the	O
drugs	O
were	O
able	O
to	O
exacerbate	O
the	O
LES	O
response	O
.	O

Thus	O
,	O
a	O
clear	O
pharmacological	O
differentiation	O
was	O
found	O
between	O
LES	O
and	O
FPS	O
.	O

The	O
ability	O
of	O
insulin	O
treatment	O
to	O
reverse	O
or	O
prevent	O
the	O
changes	O
in	O
urinary	O
bladder	O
function	O
caused	O
by	O
streptozotocin	O
-	O
induced	O
diabetes	B
mellitus	I
.	O

1	O
.	O

The	O
effects	O
of	O
insulin	O
treatment	O
on	O
in	O
vivo	O
and	O
in	O
vitro	O
urinary	O
bladder	O
function	O
in	O
streptozotocin	O
-	O
diabetic	B
rats	O
were	O
investigated	O
.	O

2	O
.	O
Diabetes	B
of	O
2	O
months	O
duration	O
resulted	O
in	O
decreases	O
in	O
body	O
weight	O
and	O
increases	O
in	O
fluid	O
consumption	O
,	O
urine	O
volume	O
,	O
frequency	O
of	O
micturition	O
,	O
and	O
average	O
volume	O
per	O
micturition	O
;	O
effects	O
which	O
were	O
prevented	O
by	O
insulin	O
treatment	O
.	O

3	O
.	O

Insulin	O
treatment	O
also	O
prevented	O
the	O
increases	O
in	O
contractile	O
responses	O
of	O
bladder	O
body	O
strips	O
from	O
diabetic	B
rats	O
to	O
nerve	O
stimulation	O
,	O
ATP	O
,	O
and	O
bethanechol	O
.	O

4	O
.	O
Diabetes	B
of	O
4	O
months	O
duration	O
also	O
resulted	O
in	O
decreases	O
in	O
body	O
weight	O
,	O
and	O
increases	O
in	O
fluid	O
consumption	O
,	O
urine	O
volume	O
,	O
frequency	O
of	O
micturition	O
,	O
and	O
average	O
volume	O
per	O
micturition	O
,	O
effects	O
which	O
were	O
reversed	O
by	O
insulin	O
treatment	O
for	O
the	O
final	O
2	O
months	O
of	O
the	O
study	O
.	O

5	O
.	O

Insulin	O
treatment	O
reversed	O
the	O
increases	O
in	O
contractile	O
responses	O
of	O
bladder	O
body	O
strips	O
from	O
diabetic	B
rats	O
to	O
nerve	O
stimulation	O
,	O
ATP	O
,	O
and	O
bethanechol	O
.	O

6	O
.	O

The	O
data	O
indicate	O
that	O
the	O
effects	O
of	O
streptozotocin	O
-	O
induced	O
diabetes	B
on	O
urinary	O
bladder	O
function	O
are	O
both	O
prevented	O
and	O
reversed	O
by	O
insulin	O
treatment	O
.	O

Severe	O
congestive	B
heart	I
failure	I
patient	O
on	O
amiodarone	O
presenting	O
with	O
myxedemic	B
coma	B
:	O
a	O
case	O
report	O
.	O

This	O
is	O
a	O
case	O
report	O
of	O
myxedema	B
coma	B
secondary	O
to	O
amiodarone	O
-	O
induced	O
hypothyroidism	B
in	O
a	O
patient	O
with	O
severe	O
congestive	B
heart	I
failure	I
(	O
CHF	B
)	O
.	O

To	O
our	O
knowledge	O
and	O
after	O
reviewing	O
the	O
literature	O
there	O
is	O
one	O
case	O
report	O
of	O
myxedema	B
coma	B
during	O
long	O
term	O
amiodarone	O
therapy	O
.	O

Myxedema	B
coma	B
is	O
a	O
life	O
threatening	O
condition	O
that	O
carries	O
a	O
mortality	O
reaching	O
as	O
high	O
as	O
20	O
%	O
with	O
treatment	O
.	O

The	O
condition	O
is	O
treated	O
with	O
intravenous	O
thyroxine	O
(	O
T4	O
)	O
or	O
intravenous	O
tri	O
-	O
iodo	O
-	O
thyronine	O
(	O
T3	O
)	O
.	O

Patients	O
with	O
CHF	B
on	O
amiodarone	O
may	O
suffer	O
serious	O
morbidity	O
and	O
mortality	O
from	O
hypothyroidism	B
,	O
and	O
thus	O
may	O
deserve	O
closer	O
follow	O
up	O
for	O
thyroid	O
stimulating	O
hormone	O
(	O
TSH	O
)	O
levels	O
.	O

This	O
case	O
report	O
carries	O
an	O
important	O
clinical	O
application	O
given	O
the	O
frequent	O
usage	O
of	O
amiodarone	O
among	O
CHF	B
patients	O
.	O

The	O
myriad	O
clinical	O
presentation	O
of	O
myxedema	B
coma	B
and	O
its	O
serious	O
morbidity	O
and	O
mortality	O
stresses	O
the	O
need	O
to	O
suspect	O
this	O
clinical	O
syndrome	O
among	O
CHF	B
patients	O
presenting	O
with	O
hypotension	B
,	O
weakness	B
or	O
other	O
unexplained	O
symptoms	O
.	O

Benzylacyclouridine	O
reverses	O
azidothymidine	O
-	O
induced	O
marrow	B
suppression	I
without	O
impairment	O
of	O
anti	O
-	O
human	O
immunodeficiency	B
virus	O
activity	O
.	O

Increased	O
extracellular	O
concentrations	O
of	O
uridine	O
(	O
Urd	O
)	O
have	O
been	O
reported	O
to	O
reduce	O
,	O
in	O
vitro	O
,	O
azidothymidine	O
(	O
AZT	O
)	O
-induced	O
inhibition	O
of	O
human	O
granulocyte	O
-	O
macrophage	O
progenitor	O
cells	O
without	O
impairment	O
of	O
its	O
antihuman	O
immunodeficiency	B
virus	O
(	O
HIV	O
)	O
activity	O
.	O

Because	O
of	O
the	O
clinical	O
toxicities	B
associated	O
with	O
chronic	O
Urd	O
administration	O
,	O
the	O
ability	O
of	O
benzylacyclouridine	O
(	O
BAU	O
)	O
to	O
effect	O
,	O
in	O
vivo	O
,	O
AZT	O
-	O
induced	O
anemia	B
and	O
leukopenia	B
was	O
assessed	O
.	O

This	O
agent	O
inhibits	O
Urd	O
catabolism	O
and	O
,	O
in	O
vivo	O
,	O
increases	O
the	O
plasma	O
concentration	O
of	O
Urd	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
,	O
without	O
Urd	O
-	O
related	O
toxicity	B
.	O

In	O
mice	O
rendered	O
anemic	B
and	O
leukopenic	B
by	O
the	O
administration	O
of	O
AZT	O
for	O
28	O
days	O
in	O
drinking	O
water	O
(	O
1.5	O
mg	O
/	O
mL	O
)	O
,	O
the	O
continued	O
administration	O
of	O
AZT	O
plus	O
daily	O
BAU	O
(	O
300	O
mg	O
/	O
kg	O
,	O
orally	O
)	O
partially	O
reversed	O
AZT	O
-	O
induced	O
anemia	B
and	O
leukopenia	B
(	O
P	O
less	O
than	O
.05	O
)	O
,	O
increased	O
peripheral	O
reticulocytes	O
(	O
to	O
4.9	O
%	O
,	O
P	O
less	O
than	O
.01	O
)	O
,	O
increased	O
cellularity	O
in	O
the	O
marrow	O
,	O
and	O
improved	O
megaloblastosis	B
.	O

When	O
coadministered	O
with	O
AZT	O
from	O
the	O
onset	O
of	O
drug	O
administration	O
,	O
BAU	O
reduced	O
AZT	O
-	O
induced	O
marrow	B
toxicity	I
.	O

In	O
vitro	O
,	O
at	O
a	O
concentration	O
of	O
100	O
mumol	O
/	O
L	O
,	O
BAU	O
possesses	O
minimal	O
anti	O
-	O
HIV	O
activity	O
and	O
has	O
no	O
effect	O
on	O
the	O
ability	O
of	O
AZT	O
to	O
reverse	O
the	O
HIV	O
-	O
induced	O
cytopathic	O
effect	O
in	O
MT4	O
cells	O
.	O

The	O
clinical	O
and	O
biochemical	O
implications	O
of	O
these	O
findings	O
are	O
discussed	O
.	O

Late	O
-	O
onset	O
scleroderma	B
renal	I
crisis	I
induced	O
by	O
tacrolimus	O
and	O
prednisolone	O
:	O
a	O
case	O
report	O
.	O

Scleroderma	B
renal	I
crisis	I
(	O
SRC	B
)	O
is	O
a	O
rare	O
complication	O
of	O
systemic	B
sclerosis	I
(	O
SSc	B
)	O
but	O
can	O
be	O
severe	O
enough	O
to	O
require	O
temporary	O
or	O
permanent	O
renal	O
replacement	O
therapy	O
.	O

Moderate	O
to	O
high	O
dose	O
corticosteroid	O
use	O
is	O
recognized	O
as	O
a	O
major	O
risk	O
factor	O
for	O
SRC	B
.	O

Furthermore	O
,	O
there	O
have	O
been	O
reports	O
of	O
thrombotic	B
microangiopathy	I
precipitated	O
by	O
cyclosporine	O
in	O
patients	O
with	O
SSc	B
.	O

In	O
this	O
article	O
,	O
we	O
report	O
a	O
patient	O
with	O
SRC	B
induced	O
by	O
tacrolimus	O
and	O
corticosteroids	O
.	O

The	O
aim	O
of	O
this	O
work	O
is	O
to	O
call	O
attention	O
to	O
the	O
risk	O
of	O
tacrolimus	O
use	O
in	O
patients	O
with	O
SSc	B
.	O

The	O
risk	O
and	O
associated	O
factors	O
of	O
methamphetamine	O
psychosis	B
in	O
methamphetamine	O
-	O
dependent	O
patients	O
in	O
Malaysia	O
.	O

OBJECTIVE	O
:	O
The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
the	O
risk	O
of	O
lifetime	O
and	O
current	O
methamphetamine	O
-	O
induced	O
psychosis	B
in	O
patients	O
with	O
methamphetamine	O
dependence	O
.	O

The	O
association	O
between	O
psychiatric	O
co	O
-	O
morbidity	O
and	O
methamphetamine	O
-	O
induced	O
psychosis	B
was	O
also	O
studied	O
.	O

METHODS	O
:	O
This	O
was	O
a	O
cross	O
-	O
sectional	O
study	O
conducted	O
concurrently	O
at	O
a	O
teaching	O
hospital	O
and	O
a	O
drug	O
rehabilitation	O
center	O
in	O
Malaysia	O
.	O

Patients	O
with	O
the	O
diagnosis	O
of	O
methamphetamine	O
based	O
on	O
DSM	O
-	O
IV	O
were	O
interviewed	O
using	O
the	O
Mini	O
International	O
Neuropsychiatric	O
Interview	O
(	O
M.I.N.I.	O
)	O
for	O
methamphetamine	O
-	O
induced	O
psychosis	B
and	O
other	O
Axis	O
I	O
psychiatric	B
disorders	I
.	O

The	O
information	O
on	O
sociodemographic	O
background	O
and	O
drug	O
use	O
history	O
was	O
obtained	O
from	O
interview	O
or	O
medical	O
records	O
.	O

RESULTS	O
:	O
Of	O
292	O
subjects	O
,	O
47.9	O
%	O
of	O
the	O
subjects	O
had	O
a	O
past	O
history	O
of	O
psychotic	B
symptoms	I
and	O
13.0	O
%	O
of	O
the	O
patients	O
were	O
having	O
current	O
psychotic	B
symptoms	I
.	O

Co	O
-	O
morbid	O
major	O
depressive	B
disorder	I
(	O
OR=7.18	O
,	O
95	O
CI=2.612	O
-	O
19.708	O
)	O
,	O
bipolar	B
disorder	I
(	O
OR=13.807	O
,	O
95	O
CI=5.194	O
-	O
36.706	O
)	O
,	O
antisocial	B
personality	I
disorder	I
(	O
OR=12.619	O
,	O
95	O
CI=6.702	O
-	O
23.759	O
)	O
and	O
heavy	O
methamphetamine	O
uses	O
were	O
significantly	O
associated	O
with	O
lifetime	O
methamphetamine	O
-	O
induced	O
psychosis	B
after	O
adjusted	O
for	O
other	O
factors	O
.	O

Major	B
depressive	I
disorder	I
(	O
OR=2.870	O
,	O
CI=1.154	O
-	O
7.142	O
)	O
and	O
antisocial	B
personality	I
disorder	I
(	O
OR=3.299	O
,	O
95	O
CI=1.375	O
-	O
7.914	O
)	O
were	O
the	O
only	O
factors	O
associated	O
with	O
current	O
psychosis	B
.	O

CONCLUSION	O
:	O
There	O
was	O
a	O
high	O
risk	O
of	O
psychosis	B
in	O
patients	O
with	O
methamphetamine	O
dependence	O
.	O

It	O
was	O
associated	O
with	O
co	O
-	O
morbid	O
affective	B
disorder	I
,	O
antisocial	B
personality	I
,	O
and	O
heavy	O
methamphetamine	O
use	O
.	O

It	O
is	O
recommended	O
that	O
all	O
cases	O
of	O
methamphetamine	O
dependence	O
should	O
be	O
screened	O
for	O
psychotic	B
symptoms	I
.	O

Seizure	B
activity	O
with	O
imipenem	O
therapy	O
:	O
incidence	O
and	O
risk	O
factors	O
.	O

Two	O
elderly	O
patients	O
with	O
a	O
history	O
of	O
either	O
cerebral	B
vascular	I
accident	I
(	O
CVA	B
)	O
or	O
head	B
trauma	I
and	O
no	O
evidence	O
of	O
renal	B
disease	I
developed	O
seizures	B
while	O
receiving	O
maximum	O
doses	O
of	O
imipenem	O
/	O
cilastatin	O
.	O

Neither	O
patient	O
had	O
reported	O
previous	O
seizures	B
or	O
seizure	B
-	O
like	O
activity	O
nor	O
was	O
receiving	O
anticonvulsant	O
agents	O
.	O

All	O
seizures	B
were	O
controlled	O
with	O
therapeutic	O
doses	O
of	O
phenytoin	O
.	O

Both	O
patients	O
had	O
received	O
maximum	O
doses	O
of	O
other	O
beta	O
-	O
lactam	O
antibiotics	O
without	O
evidence	O
of	O
seizure	B
activity	O
.	O

Cerebellar	O
sensory	O
processing	O
alterations	O
impact	O
motor	O
cortical	O
plasticity	O
in	O
Parkinson	B
's	I
disease	I
:	O
clues	O
from	O
dyskinetic	B
patients	O
.	O

The	O
plasticity	O
of	O
primary	O
motor	O
cortex	O
(	O
M1	O
)	O
in	O
patients	O
with	O
Parkinson	B
's	I
disease	I
(	O
PD	B
)	O
and	O
levodopa	O
-	O
induced	O
dyskinesias	B
(	O
LIDs	B
)	O
is	O
severely	O
impaired	O
.	O

We	O
recently	O
reported	O
in	O
young	O
healthy	O
subjects	O
that	O
inhibitory	O
cerebellar	O
stimulation	O
enhanced	O
the	O
sensorimotor	O
plasticity	O
of	O
M1	O
that	O
was	O
induced	O
by	O
paired	O
associative	O
stimulation	O
(	O
PAS	O
)	O
.	O

This	O
study	O
demonstrates	O
that	O
the	O
deficient	O
sensorimotor	O
M1	O
plasticity	O
in	O
16	O
patients	O
with	O
LIDs	B
could	O
be	O
reinstated	O
by	O
a	O
single	O
session	O
of	O
real	O
inhibitory	O
cerebellar	O
stimulation	O
but	O
not	O
sham	O
stimulation	O
.	O

This	O
was	O
evident	O
only	O
when	O
a	O
sensory	O
component	O
was	O
involved	O
in	O
the	O
induction	O
of	O
plasticity	O
,	O
indicating	O
that	O
cerebellar	O
sensory	O
processing	O
function	O
is	O
involved	O
in	O
the	O
resurgence	O
of	O
M1	O
plasticity	O
.	O

The	O
benefit	O
of	O
inhibitory	O
cerebellar	O
stimulation	O
on	O
LIDs	B
is	O
known	O
.	O

To	O
explore	O
whether	O
this	O
benefit	O
is	O
linked	O
to	O
the	O
restoration	O
of	O
sensorimotor	O
plasticity	O
of	O
M1	O
,	O
we	O
conducted	O
an	O
additional	O
study	O
looking	O
at	O
changes	O
in	O
LIDs	B
and	O
PAS	O
-	O
induced	O
plasticity	O
after	O
10	O
sessions	O
of	O
either	O
bilateral	O
,	O
real	O
inhibitory	O
cerebellar	O
stimulation	O
or	O
sham	O
stimulation	O
.	O

Only	O
real	O
and	O
not	O
sham	O
stimulation	O
had	O
an	O
antidyskinetic	O
effect	O
and	O
it	O
was	O
paralleled	O
by	O
a	O
resurgence	O
in	O
the	O
sensorimotor	O
plasticity	O
of	O
M1	O
.	O

These	O
results	O
suggest	O
that	O
alterations	O
in	O
cerebellar	O
sensory	O
processing	O
function	O
,	O
occurring	O
secondary	O
to	O
abnormal	O
basal	O
ganglia	O
signals	O
reaching	O
it	O
,	O
may	O
be	O
an	O
important	O
element	O
contributing	O
to	O
the	O
maladaptive	O
sensorimotor	O
plasticity	O
of	O
M1	O
and	O
the	O
emergence	O
of	O
abnormal	B
involuntary	I
movements	I
.	O

The	O
function	O
of	O
P2X3	O
receptor	O
and	O
NK1	O
receptor	O
antagonists	O
on	O
cyclophosphamide	O
-	O
induced	O
cystitis	B
in	O
rats	O
.	O

PURPOSE	O
:	O
The	O
purpose	O
of	O
the	O
study	O
is	O
to	O
explore	O
the	O
function	O
of	O
P2X3	O
and	O
NK1	O
receptors	O
antagonists	O
on	O
cyclophosphamide	O
(	O
CYP	O
)	O
-induced	O
cystitis	B
in	O
rats	O
.	O

METHODS	O
:	O
Sixty	O
female	O
Sprague	O
-	O
Dawley	O
(	O
SD	O
)	O
rats	O
were	O
randomly	O
divided	O
into	O
three	O
groups	O
.	O

The	O
rats	O
in	O
the	O
control	O
group	O
were	O
intraperitoneally	O
(	O
i.p	O
.	O
)	O
injected	O
with	O
0.9	O
%	O
saline	O
(	O
4	O
ml	O
/	O
kg	O
)	O
;	O
the	O
rats	O
in	O
the	O
model	O
group	O
were	O
i.p	O
.	O

injected	O
with	O
CYP	O
(	O
150	O
mg	O
/	O
kg	O
)	O
;	O
and	O
the	O
rats	O
in	O
the	O
intervention	O
group	O
were	O
i.p	O
.	O
injected	O
with	O
CYP	O
with	O
subsequently	O
perfusion	O
of	O
bladder	O
with	O
P2X3	O
and	O
NK1	O
receptors	O
'	O
antagonists	O
,	O
Suramin	O
and	O
GR	O
82334	O
.	O

Spontaneous	O
pain	B
behaviors	O
following	O
the	O
administration	O
of	O
CYP	O
were	O
observed	O
.	O

Urodynamic	O
parameters	O
,	O
bladder	O
pressure	O
-	O
volume	O
curve	O
,	O
maximum	O
voiding	O
pressure	O
(	O
MVP	O
)	O
,	O
and	O
maximum	O
cystometric	O
capacity	O
(	O
MCC	O
)	O
,	O
were	O
recorded	O
.	O

Pathological	O
changes	O
in	O
bladder	O
tissue	O
were	O
observed	O
.	O

Immunofluorescence	O
was	O
used	O
to	O
detect	O
the	O
expression	O
of	O
P2X3	O
and	O
NK1	O
receptors	O
in	O
bladder	O
.	O

RESULTS	O
:	O
Cyclophosphamide	O
treatment	O
increased	O
the	O
spontaneous	O
pain	B
behaviors	O
scores	O
.	O

The	O
incidence	O
of	O
bladder	O
instability	O
during	O
urine	O
storage	O
period	O
of	O
model	O
group	O
was	O
significantly	O
higher	O
than	O
intervention	O
group	O
(	O
X	O
(	O
2	O
)	O
=	O
7.619	O
,	O
P	O
=	O
0.007	O
)	O
and	O
control	O
group	O
(	O
X	O
(	O
2	O
)	O
=	O
13.755	O
,	O
P	O
=	O
0.000	O
)	O
.	O

MCC	O
in	O
the	O
model	O
group	O
was	O
lower	O
than	O
the	O
control	O
and	O
intervention	O
groups	O
(	O
P	O
<	O
0.01	O
)	O
.	O

Histological	O
changes	O
evident	O
in	O
model	O
and	O
intervention	O
groups	O
rats	O
'	O
bladder	O
included	O
edema	B
,	O
vasodilation	O
,	O
and	O
infiltration	O
of	O
inflammatory	O
cells	O
.	O

In	O
model	O
group	O
,	O
the	O
expression	O
of	O
P2X3	O
receptor	O
increased	O
in	O
urothelium	O
and	O
suburothelium	O
,	O
and	O
NK1	O
receptor	O
increased	O
in	O
suburothelium	O
,	O
while	O
the	O
expression	O
of	O
them	O
in	O
intervention	O
group	O
was	O
lower	O
.	O

CONCLUSIONS	O
:	O
In	O
CYP	O
-	O
induced	O
cystitis	B
,	O
the	O
expression	O
of	O
P2X3	O
and	O
NK1	O
receptors	O
increased	O
in	O
urothelium	O
and/or	O
suburothelium	O
.	O

Perfusion	O
of	O
bladder	O
with	O
P2X3	O
and	O
NK1	O
receptors	O
antagonists	O
ameliorated	O
the	O
bladder	O
function	O
.	O

Acute	O
hepatitis	B
associated	O
with	O
clopidogrel	O
:	O
a	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
.	O

Drug	O
-	O
induced	O
hepatotoxicity	B
is	O
a	O
common	O
cause	O
of	O
acute	O
hepatitis	B
,	O
and	O
the	O
recognition	O
of	O
the	O
responsible	O
drug	O
may	O
be	O
difficult	O
.	O

We	O
describe	O
a	O
case	O
of	O
clopidogrel	O
-	O
related	O
acute	O
hepatitis	B
.	O

The	O
diagnosis	O
is	O
strongly	O
suggested	O
by	O
an	O
accurate	O
medical	O
history	O
and	O
liver	O
biopsy	O
.	O

Reports	O
about	O
cases	O
of	O
hepatotoxicity	B
due	O
to	O
clopidogrel	O
are	O
increasing	O
in	O
the	O
last	O
few	O
years	O
,	O
after	O
the	O
increased	O
use	O
of	O
this	O
drug	O
.	O

In	O
conclusion	O
,	O
we	O
believe	O
that	O
physicians	O
should	O
carefully	O
consider	O
the	O
risk	O
of	O
drug	O
-	O
induced	O
hepatic	B
injury	I
when	O
clopidogrel	O
is	O
prescribed	O
.	O

Bortezomib	O
and	O
dexamethasone	O
as	O
salvage	O
therapy	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	B
myeloma	I
:	O
analysis	O
of	O
long	O
-	O
term	O
clinical	O
outcomes	O
.	O

Bortezomib	O
(	O
bort	O
)	O
-dexamethasone	O
(	O
dex	O
)	O
is	O
an	O
effective	O
therapy	O
for	O
relapsed	O
/	O
refractory	O
(	O
R	O
/	O
R	O
)	O
multiple	B
myeloma	I
(	O
MM	B
)	O
.	O

This	O
retrospective	O
study	O
investigated	O
the	O
combination	O
of	O
bort	O
(	O
1.3	O
mg	O
/	O
m	O
(	O
2	O
)	O
on	O
days	O
1	O
,	O
4	O
,	O
8	O
,	O
and	O
11	O
every	O
3	O
weeks	O
)	O
and	O
dex	O
(	O
20	O
mg	O
on	O
the	O
day	O
of	O
and	O
the	O
day	O
after	O
bort	O
)	O
as	O
salvage	O
treatment	O
in	O
85	O
patients	O
with	O
R	O
/	O
R	O
MM	B
after	O
prior	O
autologous	O
stem	O
cell	O
transplantation	O
or	O
conventional	O
chemotherapy	O
.	O

The	O
median	O
number	O
of	O
prior	O
lines	O
of	O
therapy	O
was	O
2	O
.	O

Eighty	O
-	O
seven	O
percent	O
of	O
the	O
patients	O
had	O
received	O
immunomodulatory	O
drugs	O
included	O
in	O
some	O
line	O
of	O
therapy	O
before	O
bort	O
-	O
dex	O
.	O

The	O
median	O
number	O
of	O
bort	O
-	O
dex	O
cycles	O
was	O
6	O
,	O
up	O
to	O
a	O
maximum	O
of	O
12	O
cycles	O
.	O

On	O
an	O
intention	O
-	O
to	O
-	O
treat	O
basis	O
,	O
55	O
%	O
of	O
the	O
patients	O
achieved	O
at	O
least	O
partial	O
response	O
,	O
including	O
19	O
%	O
CR	O
and	O
35	O
%	O
achieved	O
at	O
least	O
very	O
good	O
partial	O
response	O
.	O

Median	O
durations	O
of	O
response	O
,	O
time	O
to	O
next	O
therapy	O
and	O
treatment	O
-	O
free	O
interval	O
were	O
8	O
,	O
11.2	O
,	O
and	O
5.1	O
months	O
,	O
respectively	O
.	O

The	O
most	O
relevant	O
adverse	O
event	O
was	O
peripheral	B
neuropathy	I
,	O
which	O
occurred	O
in	O
78	O
%	O
of	O
the	O
patients	O
(	O
grade	O
II	O
,	O
38	O
%	O
;	O
grade	O
III	O
,	O
21	O
%	O
)	O
and	O
led	O
to	O
treatment	O
discontinuation	O
in	O
6	O
%	O
.	O

With	O
a	O
median	O
follow	O
up	O
of	O
22	O
months	O
,	O
median	O
time	O
to	O
progression	O
,	O
progression	O
-	O
free	O
survival	O
(	O
PFS	O
)	O
and	O
overall	O
survival	O
(	O
OS	O
)	O
were	O
8.9	O
,	O
8.7	O
,	O
and	O
22	O
months	O
,	O
respectively	O
.	O

Prolonged	O
PFS	O
and	O
OS	O
were	O
observed	O
in	O
patients	O
achieving	O
CR	O
and	O
receiving	O
bort	O
-	O
dex	O
a	O
single	O
line	O
of	O
prior	O
therapy	O
.	O

Bort	O
-	O
dex	O
was	O
an	O
effective	O
salvage	O
treatment	O
for	O
MM	B
patients	O
,	O
particularly	O
for	O
those	O
in	O
first	O
relapse	O
.	O

Pubertal	O
exposure	O
to	O
Bisphenol	O
A	O
increases	O
anxiety	B
-	O
like	O
behavior	O
and	O
decreases	O
acetylcholinesterase	O
activity	O
of	O
hippocampus	O
in	O
adult	O
male	O
mice	O
.	O

The	O
negative	O
effects	O
of	O
Bisphenol	O
A	O
(	O
BPA	O
)	O
on	O
neurodevelopment	O
and	O
behaviors	O
have	O
been	O
well	O
established	O
.	O

Acetylcholinesterase	O
(	O
AChE	O
)	O
is	O
a	O
regulatory	O
enzyme	O
which	O
is	O
involved	O
in	O
anxiety	B
-	O
like	O
behavior	O
.	O

This	O
study	O
investigated	O
behavioral	O
phenotypes	O
and	O
AChE	O
activity	O
in	O
male	O
mice	O
following	O
BPA	O
exposure	O
during	O
puberty	O
.	O

On	O
postnatal	O
day	O
(	O
PND	O
)	O
35	O
,	O
male	O
mice	O
were	O
exposed	O
to	O
50	O
mg	O
BPA	O
/	O
kg	O
diet	O
per	O
day	O
for	O
a	O
period	O
of	O
35	O
days	O
.	O

On	O
PND71	O
,	O
a	O
behavioral	O
assay	O
was	O
performed	O
using	O
the	O
elevated	O
plus	O
maze	O
(	O
EPM	O
)	O
and	O
the	O
light	O
/	O
dark	O
test	O
.	O

In	O
addition	O
,	O
AChE	O
activity	O
was	O
measured	O
in	O
the	O
prefrontal	O
cortex	O
,	O
hypothalamus	O
,	O
cerebellum	O
and	O
hippocampus	O
.	O

Results	O
from	O
our	O
behavioral	O
phenotyping	O
indicated	O
that	O
anxiety	B
-	O
like	O
behavior	O
was	O
increased	O
in	O
mice	O
exposed	O
to	O
BPA	O
.	O

AChE	O
activity	O
was	O
significantly	O
decreased	O
in	O
the	O
hippocampus	O
of	O
mice	O
with	O
BPA	O
compared	O
to	O
control	O
mice	O
,	O
whereas	O
no	O
difference	O
was	O
found	O
in	O
the	O
prefrontal	O
cortex	O
,	O
hypothalamus	O
and	O
cerebellum	O
.	O

Our	O
findings	O
showed	O
that	O
pubertal	O
BPA	O
exposure	O
increased	O
anxiety	B
-	O
like	O
behavior	O
,	O
which	O
may	O
be	O
associated	O
with	O
decreased	O
AChE	O
activity	O
of	O
the	O
hippocampus	O
in	O
adult	O
male	O
mice	O
.	O

Further	O
studies	O
are	O
necessary	O
to	O
investigate	O
the	O
cholinergic	O
signaling	O
of	O
the	O
hippocampus	O
in	O
PBE	O
induced	O
anxiety	B
-	O
like	O
behaviors	O
.	O

Biochemical	O
effects	O
of	O
Solidago	O
virgaurea	O
extract	O
on	O
experimental	O
cardiotoxicity	B
.	O

Cardiovascular	B
diseases	I
(	O
CVDs	B
)	O
are	O
the	O
major	O
health	O
problem	O
of	O
advanced	O
as	O
well	O
as	O
developing	O
countries	O
of	O
the	O
world	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
investigate	O
the	O
protective	O
effect	O
of	O
the	O
Solidago	O
virgaurea	O
extract	O
on	O
isoproterenol	O
-	O
induced	O
cardiotoxicity	B
in	O
rats	O
.	O

The	O
subcutaneous	O
injection	O
of	O
isoproterenol	O
(	O
30	O
mg	O
/	O
kg	O
)	O
into	O
rats	O
twice	O
at	O
an	O
interval	O
of	O
24	O
h	O
,	O
for	O
two	O
consecutive	O
days	O
,	O
led	O
to	O
a	O
significant	O
increase	O
in	O
serum	O
lactate	O
dehydrogenase	O
,	O
creatine	O
phosphokinase	O
,	O
alanine	O
transaminase	O
,	O
aspartate	O
transaminase	O
,	O
and	O
angiotensin	O
-	O
converting	O
enzyme	O
activities	O
,	O
total	O
cholesterol	O
,	O
triglycerides	O
,	O
free	O
serum	O
fatty	O
acid	O
,	O
cardiac	O
tissue	O
malondialdehyde	O
(	O
MDA	O
)	O
,	O
and	O
nitric	O
oxide	O
levels	O
and	O
a	O
significant	O
decrease	O
in	O
levels	O
of	O
glutathione	O
and	O
superoxide	O
dismutase	O
in	O
cardiac	O
tissue	O
as	O
compared	O
to	O
the	O
normal	O
control	O
group	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Pretreatment	O
with	O
S.	O
virgaurea	O
extract	O
for	O
5	O
weeks	O
at	O
a	O
dose	O
of	O
250	O
mg	O
/	O
kg	O
followed	O
by	O
isoproterenol	O
injection	O
significantly	O
prevented	O
the	O
observed	O
alterations	O
.	O

Captopril	O
(	O
50	O
mg	O
/	O
kg	O
/	O
day	O
,	O
given	O
orally	O
)	O
,	O
an	O
inhibitor	O
of	O
angiotensin	O
-	O
converting	O
enzyme	O
used	O
as	O
a	O
standard	O
cardioprotective	O
drug	O
,	O
was	O
used	O
as	O
a	O
positive	O
control	O
in	O
this	O
study	O
.	O

The	O
data	O
of	O
the	O
present	O
study	O
suggest	O
that	O
S.	O
virgaurea	O
extract	O
exerts	O
its	O
protective	O
effect	O
by	O
decreasing	O
MDA	O
level	O
and	O
increasing	O
the	O
antioxidant	O
status	O
in	O
isoproterenol	O
-	O
treated	O
rats	O
.	O

The	O
study	O
emphasizes	O
the	O
beneficial	O
action	O
of	O
S.	O
virgaurea	O
extract	O
as	O
a	O
cardioprotective	O
agent	O
.	O

""""	O
Real	O
-	O
world	O
""""	O
data	O
on	O
the	O
efficacy	O
and	O
safety	O
of	O
lenalidomide	O
and	O
dexamethasone	O
in	O
patients	O
with	O
relapsed	O
/	O
refractory	O
multiple	B
myeloma	I
who	O
were	O
treated	O
according	O
to	O
the	O
standard	O
clinical	O
practice	O
:	O
a	O
study	O
of	O
the	O
Greek	O
Myeloma	B
Study	O
Group	O
.	O

Lenalidomide	O
and	O
dexamethasone	O
(	O
RD	O
)	O
is	O
a	O
standard	O
of	O
care	O
for	O
relapsed	O
/	O
refractory	O
multiple	B
myeloma	I
(	O
RRMM	B
)	O
,	O
but	O
there	O
is	O
limited	O
published	O
data	O
on	O
its	O
efficacy	O
and	O
safety	O
in	O
the	O
""""	O
real	O
world	O
""""	O
(	O
RW	O
)	O
,	O
according	O
to	O
the	O
International	O
Society	O
of	O
Pharmacoeconomics	O
and	O
Outcomes	O
Research	O
definition	O
.	O

We	O
studied	O
212	O
RRMM	B
patients	O
who	O
received	O
RD	O
in	O
RW	O
.	O

Objective	O
response	O
(	O
>	O
PR	O
(	O
partial	O
response	O
)	O
)	O
rate	O
was	O
77.4	O
%	O
(	O
complete	O
response	O
(	O
CR	O
)	O
,	O
20.2	O
%	O
)	O
.	O

Median	O
time	O
to	O
first	O
and	O
best	O
response	O
was	O
2	O
and	O
5	O
months	O
,	O
respectively	O
.	O

Median	O
time	O
to	O
CR	O
when	O
RD	O
was	O
given	O
as	O
2nd	O
or	O
>	O
2	O
(	O
nd	O
)	O
-line	O
treatment	O
at	O
4	O
and	O
11	O
months	O
,	O
respectively	O
.	O

Quality	O
of	O
response	O
was	O
independent	O
of	O
previous	O
lines	O
of	O
therapies	O
or	O
previous	O
exposure	O
to	O
thalidomide	O
or	O
bortezomib	O
.	O

Median	O
duration	O
of	O
response	O
was	O
34.4	O
months	O
,	O
and	O
it	O
was	O
higher	O
in	O
patients	O
who	O
received	O
RD	O
until	O
progression	O
(	O
not	O
reached	O
versus	O
19	O
months	O
,	O
p	O
<	O
0.001	O
)	O
.	O

Improvement	O
of	O
humoral	O
immunity	O
occurred	O
in	O
60	O
%	O
of	O
responders	O
(	O
p	O
<	O
0.001	O
)	O
and	O
in	O
the	O
majority	O
of	O
patients	O
who	O
achieved	O
stable	O
disease	O
.	O

Adverse	O
events	O
were	O
reported	O
in	O
68.9	O
%	O
of	O
patients	O
(	O
myelosuppression	B
in	O
49.4	O
%	O
)	O
and	O
12.7	O
%	O
of	O
patients	O
needed	O
hospitalization	O
.	O

Peripheral	B
neuropathy	I
was	O
observed	O
only	O
in	O
2.5	O
%	O
of	O
patients	O
and	O
deep	B
vein	I
thrombosis	I
in	O
5.7	O
%	O
.	O

Dose	O
reductions	O
were	O
needed	O
in	O
31	O
%	O
of	O
patients	O
and	O
permanent	O
discontinuation	O
in	O
38.9	O
%	O
.	O

Median	O
time	O
to	O
treatment	O
discontinuation	O
was	O
16.8	O
months	O
.	O

Performance	O
status	O
(	O
PS	O
)	O
and	O
initial	O
lenalidomide	O
dose	O
predicted	O
for	O
treatment	O
discontinuation	O
.	O

Extra	O
-	O
medullary	O
relapses	O
occurred	O
in	O
3.8	O
%	O
of	O
patients	O
.	O

Our	O
study	O
confirms	O
that	O
RD	O
is	O
effective	O
and	O
safe	O
in	O
RRMM	B
in	O
the	O
RW	O
;	O
it	O
produces	O
durable	O
responses	O
especially	O
in	O
patients	O
who	O
continue	O
on	O
treatment	O
till	O
progression	O
and	O
improves	O
humoral	O
immunity	O
even	O
in	O
patients	O
with	O
stable	O
disease	O
.	O

The	O
cytogenetic	O
action	O
of	O
ifosfamide	O
,	O
mesna	O
,	O
and	O
their	O
combination	O
on	O
peripheral	O
rabbit	O
lymphocytes	O
:	O
an	O
in	O
vivo	O
/	O
in	O
vitro	O
cytogenetic	O
study	O
.	O

Ifosfamide	O
(	O
IFO	O
)	O
is	O
an	O
alkylating	O
nitrogen	O
mustard	O
,	O
administrated	O
as	O
an	O
antineoplasmic	O
agent	O
.	O

It	O
is	O
characterized	O
by	O
its	O
intense	O
urotoxic	O
action	O
,	O
leading	O
to	O
hemorrhagic	B
cystitis	B
.	O

This	O
side	O
effect	O
of	O
IFO	O
raises	O
the	O
requirement	O
for	O
the	O
co	O
-	O
administration	O
with	O
sodium	O
2-sulfanylethanesulfonate	O
(	O
Mesna	O
)	O
aiming	O
to	O
avoid	O
or	O
minimize	O
this	O
effect	O
.	O

IFO	O
and	O
Mesna	O
were	O
administrated	O
separately	O
on	O
rabbit	O
's	O
lymphocytes	O
in	O
vivo	O
,	O
which	O
were	O
later	O
developed	O
in	O
vitro	O
.	O

Cytogenetic	O
markers	O
for	O
sister	O
chromatid	O
exchanges	O
(	O
SCEs	O
)	O
,	O
proliferation	O
rate	O
index	O
(	O
PRI	O
)	O
and	O
Mitotic	O
Index	O
were	O
recorded	O
.	O

Mesna	O
's	O
action	O
,	O
in	O
conjunction	O
with	O
IFO	O
reduces	O
the	O
frequency	O
of	O
SCEs	O
,	O
in	O
comparison	O
with	O
the	O
SCEs	O
recordings	O
obtained	O
when	O
IFO	O
is	O
administered	O
alone	O
.	O

In	O
addition	O
to	O
this	O
,	O
when	O
high	O
concentrations	O
of	O
Mesna	O
were	O
administered	O
alone	O
significant	O
reductions	O
of	O
the	O
PRI	O
were	O
noted	O
,	O
than	O
with	O
IFO	O
acting	O
at	O
the	O
same	O
concentration	O
on	O
the	O
lymphocytes	O
.	O

Mesna	O
significantly	O
reduces	O
IFO	O
's	O
genotoxicity	B
,	O
while	O
when	O
administered	O
in	O
high	O
concentrations	O
it	O
acts	O
in	O
an	O
inhibitory	O
fashion	O
on	O
the	O
cytostatic	O
action	O
of	O
the	O
drug	O
.	O

Risk	O
factors	O
and	O
predictors	O
of	O
levodopa	O
-	O
induced	O
dyskinesia	B
among	O
multiethnic	O
Malaysians	O
with	O
Parkinson	B
's	I
disease	I
.	O

Chronic	O
pulsatile	O
levodopa	O
therapy	O
for	O
Parkinson	B
's	I
disease	I
(	O
PD	B
)	O
leads	O
to	O
the	O
development	O
of	O
motor	O
fluctuations	O
and	O
dyskinesia	B
.	O

We	O
studied	O
the	O
prevalence	O
and	O
predictors	O
of	O
levodopa	O
-	O
induced	O
dyskinesia	B
among	O
multiethnic	O
Malaysian	O
patients	O
with	O
PD	B
.	O

METHODS	O
:	O
This	O
is	O
a	O
cross	O
-	O
sectional	O
study	O
involving	O
95	O
patients	O
with	O
PD	B
on	O
uninterrupted	O
levodopa	O
therapy	O
for	O
at	O
least	O
6	O
months	O
.	O

The	O
instrument	O
used	O
was	O
the	O
UPDRS	O
questionnaires	O
.	O

The	O
predictors	O
of	O
dyskinesia	B
were	O
determined	O
using	O
multivariate	O
logistic	O
regression	O
analysis	O
.	O

RESULTS	O
:	O
The	O
mean	O
age	O
was	O
65.6	O
+	O
8.5	O
years	O
.	O

The	O
mean	O
onset	O
age	O
was	O
58.5	O
+	O
9.8	O
years	O
.	O

The	O
median	O
disease	O
duration	O
was	O
6	O
(	O
7	O
)	O
years	O
.	O

Dyskinesia	B
was	O
present	O
in	O
44	O
%	O
(	O
n	O
=	O
42	O
)	O
with	O
median	O
levodopa	O
therapy	O
of	O
3	O
years	O
.	O

There	O
were	O
64.3	O
%	O
Chinese	O
,	O
31	O
%	O
Malays	O
,	O
and	O
3.7	O
%	O
Indians	O
and	O
other	O
ethnic	O
groups	O
.	O

Eighty	O
-	O
one	O
percent	O
of	O
patients	O
with	O
dyskinesia	B
had	O
clinical	O
fluctuations	O
.	O

Patients	O
with	O
dyskinesia	B
had	O
lower	O
onset	O
age	O
(	O
p	O
<	O
0.001	O
)	O
,	O
longer	O
duration	O
of	O
levodopa	O
therapy	O
(	O
p	O
<	O
0.001	O
)	O
,	O
longer	O
disease	O
duration	O
(	O
p	O
<	O
0.001	O
)	O
,	O
higher	O
total	O
daily	O
levodopa	O
dose	O
(	O
p	O
<	O
0.001	O
)	O
,	O
and	O
higher	O
total	O
UPDRS	O
scores	O
(	O
p	O
=	O
0.005	O
)	O
than	O
patients	O
without	O
dyskinesia	B
.	O

The	O
three	O
significant	O
predictors	O
of	O
dyskinesia	B
were	O
duration	O
of	O
levodopa	O
therapy	O
,	O
onset	O
age	O
,	O
and	O
total	O
daily	O
levodopa	O
dose	O
.	O

CONCLUSIONS	O
:	O
The	O
prevalence	O
of	O
levodopa	O
-	O
induced	O
dyskinesia	B
in	O
our	O
patients	O
was	O
44	O
%	O
.	O

The	O
most	O
significant	O
predictors	O
were	O
duration	O
of	O
levodopa	O
therapy	O
,	O
total	O
daily	O
levodopa	O
dose	O
,	O
and	O
onset	O
age	O
.	O

An	O
unexpected	O
diagnosis	O
in	O
a	O
renal	O
-	O
transplant	O
patient	O
with	O
proteinuria	B
treated	O
with	O
everolimus	O
:	O
AL	B
amyloidosis	B
.	O

Proteinuria	B
is	O
an	O
expected	O
complication	O
in	O
transplant	O
patients	O
treated	O
with	O
mammalian	O
target	O
of	O
rapamycin	O
inhibitors	O
(	O
mTOR	O
-	O
i	O
)	O
.	O

However	O
,	O
clinical	O
suspicion	O
should	O
always	O
be	O
supported	O
by	O
histological	O
evidence	O
in	O
order	O
to	O
investigate	O
potential	O
alternate	O
diagnoses	O
such	O
as	O
acute	O
or	O
chronic	O
rejection	O
,	O
interstitial	O
fibrosis	B
and	O
tubular	O
atrophy	B
,	O
or	O
recurrent	O
or	O
de	O
novo	O
glomerulopathy	B
.	O

In	O
this	O
case	O
we	O
report	O
the	O
unexpected	O
diagnosis	O
of	O
amyloidosis	B
in	O
a	O
renal	O
-	O
transplant	O
patient	O
with	O
pre	O
-	O
transplant	O
monoclonal	O
gammapathy	O
of	O
undetermined	O
significance	O
who	O
developed	O
proteinuria	B
after	O
conversion	O
from	O
tacrolimus	O
to	O
everolimus	O
.	O

An	O
investigation	O
of	O
the	O
pattern	O
of	O
kidney	B
injury	I
in	O
HIV	O
-	O
positive	O
persons	O
exposed	O
to	O
tenofovir	O
disoproxil	O
fumarate	O
:	O
an	O
examination	O
of	O
a	O
large	O
population	O
database	O
(	O
MHRA	O
database	O
)	O
.	O

The	O
potential	O
for	O
tenofovir	O
to	O
cause	O
a	O
range	O
of	O
kidney	O
syndromes	O
has	O
been	O
established	O
from	O
mechanistic	O
and	O
randomised	O
clinical	O
trials	O
.	O

However	O
,	O
the	O
exact	O
pattern	O
of	O
kidney	O
involvement	O
is	O
still	O
uncertain	O
.	O

We	O
undertook	O
a	O
descriptive	O
analysis	O
of	O
Yellow	O
Card	O
records	O
of	O
407	O
HIV	O
-	O
positive	O
persons	O
taking	O
tenofovir	O
disoproxil	O
fumarate	O
(	O
TDF	O
)	O
as	O
part	O
of	O
their	O
antiretroviral	O
therapy	O
regimen	O
and	O
submitted	O
to	O
the	O
Medicines	O
and	O
Healthcare	O
Products	O
Regulatory	O
Agency	O
(	O
MHRA	O
)	O
with	O
suspected	O
kidney	O
adverse	O
effects	O
.	O

Reports	O
that	O
satisfy	O
defined	O
criteria	O
were	O
classified	O
as	O
acute	B
kidney	I
injury	I
,	O
kidney	B
tubular	I
dysfunction	I
and	O
Fanconi	B
syndrome	I
.	O

Of	O
the	O
407	O
Yellow	O
Card	O
records	O
analysed	O
,	O
106	O
satisfied	O
criteria	O
for	O
TDF	O
-	O
related	O
kidney	B
disease	I
,	O
of	O
which	O
53	O
(	O
50	O
%	O
)	O
had	O
features	O
of	O
kidney	B
tubular	I
dysfunction	I
,	O
35	O
(	O
33	O
%	O
)	O
were	O
found	O
to	O
have	O
features	O
of	O
glomerular	B
dysfunction	I
and	O
18	O
(	O
17	O
%	O
)	O
had	O
Fanconi	B
syndrome	I
.	O

The	O
median	O
TDF	O
exposure	O
was	O
316	O
days	O
(	O
interquartile	O
range	O
120	O
-	O
740	O
)	O
.	O

The	O
incidence	O
of	O
hospitalisation	O
for	O
TDF	O
kidney	O
adverse	O
effects	O
was	O
high	O
,	O
particularly	O
amongst	O
patients	O
with	O
features	O
of	O
Fanconi	B
syndrome	I
.	O

The	O
pattern	O
of	O
kidney	O
syndromes	O
in	O
this	O
population	O
series	O
mirrors	O
that	O
reported	O
in	O
randomised	O
clinical	O
trials	O
.	O

Cessation	O
of	O
TDF	O
was	O
associated	O
with	O
complete	O
restoration	O
of	O
kidney	O
function	O
in	O
up	O
half	O
of	O
the	O
patients	O
in	O
this	O
report	O
.	O

Incidence	O
of	O
postoperative	B
delirium	I
is	O
high	O
even	O
in	O
a	O
population	O
without	O
known	O
risk	O
factors	O
.	O

PURPOSE	O
:	O
Postoperative	B
delirium	I
is	O
a	O
recognized	O
complication	O
in	O
populations	O
at	O
risk	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
assess	O
the	O
prevalence	O
of	O
early	O
postoperative	B
delirium	I
in	O
a	O
population	O
without	O
known	O
risk	O
factors	O
admitted	O
to	O
the	O
ICU	O
for	O
postoperative	O
monitoring	O
after	O
elective	O
major	O
surgery	O
.	O

The	O
secondary	O
outcome	O
investigated	O
is	O
to	O
identify	O
eventual	O
independent	O
risk	O
factors	O
among	O
demographic	O
data	O
and	O
anesthetic	O
drugs	O
used	O
.	O

METHODS	O
:	O
An	O
observational	O
,	O
prospective	O
study	O
was	O
conducted	O
on	O
a	O
consecutive	O
cohort	O
of	O
patients	O
admitted	O
to	O
our	O
ICU	O
within	O
and	O
for	O
at	O
least	O
24	O
h	O
after	O
major	O
surgical	O
procedures	O
.	O

Exclusion	O
criteria	O
were	O
any	O
preexisting	O
predisposing	O
factor	O
for	O
delirium	B
or	O
other	O
potentially	O
confounding	O
neurological	B
dysfunctions	I
.	O

Patients	O
were	O
assessed	O
daily	O
using	O
the	O
confusion	B
assessment	O
method	O
for	O
the	O
ICU	O
scale	O
for	O
3	O
days	O
after	O
the	O
surgical	O
procedure	O
.	O

Early	O
postoperative	B
delirium	I
incidence	O
risk	O
factors	O
were	O
then	O
assessed	O
through	O
three	O
different	O
multiple	O
regression	O
models	O
.	O

RESULTS	O
:	O
According	O
to	O
the	O
confusion	O
assessment	O
method	O
for	O
the	O
ICU	O
scale	O
,	O
28	O
%	O
of	O
patients	O
were	O
diagnosed	O
with	O
early	O
postoperative	B
delirium	I
.	O

The	O
use	O
of	O
thiopentone	O
was	O
significantly	O
associated	O
with	O
an	O
eight	O
-	O
fold	O
-	O
higher	O
risk	O
for	O
delirium	B
compared	O
to	O
propofol	O
(	O
57.1	O
%	O
vs.	O
7.1	O
%	O
,	O
RR	O
=	O
8.0	O
,	O
X2	O
=	O
4.256	O
;	O
df	O
=	O
1	O
;	O
0.05	O
<	O
p	O
<	O
0.02	O
)	O
.	O

CONCLUSION	O
:	O
In	O
this	O
study	O
early	O
postoperative	B
delirium	I
was	O
found	O
to	O
be	O
a	O
very	O
common	O
complication	O
after	O
major	O
surgery	O
,	O
even	O
in	O
a	O
population	O
without	O
known	O
risk	O
factors	O
.	O

Thiopentone	O
was	O
independently	O
associated	O
with	O
an	O
increase	O
in	O
its	O
relative	O
risk	O
.	O

A	O
single	O
neurotoxic	B
dose	O
of	O
methamphetamine	O
induces	O
a	O
long	O
-	O
lasting	O
depressive	B
-	O
like	O
behaviour	O
in	O
mice	O
.	O

Methamphetamine	O
(	O
METH	O
)	O
triggers	O
a	O
disruption	O
of	O
the	O
monoaminergic	O
system	O
and	O
METH	O
abuse	O
leads	O
to	O
negative	O
emotional	O
states	O
including	O
depressive	B
symptoms	I
during	O
drug	O
withdrawal	O
.	O

However	O
,	O
it	O
is	O
currently	O
unknown	O
if	O
the	O
acute	O
toxic	O
dosage	O
of	O
METH	O
also	O
causes	O
a	O
long	O
-	O
lasting	O
depressive	B
phenotype	O
and	O
persistent	O
monoaminergic	O
deficits	O
.	O

Thus	O
,	O
we	O
now	O
assessed	O
the	O
depressive	B
-	O
like	O
behaviour	O
in	O
mice	O
at	O
early	O
and	O
long	O
-	O
term	O
periods	O
following	O
a	O
single	O
high	O
METH	O
dose	O
(	O
30	O
mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
.	O

METH	O
did	O
not	O
alter	O
the	O
motor	O
function	O
and	O
procedural	O
memory	O
of	O
mice	O
as	O
assessed	O
by	O
swimming	O
speed	O
and	O
escape	O
latency	O
to	O
find	O
the	O
platform	O
in	O
a	O
cued	O
version	O
of	O
the	O
water	O
maze	O
task	O
.	O

However	O
,	O
METH	O
significantly	O
increased	O
the	O
immobility	O
time	O
in	O
the	O
tail	O
suspension	O
test	O
at	O
3	O
and	O
49	O
days	O
post	O
-	O
administration	O
.	O

This	O
depressive	B
-	O
like	O
profile	O
induced	O
by	O
METH	O
was	O
accompanied	O
by	O
a	O
marked	O
depletion	O
of	O
frontostriatal	O
dopaminergic	O
and	O
serotonergic	O
neurotransmission	O
,	O
indicated	O
by	O
a	O
reduction	O
in	O
the	O
levels	O
of	O
dopamine	O
,	O
DOPAC	O
and	O
HVA	O
,	O
tyrosine	O
hydroxylase	O
and	O
serotonin	O
,	O
observed	O
at	O
both	O
3	O
and	O
49	O
days	O
post	O
-	O
administration	O
.	O

In	O
parallel	O
,	O
another	O
neurochemical	O
feature	O
of	O
depression	B
--	O
astroglial	O
dysfunction	O
--	O
was	O
unaffected	O
in	O
the	O
cortex	O
and	O
the	O
striatal	O
levels	O
of	O
the	O
astrocytic	O
protein	O
marker	O
,	O
glial	O
fibrillary	O
acidic	O
protein	O
,	O
were	O
only	O
transiently	O
increased	O
at	O
3	O
days	O
.	O

These	O
findings	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
a	O
single	O
high	O
dose	O
of	O
METH	O
induces	O
long	O
-	O
lasting	O
depressive	B
-	O
like	O
behaviour	O
in	O
mice	O
associated	O
with	O
a	O
persistent	O
disruption	O
of	O
frontostriatal	O
dopaminergic	O
and	O
serotonergic	O
homoeostasis	O
.	O

Linezolid	O
-	O
induced	O
optic	B
neuropathy	I
.	O

Many	O
systemic	O
antimicrobials	O
have	O
been	O
implicated	O
to	O
cause	O
ocular	O
adverse	O
effects	O
.	O

This	O
is	O
especially	O
relevant	O
in	O
multidrug	O
therapy	O
where	O
more	O
than	O
one	O
drug	O
can	O
cause	O
a	O
similar	O
ocular	O
adverse	O
effect	O
.	O

We	O
describe	O
a	O
case	O
of	O
progressive	O
loss	B
of	I
vision	I
associated	O
with	O
linezolid	O
therapy	O
.	O

A	O
45-year	O
-	O
old	O
male	O
patient	O
who	O
was	O
on	O
treatment	O
with	O
multiple	O
second	O
-	O
line	O
anti	O
-	O
tuberculous	O
drugs	O
including	O
linezolid	O
and	O
ethambutol	O
for	O
extensively	B
drug	I
-	I
resistant	I
tuberculosis	I
(	O
XDR	B
-	I
TB	I
)	O
presented	O
to	O
us	O
with	O
painless	O
progressive	O
loss	B
of	I
vision	I
in	O
both	O
eyes	O
.	O

Color	O
vision	O
was	O
defective	O
and	O
fundus	O
examination	O
revealed	O
optic	B
disc	I
edema	I
in	O
both	O
eyes	O
.	O

Ethambutol	O
-	O
induced	O
toxic	B
optic	I
neuropathy	I
was	O
suspected	O
and	O
tablet	O
ethambutol	O
was	O
withdrawn	O
.	O

Deterioration	B
of	I
vision	I
occurred	O
despite	O
withdrawal	O
of	O
ethambutol	O
.	O

Discontinuation	O
of	O
linezolid	O
resulted	O
in	O
marked	O
improvement	O
of	O
vision	O
.	O

Our	O
report	O
emphasizes	O
the	O
need	O
for	O
monitoring	O
of	O
visual	O
function	O
in	O
patients	O
on	O
long	O
-	O
term	O
linezolid	O
treatment	O
.	O

Resuscitation	O
with	O
lipid	O
,	O
epinephrine	O
,	O
or	O
both	O
in	O
levobupivacaine	O
-	O
induced	O
cardiac	B
toxicity	I
in	O
newborn	O
piglets	O
.	O

BACKGROUND	O
:	O
The	O
optimal	O
dosing	O
regimens	O
of	O
lipid	O
emulsion	O
,	O
epinephrine	O
,	O
or	O
both	O
are	O
not	O
yet	O
determined	O
in	O
neonates	O
in	O
cases	O
of	O
local	O
anaesthetic	O
systemic	O
toxicity	B
(	O
LAST	O
)	O
.	O

METHODS	O
:	O
Newborn	O
piglets	O
received	O
levobupivacaine	O
until	O
cardiovascular	B
collapse	I
occurred	O
.	O

Standard	O
cardiopulmonary	O
resuscitation	O
was	O
started	O
and	O
electrocardiogram	O
(	O
ECG	O
)	O
was	O
monitored	O
for	O
ventricular	B
tachycardia	I
,	O
fibrillation	B
,	O
or	O
QRS	O
prolongation	O
.	O

Piglets	O
were	O
then	O
randomly	O
allocated	O
to	O
four	O
groups	O
:	O
control	O
(	O
saline	O
)	O
,	O
Intralipid	O
(	O
)	O
alone	O
,	O
epinephrine	O
alone	O
,	O
or	O
a	O
combination	O
of	O
Intralipd	O
plus	O
epinephrine	O
.	O

Resuscitation	O
continued	O
for	O
30	O
min	O
or	O
until	O
there	O
was	O
a	O
return	O
of	O
spontaneous	O
circulation	O
(	O
ROSC	O
)	O
accompanied	O
by	O
a	O
mean	O
arterial	O
pressure	O
at	O
or	O
superior	O
to	O
the	O
baseline	O
pressure	O
and	O
normal	O
sinus	O
rhythm	O
for	O
a	O
period	O
of	O
30	O
min	O
.	O

RESULTS	O
:	O
ROSC	O
was	O
achieved	O
in	O
only	O
one	O
of	O
the	O
control	O
piglets	O
compared	O
with	O
most	O
of	O
the	O
treated	O
piglets	O
.	O

Mortality	O
was	O
not	O
significantly	O
different	O
between	O
the	O
three	O
treatment	O
groups	O
,	O
but	O
was	O
significantly	O
lower	O
in	O
all	O
the	O
treatment	O
groups	O
compared	O
with	O
control	O
.	O

The	O
number	O
of	O
ECG	O
abnormalities	O
was	O
zero	O
in	O
the	O
Intralipid	O
only	O
group	O
,	O
but	O
14	O
and	O
17	O
,	O
respectively	O
,	O
in	O
the	O
epinephrine	O
and	O
epinephrine	O
plus	O
lipid	O
groups	O
(	O
P<0.05	O
)	O
.	O

CONCLUSIONS	O
:	O
Lipid	O
emulsion	O
with	O
or	O
without	O
epinephrine	O
,	O
or	O
epinephrine	O
alone	O
were	O
equally	O
effective	O
in	O
achieving	O
a	O
return	O
to	O
spontaneous	O
circulation	O
in	O
this	O
model	O
of	O
LAST	O
.	O

Epinephrine	O
alone	O
or	O
in	O
combination	O
with	O
lipid	O
was	O
associated	O
with	O
an	O
increased	O
number	O
of	O
ECG	O
abnormalities	O
compared	O
with	O
lipid	O
emulsion	O
alone	O
.	O

Incidence	O
of	O
heparin	O
-	O
induced	O
thrombocytopenia	B
type	I
II	I
and	O
postoperative	O
recovery	O
of	O
platelet	O
count	O
in	O
liver	O
graft	O
recipients	O
:	O
a	O
retrospective	O
cohort	O
analysis	O
.	O

BACKGROUND	O
:	O
Thrombocytopenia	B
in	O
patients	O
with	O
end	B
-	I
stage	I
liver	I
disease	I
is	O
a	O
common	O
disorder	O
caused	O
mainly	O
by	O
portal	B
hypertension	I
,	O
low	O
levels	O
of	O
thrombopoetin	O
,	O
and	O
endotoxemia	B
.	O

The	O
impact	O
of	O
immune	O
-	O
mediated	O
heparin	O
-	O
induced	O
thrombocytopenia	B
type	I
II	I
(	O
HIT	B
type	I
II	I
)	O
as	O
a	O
cause	O
of	O
thrombocytopenia	B
after	O
liver	O
transplantation	O
is	O
not	O
yet	O
understood	O
,	O
with	O
few	O
literature	O
citations	O
reporting	O
contradictory	O
results	O
.	O

The	O
aim	O
of	O
our	O
study	O
was	O
to	O
demonstrate	O
the	O
perioperative	O
course	O
of	O
thrombocytopenia	B
after	O
liver	O
transplantation	O
and	O
determine	O
the	O
occurrence	O
of	O
clinical	O
HIT	B
type	I
II	I
.	O

METHOD	O
:	O
We	O
retrospectively	O
evaluated	O
the	O
medical	O
records	O
of	O
205	O
consecutive	O
adult	O
patients	O
who	O
underwent	O
full	O
-	O
size	O
liver	O
transplantation	O
between	O
January	O
2006	O
and	O
December	O
2010	O
due	O
to	O
end	B
-	I
stage	I
or	I
malignant	I
liver	I
disease	I
.	O

Preoperative	O
platelet	O
count	O
,	O
postoperative	O
course	O
of	O
platelets	O
,	O
and	O
clinical	O
signs	O
of	O
HIT	B
type	I
II	I
were	O
analyzed	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
155	O
(	O
75.6	O
%	O
)	O
of	O
205	O
patients	O
had	O
thrombocytopenia	B
before	O
transplantation	O
,	O
significantly	O
influenced	O
by	O
Model	O
of	O
End	B
-	I
Stage	I
Liver	I
Disease	I
score	O
and	O
liver	B
cirrhosis	I
.	O

The	O
platelet	O
count	O
exceeded	O
100,000	O
/	O
uL	O
in	O
most	O
of	O
the	O
patients	O
(	O
n	O
=	O
193	O
)	O
at	O
a	O
medium	O
of	O
7	O
d.	O
Regarding	O
HIT	B
II	I
,	O
there	O
were	O
four	O
(	O
1.95	O
%	O
)	O
patients	O
with	O
a	O
background	O
of	O
HIT	B
type	I
II	I
.	O

CONCLUSIONS	O
:	O
The	O
incidence	O
of	O
HIT	B
in	O
patients	O
with	O
end	B
-	I
stage	I
hepatic	I
failure	I
is	O
,	O
with	O
about	O
1.95	O
%	O
,	O
rare	O
.	O

For	O
further	O
reduction	O
of	O
HIT	B
type	I
II	I
,	O
the	O
use	O
of	O
intravenous	O
heparin	O
should	O
be	O
avoided	O
and	O
the	O
prophylactic	O
anticoagulation	O
should	O
be	O
performed	O
with	O
low	O
-	O
molecular	O
-	O
weight	O
heparin	O
after	O
normalization	O
of	O
platelet	O
count	O
.	O

Takotsubo	B
syndrome	I
(	O
or	O
apical	B
ballooning	I
syndrome	I
)	O
secondary	O
to	O
Zolmitriptan	O
.	O

Takotsubo	B
syndrome	I
(	O
TS	B
)	O
,	O
also	O
known	O
as	O
broken	B
heart	I
syndrome	I
,	O
is	O
characterized	O
by	O
left	O
ventricle	O
apical	O
ballooning	O
with	O
elevated	O
cardiac	O
biomarkers	O
and	O
electrocardiographic	O
changes	O
suggestive	O
of	O
an	O
acute	B
coronary	I
syndrome	I
(	O
ie	O
,	O
ST	O
-	O
segment	O
elevation	O
,	O
T	O
wave	O
inversions	O
,	O
and	O
pathologic	O
Q	O
waves	O
)	O
.	O

We	O
report	O
a	O
case	O
of	O
54-year	O
-	O
old	O
woman	O
with	O
medical	O
history	O
of	O
mitral	B
valve	I
prolapse	I
and	O
migraines	B
,	O
who	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
substernal	O
chest	B
pain	I
and	O
electrocardiogram	O
demonstrated	O
1	O
/	O
2	O
mm	O
ST	O
-	O
segment	O
elevation	O
in	O
leads	O
II	O
,	O
III	O
,	O
aVF	O
,	O
V5	O
,	O
and	O
V6	O
and	O
positive	O
troponin	O
I.	O
Emergent	O
coronary	O
angiogram	O
revealed	O
normal	O
coronary	O
arteries	O
with	O
moderately	O
reduced	O
left	O
ventricular	O
ejection	O
fraction	O
with	O
wall	O
motion	O
abnormalities	O
consistent	O
with	O
TS	B
.	O

Detailed	O
history	O
obtained	O
retrospectively	O
revealed	O
that	O
the	O
patient	O
took	O
zolmitriptan	O
sparingly	O
only	O
when	O
she	O
had	O
migraines	B
.	O

But	O
before	O
this	O
event	O
,	O
she	O
was	O
taking	O
zolmitriptan	O
2	O
-	O
3	O
times	O
daily	O
for	O
several	O
days	O
because	O
of	O
a	O
persistent	O
migraine	B
headache	I
.	O

She	O
otherwise	O
reported	O
that	O
she	O
is	O
quite	O
active	O
,	O
rides	O
horses	O
,	O
and	O
does	O
show	O
jumping	O
without	O
any	O
limitations	O
in	O
her	O
physical	O
activity	O
.	O

There	O
was	O
no	O
evidence	O
of	O
any	O
recent	O
stress	O
or	O
status	B
migrainosus	I
.	O

Extensive	O
literature	O
search	O
revealed	O
multiple	O
cases	O
of	O
coronary	B
artery	I
vasospasm	I
secondary	O
to	O
zolmitriptan	O
,	O
but	O
none	O
of	O
the	O
cases	O
were	O
associated	O
with	O
TS	B
.	O

Depression	B
,	O
impulsiveness	B
,	O
sleep	O
,	O
and	O
memory	O
in	O
past	O
and	O
present	O
polydrug	O
users	O
of	O
3,4-methylenedioxymethamphetamine	O
(	O
MDMA	O
,	O
ecstasy	O
)	O
.	O

RATIONALE	O
:	O
Ecstasy	O
(	O
3,4-methylenedioxymethamphetamine	O
,	O
MDMA	O
)	O
is	O
a	O
worldwide	O
recreational	O
drug	O
of	O
abuse	O
.	O

Unfortunately	O
,	O
the	O
results	O
from	O
human	O
research	O
investigating	O
its	O
psychological	O
effects	O
have	O
been	O
inconsistent	O
.	O

OBJECTIVES	O
:	O
The	O
present	O
study	O
aimed	O
to	O
be	O
the	O
largest	O
to	O
date	O
in	O
sample	O
size	O
and	O
5HT	O
-	O
related	O
behaviors	O
;	O
the	O
first	O
to	O
compare	O
present	O
ecstasy	O
users	O
with	O
past	O
users	O
after	O
an	O
abstinence	O
of	O
4	O
or	O
more	O
years	O
,	O
and	O
the	O
first	O
to	O
include	O
robust	O
controls	O
for	O
other	O
recreational	O
substances	O
.	O

METHODS	O
:	O
A	O
sample	O
of	O
997	O
participants	O
(	O
52	O
%	O
male	O
)	O
was	O
recruited	O
to	O
four	O
control	O
groups	O
(	O
non	O
-	O
drug	O
(	O
ND	O
)	O
,	O
alcohol	O
/	O
nicotine	O
(	O
AN	O
)	O
,	O
cannabis	O
/	O
alcohol	O
/	O
nicotine	O
(	O
CAN	O
)	O
,	O
non	O
-	O
ecstasy	O
polydrug	O
(	O
PD	O
)	O
)	O
,	O
and	O
two	O
ecstasy	O
polydrug	O
groups	O
(	O
present	O
(	O
MDMA	O
)	O
and	O
past	O
users	O
(	O
EX	O
-	O
MDMA	O
)	O
.	O

Participants	O
completed	O
a	O
drug	O
history	O
questionnaire	O
,	O
Beck	O
Depression	B
Inventory	O
,	O
Barratt	O
Impulsiveness	B
Scale	O
,	O
Pittsburgh	O
Sleep	O
Quality	O
Index	O
,	O
and	O
Wechsler	O
Memory	O
Scale	O
-	O
Revised	O
which	O
,	O
in	O
total	O
,	O
provided	O
13	O
psychometric	O
measures	O
.	O

RESULTS	O
:	O
While	O
the	O
CAN	O
and	O
PD	O
groups	O
tended	O
to	O
record	O
greater	O
deficits	O
than	O
the	O
non	O
-	O
drug	O
controls	O
,	O
the	O
MDMA	O
and	O
EX	O
-	O
MDMA	O
groups	O
recorded	O
greater	O
deficits	O
than	O
all	O
the	O
control	O
groups	O
on	O
ten	O
of	O
the	O
13	O
psychometric	O
measures	O
.	O

Strikingly	O
,	O
despite	O
prolonged	O
abstinence	O
(	O
mean	O
,	O
4.98	O
;	O
range	O
,	O
4	O
-	O
9	O
years	O
)	O
,	O
past	O
ecstasy	O
users	O
showed	O
few	O
signs	O
of	O
recovery	O
.	O

Compared	O
with	O
present	O
ecstasy	O
users	O
,	O
the	O
past	O
users	O
showed	O
no	O
change	O
for	O
ten	O
measures	O
,	O
increased	O
impairment	O
for	O
two	O
measures	O
,	O
and	O
improvement	O
on	O
just	O
one	O
measure	O
.	O

CONCLUSIONS	O
:	O
Given	O
this	O
record	O
of	O
impaired	B
memory	I
and	O
clinically	O
significant	O
levels	O
of	O
depression	B
,	O
impulsiveness	B
,	O
and	O
sleep	B
disturbance	I
,	O
the	O
prognosis	O
for	O
the	O
current	O
generation	O
of	O
ecstasy	O
users	O
is	O
a	O
major	O
cause	O
for	O
concern	O
.	O

Association	O
of	O
common	O
genetic	O
variants	O
of	O
HOMER1	O
gene	O
with	O
levodopa	O
adverse	O
effects	O
in	O
Parkinson	B
's	I
disease	I
patients	O
.	O

Levodopa	O
is	O
the	O
most	O
effective	O
symptomatic	O
therapy	O
for	O
Parkinson	B
's	I
disease	I
,	O
but	O
its	O
chronic	O
use	O
could	O
lead	O
to	O
chronic	O
adverse	O
outcomes	O
,	O
such	O
as	O
motor	O
fluctuations	O
,	O
dyskinesia	B
and	O
visual	B
hallucinations	I
.	O

HOMER1	O
is	O
a	O
protein	O
with	O
pivotal	O
function	O
in	O
glutamate	O
transmission	O
,	O
which	O
has	O
been	O
related	O
to	O
the	O
pathogenesis	O
of	O
these	O
complications	O
.	O

This	O
study	O
investigates	O
whether	O
polymorphisms	O
in	O
the	O
HOMER1	O
gene	O
promoter	O
region	O
are	O
associated	O
with	O
the	O
occurrence	O
of	O
the	O
chronic	O
complications	O
of	O
levodopa	O
therapy	O
.	O

A	O
total	O
of	O
205	O
patients	O
with	O
idiopathic	B
Parkinson	I
's	I
disease	I
were	O
investigated	O
.	O

Patients	O
were	O
genotyped	O
for	O
rs4704559	O
,	O
rs10942891	O
and	O
rs4704560	O
by	O
allelic	O
discrimination	O
with	O
Taqman	O
assays	O
.	O

The	O
rs4704559	O
G	O
allele	O
was	O
associated	O
with	O
a	O
lower	O
prevalence	O
of	O
dyskinesia	B
(	O
prevalence	O
ratio	O
(	O
PR	O
)	O
=0.615	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
0.426	O
-	O
0.887	O
,	O
P=0.009	O
)	O
and	O
visual	B
hallucinations	I
(	O
PR=0.515	O
,	O
95	O
%	O
CI	O
0.295	O
-	O
0.899	O
,	O
P=0.020	O
)	O
.	O

Our	O
data	O
suggest	O
that	O
HOMER1	O
rs4704559	O
G	O
allele	O
has	O
a	O
protective	O
role	O
for	O
the	O
development	O
of	O
levodopa	O
adverse	O
effects	O
.	O

Crocin	O
improves	O
lipid	O
dysregulation	O
in	O
subacute	O
diazinon	O
exposure	O
through	O
ERK1	O
/	O
2	O
pathway	O
in	O
rat	O
liver	O
.	O

INTRODUCTION	O
:	O

Diazinon	O
Yis	O
one	O
of	O
the	O
most	O
broadly	O
used	O
organophosphorus	O
insecticides	O
in	O
agriculture	O
.	O

It	O
has	O
been	O
shown	O
that	O
exposure	O
to	O
diazinon	O
may	O
interfere	O
with	O
lipid	O
metabolism	O
.	O

Moreover	O
,	O
the	O
hypolipidemic	O
effect	O
of	O
crocin	O
has	O
been	O
established	O
.	O

Earlier	O
studies	O
revealed	O
the	O
major	O
role	O
of	O
Extracellular	O
signal	O
-	O
regulated	O
kinase	O
(	O
ERK	O
)	O
pathways	O
in	O
low	O
-	O
density	O
lipoprotein	O
receptor	O
(	O
LDLr	O
)	O
expression	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
evaluate	O
changes	O
in	O
the	O
regulation	O
of	O
lipid	O
metabolism	O
,	O
ERK	O
and	O
LDLr	O
expression	O
in	O
the	O
liver	O
of	O
rats	O
exposed	O
to	O
subacute	O
diazinon	O
.	O

Furthermore	O
ameliorating	O
effect	O
of	O
crocin	O
on	O
diazinon	O
induced	O
disturbed	O
cholesterol	O
homeostasis	O
was	O
studied	O
.	O

METHODS	O
:	O
24	O
Rats	O
were	O
divided	O
into	O
4	O
groups	O
and	O
received	O
following	O
treatments	O
for	O
4	O
weeks	O
;	O
Corn	O
oil	O
(	O
control	O
)	O
,	O
diazinon	O
(	O
15mg	O
/	O
kg	O
per	O
day	O
,	O
orally	O
)	O
and	O
crocin	O
(	O
12.5	O
and	O
25mg	O
/	O
kg	O
per	O
day	O
,	O
intraperitoneally	O
)	O
in	O
combination	O
with	O
diazinon	O
(	O
15	O
mg	O
/	O
kg	O
)	O
.	O

The	O
levels	O
of	O
cholesterol	O
,	O
triglyceride	O
and	O
LDL	O
in	O
blood	O
of	O
rats	O
were	O
analyzed	O
.	O

Moreover	O
mRNA	O
levels	O
of	O
LDLr	O
and	O
ERK1	O
/	O
2	O
as	O
well	O
as	O
protein	O
levels	O
of	O
total	O
and	O
activated	O
forms	O
of	O
ERK1	O
/	O
2	O
in	O
rat	O
liver	O
were	O
evaluated	O
by	O
Western	O
blotting	O
and	O
quantitative	O
real	O
time	O
polymerase	O
chain	O
reaction	O
analysis	O
.	O

RESULTS	O
:	O
Our	O
data	O
showed	O
that	O
subacute	O
exposure	O
to	O
diazinon	O
significantly	O
increased	O
concentrations	O
of	O
cholesterol	O
,	O
triglyceride	O
and	O
LDL	O
.	O

Moreover	O
diazinon	O
decreased	O
ERK1	O
/	O
2	O
protein	O
phosphorylation	O
and	O
LDLr	O
transcript	O
.	O

Crocin	O
reduced	O
inhibition	O
of	O
ERK	O
activation	O
and	O
diazinon	O
-	O
induced	O
hyperlipemia	B
and	O
increased	O
levels	O
of	O
LDLr	O
transcript	O
.	O

CONCLUSIONS	O
:	O
Crocin	O
may	O
be	O
considered	O
as	O
a	O
novel	O
protective	O
agent	O
in	O
diazinon	O
-	O
induced	O
hyperlipemia	B
through	O
modulating	O
of	O
ERK	O
pathway	O
and	O
increase	O
of	O
LDLr	O
expression	O
.	O

GEM	O
-	O
P	O
chemotherapy	O
is	O
active	O
in	O
the	O
treatment	O
of	O
relapsed	O
Hodgkin	B
lymphoma	I
.	O

Hodgkin	B
lymphoma	I
(	O
HL	B
)	O
is	O
a	O
relatively	O
chemosensitive	O
malignancy	B
.	O

However	O
,	O
for	O
those	O
who	O
relapse	O
,	O
high	O
-	O
dose	O
chemotherapy	O
with	O
autologous	O
stem	O
cell	O
transplant	O
is	O
the	O
treatment	O
of	O
choice	O
which	O
relies	O
on	O
adequate	O
disease	O
control	O
with	O
salvage	O
chemotherapy	O
.	O

Regimens	O
commonly	O
used	O
often	O
require	O
inpatient	O
administration	O
and	O
can	O
be	O
difficult	O
to	O
deliver	O
due	O
to	O
toxicity	B
.	O

Gemcitabine	O
and	O
cisplatin	O
have	O
activity	O
in	O
HL	B
,	O
non	O
-	O
overlapping	O
toxicity	B
with	O
first	O
-	O
line	O
chemotherapeutics	O
,	O
and	O
may	O
be	O
delivered	O
in	O
an	O
outpatient	O
setting	O
.	O

In	O
this	O
retrospective	O
single	O
-	O
centre	O
analysis	O
,	O
patients	O
with	O
relapsed	O
or	O
refractory	O
HL	B
treated	O
with	O
gemcitabine	O
1,000	O
mg	O
/	O
m	O
(	O
2	O
)	O
day	O
(	O
D	O
)	O
1	O
,	O
D8	O
and	O
D15	O
;	O
methylprednisolone	O
1,000	O
mg	O
D1	O
-	O
5	O
;	O
and	O
cisplatin	O
100	O
mg	O
/	O
m	O
(	O
2	O
)	O
D15	O
,	O
every	O
28	O
days	O
(	O
GEM	O
-	O
P	O
)	O
were	O
included	O
.	O

Demographic	O
,	O
survival	O
,	O
response	O
and	O
toxicity	B
data	O
were	O
recorded	O
.	O

Forty	O
-	O
one	O
eligible	O
patients	O
were	O
identified	O
:	O
median	O
age	O
27	O
.	O

One	O
hundred	O
and	O
twenty	O
-	O
two	O
cycles	O
of	O
GEM	O
-	O
P	O
were	O
administered	O
in	O
total	O
(	O
median	O
3	O
cycles	O
;	O
range	O
1	O
-	O
6	O
)	O
.	O

Twenty	O
of	O
41	O
(	O
48	O
%	O
)	O
patients	O
received	O
GEM	O
-	O
P	O
as	O
second	O
-	O
line	O
treatment	O
and	O
11	O
/	O
41	O
(	O
27	O
%	O
)	O
as	O
third	O
-	O
line	O
therapy	O
.	O

Overall	O
response	O
rate	O
(	O
ORR	O
)	O
to	O
GEM	O
-	O
P	O
in	O
the	O
entire	O
cohort	O
was	O
80	O
%	O
(	O
complete	O
response	O
(	O
CR	O
)	O
37	O
%	O
,	O
partial	O
response	O
44	O
%	O
)	O
with	O
14	O
/	O
15	O
CR	O
confirmed	O
as	O
a	O
metabolic	O
CR	O
on	O
PET	O
and	O
ORR	O
of	O
85	O
%	O
in	O
the	O
20	O
second	O
-	O
line	O
patients	O
.	O

The	O
most	O
common	O
grade	O
3	O
/	O
4	O
toxicities	B
were	O
haematological	O
:	O
neutropenia	B
54	O
%	O
and	O
thrombocytopenia	B
51	O
%	O
.	O

Median	O
follow	O
-	O
up	O
from	O
the	O
start	O
of	O
GEM	O
-	O
P	O
was	O
4.5	O
years	O
.	O

Following	O
GEM	O
-	O
P	O
,	O
5-year	O
progression	O
-	O
free	O
survival	O
was	O
46	O
%	O
(	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
,	O
30	O
-	O
62	O
%	O
)	O
and	O
5-year	O
overall	O
survival	O
was	O
59	O
%	O
(	O
95	O
%	O
CI	O
,	O
43	O
-	O
74	O
%	O
)	O
.	O

Fourteen	O
of	O
41	O
patients	O
proceeded	O
directly	O
to	O
autologous	O
transplant	O
.	O

GEM	O
-	O
P	O
is	O
a	O
salvage	O
chemotherapy	O
with	O
relatively	O
high	O
response	O
rates	O
,	O
leading	O
to	O
successful	O
transplantation	O
in	O
appropriate	O
patients	O
,	O
in	O
the	O
treatment	O
of	O
relapsed	O
or	O
refractory	O
HL	B
.	O

Basal	O
functioning	O
of	O
the	O
hypothalamic	O
-	O
pituitary	O
-	O
adrenal	O
(	O
HPA	O
)	O
axis	O
and	O
psychological	O
distress	O
in	O
recreational	O
ecstasy	O
polydrug	O
users	O
.	O

RATIONALE	O
:	O
Ecstasy	O
(	O
MDMA	O
)	O
is	O
a	O
psychostimulant	O
drug	O
which	O
is	O
increasingly	O
associated	O
with	O
psychobiological	B
dysfunction	I
.	O

While	O
some	O
recent	O
studies	O
suggest	O
acute	O
changes	O
in	O
neuroendocrine	O
function	O
,	O
less	O
is	O
known	O
about	O
long	O
-	O
term	O
changes	O
in	O
HPA	O
functionality	O
in	O
recreational	O
users	O
.	O

OBJECTIVES	O
:	O
The	O
current	O
study	O
is	O
the	O
first	O
to	O
explore	O
the	O
effects	O
of	O
ecstasy	O
-	O
polydrug	O
use	O
on	O
psychological	O
distress	O
and	O
basal	O
functioning	O
of	O
the	O
HPA	O
axis	O
through	O
assessing	O
the	O
secretion	O
of	O
cortisol	O
across	O
the	O
diurnal	O
period	O
.	O

METHOD	O
:	O
Seventy	O
-	O
six	O
participants	O
(	O
21	O
nonusers	O
,	O
29	O
light	O
ecstasy	O
-	O
polydrug	O
users	O
,	O
26	O
heavy	O
ecstasy	O
-	O
polydrug	O
users	O
)	O
completed	O
a	O
substance	O
use	O
inventory	O
and	O
measures	O
of	O
psychological	O
distress	O
at	O
baseline	O
,	O
then	O
two	O
consecutive	O
days	O
of	O
cortisol	O
sampling	O
(	O
on	O
awakening	O
,	O
30	O
min	O
post	O
awakening	O
,	O
between	O
1400	O
and	O
1600	O
hours	O
and	O
pre	O
bedtime	O
)	O
.	O

On	O
day	O
2	O
,	O
participants	O
also	O
attended	O
the	O
laboratory	O
to	O
complete	O
a	O
20-min	O
multitasking	O
stressor	O
.	O

RESULTS	O
:	O
Both	O
user	O
groups	O
exhibited	O
significantly	O
greater	O
levels	O
of	O
anxiety	B
and	O
depression	B
than	O
nonusers	O
.	O

On	O
day	O
1	O
,	O
all	O
participants	O
exhibited	O
a	O
typical	O
cortisol	O
profile	O
,	O
though	O
light	O
users	O
had	O
significantly	O
elevated	O
levels	O
pre	O
-	O
bed	O
.	O

On	O
day	O
2	O
,	O
heavy	O
users	O
demonstrated	O
elevated	O
levels	O
upon	O
awakening	O
and	O
all	O
ecstasy	O
-	O
polydrug	O
users	O
demonstrated	O
elevated	O
pre	O
-	O
bed	O
levels	O
compared	O
to	O
non	O
-	O
users	O
.	O

Significant	O
between	O
group	O
differences	O
were	O
also	O
observed	O
in	O
afternoon	O
cortisol	O
levels	O
and	O
in	O
overall	O
cortisol	O
secretion	O
across	O
the	O
day	O
.	O

CONCLUSIONS	O
:	O
The	O
increases	O
in	O
anxiety	B
and	O
depression	B
are	O
in	O
line	O
with	O
previous	O
observations	O
in	O
recreational	O
ecstasy	O
-	O
polydrug	O
users	O
.	O

Dysregulated	O
diurnal	O
cortisol	O
may	O
be	O
indicative	O
of	O
inappropriate	O
anticipation	O
of	O
forthcoming	O
demands	O
and	O
hypersecretion	O
may	O
lead	O
to	O
the	O
increased	O
psychological	O
and	O
physical	O
morbidity	O
associated	O
with	O
heavy	O
recreational	O
use	O
of	O
ecstasy	O
.	O

Ifosfamide	O
related	O
encephalopathy	B
:	O
the	O
need	O
for	O
a	O
timely	O
EEG	O
evaluation	O
.	O

BACKGROUND	O
:	O
Ifosfamide	O
is	O
an	O
alkylating	O
agent	O
useful	O
in	O
the	O
treatment	O
of	O
a	O
wide	O
range	O
of	O
cancers	B
including	O
sarcomas	B
,	O
lymphoma	B
,	O
gynecologic	B
and	I
testicular	I
cancers	I
.	O

Encephalopathy	B
has	O
been	O
reported	O
in	O
10	O
-	O
40	O
%	O
of	O
patients	O
receiving	O
high	O
-	O
dose	O
IV	O
ifosfamide	O
.	O

OBJECTIVE	O
:	O
To	O
highlight	O
the	O
role	O
of	O
electroencephalogram	O
(	O
EEG	O
)	O
in	O
the	O
early	O
detection	O
and	O
management	O
of	O
ifosfamide	O
related	O
encephalopathy	B
.	O

METHODS	O
:	O
Retrospective	O
chart	O
review	O
including	O
clinical	O
data	O
and	O
EEG	O
recordings	O
was	O
done	O
on	O
five	O
patients	O
,	O
admitted	O
to	O
MD	O
Anderson	O
Cancer	B
Center	O
between	O
years	O
2009	O
and	O
2012	O
,	O
who	O
developed	O
ifosfamide	O
related	O
acute	O
encephalopathy	B
.	O

RESULTS	O
:	O
All	O
five	O
patients	O
experienced	O
symptoms	O
of	O
encephalopathy	B
soon	O
after	O
(	O
within	O
12	O
h-2	O
days	O
)	O
receiving	O
ifosfamide	O
.	O

Two	O
patients	O
developed	O
generalized	O
convulsions	B
while	O
one	O
patient	O
developed	O
continuous	O
non	B
-	I
convulsive	I
status	I
epilepticus	I
(	O
NCSE	B
)	O
that	O
required	O
ICU	O
admission	O
and	O
intubation	O
.	O

Initial	O
EEG	O
showed	O
epileptiform	O
discharges	O
in	O
three	O
patients	O
;	O
run	O
of	O
triphasic	O
waves	O
in	O
one	O
patient	O
and	O
moderate	O
degree	O
diffuse	O
generalized	O
slowing	O
.	O

Mixed	O
pattern	O
with	O
the	O
presence	O
of	O
both	O
sharps	O
and	O
triphasic	O
waves	O
were	O
also	O
noted	O
.	O

Repeat	O
EEGs	O
within	O
24_h	O
of	O
symptom	O
onset	O
showed	O
marked	O
improvement	O
that	O
was	O
correlated	O
with	O
clinical	O
improvement	O
.	O

CONCLUSIONS	O
:	O
Severity	O
of	O
ifosfamide	O
related	O
encephalopathy	B
correlates	O
with	O
EEG	O
changes	O
.	O

We	O
suggest	O
a	O
timely	O
EEG	O
evaluation	O
for	O
patients	O
receiving	O
ifosfamide	O
who	O
develop	O
features	O
of	O
encephalopathy	B
.	O

Incidence	O
of	O
contrast	O
-	O
induced	O
nephropathy	B
in	O
hospitalised	O
patients	O
with	O
cancer	B
.	O

OBJECTIVES	O
:	O
To	O
determine	O
the	O
frequency	O
of	O
and	O
possible	O
factors	O
related	O
to	O
contrast	O
-	O
induced	O
nephropathy	B
(	O
CIN	O
)	O
in	O
hospitalised	O
patients	O
with	O
cancer	B
.	O

METHODS	O
:	O
Ninety	O
adult	O
patients	O
were	O
enrolled	O
.	O

Patients	O
with	O
risk	O
factors	O
for	O
acute	B
renal	I
failure	I
were	O
excluded	O
.	O

Blood	O
samples	O
were	O
examined	O
the	O
day	O
before	O
contrast	O
-	O
enhanced	O
computed	O
tomography	O
(	O
CT	O
)	O
and	O
serially	O
for	O
3	O
days	O
thereafter	O
.	O

CIN	O
was	O
defined	O
as	O
an	O
increase	O
in	O
serum	O
creatinine	O
(	O
Cr	O
)	O
of	O
0.5	O
mg	O
/	O
dl	O
or	O
more	O
,	O
or	O
elevation	O
of	O
Cr	O
to	O
25	O
%	O
over	O
baseline	O
.	O

Relationships	O
between	O
CIN	O
and	O
possible	O
risk	O
factors	O
were	O
investigated	O
.	O

RESULTS	O
:	O
CIN	O
was	O
detected	O
in	O
18	O
/	O
90	O
(	O
20	O
%	O
)	O
patients	O
.	O

CIN	O
developed	O
in	O
25.5	O
%	O
patients	O
who	O
underwent	O
chemotherapy	O
and	O
in	O
11	O
%	O
patients	O
who	O
did	O
not	O
(	O
P	O
=	O
0.1	O
)	O
.	O

CIN	O
more	O
frequently	O
developed	O
in	O
patients	O
who	O
had	O
undergone	O
CT	O
within	O
45	O
days	O
after	O
the	O
last	O
chemotherapy	O
(	O
P	O
=	O
0.005	O
)	O
;	O
it	O
was	O
also	O
an	O
independent	O
risk	O
factor	O
(	O
P	O
=	O
0.017	O
)	O
.	O

CIN	O
was	O
significantly	O
more	O
after	O
treatment	O
with	O
bevacizumab	O
/	O
irinotecan	O
(	O
P	O
=	O
0.021	O
)	O
and	O
in	O
patients	O
with	O
hypertension	B
(	O
P	O
=	O
0.044	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
incidence	O
of	O
CIN	O
after	O
CT	O
in	O
hospitalised	O
oncological	O
patients	O
was	O
20	O
%	O
.	O

CIN	O
developed	O
4.5-times	O
more	O
frequently	O
in	O
patients	O
with	O
cancer	B
who	O
had	O
undergone	O
recent	O
chemotherapy	O
.	O

Hypertension	B
and	O
the	O
combination	O
of	O
bevacizumab	O
/	O
irinotecan	O
may	O
be	O
additional	O
risk	O
factors	O
for	O
CIN	O
development	O
.	O

KEY	O
POINTS	O
:	O
.	O

Contrast	O
-	O
induced	O
nephropathy	B
(	O
CIN	O
)	O
is	O
a	O
concern	O
for	O
oncological	O
patients	O
undergoing	O
CT	O
.	O
.	O

CIN	O
occurs	O
more	O
often	O
when	O
CT	O
is	O
performed	O
<	O
45	O
days	O
after	O
chemotherapy	O
.	O
.	O

Hypertension	B
and	O
treatment	O
with	O
bevacizumab	O
appear	O
to	O
be	O
additional	O
risk	O
factors	O
.	O

Syndrome	B
of	I
inappropriate	I
antidiuretic	I
hormone	I
secretion	O
associated	O
with	O
desvenlafaxine	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
a	O
case	O
of	O
syndrome	B
of	I
inappropriate	I
anti	I
-	I
diuretic	I
hormone	I
(	O
SIADH	B
)	O
secretion	O
associated	O
with	O
desvenlafaxine	O
.	O

CASE	O
SUMMARY	O
:	O
A	O
57-year	O
old	O
female	O
with	O
hyponatraemia	B
.	O

Her	O
medications	O
included	O
desvenlafaxine	O
,	O
and	O
symptoms	O
included	O
nausea	B
,	O
anxiety	B
and	O
confusion	B
.	O

The	O
serum	O
sodium	O
at	O
this	O
time	O
was	O
120	O
mmol	O
/	O
L	O
,	O
serum	O
osmolality	O
was	O
263	O
mosmol	O
/	O
kg	O
,	O
urine	O
osmolality	O
410	O
mosmol	O
/	O
kg	O
and	O
urine	O
sodium	O
63	O
mmol	O
/	O
L	O
,	O
consistent	O
with	O
a	O
diagnosis	O
of	O
SIADH	B
.	O

Desvenlafaxine	O
was	O
ceased	O
and	O
fluid	O
restriction	O
implemented	O
.	O

After	O
4	O
days	O
the	O
sodium	O
increased	O
to	O
128	O
mmol	O
/	O
L	O
and	O
fluid	O
restriction	O
was	O
relaxed	O
.	O

During	O
her	O
further	O
3	O
weeks	O
inpatient	O
admission	O
the	O
serum	O
sodium	O
ranged	O
from	O
134	O
to	O
137	O
mmol	O
/	O
L	O
during	O
treatment	O
with	O
mirtazapine	O
.	O

DISCUSSION	O
:	O
SIADH	B
has	O
been	O
widely	O
reported	O
with	O
a	O
range	O
of	O
antidepressants	O
.	O

This	O
case	O
report	O
suggests	O
that	O
desvenlafaxine	O
might	O
cause	O
clinically	O
significant	O
hyponatremia	B
.	O

CONCLUSIONS	O
:	O
Clinicians	O
should	O
be	O
aware	O
of	O
the	O
potential	O
for	O
antidepressants	O
to	O
cause	O
hyponatremia	B
,	O
and	O
take	O
appropriate	O
corrective	O
action	O
where	O
necessary	O
.	O

Oxidative	O
stress	O
on	O
cardiotoxicity	B
after	O
treatment	O
with	O
single	O
and	O
multiple	O
doses	O
of	O
doxorubicin	O
.	O

The	O
mechanism	O
of	O
doxorubicin	O
(	O
DOX	O
)	O
-induced	O
cardiotoxicity	B
remains	O
controversial	O
.	O

Wistar	O
rats	O
(	O
n	O
=	O
66	O
)	O
received	O
DOX	O
injections	O
intraperitoneally	O
and	O
were	O
randomly	O
assigned	O
to	O
2	O
experimental	O
protocols	O
:	O
(	O
1	O
)	O
rats	O
were	O
killed	O
before	O
(	O
-24	O
h	O
,	O
n	O
=	O
8)	O
and	O
24	O
h	O
after	O
(	O
+	O
24	O
h	O
,	O
n	O
=	O
8)	O
a	O
single	O
dose	O
of	O
DOX	O
(	O
4	O
mg	O
/	O
kg	O
body	O
weight	O
)	O
to	O
determine	O
the	O
DOX	O
acute	O
effect	O
and	O
(	O
2	O
)	O
rats	O
(	O
n	O
=	O
58	O
)	O
received	O
4	O
injections	O
of	O
DOX	O
(	O
4	O
mg	O
/	O
kg	O
body	O
weight	O
/	O
week	O
)	O
and	O
were	O
killed	O
before	O
the	O
first	O
injection	O
(	O
M0	O
)	O
and	O
1	O
week	O
after	O
each	O
injection	O
(	O
M1	O
,	O
M2	O
,	O
M3	O
,	O
and	O
M4	O
)	O
to	O
determine	O
the	O
chronological	O
effects	O
.	O

Animals	O
used	O
at	O
M0	O
(	O
n	O
=	O
8)	O
were	O
also	O
used	O
at	O
moment	O
-24	O
h	O
of	O
acute	O
study	O
.	O

Cardiac	O
total	O
antioxidant	O
performance	O
(	O
TAP	O
)	O
,	O
DNA	O
damage	O
,	O
and	O
morphology	O
analyses	O
were	O
carried	O
out	O
at	O
each	O
time	O
point	O
.	O

Single	O
dose	O
of	O
DOX	O
was	O
associated	O
with	O
increased	O
cardiac	B
disarrangement	I
,	O
necrosis	B
,	O
and	O
DNA	O
damage	O
(	O
strand	O
breaks	O
(	O
SBs	O
)	O
and	O
oxidized	O
pyrimidines	O
)	O
and	O
decreased	O
TAP	O
.	O

The	O
chronological	O
study	O
showed	O
an	O
effect	O
of	O
a	O
cumulative	O
dose	O
on	O
body	O
weight	O
(	O
R	O
=	O
-0.99	O
,	O
p	O
=	O
0.011	O
)	O
,	O
necrosis	B
(	O
R	O
=	O
1.00	O
,	O
p	O
=	O
0.004	O
)	O
,	O
TAP	O
(	O
R	O
=	O
0.95	O
,	O
p	O
=	O
0.049	O
)	O
,	O
and	O
DNA	O
SBs	O
(	O
R	O
=	O
-0.95	O
,	O
p	O
=	O
0.049	O
)	O
.	O

DNA	O
SBs	O
damage	O
was	O
negatively	O
associated	O
with	O
TAP	O
(	O
R	O
=	O
-0.98	O
,	O
p	O
=	O
0.018	O
)	O
,	O
and	O
necrosis	B
(	O
R	O
=	O
-0.97	O
,	O
p	O
=	O
0.027	O
)	O
.	O

Our	O
results	O
suggest	O
that	O
oxidative	O
damage	O
is	O
associated	O
with	O
acute	O
cardiotoxicity	B
induced	O
by	O
a	O
single	O
dose	O
of	O
DOX	O
only	O
.	O

Increased	O
resistance	O
to	O
the	O
oxidative	O
stress	O
is	O
plausible	O
for	O
the	O
multiple	O
dose	O
of	O
DOX	O
.	O

Thus	O
,	O
different	O
mechanisms	O
may	O
be	O
involved	O
in	O
acute	O
toxicity	B
versus	O
chronic	O
toxicity	B
.	O

Tacrolimus	O
-	O
related	O
seizure	B
after	O
pediatric	O
liver	O
transplantation	O
--	O
a	O
single	O
-	O
center	O
experience	O
.	O

To	O
identify	O
the	O
risk	O
factors	O
for	O
new	O
-	O
onset	O
seizures	B
after	O
pediatric	O
LT	O
and	O
to	O
assess	O
their	O
clinical	O
implications	O
and	O
long	O
-	O
term	O
prognosis	O
.	O

The	O
clinical	O
and	O
laboratory	O
data	O
of	O
27	O
consecutive	O
children	O
who	O
underwent	O
LT	O
from	O
January	O
2007	O
to	O
December	O
2010	O
in	O
our	O
center	O
were	O
analyzed	O
retrospectively	O
.	O

Patients	O
were	O
divided	O
into	O
seizures	B
group	O
and	O
a	O
non	O
-	O
seizures	B
group	O
.	O

Pre	O
-	O
operative	O
,	O
intra	O
-	O
operative	O
,	O
and	O
post	O
-	O
operative	O
data	O
were	O
collected	O
.	O

Seizures	B
occurred	O
in	O
four	O
children	O
,	O
an	O
incidence	O
of	O
14.8	O
%	O
.	O

All	O
exhibited	O
generalized	O
tonic	B
-	I
clonic	I
seizures	I
within	O
the	O
first	O
two	O
wk	O
after	O
LT	O
.	O

Univariate	O
analysis	O
showed	O
that	O
the	O
risk	O
factors	O
associated	O
with	O
seizures	B
after	O
pediatric	O
LT	O
included	O
gender	O
,	O
pediatric	O
end	B
-	I
stage	I
liver	I
disease	I
score	O
before	O
surgery	O
,	O
Child	O
-	O
Pugh	O
score	O
before	O
surgery	O
,	O
serum	O
total	O
bilirubin	O
after	O
surgery	O
,	O
and	O
trough	O
TAC	O
level	O
.	O

Multivariate	O
analysis	O
showed	O
that	O
trough	O
TAC	O
level	O
was	O
the	O
only	O
independent	O
risk	O
factor	O
associated	O
with	O
the	O
seizures	B
.	O

All	O
children	O
who	O
experienced	O
seizures	B
survived	O
with	O
good	O
graft	O
function	O
and	O
remained	O
seizure	B
-	O
free	O
without	O
anti	O
-	O
epileptic	B
drugs	O
over	O
a	O
mean	O
follow	O
-	O
up	O
period	O
of	O
33.7	O
+	O
14.6	O
months	O
.	O

High	O
trough	O
TAC	O
level	O
was	O
the	O
predominant	O
factor	O
that	O
contributed	O
to	O
seizures	B
in	O
the	O
early	O
post	O
-	O
operative	O
period	O
after	O
pediatric	O
LT	O
.	O

High	O
PELD	O
and	O
Child	O
-	O
Pugh	O
scores	O
before	O
LT	O
and	O
high	O
post	O
-	O
operative	O
serum	O
Tbil	O
may	O
be	O
contributory	O
risk	O
factors	O
for	O
TAC	O
-	O
related	O
seizures	B
.	O

The	O
flavonoid	O
apigenin	O
delays	O
forgetting	O
of	O
passive	O
avoidance	O
conditioning	O
in	O
rats	O
.	O

The	O
present	O
experiments	O
were	O
performed	O
to	O
study	O
the	O
effect	O
of	O
the	O
flavonoid	O
apigenin	O
(	O
20	O
mg	O
/	O
kg	O
intraperitoneally	O
(	O
i.p	O
.	O
)	O
,	O
1	O
h	O
before	O
acquisition	O
)	O
,	O
on	O
24	O
h	O
retention	O
performance	O
and	O
forgetting	O
of	O
a	O
step	O
-	O
through	O
passive	O
avoidance	O
task	O
,	O
in	O
young	O
male	O
Wistar	O
rats	O
.	O

There	O
were	O
no	O
differences	O
between	O
saline-	O
and	O
apigenin	O
-	O
treated	O
groups	O
in	O
the	O
24	O
h	O
retention	O
trial	O
.	O

Furthermore	O
,	O
apigenin	O
did	O
not	O
prevent	O
the	O
amnesia	B
induced	O
by	O
scopolamine	O
(	O
1mg	O
/	O
kg	O
,	O
i.p	O
.	O
,	O
30	O
min	O
before	O
the	O
acquisition	O
)	O
.	O

The	O
saline-	O
and	O
apigenin	O
-	O
treated	O
rats	O
that	O
did	O
not	O
step	O
through	O
into	O
the	O
dark	O
compartment	O
during	O
the	O
cut	O
-	O
off	O
time	O
(	O
540	O
s	O
)	O
were	O
retested	O
weekly	O
for	O
up	O
to	O
eight	O
weeks	O
.	O

In	O
the	O
saline	O
treated	O
group	O
,	O
the	O
first	O
significant	O
decline	O
in	O
passive	O
avoidance	O
response	O
was	O
observed	O
at	O
four	O
weeks	O
,	O
and	O
complete	O
memory	B
loss	I
was	O
found	O
five	O
weeks	O
after	O
the	O
acquisition	O
of	O
the	O
passive	O
avoidance	O
task	O
.	O

At	O
the	O
end	O
of	O
the	O
experimental	O
period	O
,	O
60	O
%	O
of	O
the	O
animals	O
treated	O
with	O
apigenin	O
still	O
did	O
not	O
step	O
through	O
.	O

These	O
data	O
suggest	O
that	O
1	O
)	O
apigenin	O
delays	O
the	O
long	O
-	O
term	O
forgetting	O
but	O
did	O
not	O
modulate	O
the	O
24	O
h	O
retention	O
of	O
fear	O
memory	O
and	O
2	O
)	O
the	O
obtained	O
beneficial	O
effect	O
of	O
apigenin	O
on	O
the	O
passive	O
avoidance	O
conditioning	O
is	O
mediated	O
by	O
mechanisms	O
that	O
do	O
not	O
implicate	O
its	O
action	O
on	O
the	O
muscarinic	O
cholinergic	O
system	O
.	O

Cholecystokinin	O
-	O
octapeptide	O
restored	O
morphine	O
-	O
induced	O
hippocampal	O
long	O
-	O
term	O
potentiation	O
impairment	O
in	O
rats	O
.	O

Cholecystokinin	O
-	O
octapeptide	O
(	O
CCK-8	O
)	O
,	O
which	O
is	O
a	O
typical	O
brain	O
-	O
gut	O
peptide	O
,	O
exerts	O
a	O
wide	O
range	O
of	O
biological	O
activities	O
on	O
the	O
central	O
nervous	O
system	O
.	O

We	O
have	O
previously	O
reported	O
that	O
CCK-8	O
significantly	O
alleviated	O
morphine	O
-	O
induced	O
amnesia	B
and	O
reversed	O
spine	O
density	O
decreases	O
in	O
the	O
CA1	O
region	O
of	O
the	O
hippocampus	O
in	O
morphine	O
-	O
treated	O
animals	O
.	O

Here	O
,	O
we	O
investigated	O
the	O
effects	O
of	O
CCK-8	O
on	O
long	O
-	O
term	O
potentiation	O
(	O
LTP	O
)	O
in	O
the	O
lateral	O
perforant	O
path	O
(	O
LPP	O
)	O
-granule	O
cell	O
synapse	O
of	O
rat	O
dentate	O
gyrus	O
(	O
DG	O
)	O
in	O
acute	O
saline	O
or	O
morphine	O
-	O
treated	O
rats	O
.	O

Population	O
spikes	O
(	O
PS	O
)	O
,	O
which	O
were	O
evoked	O
by	O
stimulation	O
of	O
the	O
LPP	O
,	O
were	O
recorded	O
in	O
the	O
DG	O
region	O
.	O

Acute	O
morphine	O
(	O
30mg	O
/	O
kg	O
,	O
s.c	O
.	O
)	O
treatment	O
significantly	O
attenuated	O
hippocampal	O
LTP	O
and	O
CCK-8	O
(	O
1ug	O
,	O
i.c.v	O
.	O
)	O
restored	O
the	O
amplitude	O
of	O
PS	O
that	O
was	O
attenuated	O
by	O
morphine	O
injection	O
.	O

Furthermore	O
,	O
microinjection	O
of	O
CCK-8	O
(	O
0.1	O
and	O
1ug	O
,	O
i.c.v	O
.	O
)	O
also	O
significantly	O
augmented	O
hippocampal	O
LTP	O
in	O
saline	O
-	O
treated	O
(	O
1ml	O
/	O
kg	O
,	O
s.c	O
.	O
)	O
rats	O
.	O

Pre	O
-	O
treatment	O
of	O
the	O
CCK2	O
receptor	O
antagonist	O
L-365,260	O
(	O
10ug	O
,	O
i.c.v	O
)	O
reversed	O
the	O
effects	O
of	O
CCK-8	O
,	O
but	O
the	O
CCK1	O
receptor	O
antagonist	O
L-364,718	O
(	O
10ug	O
,	O
i.c.v	O
)	O
did	O
not	O
.	O

The	O
present	O
results	O
demonstrate	O
that	O
CCK-8	O
attenuates	O
the	O
effect	O
of	O
morphine	O
on	O
hippocampal	O
LTP	O
through	O
CCK2	O
receptors	O
and	O
suggest	O
an	O
ameliorative	O
function	O
of	O
CCK-8	O
on	O
morphine	O
-	O
induced	O
memory	B
impairment	I
.	O

Glial	O
activation	O
and	O
post	O
-	O
synaptic	O
neurotoxicity	B
:	O
the	O
key	O
events	O
in	O
Streptozotocin	O
(	O
ICV	O
)	O
induced	O
memory	B
impairment	I
in	O
rats	O
.	O

In	O
the	O
present	O
study	O
the	O
role	O
of	O
glial	O
activation	O
and	O
post	O
synaptic	O
toxicity	B
in	O
ICV	O
Streptozotocin	O
(	O
STZ	O
)	O
induced	O
memory	B
impaired	I
rats	O
was	O
explored	O
.	O

In	O
experiment	O
set	O
up	O
1	O
:	O
Memory	B
deficit	I
was	O
found	O
in	O
Morris	O
water	O
maze	O
test	O
on	O
14	O
-	O
16	O
days	O
after	O
STZ	O
(	O
ICV	O
;	O
3mg	O
/	O
Kg	O
)	O
administration	O
.	O

STZ	O
causes	O
increased	O
expression	O
of	O
GFAP	O
,	O
CD11b	O
and	O
TNF	O
-	O
a	O
indicating	O
glial	O
activation	O
and	O
neuroinflammation	B
.	O

STZ	O
also	O
significantly	O
increased	O
the	O
level	O
of	O
ROS	O
,	O
nitrite	O
,	O
Ca	O
(	O
2	O
+	O
)	O
and	O
reduced	O
the	O
mitochondrial	O
activity	O
in	O
synaptosomal	O
preparation	O
illustrating	O
free	O
radical	O
generation	O
and	O
excitotoxicity	B
.	O

Increased	O
expression	O
and	O
activity	O
of	O
Caspase-3	O
was	O
also	O
observed	O
in	O
STZ	O
treated	O
rat	O
which	O
specify	O
apoptotic	O
cell	O
death	O
in	O
hippocampus	O
and	O
cortex	O
.	O

STZ	O
treatment	O
showed	O
decrease	O
expression	O
of	O
post	O
synaptic	O
markers	O
CaMKIIa	O
and	O
PSD-95	O
,	O
while	O
,	O
expression	O
of	O
pre	O
synaptic	O
markers	O
(	O
synaptophysin	O
and	O
SNAP-25	O
)	O
remains	O
unaltered	O
indicating	O
selective	O
post	O
synaptic	O
neurotoxicity	B
.	O

Oral	O
treatment	O
with	O
Memantine	O
(	O
10mg	O
/	O
kg	O
)	O
and	O
Ibuprofen	O
(	O
50	O
mg	O
/	O
kg	O
)	O
daily	O
for	O
13	O
days	O
attenuated	O
STZ	O
induced	O
glial	O
activation	O
,	O
apoptotic	O
cell	O
death	O
and	O
post	O
synaptic	O
neurotoxicity	B
in	O
rat	O
brain	O
.	O

Further	O
,	O
in	O
experiment	O
set	O
up	O
2	O
:	O
where	O
memory	O
function	O
was	O
not	O
affected	O
i.e.	O
7	O
-	O
9	O
days	O
after	O
STZ	O
treatment	O
.	O

The	O
level	O
of	O
GFAP	O
,	O
CD11b	O
,	O
TNF	O
-	O
a	O
,	O
ROS	O
and	O
nitrite	O
levels	O
were	O
increased	O
.	O

On	O
the	O
other	O
hand	O
,	O
apoptotic	O
marker	O
,	O
synaptic	O
markers	O
,	O
mitochondrial	O
activity	O
and	O
Ca	O
(	O
2	O
+	O
)	O
levels	O
remained	O
unaffected	O
.	O

Collective	O
data	O
indicates	O
that	O
neuroinflammatory	B
process	O
and	O
oxidative	O
stress	O
occurs	O
earlier	O
to	O
apoptosis	O
and	O
does	O
not	O
affect	O
memory	O
function	O
.	O

Present	O
study	O
clearly	O
suggests	O
that	O
glial	O
activation	O
and	O
post	O
synaptic	O
neurotoxicity	B
are	O
the	O
key	O
factors	O
in	O
STZ	O
induced	O
memory	B
impairment	I
and	O
neuronal	O
cell	O
death	O
.	O

Comparison	O
of	O
effects	O
of	O
isotonic	O
sodium	O
chloride	O
with	O
diltiazem	O
in	O
prevention	O
of	O
contrast	O
-	O
induced	O
nephropathy	B
.	O

INTRODUCTION	O
AND	O
OBJECTIVE	O
:	O
Contrast	O
-	O
induced	O
nephropathy	B
(	O
CIN	O
)	O
significantly	O
increases	O
the	O
morbidity	O
and	O
mortality	O
of	O
patients	O
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
and	O
compare	O
the	O
protective	O
effects	O
of	O
isotonic	O
sodium	O
chloride	O
with	O
sodium	O
bicarbonate	O
infusion	O
and	O
isotonic	O
sodium	O
chloride	O
infusion	O
with	O
diltiazem	O
,	O
a	O
calcium	O
channel	O
blocker	O
,	O
in	O
preventing	O
CIN	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Our	O
study	O
included	O
patients	O
who	O
were	O
administered	O
30	O
-	O
60	O
mL	O
of	O
iodinated	O
contrast	O
agent	O
for	O
percutaneous	O
coronary	O
angiography	O
(	O
PCAG	O
)	O
,	O
all	O
with	O
creatinine	O
values	O
between	O
1.1	O
and	O
3.1	O
mg	O
/	O
dL.	O
Patients	O
were	O
divided	O
into	O
three	O
groups	O
and	O
each	O
group	O
had	O
20	O
patients	O
.	O

The	O
first	O
group	O
of	O
patients	O
was	O
administered	O
isotonic	O
sodium	O
chloride	O
;	O
the	O
second	O
group	O
was	O
administered	O
a	O
solution	O
that	O
of	O
5	O
%	O
dextrose	O
and	O
sodium	O
bicarbonate	O
,	O
while	O
the	O
third	O
group	O
was	O
administered	O
isotonic	O
sodium	O
chloride	O
before	O
and	O
after	O
the	O
contrast	O
injection	O
.	O

The	O
third	O
group	O
received	O
an	O
additional	O
injection	O
of	O
diltiazem	O
the	O
day	O
before	O
and	O
first	O
2	O
days	O
after	O
the	O
contrast	O
injection	O
.	O

All	O
of	O
the	O
patients	O
'	O
plasma	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
and	O
creatinine	O
levels	O
were	O
measured	O
on	O
the	O
second	O
and	O
seventh	O
day	O
after	O
the	O
administration	O
of	O
intravenous	O
contrast	O
material	O
.	O

RESULTS	O
:	O
The	O
basal	O
creatinine	O
levels	O
were	O
similar	O
for	O
all	O
three	O
groups	O
(	O
p	O
>	O
0.05	O
)	O
.	O

Among	O
a	O
total	O
of	O
60	O
patients	O
included	O
in	O
the	O
study	O
,	O
16	O
patients	O
developed	O
acute	B
renal	I
failure	I
(	O
ARF	B
)	O
on	O
the	O
second	O
day	O
after	O
contrast	O
material	O
was	O
injected	O
(	O
26.6	O
%	O
)	O
.	O

The	O
number	O
of	O
patients	O
who	O
developed	O
ARF	B
on	O
the	O
second	O
day	O
after	O
the	O
injection	O
in	O
the	O
first	O
group	O
was	O
five	O
(	O
25	O
%	O
)	O
,	O
in	O
the	O
second	O
group	O
was	O
six	O
(	O
30	O
%	O
)	O
and	O
the	O
third	O
group	O
was	O
five	O
(	O
25	O
%	O
)	O
(	O
p	O
>	O
0.05	O
)	O
.	O

CONCLUSION	O
:	O
There	O
was	O
no	O
significant	O
difference	O
between	O
isotonic	O
sodium	O
chloride	O
,	O
sodium	O
bicarbonate	O
and	O
isotonic	O
sodium	O
chloride	O
with	O
diltiazem	O
application	O
in	O
prevention	O
of	O
CIN	O
.	O

Neurocognitive	O
and	O
neuroradiologic	O
central	O
nervous	O
system	O
late	O
effects	O
in	O
children	O
treated	O
on	O
Pediatric	O
Oncology	O
Group	O
(	O
POG	O
)	O
P9605	O
(	O
standard	O
risk	O
)	O
and	O
P9201	O
(	O
lesser	O
risk	O
)	O
acute	B
lymphoblastic	I
leukemia	I
protocols	O
(	O
ACCL0131	O
)	O
:	O
a	O
methotrexate	O
consequence	O
?	O

A	O
report	O
from	O
the	O
Children	O
's	O
Oncology	O
Group	O
.	O

Concerns	O
about	O
long	O
-	O
term	O
methotrexate	O
(	O
MTX	O
)	O
neurotoxicity	B
in	O
the	O
1990s	O
led	O
to	O
modifications	O
in	O
intrathecal	O
(	O
IT	O
)	O
therapy	O
,	O
leucovorin	O
rescue	O
,	O
and	O
frequency	O
of	O
systemic	O
MTX	O
administration	O
in	O
children	O
with	O
acute	B
lymphoblastic	I
leukemia	I
.	O

In	O
this	O
study	O
,	O
neurocognitive	O
outcomes	O
and	O
neuroradiologic	O
evidence	O
of	O
leukoencephalopathy	B
were	O
compared	O
in	O
children	O
treated	O
with	O
intense	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
-directed	O
therapy	O
(	O
P9605	O
)	O
versus	O
those	O
receiving	O
fewer	O
CNS	O
-	O
directed	O
treatment	O
days	O
during	O
intensive	O
consolidation	O
(	O
P9201	O
)	O
.	O

A	O
total	O
of	O
66	O
children	O
from	O
16	O
Pediatric	O
Oncology	O
Group	O
institutions	O
with	O
""""	O
standard	O
-	O
risk	O
""""	O
acute	B
lymphoblastic	I
leukemia	I
,	O
1.00	O
to	O
9.99	O
years	O
at	O
diagnosis	O
,	O
without	O
evidence	O
of	O
CNS	O
leukemia	B
at	O
diagnosis	O
were	O
enrolled	O
on	O
ACCL0131	O
:	O
28	O
from	O
P9201	O
and	O
38	O
from	O
P9605	O
.	O

Magnetic	O
resonance	O
imaging	O
scans	O
and	O
standard	O
neuropsychological	O
tests	O
were	O
performed	O
>	O
2.6	O
years	O
after	O
the	O
end	O
of	O
treatment	O
.	O

Significantly	O
more	O
P9605	O
patients	O
developed	O
leukoencephalopathy	B
compared	O
with	O
P9201	O
patients	O
(	O
68	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
49%-83	O
%	O
vs.	O
22	O
%	O
,	O
95	O
%	O
confidence	O
interval	O
5%-44	O
%	O
;	O
P=0.001	O
)	O
identified	O
as	O
late	O
as	O
7.7	O
years	O
after	O
the	O
end	O
of	O
treatment	O
.	O

Overall	O
,	O
40	O
%	O
of	O
patients	O
scored	O
<	O
85	O
on	O
either	O
Verbal	O
or	O
Performance	O
IQ	O
.	O

Children	O
on	O
both	O
studies	O
had	O
significant	O
attention	B
problems	I
,	O
but	O
P9605	O
children	O
scored	O
below	O
average	O
on	O
more	O
neurocognitive	O
measures	O
than	O
those	O
treated	O
on	O
P9201	O
(	O
82	O
%	O
,	O
14	O
/	O
17	O
measures	O
vs.	O
24	O
%	O
,	O
4	O
/	O
17	O
measures	O
)	O
.	O

This	O
supports	O
ongoing	O
concerns	O
about	O
intensive	O
MTX	O
exposure	O
as	O
a	O
major	O
contributor	O
to	O
CNS	O
late	O
effects	O
.	O

Tranexamic	O
acid	O
overdosage	O
-	O
induced	O
generalized	O
seizure	B
in	O
renal	B
failure	I
.	O

We	O
report	O
a	O
45-year	O
-	O
old	O
lady	O
with	O
chronic	B
kidney	I
disease	I
stage	O
4	O
due	O
to	O
chronic	O
tubulointerstial	B
disease	I
.	O

She	O
was	O
admitted	O
to	O
our	O
center	O
for	O
severe	O
anemia	B
due	O
to	O
menorrhagia	B
and	O
deterioration	B
of	I
renal	I
function	I
.	O

She	O
was	O
infused	O
three	O
units	O
of	O
packed	O
cells	O
during	O
a	O
session	O
of	O
hemodialysis	O
.	O

Tranexamic	O
acid	O
(	O
TNA	O
)	O
1	O
g	O
8-hourly	O
was	O
administered	O
to	O
her	O
to	O
control	O
bleeding	B
per	O
vaginum	O
.	O

Two	O
hours	O
after	O
the	O
sixth	O
dose	O
of	O
TNA	O
,	O
she	O
had	O
an	O
episode	O
of	O
generalized	O
tonic	B
clonic	I
convulsions	I
.	O

TNA	O
was	O
discontinued	O
.	O

Investigations	O
of	O
the	O
patient	O
revealed	O
no	O
biochemical	O
or	O
structural	O
central	O
nervous	B
system	I
abnormalities	I
that	O
could	O
have	O
provoked	O
the	O
convulsions	B
.	O

She	O
did	O
not	O
require	O
any	O
further	O
dialytic	O
support	O
.	O

She	O
had	O
no	O
further	O
episodes	O
of	O
convulsion	B
till	O
dis	O
-	O
charge	O
and	O
during	O
the	O
two	O
months	O
of	O
follow	O
-	O
up	O
.	O

Thus	O
,	O
the	O
precipitating	O
cause	O
of	O
convulsions	B
was	O
believed	O
to	O
be	O
an	O
overdose	B
of	O
TNA	O
.	O

Pre	O
-	O
treatment	O
of	O
bupivacaine	O
-	O
induced	O
cardiovascular	B
depression	I
using	O
different	O
lipid	O
formulations	O
of	O
propofol	O
.	O

BACKGROUND	O
:	O
Pre	O
-	O
treatment	O
with	O
lipid	O
emulsions	O
has	O
been	O
shown	O
to	O
increase	O
lethal	O
doses	O
of	O
bupivacaine	O
,	O
and	O
the	O
lipid	O
content	O
of	O
propofol	O
may	O
alleviate	O
bupivacaine	O
-	O
induced	O
cardiotoxicity	B
.	O

The	O
aim	O
of	O
this	O
study	O
is	O
to	O
investigate	O
the	O
effects	O
of	O
propofol	O
in	O
intralipid	O
or	O
medialipid	O
emulsions	O
on	O
bupivacaine	O
-	O
induced	O
cardiotoxicity	B
.	O

METHODS	O
:	O
Rats	O
were	O
anaesthetised	O
with	O
ketamine	O
and	O
were	O
given	O
0.5	O
mg	O
/	O
kg	O
/	O
min	O
propofol	O
in	O
intralipid	O
(	O
Group	O
P	O
)	O
,	O
propofol	O
in	O
medialipid	O
(	O
Group	O
L	O
)	O
,	O
or	O
saline	O
(	O
Group	O
C	O
)	O
over	O
20	O
min	O
.	O

Thereafter	O
,	O
2	O
mg	O
/	O
kg	O
/	O
min	O
bupivacaine	O
0.5	O
%	O
was	O
infused	O
.	O

We	O
recorded	O
time	O
to	O
first	O
dysrhythmia	B
occurrence	O
,	O
respective	O
times	O
to	O
25	O
%	O
and	O
50	O
%	O
reduction	O
of	O
the	O
heart	O
rate	O
(	O
HR	O
)	O
and	O
mean	O
arterial	O
pressure	O
,	O
and	O
time	O
to	O
asystole	B
and	O
total	O
amount	O
of	O
bupivacaine	O
consumption	O
.	O

Blood	O
and	O
tissue	O
samples	O
were	O
collected	O
following	O
asystole	B
.	O

RESULTS	O
:	O
The	O
time	O
to	O
first	O
dysrhythmia	B
occurrence	O
,	O
time	O
to	O
25	O
%	O
and	O
50	O
%	O
reductions	O
in	O
HR	O
,	O
and	O
time	O
to	O
asystole	B
were	O
longer	O
in	O
Group	O
P	O
than	O
the	O
other	O
groups	O
.	O

The	O
cumulative	O
bupivacaine	O
dose	O
given	O
at	O
those	O
time	O
points	O
was	O
higher	O
in	O
Group	O
P.	O
Plasma	O
bupivacaine	O
levels	O
were	O
significantly	O
lower	O
in	O
Group	O
P	O
than	O
in	O
Group	O
C.	O
Bupivacaine	O
levels	O
in	O
the	O
brain	O
and	O
heart	O
were	O
significantly	O
lower	O
in	O
Group	O
P	O
and	O
Group	O
L	O
than	O
in	O
Group	O
C.	O
CONCLUSION	O
:	O
We	O
conclude	O
that	O
pre	O
-	O
treatment	O
with	O
propofol	O
in	O
intralipid	O
,	O
compared	O
with	O
propofol	O
in	O
medialipid	O
or	O
saline	O
,	O
delayed	O
the	O
onset	O
of	O
bupivacaine	O
-	O
induced	O
cardiotoxic	B
effects	O
as	O
well	O
as	O
reduced	O
plasma	O
bupivacaine	O
levels	O
.	O

Further	O
studies	O
are	O
needed	O
to	O
explore	O
tissue	O
bupivacaine	O
levels	O
of	O
propofol	O
in	O
medialipid	O
and	O
adapt	O
these	O
results	O
to	O
clinical	O
practice	O
.	O

Drug	B
-	I
Induced	I
Acute	I
Liver	I
Injury	I

Within	O
12	O
Hours	O
After	O
Fluvastatin	O
Therapy	O
.	O

Although	O
statins	O
are	O
generally	O
well	O
-	O
tolerated	O
drugs	O
,	O
recent	O
cases	O
of	O
drug	B
-	I
induced	I
liver	I
injury	I
associated	O
with	O
their	O
use	O
have	O
been	O
reported	O
.	O

A	O
52-year	O
-	O
old	O
Chinese	O
man	O
reported	O
with	O
liver	B
damage	I
,	O
which	O
appeared	O
12	O
hours	O
after	O
beginning	O
treatment	O
with	O
fluvastatin	O
.	O

Patient	O
presented	O
with	O
complaints	O
of	O
increasing	O
nausea	B
,	O
anorexia	B
,	O
and	O
upper	O
abdominal	B
pain	I
.	O

His	O
laboratory	O
values	O
showed	O
elevated	O
creatine	O
kinase	O
and	O
transaminases	O
.	O

Testing	O
for	O
autoantibodies	O
was	O
also	O
negative	O
.	O

The	O
liver	O
biochemistries	O
eventually	O
normalized	O
within	O
3	O
weeks	O
of	O
stopping	O
the	O
fluvastatin	O
.	O

Therefore	O
,	O
when	O
prescribing	O
statins	O
,	O
the	O
possibility	O
of	O
hepatic	B
damage	I
should	O
be	O
taken	O
into	O
account	O
.	O

Fluconazole	O
associated	O
agranulocytosis	B
and	O
thrombocytopenia	B
.	O

CASE	O
:	O
We	O
describe	O
a	O
second	O
case	O
of	O
fluconazole	O
associated	O
agranulocytosis	B
with	O
thrombocytopenia	B
and	O
recovery	O
upon	O
discontinuation	O
of	O
therapy	O
.	O

The	O
patient	O
began	O
to	O
have	O
changes	O
in	O
white	O
blood	O
cells	O
and	O
platelets	O
within	O
48	O
h	O
of	O
administration	O
of	O
fluconazole	O
and	O
began	O
to	O
recover	O
with	O
48	O
h	O
of	O
discontinuation	O
.	O

This	O
case	O
highlights	O
that	O
drug	O
-	O
induced	O
blood	B
dyscrasias	I
can	O
occur	O
unexpectedly	O
as	O
a	O
result	O
of	O
treatment	O
with	O
a	O
commonly	O
used	O
drug	O
thought	O
to	O
be	O
""""	O
safe	O
""""	O
.	O

CONCLUSION	O
:	O
According	O
to	O
Naranjo	O
's	O
algorithm	O
the	O
likelihood	O
that	O
our	O
patient	O
's	O
agranulocytosis	B
and	O
thrombocytopenia	B
occurred	O
as	O
a	O
result	O
of	O
therapy	O
with	O
fluconazole	O
is	O
probable	O
,	O
with	O
a	O
total	O
of	O
six	O
points	O
.	O

We	O
feel	O
that	O
the	O
weight	O
of	O
the	O
overall	O
evidence	O
of	O
this	O
evidence	O
is	O
strong	O
.	O

In	O
particular	O
the	O
temporal	O
relationship	O
of	O
bone	B
marrow	I
suppression	I
to	O
the	O
initiation	O
of	O
fluconazole	O
and	O
the	O
abatement	O
of	O
symptoms	O
that	O
rapidly	O
reversed	O
immediately	O
following	O
discontinuation	O
.	O

Two	O
-	O
dimensional	O
speckle	O
tracking	O
echocardiography	O
combined	O
with	O
high	O
-	O
sensitive	O
cardiac	O
troponin	O
T	O
in	O
early	O
detection	O
and	O
prediction	O
of	O
cardiotoxicity	B
during	O
epirubicine	O
-	O
based	O
chemotherapy	O
.	O

AIMS	O
:	O
To	O
investigate	O
whether	O
alterations	O
of	O
myocardial	B
strain	I
and	O
high	O
-	O
sensitive	O
cardiac	O
troponin	O
T	O
(	O
cTnT	O
)	O
could	O
predict	O
future	O
cardiac	B
dysfunction	I
in	O
patients	O
after	O
epirubicin	O
exposure	O
.	O

METHODS	O
:	O
Seventy	O
-	O
five	O
patients	O
with	O
non	B
-	I
Hodgkin	I
lymphoma	I
treated	O
with	O
epirubicin	O
were	O
studied	O
.	O

Blood	O
collection	O
and	O
echocardiography	O
were	O
performed	O
at	O
baseline	O
,	O
1	O
day	O
after	O
the	O
third	O
cycle	O
,	O
and	O
1	O
day	O
after	O
completion	O
of	O
chemotherapy	O
.	O

Patients	O
were	O
studied	O
using	O
echocardiography	O
during	O
follow	O
-	O
up	O
.	O

Global	O
longitudinal	O
(	O
GLS	O
)	O
,	O
circumferential	O
(	O
GCS	O
)	O
,	O
and	O
radial	O
strain	O
(	O
GRS	O
)	O
were	O
calculated	O
using	O
speckle	O
tracking	O
echocardiography	O
.	O

Left	O
ventricular	O
ejection	O
fraction	O
was	O
analysed	O
by	O
real	O
-	O
time	O
3D	O
echocardiography	O
.	O

Cardiotoxicity	B
was	O
defined	O
as	O
a	O
reduction	O
of	O
the	O
LVEF	O
of	O
>	O
5	O
%	O
to	O
<	O
55	O
%	O
with	O
symptoms	O
of	O
heart	B
failure	I
or	O
an	O
asymptomatic	O
reduction	O
of	O
the	O
LVEF	O
of	O
>	O
10	O
%	O
to	O
<	O
55	O
%	O
.	O

RESULTS	O
:	O
Fourteen	O
patients	O
(	O
18.67	O
%	O
)	O
developed	O
cardiotoxicity	B
after	O
treatment	O
.	O

GLS	O
(	O
-18.48	O
+	O
1.72	O
%	O
vs.	O
-15.96	O
+	O
1.6	O
%	O
)	O
,	O
GCS	O
(	O
-20.93	O
+	O
2.86	O
%	O
vs.	O
-19.20	O
+	O
3.21	O
%	O
)	O
,	O
and	O
GRS	O
(	O
39.23	O
+	O
6.44	O
%	O
vs.	O
34.98	O
+	O
6.2	O
%	O
)	O
were	O
markedly	O
reduced	O
and	O
cTnT	O
was	O
elevated	O
from	O
0.0010	O
+	O
0.0020	O
to	O
0.0073	O
+	O
0.0038	O
ng	O
/	O
mL	O
(	O
P	O
all	O
<	O
0.01	O
)	O
at	O
the	O
completion	O
of	O
chemotherapy	O
compared	O
with	O
baseline	O
values	O
.	O

A	O
>	O
15.9	O
%	O
decrease	O
in	O
GLS	O
[	O
sensitivity	O
,	O
86	O
%	O
;	O
specificity	O
,	O
75	O
%	O
;	O
area	O
under	O
the	O
curve	O
(	O
AUC	O
)	O
=	O
0.815	O
;	O
P	O
=	O
0.001	O
]	O
and	O
a	O
>	O
0.004	O
ng	O
/	O
mL	O
elevation	O
in	O
cTnT	O
(	O
sensitivity	O
,	O
79	O
%	O
;	O
specificity	O
,	O
64	O
%	O
;	O
AUC	O
=	O
0.757	O
;	O
P	O
=	O
0.005	O
)	O
from	O
baseline	O
to	O
the	O
third	O
cycle	O
of	O
chemotherapy	O
predicted	O
later	O
cardiotoxicity	B
.	O

The	O
decrease	O
in	O
GLS	O
remained	O
the	O
only	O
independent	O
predictor	O
of	O
cardiotoxicity	B
(	O
P	O
=	O
0.000	O
)	O
.	O

CONCLUSIONS	O
:	O
GLS	O
combined	O
with	O
cTnT	O
may	O
provide	O
a	O
reliable	O
and	O
non	O
-	O
invasive	O
method	O
to	O
predict	O
cardiac	B
dysfunction	I
in	O
patients	O
receiving	O
anthracycline	O
-	O
based	O
chemotherapy	O
.	O

Prevention	O
of	O
etomidate	O
-	O
induced	O
myoclonus	B
:	O
which	O
is	O
superior	O
:	O
Fentanyl	O
,	O
midazolam	O
,	O
or	O
a	O
combination	O
?	O

A	O
Retrospective	O
comparative	O
study	O
.	O

BACKGROUND	O
:	O
In	O
this	O
retrospective	O
comparative	O
study	O
,	O
we	O
aimed	O
to	O
compare	O
the	O
effectiveness	O
of	O
fentanyl	O
,	O
midazolam	O
,	O
and	O
a	O
combination	O
of	O
fentanyl	O
and	O
midazolam	O
to	O
prevent	O
etomidate	O
-	O
induced	O
myoclonus	B
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
This	O
study	O
was	O
performed	O
based	O
on	O
anesthesia	O
records	O
.	O

Depending	O
on	O
the	O
drugs	O
that	O
would	O
be	O
given	O
before	O
the	O
induction	O
of	O
anesthesia	O
with	O
etomidate	O
,	O
the	O
patients	O
were	O
separated	O
into	O
4	O
groups	O
:	O
no	O
pretreatment	O
(	O
Group	O
NP	O
)	O
,	O
fentanyl	O
1	O
ug.kg-1	O
(	O
Group	O
F	O
)	O
,	O
midazolam	O
0.03	O
mg.kg-1	O
(	O
Group	O
M	O
)	O
,	O
and	O
midazolam	O
0.015	O
mg.kg-1	O
+	O
fentanyl	O
0.5	O
ug.kg-1	O
(	O
Group	O
FM	O
)	O
.	O

Patients	O
who	O
received	O
the	O
same	O
anesthetic	O
procedure	O
were	O
selected	O
:	O
2	O
minutes	O
after	O
intravenous	O
injections	O
of	O
the	O
pretreatment	O
drugs	O
,	O
anesthesia	O
is	O
induced	O
with	O
0.3	O
mg.kg-1	O
etomidate	O
injected	O
intravenously	O
over	O
a	O
period	O
of	O
20	O
-	O
30	O
seconds	O
.	O

Myoclonic	B
movements	I
are	O
evaluated	O
,	O
which	O
were	O
observed	O
and	O
graded	O
according	O
to	O
clinical	O
severity	O
during	O
the	O
2	O
minutes	O
after	O
etomidate	O
injection	O
.	O

The	O
severity	O
of	O
pain	B
due	O
to	O
etomidate	O
injection	O
,	O
mean	O
arterial	O
pressure	O
,	O
heart	O
rate	O
,	O
and	O
adverse	O
effects	O
were	O
also	O
evaluated	O
.	O

RESULTS	O
:	O
Study	O
results	O
showed	O
that	O
myoclonus	B
incidence	O
was	O
85	O
%	O
,	O
40	O
%	O
,	O
70	O
%	O
,	O
and	O
25	O
%	O
in	O
Group	O
NP	O
,	O
Group	O
F	O
,	O
Group	O
M	O
,	O
and	O
Group	O
FM	O
,	O
respectively	O
,	O
and	O
were	O
significantly	O
lower	O
in	O
Group	O
F	O
and	O
Group	O
FM	O
.	O

CONCLUSIONS	O
:	O
We	O
conclude	O
that	O
pretreatment	O
with	O
fentanyl	O
or	O
combination	O
of	O
fentanyl	O
and	O
midazolam	O
was	O
effective	O
in	O
preventing	O
etomidate	O
-	O
induced	O
myoclonus	B
.	O

Cholestatic	B
presentation	O
of	O
yellow	O
phosphorus	O
poisoning	B
.	O

Yellow	O
phosphorus	O
,	O
a	O
component	O
of	O
certain	O
pesticide	O
pastes	O
and	O
fireworks	O
,	O
is	O
well	O
known	O
to	O
cause	O
hepatotoxicity	B
.	O

Poisoning	B
with	O
yellow	O
phosphorus	O
classically	O
manifests	O
with	O
acute	B
hepatitis	I
leading	O
to	O
acute	B
liver	I
failure	I
which	O
may	O
need	O
liver	O
transplantation	O
.	O

We	O
present	O
a	O
case	O
of	O
yellow	O
phosphorus	O
poisoning	B
in	O
which	O
a	O
patient	O
presented	O
with	O
florid	O
clinical	O
features	O
of	O
cholestasis	B
highlighting	O
the	O
fact	O
that	O
cholestasis	B
can	O
rarely	O
be	O
a	O
presenting	O
feature	O
of	O
yellow	O
phosphorus	O
hepatotoxicity	B
.	O

Vasovagal	B
syncope	I
and	O
severe	O
bradycardia	B
following	O
intranasal	O
dexmedetomidine	O
for	O
pediatric	O
procedural	O
sedation	O
.	O

We	O
report	O
syncope	B
and	O
bradycardia	B
in	O
an	O
11-year	O
-	O
old	O
girl	O
following	O
administration	O
of	O
intranasal	O
dexmedetomidine	O
for	O
sedation	O
for	O
a	O
voiding	O
cystourethrogram	O
.	O

Following	O
successful	O
completion	O
of	O
VCUG	O
and	O
a	O
60-min	O
recovery	O
period	O
,	O
the	O
patient	O
's	O
level	O
of	O
consciousness	O
and	O
vital	O
signs	O
returned	O
to	O
presedation	O
levels	O
.	O

Upon	O
leaving	O
the	O
sedation	O
area	O
,	O
the	O
patient	O
collapsed	O
,	O
with	O
no	O
apparent	O
inciting	O
event	O
.	O

The	O
patient	O
quickly	O
regained	O
consciousness	O
and	O
no	O
injury	O
occurred	O
.	O

The	O
primary	O
abnormality	O
found	O
was	O
persistent	O
bradycardia	B
,	O
and	O
she	O
was	O
admitted	O
to	O
the	O
hospital	O
for	O
telemetric	O
observation	O
.	O

The	O
bradycardia	B
lasted	O
~2	O
h	O
,	O
and	O
further	O
cardiac	O
workup	O
revealed	O
no	O
underlying	O
abnormality	O
.	O

Unanticipated	O
and	O
previously	O
unreported	O
outcomes	O
may	O
be	O
witnessed	O
as	O
we	O
expand	O
the	O
use	O
of	O
certain	O
sedatives	O
to	O
alternative	O
routes	O
of	O
administration	O
.	O

Paradoxical	O
severe	O
agitation	B
induced	O
by	O
add	O
-	O
on	O
high	O
-	O
doses	O
quetiapine	O
in	O
schizo	B
-	I
affective	I
disorder	I
.	O

We	O
report	O
the	O
case	O
of	O
a	O
35-year	O
-	O
old	O
patient	O
suffering	O
from	O
schizo	B
-	I
affective	I
disorder	I
since	O
the	O
age	O
of	O
19	O
years	O
,	O
treated	O
by	O
a	O
combination	O
of	O
first	O
-	O
generation	O
antipsychotics	O
,	O
zuclopenthixol	O
(	O
100	O
mg	O
/	O
day	O
)	O
and	O
lithium	O
(	O
1200	O
mg	O
/	O
day	O
)	O
(	O
serum	O
lithium=0.85	O
mEq	O
/	O
l	O
)	O
.	O

This	O
patient	O
had	O
no	O
associated	O
personality	B
disorder	I
(	O
particularly	O
no	O
antisocial	B
disorder	I
)	O
and	O
no	O
substance	B
abuse	I
disorder	I
.	O

Within	O
the	O
48	O
h	O
following	O
the	O
gradual	O
introduction	O
of	O
quetiapine	O
(	O
up	O
to	O
600	O
mg	O
/	O
day	O
)	O
,	O
the	O
patient	O
presented	O
severe	O
agitation	B
without	O
an	O
environmental	O
explanation	O
,	O
contrasting	O
with	O
the	O
absence	O
of	O
a	O
history	O
of	O
aggressiveness	B
or	O
personality	B
disorder	I
.	O

The	O
diagnoses	O
of	O
manic	B
shift	O
and	O
akathisia	B
were	O
dismissed	O
.	O

The	O
withdrawal	O
and	O
the	O
gradual	O
reintroduction	O
of	O
quetiapine	O
2	O
weeks	O
later	O
,	O
which	O
led	O
to	O
another	O
severe	O
agitation	B
,	O
enabled	O
us	O
to	O
attribute	O
the	O
agitation	B
specifically	O
to	O
quetiapine	O
.	O

Antioxidant	O
effects	O
of	O
bovine	O
lactoferrin	O
on	O
dexamethasone	O
-	O
induced	O
hypertension	B
in	O
rat	O
.	O

Dexamethasone-	O
(	O
Dex-	O
)	O
induced	O
hypertension	B
is	O
associated	O
with	O
enhanced	O
oxidative	O
stress	O
.	O

Lactoferrin	O
(	O
LF	O
)	O
is	O
an	O
iron	O
-	O
binding	O
glycoprotein	O
with	O
antihypertensive	O
properties	O
.	O

In	O
this	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
chronic	O
administration	O
of	O
LF	O
on	O
oxidative	O
stress	O
and	O
hypertension	B
upon	O
Dex	O
administration	O
.	O

Male	O
Wistar	O
rats	O
were	O
treated	O
by	O
Dex	O
(	O
30	O
u	O
g	O
/	O
kg	O
/	O
day	O
subcutaneously	O
)	O
or	O
saline	O
for	O
14	O
days	O
.	O

Oral	O
bovine	O
LF	O
(	O
30	O
,	O
100	O
,	O
300	O
mg	O
/	O
kg	O
)	O
was	O
given	O
from	O
day	O
8	O
to	O
14	O
in	O
a	O
reversal	O
study	O
.	O

In	O
a	O
prevention	O
study	O
,	O
rats	O
received	O
4	O
days	O
of	O
LF	O
treatment	O
followed	O
by	O
Dex	O
and	O
continued	O
during	O
the	O
test	O
period	O
.	O

Systolic	O
blood	O
pressure	O
(	O
SBP	O
)	O
was	O
measured	O
using	O
tail	O
-	O
cuff	O
method	O
.	O

Thymus	O
weight	O
was	O
used	O
as	O
a	O
marker	O
of	O
glucocorticoid	O
activity	O
.	O

Plasma	O
hydrogen	O
peroxide	O
(	O
H2O2	O
)	O
concentration	O
and	O
ferric	O
reducing	O
antioxidant	O
power	O
(	O
FRAP	O
)	O
value	O
were	O
determined	O
.	O

Dexamethasone	O
significantly	O
increased	O
SBP	O
and	O
plasma	O
H2O2	O
level	O
and	O
decreased	O
thymus	O
and	O
body	O
weights	O
.	O

LF	O
lowered	O
(	O
P	O
<	O
0.01	O
)	O
and	O
dose	O
dependently	O
prevented	O
(	O
P	O
<	O
0.001	O
)	O
Dex	O
-	O
induced	O
hypertension	B
.	O

LF	O
prevented	O
body	O
weight	B
loss	I
and	O
significantly	O
reduced	O
the	O
elevated	O
plasma	O
H2O2	O
and	O
increased	O
FRAP	O
values	O
.	O

Chronic	O
administration	O
of	O
LF	O
strongly	O
reduced	O
the	O
blood	O
pressure	O
and	O
production	O
of	O
ROS	O
and	O
improved	O
antioxidant	O
capacity	O
in	O
Dex	O
-	O
induced	O
hypertension	B
,	O
suggesting	O
the	O
role	O
of	O
inhibition	O
of	O
oxidative	O
stress	O
as	O
another	O
mechanism	O
of	O
antihypertensive	O
action	O
of	O
LF	O
.	O

The	O
association	O
between	O
tranexamic	O
acid	O
and	O
convulsive	B
seizures	B
after	O
cardiac	O
surgery	O
:	O
a	O
multivariate	O
analysis	O
in	O
11	O
529	O
patients	O
.	O

Because	O
of	O
a	O
lack	O
of	O
contemporary	O
data	O
regarding	O
seizures	B
after	O
cardiac	O
surgery	O
,	O
we	O
undertook	O
a	O
retrospective	O
analysis	O
of	O
prospectively	O
collected	O
data	O
from	O
11	O
529	O
patients	O
in	O
whom	O
cardiopulmonary	O
bypass	O
was	O
used	O
from	O
January	O
2004	O
to	O
December	O
2010	O
.	O

A	O
convulsive	B
seizure	B
was	O
defined	O
as	O
a	O
transient	O
episode	O
of	O
disturbed	O
brain	O
function	O
characterised	O
by	O
abnormal	B
involuntary	I
motor	I
movements	I
.	O

Multivariate	O
regression	O
analysis	O
was	O
performed	O
to	O
identify	O
independent	O
predictors	O
of	O
postoperative	O
seizures	B
.	O

A	O
total	O
of	O
100	O
(	O
0.9	O
%	O
)	O
patients	O
developed	O
postoperative	O
convulsive	B
seizures	B
.	O

Generalised	B
and	I
focal	I
seizures	I
were	O
identified	O
in	O
68	O
and	O
32	O
patients	O
,	O
respectively	O
.	O

The	O
median	O
(	O
IQR	O
[	O
range	O
]	O
)	O
time	O
after	O
surgery	O
when	O
the	O
seizure	B
occurred	O
was	O
7	O
(	O
6	O
-	O
12	O
[	O
1	O
-	O
216	O
]	O
)	O
h	O
and	O
8	O
(	O
6	O
-	O
11	O
[	O
4	O
-	O
18	O
]	O
)	O
h	O
,	O
respectively	O
.	O

Epileptiform	O
findings	O
on	O
electroencephalography	O
were	O
seen	O
in	O
19	O
patients	O
.	O

Independent	O
predictors	O
of	O
postoperative	O
seizures	B
included	O
age	O
,	O
female	O
sex	O
,	O
redo	O
cardiac	O
surgery	O
,	O
calcification	O
of	O
ascending	O
aorta	O
,	O
congestive	B
heart	I
failure	I
,	O
deep	O
hypothermic	B
circulatory	O
arrest	O
,	O
duration	O
of	O
aortic	O
cross	O
-	O
clamp	O
and	O
tranexamic	O
acid	O
.	O

When	O
tested	O
in	O
a	O
multivariate	O
regression	O
analysis	O
,	O
tranexamic	O
acid	O
was	O
a	O
strong	O
independent	O
predictor	O
of	O
seizures	B
(	O
OR	O
14.3	O
,	O
95	O
%	O
CI	O
5.5	O
-	O
36.7	O
;	O
p	O
<	O
0.001	O
)	O
.	O

Patients	O
with	O
convulsive	B
seizures	B
had	O
2.5	O
times	O
higher	O
in	O
-	O
hospital	O
mortality	O
rates	O
and	O
twice	O
the	O
length	O
of	O
hospital	O
stay	O
compared	O
with	O
patients	O
without	O
convulsive	B
seizures	B
.	O

Mean	O
(	O
IQR	O
[	O
range	O
]	O
)	O
length	O
of	O
stay	O
in	O
the	O
intensive	O
care	O
unit	O
was	O
115	O
(	O
49	O
-	O
228	O
[	O
32	O
-	O
481	O
]	O
)	O
h	O
in	O
patients	O
with	O
convulsive	B
seizures	B
compared	O
with	O
26	O
(	O
22	O
-	O
69	O
[	O
14	O
-	O
1080	O
]	O
)	O
h	O
in	O
patients	O
without	O
seizures	B
(	O
p	O
<	O
0.001	O
)	O
.	O

Convulsive	B
seizures	B
are	O
a	O
serious	O
postoperative	B
complication	I
after	O
cardiac	O
surgery	O
.	O

As	O
tranexamic	O
acid	O
is	O
the	O
only	O
modifiable	O
factor	O
,	O
its	O
administration	O
,	O
particularly	O
in	O
doses	O
exceeding	O
80	O
mg.kg	O
(	O
-1	O
)	O
,	O
should	O
be	O
weighed	O
against	O
the	O
risk	O
of	O
postoperative	O
seizures	B
.	O

Dysfunctional	B
overnight	I
memory	I
consolidation	O
in	O
ecstasy	O
users	O
.	O

Sleep	O
plays	O
an	O
important	O
role	O
in	O
the	O
consolidation	O
and	O
integration	O
of	O
memory	O
in	O
a	O
process	O
called	O
overnight	O
memory	O
consolidation	O
.	O

Previous	O
studies	O
indicate	O
that	O
ecstasy	O
users	O
have	O
marked	O
and	O
persistent	O
neurocognitive	O
and	O
sleep	B
-	I
related	I
impairments	I
.	O

We	O
extend	O
past	O
research	O
by	O
examining	O
overnight	O
memory	O
consolidation	O
among	O
regular	O
ecstasy	O
users	O
(	O
n=12	O
)	O
and	O
drug	O
naive	O
healthy	O
controls	O
(	O
n=26	O
)	O
.	O

Memory	O
recall	O
of	O
word	O
pairs	O
was	O
evaluated	O
before	O
and	O
after	O
a	O
period	O
of	O
sleep	O
,	O
with	O
and	O
without	O
interference	O
prior	O
to	O
testing	O
.	O

In	O
addition	O
,	O
we	O
assessed	O
neurocognitive	O
performances	O
across	O
tasks	O
of	O
learning	O
,	O
memory	O
and	O
executive	O
functioning	O
.	O

Ecstasy	O
users	O
demonstrated	O
impaired	B
overnight	I
memory	I
consolidation	O
,	O
a	O
finding	O
that	O
was	O
more	O
pronounced	O
following	O
associative	O
interference	O
.	O

Additionally	O
,	O
ecstasy	O
users	O
demonstrated	O
impairments	O
on	O
tasks	O
recruiting	O
frontostriatal	O
and	O
hippocampal	O
neural	O
circuitry	O
,	O
in	O
the	O
domains	O
of	O
proactive	O
interference	O
memory	O
,	O
long	O
-	O
term	O
memory	O
,	O
encoding	O
,	O
working	O
memory	O
and	O
complex	O
planning	O
.	O

We	O
suggest	O
that	O
ecstasy	O
-	O
associated	O
dysfunction	O
in	O
fronto	O
-	O
temporal	O
circuitry	O
may	O
underlie	O
overnight	O
consolidation	O
memory	B
impairments	I
in	O
regular	O
ecstasy	O
users	O
.	O

Normoammonemic	O
encephalopathy	B
:	O
solely	O
valproate	O
induced	O
or	O
multiple	O
mechanisms	O
?	O

A	O
77-year	O
-	O
old	O
woman	O
presented	O
with	O
subacute	O
onset	O
progressive	O
confusion	B
,	O
aggression	B
,	O
auditory	B
hallucinations	I
and	O
delusions	B
.	O

In	O
the	O
preceding	O
months	O
,	O
the	O
patient	O
had	O
a	O
number	O
of	O
admissions	O
with	O
transient	O
unilateral	O
hemiparesis	B
with	O
facial	O
droop	O
,	O
and	O
had	O
been	O
started	O
on	O
valproate	O
for	O
presumed	O
hemiplegic	B
migraine	I
.	O

Valproate	O
was	O
withdrawn	O
soon	O
after	O
admission	O
and	O
her	O
cognitive	O
abilities	O
have	O
gradually	O
improved	O
over	O
3	O
months	O
of	O
follow	O
-	O
up	O
.	O

Valproate	O
levels	O
taken	O
prior	O
to	O
withdrawal	O
were	O
subtherapeutic	O
and	O
the	O
patient	O
was	O
normoammonaemic	O
.	O

EEG	O
undertaken	O
during	O
inpatient	O
stay	O
showed	O
changes	O
consistent	O
with	O
encephalopathy	B
,	O
and	O
low	O
titre	O
N	O
-	O
methyl	O
-	O
D	O
-	O
aspartate	O
(	O
NMDA	O
)	O
receptor	O
antibodies	O
were	O
present	O
in	O
this	O
patient	O
.	O

The	O
possible	O
aetiologies	O
of	O
valproate	O
-	O
induced	O
encephalopathy	B
and	O
NMDA	O
receptor	O
-	O
associated	O
encephalitis	B
present	O
a	O
diagnostic	O
dilemma	O
.	O

We	O
present	O
a	O
putative	O
combinatorial	O
hypothesis	O
to	O
explain	O
this	O
patient	O
's	O
symptoms	O
.	O

Dexmedetomidine	O
,	O
acting	O
through	O
central	O
alpha-2	O
adrenoceptors	O
,	O
prevents	O
opiate	O
-	O
induced	O
muscle	B
rigidity	I
in	O
the	O
rat	O
.	O

The	O
highly	O
-	O
selective	O
alpha-2	O
adrenergic	O
agonist	O
dexmedetomidine	O
(	O
D	O
-	O
MED	O
)	O
is	O
capable	O
of	O
inducing	O
muscle	B
flaccidity	I
and	O
anesthesia	O
in	O
rats	O
and	O
dogs	O
.	O

Intense	O
generalized	O
muscle	B
rigidity	I
is	O
an	O
undesirable	O
side	O
effect	O
of	O
potent	O
opiate	O
agonists	O
.	O

Although	O
the	O
neurochemistry	O
of	O
opiate	O
-	O
induced	O
rigidity	B
has	O
yet	O
to	O
be	O
fully	O
elucidated	O
,	O
recent	O
work	O
suggests	O
a	O
role	O
for	O
a	O
central	O
adrenergic	O
mechanism	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
authors	O
determined	O
if	O
treatment	O
with	O
D	O
-	O
MED	O
prevents	O
the	O
muscle	B
rigidity	I
caused	O
by	O
high	O
-	O
dose	O
alfentanil	O
anesthesia	O
in	O
the	O
rat	O
.	O

Animals	O
(	O
n	O
=	O
42	O
)	O
were	O
treated	O
intraperitoneally	O
with	O
one	O
of	O
the	O
following	O
six	O
regimens	O
:	O
1	O
)	O
L	O
-	O
MED	O
(	O
the	O
inactive	O
L	O
-	O
isomer	O
of	O
medetomidine	O
)	O
,	O
30	O
micrograms	O
/	O
kg	O
;	O
2	O
)	O
D	O
-	O
MED	O
,	O
10	O
micrograms	O
/	O
kg	O
;	O
3	O
)	O
D	O
-	O
MED	O
,	O
30	O
micrograms	O
/	O
kg	O
;	O
4	O
)	O
D	O
-	O
MED	O
[	O
30	O
micrograms	O
/	O
kg	O
]	O
and	O
the	O
central	O
-	O
acting	O
alpha-2	O
antagonist	O
,	O
idazoxan	O
[	O
10	O
mg	O
/	O
kg	O
]	O
;	O
5	O
)	O
D	O
-	O
MED	O
[	O
30	O
micrograms	O
/	O
kg	O
]	O
and	O
the	O
peripheral	O
-	O
acting	O
alpha-2	O
antagonist	O
DG-5128	O
[	O
10	O
mg	O
/	O
kg	O
]	O
,	O
or	O
;	O
6	O
)	O
saline	O
.	O

Baseline	O
electromyographic	O
activity	O
was	O
recorded	O
from	O
the	O
gastrocnemius	O
muscle	O
before	O
and	O
after	O
drug	O
treatment	O
.	O

Each	O
rat	O
was	O
then	O
injected	O
with	O
alfentanil	O
(	O
ALF	O
,	O
0.5	O
mg	O
/	O
kg	O
sc	O
)	O
.	O

ALF	O
injection	O
resulted	O
in	O
a	O
marked	O
increase	O
in	O
hindlimb	O
EMG	O
activity	O
in	O
the	O
L	O
-	O
MED	O
treatment	O
group	O
which	O
was	O
indistinguishable	O
from	O
that	O
seen	O
in	O
animals	O
treated	O
with	O
saline	O
.	O

In	O
contrast	O
,	O
D	O
-	O
MED	O
prevented	O
alfentanil	O
-	O
induced	O
muscle	B
rigidity	I
in	O
a	O
dose	O
-	O
dependent	O
fashion	O
.	O

The	O
small	O
EMG	O
values	O
obtained	O
in	O
the	O
high	O
-	O
dose	O
D	O
-	O
MED	O
group	O
were	O
comparable	O
with	O
those	O
recorded	O
in	O
earlier	O
studies	O
from	O
control	O
animals	O
not	O
given	O
any	O
opiate	O
.	O

The	O
high	O
-	O
dose	O
D	O
-	O
MED	O
animals	O
were	O
flaccid	O
,	O
akinetic	B
,	O
and	O
lacked	O
a	O
startle	B
response	O
during	O
the	O
entire	O
experimental	O
period.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Some	O
central	O
effects	O
of	O
repeated	O
treatment	O
with	O
fluvoxamine	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
repeated	O
treatment	O
with	O
fluvoxamine	O
,	O
a	O
selective	O
serotonin	O
uptake	O
inhibitor	O
,	O
on	O
behavioral	O
effects	O
of	O
dopaminomimetics	O
and	O
methoxamine	O
and	O
on	O
the	O
animal	O
behavior	O
in	O
the	O
""""	O
behavioral	O
despair	O
""""	O
test	O
.	O

A	O
repeated	O
treatment	O
with	O
fluvoxamine	O
(	O
twice	O
daily	O
for	O
14	O
days	O
)	O
potentiated	O
in	O
mice	O
and	O
in	O
rats	O
(	O
weaker	O
)	O
the	O
amphetamine	O
-	O
induced	O
hyperactivity	B
.	O

The	O
hyperactivity	B
induced	O
by	O
nomifensine	O
in	O
mice	O
remained	O
unaffected	O
by	O
fluvoxamine	O
.	O

The	O
stimulation	O
of	O
locomotor	O
activity	O
by	O
intracerebroventricularly	O
administered	O
methoxamine	O
was	O
not	O
affected	O
by	O
repeated	O
treatment	O
with	O
fluvoxamine	O
.	O

Given	O
three	O
times	O
fluvoxamine	O
had	O
no	O
effect	O
on	O
the	O
immobilization	O
time	O
in	O
the	O
""""	O
behavioral	O
despair	O
""""	O
test	O
in	O
rats	O
.	O

The	O
results	O
indicate	O
that	O
fluvoxamine	O
given	O
repeatedly	O
acts	O
differently	O
than	O
citalopram	O
,	O
another	O
selective	O
serotonin	O
uptake	O
inhibitor	O
,	O
and	O
differs	O
also	O
from	O
other	O
antidepressant	O
drugs	O
.	O

Protective	O
effect	O
of	O
a	O
specific	O
platelet	O
-	O
activating	O
factor	O
antagonist	O
,	O
BN	O
52021	O
,	O
on	O
bupivacaine	O
-	O
induced	O
cardiovascular	B
impairments	I
in	O
rats	O
.	O

Administration	O
of	O
the	O
local	O
anaesthetic	O
bupivacaine	O
(	O
1.5	O
or	O
2	O
mg	O
/	O
kg	O
,	O
i.v	O
.	O
)	O
to	O
rats	O
elicited	O
a	O
marked	O
decrease	B
of	I
mean	I
arterial	I
blood	I
pressure	I
(	I
MBP	I
)	I
and	B
heart	I
rate	I
(	I
HR	I
)	I
leading	O
to	O
death	O
(	O
in	O
67	O
%	O
or	O
90	O
%	O
of	O
animals	O
respectively	O
)	O
.	O

Intravenous	O
injection	O
of	O
the	O
specific	O
platelet	O
-	O
activating	O
factor	O
(	O
PAF	O
)	O
antagonist	O
BN	O
52021	O
(	O
10	O
mg	O
/	O
kg	O
)	O
,	O
30	O
min	O
before	O
bupivacaine	O
administration	O
(	O
2	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
suppressed	O
both	O
the	O
decrease	B
of	I
MBP	I
and	B
HR	I
.	O

In	O
contrast	O
,	O
doses	O
of	O
1	O
mg	O
/	O
kg	O
BN	O
52021	O
given	O
30	O
min	O
before	O
or	O
10	O
mg	O
/	O
kg	O
administered	O
5	O
min	O
before	O
i.v	O
.	O

injection	O
of	O
bupivacaine	O
were	O
ineffective	O
.	O

When	O
BN	O
52021	O
(	O
20	O
mg	O
/	O
kg	O
i.v	O
.	O
)	O
was	O
injected	O
immediately	O
after	O
bupivacaine	O
(	O
2	O
mg	O
/	O
kg	O
)	O
,	O
a	O
partial	O
reversion	O
of	O
the	O
decrease	B
of	I
MBP	I
and	B
HR	I
was	O
observed	O
,	O
whereas	O
the	O
dose	O
of	O
10	O
mg	O
/	O
kg	O
was	O
ineffective	O
.	O

A	O
partial	O
recovery	O
of	O
bupivacaine	O
-	O
induced	O
ECG	O
alterations	O
was	O
observed	O
after	O
pretreatment	O
of	O
the	O
rats	O
with	O
BN	O
52021	O
.	O

Since	O
the	O
administration	O
of	O
BN	O
52021	O
,	O
at	O
all	O
doses	O
studied	O
,	O
did	O
not	O
alter	O
MBP	O
and	O
HR	O
at	O
the	O
doses	O
used	O
,	O
the	O
bulk	O
of	O
these	O
results	O
clearly	O
demonstrate	O
a	O
protective	O
action	O
of	O
BN	O
52021	O
,	O
a	O
specific	O
antagonist	O
of	O
PAF	O
,	O
against	O
bupivacaine	O
-	O
induced	O
cardiovascular	B
toxicity	I
.	O

Thus	O
,	O
consistent	O
with	O
its	O
direct	O
effect	O
on	O
heart	O
,	O
PAF	O
appears	O
to	O
be	O
implicated	O
in	O
bupivacaine	O
-	O
induced	O
cardiovascular	B
alterations	I
.	O

The	O
epidemiology	O
of	O
the	O
acute	O
flank	B
pain	I
syndrome	O
from	O
suprofen	O
.	O

Suprofen	O
,	O
a	O
new	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drug	O
,	O
was	O
marketed	O
in	O
early	O
1986	O
as	O
an	O
analgesic	O
agent	O
.	O

Until	O
physicians	O
began	O
reporting	O
an	O
unusual	O
acute	O
flank	B
pain	I
syndrome	O
to	O
the	O
spontaneous	O
reporting	O
system	O
,	O
700,000	O
persons	O
used	O
the	O
drug	O
in	O
the	O
United	O
States	O
.	O

Through	O
August	O
1986	O
,	O
a	O
total	O
of	O
163	O
cases	O
of	O
this	O
syndrome	O
were	O
reported	O
.	O

To	O
elucidate	O
the	O
epidemiology	O
of	O
the	O
syndrome	O
,	O
a	O
case	O
-	O
control	O
study	O
was	O
performed	O
,	O
comparing	O
62	O
of	O
the	O
case	O
patients	O
who	O
had	O
been	O
reported	O
to	O
the	O
spontaneous	O
reporting	O
system	O
to	O
185	O
suprofen	O
-	O
exposed	O
control	O
subjects	O
who	O
did	O
not	O
have	O
the	O
syndrome	O
.	O

Case	O
patients	O
were	O
more	O
likely	O
to	O
be	O
men	O
(	O
odds	O
ratio	O
,	O
3.8	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.2	O
-	O
12.1	O
)	O
,	O
suffer	O
from	O
hay	B
fever	I
and	O
asthma	B
(	O
odds	O
ratio	O
,	O
3.4	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.0	O
-	O
11.9	O
)	O
;	O
to	O
participate	O
in	O
regular	O
exercise	O
(	O
odds	O
ratio	O
,	O
5.9	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.1	O
-	O
30.7	O
)	O
,	O
especially	O
in	O
the	O
use	O
of	O
Nautilus	O
equipment	O
(	O
p	O
=	O
0.02	O
)	O
;	O
and	O
to	O
use	O
alcohol	O
(	O
odds	O
ratio	O
,	O
4.4	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
1.1	O
-	O
17.5	O
)	O
.	O

Possible	O
risk	O
factors	O
included	O
young	O
age	O
,	O
concurrent	O
use	O
of	O
other	O
analgesic	O
agents	O
(	O
especially	O
ibuprofen	O
)	O
,	O
preexisting	O
renal	B
disease	I
,	O
a	O
history	O
of	O
kidney	B
stones	I
,	O
a	O
history	O
of	O
gout	B
,	O
a	O
recent	O
increase	O
in	O
activity	O
,	O
a	O
recent	O
increase	O
in	O
sun	O
exposure	O
,	O
and	O
residence	O
in	O
the	O
Sunbelt	O
.	O

These	O
were	O
findings	O
that	O
were	O
suggestive	O
but	O
did	O
not	O
reach	O
conventional	O
statistical	O
significance	O
.	O

These	O
findings	O
are	O
consistent	O
with	O
the	O
postulated	O
mechanism	O
for	O
this	O
unusual	O
syndrome	O
:	O
acute	O
diffuse	O
crystallization	O
of	O
uric	O
acid	O
in	O
renal	O
tubules	O
.	O

A	O
dystonia	B
-	O
like	O
syndrome	O
after	O
neuropeptide	O
(	O
MSH	O
/	O
ACTH	O
)	O
stimulation	O
of	O
the	O
rat	O
locus	O
ceruleus	O
.	O

The	O
movement	B
disorder	I
investigated	O
in	O
these	O
studies	O
has	O
some	O
features	O
in	O
common	O
with	O
human	O
idiopathic	O
dystonia	B
,	O
and	O
information	O
obtained	O
in	O
these	O
studies	O
may	O
be	O
of	O
potential	O
clinical	O
benefit	O
.	O

The	O
present	O
experimental	O
results	O
indicated	O
that	O
peptidergic	O
stimulation	O
of	O
the	O
LC	O
resulted	O
in	O
a	O
NE	O
-	O
mediated	O
inhibition	O
of	O
cerebellar	O
Purkinje	O
cells	O
located	O
at	O
terminals	O
of	O
the	O
ceruleo	O
-	O
cerebellar	O
pathway	O
.	O

However	O
,	O
it	O
is	O
not	O
certain	O
as	O
to	O
the	O
following	O
:	O
(	O
a	O
)	O
what	O
receptors	O
were	O
stimulated	O
by	O
the	O
ACTH	O
N	O
-	O
terminal	O
fragments	O
at	O
the	O
LC	O
that	O
resulted	O
in	O
this	O
disorder	O
;	O
(	O
b	O
)	O
whether	O
NE	O
,	O
released	O
onto	O
Purkinje	O
cell	O
synapses	O
located	O
at	O
terminals	O
of	O
the	O
ceruleo	O
-	O
cerebellar	O
pathway	O
,	O
did	O
indeed	O
cause	O
the	O
long	O
-	O
term	O
depression	B
at	O
Purkinje	O
cell	O
synapses	O
(	O
previously	O
described	O
by	O
others	O
)	O
that	O
resulted	O
in	O
the	O
long	O
duration	O
of	O
the	O
movement	B
disorder	I
;	O
(	O
c	O
)	O
whether	O
the	O
inhibition	O
of	O
inhibitory	O
Purkinje	O
cells	O
resulted	O
in	O
disinhibition	O
or	O
increased	O
excitability	O
of	O
the	O
unilateral	O
cerebellar	O
fastigial	O
or	O
interpositus	O
nuclei	O
,	O
the	O
output	O
targets	O
of	O
the	O
Purkinje	O
cell	O
axons	O
,	O
that	O
may	O
have	O
been	O
an	O
important	O
contributing	O
factor	O
to	O
this	O
disorder	O
.	O

These	O
questions	O
are	O
currently	O
being	O
investigated	O
.	O

Enhanced	O
stimulus	O
-	O
induced	O
neurotransmitter	O
overflow	O
in	O
epinephrine	O
-	O
induced	O
hypertensive	B
rats	O
is	O
not	O
mediated	O
by	O
prejunctional	O
beta	O
-	O
adrenoceptor	O
activation	O
.	O

The	O
present	O
study	O
examines	O
the	O
effect	O
of	O
6-day	O
epinephrine	O
treatment	O
(	O
100	O
micrograms	O
/	O
kg	O
per	O
h	O
,	O
s.c	O
.	O
)	O
on	O
stimulus	O
-	O
induced	O
(	O
1	O
Hz	O
)	O
endogenous	O
neurotransmitter	O
overflow	O
from	O
the	O
isolated	O
perfused	O
kidney	O
of	O
vehicle-	O
and	O
epinephrine	O
-	O
treated	O
rats	O
.	O

Renal	O
catecholamine	O
stores	O
and	O
stimulus	O
-	O
induced	O
overflow	O
in	O
the	O
vehicle	O
-	O
treated	O
group	O
consisted	O
of	O
norepinephrine	O
only	O
.	O

However	O
,	O
epinephrine	O
treatment	O
resulted	O
in	O
the	O
incorporation	O
of	O
epinephrine	O
into	O
renal	O
catecholamine	O
stores	O
such	O
that	O
approximately	O
40	O
%	O
of	O
the	O
catecholamine	O
present	O
was	O
epinephrine	O
while	O
the	O
norepinephrine	O
content	O
was	O
reduced	O
by	O
a	O
similar	O
degree	O
.	O

Total	O
tissue	O
catecholamine	O
content	O
of	O
the	O
kidney	O
on	O
a	O
molar	O
basis	O
was	O
unchanged	O
.	O

Stimulus	O
-	O
induced	O
fractional	O
overflow	O
of	O
neurotransmitter	O
from	O
the	O
epinephrine	O
-	O
treated	O
kidneys	O
was	O
approximately	O
twice	O
normal	O
and	O
consisted	O
of	O
both	O
norepinephrine	O
and	O
epinephrine	O
in	O
proportions	O
similar	O
to	O
those	O
found	O
in	O
the	O
kidney	O
.	O

This	O
difference	O
in	O
fractional	O
overflow	O
between	O
groups	O
was	O
not	O
affected	O
by	O
neuronal	O
and	O
extraneuronal	O
uptake	O
blockade	O
.	O

Propranolol	O
had	O
no	O
effect	O
on	O
stimulus	O
-	O
induced	O
overflow	O
in	O
either	O
group	O
.	O

Phentolamine	O
increased	O
stimulus	O
-	O
induced	O
overflow	O
in	O
both	O
groups	O
although	O
the	O
increment	O
in	O
overflow	O
was	O
greater	O
in	O
the	O
epinephrine	O
-	O
treated	O
group	O
.	O

In	O
conclusion	O
,	O
chronic	O
epinephrine	O
treatment	O
results	O
in	O
enhanced	O
fractional	O
neurotransmitter	O
overflow	O
.	O

However	O
,	O
neither	O
alterations	O
in	O
prejunctional	O
beta	O
-	O
adrenoceptor	O
influences	O
nor	O
alterations	O
in	O
neuronal	O
and	O
extraneuronal	O
uptake	O
mechanisms	O
appear	O
to	O
be	O
responsible	O
for	O
this	O
alteration	O
.	O

Furthermore	O
,	O
data	O
obtained	O
with	O
phentolamine	O
alone	O
do	O
not	O
suggest	O
alpha	O
-	O
adrenoceptor	O
desensitization	O
as	O
the	O
cause	O
of	O
the	O
enhanced	O
neurotransmitter	O
overflow	O
after	O
epinephrine	O
treatment	O
.	O

Initial	O
potassium	O
loss	O
and	O
hypokalaemia	B
during	O
chlorthalidone	O
administration	O
in	O
patients	O
with	O
essential	O
hypertension	B
:	O
the	O
influence	O
of	O
dietary	O
sodium	O
restriction	O
.	O

To	O
investigate	O
the	O
initial	O
potassium	O
loss	O
and	O
development	O
of	O
hypokalaemia	B
during	O
the	O
administration	O
of	O
an	O
oral	O
diuretic	O
,	O
metabolic	O
balance	O
studies	O
were	O
performed	O
in	O
ten	O
patients	O
with	O
essential	O
hypertension	B
who	O
had	O
shown	O
hypokalaemia	B
under	O
prior	O
oral	O
diuretic	O
treatment	O
.	O

Chlorthalidone	O
(	O
50	O
mg	O
daily	O
)	O
was	O
given	O
for	O
14	O
days	O
.	O

Six	O
patients	O
received	O
a	O
normal	O
-	O
sodium	O
diet	O
and	O
four	O
a	O
low	O
-	O
sodium	O
(	O
17	O
mmol	O
/	O
day	O
)	O
diet	O
.	O

All	O
patients	O
had	O
a	O
normal	O
initial	O
total	O
body	O
potassium	O
(	O
40	O
K	O
)	O
.	O

The	O
electrolyte	O
balances	O
,	O
weight	O
,	O
bromide	O
space	O
,	O
plasma	O
renin	O
activity	O
,	O
and	O
aldosterone	O
secretion	O
rate	O
were	O
measured	O
.	O

In	O
both	O
groups	O
a	O
potassium	O
deficit	O
developed	O
,	O
with	O
proportionally	O
larger	O
losses	O
from	O
the	O
extracellular	O
than	O
from	O
the	O
intracellular	O
compartment	O
.	O

In	O
the	O
normal	O
-	O
sodium	O
group	O
the	O
highest	O
mean	O
potassium	O
deficit	O
was	O
176	O
mmol	O
on	O
day	O
9	O
,	O
after	O
which	O
some	O
potassium	O
was	O
regained	O
;	O
in	O
the	O
low	O
-	O
sodium	O
group	O
the	O
highest	O
deficit	O
was	O
276	O
mmol	O
on	O
day	O
13	O
.	O

The	O
normal	O
-	O
sodium	O
group	O
showed	O
an	O
immediate	O
but	O
temporary	O
rise	O
of	O
the	O
renin	O
and	O
aldosterone	O
levels	O
;	O
in	O
the	O
low	O
-	O
sodium	O
group	O
renin	O
and	O
aldosterone	O
increased	O
more	O
slowly	O
but	O
remained	O
elevated	O
.	O

It	O
is	O
concluded	O
that	O
dietary	O
sodium	O
restriction	O
increases	O
diuretic	O
-	O
induced	O
potassium	O
loss	O
,	O
presumably	O
by	O
an	O
increased	O
activity	O
of	O
the	O
renin	O
-	O
angiotensin	O
-	O
aldosterone	O
system	O
,	O
while	O
sodium	O
delivery	O
to	O
the	O
distal	O
renal	O
tubules	O
remains	O
sufficiently	O
high	O
to	O
allow	O
increased	O
potassium	O
secretion	O
.	O

Toxicity	B
due	O
to	O
remission	O
inducing	O
drugs	O
in	O
rheumatoid	B
arthritis	I
.	O

Association	O
with	O
HLA	O
-	O
B35	O
and	O
Cw4	O
antigens	O
.	O

Twenty	O
-	O
five	O
patients	O
with	O
rheumatoid	B
arthritis	I
(	O
RA	B
)	O
who	O
developed	O
toxicity	B
while	O
taking	O
remission	O
inducing	O
drugs	O
and	O
30	O
without	O
toxicity	B
were	O
studied	O
for	O
possible	O
associations	O
with	O
class	O
I	O
and	O
II	O
HLA	O
antigens	O
.	O

A	O
strong	O
association	O
has	O
been	O
found	O
between	O
nephritis	B
and	O
dermatitis	B
due	O
to	O
Tiopronin	O
(	O
a	O
D	O
-	O
Penicillamine	O
like	O
compound	O
)	O
and	O
class	O
I	O
antigens	O
B35-Cw4	O
,	O
and	O
between	O
dermatitis	B
due	O
to	O
gold	O
thiosulphate	O
and	O
B35	O
.	O

Compared	O
to	O
healthy	O
controls	O
a	O
lower	O
DR5	O
frequency	O
was	O
observed	O
in	O
patients	O
with	O
RA	B
except	O
for	O
the	O
Tiopronin	O
related	O
nephritis	B
group	O
.	O

Antagonism	O
of	O
diazepam	O
-	O
induced	O
sedative	O
effects	O
by	O
Ro15	O
-	O
1788	O
in	O
patients	O
after	O
surgery	O
under	O
lumbar	O
epidural	O
block	O
.	O

A	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
investigation	O
of	O
efficacy	O
and	O
safety	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
assess	O
the	O
efficacy	O
of	O
Ro15	O
-	O
1788	O
and	O
a	O
placebo	O
in	O
reversing	O
diazepam	O
-	O
induced	O
effects	O
after	O
surgery	O
under	O
epidural	O
block	O
,	O
and	O
to	O
evaluate	O
the	O
local	O
tolerance	O
and	O
general	O
safety	O
of	O
Ro15	O
-	O
1788	O
.	O

Fifty	O
-	O
seven	O
patients	O
were	O
sedated	O
with	O
diazepam	O
for	O
surgery	O
under	O
epidural	O
anaesthesia	O
.	O

Antagonism	O
of	O
diazepam	O
-	O
induced	O
effects	O
by	O
Ro15	O
-	O
1788	O
was	O
investigated	O
postoperatively	O
in	O
a	O
double	O
-	O
blind	O
placebo	O
-	O
controlled	O
trial	O
.	O

The	O
patient	O
's	O
subjective	O
assessment	O
of	O
mood	O
rating	O
,	O
an	O
objective	O
test	O
of	O
performance	O
,	O
a	O
test	O
for	O
amnesia	B
,	O
and	O
vital	O
signs	O
were	O
recorded	O
for	O
up	O
to	O
300	O
min	O
after	O
administration	O
of	O
the	O
trial	O
drug	O
.	O

No	O
significant	O
differences	O
between	O
the	O
two	O
groups	O
were	O
observed	O
for	O
mood	O
rating	O
,	O
amnesia	B
,	O
or	O
vital	O
signs	O
.	O

The	O
Ro15	O
-	O
1788	O
group	O
showed	O
a	O
significant	O
improvement	O
in	O
the	O
performance	O
test	O
up	O
to	O
120	O
min	O
after	O
administration	O
of	O
the	O
drug	O
.	O

There	O
was	O
no	O
evidence	O
of	O
reaction	O
at	O
the	O
injection	O
site	O
.	O

Reversible	O
cerebral	B
lesions	I
associated	O
with	O
tiazofurin	O
usage	O
:	O
MR	O
demonstration	O
.	O

Tiazofurin	O
is	O
an	O
experimental	O
chemotherapeutic	O
agent	O
currently	O
undergoing	O
clinical	O
evaluation	O
.	O

We	O
report	O
our	O
results	O
with	O
magnetic	O
resonance	O
(	O
MR	O
)	O
in	O
demonstrating	O
reversible	O
cerebral	B
abnormalities	I
concurrent	O
with	O
the	O
use	O
of	O
this	O
drug	O
.	O

The	O
abnormalities	O
on	O
MR	O
were	O
correlated	O
with	O
findings	O
on	O
CT	O
as	O
well	O
as	O
with	O
cerebral	O
angiography	O
.	O

The	O
utility	O
of	O
MR	O
in	O
the	O
evaluation	O
of	O
patients	O
receiving	O
this	O
new	O
agent	O
is	O
illustrated	O
.	O

Quinidine	O
phenylethylbarbiturate	O
-	O
induced	O
fulminant	O
hepatitis	B
in	O
a	O
pregnant	O
woman	O
.	O

A	O
case	O
report	O
.	O

We	O
report	O
the	O
case	O
of	O
a	O
19-year	O
-	O
old	O
Laotian	O
patient	O
affected	O
by	O
fulminant	O
hepatitis	B
during	O
the	O
third	O
trimester	O
of	O
her	O
pregnancy	O
after	O
a	O
1-month	O
administration	O
of	O
quinidine	O
phenylethylbarbiturate	O
.	O

After	O
delivery	O
,	O
the	O
patient	O
underwent	O
orthotopic	O
liver	O
transplantation	O
.	O

The	O
patient	O
was	O
in	O
good	O
condition	O
16	O
months	O
after	O
liver	O
transplantation	O
.	O

Quinidine	O
itself	O
or	O
phenylethylbarbiturate	O
may	O
be	O
responsible	O
for	O
fulminant	O
hepatitis	B
in	O
this	O
patient	O
.	O

Production	O
of	O
autochthonous	O
prostate	B
cancer	I
in	O
Lobund	O
-	O
Wistar	O
rats	O
by	O
treatments	O
with	O
N	O
-	O
nitroso	O
-	O
N	O
-	O
methylurea	O
and	O
testosterone	O
.	O

More	O
than	O
50	O
%	O
of	O
Lobund	O
-	O
Wistar	O
(	O
L	O
-	O
W	O
)	O
strain	O
rats	O
developed	O
large	O
,	O
palpable	O
prostate	B
adenocarcinomas	I
(	O
PAs	B
)	O
following	O
treatments	O
with	O
N	O
-	O
nitroso	O
-	O
N	O
-	O
methylurea	O
(	O
CAS	O
:	O
684	O
-	O
93	O
-	O
5	O
)	O
and	O
testosterone	O
propionate	O
[	O
(	O
TP	O
)	O
CAS	O
:	O
57	O
-	O
85	O
-	O
2	O
]	O
,	O
and	O
most	O
of	O
the	O
tumor	B
-	O
bearing	O
rats	O
manifested	O
metastatic	O
lesions	O
.	O

The	O
incubation	O
periods	O
averaged	O
10.6	O
months	O
.	O

Within	O
the	O
same	O
timeframe	O
,	O
no	O
L	O
-	O
W	O
rat	O
developed	O
a	O
similar	O
palpable	O
PA	B
when	O
treated	O
only	O
with	O
TP	O
.	O

In	O
L	O
-	O
W	O
rats	O
,	O
TP	O
acted	O
as	O
a	O
tumor	B
enhancement	O
agent	O
,	O
with	O
primary	O
emphasis	O
on	O
the	O
development	O
of	O
prostate	B
cancer	I
.	O

A	O
prospective	O
study	O
of	O
adverse	O
reactions	O
associated	O
with	O
vancomycin	O
therapy	O
.	O

A	O
prospective	O
evaluation	O
of	O
the	O
efficacy	O
and	O
safety	O
of	O
vancomycin	O
was	O
conducted	O
in	O
54	O
consecutive	O
patients	O
over	O
a	O
16-month	O
period	O
.	O

Vancomycin	O
was	O
curative	O
in	O
95	O
%	O
of	O
43	O
patients	O
with	O
proven	O
infection	B
.	O

Drugs	O
were	O
ceased	O
in	O
six	O
patients	O
because	O
of	O
adverse	O
reactions	O
;	O
in	O
three	O
of	O
these	O
vancomycin	O
was	O
considered	O
the	O
likely	O
cause	O
.	O

Reactions	O
included	O
thrombophlebitis	B
(	O
20	O
of	O
54	O
patients	O
)	O
,	O
rash	B
(	O
4	O
of	O
54	O
)	O
,	O
nephrotoxicity	B
(	O
4	O
of	O
50	O
)	O
,	O
proteinuria	B
(	O
1	O
of	O
50	O
)	O
and	O
ototoxicity	B
(	O
1	O
of	O
11	O
patients	O
tested	O
by	O
audiometry	O
)	O
.	O

Thrombophlebitis	B
occurred	O
only	O
with	O
infusion	O
through	O
peripheral	O
cannulae	O
;	O
nephrotoxicity	B
and	O
ototoxicity	B
were	O
confined	O
to	O
patients	O
receiving	O
an	O
aminoglycoside	O
plus	O
vancomycin	O
.	O

We	O
conclude	O
that	O
vancomycin	O
,	O
administered	O
appropriately	O
,	O
constitutes	O
safe	O
,	O
effective	O
therapy	O
for	O
infections	B
caused	O
by	O
susceptible	O
bacteria	O
.	O

Cardiac	B
toxicity	I
of	O
5-fluorouracil	O
.	O

Report	O
of	O
a	O
case	O
of	O
spontaneous	O
angina	B
.	O

We	O
report	O
a	O
case	O
of	O
a	O
patient	O
with	O
colon	B
carcinoma	I
and	O
liver	O
metastasis	B
who	O
presented	O
chest	B
pain	I
after	O
5-fluorouracil	O
(	O
5-FU	O
)	O
administration	O
.	O

Clinical	O
electrocardiographic	O
evolution	O
was	O
similar	O
to	O
that	O
observed	O
in	O
Prinzmetal	B
's	I
angina	I
,	O
and	O
chest	B
pain	I
promptly	O
resolved	O
with	O
nifedipine	O
.	O

These	O
data	O
suggest	O
that	O
coronary	B
spasm	I
may	O
be	O
the	O
cause	O
of	O
cardiotoxicity	B
due	O
to	O
5-FU	O
,	O
and	O
that	O
calcium	O
antagonists	O
may	O
probably	O
be	O
used	O
in	O
the	O
prevention	O
or	O
treatment	O
of	O
5-FU	O
cardiotoxicity	B
.	O

Time	O
course	O
alterations	O
of	O
QTC	O
interval	O
due	O
to	O
hypaque	O
76	O
.	O

Sequential	O
measurement	O
of	O
QT	O
interval	O
during	O
left	O
ventricular	O
angiography	O
was	O
made	O
30	O
seconds	O
and	O
one	O
,	O
three	O
,	O
five	O
and	O
ten	O
minutes	O
after	O
injection	O
of	O
hypaque	O
76	O
.	O

The	O
subjects	O
were	O
ten	O
patients	O
found	O
to	O
have	O
normal	O
left	O
ventricles	O
and	O
coronary	O
arteries	O
.	O

Significant	O
QTC	B
prolongation	I
occurred	O
in	O
30	O
seconds	O
to	O
one	O
minute	O
in	O
association	O
with	O
marked	O
hypotension	B
and	O
elevation	O
of	O
cardiac	O
output	O
.	O

Transient	O
hemiparesis	B
:	O
a	O
rare	O
manifestation	O
of	O
diphenylhydantoin	O
toxicity	B
.	O

Report	O
of	O
two	O
cases	O
.	O

Among	O
the	O
common	O
side	O
effects	O
of	O
diphenylhydantoin	O
(	O
DPH	O
)	O
overdose	B
,	O
the	O
most	O
frequently	O
encountered	O
neurological	O
signs	O
are	O
those	O
of	O
cerebellar	B
dysfunction	I
.	O

Very	O
rarely	O
,	O
the	O
toxic	O
neurological	O
manifestations	O
of	O
this	O
drug	O
are	O
of	O
cerebral	O
origin	O
.	O

Two	O
patients	O
are	O
presented	O
who	O
suffered	O
progressive	O
hemiparesis	B
due	O
to	O
DPH	O
overdose	B
.	O

Both	O
had	O
brain	O
surgery	O
before	O
DPH	O
treatment	O
.	O

It	O
is	O
assumed	O
that	O
patients	O
with	O
some	O
cerebral	B
damage	I
are	O
liable	O
to	O
manifest	O
DPH	O
toxicity	B
as	O
focal	O
neurological	O
signs	O
.	O

Indomethacin	O
induced	O
hypotension	B
in	O
sodium	O
and	O
volume	O
depleted	O
rats	O
.	O

After	O
a	O
single	O
oral	O
dose	O
of	O
4	O
mg	O
/	O
kg	O
indomethacin	O
(	O
IDM	O
)	O
to	O
sodium	O
and	O
volume	O
depleted	O
rats	O
plasma	O
renin	O
activity	O
(	O
PRA	O
)	O
and	O
systolic	O
blood	O
pressure	O
fell	O
significantly	O
within	O
four	O
hours	O
.	O

In	O
sodium	O
repleted	O
animals	O
indomethacin	O
did	O
not	O
change	O
systolic	O
blood	O
pressure	O
(	O
BP	O
)	O
although	O
plasma	O
renin	O
activity	O
was	O
decreased	O
.	O

Thus	O
,	O
indomethacin	O
by	O
inhibition	O
of	O
prostaglandin	O
synthesis	O
may	O
diminish	O
the	O
blood	O
pressure	O
maintaining	O
effect	O
of	O
the	O
stimulated	O
renin	O
-	O
angiotensin	O
system	O
in	O
sodium	O
and	O
volume	O
depletion	O
.	O

Quinidine	O
hepatitis	B
.	O

Long	O
-	O
term	O
administration	O
of	O
quinidine	O
was	O
associated	O
with	O
persistent	O
elevation	O
of	O
serum	O
concentrations	O
of	O
SGOT	O
,	O
lactic	O
acid	O
dehydrogenase	O
,	O
and	O
alkaline	O
phosphatase	O
.	O

Liver	O
biopsy	O
showed	O
active	O
hepatitis	B
.	O

Discontinuance	O
of	O
quinidine	O
therapy	O
led	O
to	O
normalization	O
of	O
liver	O
function	O
tests	O
.	O

A	O
challenge	O
dose	O
of	O
quinidine	O
caused	O
clinical	O
symptoms	O
and	O
abrupt	O
elevation	O
of	O
SGOT	O
,	O
alkaline	O
phosphatase	O
,	O
and	O
lactic	O
acid	O
dehydrogenase	O
values	O
.	O

We	O
concluded	O
that	O
this	O
patient	O
had	O
quinidine	O
hepatotoxicity	B
and	O
believe	O
that	O
this	O
is	O
the	O
first	O
case	O
reported	O
with	O
liver	O
biopsy	O
documentation	O
.	O

This	O
report	O
also	O
suggests	O
that	O
,	O
even	O
after	O
long	O
-	O
term	O
administration	O
,	O
the	O
hepatic	B
toxicity	I
is	O
reversible	O
.	O

Epileptogenic	O
properties	O
of	O
enflurane	O
and	O
their	O
clinical	O
interpretation	O
.	O

Three	O
cases	O
of	O
EEG	O
changes	O
induced	O
by	O
single	O
exposure	O
to	O
enflurane	O
anesthesia	O
are	O
reported	O
.	O

In	O
one	O
patient	O
,	O
enflurane	O
administered	O
during	O
a	O
donor	O
nephrectomy	O
resulted	O
in	O
unexpected	O
partial	O
motor	O
seizures	B
.	O

Until	O
the	O
cause	O
of	O
the	O
seizures	B
was	O
correctly	O
identified	O
,	O
the	O
patient	O
was	O
inappropriately	O
treated	O
with	O
anticonvulsants	O
.	O

Two	O
other	O
patients	O
suffered	O
from	O
partial	O
,	O
complex	O
and	O
generalized	O
seizures	B
uncontrolled	O
by	O
medication	O
.	O

Epileptic	B
foci	O
delineated	O
and	O
activated	O
by	O
enflurane	O
were	O
surgically	O
ablated	O
and	O
the	O
patients	O
are	O
now	O
seizure	B
-	O
free	O
.	O

Previous	O
exposures	O
to	O
enflurane	O
have	O
to	O
be	O
disclosed	O
to	O
avoid	O
mistakes	O
in	O
clinical	O
interpretation	O
of	O
the	O
EEG	O
.	O

On	O
the	O
other	O
hand	O
,	O
enflurane	O
may	O
prove	O
to	O
be	O
a	O
safe	O
fast	O
acting	O
activator	O
of	O
epileptic	B
foci	O
during	O
corticography	O
or	O
depth	O
electrode	O
intraoperative	O
recordings	O
.	O

Naloxazone	O
pretreatment	O
modifies	O
cardiorespiratory	O
,	O
temperature	O
,	O
and	O
behavioral	O
effects	O
of	O
morphine	O
.	O

Behavioral	O
and	O
cardiorespiratory	O
responses	O
to	O
a	O
lethal	O
dose	O
of	O
morphine	O
were	O
evaluated	O
in	O
rats	O
pretreated	O
with	O
saline	O
or	O
naloxazone	O
,	O
an	O
antagonist	O
of	O
high	O
-	O
affinity	O
mu	O
1	O
opioid	O
receptors	O
.	O

Pretreatment	O
with	O
naloxazone	O
significantly	O
blocked	O
morphine	O
analgesia	B
,	O
catalepsy	B
and	O
hypothermia	B
at	O
a	O
dose	O
which	O
completely	O
eliminated	O
high	O
-	O
affinity	O
binding	O
in	O
brain	O
membranes	O
.	O

Moreover	O
,	O
naloxazone	O
significantly	O
attenuated	O
the	O
morphine	O
-	O
induced	O
hypotension	B
and	O
respiratory	B
depression	I
,	O
whereas	O
morphine	O
-	O
induced	O
bradycardia	B
was	O
less	O
affected	O
.	O

Results	O
indicate	O
that	O
subpopulations	O
of	O
mu	O
receptors	O
may	O
mediate	O
selective	O
behavioral	O
and	O
cardiorespiratory	O
responses	O
to	O
morphine	O
.	O

Treatment	O
of	O
ifosfamide	O
-	O
induced	O
urothelial	B
toxicity	I
by	O
oral	O
administration	O
of	O
sodium	O
2-mercaptoethane	O
sulphonate	O
(	O
MESNA	O
)	O
to	O
patients	O
with	O
inoperable	O
lung	B
cancer	I
.	O

The	O
protective	O
effect	O
of	O
oral	O
administration	O
of	O
the	O
thiol	O
compound	O
sodium	O
2-mercaptoethane	O
sulphonate	O
(	O
MESNA	O
)	O
against	O
urothelial	B
toxicity	I
induced	O
by	O
ifosfamide	O
(	O
IF	O
)	O
was	O
tested	O
in	O
a	O
group	O
of	O
45	O
patients	O
with	O
inoperable	O
lung	B
cancer	I
under	O
treatment	O
with	O
IF	O
(	O
2250	O
mg	O
/	O
m2	O
on	O
days	O
2	O
-	O
5	O
)	O
as	O
part	O
of	O
a	O
polychemotherapy	O
regimen	O
repeated	O
in	O
a	O
4-week	O
cycle	O
.	O

MESNA	O
was	O
given	O
orally	O
on	O
the	O
days	O
of	O
treatment	O
with	O
IF	O
in	O
3	O
doses	O
of	O
840	O
mg	O
/	O
m2	O
,	O
each	O
administered	O
at	O
0	O
hr	O
(=	O
injection	O
of	O
IF	O
)	O
,	O
4	O
hr	O
and	O
8	O
hr	O
p.i	O
.	O

Out	O
of	O
a	O
total	O
of	O
88	O
courses	O
of	O
this	O
treatment	O
we	O
observed	O
10	O
episodes	O
of	O
asymptomatic	O
microscopic	O
haematuria	B
and	O
no	O
episodes	O
of	O
gross	O
haematuria	B
.	O

In	O
this	O
group	O
of	O
45	O
patients	O
under	O
protection	O
with	O
MESNA	O
there	O
were	O
5	O
complete	O
remissions	O
and	O
9	O
partial	O
remissions	O
(	O
total	O
31	O
%	O
)	O
.	O

A	O
further	O
group	O
of	O
25	O
patients	O
under	O
polychemotherapy	O
with	O
IF	O
were	O
treated	O
by	O
conventional	O
prophylactic	O
measures	O
(	O
raised	O
fluid	O
intake	O
and	O
forced	O
diuresis	O
)	O
.	O

In	O
this	O
group	O
there	O
were	O
1	O
complete	O
and	O
5	O
partial	O
remissions	O
(	O
total	O
24	O
%	O
)	O
,	O
but	O
nearly	O
all	O
patients	O
developed	O
either	O
gross	O
haematuria	B
and/or	O
symptoms	O
of	O
bladder	B
irritation	I
(	O
cystitis	B
and	O
pollakisuria	B
)	O
.	O

There	O
were	O
no	O
appreciable	O
differences	O
between	O
the	O
MESNA	O
series	O
and	O
the	O
conventional	O
prophylaxis	O
series	O
with	O
respect	O
to	O
either	O
haematological	O
or	O
systemic	O
toxicity	B
of	O
the	O
cytostatic	O
treatment	O
.	O

Our	O
results	O
support	O
the	O
view	O
that	O
MESNA	O
,	O
given	O
orally	O
in	O
conjunction	O
with	O
combined	O
cytostatic	O
regimens	O
which	O
include	O
IF	O
,	O
simplifies	O
the	O
treatment	O
and	O
provides	O
optimum	O
protection	O
for	O
the	O
urinary	O
epithelium	O
.	O

Protection	O
with	O
oral	O
MESNA	O
is	O
particularly	O
suitable	O
for	O
outpatients	O
.	O

Effect	O
of	O
captopril	O
on	O
pre	O
-	O
existing	O
and	O
aminonucleoside	O
-	O
induced	O
proteinuria	B
in	O
spontaneously	O
hypertensive	B
rats	O
.	O

Proteinuria	B
is	O
a	O
side	O
effect	O
of	O
captopril	O
treatment	O
in	O
hypertensive	B
patients	O
.	O

The	O
possibility	O
of	O
reproducing	O
the	O
same	O
renal	B
abnormality	I
with	O
captopril	O
was	O
examined	O
in	O
SHR	O
.	O

Oral	O
administration	O
of	O
captopril	O
at	O
100	O
mg	O
/	O
kg	O
for	O
14	O
days	O
failed	O
to	O
aggravate	O
proteinuria	B
pre	O
-	O
existing	O
in	O
SHR	O
.	O

Also	O
,	O
captopril	O
treatment	O
failed	O
to	O
potentiate	O
or	O
facilitate	O
development	O
of	O
massive	O
proteinuria	B
invoked	O
by	O
puromycin	O
aminonucleoside	O
in	O
SHR	O
.	O

Captopril	O
had	O
little	O
or	O
no	O
demonstrable	O
effects	O
on	O
serum	O
electrolyte	O
concentrations	O
,	O
excretion	O
of	O
urine	O
,	O
sodium	O
and	O
potassium	O
,	O
endogenous	O
creatinine	O
clearance	O
,	O
body	O
weight	O
,	O
and	O
food	O
and	O
water	O
consumption	O
.	O

However	O
,	O
ketone	O
bodies	O
were	O
consistently	O
present	O
in	O
urine	O
and	O
several	O
lethalities	O
occurred	O
during	O
multiple	O
dosing	O
of	O
captopril	O
in	O
SHR	O
.	O

Complete	O
heart	B
block	I
following	O
a	O
single	O
dose	O
of	O
trazodone	O
.	O

Forty	O
minutes	O
after	O
receiving	O
a	O
single	O
starting	O
dose	O
of	O
trazodone	O
,	O
a	O
patient	O
developed	O
complete	O
heart	B
block	I
.	O

The	O
case	O
illustrates	O
that	O
,	O
despite	O
the	O
results	O
of	O
earlier	O
studies	O
,	O
trazodone	O
's	O
effect	O
on	O
cardiac	O
conduction	O
may	O
be	O
severe	O
in	O
individuals	O
at	O
risk	O
for	O
conduction	O
delay	O
.	O

Heparin	O
-	O
induced	O
thrombocytopenia	B
,	O
thrombosis	B
,	O
and	O
hemorrhage	B
.	O

Sixty	O
-	O
two	O
patients	O
with	O
a	O
heparin	O
-	O
induced	O
thrombocytopenia	B
are	O
reported	O
.	O

Clinical	O
manifestations	O
of	O
this	O
disorder	O
include	O
hemorrhage	B
or	O
,	O
more	O
frequently	O
,	O
thromboembolic	B
events	O
in	O
patients	O
receiving	O
heparin	O
.	O

Laboratory	O
testing	O
has	O
revealed	O
a	B
falling	I
platelet	I
count	I
,	O
increased	O
resistance	O
to	O
heparin	O
,	O
and	O
aggregation	O
of	O
platelets	O
by	O
the	O
patient	O
's	O
plasma	O
when	O
heparin	O
is	O
added	O
.	O

Immunologic	O
testing	O
has	O
demonstrated	O
the	O
presence	O
of	O
a	O
heparin	O
-	O
dependent	O
platelet	O
membrane	O
antibody	O
.	O

The	O
20	O
deaths	O
,	O
52	O
hemorrhagic	B
and	I
thromboembolic	I
complications	I
,	O
and	O
21	O
surgical	O
procedures	O
to	O
manage	O
the	O
complications	O
confirm	O
the	O
seriousness	O
of	O
the	O
disorder	O
.	O

Specific	O
risk	O
factors	O
have	O
not	O
been	O
identified	O
;	O
therefore	O
,	O
all	O
patients	O
receiving	O
heparin	O
should	O
be	O
monitored	O
.	O

If	O
the	O
platelet	O
count	O
falls	O
to	O
less	O
than	O
100,000	O
/	O
mm3	O
,	O
while	O
the	O
patient	O
is	O
receiving	O
heparin	O
,	O
platelet	B
aggregation	I
testing	O
,	O
using	O
the	O
patient	O
's	O
plasma	O
,	O
is	O
indicated	O
.	O

Management	O
consists	O
of	O
cessation	O
of	O
heparin	O
,	O
platelet	O
anti	O
-	O
aggregating	O
agents	O
,	O
and	O
alternate	O
forms	O
of	O
anticoagulation	O
when	O
indicated	O
.	O

Induction	O
of	O
the	O
obstructive	B
sleep	I
apnea	I
syndrome	I
in	O
a	O
woman	O
by	O
exogenous	O
androgen	O
administration	O
.	O

We	O
documented	O
airway	O
occlusion	O
during	O
sleep	O
and	O
an	O
abnormally	O
high	O
supraglottic	O
resistance	O
while	O
awake	O
in	O
a	O
54-yr	O
-	O
old	O
woman	O
who	O
had	O
developed	O
physical	O
changes	O
and	O
the	O
syndrome	B
of	I
obstructive	I
sleep	I
apnea	I
while	O
being	O
administered	O
exogenous	O
androgens	O
.	O

When	O
the	O
androgens	O
were	O
withdrawn	O
,	O
the	O
patient	O
's	O
physical	O
changes	O
,	O
symptoms	O
,	O
sleep	O
study	O
,	O
and	O
supraglottic	O
resistance	O
all	O
returned	O
to	O
normal	O
.	O

A	O
rechallenge	O
with	O
androgen	O
produced	O
symptoms	O
of	O
obstructive	B
sleep	I
apnea	I
that	O
abated	O
upon	O
withdrawal	O
of	O
the	O
hormone	O
.	O

Previous	O
reports	O
have	O
favored	O
a	O
role	O
of	O
androgens	O
in	O
the	O
pathogenesis	O
of	O
sleep	B
apnea	I
.	O

Our	O
report	O
provides	O
direct	O
evidence	O
for	O
this	O
role	O
.	O

Structural	O
and	O
functional	O
measurements	O
indicate	O
that	O
androgens	O
exert	O
a	O
permissive	O
or	O
necessary	O
action	O
on	O
the	O
structural	O
configuration	O
of	O
the	O
oropharynx	O
that	O
predisposes	O
to	O
obstruction	O
during	O
sleep	O
.	O

Development	O
of	O
the	O
obstructive	B
sleep	I
apnea	I
syndrome	I
must	O
be	O
considered	O
a	O
possible	O
side	O
effect	O
of	O
androgen	O
therapy	O
.	O

Effects	O
of	O
the	O
novel	O
compound	O
aniracetam	O
(	O
Ro	O
13	O
-	O
5057	O
)	O
upon	O
impaired	B
learning	I
and	B
memory	I
in	O
rodents	O
.	O

The	O
effect	O
of	O
aniracetam	O
(	O
Ro	O
13	O
-	O
5057	O
,	O
1-anisoyl-2-pyrrolidinone	O
)	O
was	O
studied	O
on	O
various	O
forms	O
of	O
experimentally	O
impaired	B
cognitive	I
functions	I
(	O
learning	O
and	O
memory	O
)	O
in	O
rodents	O
and	O
produced	O
the	O
following	O
effects	O
:	O
(	O
1	O
)	O
almost	O
complete	O
prevention	O
of	O
the	O
incapacity	O
to	O
learn	O
a	O
discrete	O
escape	O
response	O
in	O
rats	O
exposed	O
to	O
sublethal	O
hypercapnia	B
immediately	O
before	O
the	O
acquisition	O
session	O
;	O
(	O
2	O
)	O
partial	O
(	O
rats	O
)	O
or	O
complete	O
(	O
mice	O
)	O
prevention	O
of	O
the	O
scopolamine	O
-	O
induced	O
short	O
-	O
term	O
amnesia	B
for	O
a	O
passive	O
avoidance	O
task	O
;	O
(	O
3	O
)	O
complete	O
protection	O
against	O
amnesia	B
for	O
a	O
passive	O
avoidance	O
task	O
in	O
rats	O
submitted	O
to	O
electroconvulsive	O
shock	O
immediately	O
after	O
avoidance	O
acquisition	O
;	O
(	O
4	O
)	O
prevention	O
of	O
the	O
long	O
-	O
term	O
retention-	O
or	O
retrieval	O
-	O
deficit	O
for	O
a	O
passive	O
avoidance	O
task	O
induced	O
in	O
rats	O
and	O
mice	O
by	O
chloramphenicol	O
or	O
cycloheximide	O
administered	O
immediately	O
after	O
acquisition	O
;	O
(	O
5	O
)	O
reversal	O
,	O
when	O
administered	O
as	O
late	O
as	O
1	O
h	O
before	O
the	O
retention	O
test	O
,	O
of	O
the	O
deficit	O
in	O
retention	O
or	O
retrieval	O
of	O
a	O
passive	O
avoidance	O
task	O
induced	O
by	O
cycloheximide	O
injected	O
2	O
days	O
previously	O
;	O
(	O
6	O
)	O
prevention	O
of	O
the	O
deficit	O
in	O
the	O
retrieval	O
of	O
an	O
active	O
avoidance	O
task	O
induced	O
in	O
mice	O
by	O
subconvulsant	O
electroshock	O
or	O
hypercapnia	B
applied	O
immediately	O
before	O
retrieval	O
testing	O
(	O
24	O
h	O
after	O
acquisition	O
)	O
.	O

These	O
improvements	O
or	O
normalizations	O
of	O
impaired	B
cognitive	I
functions	I
were	O
seen	O
at	O
oral	O
aniracetam	O
doses	O
of	O
10	O
-	O
100	O
mg	O
/	O
kg	O
.	O

Generally	O
,	O
the	O
dose	O
-	O
response	O
curves	O
were	O
bell	O
-	O
shaped	O
.	O

The	O
mechanisms	O
underlying	O
the	O
activity	O
of	O
aniracetam	O
and	O
its	O
'	O
therapeutic	O
window	O
'	O
are	O
unknown	O
.	O

Piracetam	O
,	O
another	O
pyrrolidinone	O
derivative	O
was	O
used	O
for	O
comparison	O
.	O

It	O
was	O
active	O
only	O
in	O
six	O
of	O
nine	O
tests	O
and	O
had	O
about	O
one	O
-	O
tenth	O
the	O
potency	O
of	O
aniracetam	O
.	O

The	O
results	O
indicate	O
that	O
aniracetam	O
improves	O
cognitive	O
functions	O
which	O
are	O
impaired	O
by	O
different	O
procedure	O
and	O
in	O
different	O
phases	O
of	O
the	O
learning	O
and	O
memory	O
process	O
.	O

Hepatic	B
veno	I
-	I
occlusive	I
disease	I
caused	O
by	O
6-thioguanine	O
.	O

Clinically	O
reversible	O
veno	B
-	I
occlusive	I
disease	I
of	I
the	I
liver	I
developed	O
in	O
a	O
23-year	O
-	O
old	O
man	O
with	O
acute	B
lymphocytic	I
leukemia	I
after	O
10	O
months	O
of	O
maintenance	O
therapy	O
with	O
6-thioguanine	O
.	O

Serial	O
liver	O
biopsies	O
showed	O
the	O
development	O
and	O
resolution	O
of	O
intense	O
sinusoidal	O
engorgement	O
.	O

Although	O
this	O
disease	O
was	O
clinically	O
reversible	O
,	O
some	O
subintimal	O
fibrosis	B
about	O
the	O
terminal	O
hepatic	O
veins	O
persisted	O
.	O

This	O
case	O
presented	O
a	O
unique	O
opportunity	O
to	O
observe	O
the	O
histologic	O
features	O
of	O
clinically	O
reversible	O
hepatic	B
veno	I
-	I
occlusive	I
disease	I
over	O
time	O
,	O
and	O
may	O
be	O
the	O
first	O
case	O
of	O
veno	O
-	O
occlusive	O
related	O
solely	O
to	O
6-thioguanine	O
.	O

Extrapyramidal	O
side	O
effects	O
and	O
oral	O
haloperidol	O
:	O
an	O
analysis	O
of	O
explanatory	O
patient	O
and	O
treatment	O
characteristics	O
.	O

The	O
incidence	O
of	O
extrapyramidal	O
side	O
effects	O
(	O
EPS	O
)	O
was	O
evaluated	O
in	O
98	O
patients	O
treated	O
with	O
haloperidol	O
.	O

The	O
incidence	O
of	O
parkinsonism	B
was	O
higher	O
at	O
higher	O
doses	O
of	O
haloperidol	O
and	O
in	O
younger	O
patients	O
.	O

Prophylactic	O
antiparkinsonian	O
medication	O
was	O
effective	O
in	O
younger	O
but	O
not	O
in	O
older	O
patients	O
.	O

However	O
,	O
these	O
medications	O
were	O
more	O
effective	O
in	O
both	O
young	O
and	O
old	O
patients	O
when	O
given	O
after	O
parkinsonism	B
developed	O
.	O

Akathisia	B
was	O
controlled	O
by	O
the	O
benzodiazepine	O
lorazepam	O
in	O
14	O
out	O
of	O
16	O
patients	O
,	O
while	O
prophylactic	O
antiparkinsonians	O
were	O
ineffective	O
.	O

The	O
present	O
study	O
points	O
to	O
patient	O
characteristics	O
that	O
may	O
be	O
of	O
significance	O
in	O
the	O
development	O
of	O
EPS	O
due	O
to	O
haloperidol	O
.	O

REM	B
sleep	I
deprivation	I
changes	O
behavioral	O
response	O
to	O
catecholaminergic	O
and	O
serotonergic	O
receptor	O
activation	O
in	O
rats	O
.	O

The	O
effects	O
of	O
REM	B
sleep	I
deprivation	I
(	O
REMD	B
)	O
on	O
apomorphine	O
-	O
induced	O
aggressiveness	B
and	O
quipazine	O
-	O
induced	O
head	B
twitches	I
in	O
rats	O
were	O
determined	O
.	O

Forty	O
-	O
eight	O
hr	O
of	O
REMD	B
increased	O
apomorphine	O
-	O
induced	O
aggressiveness	B
,	O
and	O
reduced	O
(	O
immediately	O
after	O
completing	O
of	O
REMD	B
)	O
or	O
increased	O
(	O
96	O
hr	O
after	O
completing	O
of	O
REMD	B
)	O
quipazine	O
-	O
induced	O
head	B
twitches	I
.	O

Results	O
are	O
discussed	O
in	O
terms	O
of	O
similarity	O
to	O
pharmacological	O
effects	O
of	O
other	O
antidepressive	O
treatments	O
.	O

Endometrial	B
carcinoma	I
after	O
Hodgkin	B
disease	I
in	O
childhood	O
.	O

A	O
34-year	O
-	O
old	O
patient	O
developed	O
metastic	O
endometrial	B
carcinoma	I
after	O
Hodgkin	B
disease	I
in	O
childhood	O
.	O

She	O
had	O
ovarian	B
failure	I
after	O
abdominal	O
irradiation	O
and	O
chemotherapy	O
for	O
Hodgkin	B
disease	I
,	O
and	O
received	O
exogenous	O
estrogens	O
,	O
a	O
treatment	O
implicated	O
in	O
the	O
development	O
of	O
endometrial	B
cancer	I
in	O
menopausal	O
women	O
.	O

Young	O
women	O
on	O
replacement	O
estrogens	O
for	O
ovarian	B
failure	I
after	O
cancer	B
therapy	O
may	O
also	O
have	O
increased	O
risk	O
of	O
endometrial	B
carcinoma	I
and	O
should	O
be	O
examined	O
periodically	O
.	O

Long	O
-	O
term	O
lithium	O
treatment	O
and	O
the	O
kidney	O
.	O

Interim	O
report	O
on	O
fifty	O
patients	O
.	O

This	O
is	O
a	O
report	O
on	O
the	O
first	O
part	O
of	O
our	O
study	O
of	O
the	O
effects	O
of	O
long	O
-	O
term	O
lithium	O
treatment	O
on	O
the	O
kidney	O
.	O

Creatinine	O
clearance	O
,	O
maximum	O
urinary	O
osmolality	O
and	O
24	O
hour	O
urine	O
volume	O
have	O
been	O
tested	O
in	O
50	O
affectively	O
ill	O
patients	O
who	O
have	O
been	O
on	O
long	O
-	O
term	O
lithium	O
for	O
more	O
than	O
one	O
year	O
.	O

These	O
findings	O
have	O
been	O
compared	O
with	O
norms	O
and	O
with	O
values	O
of	O
the	O
same	O
tests	O
from	O
screening	O
prior	O
to	O
lithium	O
,	O
available	O
for	O
most	O
of	O
our	O
patients	O
.	O

No	O
evidence	O
was	O
found	O
for	O
any	O
reduction	O
of	O
glomerular	O
filtration	O
during	O
lithium	O
treatment	O
.	O

Low	O
clearance	O
values	O
found	O
in	O
several	O
patients	O
could	O
be	O
accounted	O
for	O
by	O
their	O
age	O
and	O
their	O
pre	O
-	O
lithium	O
values	O
.	O

Urinary	O
concentration	O
defect	O
appeared	O
frequent	O
but	O
the	O
extent	O
of	O
the	O
impairment	O
is	O
difficult	O
to	O
assess	O
because	O
of	O
the	O
uncertainty	O
about	O
the	O
norms	O
applicable	O
to	O
this	O
group	O
of	O
patients	O
.	O

The	O
concentration	O
defect	O
appeared	O
reversible	O
,	O
at	O
least	O
in	O
part	O
.	O

Polyuria	B
above	O
3	O
litres	O
/	O
24	O
hours	O
was	O
found	O
in	O
10	O
%	O
of	O
patients	O
.	O

An	O
attempt	O
is	O
made	O
to	O
draw	O
practical	O
conclusions	O
from	O
the	O
preliminary	O
findings	O
.	O

Acute	B
renal	I
failure	I
in	O
high	O
dose	O
carboplatin	O
chemotherapy	O
.	O

Carboplatin	O
has	O
been	O
reported	O
to	O
cause	O
acute	B
renal	I
failure	I
when	O
administered	O
in	O
high	O
doses	O
to	O
adult	O
patients	O
.	O

We	O
report	O
a	O
4	O
1	O
/	O
2-year	O
-	O
old	O
girl	O
who	O
was	O
treated	O
with	O
high	O
-	O
dose	O
carboplatin	O
for	O
metastatic	O
parameningeal	O
embryonal	B
rhabdomyosarcoma	I
.	O

Acute	B
renal	I
failure	I
developed	O
followed	O
by	O
a	O
slow	O
partial	O
recovery	O
of	O
renal	O
function	O
.	O

Possible	O
contributing	O
factors	O
are	O
discussed	O
.	O

Cholinergic	O
toxicity	B
resulting	O
from	O
ocular	O
instillation	O
of	O
echothiophate	O
iodide	O
eye	O
drops	O
.	O

A	O
patient	O
developed	O
a	O
severe	O
cholinergic	O
syndrome	O
from	O
the	O
use	O
of	O
echothiophate	O
iodide	O
ophthalmic	O
drops	O
,	O
presented	O
with	O
profound	O
muscle	B
weakness	I
and	O
was	O
initially	O
given	O
the	O
diagnosis	O
of	O
myasthenia	B
gravis	I
.	O

Red	O
blood	O
cell	O
and	O
serum	O
cholinesterase	O
levels	O
were	O
severely	O
depressed	O
and	O
symptoms	O
resolved	O
spontaneously	O
following	O
discontinuation	O
of	O
the	O
eye	O
drops	O
.	O

Time	O
dependence	O
of	O
plasma	O
malondialdehyde	O
,	O
oxypurines	O
,	O
and	O
nucleosides	O
during	O
incomplete	O
cerebral	B
ischemia	I
in	O
the	O
rat	O
.	O

Incomplete	O
cerebral	B
ischemia	I
(	O
30	O
min	O
)	O
was	O
induced	O
in	O
the	O
rat	O
by	O
bilaterally	O
clamping	O
the	O
common	O
carotid	O
arteries	O
.	O

Peripheral	O
venous	O
blood	O
samples	O
were	O
withdrawn	O
from	O
the	O
femoral	O
vein	O
four	O
times	O
(	O
once	O
every	O
5	O
min	O
)	O
before	O
ischemia	B
(	O
0	O
time	O
)	O
and	O
5	O
,	O
15	O
,	O
and	O
30	O
min	O
after	O
ischemia	B
.	O

Plasma	O
extracts	O
were	O
analyzed	O
by	O
a	O
highly	O
sensitive	O
high	O
-	O
performance	O
liquid	O
chromatographic	O
method	O
for	O
the	O
direct	O
determination	O
of	O
malondialdehyde	O
,	O
oxypurines	O
,	O
and	O
nucleosides	O
.	O

During	O
ischemia	B
,	O
a	O
time	O
-	O
dependent	O
increase	O
of	O
plasma	O
oxypurines	O
and	O
nucleosides	O
was	O
observed	O
.	O

Plasma	O
malondialdehyde	O
,	O
which	O
was	O
present	O
in	O
minimal	O
amount	O
at	O
zero	O
time	O
(	O
0.058	O
mumol	O
/	O
liter	O
plasma	O
;	O
SD	O
0.015	O
)	O
,	O
increased	O
after	O
5	O
min	O
of	O
ischemia	B
,	O
resulting	O
in	O
a	O
fivefold	O
increase	O
after	O
30	O
min	O
of	O
carotid	O
occlusion	O
(	O
0.298	O
mumol	O
/	O
liter	O
plasma	O
;	O
SD	O
0.078	O
)	O
.	O

Increased	O
plasma	O
malondialdehyde	O
was	O
also	O
recorded	O
in	O
two	O
other	O
groups	O
of	O
animals	O
subjected	O
to	O
the	O
same	O
experimental	O
model	O
,	O
one	O
receiving	O
20	O
mg	O
/	O
kg	O
b.w	O
.	O

of	O
the	O
cyclooxygenase	O
inhibitor	O
acetylsalicylate	O
intravenously	O
immediately	O
before	O
ischemia	B
,	O
the	O
other	O
receiving	O
650	O
micrograms	O
/	O
kg	O
b.w	O
.	O
of	O
the	O
hypotensive	B
drug	O
nitroprusside	O
at	O
a	O
flow	O
rate	O
of	O
103	O
microliters	O
/	O
min	O
intravenously	O
during	O
ischemia	B
,	O
although	O
in	O
this	O
latter	O
group	O
malondialdehyde	O
was	O
significantly	O
higher	O
.	O

The	O
present	O
data	O
indicate	O
that	O
the	O
determination	O
of	O
malondialdehyde	O
,	O
oxypurines	O
,	O
and	O
nucleosides	O
in	O
peripheral	O
blood	O
,	O
may	O
be	O
used	O
to	O
monitor	O
the	O
metabolic	O
alterations	O
of	O
tissues	O
occurring	O
during	O
ischemic	B
phenomena.	O
(	O
ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O

Cognitive	B
deterioration	I
from	O
long	O
-	O
term	O
abuse	O
of	O
dextromethorphan	O
:	O
a	O
case	O
report	O
.	O

Dextromethorphan	O
(	O
DM	O
)	O
,	O
the	O
dextrorotatory	O
isomer	O
of	O
3-hydroxy	O
-	O
N	O
-	O
methylmorphinan	O
,	O
is	O
the	O
main	O
ingredient	O
in	O
a	O
number	O
of	O
widely	O
available	O
,	O
over	O
-	O
the	O
-	O
counter	O
antitussives	O
.	O

Initial	O
studies	O
(	O
Bornstein	O
1968	O
)	O
showed	O
that	O
it	O
possessed	O
no	O
respiratory	O
suppressant	O
effects	O
and	O
no	O
addiction	O
liability	O
.	O

Subsequently	O
,	O
however	O
,	O
several	O
articles	O
reporting	O
abuse	O
of	O
this	O
drug	O
have	O
appeared	O
in	O
the	O
literature	O
.	O

The	O
drug	O
is	O
known	O
to	O
cause	O
a	O
variety	O
of	O
acute	O
toxic	O
effects	O
,	O
ranging	O
from	O
nausea	B
,	O
restlessness	B
,	O
insomnia	B
,	O
ataxia	B
,	O
slurred	O
speech	O
and	O
nystagmus	B
to	O
mood	O
changes	O
,	O
perceptual	O
alterations	O
,	O
inattention	O
,	O
disorientation	O
and	O
aggressive	B
behavior	I
(	O
Rammer	O
et	O
al	O
1988	O
;	O
Katona	O
and	O
Watson	O
1986	O
;	O
Isbell	O
and	O
Fraser	O
1953	O
;	O
Devlin	O
et	O
al	O
1985	O
;	O
McCarthy	O
1971	O
;	O
Dodds	O
and	O
Revai	O
1967	O
;	O
Degkwitz	O
1964	O
;	O
Hildebrand	O
et	O
al	O
1989	O
)	O
.	O

There	O
have	O
also	O
been	O
two	O
reported	O
fatalities	O
from	O
DM	O
overdoses	O
(	O
Fleming	O
1986	O
)	O
.	O

However	O
,	O
there	O
are	O
no	O
reports	O
describing	O
the	O
effects	O
of	O
chronic	O
abuse	O
.	O

This	O
report	O
describes	O
a	O
case	O
of	O
cognitive	B
deterioration	I
resulting	O
from	O
prolonged	O
use	O
of	O
DM	O
.	O

Dexamethasone	O
-	O
induced	O
ocular	B
hypertension	I
in	O
perfusion	O
-	O
cultured	O
human	O
eyes	O
.	O

PURPOSE	O
:	O
Glucocorticoid	O
administration	O
can	O
lead	O
to	O
the	O
development	O
of	O
ocular	B
hypertension	I
and	O
corticosteroid	B
glaucoma	I
in	O
a	O
subset	O
of	O
the	O
population	O
through	O
a	O
decrease	O
in	O
the	O
aqueous	O
humor	O
outflow	O
facility	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
glucocorticoid	O
treatment	O
can	O
directly	O
affect	O
the	O
outflow	O
facility	O
of	O
isolated	O
,	O
perfusion	O
-	O
cultured	O
human	O
eyes	O
.	O

METHODS	O
:	O
The	O
anterior	O
segments	O
of	O
human	O
donor	O
eyes	O
from	O
regional	O
eye	O
banks	O
were	O
placed	O
in	O
a	O
constant	O
flow	O
,	O
variable	O
pressure	O
perfusion	O
culture	O
system	O
.	O

Paired	O
eyes	O
were	O
perfused	O
in	O
serum	O
-	O
free	O
media	O
with	O
or	O
without	O
10	O
(	O
-7	O
)	O
M	O
dexamethasone	O
for	O
12	O
days	O
.	O

Intraocular	O
pressure	O
was	O
monitored	O
daily	O
.	O

After	O
incubation	O
,	O
the	O
eyes	O
were	O
morphologically	O
characterized	O
by	O
light	O
microscopy	O
,	O
transmission	O
and	O
scanning	O
electron	O
microscopy	O
,	O
and	O
scanning	O
laser	O
confocal	O
microscopy	O
.	O

RESULTS	O
:	O
A	O
significant	O
increase	O
in	O
intraocular	O
pressure	O
developed	O
in	O
13	O
of	O
the	O
44	O
pairs	O
of	O
eyes	O
perfused	O
with	O
dexamethasone	O
with	O
an	O
average	O
pressure	O
rise	O
of	O
17.5	O
+	O
/-	O

3.8	O
mm	O
Hg	O
after	O
12	O
days	O
of	O
dexamethasone	O
exposure	O
.	O

The	O
contralateral	O
control	O
eyes	O
,	O
which	O
did	O
not	O
receive	O
dexamethasone	O
,	O
maintained	O
a	O
stable	O
intraocular	O
pressure	O
during	O
the	O
same	O
period	O
.	O

The	O
outflow	O
pathway	O
of	O
the	O
untreated	O
eyes	O
appeared	O
morphologically	O
normal	O
.	O

In	O
contrast	O
,	O
the	O
dexamethasone	O
-	O
treated	O
hypertensive	B
eyes	I
had	O
thickened	O
trabecular	O
beams	O
,	O
decreased	O
intertrabecular	O
spaces	O
,	O
thickened	O
juxtacanalicular	O
tissue	O
,	O
activated	O
trabecular	O
meshwork	O
cells	O
,	O
and	O
increased	O
amounts	O
of	O
amorphogranular	O
extracellular	O
material	O
,	O
especially	O
in	O
the	O
juxtacanalicular	O
tissue	O
and	O
beneath	O
the	O
endothelial	O
lining	O
of	O
the	O
canal	O
of	O
Schlemm	O
.	O

The	O
dexamethasone	O
-	O
treated	O
nonresponder	O
eyes	O
appeared	O
to	O
be	O
morphologically	O
similar	O
to	O
the	O
untreated	O
eyes	O
,	O
although	O
several	O
subtle	O
dexamethasone	O
-	O
induced	O
morphologic	O
changes	O
were	O
evident	O
.	O

CONCLUSION	O
:	O
Dexamethasone	O
treatment	O
of	O
isolated	O
,	O
perfusion	O
-	O
cultured	O
human	O
eyes	O
led	O
to	O
the	O
generation	O
of	O
ocular	B
hypertension	I
in	O
approximately	O
30	O
%	O
of	O
the	O
dexamethasone	O
-	O
treated	O
eyes	O
.	O

Steroid	O
treatment	O
resulted	O
in	O
morphologic	O
changes	O
in	O
the	O
trabecular	O
meshwork	O
similar	O
to	O
those	O
reported	O
for	O
corticosteroid	B
glaucoma	I
and	O
open	B
angle	I
glaucoma	I
.	O

This	O
system	O
may	O
provide	O
an	O
acute	O
model	O
in	O
which	O
to	O
study	O
the	O
pathogenic	O
mechanisms	O
involved	O
in	O
steroid	B
glaucoma	I
and	O
primary	B
open	I
angle	I
glaucoma	I
.	O

Water	B
intoxication	I
associated	O
with	O
oxytocin	O
administration	O
during	O
saline	O
-	O
induced	O
abortion	B
.	O

Four	O
cases	O
of	O
water	B
intoxication	I
in	O
connection	O
with	O
oxytocin	O
administration	O
during	O
saline	O
-	O
induced	O
abortions	B
are	O
described	O
.	O

The	O
mechanism	O
of	O
water	B
intoxication	I
is	O
discussed	O
in	O
regard	O
to	O
these	O
cases	O
.	O

Oxytocin	O
administration	O
during	O
midtrimester	O
-	O
induced	O
abortions	B
is	O
advocated	O
only	O
if	O
it	O
can	O
be	O
carried	O
out	O
under	O
careful	O
observations	O
of	O
an	O
alert	O
nursing	O
staff	O
,	O
aware	O
of	O
the	O
symptoms	O
of	O
water	B
intoxication	I
and	O
instructed	O
to	O
watch	O
the	O
diuresis	O
and	O
report	O
such	O
early	O
signs	O
of	O
the	O
syndrome	O
as	O
asthenia	B
,	O
muscular	O
irritability	B
,	O
or	O
headaches	B
.	O

The	O
oxytocin	O
should	O
be	O
given	O
only	O
in	O
Ringers	O
lactate	O
or	O
,	O
alternately	O
,	O
in	O
Ringers	O
lactate	O
and	O
a	O
5	O
per	O
cent	O
dextrose	O
and	O
water	O
solutions	O
.	O

The	O
urinary	O
output	O
should	O
be	O
monitored	O
and	O
the	O
oxytocin	O
administration	O
discontinued	O
and	O
the	O
serum	O
electrolytes	O
checked	O
if	O
the	O
urinary	O
output	O
decreases	O
.	O

The	O
oxytocin	O
should	O
not	O
be	O
administered	O
in	O
excess	O
of	O
36	O
hours	O
.	O

If	O
the	O
patient	O
has	O
not	O
aborted	O
by	O
then	O
the	O
oxytocin	O
should	O
be	O
discontinued	O
for	O
10	O
to	O
12	O
hours	O
in	O
order	O
to	O
perform	O
electrolyte	O
determinations	O
and	O
correct	O
any	O
electrolyte	O
imbalance	O
.	O

Light	O
chain	O
proteinuria	B
and	O
cellular	O
mediated	O
immunity	O
in	O
rifampin	O
treated	O
patients	O
with	O
tuberculosis	B
.	O

Light	O
chain	O
proteinuria	B
was	O
found	O
in	O
9	O
of	O
17	O
tuberculosis	B
patients	O
treated	O
with	O
rifampin	O
.	O

Concomitant	O
assay	O
of	O
cellular	O
mediated	O
immunity	O
in	O
these	O
patients	O
using	O
skin	O
test	O
antigen	O
and	O
a	O
lymphokine	O
in	O
vitro	O
test	O
provided	O
results	O
that	O
were	O
different	O
.	O

Response	O
to	O
Varidase	O
skin	O
test	O
antigen	O
was	O
negative	O
for	O
all	O
eight	O
tuberculosis	B
patients	O
tested	O
,	O
but	O
there	O
occurred	O
a	O
hyper	O
-	O
responsiveness	O
of	O
the	O
lymphocytes	O
of	O
these	O
eight	O
patients	O
to	O
phytomitogen	O
(	O
PHA	O
-	O
P	O
)	O
.	O

as	O
well	O
as	O
of	O
those	O
of	O
seven	O
other	O
tuberculous	B
patients	O
.	O

This	O
last	O
finding	O
may	O
be	O
related	O
to	O
time	O
of	O
testing	O
and/or	O
endogenous	O
serum	O
binding	O
of	O
rifampin	O
which	O
could	O
have	O
inhibited	O
mitogen	O
activity	O
for	O
the	O
lymphocyte	O
.	O

KF17837	O
:	O
a	O
novel	O
selective	O
adenosine	O
A2A	O
receptor	O
antagonist	O
with	O
anticataleptic	O
activity	O
.	O

KF17837	O
is	O
a	O
novel	O
selective	O
adenosine	O
A2A	O
receptor	O
antagonist	O
.	O

Oral	O
administration	O
of	O
KF17837	O
(	O
2.5	O
,	O
10.0	O
and	O
30.0	O
mg	O
/	O
kg	O
)	O
significantly	O
ameliorated	O
the	O
cataleptic	B
responses	O
induced	O
by	O
intracerebroventricular	O
administration	O
of	O
an	O
adenosine	O
A2A	O
receptor	O
agonist	O
,	O
CGS	O
21680	O
(	O
10	O
micrograms	O
)	O
,	O
in	O
a	O
dose	O
-	O
dependent	O
manner	O
.	O

KF17837	O
also	O
reduced	O
the	O
catalepsy	B
induced	O
by	O
haloperidol	O
(	O
1	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
and	O
by	O
reserpine	O
(	O
5	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
.	O

These	O
anticataleptic	O
effects	O
were	O
exhibited	O
dose	O
dependently	O
at	O
doses	O
from	O
0.625	O
and	O
2.5	O
mg	O
/	O
kg	O
p.o	O
.	O
,	O
respectively	O
.	O

Moreover	O
,	O
KF17837	O
(	O
0.625	O
mg	O
/	O
kg	O
p.o	O
.	O
)	O
potentiated	O
the	O
anticataleptic	O
effects	O
of	O
a	O
subthreshold	O
dose	O
of	O
L-3,4-dihydroxyphenylalanine	O
(	O
L	O
-	O
DOPA	O
;	O
25	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
plus	O
benserazide	O
(	O
6.25	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
.	O

These	O
results	O
suggested	O
that	O
KF17837	O
is	O
a	O
centrally	O
active	O
adenosine	O
A2A	O
receptor	O
antagonist	O
and	O
that	O
the	O
dopaminergic	O
function	O
of	O
the	O
nigrostriatal	O
pathway	O
is	O
potentiated	O
by	O
adenosine	O
A2A	O
receptor	O
antagonists	O
.	O

Furthermore	O
,	O
KF17837	O
may	O
be	O
a	O
useful	O
drug	O
in	O
the	O
treatment	O
of	O
parkinsonism	B
.	O

Hyperalgesia	B
and	O
myoclonus	B
in	O
terminal	O
cancer	B
patients	O
treated	O
with	O
continuous	O
intravenous	O
morphine	O
.	O

Eight	O
cancer	B
patients	O
in	O
the	O
terminal	O
stages	O
of	O
the	O
disease	O
treated	O
with	O
high	O
doses	O
of	O
intravenous	O
morphine	O
developed	O
hyperalgesia	B
.	O

All	O
cases	O
were	O
retrospectively	O
sampled	O
from	O
three	O
different	O
hospitals	O
in	O
Copenhagen	O
.	O

Five	O
patients	O
developed	O
universal	O
hyperalgesia	B
and	O
hyperesthesia	B
which	O
in	O
2	O
cases	O
were	O
accompanied	O
by	O
myoclonus	B
.	O

In	O
3	O
patients	O
a	O
pre	O
-	O
existing	O
neuralgia	B
increased	O
to	O
excruciating	O
intensity	O
and	O
in	O
2	O
of	O
these	O
cases	O
myoclonus	B
occurred	O
simultaneously	O
.	O

Although	O
only	O
few	O
clinical	O
descriptions	O
of	O
the	O
relationship	O
between	O
hyperalgesia	B
/	O
myoclonus	B
and	O
high	O
doses	O
of	O
morphine	O
are	O
available	O
,	O
experimental	O
support	O
from	O
animal	O
studies	O
indicates	O
that	O
morphine	O
,	O
or	O
its	O
metabolites	O
,	O
plays	O
a	O
causative	O
role	O
for	O
the	O
observed	O
behavioural	O
syndrome	O
.	O

The	O
possible	O
mechanisms	O
are	O
discussed	O
and	O
treatment	O
proposals	O
given	O
suggesting	O
the	O
use	O
of	O
more	O
efficacious	O
opioids	O
with	O
less	O
excitatory	O
potency	O
in	O
these	O
situations	O
.	O

Case	O
report	O
:	O
pentamidine	O
and	O
polymorphic	O
ventricular	B
tachycardia	I
revisited	O
.	O

Pentamidine	O
isethionate	O
has	O
been	O
associated	O
with	O
ventricular	B
tachyarrhythmias	I
,	O
including	O
torsade	B
de	I
pointes	I
.	O

This	O
article	O
reports	O
two	O
cases	O
of	O
this	O
complication	O
and	O
reviews	O
all	O
reported	O
cases	O
to	O
date	O
.	O

Pentamidine	O
-	O
induced	O
torsade	B
de	I
pointes	I
may	O
be	O
related	O
to	O
serum	O
magnesium	O
levels	O
and	O
hypomagnesemia	B
may	O
synergistically	O
induce	O
torsade	O
.	O

Torsade	B
de	I
pointes	I
occurred	O
after	O
an	O
average	O
of	O
10	O
days	O
of	O
treatment	O
with	O
pentamidine	O
.	O

In	O
these	O
patients	O
,	O
no	O
other	O
acute	O
side	O
effects	O
of	O
pentamidine	O
were	O
observed	O
.	O

Torsade	B
de	I
pointes	I
can	O
be	O
treated	O
when	O
recognized	O
early	O
,	O
possibly	O
without	O
discontinuation	O
of	O
pentamidine	O
.	O

When	O
QTc	B
interval	I
prolongation	I
is	O
observed	O
,	O
early	O
magnesium	O
supplementation	O
is	O
advocated	O
.	O

Efficacy	O
and	O
tolerability	O
of	O
lovastatin	O
in	O
3390	O
women	O
with	O
moderate	O
hypercholesterolemia	B
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
the	O
efficacy	O
and	O
safety	O
of	O
lovastatin	O
in	O
women	O
with	O
moderate	O
hypercholesterolemia	B
.	O

DESIGN	O
:	O
The	O
Expanded	O
Clinical	O
Evaluation	O
of	O
Lovastatin	O
(	O
EXCEL	O
)	O
Study	O
,	O
a	O
multicenter	O
,	O
double	O
-	O
blind	O
,	O
diet-	O
and	O
placebo	O
-	O
controlled	O
trial	O
,	O
in	O
which	O
participants	O
were	O
randomly	O
assigned	O
to	O
receive	O
placebo	O
or	O
lovastatin	O
at	O
doses	O
of	O
20	O
or	O
40	O
mg	O
once	O
daily	O
,	O
or	O
20	O
or	O
40	O
mg	O
twice	O
daily	O
for	O
48	O
weeks	O
.	O

SETTING	O
:	O
Ambulatory	O
patients	O
recruited	O
by	O
362	O
participating	O
centers	O
throughout	O
the	O
United	O
States	O
.	O

PATIENTS	O
:	O
Women	O
(	O
n	O
=	O
3390	O
)	O
from	O
the	O
total	O
cohort	O
of	O
8245	O
volunteers	O
.	O

MEASUREMENTS	O
:	O
Plasma	O
total	O
,	O
low	O
-	O
density	O
lipoprotein	O
(	O
LDL	O
)	O
,	O
and	O
high	O
-	O
density	O
lipoprotein	O
(	O
HDL	O
)	O
cholesterol	O
,	O
and	O
triglycerides	O
;	O
and	O
laboratory	O
and	O
clinical	O
evidence	O
of	O
adverse	O
events	O
monitored	O
periodically	O
throughout	O
the	O
study	O
.	O

RESULTS	O
:	O
Among	O
women	O
,	O
lovastatin	O
(	O
20	O
to	O
80	O
mg	O
/	O
d	O
)	O
produced	O
sustained	O
(	O
12-	O
to	O
48-week	O
)	O
,	O
dose	O
-	O
related	O
changes	O
(	O
P	O
<	O
0.001	O
)	O
:	O
decreases	O
in	O
LDL	O
cholesterol	O
(	O
24	O
%	O
to	O
40	O
%	O
)	O
and	O
triglycerides	O
(	O
9	O
%	O
to	O
18	O
%	O
)	O
,	O
and	O
increases	O
in	O
HDL	O
cholesterol	O
(	O
6.7	O
%	O
to	O
8.6	O
%	O
)	O
.	O

Depending	O
on	O
the	O
dose	O
,	O
from	O
82	O
%	O
to	O
95	O
%	O
of	O
lovastatin	O
-	O
treated	O
women	O
achieved	O
the	O
National	O
Cholesterol	O
Education	O
Program	O
goal	O
of	O
LDL	O
cholesterol	O
levels	O
less	O
than	O
4.14	O
mmol	O
/	O
L	O
(	O
160	O
mg	O
/	O
dL	O
)	O
,	O
and	O
40	O
%	O
to	O
87	O
%	O
achieved	O
the	O
goal	O
of	O
3.36	O
mmol	O
/	O
L	O
(	O
130	O
mg	O
/	O
dL	O
)	O
.	O

Successive	O
transaminase	O
elevations	O
greater	O
than	O
three	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
occurred	O
in	O
0.1	O
%	O
of	O
women	O
and	O
were	O
dose	O
dependent	O
above	O
the	O
20-mg	O
dose	O
.	O

Myopathy	B
,	O
defined	O
as	O
muscle	O
symptoms	O
with	O
creatine	O
kinase	O
elevations	O
greater	O
than	O
10	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
,	O
was	O
rare	O
and	O
associated	O
with	O
the	O
highest	O
recommended	O
daily	O
dose	O
of	O
lovastatin	O
(	O
80	O
mg	O
)	O
.	O

Estrogen	O
-	O
replacement	O
therapy	O
appeared	O
to	O
have	O
no	O
effect	O
on	O
either	O
the	O
efficacy	O
or	O
safety	O
profile	O
of	O
lovastatin	O
.	O

CONCLUSION	O
:	O
Lovastatin	O
is	O
highly	O
effective	O
and	O
generally	O
well	O
tolerated	O
as	O
therapy	O
for	O
primary	O
hypercholesterolemia	B
in	O
women	O
.	O

Ciprofloxacin	O
-	O
induced	O
nephrotoxicity	B
in	O
patients	O
with	O
cancer	B
.	O

Nephrotoxicity	B
associated	O
with	O
ciprofloxacin	O
is	O
uncommon	O
.	O

Five	O
patients	O
with	O
cancer	B
who	O
developed	O
acute	B
renal	I
failure	I
that	O
followed	O
treatment	O
with	O
ciprofloxacin	O
are	O
described	O
and	O
an	O
additional	O
15	O
cases	O
reported	O
in	O
the	O
literature	O
are	O
reviewed	O
.	O

Other	O
than	O
elevation	O
of	O
serum	O
creatinine	O
levels	O
,	O
characteristic	O
clinical	O
manifestations	O
and	O
abnormal	O
laboratory	O
findings	O
are	O
not	O
frequently	O
present	O
.	O

Allergic	O
interstitial	B
nephritis	I
is	O
believed	O
to	O
be	O
the	O
underlying	O
pathological	O
-	O
process	O
.	O

Definitive	O
diagnosis	O
requires	O
performance	O
of	O
renal	O
biopsy	O
,	O
although	O
this	O
is	O
not	O
always	O
feasible	O
.	O

An	O
improvement	O
in	O
renal	O
function	O
that	O
followed	O
the	O
discontinuation	O
of	O
the	O
offending	O
antibiotic	O
supports	O
the	O
presumptive	O
diagnosis	O
of	O
ciprofloxacin	O
-	O
induced	O
acute	B
renal	I
failure	I
.	O

Changes	O
in	O
peroxisomes	O
in	O
preneoplastic	O
liver	O
and	O
hepatoma	B
of	O
mice	O
induced	O
by	O
alpha	O
-	O
benzene	O
hexachloride	O
.	O

Peroxisomes	O
in	O
hepatomas	B
and	O
hyperplastic	O
preneoplastic	O
liver	B
lesions	I
induced	O
in	O
mice	O
by	O
500	O
ppm	O
alpha	O
-	O
benzene	O
hexachloride	O
were	O
examined	O
histochemically	O
and	O
electron	O
microscopically	O
.	O

Although	O
most	O
of	O
the	O
hepatomas	B
were	O
well	O
-	O
differentiated	O
tumors	B
and	O
contained	O
a	O
considerable	O
number	O
of	O
peroxisomes	O
,	O
the	O
tumor	B
cells	O
did	O
not	O
respond	O
to	O
ethyl	O
-	O
alpha	O
-	O
p	O
-	O
chlorophenoxyisobutyrate	O
with	O
proliferation	O
of	O
peroxisomes	O
.	O

At	O
the	O
16th	O
week	O
of	O
carcinogen	O
feeding	O
,	O
hyperplastic	O
nodules	O
appeared	O
and	O
advanced	O
to	O
further	O
stages	O
.	O

A	O
majority	O
of	O
the	O
nodules	O
showed	O
a	O
considerable	O
number	O
of	O
peroxisomes	O
and	O
the	O
inductive	O
proliferation	O
of	O
peroxisomes	O
.	O

Within	O
the	O
nodules	O
,	O
foci	O
of	O
proliferation	O
of	O
the	O
cells	O
that	O
showed	O
no	O
inducibility	O
of	O
proliferation	O
of	O
peroxisomes	O
appeared	O
.	O

These	O
cells	O
proliferated	O
further	O
,	O
replacing	O
the	O
most	O
part	O
of	O
the	O
nodules	O
,	O
and	O
with	O
this	O
process	O
hepatomas	B
appeared	O
to	O
have	O
been	O
formed	O
.	O

No	O
abnormal	O
matrical	O
inclusions	O
of	O
peroxisomes	O
were	O
formed	O
in	O
the	O
cells	O
of	O
hyperplastic	O
nodules	O
by	O
ethyl	O
-	O
alpha	O
-	O
p	O
-	O
chlorophenoxyisobutyrate	O
unlike	O
in	O
the	O
case	O
of	O
rats	O
.	O

Absence	O
of	O
effect	O
of	O
sertraline	O
on	O
time	O
-	O
based	O
sensitization	O
of	O
cognitive	B
impairment	I
with	O
haloperidol	O
.	O

This	O
double	O
-	O
blind	O
,	O
randomized	O
,	O
placebo	O
-	O
controlled	O
study	O
evaluated	O
the	O
effects	O
of	O
haloperidol	O
alone	O
and	O
haloperidol	O
plus	O
sertraline	O
on	O
cognitive	O
and	O
psychomotor	O
function	O
in	O
24	O
healthy	O
male	O
subjects	O
.	O

METHOD	O
:	O
All	O
subjects	O
received	O
placebo	O
on	O
Day	O
1	O
and	O
haloperidol	O
2	O
mg	O
on	O
Days	O
2	O
and	O
25	O
.	O

From	O
Days	O
9	O
to	O
25	O
,	O
subjects	O
were	O
randomly	O
assigned	O
to	O
either	O
sertraline	O
(	O
12	O
subjects	O
)	O
or	O
placebo	O
(	O
12	O
subjects	O
)	O
;	O
the	O
sertraline	O
dose	O
was	O
titrated	O
from	O
50	O
to	O
200	O
mg	O
/	O
day	O
from	O
Days	O
9	O
to	O
16	O
,	O
and	O
remained	O
at	O
200	O
mg	O
/	O
day	O
for	O
the	O
final	O
10	O
days	O
of	O
the	O
drug	O
administration	O
period	O
.	O

Cognitive	O
function	O
testing	O
was	O
performed	O
before	O
dosing	O
and	O
over	O
a	O
24-hour	O
period	O
after	O
dosing	O
on	O
Days	O
1	O
,	O
2	O
,	O
and	O
25	O
.	O

RESULTS	O
:	O
Impairment	B
of	I
cognitive	I
function	I
was	O
observed	O
6	O
to	O
8	O
hours	O
after	O
administration	O
of	O
haloperidol	O
on	O
Day	O
2	O
but	O
was	O
not	O
evident	O
23	O
hours	O
after	O
dosing	O
.	O

When	O
single	O
-	O
dose	O
haloperidol	O
was	O
given	O
again	O
25	O
days	O
later	O
,	O
greater	O
impairment	O
with	O
earlier	O
onset	O
was	O
noted	O
in	O
several	O
tests	O
in	O
both	O
treatment	O
groups	O
,	O
suggesting	O
enhancement	O
of	O
this	O
effect	O
.	O

There	O
was	O
no	O
indication	O
that	O
sertraline	O
exacerbated	O
the	O
impairment	O
produced	O
by	O
haloperidol	O
since	O
an	O
equivalent	O
effect	O
also	O
occurred	O
in	O
the	O
placebo	O
group	O
.	O

Three	O
subjects	O
(	O
2	O
on	O
sertraline	O
and	O
1	O
on	O
placebo	O
)	O
withdrew	O
from	O
the	O
study	O
because	O
of	O
side	O
effects	O
.	O

Ten	O
subjects	O
in	O
each	O
group	O
reported	O
side	O
effects	O
related	O
to	O
treatment	O
.	O

The	O
side	O
effect	O
profiles	O
of	O
sertraline	O
and	O
of	O
placebo	O
were	O
similar	O
.	O

CONCLUSION	O
:	O
Haloperidol	O
produced	O
a	O
clear	O
profile	O
of	O
cognitive	B
impairment	I
that	O
was	O
not	O
worsened	O
by	O
concomitant	O
sertraline	O
administration	O
.	O

Famotidine	O
-	O
associated	O
delirium	B
.	O

A	O
series	O
of	O
six	O
cases	O
.	O

Famotidine	O
is	O
a	O
histamine	O
H2-receptor	O
antagonist	O
used	O
in	O
inpatient	O
settings	O
for	O
prevention	O
of	O
stress	O
ulcers	B
and	O
is	O
showing	O
increasing	O
popularity	O
because	O
of	O
its	O
low	O
cost	O
.	O

Although	O
all	O
of	O
the	O
currently	O
available	O
H2-receptor	O
antagonists	O
have	O
shown	O
the	O
propensity	O
to	O
cause	O
delirium	B
,	O
only	O
two	O
previously	O
reported	O
cases	O
have	O
been	O
associated	O
with	O
famotidine	O
.	O

The	O
authors	O
report	O
on	O
six	O
cases	O
of	O
famotidine	O
-	O
associated	O
delirium	B
in	O
hospitalized	O
patients	O
who	O
cleared	O
completely	O
upon	O
removal	O
of	O
famotidine	O
.	O

The	O
pharmacokinetics	O
of	O
famotidine	O
are	O
reviewed	O
,	O
with	O
no	O
change	O
in	O
its	O
metabolism	O
in	O
the	O
elderly	O
population	O
seen	O
.	O

The	O
implications	O
of	O
using	O
famotidine	O
in	O
elderly	O
persons	O
are	O
discussed	O
.	O

Valsartan	O
,	O
a	O
new	O
angiotensin	O
II	O
antagonist	O
for	O
the	O
treatment	O
of	O
essential	O
hypertension	B
:	O
a	O
comparative	O
study	O
of	O
the	O
efficacy	O
and	O
safety	O
against	O
amlodipine	O
.	O

OBJECTIVE	O
:	O
To	O
compare	O
the	O
antihypertensive	O
efficacy	O
of	O
a	O
new	O
angiotensin	O
II	O
antagonist	O
,	O
valsartan	O
,	O
with	O
a	O
reference	O
therapy	O
,	O
amlodipine	O
.	O

METHODS	O
:	O
One	O
hundred	O
sixty	O
-	O
eight	O
adult	O
outpatients	O
with	O
mild	O
to	O
moderate	O
hypertension	B
were	O
randomly	O
allocated	O
in	O
double	O
-	O
blind	O
fashion	O
and	O
equal	O
number	O
to	O
receive	O
80	O
mg	O
valsartan	O
or	O
5	O
mg	O
amlodipine	O
for	O
12	O
weeks	O
.	O

After	O
8	O
weeks	O
of	O
therapy	O
,	O
in	O
patients	O
whose	O
blood	O
pressure	O
remained	O
uncontrolled	O
,	O
5	O
mg	O
amlodipine	O
was	O
added	O
to	O
the	O
initial	O
therapy	O
.	O

Patients	O
were	O
assessed	O
at	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
.	O

The	O
primary	O
efficacy	O
variable	O
was	O
change	O
from	O
baseline	O
in	O
mean	O
sitting	O
diastolic	O
blood	O
pressure	O
at	O
8	O
weeks	O
.	O

Secondary	O
variables	O
included	O
change	O
in	O
sitting	O
systolic	O
blood	O
pressure	O
and	O
responder	O
rates	O
.	O

RESULTS	O
:	O
Both	O
valsartan	O
and	O
amlodipine	O
were	O
effective	O
at	O
lowering	O
blood	O
pressure	O
at	O
4	O
,	O
8	O
,	O
and	O
12	O
weeks	O
.	O

Similar	O
decreases	O
were	O
observed	O
in	O
both	O
groups	O
,	O
with	O
no	O
statistically	O
significant	O
differences	O
between	O
the	O
groups	O
for	O
any	O
variable	O
analyzed	O
.	O

For	O
the	O
primary	O
variable	O
the	O
difference	O
was	O
0.5	O
mm	O
Hg	O
in	O
favor	O
of	O
valsartan	O
(	O
p	O
=	O
0.68	O
;	O
95	O
%	O
confidence	O
interval	O
,	O
-2.7	O
to	O
1.7	O
)	O
.	O

Responder	O
rates	O
at	O
8	O
weeks	O
were	O
66.7	O
%	O
for	O
valsartan	O
and	O
60.2	O
%	O
for	O
amlodipine	O
(	O
p	O
=	O
0.39	O
)	O
.	O

Both	O
treatments	O
were	O
well	O
tolerated	O
.	O

The	O
incidence	O
of	O
drug	O
-	O
related	O
dependent	O
edema	B
was	O
somewhat	O
higher	O
in	O
the	O
amlodipine	O
group	O
,	O
particularly	O
at	O
a	O
dose	O
of	O
10	O
mg	O
per	O
day	O
(	O
2.4	O
%	O
for	O
80	O
mg	O
valsartan	O
;	O
3.6	O
%	O
for	O
5	O
mg	O
amlodipine	O
;	O
0	O
%	O
for	O
valsartan	O
plus	O
5	O
mg	O
amlodipine	O
;	O
14.3	O
%	O
for	O
10	O
mg	O
amlodipine	O
)	O
.	O

CONCLUSIONS	O
:	O
The	O
data	O
show	O
that	O
valsartan	O
is	O
at	O
least	O
as	O
effective	O
as	O
amlodipine	O
in	O
the	O
treatment	O
of	O
mild	O
to	O
moderate	O
hypertension	B
.	O

The	O
results	O
also	O
show	O
valsartan	O
to	O
be	O
well	O
tolerated	O
and	O
suggest	O
that	O
it	O
is	O
not	O
associated	O
with	O
side	O
effects	O
characteristic	O
of	O
this	O
comparator	O
class	O
,	O
dihydropyridine	O
calcium	O
antagonists	O
.	O

Fatal	O
excited	O
delirium	B
following	O
cocaine	O
use	O
:	O
epidemiologic	O
findings	O
provide	O
new	O
evidence	O
for	O
mechanisms	O
of	O
cocaine	O
toxicity	B
.	O

We	O
describe	O
an	O
outbreak	O
of	O
deaths	O
from	O
cocaine	O
-	O
induced	O
excited	O
delirium	B
(	O
EDDs	B
)	O
in	O
Dade	O
County	O
,	O
Florida	O
between	O
1979	O
and	O
1990	O
.	O

From	O
a	O
registry	O
of	O
all	O
cocaine	O
-	O
related	O
deaths	O
in	O
Dade	O
County	O
,	O
Florida	O
,	O
from	O
1969	O
-	O
1990	O
,	O
58	O
EDDs	B
were	O
compared	O
with	O
125	O
victims	O
of	O
accidental	O
cocaine	O
overdose	B
without	O
excited	O
delirium	B
.	O

Compared	O
with	O
controls	O
,	O
EDDs	B
were	O
more	O
frequently	O
black	O
,	O
male	O
,	O
and	O
younger	O
.	O

They	O
were	O
less	O
likely	O
to	O
have	O
a	O
low	O
body	O
mass	O
index	O
,	O
and	O
more	O
likely	O
to	O
have	O
died	O
in	O
police	O
custody	O
,	O
to	O
have	O
received	O
medical	O
treatment	O
immediately	O
before	O
death	O
,	O
to	O
have	O
survived	O
for	O
a	O
longer	O
period	O
,	O
to	O
have	O
developed	O
hyperthermia	B
,	O
and	O
to	O
have	O
died	O
in	O
summer	O
months	O
.	O

EDDs	B
had	O
concentrations	O
of	O
cocaine	O
and	O
benzoylecgonine	O
in	O
autopsy	O
blood	O
that	O
were	O
similar	O
to	O
those	O
for	O
controls	O
.	O

The	O
epidemiologic	O
findings	O
are	O
most	O
consistent	O
with	O
the	O
hypothesis	O
that	O
chronic	O
cocaine	O
use	O
disrupts	O
dopaminergic	O
function	O
and	O
,	O
when	O
coupled	O
with	O
recent	O
cocaine	O
use	O
,	O
may	O
precipitate	O
agitation	B
,	O
delirium	B
,	O
aberrant	O
thermoregulation	O
,	O
rhabdomyolysis	B
,	O
and	O
sudden	B
death	I
.	O

Neutrophil	O
superoxide	O
and	O
hydrogen	O
peroxide	O
production	O
in	O
patients	O
with	O
acute	B
liver	I
failure	I
.	O

Defects	O
in	O
superoxide	O
and	O
hydrogen	O
peroxide	O
production	O
may	O
be	O
implicated	O
in	O
the	O
high	O
incidence	O
of	O
bacterial	B
infections	I
in	O
patients	O
with	O
acute	B
liver	I
failure	I
(	O
ALF	B
)	O
.	O

In	O
the	O
present	O
study	O
,	O
oxygen	O
radical	O
production	O
in	O
patients	O
with	O
ALF	B
due	O
to	O
paracetamol	O
overdose	B
was	O
compared	O
with	O
that	O
of	O
healthy	O
volunteers	O
.	O

Neutrophils	O
from	O
14	O
ALF	B
patients	O
were	O
stimulated	O
via	O
the	O
complement	O
receptors	O
using	O
zymosan	O
opsonized	O
with	O
ALF	B
or	O
control	O
serum	O
.	O

Superoxide	O
and	O
hydrogen	O
peroxide	O
production	O
by	O
ALF	B
neutrophils	O
stimulated	O
with	O
zymosan	O
opsonized	O
with	O
ALF	B
serum	O
was	O
significantly	O
reduced	O
compared	O
with	O
the	O
control	O
subjects	O
(	O
P	O
<	O
0.01	O
)	O
.	O

This	O
defect	O
persisted	O
when	O
zymosan	O
opsonized	O
by	O
control	O
serum	O
was	O
used	O
(	O
P	O
<	O
0.05	O
)	O
.	O

Superoxide	O
and	O
hydrogen	O
peroxide	O
production	O
in	O
neutrophils	O
stimulated	O
with	O
formyl	O
-	O
methionyl	O
-	O
leucyl	O
-	O
phenylalanine	O
(	O
fMLP	O
)	O
from	O
a	O
further	O
18	O
ALF	B
patients	O
was	O
unaffected	O
compared	O
with	O
control	O
neutrophils	O
.	O

Serum	O
C3	O
complement	O
levels	O
were	O
significantly	O
reduced	O
in	O
ALF	B
patients	O
compared	O
with	O
control	O
subjects	O
(	O
P	O
<	O
0.0005	O
)	O
.	O

These	O
results	O
demonstrate	O
a	O
neutrophil	O
defect	O
in	O
ALF	B
due	O
to	O
paracetamol	O
overdose	B
,	O
that	O
is	O
complement	O
dependent	O
but	O
independent	O
of	O
serum	O
complement	O
,	O
possibly	O
connected	O
to	O
the	O
complement	O
receptor	O
.	O

Cholesteryl	O
hemisuccinate	O
treatment	O
protects	O
rodents	O
from	O
the	O
toxic	O
effects	O
of	O
acetaminophen	O
,	O
adriamycin	O
,	O
carbon	O
tetrachloride	O
,	O
chloroform	O
and	O
galactosamine	O
.	O

In	O
addition	O
to	O
its	O
use	O
as	O
a	O
stabilizer	O
/	O
rigidifier	O
of	O
membranes	O
,	O
cholesteryl	O
hemisuccinate	O
,	O
tris	O
salt	O
(	O
CS	O
)	O
administration	O
has	O
also	O
been	O
shown	O
to	O
protect	O
rats	O
from	O
the	O
hepatotoxic	B
effects	O
of	O
carbon	O
tetrachloride	O
(	O
CCl4	O
)	O
.	O

To	O
further	O
our	O
understanding	O
of	O
the	O
mechanism	O
of	O
CS	O
cytoprotection	O
,	O
we	O
examined	O
in	O
rats	O
and	O
mice	O
the	O
protective	O
abilities	O
of	O
CS	O
and	O
the	O
non	O
-	O
hydrolyzable	O
ether	O
form	O
of	O
CS	O
,	O
gamma	O
-	O
cholesteryloxybutyric	O
acid	O
,	O
tris	O
salt	O
(	O
CSE	O
)	O
against	O
acetaminophen-	O
,	O
adriamycin-	O
,	O
carbon	O
tetrachloride-	O
,	O
chloroform-	O
and	O
galactosamine	O
-	O
induced	O
toxicity	B
.	O

The	O
results	O
of	O
these	O
studies	O
demonstrated	O
that	O
CS	O
-	O
mediated	O
protection	O
is	O
not	O
selective	O
for	O
a	O
particular	O
species	O
,	O
organ	O
system	O
or	O
toxic	O
chemical	O
.	O

A	O
24-h	O
pretreatment	O
of	O
both	O
rats	O
and	O
mice	O
with	O
a	O
single	O
dose	O
of	O
CS	O
(	O
100mg	O
/	O
kg	O
,	O
i.p	O
.	O
)	O
,	O
resulted	O
in	O
significant	O
protection	O
against	O
the	O
hepatotoxic	B
effects	O
of	O
CCl4	O
,	O
CHCl3	O
,	O
acetaminophen	O
and	O
galactosamine	O
and	O
against	O
the	O
lethal	O
(	O
and	O
presumably	O
cardiotoxic	B
)	O
effect	O
of	O
adriamycin	O
administration	O
.	O

Maximal	O
CS	O
-	O
mediated	O
protection	O
was	O
observed	O
in	O
experimental	O
animals	O
pretreated	O
24	O
h	O
prior	O
to	O
the	O
toxic	O
insult	O
.	O

These	O
data	O
suggest	O
that	O
CS	O
intervenes	O
in	O
a	O
critical	O
cellular	O
event	O
that	O
is	O
an	O
important	O
common	O
pathway	O
to	O
toxic	O
cell	O
death	O
.	O

The	O
mechanism	O
of	O
CS	O
protection	O
does	O
not	O
appear	O
to	O
be	O
dependent	O
on	O
the	O
inhibition	O
of	O
chemical	O
bioactivation	O
to	O
a	O
toxic	O
reactive	O
intermediate	O
(	O
in	O
light	O
of	O
the	O
protection	O
observed	O
against	O
galactosamine	O
hepatotoxicity	B
)	O
.	O

However	O
,	O
based	O
on	O
the	O
data	O
presented	O
,	O
we	O
can	O
not	O
exclude	O
the	O
possibility	O
that	O
CS	O
administration	O
inhibits	O
chemical	O
bioactivation	O
.	O

Our	O
findings	O
do	O
suggest	O
that	O
CS	O
-	O
mediated	O
protection	O
is	O
dependent	O
on	O
the	O
action	O
of	O
the	O
intact	O
anionic	O
CS	O
molecule	O
(	O
non	O
-	O
hydrolyzable	O
CSE	O
was	O
as	O
protective	O
as	O
CS	O
)	O
,	O
whose	O
mechanism	O
has	O
yet	O
to	O
be	O
defined	O
.	O

Contribution	O
of	O
the	O
glycine	O
site	O
of	O
NMDA	O
receptors	O
in	O
rostral	O
and	O
intermediate	O
-	O
caudal	O
parts	O
of	O
the	O
striatum	O
to	O
the	O
regulation	O
of	O
muscle	O
tone	O
in	O
rats	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
assess	O
the	O
contribution	O
of	O
the	O
glycine	O
site	O
of	O
NMDA	O
receptors	O
in	O
the	O
striatum	O
to	O
the	O
regulation	O
of	O
muscle	O
tone	O
.	O

Muscle	O
tone	O
was	O
examined	O
using	O
a	O
combined	O
mechanoand	O
electromyographic	O
method	O
,	O
which	O
measured	O
simultaneously	O
the	O
muscle	O
resistance	O
(	O
MMG	O
)	O
of	O
the	O
rat	O
's	O
hind	O
foot	O
to	O
passive	O
extension	O
and	O
flexion	O
in	O
the	O
ankle	O
joint	O
and	O
the	O
electromyographic	O
activity	O
(	O
EMG	O
)	O
of	O
the	O
antagonistic	O
muscles	O
of	O
that	O
joint	O
:	O
gastrocnemius	O
and	O
tibialis	O
anterior	O
.	O

Muscle	B
rigidity	I
was	O
induced	O
by	O
haloperidol	O
(	O
2.5	O
mg	O
/	O
kg	O
i.p	O
.	O
)	O
.	O

5,7-dichlorokynurenic	O
acid	O
(	O
5,7-DCKA	O
)	O
,	O
a	O
selective	O
glycine	O
site	O
antagonist	O
,	O
injected	O
in	O
doses	O
of	O
2.5	O
and	O
4.5	O
microg	O
/	O
0.5	O
microl	O
bilaterally	O
,	O
into	O
the	O
rostral	O
region	O
of	O
the	O
striatum	O
,	O
decreased	O
both	O
the	O
haloperidol	O
-	O
induced	O
muscle	B
rigidity	I
(	O
MMG	O
)	O
and	O
the	O
enhanced	O
electromyographic	O
activity	O
(	O
EMG	O
)	O
.	O

5,7-DCKA	O
injected	O
bilaterally	O
in	O
a	O
dose	O
of	O
4.5	O
microg	O
/	O
0.5	O
microl	O
into	O
the	O
intermediate	O
-	O
caudal	O
region	O
of	O
the	O
striatum	O
of	O
rats	O
not	O
pretreated	O
with	O
haloperidol	O
had	O
no	O
effect	O
on	O
the	O
muscle	O
tone	O
.	O

The	O
present	O
results	O
suggest	O
that	O
blockade	O
of	O
the	O
glycine	O
site	O
of	O
NMDA	O
receptors	O
in	O
the	O
rostral	O
part	O
of	O
the	O
striatum	O
may	O
be	O
mainly	O
responsible	O
for	O
the	O
antiparkinsonian	O
action	O
of	O
this	O
drug	O
.	O

We	O
report	O
here	O
on	O
a	O
patient	O
who	O
was	O
treated	O
for	O
an	O
atypical	O
brain	O
meningioma	B
with	O
multiple	O
surgeries	O
and	O
multiple	O
sessions	O
of	O
stereotactic	O
radiosurgery	O
with	O
good	O
control	O
of	O
his	O
brain	B
disease	I
.	O

Thirteen	O
years	O
after	O
diagnosis	O
,	O
he	O
developed	O
bilateral	O
large	O
sacroiliac	O
and	O
abdominal	O
metastases	O
.	O

Extracranial	O
metastases	O
from	O
brain	O
meningiomas	B
is	O
a	O
rare	O
,	O
but	O
well	O
-	O
documented	O
entity	O
.	O

Metastases	O
occur	O
mostly	O
in	O
the	O
lungs	O
,	O
pleura	O
and	O
liver	O
,	O
but	O
may	O
also	O
affect	O
lymph	O
nodes	O
and	O
bones	O
.	O

Extraneural	O
metastases	O
from	O
cranial	B
meningioma	I
:	O
a	O
case	O
report	O
.	O

Here	O
we	O
expand	O
the	O
role	O
of	O
GRN	O
in	O
FTLD	B
-	I
U	I
and	O
demonstrate	O
that	O
a	O
common	O
genetic	O
variant	O
(	O
rs5848	O
)	O
,	O
located	O
in	O
the	O
3'-untranslated	O
region	O
(	O
UTR	O
)	O
of	O
GRN	O
in	O
a	O
binding	O
-	O
site	O
for	O
miR-659	O
,	O
is	O
a	O
major	O
susceptibility	O
factor	O
for	O
FTLD	B
-	I
U.	I

Loss	O
-	O
of	O
-	O
function	O
mutations	O
in	O
progranulin	O
(	O
GRN	O
)	O
cause	O
ubiquitin-	O
and	O
TAR	O
DNA	O
-	O
binding	O
protein	O
43	O
(	O
TDP-43	O
)	O
-positive	O
frontotemporal	B
dementia	I
(	O
FTLD	B
-	I
U	I
)	O
,	O
a	O
progressive	B
neurodegenerative	I
disease	I
affecting	O
approximately	O
10	O
%	O
of	O
early	B
-	I
onset	I
dementia	I
patients	O
.	O

Common	O
variation	O
in	O
the	O
miR-659	O
binding	O
-	O
site	O
of	O
GRN	O
is	O
a	O
major	O
risk	O
factor	O
for	O
TDP43-positive	O
frontotemporal	B
dementia	I
.	O

In	O
support	O
of	O
these	O
findings	O
,	O
the	O
neuropathology	O
of	O
homozygous	O
rs5848	O
T	O
-	O
allele	O
carriers	O
frequently	O
resembled	O
the	O
pathological	O
FTLD	B
-	I
U	I
subtype	O
of	O
GRN	O
mutation	O
carriers	O
.	O

A	O
significant	O
reduction	O
in	O
GRN	O
protein	O
was	O
observed	O
in	O
homozygous	O
T	O
-	O
allele	O
carriers	O
in	O
vivo	O
,	O
through	O
biochemical	O
and	O
immunohistochemical	O
methods	O
,	O
mimicking	O
the	O
effect	O
of	O
heterozygous	O
loss	O
-	O
of	O
-	O
function	O
GRN	O
mutations	O
.	O

We	O
further	O
demonstrate	O
that	O
miR-659	O
can	O
regulate	O
GRN	O
expression	O
in	O
vitro	O
,	O
with	O
miR-659	O
binding	O
more	O
efficiently	O
to	O
the	O
high	O
risk	O
T	O
-	O
allele	O
of	O
rs5848	O
resulting	O
in	O
augmented	O
translational	O
inhibition	O
of	O
GRN	O
.	O

In	O
a	O
series	O
of	O
pathologically	O
confirmed	O
FTLD	B
-	I
U	I
patients	O
without	O
GRN	O
mutations	O
,	O
we	O
show	O
that	O
carriers	O
homozygous	O
for	O
the	O
T	O
-	O
allele	O
of	O
rs5848	O
have	O
a	O
3.2-fold	O
increased	O
risk	O
to	O
develop	O
FTLD	B
-	I
U	I
compared	O
with	O
homozygous	O
C	O
-	O
allele	O
carriers	O
(	O
95	O
%	O
CI	O
:	O
1.50	O
-	O
6.73	O
)	O
.	O

Translational	O
regulation	O
by	O
miRNAs	O
may	O
represent	O
a	O
common	O
mechanism	O
underlying	O
complex	O
neurodegenerative	B
disorders	I
.	O

We	O
suggest	O
that	O
the	O
expression	O
of	O
GRN	O
is	O
regulated	O
by	O
miRNAs	O
and	O
that	O
common	O
genetic	O
variability	O
in	O
a	O
miRNA	O
binding	O
-	O
site	O
can	O
significantly	O
increase	O
the	O
risk	O
for	O
FTLD	B
-	I
U.	I

Here	O
,	O
we	O
discuss	O
recent	O
data	O
that	O
support	O
a	O
view	O
that	O
endolysosomal	O
positioning	O
of	O
RNA	O
might	O
facilitate	O
intercellular	O
transmission	O
of	O
RNA	O
and	O
host	O
defence	O
against	O
viruses	O
and	O
retrotransposons	O
.	O

Positioning	O
of	O
RNA	O
regulatory	O
mechanisms	O
on	O
endolysosomal	O
membranes	O
might	O
permit	O
rapid	O
and	O
localized	O
control	O
of	O
microRNA	O
(	O
miRNA	O
)	O
gene	O
regulatory	O
programs	O
and	O
mRNA	O
translation	O
in	O
response	O
to	O
environmental	O
signals	O
,	O
such	O
as	O
activated	O
plasma	O
membrane	O
receptors	O
transported	O
on	O
endosomes	O
.	O

Finally	O
,	O
we	O
suggest	O
that	O
the	O
pathology	O
of	O
several	O
conditions	O
,	O
including	O
Huntington	B
's	I
disease	I
,	O
might	O
be	O
a	O
consequence	O
of	O
the	O
disruption	O
of	O
the	O
control	O
of	O
RNA	O
via	O
endolysosomal	O
membranes	O
.	O

Control	O
of	O
RNA	O
silencing	O
and	O
localization	O
by	O
endolysosomes	O
.	O

Recent	O
advances	O
in	O
the	O
cell	O
biology	O
of	O
RNA	O
silencing	O
have	O
unraveled	O
an	O
intriguing	O
association	O
of	O
post	O
-	O
transcriptionally	O
regulated	O
RNA	O
with	O
endolysosomal	O
membranes	O
in	O
several	O
circumstances	O
of	O
mRNA	O
localization	O
,	O
microRNA	O
activity	O
and	O
viral	O
RNA	O
transport	O
and	O
packaging	O
.	O

Endolysosomal	O
membranes	O
are	O
a	O
nexus	O
of	O
communication	O
and	O
transport	O
between	O
cells	O
and	O
their	O
exterior	O
environment	O
for	O
signaling	O
receptors	O
,	O
pathogens	O
and	O
nutrients	O
.	O

The	O
method	O
by	O
which	O
MSCs	O
could	O
be	O
applied	O
for	O
future	O
therapies	O
might	O
require	O
trans	O
-	O
disciplinary	O
approaches	O
for	O
personalized	O
treatments	O
.	O

Implantation	O
of	O
adult	O
human	O
mesenchymal	O
stem	O
cells	O
(	O
MSCs	O
)	O
to	O
treat	O
neural	B
disorders	I
shows	O
promise	O
.	O

Depending	O
on	O
their	O
microenvironment	O
,	O
MSCs	O
could	O
potentially	O
be	O
used	O
for	O
the	O
repair	O
and/or	O
replacement	O
of	O
neurons	O
in	O
traumatic	O
brain	B
injury	I
or	O
the	O
treatment	O
of	O
Parkinson	B
's	I
disease	I
.	O

This	O
cross	O
-	O
disciplinary	O
review	O
incorporates	O
aspects	O
of	O
neuroscience	O
,	O
stem	O
cell	O
biology	O
,	O
cancer	B
biology	O
and	O
immunology	O
to	O
discuss	O
interactions	O
between	O
inflammatory	O
mediators	O
and	O
MSCs	O
.	O

We	O
first	O
discuss	O
the	O
role	O
of	O
microRNAs	O
(	O
miRNAs	O
)	O
in	O
neurological	O
development	O
.	O

Neurogenesis	O
:	O
role	O
for	O
microRNAs	O
and	O
mesenchymal	O
stem	O
cells	O
in	O
pathological	O
states	O
.	O

Exploring	O
the	O
predisposition	O
of	O
MSCs	O
to	O
oncogenesis	O
is	O
critical	O
for	O
translational	O
science	O
since	O
the	O
implementation	O
of	O
safeguarding	O
measures	O
prior	O
to	O
therapy	O
can	O
lead	O
to	O
the	O
successful	O
delivery	O
of	O
stem	O
cells	O
to	O
patients	O
.	O

The	O
administration	O
of	O
effective	O
and	O
safe	O
MSC	O
therapy	O
must	O
acknowledge	O
immune	O
mediators	O
that	O
may	O
predispose	O
the	O
early	O
differentiating	O
MSCs	O
to	O
oncogenic	O
insults	O
.	O

Secondly	O
,	O
we	O
discuss	O
the	O
ability	O
of	O
MSCs	O
to	O
transdifferentiate	O
into	O
functional	O
neurons	O
,	O
which	O
are	O
regulated	O
by	O
miRNAs	O
,	O
and	O
the	O
implications	O
of	O
these	O
cells	O
for	O
the	O
therapy	O
of	O
neuropathological	O
states	O
.	O

Immune	O
mediators	O
could	O
be	O
central	O
to	O
MSC	O
responses	O
within	O
a	O
region	O
of	O
tissue	B
injury	I
and	O
are	O
also	O
discussed	O
in	O
detail	O
.	O

Thus	O
,	O
we	O
discuss	O
a	O
key	O
gene	O
,	O
RE-1	O
silencing	O
transcription	O
factor	O
(	O
REST	O
)	O
,	O
based	O
on	O
its	O
dual	O
role	O
in	O
neurogenesis	O
and	O
cancer	B
development	O
.	O

Finally	O
,	O
a	O
phylogenetic	O
analysis	O
shows	O
that	O
ADCK3	O
belongs	O
to	O
the	O
family	O
of	O
atypical	O
kinases	O
,	O
which	O
includes	O
phosphoinositide	O
and	O
choline	O
kinases	O
,	O
suggesting	O
that	O
ADCK3	O
plays	O
an	O
indirect	O
regulatory	O
role	O
in	O
ubiquinone	O
biosynthesis	O
possibly	O
as	O
part	O
of	O
a	O
feedback	O
loop	O
that	O
regulates	O
ATP	O
production	O
.	O

ADCK3	O
,	O
an	O
ancestral	O
kinase	O
,	O
is	O
mutated	O
in	O
a	O
form	O
of	O
recessive	B
ataxia	I
associated	O
with	O
coenzyme	O
Q10	O
deficiency	O
.	O

Muscle	O
coenzyme	O
Q	O
(	O
10	O
)	O
(	O
CoQ	O
(	O
10	O
)	O
or	O
ubiquinone	O
)	O
deficiency	O
has	O
been	O
identified	O
in	O
more	O
than	O
20	O
patients	O
with	O
presumed	O
autosomal	B
-	I
recessive	I
ataxia	I
.	O

However	O
,	O
mutations	O
in	O
genes	O
required	O
for	O
CoQ	O
(	O
10	O
)	O
biosynthetic	O
pathway	O
have	O
been	O
identified	O
only	O
in	O
patients	O
with	O
infantile	O
-	O
onset	O
multisystemic	O
diseases	O
or	O
isolated	B
nephropathy	I
.	O

Our	O
SNP	O
-	O
based	O
genome	O
-	O
wide	O
scan	O
in	O
a	O
large	O
consanguineous	O
family	O
revealed	O
a	O
locus	O
for	O
autosomal	B
-	I
recessive	I
ataxia	I
at	O
chromosome	O
1q41	O
.	O

The	O
causative	O
mutation	O
is	O
a	O
homozygous	O
splice	O
-	O
site	O
mutation	O
in	O
the	O
aarF	O
-	O
domain	O
-	O
containing	O
kinase	O
3	O
gene	O
(	O
ADCK3	O
)	O
.	O

Five	O
additional	O
mutations	O
in	O
ADCK3	O
were	O
found	O
in	O
three	O
patients	O
with	O
sporadic	B
ataxia	I
,	O
including	O
one	O
known	O
to	O
have	O
CoQ	O
(	O
10	O
)	O
deficiency	O
in	O
muscle	O
.	O

All	O
of	O
the	O
patients	O
have	O
childhood	O
-	O
onset	O
cerebellar	B
ataxia	I
with	O
slow	O
progression	O
,	O
and	O
three	O
of	O
six	O
have	O
mildly	O
elevated	O
lactate	O
levels	O
.	O

ADCK3	O
is	O
a	O
mitochondrial	O
protein	O
homologous	O
to	O
the	O
yeast	O
COQ8	O
and	O
the	O
bacterial	O
UbiB	O
proteins	O
,	O
which	O
are	O
required	O
for	O
CoQ	O
biosynthesis	O
.	O

Three	O
out	O
of	O
four	O
patients	O
tested	O
showed	O
a	O
low	O
endogenous	O
pool	O
of	O
CoQ	O
(	O
10	O
)	O
in	O
their	O
fibroblasts	O
or	O
lymphoblasts	O
,	O
and	O
two	O
out	O
of	O
three	O
patients	O
showed	O
impaired	O
ubiquinone	O
synthesis	O
,	O
strongly	O
suggesting	O
that	O
ADCK3	O
is	O
also	O
involved	O
in	O
CoQ	O
(	O
10	O
)	O
biosynthesis	O
.	O

The	O
deleterious	O
nature	O
of	O
the	O
three	O
identified	O
missense	O
changes	O
was	O
confirmed	O
by	O
the	O
introduction	O
of	O
them	O
at	O
the	O
corresponding	O
positions	O
of	O
the	O
yeast	O
COQ8	O
gene	O
.	O

Interpretation	O
and	O
applicability	O
of	O
microRNA	O
data	O
to	O
the	O
context	O
of	O
Alzheimer	B
's	I
and	O
age	O
-	O
related	O
diseases	O
.	O

Generated	O
by	O
the	O
ribonuclease	O
III	O
Dicer	O
,	O
microRNAs	O
(	O
miRNAs	O
)	O
are	O
predicted	O
to	O
regulate	O
up	O
to	O
90	O
%	O
of	O
the	O
genes	O
in	O
humans	O
,	O
suggesting	O
that	O
they	O
may	O
control	O
every	O
cellular	O
processes	O
in	O
all	O
cells	O
and	O
tissues	O
of	O
the	O
human	O
body	O
!	O

Likely	O
to	O
play	O
a	O
central	O
role	O
in	O
health	O
and	O
disease	O
,	O
a	O
dysfunctional	O
miRNA	O
-	O
based	O
regulation	O
of	O
gene	O
expression	O
may	O
represent	O
the	O
main	O
etiologic	O
factor	O
underlying	O
age	O
-	O
related	O
diseases	O
affecting	O
major	O
organs	O
,	O
such	O
as	O
the	O
brain	O
.	O

Here	O
,	O
we	O
discuss	O
some	O
of	O
the	O
limitations	O
associated	O
to	O
the	O
interpretation	O
and	O
applicability	O
of	O
miRNA	O
data	O
,	O
based	O
on	O
our	O
recent	O
study	O
on	O
the	O
etiology	O
of	O
Alzheimer	B
's	I
disease	I
(	O
AD	B
)	O
.	O

Using	O
transiently	O
transfected	O
murine	O
neuronal	O
N2a	O
cells	O
in	O
culture	O
,	O
in	O
parallel	O
to	O
a	O
mouse	O
model	O
of	O
AD	B
,	O
we	O
were	O
able	O
to	O
demonstrate	O
a	O
role	O
for	O
two	O
miRNAs	O
(	O
miR-298	O
and	O
miR-328	O
)	O
in	O
the	O
regulation	O
of	O
beta	O
-	O
amyloid	O
(	O
Abeta	O
)	O
precursor	O
protein	O
(	O
APP	O
)	O
-converting	O
enzyme	O
(	O
BACE	O
)	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
translation	O
,	O
thereby	O
providing	O
key	O
insights	O
into	O
the	O
molecular	O
basis	O
underlying	O
BACE	O
deregulation	O
in	O
AD	B
.	O

However	O
,	O
whether	O
miRNA	O
data	O
can	O
be	O
extrapolated	O
and	O
transposed	O
to	O
the	O
human	O
context	O
of	O
age	O
-	O
related	O
diseases	O
,	O
such	O
as	O
AD	B
,	O
not	O
only	O
requires	O
caution	O
,	O
but	O
also	O
warrants	O
several	O
considerations	O
.	O

Levels	O
of	O
protein	O
expression	O
of	O
endothelial	O
NO	O
synthase	O
(	O
eNOS	O
)	O
,	O
caveolin-1	O
,	O
and	O
calmodulin	O
were	O
assessed	O
in	O
carotid	O
arteries	O
using	O
Western	O
analysis	O
.	O

Plasma	O
NO	O
levels	O
were	O
doubled	O
by	O
daidzein	O
or	O
17beta	O
-	O
estradiol	O
.	O

NO	O
production	O
and	O
endothelium	O
-	O
dependent	O
contraction	O
in	O
response	O
to	O
the	O
NOS	O
inhibitor	O
NG	O
-	O
nitro	O
-	O
L	O
-	O
arginine	O
(	O
L	O
-	O
NNA	O
;	O
100	O
microM	O
)	O
was	O
enhanced	O
by	O
50	O
to	O
100	O
%	O
in	O
carotid	O
arteries	O
from	O
rats	O
treated	O
with	O
daidzein	O
or	O
17beta	O
-	O
estradiol	O
.	O

Acetylcholine	O
-	O
induced	O
relaxation	O
was	O
selectively	O
enhanced	O
in	O
carotid	O
arteries	O
from	O
rats	O
treated	O
with	O
daidzein	O
.	O

The	O
use	O
of	O
estrogen	O
for	O
protection	O
against	O
vascular	B
dysfunction	I
is	O
limited	O
due	O
to	O
its	O
effects	O
on	O
the	O
reproductive	O
system	O
,	O
particularly	O
in	O
males	O
.	O

We	O
postulated	O
that	O
daidzein	O
,	O
an	O
isoflavone	O
with	O
estrogen	O
-	O
like	O
effects	O
on	O
the	O
systemic	O
vasculature	O
but	O
not	O
the	O
reproductive	O
system	O
,	O
might	O
enhance	O
nitric	O
oxide	O
(	O
NO	O
)	O
-mediated	O
cerebral	O
vasodilatation	O
.	O

Male	O
rats	O
were	O
administered	O
vehicle	O
,	O
17beta	O
-	O
estradiol	O
(	O
0.1	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
,	O
or	O
daidzein	O
(	O
0.2	O
mg	O
/	O
kg	O
s.c	O
.	O
)	O
daily	O
for	O
7	O
days	O
.	O

Basal	O
and	O
acetylcholine	O
-	O
stimulated	O
NO	O
release	O
was	O
assessed	O
in	O
vitro	O
via	O
carotid	O
arterial	O
rings	O
or	O
in	O
vivo	O
by	O
measuring	O
changes	O
in	O
basilar	O
artery	O
diameter	O
.	O

Similarly	O
,	O
constrictor	O
responses	O
of	O
the	O
basilar	O
artery	O
to	O
L	O
-	O
NNA	O
in	O
vivo	O
were	O
selectively	O
augmented	O
by	O
approximately	O
100	O
%	O
by	O
17beta	O
-	O
estradiol	O
treatment	O
and	O
tended	O
to	O
be	O
approximately	O
50	O
%	O
greater	O
in	O
daidzein	O
-	O
treated	O
rats	O
.	O

Effect	O
of	O
short	O
-	O
term	O
phytoestrogen	O
treatment	O
in	O
male	O
rats	O
on	O
nitric	O
oxide	O
-	O
mediated	O
responses	O
of	O
carotid	O
and	O
cerebral	O
arteries	O
:	O
comparison	O
with	O
17beta	O
-	O
estradiol	O
.	O

These	O
data	O
suggest	O
that	O
short	O
-	O
term	O
administration	O
of	O
daidzein	O
or	O
17beta	O
-	O
estradiol	O
modulates	O
cerebral	O
artery	O
reactivity	O
in	O
males	O
by	O
enhancing	O
synthesis	O
and	O
release	O
of	O
endothelium	O
-	O
derived	O
NO	O
.	O
Isoflavone	O
therapy	O
may	O
therefore	O
be	O
a	O
feasible	O
approach	O
to	O
protect	O
against	O
cerebrovascular	B
disease	I
and	O
stroke	B
.	O

Expression	O
of	O
caveolin-1	O
was	O
decreased	O
,	O
and	O
calmodulin	O
was	O
increased	O
,	O
in	O
vessels	O
from	O
daidzein-	O
or	O
17beta	O
-	O
estradiol	O
-	O
treated	O
rats	O
.	O

eNOS	O
expression	O
was	O
unaffected	O
by	O
the	O
treatments	O
.	O

However	O
,	O
we	O
report	O
the	O
experience	O
of	O
a	O
patient	O
who	O
inadvertently	O
received	O
live	O
polio	B
vaccine	O
whilst	O
receiving	O
anti	O
-	O
TNF	O
therapy	O
.	O

International	O
guidelines	O
state	O
that	O
live	O
vaccines	O
are	O
contraindicated	O
in	O
patients	O
on	O
anti	O
-	O
TNF	O
therapy	O
.	O

Live	O
polio	B
vaccine	O
exposure	O
while	O
receiving	O
anti	O
-	O
TNF	O
therapy	O
for	O
reactive	O
arthritis	B
.	O

Patients	O
should	O
be	O
counseled	O
regarding	O
the	O
risks	O
of	O
live	O
vaccines	O
prior	O
to	O
treatment	O
with	O
anti	O
-	O
TNF	O
therapy	O
.	O

However	O
,	O
if	O
we	O
consider	O
adult	O
patients	O
with	O
rheumatic	B
diseases	I
to	O
have	O
altered	O
immunocompetence	O
,	O
it	O
is	O
recommended	O
that	O
they	O
receive	O
the	O
usual	O
inactivated	O
vaccines	O
according	O
to	O
standard	O
schedules	O
,	O
and	O
live	O
vaccines	O
should	O
be	O
avoided	O
in	O
those	O
who	O
are	O
treated	O
with	O
more	O
potent	O
forms	O
of	O
immune	O
suppression	O
.	O

No	O
clear	O
guidelines	O
are	O
available	O
for	O
all	O
vaccines	O
in	O
patients	O
with	O
specific	O
rheumatic	B
diseases	I
.	O

Patient	O
did	O
not	O
suffer	O
from	O
any	O
infectious	O
sequel	O
as	O
a	O
result	O
.	O

Autosomal	B
-	I
recessive	I
cerebellar	I
ataxias	I
comprise	O
a	O
clinically	O
and	O
genetically	O
heterogeneous	O
group	O
of	O
neurodegenerative	B
disorders	I
.	O

In	O
contrast	O
to	O
their	O
dominant	O
counterparts	O
,	O
unraveling	O
the	O
molecular	O
background	O
of	O
these	O
ataxias	B
has	O
proven	O
to	O
be	O
more	O
complicated	O
and	O
the	O
currently	O
known	O
mutations	O
provide	O
incomplete	O
coverage	O
for	O
genotyping	O
of	O
patients	O
.	O

By	O
combining	O
SNP	O
array	O
-	O
based	O
linkage	O
analysis	O
and	O
targeted	O
resequencing	O
of	O
relevant	O
sequences	O
in	O
the	O
linkage	O
interval	O
with	O
the	O
use	O
of	O
next	O
-	O
generation	O
sequencing	O
technology	O
,	O
we	O
identified	O
a	O
mutation	O
in	O
a	O
gene	O
and	O
have	O
shown	O
its	O
association	O
with	O
autosomal	B
-	I
recessive	I
cerebellar	I
ataxia	I
.	O

In	O
a	O
Dutch	O
consanguineous	O
family	O
with	O
three	O
affected	O
siblings	O
a	O
homozygous	O
12.5	O
Mb	O
region	O
on	O
chromosome	O
3	O
was	O
targeted	O
by	O
array	O
-	O
based	O
sequence	O
capture	O
.	O

Targeted	O
next	O
-	O
generation	O
sequencing	O
of	O
a	O
12.5	O
Mb	O
homozygous	O
region	O
reveals	O
ANO10	O
mutations	O
in	O
patients	O
with	O
autosomal	B
-	I
recessive	I
cerebellar	I
ataxia	I
.	O

The	O
analysis	O
of	O
ANO10	O
by	O
Sanger	O
sequencing	O
revealed	O
three	O
additional	O
mutations	O
:	O
a	O
homozygous	O
mutation	O
(	O
c.1150_1151del	O
[	O
p	O
.	O
Leu384fs	O
]	O
)	O
in	O
a	O
Serbian	O
family	O
and	O
a	O
compound	O
-	O
heterozygous	O
splice	O
-	O
site	O
mutation	O
(	O
c.1476	O
+	O
1G	O
>	O
T	O
)	O
and	O
a	O
frameshift	O
mutation	O
(	O
c.1604del	O
[	O
p	O
.	O
Leu535X	O
]	O
)	O
in	O
a	O
French	O
family	O
.	O

This	O
illustrates	O
the	O
power	O
of	O
using	O
initial	O
homozygosity	O
mapping	O
with	O
next	O
-	O
generation	O
sequencing	O
technology	O
to	O
identify	O
genes	O
involved	O
in	O
autosomal	O
-	O
recessive	O
diseases	O
.	O

Prioritization	O
of	O
all	O
detected	O
sequence	O
variants	O
led	O
to	O
four	O
candidate	O
genes	O
,	O
one	O
of	O
which	O
contained	O
a	O
variant	O
with	O
a	O
high	O
base	O
pair	O
conservation	O
score	O
(	O
phyloP	O
score	O
:	O
5.26	O
)	O
.	O

This	O
variant	O
was	O
a	O
leucine	O
-	O
to	O
-	O
arginine	O
substitution	O
in	O
the	O
DUF	O
590	O
domain	O
of	O
a	O
16	O
K	O
transmembrane	O
protein	O
,	O
a	O
putative	O
calcium	O
-	O
activated	O
chloride	O
channel	O
encoded	O
by	O
anoctamin	O
10	O
(	O
ANO10	O
)	O
.	O

Moreover	O
,	O
identifying	O
a	O
putative	O
calcium	O
-	O
dependent	O
chloride	O
channel	O
involved	O
in	O
cerebellar	B
ataxia	I
adds	O
another	O
pathway	O
to	O
the	O
list	O
of	O
pathophysiological	O
mechanisms	O
that	O
may	O
cause	O
cerebellar	B
ataxia	I
.	O

These	O
findings	O
further	O
support	O
the	O
idea	O
that	O
iron-	O
and	O
aluminum	O
-	O
sulfates	O
induce	O
genotoxicity	O
via	O
a	O
ROS	O
-	O
mediated	O
up	O
-	O
regulation	O
of	O
specific	O
regulatory	O
elements	O
and	O
pathogenic	O
genes	O
that	O
redirect	O
brain	O
cell	O
fate	O
towards	O
progressive	O
dysfunction	O
and	O
apoptotic	O
cell	O
death	O
.	O

Notably	O
,	O
these	O
same	O
miRNAs	O
are	O
up	O
-	O
regulated	O
in	O
AD	B
brain	O
.	O

The	O
main	O
finding	O
was	O
that	O
these	O
ROS	O
-	O
generating	O
neurotoxic	O
metal	O
sulfates	O
also	O
up	O
-	O
regulate	O
a	O
specific	O
set	O
of	O
miRNAs	O
that	O
includes	O
miR-9	O
,	O
miR-125b	O
and	O
miR-128	O
.	O

In	O
this	O
study	O
we	O
have	O
extended	O
our	O
investigations	O
to	O
analyze	O
the	O
expression	O
of	O
micro	O
RNA	O
(	O
miRNA	O
)	O
populations	O
in	O
iron-	O
and	O
aluminum	O
-	O
sulfate	O
treated	O
human	O
neural	O
cells	O
in	O
primary	O
culture	O
.	O

Notably	O
,	O
iron-	O
and	O
aluminum	O
-	O
sulfate	O
induce	O
genes	O
in	O
cultured	O
human	O
brain	O
cells	O
that	O
exhibit	O
expression	O
patterns	O
similar	O
to	O
those	O
observed	O
to	O
be	O
up	O
-	O
regulated	O
in	O
moderate-	O
to	O
late	O
-	O
stage	O
Alzheimer	B
's	I
disease	I
(	O
AD	B
)	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
following	O
ROS	O
induction	O
,	O
a	O
family	O
of	O
pathogenic	O
brain	O
genes	O
that	O
promote	O
inflammatory	O
signalling	O
,	O
cellular	O
apoptosis	O
and	O
brain	O
cell	O
death	O
is	O
significantly	O
over	O
-	O
expressed	O
.	O

Iron-	O
and	O
aluminum	O
-	O
sulfate	O
together	O
,	O
at	O
nanomolar	O
concentrations	O
,	O
trigger	O
the	O
production	O
of	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
in	O
cultures	O
of	O
human	O
brain	O
cells	O
.	O

Induction	O
of	O
specific	O
micro	O
RNA	O
(	O
miRNA	O
)	O
species	O
by	O
ROS	O
-	O
generating	O
metal	O
sulfates	O
in	O
primary	O
human	O
brain	O
cells	O
.	O

The	O
rapid	O
and	O
exciting	O
pace	O
of	O
advances	O
in	O
glioblastoma	B
genetics	O
has	O
prompted	O
this	O
up	O
-	O
to	O
-	O
date	O
review	O
.	O

The	O
likely	O
impact	O
on	O
care	O
delivery	O
in	O
the	O
clinic	O
may	O
only	O
be	O
a	O
few	O
years	O
away	O
.	O

Within	O
the	O
last	O
few	O
years	O
,	O
high	O
-	O
throughput	O
efforts	O
such	O
as	O
The	O
Cancer	O
Genome	O
Atlas	O
and	O
a	O
massive	O
sequencing	O
project	O
have	O
yielded	O
novel	O
insights	O
and	O
classifications	O
of	O
this	O
dreaded	O
cancer	B
.	O

It	O
has	O
been	O
hoped	O
that	O
dissection	O
of	O
the	O
genetics	O
of	O
this	O
cancer	B
would	O
lead	O
to	O
more	O
targeted	O
and	O
effective	O
treatments	O
,	O
and	O
new	O
advances	O
may	O
finally	O
be	O
bringing	O
this	O
closer	O
to	O
fruition	O
.	O

Glioblastoma	B
genetics	O
:	O
in	O
rapid	O
flux	O
.	O

Glioblastoma	B
is	O
the	O
most	O
common	O
and	O
most	O
lethal	O
primary	B
brain	I
tumor	I
.	O

While	O
small	O
progress	O
has	O
been	O
made	O
in	O
treating	O
this	O
cancer	B
in	O
recent	O
years	O
,	O
glioblastoma	B
remains	O
largely	O
resistant	O
to	O
all	O
existing	O
therapies	O
.	O

Novel	O
animal	O
models	O
for	O
studying	O
complex	O
brain	B
disorders	I
:	O
BAC	O
-	O
driven	O
miRNA	O
-	O
mediated	O
in	O
vivo	O
silencing	O
of	O
gene	O
expression	O
.	O

In	O
schizophrenia	B
,	O
glutamic	O
acid	O
decarboxylase	O
1	O
(	O
GAD1	O
)	O
disturbances	O
are	O
robust	O
,	O
consistently	O
observed	O
,	O
cell	O
-	O
type	O
specific	O
and	O
represent	O
a	O
core	O
feature	O
of	O
the	O
disease	O
.	O

In	O
addition	O
,	O
neuropeptide	O
Y	O
(	O
NPY	O
)	O
,	O
which	O
is	O
a	O
phenotypic	O
marker	O
of	O
a	O
sub	O
-	O
population	O
of	O
GAD1-containing	O
interneurons	O
,	O
has	O
shown	O
reduced	O
expression	O
in	O
the	O
prefrontal	O
cortex	O
in	O
subjects	O
with	O
schizophrenia	B
,	O
suggesting	O
that	O
dysfunction	O
of	O
the	O
NPY+	O
cortical	O
interneuronal	O
sub	O
-	O
population	O
might	O
be	O
a	O
core	O
feature	O
of	O
this	O
devastating	O
disorder	O
.	O

However	O
,	O
modeling	O
gene	O
expression	O
disturbances	O
in	O
schizophrenia	B
in	O
a	O
cell	O
type	O
-	O
specific	O
manner	O
has	O
been	O
extremely	O
challenging	O
.	O

To	O
more	O
closely	O
mimic	O
these	O
molecular	O
and	O
cellular	O
human	O
post	O
-	O
mortem	O
findings	O
,	O
we	O
generated	O
a	O
transgenic	O
mouse	O
in	O
which	O
we	O
downregulated	O
GAD1	O
mRNA	O
expression	O
specifically	O
in	O
NPY+	O
neurons	O
.	O

This	O
novel	O
,	O
cell	O
type	O
-	O
specific	O
in	O
vivo	O
system	O
for	O
reducing	O
gene	O
expression	O
uses	O
a	O
bacterial	O
artificial	O
chromosome	O
(	O
BAC	O
)	O
containing	O
the	O
NPY	O
promoter	O
-	O
enhancer	O
elements	O
,	O
the	O
reporter	O
molecule	O
(	O
eGFP	O
)	O
and	O
a	O
modified	O
intron	O
containing	O
a	O
synthetic	O
microRNA	O
(	O
miRNA	O
)	O
targeted	O
to	O
GAD1	O
.	O

The	O
animals	O
of	O
isogenic	O
strains	O
are	O
generated	O
rapidly	O
,	O
providing	O
a	O
new	O
tool	O
for	O
better	O
understanding	O
the	O
molecular	O
disturbances	O
in	O
the	O
GABAergic	O
system	O
observed	O
in	O
complex	O
neuropsychiatric	B
disorders	I
such	O
as	O
schizophrenia	B
.	O

In	O
the	O
future	O
,	O
because	O
of	O
the	O
small	O
size	O
of	O
the	O
silencing	O
miRNAs	O
combined	O
with	O
our	O
BAC	O
strategy	O
,	O
this	O
method	O
may	O
be	O
modified	O
to	O
allow	O
generation	O
of	O
mice	O
with	O
simultaneous	O
silencing	O
of	O
multiple	O
genes	O
in	O
the	O
same	O
cells	O
with	O
a	O
single	O
construct	O
,	O
and	O
production	O
of	O
splice	O
-	O
variant	O
-	O
specific	O
knockdown	O
animals	O
.	O

Biomarkers	O
associated	O
with	O
metastasis	O
of	O
lung	B
cancer	I
to	O
brain	O
predict	O
patient	O
survival	O
.	O

This	O
research	O
involves	O
comprehensive	O
miRNA	O
expression	O
profiling	O
,	O
evaluation	O
of	O
normalisation	O
techniques	O
and	O
combination	O
of	O
miRNA	O
with	O
imaging	O
features	O
FDG	O
-	O
PET	O
/	O
CT	O
and	O
CT	O
Scan	O
.	O

We	O
combine	O
validated	O
miRNA	O
expression	O
values	O
with	O
imaging	O
features	O
to	O
classify	O
NSCLC	O
brain	O
mets	O
from	O
non	O
-	O
brain	O
mets	O
and	O
identify	O
possible	O
biomarkers	O
of	O
brain	O
mets	O
.	O

Generally	O
,	O
one	O
miRNA	O
is	O
predicted	O
to	O
regulate	O
several	O
hundred	O
genes	O
,	O
and	O
as	O
a	O
result	O
,	O
miRNAs	O
could	O
serve	O
as	O
a	O
better	O
classifier	O
than	O
gene	O
expression	O
.	O

MicroRNAs	O
influence	O
cell	O
physiology	O
;	O
alteration	O
in	O
miRNA	O
regulation	O
can	O
be	O
implicated	O
in	O
carcinogenesis	O
and	O
disease	O
progression	O
.	O

The	O
biomarkers	O
were	O
validated	O
on	O
an	O
independent	O
data	O
set	O
to	O
predict	O
potential	O
brain	O
mets	O
.	O

Through	O
various	O
experimental	O
approaches	O
,	O
we	O
validated	O
computational	O
predictions	O
and	O
demonstrated	O
that	O
miR-298	O
and	O
miR-328	O
recognize	O
specific	O
binding	O
sites	O
in	O
the	O
3'-UTR	O
of	O
BACE1	O
mRNA	O
and	O
exert	O
regulatory	O
effects	O
on	O
BACE1	O
protein	O
expression	O
in	O
cultured	O
neuronal	O
cells	O
.	O

Here	O
we	O
also	O
observed	O
a	O
loss	O
of	O
correlation	O
between	O
BACE1	O
mRNA	O
and	O
protein	O
levels	O
in	O
the	O
hippocampus	O
of	O
a	O
mouse	O
model	O
of	O
AD	B
.	O
Consistent	O
with	O
an	O
impairment	O
of	O
miRNA	O
-	O
mediated	O
regulation	O
of	O
BACE1	O
expression	O
,	O
these	O
findings	O
prompted	O
us	O
to	O
investigate	O
the	O
regulatory	O
role	O
of	O
the	O
BACE1	O
3'-UTR	O
element	O
and	O
the	O
possible	O
involvement	O
of	O
specific	O
miRNAs	O
in	O
cultured	O
neuronal	O
(	O
N2a	O
)	O
and	O
fibroblastic	O
(	O
NIH	O
3T3	O
)	O
cells	O
.	O

Our	O
results	O
may	O
provide	O
the	O
molecular	O
basis	O
underlying	O
BACE1	O
deregulation	O
in	O
AD	B
and	O
offer	O
new	O
perspectives	O
on	O
the	O
etiology	O
of	O
this	O
neurological	B
disorder	I
.	O

MicroRNAs	O
(	O
miRNAs	O
)	O
are	O
key	O
regulatory	O
RNAs	O
known	O
to	O
repress	O
mRNA	O
translation	O
through	O
recognition	O
of	O
specific	O
binding	O
sites	O
located	O
mainly	O
in	O
their	O
3'-untranslated	O
region	O
(	O
UTR	O
)	O
.	O

MicroRNA-298	O
and	O
microRNA-328	O
regulate	O
expression	O
of	O
mouse	O
beta	O
-	O
amyloid	O
precursor	O
protein	O
-	O
converting	O
enzyme	O
1	O
.	O

Intriguingly	O
,	O
previous	O
post	O
-	O
mortem	O
analyses	O
showed	O
higher	O
beta	O
-	O
amyloid	O
precursor	O
protein	O
-	O
converting	O
enzyme	O
(	O
BACE	O
)	O
protein	O
,	O
but	O
not	O
mRNA	O
,	O
levels	O
in	O
the	O
brain	O
of	O
patients	O
that	O
suffered	O
from	O
Alzheimer	B
disease	I
(	O
AD	B
)	O
.	O

Loss	O
of	O
specific	O
miRNA	O
control	O
of	O
gene	O
expression	O
is	O
thus	O
expected	O
to	O
underlie	O
serious	O
genetic	O
diseases	O
.	O

These	O
findings	O
reveal	O
a	O
significant	O
additional	O
mechanism	O
by	O
which	O
alpha	O
-	O
synuclein	O
is	O
regulated	O
and	O
point	O
toward	O
new	O
therapeutic	O
regimes	O
for	O
lowering	O
endogenous	O
alpha	O
-	O
synuclein	O
levels	O
in	O
patients	O
with	O
familial	O
or	O
sporadic	B
Parkinson	I
disease	I
.	O

Overexpression	O
of	O
mir-7	O
and	O
mir-153	O
significantly	O
reduces	O
endogenous	O
alpha	O
-	O
synuclein	O
levels	O
,	O
whereas	O
inhibition	O
of	O
mir-7	O
and	O
mir-153	O
enhances	O
translation	O
of	O
a	O
luciferase	O
construct	O
bearing	O
the	O
alpha	O
-	O
synuclein	O
3'-untranslated	O
region	O
in	O
primary	O
neurons	O
.	O

They	O
are	O
expressed	O
predominantly	O
in	O
the	O
brain	O
with	O
a	O
pattern	O
that	O
mirrors	O
synuclein	O
expression	O
in	O
different	O
tissues	O
as	O
well	O
as	O
during	O
neuronal	O
development	O
,	O
indicating	O
that	O
they	O
play	O
a	O
tuning	O
role	O
in	O
the	O
amount	O
of	O
alpha	O
-	O
synuclein	O
produced	O
.	O

These	O
microRNAs	O
bind	O
specifically	O
to	O
the	O
3'-untranslated	O
region	O
of	O
alpha	O
-	O
synuclein	O
and	O
down	O
-	O
regulate	O
its	O
mRNA	O
and	O
protein	O
levels	O
,	O
with	O
their	O
effect	O
being	O
additive	O
.	O

Here	O
,	O
two	O
microRNAs	O
,	O
namely	O
mir-7	O
and	O
mir-153	O
,	O
have	O
been	O
identified	O
to	O
regulate	O
alpha	O
-	O
synuclein	O
levels	O
post	O
-	O
transcriptionally	O
.	O

Genetic	O
and	O
biochemical	O
studies	O
have	O
established	O
a	O
central	O
role	O
for	O
alpha	O
-	O
synuclein	O
accumulation	O
in	O
the	O
pathogenesis	O
of	O
Parkinson	B
disease	I
.	O

Post	O
-	O
transcriptional	O
regulation	O
of	O
alpha	O
-	O
synuclein	O
expression	O
by	O
mir-7	O
and	O
mir-153	O
.	O

Learning	O
,	O
retention	O
and	O
generalization	O
of	O
a	O
mirror	O
tracing	O
skill	O
in	O
Alzheimer	B
's	I
disease	I
.	O

The	O
present	O
study	O
examined	O
the	O
ability	O
of	O
12	O
patients	O
with	O
probable	O
Alzheimer	B
's	I
disease	I
(	O
AD	B
)	O
and	O
12	O
age-	O
and	O
education	O
-	O
matched	O
normal	O
control	O
(	O
NC	O
)	O
subjects	O
to	O
learn	O
and	O
retain	O
the	O
visuomotor	O
skills	O
necessary	O
to	O
efficiently	O
trace	O
a	O
pattern	O
(	O
e.g.	O
,	O
a	O
4-	O
or	O
6-pointed	O
star	O
)	O
seen	O
only	O
in	O
mirror	O
-	O
reversed	O
view	O
.	O

Those	O
AD	B
(	O
N=6	O
)	O
and	O
NC	O
(	O
N=7	O
)	O
subjects	O
who	O
were	O
able	O
to	O
initially	O
perform	O
the	O
basic	O
mirror	O
tracing	O
task	O
did	O
not	O
differ	O
significantly	O
in	O
initial	O
level	O
of	O
performance	O
,	O
learning	O
over	O
trials	O
,	O
retention	O
of	O
the	O
skill	O
over	O
a	O
30-min	O
delay	O
interval	O
,	O
and	O
generalization	O
of	O
the	O
skill	O
to	O
a	O
new	O
figure	O
or	O
to	O
the	O
opposite	O
direction	O
of	O
tracing	O
.	O

The	O
AD	B
patients	O
who	O
were	O
unable	O
to	O
initially	O
perform	O
the	O
mirror	O
tracing	O
task	O
were	O
significantly	O
worse	O
than	O
those	O
who	O
could	O
perform	O
the	O
task	O
on	O
several	O
neuropsychological	O
measures	O
sensitive	O
to	O
deficits	O
in	O
problem	O
solving	O
and	O
executive	O
functions	O
,	O
but	O
not	O
on	O
tests	O
of	O
global	O
cognitive	O
decline	O
,	O
memory	O
,	O
language	O
,	O
or	O
visuoperceptual	O
functioning	O
.	O

These	O
results	O
indicate	O
that	O
acquisition	O
and	O
retention	O
of	O
a	O
complex	O
visuomotor	O
skill	O
can	O
proceed	O
normally	O
in	O
the	O
early	O
stages	O
of	O
AD	B
in	O
those	O
individuals	O
who	O
can	O
initially	O
perform	O
the	O
basic	O
task	O
,	O
and	O
that	O
inability	O
to	O
perform	O
the	O
basic	O
task	O
may	O
be	O
related	O
to	O
the	O
frontal	B
lobe	I
dysfunction	I
that	O
is	O
often	O
prominent	O
in	O
the	O
disorder	O
.	O

Thus	O
,	O
miR-206	O
slows	O
ALS	B
progression	O
by	O
sensing	B
motor	I
neuron	I
injury	I
and	O
promoting	O
the	O
compensatory	O
regeneration	O
of	O
neuromuscular	O
synapses	O
.	O

Here	O
,	O
we	O
show	O
that	O
a	O
key	O
regulator	O
of	O
this	O
signaling	O
is	O
miR-206	O
,	O
a	O
skeletal	O
muscle	O
-	O
specific	O
microRNA	O
that	O
is	O
dramatically	O
induced	O
in	O
a	O
mouse	O
model	O
of	O
ALS	B
.	O

Mice	O
that	O
are	O
genetically	O
deficient	O
in	O
miR-206	O
form	O
normal	O
neuromuscular	O
synapses	O
during	O
development	O
,	O
but	O
deficiency	O
of	O
miR-206	O
in	O
the	O
ALS	B
mouse	O
model	O
accelerates	O
disease	O
progression	O
.	O

miR-206	O
is	O
required	O
for	O
efficient	O
regeneration	O
of	O
neuromuscular	O
synapses	O
after	O
acute	B
nerve	I
injury	I
,	O
which	O
probably	O
accounts	O
for	O
its	O
salutary	O
effects	O
in	O
ALS	B
.	O

miR-206	O
mediates	O
these	O
effects	O
at	O
least	O
in	O
part	O
through	O
histone	O
deacetylase	O
4	O
and	O
fibroblast	O
growth	O
factor	O
signaling	O
pathways	O
.	O

MicroRNA-206	O
delays	O
ALS	B
progression	O
and	O
promotes	O
regeneration	O
of	O
neuromuscular	O
synapses	O
in	O
mice	O
.	O

Amyotrophic	B
lateral	I
sclerosis	I
(	O
ALS	B
)	O
is	O
a	O
neurodegenerative	B
disease	I
characterized	O
by	O
loss	O
of	O
motor	O
neurons	O
,	O
denervation	O
of	O
target	O
muscles	O
,	O
muscle	B
atrophy	I
,	O
and	O
paralysis	B
.	O

Understanding	O
ALS	B
pathogenesis	O
may	O
require	O
a	O
fuller	O
understanding	O
of	O
the	O
bidirectional	O
signaling	O
between	O
motor	O
neurons	O
and	O
skeletal	O
muscle	O
fibers	O
at	O
neuromuscular	O
synapses	O
.	O

[	O
A	O
study	O
on	O
miRNA	O
alternation	O
after	O
H2O2-induced	O
PC12	O
cell	O
apoptosis	O
using	O
microarray	O
technique	O
]	O
.	O

METHODS	O
:	O
PC12	O
cells	O
were	O
treated	O
with	O
different	O
concentrations	O
of	O
H2O2	O
for	O
12	O
hours	O
,	O
and	O
then	O
the	O
cell	O
viabilities	O
were	O
evaluated	O
by	O
MTT	O
assay	O
and	O
cell	O
apoptosis	O
rates	O
were	O
assessed	O
by	O
flow	O
cytometry	O
(	O
FCM	O
)	O
.	O

OBJECTIVE	O
:	O
To	O
screen	O
the	O
differentially	O
expressed	O
microRNAs	O
(	O
miRNA	O
)	O
between	O
H2O2-induced	O
PC12	O
cell	O
apoptosis	O
and	O
normal	O
PC12	O
cells	O
with	O
microarray	O
chips	O
.	O

Of	O
the	O
46	O
miRNAs	O
in	O
the	O
H2O2	O
treated	O
groups	O
,	O
39	O
were	O
similar	O
to	O
that	O
of	O
the	O
control	O
group	O
and	O
6	O
were	O
significantly	O
down	O
-	O
regulated	O
.	O

CONCLUSION	O
:	O
Our	O
preliminary	O
data	O
may	O
provide	O
a	O
new	O
potential	O
foundation	O
for	O
further	O
study	O
of	O
pathogenesis	O
and	O
its	O
treatment	O
of	O
nerve	O
cell	O
apoptosis	O
caused	O
by	O
cerebral	B
ischemia	I
reperfusion	I
.	O

The	O
apoptosis	O
rates	O
for	O
them	O
were	O
2.6	O
%	O
,	O
5.2	O
%	O
,	O
7.2	O
%	O
,	O
10.4	O
%	O
,	O
16.6	O
%	O
,	O
and	O
72.2	O
%	O
accordingly	O
.	O

Expression	O
of	O
68	O
miRNAs	O
and	O
46	O
miRNAs	O
were	O
detected	O
in	O
both	O
control	O
group	O
and	O
the	O
H2O2	O
treated	O
groups	O
.	O

miRNAs	O
were	O
isolated	O
from	O
control	O
(	O
0	O
nmol	O
/	O
L	O
H2O2	O
)	O
and	O
H2O2	O
treated	O
(	O
at	O
concentrations	O
of	O
50	O
,	O
100	O
,	O
200	O
,	O
and	O
400	O
nmol	O
/	O
L	O
H2O2	O
,	O
respectively	O
)	O
groups	O
of	O
the	O
PC12	O
cells	O
,	O
respectively	O
,	O
and	O
were	O
then	O
detected	O
and	O
analyzed	O
by	O
microarray	O
chips	O
.	O

RESULTS	O
:	O
The	O
P12	O
cell	O
viabilities	O
in	O
control	O
and	O
H2O2	O
treated	O
group	O
were	O
(	O
92	O
+	O
/-	O
9.8	O
)	O
%	O
,	O
(	O
90	O
+	O
/-	O
14.70	O
)	O
%	O
,	O
(	O
80	O
+	O
/-	O
13.85	O
)	O
%	O
,	O
(	O
54	O
+	O
/-	O
12.23	O
)	O
%	O
,	O
and	O
(	O
22	O
+	O
/-	O
7.35	O
)	O
%	O
,	O
respectively	O
.	O

In	O
particular	O
,	O
SNP	O
rs12720208	O
in	O
the	O
3	O
'	O
untranslated	O
region	O
(	O
3	O
'	O
UTR	O
)	O
was	O
linked	O
to	O
PD	B
-	O
risk	O
through	O
a	O
mechanism	O
that	O
would	O
implicate	O
a	O
differential	O
binding	O
to	O
microRNA-433	O
(	O
miR-433	O
)	O
.	O

The	O
reduction	O
of	O
the	O
affinity	O
of	O
miR-433	O
to	O
the	O
3	O
'	O
UTR	O
would	O
result	O
in	O
increased	O
FGF20	O
expression	O
and	O
upregulation	O
of	O
alpha	O
-	O
synuclein	O
,	O
which	O
could	O
in	O
turn	O
promote	O
dopaminergic	O
neurons	O
degeneration	O
.	O

FGF20	O
rs12720208	O
SNP	O
and	O
microRNA-433	O
variation	O
:	O
no	O
association	O
with	O
Parkinson	B
's	I
disease	I
in	O
Spanish	O
patients	O
.	O

DNA	O
variation	O
at	O
the	O
FGF20	O
gene	O
has	O
been	O
associated	O
with	O
Parkinson	B
's	I
disease	I
(	O
PD	B
)	O
.	O

In	O
conclusion	O
,	O
our	O
work	O
did	O
not	O
confirm	O
the	O
association	O
between	O
rs12720208	O
and	O
PD	B
,	O
or	O
an	O
effect	O
of	O
miR-433	O
variants	O
on	O
this	O
disease	O
.	O

None	O
of	O
the	O
patients	O
had	O
miR-433	O
variants	O
.	O

We	O
did	O
not	O
find	O
significant	O
differences	O
in	O
allele	O
and	O
genotype	O
frequencies	O
between	O
patients	O
and	O
controls	O
.	O

We	O
genotyped	O
the	O
rs12720208	O
SNP	O
in	O
a	O
total	O
of	O
512	O
PD	B
patients	O
and	O
258	O
healthy	O
controls	O
from	O
Spain	O
,	O
and	O
searched	O
for	O
miR-433	O
variants	O
in	O
the	O
patients	O
.	O

The	O
results	O
suggest	O
(	O
a	O
)	O
that	O
unless	O
specifically	O
stabilized	O
,	O
certain	O
brain	O
-	O
enriched	O
miRNAs	O
represent	O
a	O
rapidly	O
executed	O
signaling	O
system	O
employing	O
highly	O
transient	O
effectors	O
of	O
CNS	O
gene	O
expression	O
,	O
and	O
(	O
b	O
)	O
that	O
in	O
AD	B
temporal	O
lobe	O
neocortex	O
specific	O
brain	O
miRNAs	O
are	O
significantly	O
up	O
-	O
regulated	O
in	O
abundance	O
and	O
strongly	O
correlate	O
with	O
the	O
presence	O
of	O
AD	B
-	O
type	O
neuropatholgical	O
change	O
.	O

In	O
short	O
PMI	O
Alzheimer	B
's	I
disease	I
(	O
AD	B
)	O
-affected	O
temporal	O
lobe	O
neocortex	O
,	O
miRNA-9	O
,	O
miRNA-125b	O
and	O
miRNA-146a	O
were	O
found	O
to	O
be	O
significantly	O
up	O
-	O
regulated	O
,	O
an	O
effect	O
that	O
was	O
not	O
seen	O
in	O
several	O
related	O
neurological	B
disorders	I
.	O

In	O
these	O
studies	O
,	O
miRNA	O
array	O
and	O
Northern	O
blot	O
based	O
tracking	O
of	O
specific	O
miRNA	O
abundances	O
and	O
decay	O
kinetics	O
in	O
human	O
neural	O
(	O
HN	O
)	O
cells	O
in	O
primary	O
culture	O
and	O
in	O
short	O
post	O
-	O
mortem	O
interval	O
(	O
PMI	O
,	O
approximately	O
1h	O
)	O
human	O
brain	O
tissues	O
showed	O
a	O
limited	O
stability	O
and	O
relatively	O
short	O
half	O
-	O
life	O
(	O
approximately	O
1	O
-	O
3.5h	O
)	O
for	O
specific	O
brain	O
-	O
enriched	O
miRNAs	O
.	O

Micro	O
-	O
RNA	O
(	O
miRNA	O
)	O
mediated	O
regulation	O
of	O
messenger	O
RNA	O
(	O
mRNA	O
)	O
complexity	O
in	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
is	O
emerging	O
as	O
a	O
critical	O
factor	O
in	O
the	O
control	O
of	O
CNS	O
-	O
specific	O
gene	O
expression	O
during	O
development	O
,	O
plasticity	O
,	O
aging	O
and	O
disease	O
.	O

Micro	O
-	O
RNA	O
abundance	O
and	O
stability	O
in	O
human	O
brain	O
:	O
specific	O
alterations	O
in	O
Alzheimer	B
's	I
disease	I
temporal	O
lobe	O
neocortex	O
.	O

Keystone	O
symposium	O
,	O
Neurodegenerative	B
Diseases	I
:	O
New	O
Molecular	O
Mechanisms	O
17	O
-	O
22	O
February	O
2009	O
.	O

Glioma	B
angiogenesis	O
:	O
Towards	O
novel	O
RNA	O
therapeutics	O
.	O

Brain	B
tumors	I
exhibit	O
marked	O
and	O
aberrant	O
blood	O
vessel	O
formation	O
indicating	O
angiogenic	O
endothelial	O
cells	O
as	O
a	O
potential	O
target	O
for	O
brain	B
tumor	I
treatment	O
.	O

The	O
brain	B
tumor	I
blood	O
vessels	O
are	O
used	O
for	O
nutrient	O
delivery	O
,	O
and	O
possibly	O
for	O
cancer	B
cell	O
migration	O
.	O

The	O
process	O
of	O
angiogenesis	O
is	O
complex	O
and	O
involves	O
multiple	O
players	O
.	O

The	O
current	O
angiogenesis	O
inhibitors	O
used	O
in	O
clinical	O
trials	O
mostly	O
target	O
single	O
angiogenic	O
proteins	O
and	O
so	O
far	O
show	O
limited	O
effects	O
on	O
tumor	B
growth	O
.	O

Besides	O
the	O
conventional	O
angiogenesis	O
inhibitors	O
,	O
RNA	O
-	O
based	O
inhibitors	O
such	O
as	O
small	O
-	O
interfering	O
RNAs	O
(	O
siRNAs	O
)	O
are	O
being	O
analyzed	O
for	O
their	O
capacity	O
to	O
silence	O
the	O
message	O
of	O
proteins	O
involved	O
in	O
neovascularization	O
.	O

More	O
recently	O
,	O
a	O
new	O
family	O
of	O
non	O
-	O
coding	O
RNAs	O
,	O
named	O
angiomirs	O
[	O
microRNAs	O
(	O
miRNAs	O
)	O
involved	O
in	O
angiogenesis	O
]	O
has	O
emerged	O
.	O

These	O
small	O
RNAs	O
have	O
the	O
advantage	O
over	O
siRNAs	O
in	O
that	O
they	O
have	O
the	O
potential	O
of	O
silencing	O
multiple	O
messages	O
at	O
the	O
same	O
time	O
and	O
therefore	O
they	O
might	O
become	O
therapeutically	O
relevant	O
in	O
a	O
""""	O
one	O
-	O
hit	O
multiple	O
-	O
target	O
""""	O
context	O
against	O
brain	B
tumor	I
angiogenesis	O
.	O

In	O
this	O
review	O
we	O
will	O
discuss	O
the	O
emerging	O
technologies	O
in	O
anti	O
-	O
angiogenesis	O
emphasizing	O
on	O
RNA	O
-	O
based	O
therapeutics	O
.	O

Diseases	O
potentially	O
mediated	O
by	O
alterations	O
in	O
RNA	O
processes	O
include	O
tauopathies	B
,	O
myotonic	B
dystrophy	I
,	O
Alzheimer	B
disease	I
,	O
brain	B
cancer	I
,	O
and	O
many	O
others	O
.	O

Some	O
noncoding	O
RNAs	O
have	O
been	O
shown	O
to	O
be	O
involved	O
in	O
human	B
brain	I
diseases	I
.	O

Furthermore	O
,	O
there	O
is	O
poor	O
correlation	O
between	O
mRNA	O
levels	O
and	O
protein	O
levels	O
in	O
mammalian	O
cells	O
,	O
due	O
partly	O
to	O
complicated	O
post	O
-	O
transcriptional	O
regulation	O
by	O
hitherto	O
unknown	O
noncoding	O
RNAs	O
.	O

For	O
example	O
,	O
neurologic	B
illnesses	I
may	O
arise	O
because	O
of	O
perturbations	O
in	O
distinct	O
but	O
interrelated	O
tiers	O
of	O
RNA	O
-	O
based	O
genetic	O
regulation	O
:	O
pre	O
-	O
mRNA	O
splicing	O
;	O
nonsplicing	O
RNA	O
modifications	O
;	O
and	O
mRNA	O
translational	O
regulation	O
.	O

A	O
variety	O
of	O
unforeseen	O
complexities	O
have	O
been	O
identified	O
,	O
many	O
with	O
relevance	O
to	O
human	B
brain	I
disease	I
.	O

RNA	O
research	O
has	O
made	O
great	O
progress	O
in	O
recent	O
years	O
.	O

RNA	O
in	O
brain	B
disease	I
:	O
no	O
longer	O
just	O
""""	O
the	O
messenger	O
in	O
the	O
middle	O
""""	O
.	O

Here	O
we	O
present	O
an	O
overview	O
of	O
new	O
research	O
highlighting	O
functions	O
for	O
RNA	O
that	O
far	O
surpass	O
the	O
""""	O
messenger	O
in	O
the	O
middle	O
""""	O
role	O
and	O
that	O
identify	O
RNA	O
molecules	O
as	O
important	O
agents	O
in	O
the	O
human	O
brain	O
in	O
health	O
and	O
in	O
disease	O
states	O
.	O

RNA	O
editing	O
by	O
adenosine	O
deamination	O
is	O
a	O
posttranscriptional	O
mechanism	O
for	O
the	O
regulation	O
of	O
gene	O
expression	O
and	O
is	O
particularly	O
widespread	O
in	O
mammals	O
.	O

Gene	O
regulation	O
through	O
RNA	O
editing	O
.	O

Here	O
,	O
I	O
am	O
reviewing	O
main	O
features	O
of	O
this	O
epigenetic	O
phenomenon	O
,	O
its	O
relevance	O
for	O
health	O
and	O
disease	O
,	O
as	O
well	O
as	O
potential	O
prospects	O
for	O
using	O
RNA	O
editing	O
as	O
a	O
therapeutic	O
tool	O
.	O

Widespread	O
A	O
-	O
to	O
-	O
I	O
modification	O
of	O
repeat	O
sequences	O
in	O
the	O
human	O
transcriptome	O
suggests	O
additional	O
roles	O
for	O
RNA	O
editing	O
and	O
links	O
it	O
to	O
other	O
processes	O
of	O
gene	O
regulation	O
,	O
such	O
as	O
RNA	O
splicing	O
as	O
well	O
as	O
siRNA	O
mediated	O
gene	O
silencing	O
and	O
miRNA	O
function	O
.	O

The	O
deficiency	O
or	O
misregulation	O
of	O
editing	O
has	O
been	O
implicated	O
in	O
the	O
etiology	O
of	O
neurological	B
diseases	I
,	O
such	O
as	O
epilepsy	B
,	O
amyotrophic	B
lateral	I
sclerosis	I
(	O
ALS	B
)	O
,	O
depression	B
and	O
tumor	B
progression	O
.	O

Also	O
,	O
it	O
regulates	O
important	O
functional	O
properties	O
of	O
neurotransmitter	O
receptor	O
genes	O
in	O
the	O
central	O
nervous	O
system	O
by	O
changing	O
single	O
codons	O
in	O
pre	O
-	O
mRNA	O
.	O

A	O
-	O
to	O
-	O
I	O
RNA	O
editing	O
generates	O
transcriptome	O
and	O
proteome	O
diversity	O
allowing	O
organisms	O
to	O
produce	O
many	O
more	O
gene	O
products	O
and	O
functions	O
than	O
predicted	O
based	O
on	O
the	O
number	O
of	O
genes	O
within	O
their	O
genome	O
.	O

Gliomas	B
display	O
a	O
microRNA	O
expression	O
profile	O
reminiscent	O
of	O
neural	O
precursor	O
cells	O
.	O

Gliomas	B
express	O
many	O
genes	O
that	O
play	O
a	O
role	O
in	O
neural	O
precursor	O
cells	O
(	O
NPCs	O
)	O
,	O
but	O
no	O
direct	O
comparison	O
between	O
glioma	B
and	O
stem	O
cell	O
(	O
SC	O
)	O
gene	O
expression	O
profiles	O
has	O
been	O
performed	O
.	O

To	O
investigate	O
the	O
similarities	O
and	O
differences	O
between	O
gliomas	B
and	O
SCs	O
,	O
we	O
compared	O
the	O
microRNA	O
(	O
miRNA	O
)	O
expression	O
signatures	O
of	O
glial	B
tumors	I
,	O
embryonic	O
SCs	O
(	O
ESCs	O
)	O
,	O
NPCs	O
,	O
and	O
normal	O
adult	O
brains	O
from	O
both	O
human	O
and	O
mouse	O
tissues	O
.	O

We	O
demonstrated	O
that	O
both	O
human	B
gliomas	I
(	O
regardless	O
of	O
their	O
grade	O
)	O
and	O
methylcholanthrene	O
-	O
induced	O
mouse	B
glioma	I
shared	O
an	O
miRNA	O
expression	O
profile	O
that	O
is	O
reminiscent	O
of	O
NPCs	O
.	O

About	O
half	O
of	O
the	O
miRNAs	O
expressed	O
in	O
the	O
shared	O
profile	O
clustered	O
in	O
seven	O
genomic	O
regions	O
susceptible	O
to	O
genetic	O
/	O
epigenetic	O
alterations	O
in	O
various	O
cancers	B
.	O

These	O
clusters	O
comprised	O
the	O
miR17	O
family	O
,	O
mir183	O
-	O
182	O
,	O
and	O
the	O
SC	O
-	O
specific	O
clusters	O
mir367	O
-	O
302	O
and	O
mir371	O
-	O
373	O
,	O
which	O
are	O
upregulated	O
in	O
gliomas	B
,	O
ESCs	O
,	O
and	O
NPCs	O
.	O

The	O
bipartite	O
cluster	O
of	O
7	O
+	O
46	O
miRNAs	O
on	O
chromosome	O
14q32.31	O
,	O

which	O
might	O
represent	O
the	O
largest	O
tumor	O
suppressor	O
miRNA	O
cluster	O
,	O
was	O
downregulated	O
in	O
the	O
shared	O
expression	O
profile	O
.	O

This	O
study	O
provides	O
the	O
first	O
evidence	O
for	O
association	O
between	O
these	O
clusters	O
and	O
gliomas	B
.	O

Despite	O
the	O
broad	O
similarity	O
in	O
the	O
miRNA	O
expression	O
profiles	O
,	O
15	O
miRNAs	O
showed	O
disparate	O
expression	O
between	O
SC	O
and	O
gliomas	B
.	O

Ten	O
miRNAs	O
belong	O
to	O
the	O
2	O
SC	O
-	O
specific	O
clusters	O
and	O
the	O
remaining	O
(	O
mir135b	O
,	O
mir141	O
,	O
mir205	O
,	O
mir200C	O
,	O
and	O
mir301a	O
)	O
have	O
been	O
previously	O
shown	O
to	O
associate	O
with	O
malignancies	O
.	O

Our	O
finding	O
showed	O
that	O
all	O
gliomas	B
displayed	O
NPC	O
-	O
like	O
miRNA	O
signatures	O
,	O
which	O
may	O
have	O
implications	O
for	O
studies	O
of	O
glioma	B
origins	O
.	O

Furthermore	O
,	O
careful	O
study	O
of	O
the	O
15	O
miRNAs	O
that	O
differ	O
in	O
expression	O
between	O
SCs	O
and	O
gliomas	B
,	O
particularly	O
those	O
5	O
that	O
are	O
not	O
SC	O
-	O
specific	O
,	O
may	O
enhance	O
our	O
understanding	O
of	O
gliomagenesis	O
.	O

New	O
insights	O
into	O
the	O
roles	O
of	O
microRNAs	O
in	O
drug	B
addiction	I
and	O
neuroplasticity	O
.	O

In	O
this	O
review	O
,	O
the	O
aim	O
is	O
to	O
provide	O
an	O
overview	O
of	O
the	O
emerging	O
role	O
of	O
miRNAs	O
in	O
addiction	O
.	O

miRNAs	O
are	O
small	O
non	O
-	O
coding	O
RNAs	O
,	O
particularly	O
abundant	O
in	O
the	O
nervous	O
system	O
,	O
that	O
play	O
key	O
roles	O
as	O
regulatory	O
molecules	O
in	O
processes	O
such	O
as	O
neurogenesis	O
,	O
synapse	O
development	O
and	O
plasticity	O
in	O
the	O
brain	O
.	O

They	O
also	O
act	O
as	O
key	O
spatiotemporal	O
regulators	O
during	O
dendritic	O
morphogenesis	O
,	O
controlling	O
the	O
expression	O
of	O
hundreds	O
of	O
genes	O
involved	O
in	O
neuroplasticity	O
and	O
in	O
the	O
function	O
of	O
synapses	O
.	O

Recent	O
studies	O
have	O
identified	O
changes	O
of	O
several	O
specific	O
miRNA	O
expression	O
profiles	O
and	O
polymorphisms	O
affecting	O
the	O
interactions	O
between	O
miRNAs	O
and	O
their	O
targets	O
in	O
various	O
brain	B
disorders	I
,	O
including	O
addiction	O
:	O
miR-16	O
causes	O
adaptive	O
changes	O
in	O
production	O
of	O
the	O
serotonin	O
transporter	O
;	O
miR-133b	O
is	O
specifically	O
expressed	O
in	O
midbrain	O
dopaminergic	O
neurons	O
,	O
and	O
regulates	O
the	O
production	O
of	O
tyrosine	O
hydroxylase	O
and	O
the	O
dopamine	O
transporter	O
;	O
miR-212	O
affects	O
production	O
of	O
striatal	O
brain	O
-	O
derived	O
neurotrophic	O
factor	O
and	O
synaptic	O
plasticity	O
upon	O
cocaine	O
.	O

Clearly	O
,	O
specific	O
miRNAs	O
have	O
emerged	O
as	O
key	O
regulators	O
leading	O
to	O
addiction	O
,	O
and	O
could	O
serve	O
as	O
valuable	O
targets	O
for	O
more	O
efficient	O
therapies	O
.	O

ABSTRACT	O
:	O
Drug	B
addiction	I
is	O
a	O
major	O
public	O
health	O
issue	O
.	O

It	O
is	O
typically	O
a	O
multigenetic	O
brain	B
disorder	I
,	O
implying	O
combined	O
changes	O
of	O
expression	O
of	O
several	O
hundred	O
genes	O
.	O

Psychostimulants	O
(	O
such	O
as	O
cocaine	O
,	O
heroin	O
and	O
amphetamines	O
)	O
induce	O
strong	O
and	O
persistent	O
neuroadaptive	O
changes	O
through	O
a	O
surfeit	O
of	O
gene	O
regulatory	O
mechanisms	O
leading	O
to	O
addiction	O
.	O

Activity	O
-	O
dependent	O
synaptic	O
plasticity	O
of	O
the	O
mesolimbic	O
dopaminergic	O
system	O
,	O
known	O
as	O
the	O
'	O
reward	O
pathway	O
'	O
,	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
development	O
of	O
drug	B
dependence	I
.	O

Germline	O
E	O
-	O
cadherin	O
gene	O
(	O
CDH1	O
)	O
mutations	O
predispose	O
to	O
familial	B
gastric	I
cancer	I
and	O
colorectal	B
cancer	I
.	O

Inherited	O
mutations	O
in	O
the	O
E	O
-	O
cadherin	O
gene	O
(	O
CDH1	O
)	O
were	O
described	O
recently	O
in	O
three	O
Maori	O
kindreds	O
with	O
familial	B
gastric	I
cancer	I
.	O

Familial	B
gastric	I
cancer	I
is	O
genetically	O
heterogeneous	O
and	O
it	O
is	O
not	O
clear	O
what	O
proportion	O
of	O
gastric	B
cancer	I
susceptibility	O
in	O
non	O
-	O
Maori	O
populations	O
is	O
due	O
to	O
germline	O
CDH1	O
mutations	O
.	O

Therefore	O
,	O
we	O
screened	O
eight	O
familial	B
gastric	I
cancer	I
kindreds	O
of	O
British	O
and	O
Irish	O
origin	O
for	O
germline	O
CDH1	O
mutations	O
,	O
by	O
SSCP	O
analysis	O
of	O
all	O
16	O
exons	O
and	O
flanking	O
sequences	O
.	O

Each	O
family	O
contained	O
(	O
i	O
)	O
two	O
cases	O
of	O
gastric	B
cancer	I
in	O
first	O
degree	O
relatives	O
with	O
one	O
affected	O
before	O
age	O
50	O
years	O
;	O
or	O
(	O
ii	O
)	O
three	O
or	O
more	O
cases	O
of	O
gastric	B
cancer	I
.	O

Novel	O
germline	O
CDH1	O
mutations	O
(	O
a	O
nonsense	O
and	O
a	O
splice	O
site	O
)	O
were	O
detected	O
in	O
two	O
families	O
(	O
25	O
%	O
)	O
.	O

Both	O
mutations	O
were	O
predicted	O
to	O
truncate	O
the	O
E	O
-	O
cadherin	O
protein	O
in	O
the	O
signal	O
peptide	O
domain	O
.	O

In	O
one	O
family	O
there	O
was	O
evidence	O
of	O
non	O
-	O
penetrance	O
and	O
susceptibility	O
to	O
both	O
gastric	B
and	I
colorectal	I
cancer	I
;	O
thus	O
,	O
in	O
addition	O
to	O
six	O
cases	O
of	O
gastric	B
cancer	I
,	O
a	O
CDH1	O
mutation	O
carrier	O
developed	O
colorectal	B
cancer	I
at	O
age	O
30	O
years	O
.	O

We	O
have	O
confirmed	O
that	O
germline	O
mutations	O
in	O
the	O
CDH1	O
gene	O
cause	O
familial	B
gastric	I
cancer	I
in	O
non	O
-	O
Maori	O
populations	O
.	O

However	O
,	O
only	O
a	O
minority	O
of	O
familial	O
gastric	B
cancers	I
can	O
be	O
accounted	O
for	O
by	O
CDH1	O
mutations	O
.	O

Loss	O
of	O
E	O
-	O
cadherin	O
function	O
has	O
been	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
sporadic	O
colorectal	B
and	I
other	I
cancers	I
,	O
and	O
our	O
findings	O
provide	O
evidence	O
that	O
germline	O
CDH1	O
mutations	O
predispose	O
to	O
early	O
onset	O
colorectal	B
cancer	I
.	O

Thus	O
,	O
CDH1	O
should	O
be	O
investigated	O
as	O
a	O
cause	O
of	O
inherited	O
susceptibility	O
to	O
both	O
gastric	B
and	I
colorectal	I
cancers	I
.	O

A	O
retrospective	O
anonymous	O
pilot	O
study	O
in	O
screening	O
newborns	O
for	O
HFE	O
mutations	O
in	O
Scandinavian	O
populations	O
.	O

We	O
have	O
retrospectively	O
analyzed	O
837	O
random	O
anonymized	O
dried	O
blood	O
spot	O
(	O
DBS	O
)	O
samples	O
from	O
neonatal	O
screening	O
programs	O
in	O
Scandinavia	O
for	O
mutations	O
in	O
HFE	O
,	O
the	O
candidate	O
gene	O
for	O
hemochromatosis	B
.	O

We	O
have	O
found	O
C282Y	O
allele	O
frequencies	O
of	O
2	O
.	O
3	O
%	O
(	O
+	O
2	O
.	O
0	O
%	O
)	O
(	O
-1	O
.	O
3	O
%	O
)	O
in	O
Greenland	O
,	O
4	O
.	O
5	O
%	O
+	O
/-1	O
.	O

9	O
%	O
in	O
Iceland	O
,	O
5	O
.	O
1	O
%	O
+	O
/-2	O
.	O

3	O
%	O
in	O
the	O
Faeroe	O
Islands	O
,	O
and	O
8	O
.	O
2	O
%	O
+	O
/-2	O
.	O

7	O
%	O
in	O
Denmark	O
.	O

The	O
high	O
prevalence	O
of	O
HFE	O
mutations	O
in	O
Denmark	O
suggests	O
that	O
population	O
screening	O
for	O
the	O
C282Y	O
mutation	O
could	O
be	O
highly	O
advantageous	O
in	O
terms	O
of	O
preventive	O
health	O
care	O
.	O

Long	O
-	O
term	O
follow	O
-	O
up	O
evaluation	O
of	O
C282Y	O
homozygotes	O
and	O
H63D	O
/	O
C282Y	O
compound	O
heterozygotes	O
will	O
give	O
an	O
indication	O
of	O
the	O
penetrance	O
of	O
the	O
mutations	O
.	O

Identification	O
of	O
the	O
mutation	O
in	O
the	O
alkaptonuria	B
mouse	O
model	O
.	O

Alkaptonuria	B
(	O
aku	B
)	O
,	O
an	O
inborn	B
error	I
of	I
metabolism	I
caused	O
by	O
the	O
loss	O
of	O
homogentisate	O
1	O
,	O
2-dioxygenase	O
(	O
HGD	O
)	O
,	O
has	O
been	O
described	O
in	O
a	O
mouse	O
model	O
created	O
by	O
ethylnitrosourea	O
mutagenesis	O
but	O
the	O
mutation	O
in	O
these	O
mice	O
has	O
not	O
previously	O
been	O
identified	O
.	O

We	O
used	O
RT	O
-	O
PCR	O
to	O
amplify	O
the	O
Hgd	O
cDNA	O
from	O
Hgd	O
(	O
aku	O
)	O
/	O
Hgd	O
(	O
aku	O
)	O
mice	O
.	O

Two	O
products	O
shorter	O
than	O
the	O
wild	O
-	O
type	O
product	O
were	O
amplified	O
.	O

Restriction	O
mapping	O
and	O
DNA	O
sequencing	O
were	O
then	O
used	O
to	O
identify	O
the	O
Hgd	O
(	O
aku	O
)	O
mouse	O
mutation	O
,	O
found	O
to	O
be	O
a	O
single	O
base	O
change	O
in	O
a	O
splice	O
donor	O
consensus	O
sequence	O
,	O
causing	O
exon	O
skipping	O
and	O
frame	O
-	O
shifted	O
products	O
.	O

This	O
base	O
change	O
allowed	O
us	O
to	O
create	O
a	O
non	O
-	O
radioactive	O
genotyping	O
assay	O
for	O
this	O
allele	O
.	O

Mutational	O
analysis	O
and	O
genotype	O
-	O
phenotype	O
correlation	O
of	O
29	O
unrelated	O
Japanese	O
patients	O
with	O
X	B
-	I
linked	I
adrenoleukodystrophy	I
.	O

BACKGROUND	O
X	B
-	I
linked	I
adrenoleukodystrophy	I
(	O
ALD	B
)	O
is	O
an	O
inherited	B
disease	I
characterized	O
by	O
progressive	O
neurologic	B
dysfunction	I
,	O
occasionally	O
associated	O
with	O
adrenal	B
insufficiency	I
.	O

The	O
classic	O
form	O
of	O
ALD	B
usually	O
has	O
onset	O
in	O
childhood	O
(	O
childhood	B
cerebral	I
ALD	I
)	O
,	O
with	O
rapid	O
neurologic	B
deterioration	I
leading	O
to	O
a	O
vegetative	O
state	O
.	O

Adult	O
-	O
onset	O
cerebral	B
ALD	I
also	O
presents	O
with	O
rapidly	O
progressive	O
neurologic	B
dysfunction	I
.	O

Milder	O
phenotypes	O
such	O
as	O
adrenomyeloneuropathy	B
and	O
Addison	B
disease	I
only	O
also	O
have	O
been	O
recognized	O
.	O

Despite	O
discovery	O
of	O
the	O
causative	O
gene	O
,	O
a	O
molecular	O
basis	O
for	O
the	O
diverse	O
clinical	O
presentations	O
remains	O
to	O
be	O
elucidated	O
.	O

OBJECTIVES	O
To	O
conduct	O
mutational	O
analyses	O
in	O
29	O
Japanese	O
patients	O
with	O
ALD	B
from	O
29	O
unrelated	O
families	O
,	O
to	O
obtain	O
knowledge	O
of	O
the	O
spectrum	O
of	O
mutations	O
in	O
this	O
gene	O
,	O
and	O
to	O
study	O
genotype	O
-	O
phenotype	O
correlations	O
in	O
Japanese	O
patients	O
.	O

METHODS	O
The	O
29	O
patients	O
comprised	O
13	O
patients	O
with	O
childhood	B
cerebral	I
ALD	I
,	O
11	O
patients	O
with	O
adult	O
-	O
onset	O
cerebral	B
ALD	I
,	O
and	O
5	O
patients	O
with	O
adrenomyeloneuropathy	B
.	O

We	O
conducted	O
detailed	O
mutational	O
analyses	O
of	O
29	O
unrelated	O
Japanese	O
patients	O
with	O
ALD	B
by	O
genomic	O
Southern	O
blot	O
analysis	O
and	O
direct	O
nucleotide	O
sequence	O
analysis	O
of	O
reverse	O
transcriptase	O
-	O
polymerase	O
chain	O
reaction	O
products	O
derived	O
from	O
total	O
RNA	O
that	O
was	O
extracted	O
from	O
cultured	O
skin	O
fibroblasts	O
,	O
lymphoblastoid	O
cells	O
,	O
or	O
peripheral	O
blood	O
leukocytes	O
.	O

RESULTS	O
Three	O
patients	O
with	O
adult	O
-	O
onset	O
cerebral	B
ALD	I
were	O
identified	O
as	O
having	O
large	O
genomic	O
rearrangements	O
.	O

The	O
remaining	O
26	O
patients	O
were	O
identified	O
as	O
having	O
21	O
independent	O
mutations	O
,	O
including	O
12	O
novel	O
mutations	O
resulting	O
in	O
small	O
nucleotide	O
alterations	O
in	O
the	O
ALD	B
gene	O
.	O

Eighteen	O
(	O
69	O
%	O
)	O
of	O
26	O
mutations	O
were	O
missense	O
mutations	O
.	O

Most	O
missense	O
mutations	O
involved	O
amino	O
acids	O
conserved	O
in	O
homologous	O
gene	O
products	O
,	O
including	O
PMP70	O
,	O
mALDRP	O
,	O
and	O
Pxa1p	O
.	O

The	O
AG	O
dinucleotide	O
deletion	O
at	O
position	O
1081	O
-	O
1082	O
,	O
which	O
has	O
been	O
reported	O
previously	O
to	O
be	O
the	O
most	O
common	O
mutation	O
in	O
white	O
patients	O
(	O
12	O
%	O
-17	O
%	O
)	O
,	O
was	O
also	O
identified	O
as	O
the	O
most	O
common	O
mutation	O
in	O
Japanese	O
patients	O
(	O
12	O
%	O
)	O
.	O

All	O
phenotypes	O
were	O
associated	O
with	O
mutations	O
resulting	O
in	O
protein	O
truncation	O
or	O
subtle	O
amino	O
acid	O
changes	O
.	O

There	O
were	O
no	O
differences	O
in	O
phenotypic	O
expressions	O
between	O
missense	O
mutations	O
involving	O
conserved	O
amino	O
acids	O
and	O
those	O
involving	O
nonconserved	O
amino	O
acids	O
.	O

CONCLUSIONS	O
There	O
are	O
no	O
obvious	O
correlations	O
between	O
the	O
phenotypes	O
of	O
patients	O
with	O
ALD	B
and	O
their	O
genotypes	O
,	O
suggesting	O
that	O
other	O
genetic	O
or	O
environmental	O
factors	O
modify	O
the	O
phenotypic	O
expressions	O
of	O
ALD	B
..	O

Germline	O
BRCA1	O
alterations	O
in	O
a	O
population	O
-	O
based	O
series	O
of	O
ovarian	B
cancer	I
cases	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
provide	O
more	O
accurate	O
frequency	O
estimates	O
of	O
breast	B
cancer	I
susceptibility	O
gene	O
1	O
(	O
BRCA1	O
)	O
germline	O
alterations	O
in	O
the	O
ovarian	B
cancer	I
population	O
.	O

To	O
achieve	O
this	O
,	O
we	O
determined	O
the	O
prevalence	O
of	O
BRCA1	O
alterations	O
in	O
a	O
population	O
-	O
based	O
series	O
of	O
consecutive	O
ovarian	B
cancer	I
cases	O
.	O

This	O
is	O
the	O
first	O
population	O
-	O
based	O
ovarian	B
cancer	I
study	O
reporting	O
BRCA1	O
alterations	O
derived	O
from	O
a	O
comprehensive	O
screen	O
of	O
the	O
entire	O
coding	O
region	O
.	O

One	O
hundred	O
and	O
seven	O
ovarian	B
cancer	I
cases	O
were	O
analyzed	O
for	O
BRCA1	O
alterations	O
using	O
the	O
RNase	O
mismatch	O
cleavage	O
assay	O
followed	O
by	O
direct	O
sequencing	O
.	O

Two	O
truncating	O
mutations	O
,	O
962del4	O
and	O
3600del11	O
,	O
were	O
identified	O
.	O

Both	O
patients	O
had	O
a	O
family	O
history	O
of	O
breast	B
or	I
ovarian	I
cancer	I
.	O

Several	O
novel	O
as	O
well	O
as	O
previously	O
reported	O
uncharacterized	O
variants	O
were	O
also	O
identified	O
,	O
some	O
of	O
which	O
were	O
associated	O
with	O
a	O
family	O
history	O
of	O
cancer	B
.	O

The	O
frequency	O
distribution	O
of	O
common	O
polymorphisms	O
was	O
determined	O
in	O
the	O
91	O
Caucasian	O
cancer	B
cases	O
in	O
this	O
series	O
and	O
24	O
sister	O
controls	O
using	O
allele	O
-	O
specific	O
amplification	O
.	O

The	O
rare	O
form	O
of	O
the	O
Q356R	O
polymorphism	O
was	O
significantly	O
(	O
P	O
=	O
0	O
.	O
03	O
)	O
associated	O
with	O
a	O
family	O
history	O
of	O
ovarian	B
cancer	I
,	O
suggesting	O
that	O
this	O
polymorphism	O
may	O
influence	O
ovarian	B
cancer	I
risk	O
.	O

In	O
summary	O
,	O
our	O
data	O
suggest	O
a	O
role	O
for	O
some	O
uncharacterized	O
variants	O
and	O
rare	O
forms	O
of	O
polymorphisms	O
in	O
determining	O
ovarian	B
cancer	I
risk	O
,	O
and	O
highlight	O
the	O
necessity	O
to	O
screen	O
for	O
missense	O
alterations	O
as	O
well	O
as	O
truncating	O
mutations	O
in	O
this	O
population	O
.	O

Adrenoleukodystrophy	O
-	O
related	O
protein	O
can	O
compensate	O
functionally	O
for	O
adrenoleukodystrophy	B
protein	I
deficiency	I
(	O
X	B
-	I
ALD	I
)	O
:	O
implications	O
for	O
therapy	O
.	O

Inherited	B
defects	I
in	O
the	O
peroxisomal	O
ATP	O
-	O
binding	O
cassette	O
(	O
ABC	O
)	O
transporter	O
adrenoleukodystrophy	B
protein	O
(	O
ALDP	O
)	O
lead	O
to	O
the	O
lethal	O
peroxisomal	B
disorder	I
X	B
-	I
linked	I
adrenoleukodystrophy	I
(	O
X	B
-	I
ALD	I
)	O
,	O
for	O
which	O
no	O
efficient	O
treatment	O
has	O
been	O
established	O
so	O
far	O
.	O

Three	O
other	O
peroxisomal	O
ABC	O
transporters	O
currently	O
are	O
known	O
adrenoleukodystrophy	O
-	O
related	O
protein	O
(	O
ALDRP	O
)	O
,	O
70	O
kDa	O
peroxisomal	O
membrane	O
protein	O
(	O
PMP70	O
)	O
and	O
PMP70-	O
related	O
protein	O
.	O

By	O
using	O
transient	O
and	O
stable	O
overexpression	O
of	O
human	O
cDNAs	O
encoding	O
ALDP	O
and	O
its	O
closest	O
relative	O
ALDRP	O
,	O
we	O
could	O
restore	O
the	O
impaired	O
peroxisomal	O
beta	O
-	O
oxidation	O
in	O
fibroblasts	O
of	O
X	B
-	I
ALD	I
patients	O
.	O

The	O
pathognomonic	O
accumulation	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
could	O
also	O
be	O
prevented	O
by	O
overexpression	O
of	O
ALDRP	O
in	O
immortalized	O
X	O
-	O
ALD	O
cells	O
.	O

Immunofluorescence	O
analysis	O
demonstrated	O
that	O
the	O
functional	O
replacement	O
of	O
ALDP	O
by	O
ALDRP	O
was	O
not	O
due	O
to	O
stabilization	O
of	O
the	O
mutated	O
ALDP	O
itself	O
.	O

Moreover	O
,	O
we	O
were	O
able	O
to	O
restore	O
the	O
peroxisomal	O
beta	O
-	O
oxidation	O
defect	O
in	O
the	O
liver	O
of	O
ALDP	O
-	O
deficient	O
mice	O
by	O
stimulation	O
of	O
ALDRP	O
and	O
PMP70	O
gene	O
expression	O
through	O
a	O
dietary	O
treatment	O
with	O
the	O
peroxisome	O
proliferator	O
fenofibrate	O
.	O

These	O
results	O
suggest	O
that	O
a	O
correction	O
of	O
the	O
biochemical	O
defect	O
in	O
X	B
-	I
ALD	I
could	O
be	O
possible	O
by	O
drug	O
-	O
induced	O
overexpression	O
or	O
ectopic	O
expression	O
of	O
ALDRP	O
..	O

Alpha	O
-	O
cardiac	O
actin	O
is	O
a	O
novel	O
disease	O
gene	O
in	O
familial	B
hypertrophic	I
cardiomyopathy	I
.	O

We	O
identified	O
the	O
alpha	O
-	O
cardiac	O
actin	O
gene	O
(	O
ACTC	O
)	O
as	O
a	O
novel	O
disease	O
gene	O
in	O
a	O
pedigree	O
suffering	O
from	O
familial	B
hypertrophic	I
cardiomyopathy	I
(	O
FHC	B
)	O
.	O

Linkage	O
analyses	O
excluded	O
all	O
the	O
previously	O
reported	O
FHC	B
loci	O
as	O
possible	O
disease	O
loci	O
in	O
the	O
family	O
studied	O
,	O
with	O
lod	O
scores	O
varying	O
between	O
-2	O
.	O
5	O
and	O
-6	O
.	O

0	O
0	O
.	O

Further	O
linkage	O
analyses	O
of	O
plausible	O
candidate	O
genes	O
highly	O
expressed	O
in	O
the	O
adult	O
human	O
heart	O
identified	O
ACTC	O
as	O
the	O
most	O
likely	O
disease	O
gene	O
,	O
showing	O
a	O
maximal	O
lod	O
score	O
of	O
3	O
.	O
6	O
6	O
.	O

Mutation	O
analysis	O
of	O
ACTC	O
revealed	O
an	O
Ala295Ser	O
mutation	O
in	O
exon	O
5	O
close	O
to	O
2	O
missense	O
mutations	O
recently	O
described	O
to	O
cause	O
the	O
inherited	O
form	O
of	O
idiopathic	B
dilated	I
cardiomyopathy	I
(	O
IDC	B
)	O
.	O

Characterization	O
of	O
a	O
germline	O
mosaicism	O
in	O
families	O
with	O
Lowe	B
syndrome	I
,	O
and	O
identification	O
of	O
seven	O
novel	O
mutations	O
in	O
the	O
OCRL1	O
gene	O
.	O

The	O
oculocerebrorenal	B
syndrome	I
of	I
Lowe	I
(	O
OCRL	B
)	O
is	O
an	O
X	B
-	I
linked	I
disorder	I
characterized	O
by	O
major	O
abnormalities	B
of	I
eyes	I
,	I
nervous	I
system	I
,	I
and	I
kidneys	I
.	O

Mutations	O
in	O
the	O
OCRL1	O
gene	O
have	O
been	O
associated	O
with	O
the	O
disease	O
.	O

OCRL1	O
encodes	O
a	O
phosphatidylinositol	O
4	O
,	O
5-biphosphate	O
(	O
PtdIns	O
[	O
4	O
,	O
5	O
]	O
P2	O
)	O
5-phosphatase	O
.	O

We	O
have	O
examined	O
the	O
OCRL1	O
gene	O
in	O
eight	O
unrelated	O
patients	O
with	O
OCRL	B
and	O
have	O
found	O
seven	O
new	O
mutations	O
and	O
one	O
recurrent	O
in	O
-	O
frame	O
deletion	O
.	O

Among	O
the	O
new	O
mutations	O
,	O
two	O
nonsense	O
mutations	O
(	O
R317X	O
and	O
E558X	O
)	O
and	O
three	O
other	O
frameshift	O
mutations	O
caused	O
premature	O
termination	O
of	O
the	O
protein	O
.	O

A	O
missense	O
mutation	O
,	O
R483	O
G	O
,	O
was	O
located	O
in	O
the	O
highly	O
conserved	O
PtdIns	O
(	O
4	O
,	O
5	O
)	O
P2	O
5-phosphatase	O
domain	O
.	O

Finally	O
,	O
one	O
frameshift	O
mutation	O
,	O
2799delC	O
,	O
modifies	O
the	O
C	O
-	O
terminal	O
part	O
of	O
OCRL1	O
,	O
with	O
an	O
extension	O
of	O
six	O
amino	O
acids	O
.	O

Altogether	O
,	O
70	O
%	O
of	O
missense	O
mutations	O
are	O
located	O
in	O
exon	O
15	O
,	O
and	O
52	O
%	O
of	O
all	O
mutations	O
cluster	O
in	O
exons	O
11	O
-	O
15	O
.	O

We	O
also	O
identified	O
two	O
new	O
microsatellite	O
markers	O
for	O
the	O
OCRL1	O
locus	O
,	O
and	O
we	O
detected	O
a	O
germline	O
mosaicism	O
in	O
one	O
family	O
.	O

This	O
observation	O
has	O
direct	O
implications	O
for	O
genetic	O
counseling	O
of	O
Lowe	B
syndrome	I
families	O
..	O

Beta	O
-	O
catenin	O
accumulation	O
and	O
mutation	O
of	O
the	O
CTNNB1	O
gene	O
in	O
hepatoblastoma	B
.	O

Hepatoblastoma	B
is	O
a	O
rare	O
malignant	B
tumor	I
of	I
the	I
liver	I
that	O
occurs	O
in	O
children	O
at	O
an	O
average	O
age	O
of	O
2	O
to	O
3	O
years	O
.	O

Epidemiologic	O
studies	O
have	O
shown	O
an	O
increased	O
frequency	O
of	O
this	O
tumor	B
type	O
in	O
families	O
affected	O
by	O
adenomatous	B
polyposis	I
coli	I
.	O

In	O
addition	O
to	O
the	O
epidemiologic	O
data	O
,	O
molecular	O
genetic	O
studies	O
suggest	O
that	O
inactivation	O
of	O
the	O
APC	B
tumor	I
suppressor	O
may	O
be	O
involved	O
in	O
hepatoblastoma	B
tumorigenesis	O
.	O

A	O
major	O
function	O
of	O
APC	O
is	O
the	O
downregulation	O
of	O
beta	O
-	O
catenin	O
,	O
a	O
transcription	O
-	O
activating	O
protein	O
with	O
oncogenic	O
potential	O
.	O

In	O
an	O
ongoing	O
immunohistochemical	O
study	O
of	O
beta	O
-	O
catenin	O
expression	O
in	O
sporadic	O
cases	O
of	O
tumor	B
types	O
that	O
are	O
associated	O
with	O
adenomatous	B
polyposis	I
coli	I
,	O
we	O
observed	O
increased	O
beta	O
-	O
catenin	O
levels	O
in	O
the	O
cytoplasm	O
and	O
in	O
the	O
nuclei	O
of	O
three	O
investigated	O
hepatoblastomas	B
.	O

Sequencing	O
of	O
exon	O
3	O
of	O
the	O
beta	O
-	O
catenin	O
gene	O
(	O
CTNNB1	O
)	O
revealed	O
an	O
activating	O
mutation	O
in	O
one	O
of	O
the	O
tumor	B
samples	O
.	O

Our	O
data	O
indicate	O
for	O
the	O
first	O
time	O
that	O
beta	O
-	O
catenin	O
accumulation	O
may	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
hepatoblastoma	B
and	O
that	O
activating	O
mutations	O
of	O
the	O
beta	O
-	O
catenin	O
gene	O
may	O
substitute	O
biallelic	O
APC	O
inactivation	O
in	O
this	O
tumor	B
type	O
.	O

Genes	O
Chromosomes	O
Cancer	O
25	O
399	O
-	O
402	O
,	O
1999	O
..	O

Association	O
of	O
BRCA1	O
with	O
the	O
hRad50-hMre11-p95	O
complex	O
and	O
the	O
DNA	O
damage	O
response	O
.	O

BRCA1	O
encodes	O
a	O
tumor	B
suppressor	O
that	O
is	O
mutated	O
in	O
familial	B
breast	I
and	I
ovarian	I
cancers	I
.	O

Here	O
,	O
it	O
is	O
shown	O
that	O
BRCA1	O
interacts	O
in	O
vitro	O
and	O
in	O
vivo	O
with	O
hRad50	O
,	O
which	O
forms	O
a	O
complex	O
with	O
hMre11	O
and	O
p95	O
/	O
nibrin	O
.	O

Upon	O
irradiation	O
,	O
BRCA1	O
was	O
detected	O
in	O
discrete	O
foci	O
in	O
the	O
nucleus	O
,	O
which	O
colocalize	O
with	O
hRad50	O
.	O

Formation	O
of	O
irradiation	O
-	O
induced	O
foci	O
positive	O
for	O
BRCA1	O
,	O
hRad50	O
,	O
hMre11	O
,	O
or	O
p95	O
was	O
dramatically	O
reduced	O
in	O
HCC	O
/	O
1937	O
breast	B
cancer	I
cells	O
carrying	O
a	O
homozygous	O
mutation	O
in	O
BRCA1	O
but	O
was	O
restored	O
by	O
transfection	O
of	O
wild	O
-	O
type	O
BRCA1	O
.	O

Ectopic	O
expression	O
of	O
wild	O
-	O
type	O
,	O
but	O
not	O
mutated	O
,	O
BRCA1	O
in	O
these	O
cells	O
rendered	O
them	O
less	O
sensitive	O
to	O
the	O
DNA	O
damage	O
agent	O
,	O
methyl	O
methanesulfonate	O
.	O

These	O
data	O
suggest	O
that	O
BRCA1	O
is	O
important	O
for	O
the	O
cellular	O
responses	O
to	O
DNA	O
damage	O
that	O
are	O
mediated	O
by	O
the	O
hRad50-hMre11-p95	O
complex	O
..	O

Linkage	O
analysis	O
of	O
5	O
novel	O
van	B
der	I
Woude	I
syndrome	I
kindreds	O
to	O
1q32-q41	O
markers	O
further	O
supports	O
locus	O
homogeneity	O
of	O
the	O
disease	O
trait	O
.	O

van	B
der	I
Woude	I
syndrome	I
(	O
vWS	B
,	O
MIM	O
119300	O
)	O
is	O
a	O
rare	O
autosomal	B
dominant	I
clefting	I
condition	I
with	O
cardinal	O
features	O
of	O
mucous	B
cysts	I
(	O
lower	B
-	I
lip	I
pits	I
)	O
and	O
clefts	B
to	I
the	I
lip	I
and/or	I
palate	I
.	O

The	O
vWS	B
gene	O
has	O
been	O
assigned	O
to	O
a	O
locus	O
in	O
1q32-q41	O
by	O
linkage	O
analysis	O
and	O
physical	O
mapping	O
.	O

We	O
have	O
investigated	O
5	O
novel	O
vWS	B
families	O
through	O
probands	O
attended	O
for	O
cleft	B
lip	I
and/or	I
palate	I
repair	O
at	O
the	O
Department	O
of	O
Maxillofacial	O
Surgery	O
of	O
Hopital	O
Trousseau	O
,	O
Paris	O
,	O
in	O
order	O
to	O
tentatively	O
refine	O
the	O
genetic	O
map	O
of	O
the	O
vWS	B
region	O
in	O
1q32-q41	O
and	O
possibly	O
identify	O
unlinked	O
pedigrees	O
.	O

Linkage	O
analysis	O
was	O
carried	O
out	O
to	O
6	O
microsatellite	O
markers	O
(	O
D1S249	O
,	O
D1S425	O
,	O
D1S491	O
,	O
D1S205	O
,	O
D1S414	O
,	O
D1S425	O
)	O
,	O
yielding	O
a	O
maximum	O
cumulative	O
LOD	O
score	O
of	O
Z	O
=	O
3	O
.	O
27	O
at	O
theta	O
=	O
0	O
.	O
00	O
for	O
D1S245	O
.	O

The	O
innermost	O
four	O
markers	O
were	O
found	O
to	O
be	O
tightly	O
linked	O
to	O
one	O
another	O
,	O
with	O
no	O
evidence	O
for	O
recombination	O
.	O

Our	O
results	O
support	O
linkage	O
of	O
vWS	B
within	O
a	O
region	O
of	O
tightly	O
linked	O
markers	O
and	O
do	O
not	O
favour	O
locus	O
heterogeneity	O
of	O
the	O
disease	O
trait	O
.	O

Mutation	O
of	O
the	O
sterol	O
27-hydroxylase	O
gene	O
(	O
CYP27	O
)	O
results	O
in	O
truncation	O
of	O
mRNA	O
expressed	O
in	O
leucocytes	O
in	O
a	O
Japanese	O
family	O
with	O
cerebrotendinous	B
xanthomatosis	I
.	O

OBJECTIVES	O
A	O
Japanese	O
family	O
with	O
cerebrotendinous	B
xanthomatosis	I
(	O
CTX	B
)	O
was	O
investigated	O
for	O
a	O
sequence	O
alteration	O
in	O
the	O
sterol	O
27-hydroxylase	O
gene	O
(	O
CYP27	O
)	O
.	O

The	O
expression	O
of	O
CYP27	O
has	O
been	O
mostly	O
explored	O
using	O
cultured	O
fibroblasts	O
,	O
prompting	O
the	O
examination	O
of	O
the	O
transcripts	O
from	O
blood	O
leucocytes	O
as	O
a	O
simple	O
and	O
rapid	O
technique	O
.	O

METHODS	O
An	O
alteration	O
in	O
CYP27	O
of	O
the	O
proband	O
was	O
searched	O
for	O
by	O
polymerase	O
chain	O
reaction	O
-	O
single	O
strand	O
conformation	O
polymorphism	O
(	O
PCR	O
-	O
SSCP	O
)	O
analysis	O
and	O
subsequent	O
sequencing	O
.	O

Samples	O
of	O
RNA	O
were	O
subjected	O
to	O
reverse	O
transcription	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
the	O
product	O
of	O
the	O
proband	O
was	O
amplified	O
with	O
nested	O
primers	O
and	O
sequenced	O
.	O

RESULTS	O
A	O
homozygous	O
G	O
to	O
A	O
transition	O
at	O
the	O
5	O
end	O
of	O
intron	O
7	O
was	O
detected	O
in	O
the	O
patient	O
.	O

In	O
RT	O
-	O
PCR	O
analysis	O
,	O
only	O
a	O
truncated	O
transcript	O
was	O
detected	O
in	O
the	O
patient	O
,	O
whereas	O
both	O
normal	O
and	O
truncated	O
transcripts	O
were	O
detected	O
in	O
the	O
siblings	O
.	O

The	O
sequencing	O
of	O
the	O
patients	O
cDNA	O
fragment	O
disclosed	O
a	O
direct	O
conjuction	O
of	O
exon	O
6	O
and	O
exon	O
8	O
.	O

CONCLUSION	O
The	O
mutation	O
at	O
splice	O
donor	O
site	O
and	O
the	O
truncation	O
of	O
mRNA	O
were	O
identical	O
with	O
those	O
of	O
a	O
recently	O
reported	O
Italian	O
patient	O
,	O
although	O
different	O
in	O
symptomatology	O
.	O

The	O
application	O
of	O
blood	O
leucocytes	O
can	O
be	O
a	O
simple	O
technique	O
on	O
analysing	O
a	O
constructive	O
abnormality	B
of	I
CYP27	I
mRNA	O
..	O

Late	O
-	O
onset	O
familial	B
Mediterranean	I
fever	I
(	O
FMF	B
)	O
:	O
a	O
subset	O
with	O
distinct	O
clinical	O
,	O
demographic	O
,	O
and	O
molecular	O
genetic	O
characteristics	O
.	O

To	O
determine	O
the	O
prevalence	O
and	O
characterize	O
demographic	O
,	O
clinical	O
,	O
and	O
genetic	O
features	O
of	O
familial	B
Mediterranean	I
fever	I
(	O
FMF	B
)	O
of	O
late	O
onset	O
,	O
all	O
patients	O
experiencing	O
their	O
first	O
FMF	B
attack	O
at	O
age	O
40	O
years	O
or	O
more	O
were	O
identified	O
using	O
the	O
computerized	O
registry	O
of	O
our	O
FMF	B
clinic	O
,	O
and	O
then	O
thoroughly	O
interviewed	O
and	O
examined	O
.	O

The	O
control	O
group	O
consisted	O
of	O
40	O
consecutive	O
FMF	B
patients	O
,	O
who	O
arrived	O
at	O
the	O
FMF	B
clinic	O
for	O
their	O
regular	O
follow	O
-	O
up	O
visit	O
and	O
were	O
40	O
years	O
of	O
age	O
or	O
older	O
at	O
the	O
time	O
of	O
the	O
examination	O
.	O

The	O
severity	O
of	O
the	O
disease	O
in	O
patients	O
and	O
controls	O
was	O
determined	O
using	O
a	O
modified	O
score	O
,	O
developed	O
previously	O
.	O

Mutational	O
analysis	O
in	O
the	O
FMF	B
gene	O
was	O
performed	O
using	O
a	O
commercial	O
kit	O
.	O

Only	O
20	O
of	O
4000	O
(	O
0	O
.	O
5	O
%	O
)	O
patients	O
had	O
late	O
-	O
onset	O
FMF	B
.	O

These	O
patients	O
were	O
mostly	O
men	O
,	O
of	O
non	O
-	O
North	O
African	O
origin	O
,	O
P	O
<	O
0	O
.	O
05	O
compared	O
to	O
controls	O
.	O

All	O
had	O
abdominal	O
attacks	O
and	O
in	O
most	O
these	O
were	O
the	O
only	O
manifestation	O
of	O
their	O
disease	O
,	O
P	O
<	O
0	O
.	O
001	O
001	O
.	O

None	O
had	O
chronic	O
or	O
prolonged	O
manifestations	O
of	O
FMF	B
,	O
for	O
example	O
,	O
amyloidosis	B
,	O
chronic	B
arthritis	I
,	O
or	O
protracted	O
myalgia	B
,	O
P	O
<	O
0	O
.	O
001	O
.	O

The	O
response	O
to	O
treatment	O
was	O
good	O
despite	O
using	O
low	O
colchicine	O
dose	O
,	O
P	O
<	O
0	O
.	O
05	O
.	O

The	O
overall	O
severity	O
score	O
indicated	O
a	O
mild	O
disease	O
,	O
P	O
<	O
0	O
.	O
001	O
.	O

Mutational	O
analysis	O
revealed	O
absence	O
of	O
M694V	O
homozygosity	O
,	O
P	O
<	O
0	O
.	O
01	O
,	O
compared	O
to	O
our	O
regular	O
FMF	B
population	O
.	O

We	O
conclude	O
that	O
the	O
onset	O
of	O
FMF	B
in	O
a	O
late	O
age	O
defines	O
a	O
milder	O
form	O
of	O
disease	O
with	O
typical	O
clinical	O
,	O
demographic	O
,	O
and	O
molecular	O
genetic	O
characteristics	O

Meiotic	O
segregation	O
analysis	O
of	O
RB1	O
alleles	O
in	O
retinoblastoma	B
pedigrees	O
by	O
use	O
of	O
single	O
-	O
sperm	O
typing	O
.	O

In	O
hereditary	B
retinoblastoma	I
,	O
different	O
epidemiological	O
studies	O
have	O
indicated	O
a	O
preferential	O
paternal	O
transmission	O
of	O
mutant	O
retinoblastoma	B
alleles	O
to	O
offspring	O
,	O
suggesting	O
the	O
occurrence	O
of	O
a	O
meiotic	O
drive	O
.	O

To	O
investigate	O
this	O
mechanism	O
,	O
we	O
analyzed	O
sperm	O
samples	O
from	O
six	O
individuals	O
from	O
five	O
unrelated	O
families	O
affected	O
with	O
hereditary	B
retinoblastoma	I
.	O

Single	O
-	O
sperm	O
typing	O
techniques	O
were	O
performed	O
for	O
each	O
sample	O
by	O
study	O
of	O
two	O
informative	O
short	O
tandem	O
repeats	O
located	O
either	O
in	O
or	O
close	O
to	O
the	O
retinoblastoma	B
gene	O
(	O
RB1	O
)	O
.	O

The	O
segregation	O
probability	O
of	O
mutant	O
RB1	O
alleles	O
in	O
sperm	O
samples	O
was	O
assessed	O
by	O
use	O
of	O
the	O
SPERMSEG	O
program	O
,	O
which	O
includes	O
experimental	O
parameters	O
,	O
recombination	O
fractions	O
between	O
the	O
markers	O
,	O
and	O
segregation	O
parameters	O
.	O

A	O
total	O
of	O
2	O
,	O
952	O
single	O
sperm	O
from	O
the	O
six	O
donors	O
were	O
analyzed	O
.	O

We	O
detected	O
a	O
significant	O
segregation	O
distortion	O
in	O
the	O
data	O
as	O
a	O
whole	O
(	O
P	O
=	O
.	O
0099	O
)	O
and	O
a	O
significant	O
heterogeneity	O
in	O
the	O
segregation	O
rate	O
across	O
donors	O
(	O
.	O
0092	O
)	O
.	O

Further	O
analysis	O
shows	O
that	O
this	O
result	O
can	O
be	O
explained	O
by	O
segregation	O
distortion	O
in	O
favor	O
of	O
the	O
normal	O
allele	O
in	O
one	O
donor	O
only	O
and	O
that	O
it	O
does	O
not	O
provide	O
evidence	O
of	O
a	O
significant	O
segregation	O
distortion	O
in	O
the	O
other	O
donors	O
.	O

The	O
segregation	O
distortion	O
favoring	O
the	O
mutant	O
RB1	O
allele	O
does	O
not	O
seem	O
to	O
occur	O
during	O
spermatogenesis	O
,	O
and	O
,	O
thus	O
,	O
meiotic	O
drive	O
may	O
result	O
either	O
from	O
various	O
mechanisms	O
,	O
including	O
a	O
fertilization	O
advantage	O
or	O
a	O
better	O
mobility	O
in	O
sperm	O
bearing	O
a	O
mutant	O
RB1	O
gene	O
,	O
or	O
from	O
the	O
existence	O
of	O
a	O
defectively	O
imprinted	O
gene	O
located	O
on	O
the	O
human	O
X	O
chromosome	O
.	O

Atm	O
and	O
Bax	O
cooperate	O
in	O
ionizing	O
radiation	O
-	O
induced	O
apoptosis	O
in	O
the	O
central	O
nervous	O
system	O
.	O

Ataxia	B
-	I
telangiectasia	I
is	O
a	O
hereditary	B
multisystemic	I
disease	I
resulting	O
from	O
mutations	O
of	O
ataxia	B
telangiectasia	I
,	O
mutated	O
(	O
ATM	O
)	O
and	O
is	O
characterized	O
by	O
neurodegeneration	B
,	O
cancer	B
,	O
immune	B
defects	I
,	O
and	O
hypersensitivity	B
to	I
ionizing	I
radiation	I
.	O

The	O
molecular	O
details	O
of	O
ATM	O
function	O
in	O
the	O
nervous	O
system	O
are	O
unclear	O
,	O
although	O
the	O
neurological	B
lesion	I
in	O
ataxia	B
-	I
telangiectasia	I
becomes	O
apparent	O
early	O
in	O
life	O
,	O
suggesting	O
a	O
developmental	O
origin	O
.	O

The	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
of	O
Atm	O
-	O
null	O
mice	O
shows	O
a	O
pronounced	O
defect	O
in	O
apoptosis	O
induced	O
by	O
genotoxic	O
stress	O
,	O
suggesting	O
ATM	O
functions	O
to	O
eliminate	O
neurons	O
with	O
excessive	O
genomic	O
damage	O
.	O

Here	O
,	O
we	O
report	O
that	O
the	O
death	O
effector	O
Bax	O
is	O
required	O
for	O
a	O
large	O
proportion	O
of	O
Atm	O
-	O
dependent	O
apoptosis	O
in	O
the	O
developing	O
CNS	O
after	O
ionizing	O
radiation	O
(	O
IR	O
)	O
.	O

Although	O
many	O
of	O
the	O
same	O
regions	O
of	O
the	O
CNS	O
in	O
both	O
Bax-	O
/	O
-	O
and	O
Atm-	O
/	O
-	O
mice	O
were	O
radioresistant	O
,	O
mice	O
nullizygous	O
for	O
both	O
Bax	O
and	O
Atm	O
showed	O
additional	O
reduction	O
in	O
IR	O
-	O
induced	O
apoptosis	O
in	O
the	O
CNS	O
.	O

Therefore	O
,	O
although	O
the	O
major	O
IR	O
-	O
induced	O
apoptotic	O
pathway	O
in	O
the	O
CNS	O
requires	O
Atm	O
and	O
Bax	O
,	O
a	O
p53-dependent	O
collateral	O
pathway	O
exists	O
that	O
has	O
both	O
Atm-	O
and	O
Bax	O
-	O
independent	O
branches	O
.	O

Further	O
,	O
Atm-	O
and	O
Bax	O
-	O
dependent	O
apoptosis	O
in	O
the	O
CNS	O
also	O
required	O
caspase-3	O
activation	O
.	O

These	O
data	O
implicate	O
Bax	O
and	O
caspase-3	O
as	O
death	O
effectors	O
in	O
neurodegenerative	O
pathways	O
..	O

ATM	O
-	O
heterozygous	O
germline	O
mutations	O
contribute	O
to	O
breast	B
cancer	I
-	O
susceptibility	O
.	O

Approximately	O
0	O
.	O
5	O
%	O
-1	O
%	O
of	O
the	O
general	O
population	O
has	O
been	O
estimated	O
to	O
be	O
heterozygous	O
for	O
a	O
germline	O
mutation	O
in	O
the	O
ATM	O
gene	O
.	O

Mutations	O
in	O
the	O
ATM	O
gene	O
are	O
responsible	O
for	O
the	O
autosomal	B
recessive	I
disorder	I
ataxia	B
-	I
telangiectasia	I
(	O
A	B
-	I
T	I
)	O
(	O
MIM	O
208900	O
)	O
.	O

The	O
finding	O
that	O
ATM	O
-	O
heterozygotes	O
have	O
an	O
increased	O
relative	O
risk	O
for	O
breast	B
cancer	I
was	O
supported	O
by	O
some	O
studies	O
but	O
not	O
confirmed	O
by	O
others	O
.	O

In	O
view	O
of	O
this	O
discrepancy	O
,	O
we	O
examined	O
the	O
frequency	O
of	O
ATM	O
germline	O
mutations	O
in	O
a	O
selected	O
group	O
of	O
Dutch	O
patients	O
with	O
breast	B
cancer	I
.	O

We	O
have	O
analyzed	O
ATM	O
germline	O
mutations	O
in	O
normal	O
blood	O
lymphocytes	O
,	O
using	O
the	O
protein	O
-	O
truncation	O
test	O
followed	O
by	O
genomic	O
-	O
sequence	O
analysis	O
.	O

A	O
high	O
percentage	O
of	O
ATM	O
germline	O
mutations	O
was	O
demonstrated	O
among	O
patients	O
with	O
sporadic	B
breast	I
cancer	I
.	O

The	O
82	O
patients	O
included	O
in	O
this	O
study	O
had	O
developed	O
breast	B
cancer	I
at	O
age	O
<	O
45	O
and	O
had	O
survived	O
>	O
/=	O
5	O
years	O
(	O
mean	O
15	O
years	O
)	O
,	O
and	O
in	O
33	O
(	O
40	O
%	O
)	O
of	O
the	O
patients	O
a	O
contralateral	O
breast	O
tumor	O
had	O
been	O
diagnosed	O
.	O

Among	O
these	O
patients	O
we	O
identified	O
seven	O
(	O
8	O
.	O
5	O
%	O
)	O
ATM	O
germline	O
mutations	O
,	O
of	O
which	O
five	O
are	O
distinct	O
.	O

One	O
splice	O
-	O
site	O
mutation	O
(	O
IVS10	O
-	O
6T--	O
>	O
G	O
)	O
was	O
detected	O
three	O
times	O
in	O
our	O
series	O
.	O

Four	O
heterozygous	O
carriers	O
were	O
patients	O
with	O
bilateral	O
breast	O
cancer	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
mutations	O
identified	O
in	O
this	O
study	O
are	O
""""	O
A	O
-	O
T	O
disease	O
-	O
causing	O
""""	O
mutations	O
that	O
might	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
breast	O
cancer	O
in	O
heterozygotes	O
.	O

We	O
conclude	O
that	O
ATM	O
heterozygotes	O
have	O
an	O
approximately	O
ninefold	O
-	O
increased	O
risk	O
of	O
developing	O
a	O
type	O
of	O
breast	O
cancer	O
characterized	O
by	O
frequent	O
bilateral	O
occurrence	O
,	O
early	O
age	O
at	O
onset	O
,	O
and	O
long	O
-	O
term	O
survival	O
.	O

The	O
specific	O
characteristics	O
of	O
our	O
population	O
of	O
patients	O
may	O
explain	O
why	O
such	O
a	O
high	O
frequency	O
was	O
not	O
found	O
in	O
other	O
series	O
.	O

hCds1-mediated	O
phosphorylation	O
of	O
BRCA1	O
regulates	O
the	O
DNA	O
damage	O
response	O
.	O

Mutations	O
in	O
the	O
BRCA1	O
(	O
ref	O
.	O

1	O
)	O
tumour	B
suppressor	O
gene	O
are	O
found	O
in	O
almost	O
all	O
of	O
the	O
families	O
with	O
inherited	B
breast	I
and	I
ovarian	I
cancers	I
and	O
about	O
half	O
of	O
the	O
families	O
with	O
only	O
breast	B
cancer	I
.	O

Although	O
the	O
biochemical	O
function	O
of	O
BRCA1	O
is	O
not	O
well	O
understood	O
,	O
it	O
is	O
important	O
for	O
DNA	O
damage	O
repair	O
and	O
cell	O
-	O
cycle	O
checkpoint	O
.	O

BRCA1	O
exists	O
in	O
nuclear	O
foci	O
but	O
is	O
hyperphosphorylated	O
and	O
disperses	O
after	O
DNA	O
damage	O
.	O

It	O
is	O
not	O
known	O
whether	O
BRCA1	O
phosphorylation	O
and	O
dispersion	O
and	O
its	O
function	O
in	O
DNA	O
damage	O
response	O
are	O
related	O
.	O

In	O
yeast	O
the	O
DNA	O
damage	O
response	O
and	O
the	O
replication	O
-	O
block	O
checkpoint	O
are	O
mediated	O
partly	O
through	O
the	O
Cds1	O
kinase	O
family	O
.	O

Here	O
we	O
report	O
that	O
the	O
human	O
Cds1	O
kinase	O
(	O
hCds1	O
/	O
Chk2	O
)	O
regulates	O
BRCA1	O
function	O
after	O
DNA	O
damage	O
by	O
phosphorylating	O
serine	O
988	O
of	O
BRCA1	O
.	O

We	O
show	O
that	O
hCds1	O
and	O
BRCA1	O
interact	O
and	O
co	O
-	O
localize	O
within	O
discrete	O
nuclear	O
foci	O
but	O
separate	O
after	O
gamma	O
irradiation	O
.	O

Phosphorylation	O
of	O
BRCA1	O
at	O
serine	O
988	O
is	O
required	O
for	O
the	O
release	O
of	O
BRCA1	O
from	O
hCds1	O
.	O

This	O
phosphorylation	O
is	O
also	O
important	O
for	O
the	O
ability	O
of	O
BRCA1	O
to	O
restore	O
survival	O
after	O
DNA	O
damage	O
in	O
the	O
BRCA1-mutated	O
cell	O
line	O
HCC1937	O
..	O

Clinicopathologic	O
features	O
of	O
BRCA	B
-	I
linked	I
and	I
sporadic	I
ovarian	I
cancer	I
.	O

CONTEXT	O
Most	O
hereditary	B
ovarian	I
cancers	I
are	O
associated	O
with	O
germline	O
mutations	O
in	O
BRCA1	O
or	O
BRCA2	O
.	O

Attempts	O
to	O
define	O
the	O
clinical	O
significance	O
of	O
BRCA	O
mutation	O
status	O
in	O
ovarian	B
cancer	I
have	O
produced	O
conflicting	O
results	O
,	O
especially	O
regarding	O
survival	O
.	O

OBJECTIVE	O
To	O
determine	O
whether	O
hereditary	B
ovarian	I
cancers	I
have	O
distinct	O
clinical	O
and	O
pathological	O
features	O
compared	O
with	O
sporadic	B
(	I
nonhereditary	I
)	I
ovarian	I
cancers	I
.	O

DESIGN	O
AND	O
SETTING	O
Retrospective	O
cohort	O
study	O
of	O
a	O
consecutive	O
series	O
of	O
933	O
ovarian	B
cancers	I
diagnosed	O
and	O
treated	O
at	O
our	O
institution	O
,	O
which	O
is	O
a	O
comprehensive	O
cancer	B
center	O
as	O
designated	O
by	O
the	O
National	O
Cancer	B
Institute	O
,	O
over	O
a	O
12-year	O
period	O
(	O
December	O
1986	O
to	O
August	O
1998	O
)	O
.	O

PATIENTS	O
The	O
study	O
was	O
restricted	O
to	O
patients	O
of	O
Jewish	O
origin	O
because	O
of	O
the	O
ease	O
of	O
BRCA1	O
and	O
BRCA2	O
genotyping	O
in	O
this	O
ethnic	O
group	O
.	O

From	O
the	O
189	O
patients	O
who	O
identified	O
themselves	O
as	O
Jewish	O
,	O
88	O
hereditary	O
cases	O
were	O
identified	O
with	O
the	O
presence	O
of	O
a	O
germline	O
founder	O
mutation	O
in	O
BRCA1	O
or	O
BRCA2	O
.	O

The	O
remaining	O
101	O
cases	O
from	O
the	O
same	O
series	O
not	O
associated	O
with	O
a	O
BRCA	O
mutation	O
and	O
2	O
additional	O
groups	O
(	O
Gynecologic	O
Oncology	O
Group	O
protocols	O
52	O
and	O
111	O
)	O
with	O
ovarian	B
cancer	I
from	O
clinical	O
trials	O
(	O
for	O
the	O
survival	O
analysis	O
)	O
were	O
included	O
for	O
comparison	O
.	O

MAIN	O
OUTCOME	O
MEASURES	O
Age	O
at	O
diagnosis	O
,	O
surgical	O
stage	O
,	O
histologic	O
cell	O
type	O
and	O
grade	O
,	O
and	O
surgical	O
outcome	O
;	O
and	O
response	O
to	O
chemotherapy	O
and	O
survival	O
for	O
advanced	O
-	O
stage	O
(	O
II	O
and	O
IV	O
)	O
cases	O
.	O

RESULTS	O
Hereditary	B
cancers	I
were	O
rarely	O
diagnosed	O
before	O
age	O
40	O
years	O
and	O
were	O
common	O
after	O
age	O
60	O
years	O
,	O
with	O
mean	O
age	O
at	O
diagnosis	O
being	O
significantly	O
younger	O
for	O
BRCA1-	O
vs	O
BRCA2-linked	O
patients	O
(	O
54	O
vs	O
62	O
years	O
;	O
P	O
=	O
.	O
04	O
)	O
.	O

Histology	O
,	O
grade	O
,	O
stage	O
,	O
and	O
success	O
of	O
cytoreductive	O
surgery	O
were	O
similar	O
for	O
hereditary	O
and	O
sporadic	O
cases	O
.	O

The	O
hereditary	O
group	O
had	O
a	O
longer	O
disease	O
-	O
free	O
interval	O
following	O
primary	O
chemotherapy	O
in	O
comparison	O
with	O
the	O
nonhereditary	O
group	O
,	O
with	O
a	O
median	O
time	O
to	O
recurrence	O
of	O
14	O
months	O
and	O
7	O
months	O
,	O
respectively	O
(	O
P	O
<	O
.	O

001	O
)	O
.	O

Those	O
with	O
hereditary	B
cancers	I
had	O
improved	O
survival	O
compared	O
with	O
the	O
nonhereditary	O
group	O
(	O
P	O
=	O
.	O
004	O
)	O
.	O

For	O
stage	B
III	I
cancers	I
,	O
BRCA	O
mutation	O
status	O
was	O
an	O
independent	O
prognostic	O
variable	O
(	O
P	O
=	O
.	O
03	O
)	O
.	O

CONCLUSIONS	O
Although	O
BRCA	B
-	I
associated	I
hereditary	I
ovarian	I
cancers	I
in	O
this	O
population	O
have	O
surgical	O
and	O
pathological	O
characteristics	O
similar	O
to	O
those	O
of	O
sporadic	B
cancers	I
,	O
advanced	B
-	I
stage	I
hereditary	I
cancer	I
patients	O
survive	O
longer	O
than	O
nonhereditary	B
cancer	I
patients	O
.	O

Age	O
penetrance	O
is	O
greater	O
for	O
BRCA1-linked	B
than	I
for	I
BRCA2-linked	I
cancers	I
in	O
this	O
population	O
.	O

Expression	O
and	O
imprinting	O
of	O
MAGEL2	O
suggest	O
a	O
role	O
in	O
Prader	B
-	I
willi	I
syndrome	I
and	O
the	O
homologous	O
murine	O
imprinting	O
phenotype	O
.	O

Prader	B
-	I
Willi	I
syndrome	I
(	O
PWS	B
)	O
is	O
caused	O
by	O
the	O
loss	O
of	O
expression	O
of	O
imprinted	O
genes	O
in	O
chromosome	O
15q11-q13	O
.	O

Affected	O
individuals	O
exhibit	O
neonatal	B
hypotonia	I
,	O
developmental	B
delay	I
and	O
childhood	B
-	I
onset	I
obesity	I
.	O

Necdin	O
,	O
a	O
protein	O
implicated	O
in	O
the	O
terminal	O
differentiation	O
of	O
neurons	O
,	O
is	O
the	O
only	O
PWS	B
candidate	O
gene	O
to	O
reduce	O
viability	O
when	O
disrupted	O
in	O
a	O
mouse	O
model	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
characterized	O
MAGEL2	O
(	O
also	O
known	O
as	O
NDNL1	O
)	O
,	O
a	O
gene	O
with	O
51	O
%	O
amino	O
acid	O
sequence	O
similarity	O
to	O
necdin	O
and	O
located	O
41	O
kb	O
distal	O
to	O
NDN	O
in	O
the	O
PWS	B
deletion	O
region	O
.	O

MAGEL2	O
is	O
expressed	O
predominantly	O
in	O
brain	O
,	O
the	O
primary	O
tissue	O
affected	O
in	O
PWS	B
and	O
in	O
several	O
fetal	O
tissues	O
as	O
shown	O
by	O
northern	O
blot	O
analysis	O
.	O

MAGEL2	O
is	O
imprinted	O
with	O
monoallelic	O
expression	O
in	O
control	O
brain	O
,	O
and	O
paternal	O
-	O
only	O
expression	O
in	O
the	O
central	O
nervous	O
system	O
as	O
demonstrated	O
by	O
its	O
lack	O
of	O
expression	O
in	O
brain	O
from	O
a	O
PWS	B
-	O
affected	O
individual	O
.	O

The	O
orthologous	O
mouse	O
gene	O
(	O
Magel2	O
)	O
is	O
located	O
within	O
150	O
kb	O
of	O
NDN	O
,	O
is	O
imprinted	O
with	O
paternal	O
-	O
only	O
expression	O
and	O
is	O
expressed	O
predominantly	O
in	O
late	O
developmental	O
stages	O
and	O
adult	O
brain	O
as	O
shown	O
by	O
northern	O
blotting	O
,	O
RT	O
-	O
PCR	O
and	O
whole	O
-	O
mount	O
RNA	O
in	O
situ	O
hybridization	O
.	O

Magel2	O
distribution	O
partially	O
overlaps	O
that	O
of	O
NDN	O
,	O
with	O
strong	O
expression	O
being	O
detected	O
in	O
the	O
central	O
nervous	O
system	O
in	O
mid	O
-	O
gestation	O
mouse	O
embryos	O
by	O
in	O
situ	O
hybridization	O
.	O

We	O
hypothesize	O
that	O
,	O
although	O
loss	O
of	O
necdin	O
expression	O
may	O
be	O
important	O
in	O
the	O
neonatal	O
presentation	O
of	O
PWS	B
,	O
loss	O
of	O
MAGEL2	O
may	O
be	O
critical	O
to	O
abnormalities	B
in	I
brain	I
development	I
and	O
dysmorphic	B
features	I
in	O
individuals	O
with	O
PWS	B
..	O

Retinoschisin	O
,	O
the	O
X	B
-	I
linked	I
retinoschisis	I
protein	O
,	O
is	O
a	O
secreted	O
photoreceptor	O
protein	O
,	O
and	O
is	O
expressed	O
and	O
released	O
by	O
Weri	O
-	O
Rb1	O
cells	O
.	O

X	B
-	I
linked	I
retinoschisis	I
is	O
characterized	O
by	O
microcystic	O
-	O
like	O
changes	O
of	O
the	O
macular	O
region	O
and	O
schisis	O
within	O
the	O
inner	O
retinal	O
layers	O
,	O
leading	O
to	O
visual	B
deterioration	I
in	O
males	O
.	O

Many	O
missense	O
and	O
protein	O
-	O
truncating	O
mutations	O
of	O
the	O
causative	O
gene	O
RS1	O
have	O
now	O
been	O
identified	O
and	O
are	O
thought	O
to	O
be	O
inactivating	O
.	O

RS1	O
encodes	O
a	O
224	O
amino	O
acid	O
protein	O
,	O
retinoschisin	O
,	O
which	O
contains	O
a	O
discoidin	O
domain	O
but	O
is	O
of	O
unknown	O
function	O
.	O

We	O
have	O
generated	O
a	O
polyclonal	O
antibody	O
against	O
a	O
peptide	O
from	O
a	O
unique	O
region	O
within	O
retinoschisin	O
,	O
which	O
detects	O
a	O
protein	O
of	O
approximately	O
28	O
kDa	O
in	O
retinal	O
samples	O
reduced	O
with	O
dithiothreitol	O
,	O
but	O
multimers	O
sized	O
>	O
40	O
kDa	O
under	O
non	O
-	O
reducing	O
conditions	O
.	O

A	O
screen	O
of	O
human	O
tissues	O
with	O
this	O
antibody	O
reveals	O
retinoschisin	O
to	O
be	O
retina	O
specific	O
and	O
the	O
antibody	O
detects	O
a	O
protein	O
of	O
similar	O
size	O
in	O
bovine	O
and	O
murine	O
retinae	O
.	O

We	O
investigated	O
the	O
expression	O
pattern	O
in	O
the	O
retina	O
of	O
both	O
RS1	O
mRNA	O
(	O
using	O
in	O
situ	O
hybridization	O
with	O
riboprobes	O
)	O
and	O
retinoschisin	O
(	O
using	O
immunohistochemistry	O
)	O
.	O

The	O
antisense	O
riboprobe	O
detected	O
RS1	O
mRNA	O
only	O
in	O
the	O
photoreceptor	O
layer	O
but	O
the	O
protein	O
product	O
of	O
the	O
gene	O
was	O
present	O
both	O
in	O
the	O
photoreceptors	O
and	O
within	O
the	O
inner	O
portions	O
of	O
the	O
retina	O
.	O

Furthermore	O
,	O
differentiated	O
retinoblastoma	B
cells	O
(	O
Weri	O
-	O
Rb1	O
cells	O
)	O
were	O
found	O
to	O
express	O
RS1	O
mRNA	O
and	O
to	O
release	O
retinoschisin	O
.	O

These	O
results	O
suggest	O
that	O
retinoschisin	O
is	O
released	O
by	O
photo	O
-	O
receptors	O
and	O
has	O
functions	O
within	O
the	O
inner	O
retinal	O
layers	O
.	O

Thus	O
,	O
X	B
-	I
linked	I
retinoschisis	I
is	O
caused	O
by	O
abnormalities	O
in	O
a	O
putative	O
secreted	O
photoreceptor	O
protein	O
and	O
is	O
the	O
first	O
example	O
of	O
a	O
secreted	O
photo	O
-	O
receptor	O
protein	O
associated	O
with	O
a	O
retinal	B
dystrophy	I
..	O

Study	O
of	O
the	O
voltage	O
-	O
gated	O
sodium	O
channel	O
beta	O
1	O
subunit	O
gene	O
(	O
SCN1B	O
)	O
in	O
the	O
benign	B
familial	I
infantile	I
convulsions	I
syndrome	I
(	O
BFIC	B
)	O
.	O

Benign	B
familial	I
infantile	I
convulsions	I
(	O
BFIC	B
)	O
is	O
a	O
rare	O
autosomal	B
dominant	I
epilepsy	I
syndrome	I
.	O

This	O
syndrome	O
has	O
been	O
recently	O
described	O
in	O
Italian	O
and	O
French	O
pedigrees	O
.	O

Patients	O
present	O
with	O
partial	O
,	O
then	O
generalized	O
seizures	O
,	O
with	O
onset	O
at	O
age	O
three	O
months	O
.	O

The	O
seizures	O
usually	O
spontaneously	O
cease	O
after	O
one	O
year	O
without	O
treatment	O
,	O
leaving	O
no	O
neurological	B
abnormalities	I
.	O

We	O
have	O
mapped	O
BFIC	B
to	O
chromosome	O
19q	O
in	O
five	O
Italian	O
pedigrees	O
.	O

The	O
sodium	O
channel	O
beta1	O
subunit	O
gene	O
(	O
SCN1B	O
)	O
maps	O
to	O
this	O
candidate	O
region	O
and	O
has	O
been	O
shown	O
to	O
be	O
involved	O
in	O
one	O
Australian	O
pedigree	O
with	O
generalized	B
epilepsy	I
and	I
febrile	I
seizures	I
""""	I
plus	I
""""	I
(	O
GEFS	O
+	O
)	O
.	O

In	O
this	O
family	O
,	O
a	O
missense	O
mutation	O
in	O
SCN1B	O
cosegregates	O
with	O
the	O
GEFS	O
+	O
phenotype	O
.	O

BFIC	B
and	O
GEFS	O
+	O
have	O
clinical	O
features	O
in	O
common	O
,	O
therefore	O
SCN1B	O
is	O
a	O
candidate	O
gene	O
for	O
BFIC	B
.	O

We	O
studied	O
SCN1B	O
exons	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
,	O
using	O
four	O
SSCP	O
methods	O
in	O
10	O
Caucasian	O
BFIC	B
probands	O
of	O
Western	O
Europe	O
.	O

We	O
found	O
no	O
exon	O
variants	O
.	O

One	O
variant	O
was	O
identified	O
in	O
intron	O
5	O
(	O
IVS5	O
-	O
10C	O
>	O
G	O
)	O
,	O
which	O
did	O
not	O
segregate	O
with	O
BFIC	B
and	O
was	O
observed	O
in	O
9	O
.	O
2	O
%	O
controls	O
.	O

A	O
second	O
variant	O
in	O
intron	O
5	O
was	O
identified	O
(	O
IVS5	O
+	O
30	O
G	O
>	O
A	O
)	O
.	O

It	O
was	O
rare	O
,	O
as	O
not	O
observed	O
in	O
controls	O
,	O
but	O
not	O
segregating	O
with	O
the	O
BFIC	B
phenotype	O
.	O

Inactivation	O
of	O
germline	O
mutant	O
APC	B
alleles	O
by	O
attenuated	O
somatic	O
mutations	O
:	O
a	O
molecular	O
genetic	O
mechanism	O
for	O
attenuated	B
familial	I
adenomatous	I
polyposis	I
.	O

Germline	O
mutations	O
of	O
the	O
adenomatous	B
polyposis	I
coli	I
(	I
APC	I
)	I
tumor	I
-	O
suppressor	O
gene	O
result	O
in	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
.	O

Patients	O
with	O
FAP	B
typically	O
develop	O
hundreds	O
to	O
thousands	O
of	O
benign	B
colorectal	I
tumors	I
and	O
early	O
-	O
onset	O
colorectal	B
cancer	I
.	O

A	O
subset	O
of	O
germline	O
APC	B
mutations	O
results	O
in	O
an	O
attenuated	B
FAP	I
(	O
AFAP	B
)	O
phenotype	O
,	O
in	O
which	O
patients	O
develop	O
fewer	O
tumors	B
and	O
develop	O
them	O
at	O
an	O
older	O
age	O
.	O

Although	O
a	O
genotype	O
-	O
phenotype	O
correlation	O
between	O
the	O
locations	O
of	O
APC	B
germline	O
mutations	O
and	O
the	O
development	O
of	O
AFAP	B
has	O
been	O
well	O
documented	O
,	O
the	O
mechanism	O
for	O
AFAP	B
has	O
not	O
been	O
well	O
defined	O
.	O

We	O
investigated	O
the	O
mechanism	O
for	O
AFAP	B
in	O
patients	O
carrying	O
a	O
mutant	O
APC	B
allele	O
(	O
APC	O
(	O
AS9	O
)	O
)	O
that	O
has	O
a	O
mutation	O
in	O
the	O
alternatively	O
spliced	O
region	O
of	O
exon	O
9	O
.	O

APC	O
(	O
AS9	O
)	O
was	O
found	O
to	O
down	O
-	O
regulate	O
beta	O
-	O
catenin	O
-	O
regulated	O
transcription	O
,	O
the	O
major	O
tumor	B
-	O
suppressor	O
function	O
of	O
APC	O
,	O
as	O
did	O
the	O
wild	O
-	O
type	O
APC	O
.	O

Mutation	O
analysis	O
showed	O
that	O
both	O
APC	O
(	O
AS9	O
)	O
and	O
the	O
wild	O
-	O
type	O
APC	B
alleles	O
were	O
somatically	O
mutated	O
in	O
most	O
colorectal	B
tumors	I
from	O
these	O
patients	O
.	O

Functional	O
analysis	O
showed	O
that	O
4666insA	O
,	O
a	O
common	O
somatic	O
mutation	O
in	O
APC	O
(	O
AS9	O
)	O
in	O
these	O
tumors	B
,	O
did	O
not	O
inactivate	O
the	O
wild	O
-	O
type	O
APC	O
.	O

Our	O
results	O
indicate	O
that	O
carriers	O
of	O
APC	O
(	O
AS9	O
)	O
develop	O
fewer	O
colorectal	B
tumors	I
than	O
do	O
typical	O
patients	O
with	O
FAP	B
because	O
somatic	O
inactivation	O
of	O
both	O
APC	B
alleles	O
is	O
necessary	O
for	O
colorectal	O
tumorigenesis	O
.	O

However	O
,	O
these	O
patients	O
develop	O
colorectal	B
tumors	I
more	O
frequently	O
than	O
does	O
the	O
general	O
population	O
because	O
APC	O
(	O
AS9	O
)	O
is	O
inactivated	O
by	O
mutations	O
that	O
do	O
not	O
inactivate	O
the	O
wild	O
-	O
type	O
APC	O
..	O

Amino	O
-	O
terminal	O
fragments	O
of	O
mutant	O
huntingtin	O
show	O
selective	O
accumulation	O
in	O
striatal	O
neurons	O
and	O
synaptic	O
toxicity	O
.	O

Huntington	B
disease	I
(	O
HD	B
)	O
is	O
caused	O
by	O
expansion	O
of	O
a	O
glutamine	O
repeat	O
in	O
the	O
amino	O
-	O
terminal	O
region	O
of	O
huntingtin	O
.	O

Despite	O
its	O
widespread	O
expression	O
,	O
mutant	O
huntingtin	O
induces	O
selective	O
neuronal	O
loss	O
in	O
striatal	O
neurons	O
.	O

Here	O
we	O
report	O
that	O
,	O
in	O
mutant	O
mice	O
expressing	O
HD	B
repeats	O
,	O
the	O
production	O
and	O
aggregation	O
of	O
N	O
-	O
terminal	O
huntingtin	O
fragments	O
preferentially	O
occur	O
in	O
HD	B
-	O
affected	O
neurons	O
and	O
their	O
processes	O
and	O
axonal	O
terminals	O
.	O

N	O
-	O
terminal	O
fragments	O
of	O
mutant	O
huntingtin	O
form	O
aggregates	O
and	O
induce	O
neuritic	B
degeneration	I
in	O
cultured	O
striatal	O
neurons	O
.	O

N	O
-	O
terminal	O
mutant	O
huntingtin	O
also	O
binds	O
to	O
synaptic	O
vesicles	O
and	O
inhibits	O
their	O
glutamate	O
uptake	O
in	O
vitro	O
.	O

The	O
specific	O
processing	O
and	O
accumulation	O
of	O
toxic	O
fragments	O
of	O
N	O
-	O
terminal	O
huntingtin	O
in	O
HD	B
-	O
affected	O
striatal	O
neurons	O
,	O
especially	O
in	O
their	O
neuronal	O
processes	O
and	O
axonal	O
terminals	O
,	O
may	O
contribute	O
to	O
the	O
selective	O
neuropathology	O
of	O
HD	B
..	O

Histidinemia	B
.	O

Classical	O
and	O
atypical	O
form	O
in	O
siblings	O
.	O

Two	O
brothers	O
,	O
6	O
and	O
13	O
years	O
old	O
,	O
had	O
histidinemia	B
.	O

On	O
the	O
basis	O
of	O
clinical	O
and	O
biochemical	O
observations	O
,	O
the	O
younger	O
boy	O
was	O
considered	O
to	O
have	O
a	O
classical	O
type	O
of	O
the	O
disease	O
,	O
while	O
the	O
older	O
boy	O
had	O
an	O
atypical	O
form	O
characterized	O
by	O
partial	O
impairment	O
of	O
the	O
skin	O
histidase	O
activity	O
and	O
a	O
moderately	O
prolonged	O
half	O
-	O
life	O
of	O
blood	O
histidine	O
.	O

The	O
mother	O
is	O
a	O
heterozygous	O
carrier	O
,	O
while	O
the	O
father	O
and	O
sister	O
seem	O
to	O
be	O
normal	O
..	O

Carrier	O
detection	O
of	O
pyruvate	B
carboxylase	I
deficiency	I
in	O
fibroblasts	O
and	O
lymphocytes	O
.	O

Pyruvate	O
carboxylase	O
(	O
E.	O
C.	O
6	O
.	O
4	O
.	O
1	O
.	O
1	O
)	O
activity	O
was	O
determined	O
in	O
the	O
circulating	O
peripheral	O
lymphocytes	O
and	O
cultured	O
skin	O
fibroblasts	O
from	O
the	O
family	O
of	O
a	O
patient	O
with	O
hepatic	O
,	O
cerebral	O
,	O
renal	O
cortical	O
,	O
leukocyte	O
,	O
and	O
fibroblast	O
pyruvate	B
carboxylase	I
deficiency	I
(	O
PC	B
Portland	I
deficiency	I
)	O
.	O

Lymphocyte	O
activities	O
were	O
mother	O
,	O
33	O
-	O
-39	O
%	O
;	O
father	O
,	O
11	O
-	O
-29	O
%	O
;	O
brother	O
,	O
82	O
-	O
-103	O
%	O
;	O
and	O
sister	O
,	O
38	O
-	O
-48	O
%	O
of	O
the	O
lowest	O
normal	O
.	O

Fibroblasts	O
from	O
the	O
patients	O
mother	O
and	O
father	O
had	O
42	O
and	O
34	O
%	O
,	O
respectively	O
,	O
of	O
the	O
activity	O
of	O
the	O
lowest	O
normal	O
.	O

These	O
data	O
demonstrate	O
that	O
the	O
disease	O
is	O
inherited	O
in	O
an	O
autosomal	O
recessive	O
manner	O
and	O
that	O
lymphocytes	O
and	O
fibroblasts	O
can	O
be	O
used	O
to	O
detect	O
carriers	O
.	O

Neither	O
pyruvate	O
carboxylase	O
nor	O
mitochondrial	O
PEPCK	O
activity	O
in	O
lymphocytes	O
was	O
increased	O
by	O
a	O
21-hr	O
fast	O
.	O

Prenatal	O
diagnosis	O
of	O
Wolman	B
disease	I
.	O

Two	O
pregnancies	O
at	O
risk	O
for	O
Wolman	B
disease	I
were	O
monitored	O
by	O
assay	O
and	O
electrophoresis	O
of	O
acid	O
lipase	O
in	O
cultured	O
amniotic	O
-	O
fluid	O
cells	O
.	O

Cells	O
from	O
patient	O
1	O
had	O
5	O
%	O
of	O
control	O
levels	O
of	O
acid	O
lipase	O
,	O
using	O
14C	O
-	O
triolein	O
as	O
substrate	O
;	O
however	O
,	O
when	O
artificial	O
substrates	O
(	O
esters	O
of	O
4-methylumbelliferone	O
and	O
p	O
-	O
nitrophenol	O
)	O
were	O
used	O
to	O
measure	O
acid	O
lipase	O
,	O
these	O
cells	O
had	O
30	O
%	O
of	O
control	O
levels	O
.	O

Electrophoresis	O
of	O
cell	O
extracts	O
revealed	O
the	O
absence	O
of	O
the	O
A	O
form	O
of	O
acid	O
lipase	O
,	O
consistent	O
with	O
the	O
diagnosis	O
of	O
Wolman	B
disease	I
.	O

Analysis	O
of	O
fetal	O
tissues	O
following	O
prostaglandin	O
termination	O
of	O
this	O
pregnancy	O
confirmed	O
the	O
diagnosis	O
.	O

Assay	O
of	O
fetal	O
-	O
skin	O
fibroblasts	O
with	O
14C	O
-	O
triolein	O
,	O
as	O
well	O
as	O
with	O
artificial	O
substrates	O
,	O
showed	O
marked	O
deficiency	O
of	O
acid	O
lipase	O
activity	O
.	O

Electrophoresis	O
of	O
fetal	O
-	O
tissue	O
extracts	O
also	O
demonstrated	O
the	O
absence	O
of	O
the	O
A	O
form	O
of	O
acid	O
lipase	O
.	O

Amniotic	O
-	O
fluid	O
cells	O
from	O
patient	O
2	O
showed	O
normal	O
levels	O
of	O
acid	O
lipase	O
with	O
all	O
substrates	O
tested	O
;	O
the	O
electrophoretic	O
pattern	O
of	O
acid	O
lipase	O
was	O
normal	O
.	O

The	O
results	O
suggest	O
that	O
the	O
prenatal	O
diagnosis	O
of	O
Wolman	B
disease	I
be	O
made	O
using	O
the	O
radioassay	O
of	O
acid	O
lipase	O
and/or	O
electrophoresis	O
..	O

A	O
71-kilodalton	O
protein	O
is	O
a	O
major	O
product	O
of	O
the	O
Duchenne	B
muscular	I
dystrophy	I
gene	O
in	O
brain	O
and	O
other	O
nonmuscle	O
tissues	O
.	O

The	O
known	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
gene	O
products	O
,	O
the	O
muscle-	O
and	O
brain	O
-	O
type	O
dystrophin	O
isoforms	O
,	O
are	O
427-kDa	O
proteins	O
translated	O
from	O
14-kilobase	O
(	O
kb	O
)	O
mRNAs	O
.	O

Recently	O
we	O
described	O
a	O
6	O
.	O

5-kb	O
mRNA	O
that	O
also	O
is	O
transcribed	O
from	O
the	O
DMD	B
gene	O
.	O

Cloning	O
and	O
in	O
vitro	O
transcription	O
and	O
translation	O
of	O
the	O
entire	O
coding	O
region	O
show	O
that	O
the	O
6	O
.	O

5-kb	O
mRNA	O
encodes	O
a	O
70	O
.	O

8-kDa	O
protein	O
that	O
is	O
a	O
major	O
product	O
of	O
the	O
DMD	B
gene	O
.	O

It	O
contains	O
the	O
C	O
-	O
terminal	O
and	O
the	O
cysteine	O
-	O
rich	O
domains	O
of	O
dystrophin	O
,	O
seven	O
additional	O
amino	O
acids	O
at	O
the	O
N	O
terminus	O
,	O
and	O
some	O
modifications	O
formed	O
by	O
alternative	O
splicing	O
in	O
the	O
C	O
-	O
terminal	O
domain	O
.	O

It	O
lacks	O
the	O
entire	O
large	O
domain	O
of	O
spectrin	O
-	O
like	O
repeats	O
and	O
the	O
actin	O
-	O
binding	O
N	O
-	O
terminal	O
domain	O
of	O
dystrophin	O
.	O

This	O
protein	O
is	O
the	O
major	O
DMD	B
gene	O
product	O
in	O
brain	O
and	O
other	O
nonmuscle	O
tissues	O
but	O
is	O
undetectable	O
in	O
skeletal	O
muscle	O
extracts	O
.	O

Detection	O
of	O
an	O
unstable	O
fragment	O
of	O
DNA	O
specific	O
to	O
individuals	O
with	O
myotonic	B
dystrophy	I
.	O

Myotonic	B
dystrophy	I
(	O
DM	B
)	O
is	O
the	O
most	O
common	O
form	O
of	O
adult	O
muscular	B
dystrophy	I
,	O
with	O
a	O
prevalence	O
of	O
2	O
-	O
14	O
per	O
100	O
,	O
000	O
individuals	O
.	O

The	O
disease	O
is	O
characterized	O
by	O
progressive	O
muscle	B
weakness	I
and	O
sustained	B
muscle	I
contraction	I
,	O
often	O
with	O
a	O
wide	O
range	O
of	O
accompanying	O
symptoms	O
.	O

The	O
age	O
at	O
onset	O
and	O
severity	O
of	O
the	O
disease	O
show	O
extreme	O
variation	O
,	O
both	O
within	O
and	O
between	O
families	O
.	O

Despite	O
its	O
clinical	O
variability	O
,	O
this	O
dominant	O
condition	O
segregates	O
as	O
a	O
single	O
locus	O
at	O
chromosome	O
19q13	O
.	O

3	O
in	O
every	O
population	O
studied	O
.	O

It	O
is	O
flanked	O
by	O
the	O
tightly	O
linked	O
genetic	O
markers	O
ERCC1	O
proximally	O
and	O
D19S51	O
distally	O
;	O
these	O
define	O
the	O
DM	B
critical	O
region	O
.	O

We	O
report	O
the	O
isolation	O
of	O
an	O
expressed	O
sequence	O
from	O
this	O
region	O
which	O
detects	O
a	O
DNA	O
fragment	O
that	O
is	O
larger	O
in	O
affected	O
individuals	O
than	O
in	O
normal	O
siblings	O
or	O
unaffected	O
controls	O
.	O

The	O
size	O
of	O
this	O
fragment	O
varies	O
between	O
affected	O
siblings	O
,	O
and	O
increases	O
in	O
size	O
through	O
generations	O
in	O
parallel	O
with	O
increasing	O
severity	O
of	O
the	O
disease	O
.	O

We	O
postulate	O
that	O
this	O
unstable	O
DNA	O
sequence	O
is	O
the	O
molecular	O
feature	O
that	O
underlies	O
DM	B
.	O

A	O
genetic	O
etiology	O
for	O
DiGeorge	B
syndrome	I
:	O
consistent	O
deletions	O
and	O
microdeletions	O
of	O
22q11	O
.	O

DiGeorge	B
syndrome	I
(	O
DGS	B
)	O
,	O
a	O
developmental	O
field	O
defect	O
of	O
the	O
third	O
and	O
fourth	O
pharyngeal	O
pouches	O
,	O
is	O
characterized	O
by	O
aplasia	B
or	I
hypoplasia	I
of	I
the	I
thymus	I
and	I
parathyroid	I
glands	I
and	O
by	O
conotruncal	B
cardiac	I
malformations	I
.	O

Cytogenetic	O
studies	O
support	O
the	O
presence	O
of	O
a	O
DGS	B
critical	O
region	O
in	O
band	O
22q11	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
the	O
results	O
of	O
clinical	O
,	O
cytogenetic	O
,	O
and	O
molecular	O
studies	O
of	O
14	O
patients	O
with	O
DGS	B
.	O

Chromosome	O
analysis	O
,	O
utilizing	O
high	O
-	O
resolution	O
banding	O
techniques	O
,	O
detected	O
interstitial	O
deletions	O
in	O
five	O
probands	O
and	O
was	O
inconclusive	O
for	O
a	O
deletion	O
in	O
three	O
probands	O
.	O

The	O
remaining	O
six	O
patients	O
had	O
normal	O
karyotypes	O
.	O

In	O
contrast	O
,	O
molecular	O
analysis	O
detected	O
DNA	O
deletions	O
in	O
all	O
14	O
probands	O
.	O

Two	O
of	O
10	O
loci	O
tested	O
,	O
D22S75	O
and	O
D22S259	O
,	O
are	O
deleted	O
in	O
all	O
14	O
patients	O
.	O

A	O
third	O
locus	O
,	O
D22S66	O
,	O
is	O
deleted	O
in	O
the	O
eight	O
DGS	B
probands	O
tested	O
.	O

Physical	O
mapping	O
using	O
somatic	O
cell	O
hybrids	O
places	O
D22S66	O
between	O
D22S75	O
and	O
D22S259	O
,	O
suggesting	O
that	O
it	O
should	O
be	O
deleted	O
in	O
the	O
remaining	O
six	O
cases	O
.	O

Parent	O
-	O
of	O
-	O
origin	O
studies	O
were	O
performed	O
in	O
five	O
families	O
.	O

Four	O
probands	O
failed	O
to	O
inherit	O
a	O
maternal	O
allele	O
,	O
and	O
one	O
failed	O
to	O
inherit	O
a	O
paternal	O
allele	O
.	O

On	O
the	O
basis	O
of	O
these	O
families	O
,	O
and	O
of	O
six	O
maternally	O
and	O
five	O
paternally	O
derived	O
unbalanced	O
-	O
translocation	O
DGS	B
probands	O
in	O
the	O
literature	O
,	O
parent	O
of	O
origin	O
or	O
imprinting	O
does	O
not	O
appear	O
to	O
play	O
an	O
important	O
role	O
in	O
the	O
pathogenesis	O
of	O
DGS	B
.	O

Deletion	O
of	O
the	O
same	O
three	O
loci	O
in	O
all	O
14	O
DGS	B
probands	O
begins	O
to	O
delineate	O
the	O
region	O
of	O
chromosome	O
22	O
critical	O
for	O
DGS	B
and	O
confirms	O
the	O
hypothesis	O
that	O
submicroscopic	O
deletions	O
of	O
22q11	O
are	O
etiologic	O
in	O
the	O
vast	O
majority	O
of	O
cases	O
..	O

Loss	O
of	O
normal	O
allele	O
of	O
the	O
APC	B
gene	O
in	O
an	O
adrenocortical	B
carcinoma	I
from	O
a	O
patient	O
with	O
familial	B
adenomatous	I
polyposis	I
.	O

Endocrine	B
neoplasms	I
have	O
been	O
reported	O
occasionally	O
in	O
patients	O
with	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
.	O

An	O
adrenocorotical	B
carcinoma	I
was	O
studied	O
in	O
a	O
patient	O
with	O
a	O
family	O
history	O
of	O
FAP	B
.	O

Loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
in	O
the	O
region	O
close	O
to	O
the	O
adenomatous	B
polyposis	I
coli	I
(	O
APC	B
)	O
gene	O
was	O
detected	O
in	O
this	O
carcinoma	B
,	O
and	O
evidence	O
was	O
obtained	O
that	O
there	O
was	O
a	O
loss	O
of	O
the	O
normal	O
allele	O
of	O
the	O
APC	B
gene	O
.	O

This	O
is	O
the	O
first	O
demonstration	O
of	O
LOH	O
at	O
the	O
APC	B
locus	O
in	O
adrenocortical	B
tumors	I
.	O

The	O
present	O
results	O
and	O
our	O
previous	O
data	O
on	O
LOH	O
in	O
a	O
recurring	O
desmoid	B
tumor	I
suggest	O
that	O
the	O
heterozygous	O
mutant	O
/	O
wild	O
-	O
type	O
condition	O
of	O
the	O
APC	B
gene	O
may	O
give	O
rise	O
to	O
benign	B
tumors	I
,	O
and	O
that	O
functional	O
loss	O
of	O
this	O
gene	O
leads	O
to	O
development	O
of	O
tumors	B
not	O
only	O
in	O
the	O
colon	O
but	O
also	O
in	O
other	O
various	O
parts	O
of	O
the	O
body	O
in	O
FAP	B
patients	O
..	O

New	O
variant	O
in	O
exon	O
3	O
of	O
the	O
proteolipid	O
protein	O
(	O
PLP	O
)	O
gene	O
in	O
a	O
family	O
with	O
Pelizaeus	B
-	I
Merzbacher	I
disease	I
.	O

A	O
C	O
--	O
greater	O
than	O
G	O
transversion	O
has	O
been	O
found	O
in	O
exon	O
3	O
of	O
the	O
PLP	O
gene	O
of	O
affected	O
males	O
and	O
their	O
mother	O
in	O
a	O
single	O
sibship	O
with	O
Pelizaeus	B
-	I
merzbacher	I
disease	I
(	O
PMD	B
)	O
.	O

The	O
transversion	O
should	O
not	O
result	O
in	O
an	O
amino	O
acid	O
change	O
in	O
the	O
protein	O
but	O
it	O
does	O
result	O
in	O
the	O
loss	O
of	O
a	O
HaeIII	O
restriction	O
endonuclease	O
cleavage	O
site	O
.	O

It	O
is	O
concordant	O
with	O
the	O
disease	O
in	O
this	O
family	O
.	O

One	O
-	O
hundred	O
-	O
ten	O
unrelated	O
X	O
chromosomes	O
are	O
negative	O
for	O
this	O
mutation	O
.	O

No	O
other	O
sequence	O
defect	O
was	O
found	O
in	O
the	O
PLP	O
exons	O
of	O
the	O
affected	O
males	O
.	O

The	O
cause	O
of	O
disease	O
in	O
this	O
family	O
remains	O
unknown	O
,	O
but	O
the	O
association	O
between	O
this	O
rare	O
mutation	O
and	O
PMD	B
is	O
intriguing	O
.	O

The	O
mutation	O
can	O
serve	O
as	O
a	O
marker	O
for	O
following	O
segregation	O
of	O
the	O
PLP	O
gene	O
..	O

The	O
intron	O
7	O
donor	O
splice	O
site	O
transition	O
:	O
a	O
second	O
Tay	B
-	I
Sachs	I
disease	I
mutation	O
in	O
French	O
Canada	O
.	O

Mutations	O
at	O
the	O
hexosaminidase	O
A	O
(	O
HEXA	O
)	O
gene	O
which	O
cause	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
have	O
elevated	O
frequency	O
in	O
the	O
Ashkenazi	O
Jewish	O
and	O
French	O
-	O
Canadian	O
populations	O
.	O

We	O
report	O
a	O
novel	O
TSD	B
allele	O
in	O
the	O
French	O
-	O
Canadian	O
population	O
associated	O
with	O
the	O
infantile	O
form	O
of	O
the	O
disease	O
.	O

The	O
mutation	O
,	O
a	O
G--	O
>	O
A	O
transition	O
at	O
the	O
+	O
1	O
position	O
of	O
intron	O
7	O
,	O
abolishes	O
the	O
donor	O
splice	O
site	O
.	O

Cultured	O
human	O
fibroblasts	O
from	O
a	O
compound	O
heterozygote	O
for	O
this	O
transition	O
(	O
and	O
for	O
a	O
deletion	O
mutation	O
)	O
produce	O
no	O
detectable	O
HEXA	O
mRNA	O
.	O

The	O
intron	O
7	O
+	O
1	O
mutation	O
occurs	O
in	O
the	O
base	O
adjacent	O
to	O
the	O
site	O
of	O
the	O
adult	O
-	O
onset	O
TSD	B
mutation	O
(	O
G805A	O
)	O
.	O

In	O
both	O
mutations	O
a	O
restriction	O
site	O
for	O
the	O
endonuclease	O
EcoRII	O
is	O
abolished	O
.	O

Unambiguous	O
diagnosis	O
,	O
therefore	O
,	O
requires	O
allele	O
-	O
specific	O
oligonucleotide	O
hybridization	O
to	O
distinguish	O
between	O
these	O
two	O
mutant	O
alleles	O
.	O

The	O
intron	O
7	O
+	O
1	O
mutation	O
has	O
been	O
detected	O
in	O
three	O
unrelated	O
families	O
.	O

Obligate	O
heterozygotes	O
for	O
the	O
intron	O
7	O
+	O
1	O
mutation	O
were	O
born	O
in	O
the	O
Saguenay	O
-	O
Lac	O
-	O
St	O
-	O
Jean	O
region	O
of	O
Quebec	O
.	O

The	O
most	O
recent	O
ancestors	O
common	O
to	O
obligate	O
carriers	O
of	O
this	O
mutation	O
were	O
from	O
the	O
Charlevoix	O
region	O
of	O
the	O
province	O
of	O
Quebec	O
.	O

This	O
mutation	O
thus	O
has	O
a	O
different	O
geographic	O
centre	O
of	O
diffusion	O
and	O
is	O
probably	O
less	O
common	O
than	O
the	O
exon	O
1	O
deletion	O
TSD	B
mutation	O
in	O
French	O
Canadians	O
.	O

Neither	O
mutation	O
has	O
been	O
detected	O
in	O
France	O
,	O
the	O
ancestral	O
homeland	O
of	O
French	O
Canada	O
..	O

Assignment	O
of	O
the	O
aspartylglucosaminidase	O
gene	O
(	O
AGA	O
)	O
to	O
4q33	O
-	O
---q35	O
based	O
on	O
decreased	O
activity	O
in	O
a	O
girl	O
with	O
a	O
46,XX	O
,	O
del	O
(	O
4	O
)	O
(	O
q33	O
)	O
karyotype	O
.	O

Aspartylglucosaminuria	B
(	O
AGU	B
)	O
is	O
a	O
recessive	O
autosomally	O
inherited	O
lysosomal	B
storage	I
disorder	I
due	O
to	O
deficiency	B
of	I
the	I
enzyme	I
aspartylglucosaminidase	I
(	O
AGA	O
)	O
.	O

The	O
structural	O
gene	O
for	O
this	O
human	O
enzyme	O
(	O
AGA	O
)	O
has	O
been	O
assigned	O
to	O
the	O
region	O
4q21	O
-	O
---qter	O
.	O

We	O
determined	O
the	O
AGA	O
activity	O
in	O
cultured	O
fibroblasts	O
of	O
a	O
girl	O
with	O
a	O
46	O
,	O
XX	O
,	O
del	O
(	O
4	O
)	O
(	O
q33	O
)	O
karyotype	O
.	O

The	O
results	O
indicate	O
that	O
the	O
girl	O
is	O
a	O
hemizygote	O
for	O
AGA	O
,	O
permitting	O
the	O
assignment	O
of	O
human	O
AGA	O
to	O
the	O
region	O
4q33	O
-	O
---qter	O
..	O

Identification	O
of	O
deletion	O
mutations	O
and	O
three	O
new	O
genes	O
at	O
the	O
familial	B
polyposis	I
locus	O
.	O

Small	O
(	O
100	O
-	O
260	O
kb	O
)	O
,	O
nested	O
deletions	O
were	O
characterized	O
in	O
DNA	O
from	O
two	O
unrelated	O
patients	O
with	O
familial	B
adenomatous	I
polyposis	I
coli	I
(	O
APC	B
)	O
.	O

Three	O
candidate	O
genes	O
located	O
within	O
the	O
deleted	O
region	O
were	O
ascertained	O
and	O
a	O
previous	O
candidate	O
gene	O
,	O
MCC	O
,	O
was	O
shown	O
to	O
be	O
located	O
outside	O
the	O
deleted	O
region	O
.	O

One	O
of	O
the	O
new	O
genes	O
contained	O
sequence	O
identical	O
to	O
SRP19	O
,	O
the	O
gene	O
coding	O
for	O
the	O
19	O
kd	O
component	O
of	O
the	O
ribosomal	O
signal	O
recognition	O
particle	O
.	O

The	O
second	O
,	O
provisionally	O
designated	O
DP1	O
(	O
deleted	O
in	O
polyposis	O
1	O
)	O
,	O
was	O
found	O
to	O
be	O
transcribed	O
in	O
the	O
same	O
orientation	O
as	O
MCC	O
.	O

Two	O
other	O
cDNAs	O
,	O
DP2	O
and	O
DP3	O
,	O
were	O
found	O
to	O
overlap	O
,	O
forming	O
a	O
single	O
gene	O
,	O
DP2	O
.	O

5	O
,	O
that	O
is	O
transcribed	O
in	O
the	O
same	O
orientation	O
as	O
SRP19	O
.	O

Localisation	O
of	O
the	O
myotonic	B
dystrophy	I
locus	O
to	O
19q13.2	O
-	O
19q13.3	O
and	O
its	O
relationship	O
to	O
twelve	O
polymorphic	O
loci	O
on	O
19q	O
.	O

The	O
order	O
of	O
fourteen	O
polymorphic	O
markers	O
localised	O
to	O
the	O
long	O
arm	O
of	O
human	O
chromosome	O
19	O
has	O
been	O
established	O
by	O
multipoint	O
mapping	O
in	O
a	O
set	O
of	O
40	O
CEPH	O
(	O
Centre	O
dEtude	O
de	O
Polymorphisme	O
Humain	O
,	O
Paris	O
)	O
reference	O
families	O
.	O

We	O
report	O
here	O
the	O
linkage	O
relationship	O
of	O
the	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
locus	O
to	O
twelve	O
of	O
these	O
markers	O
as	O
studied	O
in	O
45	O
families	O
with	O
DM	B
.	O

The	O
resulting	O
genetic	O
map	O
is	O
supported	O
by	O
the	O
localisation	O
of	O
the	O
DNA	O
markers	O
in	O
a	O
panel	O
of	O
somatic	O
cell	O
hybrids	O
.	O

Ten	O
of	O
the	O
twelve	O
markers	O
have	O
been	O
shown	O
to	O
be	O
proximal	O
to	O
the	O
DM	B
gene	O
and	O
two	O
,	O
PRKCG	O
and	O
D19S22	O
,	O
distal	O
but	O
at	O
distances	O
of	O
approximately	O
25	O
cM	O
and	O
15	O
cM	O
,	O
respectively	O
.	O

The	O
closest	O
proximal	O
markers	O
are	O
APOC2	O
(	O
apolipoprotein	O
C	O
-	O
II	O
)	O
and	O
CKM	O
(	O
creatine	O
kinase	O
,	O
muscle	O
)	O
approximately	O
3	O
cM	O
and	O
2	O
cM	O
from	O
the	O
DM	B
gene	O
respectively	O
,	O
in	O
the	O
order	O
APOC2-CKM	O
-	O
DM	O
.	O

The	O
distance	O
between	O
APOC2	O
,	O
CKM	O
and	O
DM	B
(	O
of	O
the	O
order	O
of	O
2	O
million	O
base	O
pairs	O
)	O
and	O
their	O
known	O
orientation	O
should	O
permit	O
directional	O
chromosome	O
walking	O
and	O
jumping	O
.	O

The	O
data	O
presented	O
here	O
should	O
enable	O
us	O
to	O
determine	O
whether	O
or	O
not	O
new	O
markers	O
are	O
distal	O
to	O
APOC2	O
/	O
CKM	O
and	O
thus	O
potentially	O
flank	O
the	O
DM	B
gene	O
..	O

Regional	O
localisation	O
of	O
the	O
Friedreich	B
ataxia	I
locus	O
to	O
human	O
chromosome	O
9q13	O
-	O
---q21.1	O
.	O

We	O
have	O
previously	O
assigned	O
the	O
Friedreich	B
ataxia	I
locus	O
(	O
FRDA	O
)	O
to	O
chromosome	O
9	O
;	O
the	O
current	O
maximal	O
lod	O
score	O
between	O
FRDA	O
and	O
MCT112	O
(	O
D9S15	O
)	O
is	O
greater	O
than	O
50	O
at	O
a	O
recombination	O
fraction	O
of	O
theta	O
=	O
0	O
.	O

The	O
physical	O
assignment	O
of	O
the	O
locus	O
defined	O
by	O
MCT112	O
,	O
and	O
hence	O
FRDA	O
,	O
has	O
not	O
been	O
determined	O
,	O
although	O
linkage	O
analysis	O
of	O
MCT112	O
with	O
other	O
chromosome	O
9	O
markers	O
inferred	O
a	O
location	O
close	O
to	O
the	O
centromere	O
.	O

We	O
have	O
used	O
in	O
situ	O
hybridisation	O
with	O
MCT112	O
,	O
a	O
corresponding	O
cosmid	O
MJ1	O
,	O
and	O
DR47	O
(	O
D9S5	O
)	O
,	O
coupled	O
with	O
mapping	O
studies	O
on	O
hybrid	O
cell	O
panels	O
,	O
to	O
define	O
more	O
precisely	O
the	O
location	O
of	O
the	O
disease	O
locus	O
.	O

The	O
in	O
situ	O
location	O
of	O
all	O
three	O
probes	O
is	O
9q13	O
-	O
---q21	O
.	O

1	O
,	O
distal	O
to	O
the	O
variable	O
heterochromatin	O
region	O
.	O

Physical	O
assignment	O
of	O
FRDA	O
will	O
allow	O
us	O
to	O
identify	O
hybrid	O
cell	O
lines	O
containing	O
the	O
mutated	O
gene	O
.	O

Genetic	O
heterogeneity	O
at	O
the	O
glucose-6-phosphate	O
dehydrogenase	O
locus	O
in	O
southern	O
Italy	O
:	O
a	O
study	O
on	O
a	O
population	O
from	O
the	O
Matera	O
district	O
.	O

Glucose-6-phosphate	O
dehydrogenase	O
(	O
G6PD	O
)	O
has	O
been	O
analyzed	O
by	O
gel	O
electrophoresis	O
and	O
by	O
quantitative	O
assay	O
in	O
an	O
unselected	O
sample	O
of	O
1524	O
schoolboys	O
from	O
the	O
province	O
of	O
Matera	O
(	O
Lucania	O
)	O
in	O
southern	O
Italy	O
.	O

We	O
have	O
identified	O
43	O
subjects	O
with	O
a	O
G6PD	O
variant	O
.	O

Of	O
these	O
,	O
31	O
had	O
severe	O
G6PD	B
deficiency	I
,	O
nine	O
had	O
mild	O
to	O
moderate	O
deficiency	O
,	O
and	O
three	O
had	O
a	O
non	O
-	O
deficient	O
electrophoretic	O
variant	O
.	O

The	O
overall	O
rate	O
of	O
G6PD	B
deficiency	I
was	O
2	O
.	O
6	O
%	O
.	O

The	O
frequency	O
of	O
G6PD	B
deficiency	I
,	O
ranging	O
from	O
7	O
.	O
2	O
%	O
on	O
the	O
Ionian	O
Coast	O
to	O
zero	O
on	O
the	O
eastern	O
side	O
of	O
the	O
Lucanian	O
Apennines	O
,	O
appears	O
to	O
be	O
inversely	O
related	O
to	O
the	O
distance	O
of	O
each	O
town	O
examined	O
from	O
the	O
Ionian	O
Coast	O
,	O
suggesting	O
that	O
this	O
geographic	O
distribution	O
may	O
reflect	O
,	O
at	O
least	O
in	O
part	O
,	O
gene	O
flow	O
from	O
Greek	O
settlers	O
.	O

Biochemical	O
characterization	O
has	O
shown	O
that	O
most	O
of	O
the	O
G6PD	B
deficiency	I
in	O
this	O
population	O
is	O
accounted	O
for	O
by	O
G6PD	O
Mediterranean	O
.	O

In	O
addition	O
,	O
we	O
have	O
found	O
several	O
examples	O
of	O
two	O
other	O
known	O
polymorphic	O
variants	O
(	O
G6PD	O
Cagliari	O
and	O
G6PD	O
A-	O
)	O
;	O
three	O
new	O
polymorphic	O
variants	O
,	O
G6PD	O
Metaponto	O
(	O
class	O
III	O
)	O
,	O
G6PD	O
Montalbano	O
(	O
class	O
III	O
)	O
,	O
and	O
G6PD	O
Pisticci	O
(	O
class	O
IV	O
)	O
;	O
and	O
two	O
sporadic	O
variants	O
,	O
G6PD	O
Tursi	O
(	O
class	O
III	O
)	O
and	O
G6PD	O
Ferrandina	O
(	O
class	O
II	O
)	O
.	O

These	O
data	O
provide	O
further	O
evidence	O
for	O
the	O
marked	O
genetic	O
heterogeneity	O
of	O
G6PD	B
deficiency	I
within	O
a	O
relatively	O
narrow	O
geographic	O
area	O
and	O
they	O
prove	O
the	O
presence	O
in	O
the	O
Italian	O
peninsula	O
of	O
a	O
gene	O
(	O
GdA-	O
)	O
regarded	O
as	O
characteristically	O
African	O
.	O

The	O
red	O
-	O
green	O
visual	O
pigment	O
gene	O
region	O
in	O
adrenoleukodystrophy	B
.	O

Although	O
recent	O
data	O
established	O
that	O
a	O
specific	O
very	O
-	O
long	O
-	O
chain	O
fatty	O
acyl	O
-	O
CoA	O
synthetase	O
is	O
defective	O
in	O
X	B
-	I
linked	I
adrenoleukodystrophy	I
(	O
ALD	B
)	O
,	O
the	O
ALD	B
gene	O
is	O
still	O
unidentified	O
.	O

The	O
ALD	B
locus	O
has	O
been	O
mapped	O
to	O
Xq28	O
,	O
like	O
the	O
red	O
and	O
green	O
color	O
pigment	O
genes	O
.	O

Abnormal	B
color	I
vision	I
has	O
been	O
observed	O
in	O
12	O
of	O
27	O
patients	O
with	O
adrenomyeloneuropathy	B
(	O
AMN	B
)	O
,	O
a	O
milder	O
form	O
of	O
ALD	B
.	O

Furthermore	O
,	O
rearrangements	O
of	O
the	O
color	O
vision	O
gene	O
cluster	O
were	O
found	O
in	O
four	O
of	O
eight	O
ALD	B
kindreds	O
.	O

This	O
led	O
us	O
to	O
propose	O
that	O
a	O
single	O
DNA	O
rearrangement	O
could	O
underlie	O
both	O
ALD	B
and	O
abnormal	B
color	I
vision	I
in	O
these	O
patients	O
.	O

Study	O
of	O
34	O
French	O
ALD	B
patients	O
failed	O
to	O
reveal	O
a	O
higher	O
than	O
expected	O
frequency	O
of	O
green	O
/	O
red	O
visual	O
pigment	O
rearrangements	O
3	O
to	O
the	O
red	O
/	O
green	O
color	O
vision	O
gene	O
complex	O
.	O

The	O
previous	O
report	O
of	O
such	O
rearrangements	O
was	O
based	O
on	O
small	O
numbers	O
and	O
lack	O
of	O
knowledge	O
that	O
the	O
frequency	O
of	O
""""	O
abnormal	O
""""	O
color	O
vision	O
arrays	O
on	O
molecular	O
analysis	O
was	O
twice	O
as	O
high	O
as	O
expected	O
on	O
the	O
basis	O
of	O
the	O
frequency	O
of	O
phenotypic	B
color	I
vision	I
defects	I
.	O

The	O
red	O
/	O
green	O
color	O
pigment	O
(	O
R	O
/	O
GCP	O
)	O
region	O
was	O
studied	O
by	O
pulsed	O
-	O
field	O
gel	O
electrophoresis	O
in	O
14	O
of	O
these	O
patients	O
,	O
and	O
we	O
did	O
not	O
find	O
any	O
fragment	O
size	O
difference	O
between	O
the	O
patients	O
and	O
normal	O
individuals	O
who	O
have	O
the	O
same	O
number	O
of	O
pigment	O
genes	O
.	O

The	O
R	O
/	O
GCP	O
region	O
was	O
also	O
analyzed	O
in	O
29	O
French	O
and	O
seven	O
North	O
American	O
ALD	B
patients	O
by	O
using	O
six	O
genomic	O
DNA	O
probes	O
,	O
isolated	O
from	O
a	O
cosmid	O
walk	O
,	O
that	O
flank	O
the	O
color	O
vision	O
genes	O
.	O

No	O
deletions	O
were	O
found	O
with	O
probes	O
that	O
lie	O
3	O
of	O
the	O
green	O
pigment	O
genes	O
.	O

One	O
of	O
the	O
eight	O
previously	O
reported	O
ALD	B
individuals	O
has	O
a	O
long	O
deletion	O
5	O
of	O
the	O
red	O
pigment	O
gene	O
,	O
a	O
deletion	O
causing	O
blue	O
cone	O
monochromacy	O
.	O

This	O
finding	O
and	O
the	O
previous	O
findings	O
of	O
a	O
45	O
%	O
frequency	O
of	O
phenotypic	O
color	O
vision	O
defects	O
in	O
patients	O
with	O
AMN	B
may	O
suggest	O
that	O
the	O
ALD	B
/	O
AMN	B
gene	O
lies	O
5	O
to	O
the	O
red	O
pigment	O
gene	O
and	O
that	O
the	O
frequent	O
phenotypic	O
color	B
vision	I
anomalies	I
owe	O
their	O
origin	O
to	O
deleted	O
DNA	O
that	O
includes	O
regulatory	O
genes	O
for	O
color	O
vision	O
.	O

It	O
is	O
possible	O
,	O
however	O
,	O
that	O
phenotypic	O
color	B
vision	I
anomalies	I
in	O
AMN	B
may	O
be	O
phenocopies	O
secondary	O
to	O
retinal	O
or	O
neural	O
involvement	O
by	O
the	O
disease	O
.	O

The	O
single	O
case	O
of	O
blue	O
cone	O
monochromacy	O
may	O
therefore	O
be	O
a	O
fortuitous	O
coincidence	O
of	O
two	O
diseases	O
..	O

Paroxysmal	B
nocturnal	I
haemoglobinuria	I
with	O
coexisting	O
deficiency	B
of	I
the	I
ninth	I
component	I
of	I
complement	I
:	O
lack	O
of	O
massive	O
haemolytic	B
attack	I
.	O

A	O
47-year	O
-	O
old	O
woman	O
with	O
paroxysmal	B
nocturnal	I
haemoglobinuria	I
(	O
PNH	B
)	O
was	O
found	O
to	O
have	O
an	O
inherited	B
deficiency	I
in	I
the	I
ninth	I
complement	I
component	I
(	O
C9	O
)	O
.	O

In	O
complement	O
-	O
sensitivity	O
lysis	O
tests	O
,	O
80	O
%	O
of	O
her	O
erythrocytes	O
were	O
markedly	O
complement	O
-	O
sensitive	O
(	O
PNH	O
-	O
III	O
)	O
.	O

Laser	O
cytofluorimetry	O
with	O
a	O
monoclonal	O
antibody	O
against	O
decay	O
-	O
accelerating	O
factor	O
(	O
DAF	O
)	O
revealed	O
that	O
95	O
%	O
of	O
her	O
erythrocytes	O
were	O
DAF	O
-	O
negative	O
.	O

Surprisingly	O
,	O
she	O
has	O
suffered	O
only	O
mild	O
haemolysis	B
and	O
has	O
never	O
experienced	O
massive	O
spontaneous	O
haemolysis	B
.	O

Gross	O
haemoglobinuria	B
and	O
jaundice	B
occurred	O
only	O
after	O
receiving	O
postoperative	O
transfusion	O
of	O
whole	O
blood	O
.	O

In	O
her	O
serum	O
,	O
C9	O
was	O
not	O
detectable	O
either	O
by	O
immunological	O
or	O
by	O
functional	O
assays	O
.	O

Both	O
the	O
Ham	O
test	O
and	O
the	O
sugar	O
water	O
test	O
using	O
normal	O
human	O
serum	O
or	O
plasma	O
yielded	O
marked	O
haemolysis	O
of	O
the	O
patients	O
erythrocytes	O
.	O

When	O
the	O
patients	O
serum	O
or	O
plasma	O
was	O
used	O
,	O
only	O
a	O
trace	O
of	O
lysis	O
was	O
detected	O
.	O

Addition	O
of	O
purified	O
human	O
C9	O
to	O
her	O
plasma	O
fully	O
restored	O
haemolysis	O
.	O

These	O
observations	O
indicated	O
that	O
C9	O
may	O
play	O
a	O
critical	O
role	O
in	O
haemolytic	B
attacks	I
in	O
patients	O
with	O
PNH	B
and	O
that	O
characteristic	O
haemolysis	B
in	O
PNH	B
may	O
be	O
tempered	O
by	O
coexisting	O
C9	B
deficiency	I
..	O

Screening	O
for	O
carriers	O
of	O
Tay	B
-	I
Sachs	I
disease	I
among	O
Ashkenazi	O
Jews	O
.	O

A	O
comparison	O
of	O
DNA	O
-	O
based	O
and	O
enzyme	O
-	O
based	O
tests	O
.	O

BACKGROUND	O
AND	O
METHODS	O
.	O

The	O
prevention	O
of	O
Tay	B
-	I
Sachs	I
disease	I
(	O
GM2	B
gangliosidosis	I
,	I
type	I
1	I
)	O
depends	O
on	O
the	O
identification	O
of	O
carriers	O
of	O
the	O
gene	O
for	O
this	O
autosomal	B
recessive	I
disorder	I
.	O

We	O
compared	O
the	O
enzyme	O
-	O
based	O
test	O
widely	O
used	O
in	O
screening	O
for	O
Tay	B
-	I
Sachs	I
disease	I
with	O
a	O
test	O
based	O
on	O
analysis	O
of	O
DNA	O
.	O

We	O
developed	O
methods	O
to	O
detect	O
the	O
three	O
mutations	O
in	O
the	O
HEXA	O
gene	O
that	O
occur	O
with	O
high	O
frequency	O
among	O
Ashkenazi	O
Jews	O
two	O
mutations	O
cause	O
infantile	O
Tay	B
-	I
Sachs	I
disease	I
,	O
and	O
the	O
third	O
causes	O
the	O
adult	O
-	O
onset	O
form	O
of	O
the	O
disease	O
.	O

DNA	O
segments	O
containing	O
these	O
mutation	O
sites	O
were	O
amplified	O
with	O
the	O
polymerase	O
chain	O
reaction	O
and	O
analyzed	O
for	O
the	O
presence	O
of	O
the	O
mutations	O
.	O

RESULTS	O
.	O

Among	O
62	O
Ashkenazi	O
obligate	O
carriers	O
of	O
Tay	B
-	I
Sachs	I
disease	I
,	O
the	O
three	O
specific	O
mutations	O
accounted	O
for	O
all	O
but	O
one	O
of	O
the	O
mutant	O
alleles	O
(	O
98	O
percent	O
)	O
.	O

In	O
216	O
Ashkenazi	O
carriers	O
identified	O
by	O
the	O
enzyme	O
test	O
,	O
DNA	O
analysis	O
showed	O
that	O
177	O
(	O
82	O
percent	O
)	O
had	O
one	O
of	O
the	O
identified	O
mutations	O
.	O

Of	O
the	O
177	O
,	O
79	O
percent	O
had	O
the	O
exon	O
11	O
insertion	O
mutation	O
,	O
18	O
percent	O
had	O
the	O
intron	O
12	O
splice	O
-	O
junction	O
mutation	O
,	O
and	O
3	O
percent	O
had	O
the	O
less	O
severe	O
exon	O
7	O
mutation	O
associated	O
with	O
adult	O
-	O
onset	O
disease	O
.	O

The	O
results	O
of	O
the	O
enzyme	O
tests	O
in	O
the	O
39	O
subjects	O
(	O
18	O
percent	O
)	O
who	O
were	O
defined	O
as	O
carriers	O
but	O
in	O
whom	O
DNA	O
analysis	O
did	O
not	O
identify	O
a	O
mutant	O
allele	O
were	O
probably	O
false	O
positive	O
(	O
although	O
there	O
remains	O
some	O
possibility	O
of	O
unidentified	O
mutations	O
)	O
.	O

In	O
addition	O
,	O
of	O
152	O
persons	O
defined	O
as	O
noncarriers	O
by	O
the	O
enzyme	O
-	O
based	O
test	O
,	O
1	O
was	O
identified	O
as	O
a	O
carrier	O
by	O
DNA	O
analysis	O
(	O
i.	O
e	O
e.	O
,	O
a	O
false	O
negative	O
enzyme	O
-	O
test	O
result	O
)	O
.	O

CONCLUSIONS	O
.	O

The	O
increased	O
specificity	O
and	O
predictive	O
value	O
of	O
the	O
DNA	O
-	O
based	O
test	O
make	O
it	O
a	O
useful	O
adjunct	O
to	O
the	O
diagnostic	O
tests	O
currently	O
used	O
to	O
screen	O
for	O
carriers	O
of	O
Tay	B
-	I
Sachs	I
disease	I
.	O

Mutations	O
in	O
the	O
RB1	O
gene	O
and	O
their	O
effects	O
on	O
transcription	O
.	O

Inactivation	O
of	O
both	O
alleles	O
of	O
the	O
RB1	O
gene	O
during	O
normal	O
retinal	O
development	O
initiates	O
the	O
formation	O
of	O
a	O
retinoblastoma	B
(	I
RB	I
)	I
tumor	I
.	O

To	O
identify	O
the	O
mutations	O
which	O
inactivate	O
RB1	O
,	O
21	O
RB	B
tumors	I
isolated	O
from	O
19	O
patients	O
were	O
analyzed	O
with	O
the	O
polymerase	O
chain	O
reaction	O
or	O
an	O
RNase	O
protection	O
assay	O
or	O
both	O
.	O

Mutations	O
were	O
identified	O
in	O
13	O
of	O
21	O
RB	B
tumors	I
;	O
in	O
8	O
tumors	B
,	O
the	O
precise	O
errors	O
in	O
nucleotide	O
sequence	O
were	O
characterized	O
.	O

Each	O
of	O
four	O
germ	O
line	O
mutations	O
involved	O
a	O
small	O
deletion	O
or	O
duplication	O
,	O
while	O
three	O
somatic	O
mutations	O
were	O
point	O
mutations	O
leading	O
to	O
splice	O
alterations	O
and	O
loss	O
of	O
an	O
exon	O
from	O
the	O
mature	O
RB1	O
mRNA	O
.	O

We	O
were	O
unable	O
to	O
detect	O
expression	O
of	O
the	O
mutant	O
allele	O
in	O
lymphoblasts	O
of	O
three	O
bilaterally	O
affected	O
patients	O
,	O
although	O
the	O
mutation	O
was	O
present	O
in	O
the	O
genomic	O
DNA	O
and	O
transcripts	O
containing	O
the	O
mutations	O
were	O
obvious	O
in	O
the	O
RB	B
tumors	I
in	O
the	O
absence	O
of	O
a	O
normal	O
RB1	O
allele	O
.	O

The	O
variations	O
in	O
the	O
level	O
of	O
expression	O
of	O
mutant	O
transcripts	O
suggest	O
deregulation	O
of	O
RB1	O
transcription	O
in	O
the	O
absence	O
of	O
a	O
functional	O
RB1	O
gene	O
product	O
..	O

Myotonic	B
dystrophy	I
is	O
closely	O
linked	O
to	O
the	O
gene	O
for	O
muscle	O
-	O
type	O
creatine	O
kinase	O
(	O
CKMM	O
)	O
.	O

We	O
have	O
studied	O
genetic	O
linkage	O
between	O
the	O
gene	O
for	O
creatine	O
kinase	O
muscle	O
type	O
(	O
CKMM	O
)	O
and	O
the	O
gene	O
for	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
.	O

In	O
a	O
panel	O
of	O
65	O
myotonic	B
dystrophy	I
families	O
from	O
Canada	O
and	O
the	O
Netherlands	O
,	O
a	O
maximum	O
lod	O
score	O
(	O
Zmax	O
)	O
of	O
22	O
.	O
8	O
at	O
a	O
recombination	O
frequency	O
(	O
theta	O
)	O
of	O
0	O
.	O
03	O
was	O
obtained	O
.	O

Tight	O
linkage	O
was	O
also	O
demonstrated	O
for	O
CKMM	O
and	O
the	O
gene	O
for	O
apolipoprotein	O
C2	O
(	O
ApoC2	O
)	O
.	O

This	O
establishes	O
CKMM	O
as	O
a	O
useful	O
marker	O
for	O
myotonic	B
dystrophy	I

Familial	B
deficiency	I
of	I
the	I
seventh	I
component	I
of	I
complement	I
associated	O
with	O
recurrent	O
meningococcal	B
infections	I
.	O

We	O
describe	O
an	O
11-year	O
-	O
old	O
girl	O
suffering	O
from	O
recurrent	B
meningitis	I
with	O
a	O
complete	O
absence	B
of	I
the	I
seventh	I
component	I
of	I
complement	I
(	O
C7	O
)	O
.	O

Diagnosis	O
was	O
established	O
by	O
haemolytic	O
titration	O
and	O
western	O
blotting	O
.	O

The	O
patients	O
serum	O
lacked	O
the	O
85	O
kDa	O
C7	O
chain	O
.	O

Haemolytic	O
activity	O
of	O
serum	O
was	O
reconstituted	O
with	O
either	O
pooled	O
normal	O
human	O
serum	O
or	O
with	O
purified	O
C7	O
.	O

The	O
relatives	O
(	O
parents	O
and	O
one	O
sister	O
)	O
had	O
half	O
-	O
normal	O
levels	O
of	O
both	O
immunochemically	O
and	O
functionally	O
determined	O
C7	O
,	O
indicating	O
a	O
heterozygous	O
state	O
for	O
C7	B
deficiency	I
..	O

Spontaneous	O
reversion	O
of	O
novel	O
Lesch	B
-	I
Nyhan	I
mutation	O
by	O
HPRT	O
gene	O
rearrangement	O
.	O

Molecular	O
analysis	O
of	O
an	O
unusual	O
patient	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
has	O
suggested	O
that	O
the	O
mutation	O
is	O
due	O
to	O
a	O
partial	O
HPRT	O
gene	O
duplication	O
.	O

We	O
now	O
report	O
the	O
cloning	O
and	O
sequencing	O
of	O
the	O
mutant	O
HPRT	O
cDNA	O
which	O
shows	O
the	O
precise	O
duplication	O
of	O
exons	O
2	O
and	O
3	O
.	O

This	O
mutation	O
is	O
the	O
result	O
of	O
an	O
internal	O
duplication	O
of	O
16	O
-	O
20	O
kilobases	O
of	O
the	O
gene	O
.	O

The	O
structure	O
of	O
the	O
mutant	O
gene	O
suggests	O
that	O
the	O
duplication	O
was	O
not	O
generated	O
by	O
a	O
single	O
unequal	O
crossing	O
-	O
over	O
event	O
between	O
two	O
normal	O
HPRT	O
alleles	O
.	O

Growth	O
of	O
Epstein	B
-	I
Barr	I
virus	O
-	O
transformed	O
lymphoblasts	O
from	O
this	O
patient	O
in	O
selective	O
medium	O
has	O
permitted	O
isolation	O
of	O
spontaneous	O
HPRT	O
+	O
revertants	O
of	O
this	O
mutation	O
.	O

The	O
reversion	O
event	O
involves	O
a	O
second	O
major	O
HPRT	O
gene	O
rearrangement	O
where	O
most	O
or	O
all	O
of	O
the	O
duplicated	O
portion	O
of	O
the	O
mutant	O
gene	O
is	O
deleted	O
.	O

The	O
original	O
mutation	O
therefore	O
has	O
the	O
potential	O
for	O
spontaneous	O
somatic	O
reversion	O
.	O

This	O
may	O
explain	O
the	O
relatively	O
mild	O
symptoms	O
of	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
exhibited	O
by	O
this	O
patient	O
..	O

Sjogren	B
-	I
Larsson	I
syndrome	I
.	O

Impaired	O
fatty	O
alcohol	O
oxidation	O
in	O
cultured	O
fibroblasts	O
due	O
to	O
deficient	O
fatty	O
alcohol	O
:	O
nicotinamide	O
adenine	O
dinucleotide	O
oxidoreductase	O
activity	O
.	O

Lipid	O
metabolism	O
was	O
studied	O
in	O
cultured	O
skin	O
fibroblasts	O
from	O
patients	O
with	O
the	O
inherited	B
disorder	I
,	O
Sjogren	B
-	I
Larsson	I
syndrome	I
(	O
SLS	B
)	O
.	O

Intact	O
SLS	B
fibroblasts	O
incubated	O
in	O
the	O
presence	O
of	O
[	O
1	O
-	O
14C	O
]	O
palmitate	O
accumulated	O
more	O
radioactive	O
hexadecanol	O
than	O
did	O
normal	O
cells	O
,	O
whereas	O
incorporation	O
of	O
radioactivity	O
into	O
other	O
cellular	O
lipids	O
was	O
unaltered	O
.	O

The	O
hexadecanol	O
content	O
of	O
SLS	B
fibroblasts	O
was	O
abnormally	O
elevated	O
.	O

Hexadecanol	O
accumulation	O
was	O
not	O
due	O
to	O
increased	O
fatty	O
alcohol	O
synthesis	O
nor	O
its	O
deficient	O
utilization	O
for	O
glycerol	O
ether	O
synthesis	O
.	O

The	O
half	O
-	O
life	O
of	O
intracellular	O
hexadecanol	O
loaded	O
into	O
SLS	B
fibroblasts	O
was	O
increased	O
(	O
70	O
min	O
)	O
compared	O
with	O
normal	O
(	O
15	O
min	O
)	O
,	O
and	O
intact	O
SLS	B
fibroblasts	O
showed	O
impaired	O
oxidation	O
of	O
[	O
14C	O
]	O
-hexadecanol	O
to	O
fatty	O
acid	O
.	O

Fatty	O
alcohol	O
NAD	O
+	O
oxidoreductase	O
,	O
the	O
enzyme	O
catalyzing	O
this	O
reaction	O
,	O
was	O
deficient	O
in	O
SLS	B
fibroblasts	O
.	O

Mean	O
total	O
activity	O
in	O
SLS	B
fibroblasts	O
(	O
n	O
=	O
5	O
)	O
was	O
13	O
%	O
of	O
that	O
in	O
normal	O
fibroblasts	O
,	O
and	O
palmitoyl	O
CoA	O
-	O
inhibitable	O
activity	O
was	O
1	O
%	O
of	O
normal	O
.	O

Fibroblasts	O
from	O
two	O
obligate	O
SLS	B
heterozygotes	O
had	O
enzyme	O
activities	O
intermediate	O
between	O
that	O
in	O
normal	O
fibroblasts	O
and	O
individuals	O
with	O
SLS	B
.	O

These	O
results	O
suggest	O
that	O
the	O
primary	O
defect	O
in	O
SLS	B
is	O
deficiency	B
of	I
fatty	I
alcohol	I
NAD	I
+	I
oxidoreductase	I
.	O

SLS	B
represents	O
the	O
first	O
inherited	B
disorder	I
in	O
man	O
associated	O
with	O
an	O
isolated	O
abnormality	B
in	I
fatty	I
alcohol	I
metabolism	I
..	O

Identification	O
and	O
localization	O
of	O
mutations	O
at	O
the	O
Lesch	B
-	I
Nyhan	I
locus	O
by	O
ribonuclease	O
A	O
cleavage	O
.	O

Many	O
mutations	O
leading	O
to	O
human	O
disease	O
are	O
the	O
result	O
of	O
single	O
DNA	O
base	O
pair	O
changes	O
that	O
can	O
not	O
be	O
identified	O
by	O
Southern	O
analysis	O
.	O

This	O
has	O
prompted	O
the	O
development	O
of	O
alternative	O
assays	O
for	O
point	O
mutation	O
detection	O
.	O

The	O
recently	O
described	O
ribonuclease	O
A	O
cleavage	O
procedure	O
,	O
with	O
a	O
polyuridylic	O
acid	O
-	O
paper	O
affinity	O
chromatography	O
step	O
,	O
has	O
been	O
used	O
to	O
identify	O
the	O
mutational	O
lesions	O
in	O
the	O
hypoxanthine	O
phosphoribosyltransferase	O
(	O
HPRT	O
)	O
messenger	O
RNAs	O
of	O
patients	O
with	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

Distinctive	O
ribonuclease	O
A	O
cleavage	O
patterns	O
were	O
identified	O
in	O
messenger	O
RNA	O
from	O
5	O
of	O
14	O
Lesch	B
-	I
Nyhan	I
patients	O
who	O
were	O
chosen	O
because	O
no	O
HPRT	O
Southern	O
or	O
Northern	O
blotting	O
pattern	O
changes	O
had	O
been	O
found	O
.	O

This	O
approach	O
now	O
allows	O
HPRT	O
mutation	O
detection	O
in	O
50	O
percent	O
of	O
the	O
cases	O
of	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

The	O
polyuridylic	O
acid	O
-	O
paper	O
affinity	O
procedure	O
provides	O
a	O
general	O
method	O
for	O
analysis	O
of	O
low	O
abundance	O
messenger	O
RNAs	O
..	O

The	O
mapping	O
of	O
a	O
cDNA	O
from	O
the	O
human	O
X	B
-	I
linked	I
Duchenne	I
muscular	I
dystrophy	I
gene	O
to	O
the	O
mouse	O
X	O
chromosome	O
.	O

The	O
recent	O
discovery	O
of	O
sequences	O
at	O
the	O
site	O
of	O
the	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
gene	O
in	O
humans	O
has	O
opened	O
up	O
the	O
possibility	O
of	O
a	O
detailed	O
molecular	O
analysis	O
of	O
the	O
genes	O
in	O
humans	O
and	O
in	O
related	O
mammalian	O
species	O
.	O

Until	O
relatively	O
recently	O
,	O
there	O
was	O
no	O
obvious	O
mouse	O
model	O
of	O
this	O
genetic	B
disease	I
for	O
the	O
development	O
of	O
therapeutic	O
strategies	O
.	O

The	O
identification	O
of	O
a	O
mouse	O
X	O
-	O
linked	O
mutant	O
showing	O
muscular	B
dystrophy	I
,	O
mdx	O
,	O
has	O
provided	O
a	O
candidate	O
mouse	O
genetic	O
homologue	O
to	O
the	O
DMD	B
locus	O
;	O
the	O
relatively	O
mild	O
pathological	O
features	O
of	O
mdx	O
suggest	O
it	O
may	O
have	O
more	O
in	O
common	O
with	O
mutations	O
of	O
the	O
Becker	B
muscular	I
dystrophy	I
type	O
at	O
the	O
same	O
human	O
locus	O
,	O
however	O
.	O

But	O
the	O
close	O
genetic	O
linkage	O
of	O
mdx	O
to	O
G6PD	O
and	O
Hprt	O
on	O
the	O
mouse	O
X	O
chromosome	O
,	O
coupled	O
with	O
its	O
comparatively	O
mild	O
pathology	O
,	O
have	O
suggested	O
that	O
the	O
mdx	O
mutation	O
may	O
instead	O
correspond	O
to	O
Emery	B
Dreifuss	I
muscular	I
dystrophy	I
which	O
itself	O
is	O
closely	O
linked	O
to	O
DNA	O
markers	O
at	O
Xq28-qter	O
in	O
the	O
region	O
of	O
G6PD	O
on	O
the	O
human	O
X	O
chromosome	O
.	O

Using	O
an	O
interspecific	O
mouse	O
domesticus	O
/	O
spretus	O
cross	O
,	O
segregating	O
for	O
a	O
variety	O
of	O
markers	O
on	O
the	O
mouse	O
X	O
chromosome	O
,	O
we	O
have	O
positioned	O
on	O
the	O
mouse	O
X	O
chromosome	O
sequences	O
homologous	O
to	O
a	O
DMD	B
cDNA	O
clone	O
.	O

These	O
sequences	O
map	O
provocatively	O
close	O
to	O
the	O
mdx	O
mutation	O
and	O
unexpectedly	O
distant	O
from	O
sparse	O
fur	O
,	O
spf	O
,	O
the	O
mouse	O
homologue	O
of	O
OTC	O
(	O
ornithine	O
transcarbamylase	O
)	O
which	O
is	O
closely	O
linked	O
to	O
DMD	B
on	O
the	O
human	O
X	O
chromosome	O
..	O

Localization	O
of	O
the	O
region	O
homologous	O
to	O
the	O
Duchenne	B
muscular	I
dystrophy	I
locus	O
on	O
the	O
mouse	O
X	O
chromosome	O
.	O

Recent	O
progress	O
has	O
resulted	O
in	O
part	O
of	O
the	O
gene	O
mutated	O
in	O
Duchenne	B
and	I
the	I
milder	I
Becker	I
muscular	I
dystrophies	I
being	O
cloned	O
and	O
has	O
suggested	O
that	O
the	O
gene	O
itself	O
extends	O
over	O
1	O
,	O
000	O
to	O
2	O
,	O
000	O
kilobases	O
(	O
kb	O
)	O
.	O

To	O
study	O
how	O
mutations	O
in	O
this	O
gene	O
affect	O
muscle	O
development	O
and	O
integrity	O
,	O
it	O
would	O
be	O
of	O
interest	O
to	O
have	O
available	O
a	O
mouse	O
model	O
of	O
the	O
human	O
disease	O
.	O

The	O
mouse	O
mdx	O
mutation	O
affects	O
muscle	O
and	O
confers	O
a	O
mild	O
dystrophic	B
syndrome	I
,	O
but	O
it	O
is	O
not	O
clear	O
whether	O
this	O
mutation	O
is	O
equivalent	O
to	O
Duchenne	B
/	I
Becker	I
muscular	I
dystrophy	I
in	O
man	O
.	O

Here	O
we	O
describe	O
the	O
use	O
of	O
two	O
sequences	O
from	O
the	O
human	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
gene	O
that	O
cross	O
-	O
hybridize	O
to	O
mouse	O
X	O
-	O
linked	O
sequences	O
to	O
localize	O
the	O
gene	O
homologous	O
to	O
DMD	B
in	O
the	O
mouse	O
.	O

Both	O
sequences	O
map	O
to	O
the	O
region	O
of	O
10	O
centimorgan	O
lying	O
between	O
the	O
Tabby	O
(	O
Ta	O
)	O
and	O
St14	O
-	O
1	O
(	O
DxPas8	O
)	O
loci	O
,	O
close	O
to	O
the	O
phosphorylase	O
b	O
kinase	O
locus	O
(	O
Phk	O
)	O
.	O

By	O
analogy	O
with	O
the	O
human	O
X	O
-	O
chromosome	O
,	O
we	O
conclude	O
that	O
the	O
region	O
in	O
the	O
mouse	O
around	O
the	O
G6pd	O
and	O
St14	O
-	O
1	O
loci	O
may	O
contain	O
two	O
genes	O
corresponding	O
to	O
distinct	O
human	O
myopathies	B
Emery	B
Dreifuss	I
muscular	I
dystrophy	I
which	O
is	O
known	O
to	O
be	O
closely	O
linked	O
to	O
St14	O
-	O
1	O
in	O
man	O
and	O
the	O
DMD	B
homologue	O
described	O
here	O
..	O

Conservation	O
of	O
the	O
Duchenne	B
muscular	I
dystrophy	I
gene	O
in	O
mice	O
and	O
humans	O
.	O

A	O
portion	O
of	O
the	O
Duchenne	B
muscular	I
dystrophy	I
(	O
DMD	B
)	O
gene	O
transcript	O
from	O
human	O
fetal	O
skeletal	O
muscle	O
and	O
mouse	O
adult	O
heart	O
was	O
sequenced	O
,	O
representing	O
approximately	O
25	O
percent	O
of	O
the	O
total	O
,	O
14-kb	O
DMD	B
transcript	O
.	O

The	O
nucleic	O
acid	O
and	O
predicted	O
amino	O
acid	O
sequences	O
from	O
the	O
two	O
species	O
are	O
nearly	O
90	O
percent	O
homologous	O
.	O

The	O
amino	O
acid	O
sequence	O
that	O
is	O
predicted	O
from	O
this	O
portion	O
of	O
the	O
DMD	B
gene	O
indicates	O
that	O
the	O
protein	O
product	O
might	O
serve	O
a	O
structural	O
role	O
in	O
muscle	O
,	O
but	O
the	O
abundance	O
and	O
tissue	O
distribution	O
of	O
the	O
messenger	O
RNA	O
suggests	O
that	O
the	O
DMD	B
protein	O
is	O
not	O
nebulin	O
..	O

Heterogeneity	O
of	O
type	B
I	I
von	I
Willebrand	I
disease	I
:	O
evidence	O
for	O
a	O
subgroup	O
with	O
an	O
abnormal	O
von	B
Willebrand	I
factor	O
.	O

Type	B
I	I
von	I
Willebrand	I
disease	I
(	O
vWD	B
)	O
is	O
characterized	O
by	O
equally	O
low	O
plasma	O
concentrations	O
of	O
von	B
Willebrand	I
factor	O
antigen	O
(	O
vWF	O
Ag	O
)	O
and	O
ristocetin	O
cofactor	O
(	O
RiCof	O
)	O
and	O
by	O
the	O
presence	O
of	O
all	O
vWF	O
multimers	O
in	O
sodium	O
dodecyl	O
sulfate	O
(	O
SDS	O
)	O
-agarose	O
gel	O
electrophoresis	O
.	O

For	O
17	O
patients	O
(	O
13	O
kindreds	O
)	O
diagnosed	O
with	O
these	O
criteria	O
,	O
we	O
have	O
studied	O
the	O
platelet	O
contents	O
of	O
vWF	O
Ag	O
and	O
RiCof	O
and	O
the	O
changes	O
of	O
these	O
in	O
plasma	O
after	O
DDAVP	O
infusion	O
.	O

Platelet	O
vWF	O
Ag	O
and	O
RiCof	O
were	O
normal	O
in	O
four	O
kindreds	O
(	O
called	O
""""	O
platelet	O
normal	O
""""	O
subgroup	O
)	O
;	O
following	O
1-deamino-8-D	O
-	O
arginine	O
vasopressin	O
;	O
plasma	O
vWF	O
Ag	O
,	O
RiCof	O
and	O
the	O
bleeding	O
time	O
(	O
BT	O
)	O
became	O
normal	O
.	O

In	O
six	O
kindreds	O
,	O
platelet	O
vWF	O
Ag	O
and	O
RiCof	O
were	O
equally	O
low	O
(	O
platelet	O
low	O
)	O
;	O
after	O
DDAVP	O
,	O
plasma	O
vWF	O
Ag	O
and	O
RiCof	O
remained	O
low	O
,	O
and	O
the	O
BT	O
was	O
prolonged	O
.	O

In	O
three	O
additional	O
kindreds	O
,	O
platelets	O
contained	O
normal	O
concentrations	O
of	O
vWF	O
Ag	O
,	O
but	O
RiCof	O
was	O
very	O
low	O
(	O
platelet	O
discordant	O
)	O
;	O
even	O
though	O
a	O
complete	O
set	O
of	O
multimers	O
was	O
found	O
in	O
plasma	O
and	O
platelets	O
,	O
there	O
was	O
a	O
relatively	O
small	O
amount	O
of	O
large	O
multimers	O
.	O

After	O
DDAVP	O
,	O
plasma	O
vWF	O
Ag	O
became	O
normal	O
,	O
but	O
RiCof	O
remained	O
low	O
and	O
the	O
BT	O
was	O
very	O
prolonged	O
.	O

These	O
findings	O
demonstrated	O
that	O
there	O
can	O
be	O
an	O
abnormal	O
vWF	O
(	O
RiCof	O
less	O
than	O
vWF	O
Ag	O
)	O
even	O
in	O
type	B
I	I
vWD	I
,	O
coexisting	O
with	O
a	O
complete	O
set	O
of	O
vWF	O
multimers	O
(	O
platelet	O
discordant	O
)	O
;	O
that	O
the	O
abnormal	O
vWF	O
can	O
be	O
shown	O
more	O
clearly	O
in	O
platelets	O
than	O
in	O
plasma	O
or	O
else	O
in	O
plasma	O
after	O
DDAVP	O
infusion	O
;	O
and	O
that	O
DDAVP	O
normalizes	O
the	O
BT	O
only	O
in	O
those	O
patients	O
with	O
normal	O
platelet	O
levels	O
of	O
both	O
vWF	O
Ag	O
and	O
RiCof	O
(	O
platelet	O
normal	O
)	O
..	O

Genetic	O
defect	B
in	I
secretion	I
of	I
complement	I
C5	I
in	O
mice	O
.	O

A	O
genetic	O
deficiency	B
of	I
the	I
fifth	I
(	I
C5	I
)	I
component	I
of	I
complement1	I
-	I
3	I
,	O
a	O
serum	O
glycoprotein	O
of	O
molecular	O
weight	O
(	O
MW	O
)	O
220	O
,	O
000	O
(	O
ref	O
.	O

4	O
)	O
,	O
has	O
been	O
found	O
in	O
39	O
%	O
of	O
inbred	O
strains	O
of	O
mice3	O
.	O

Sera	O
of	O
deficient	O
mice	O
lack	O
detectable	O
C5	O
activity	O
and	O
protein2	O
,	O
3	O
.	O

In	O
addition	O
deficient	O
mice	O
produce	O
antibody	O
to	O
mouse	O
C5	O
when	O
injected	O
with	O
sera	O
from	O
C5	O
sufficient	O
(	O
normal	O
)	O
strains	O
.	O

Levy	O
et	O
al.	O
5	O
showed	O
that	O
somatic	O
cell	O
hybrids	O
between	O
C5	O
deficient	O
(	O
B10	O
.	O

D2	O
/	O
old	O
line	O
)	O
macrophages	O
and	O
either	O
C5	O
sufficient	O
(	O
B10	O
.	O

D2	O
/	O
new	O
line	O
)	O
mouse	O
kidney	O
or	O
chicken	O
erythroblasts	O
secreted	O
haemolytically	O
active	O
mouse	O
C5	O
in	O
vitro	O
.	O

Several	O
possible	O
molecular	O
mechanisms	O
to	O
account	O
for	O
the	O
findings	O
were	O
considered	O
,	O
but	O
insufficient	O
direct	O
data	O
were	O
available	O
to	O
choose	O
among	O
them	O
.	O

We	O
recently	O
reported	O
that	O
mouse	O
(	O
CD	O
.	O
1	O
strain	O
)	O
peritoneal	O
cells	O
in	O
culture	O
synthesise	O
and	O
secrete	O
a	O
single	O
chain	O
precursor	O
,	O
pro	O
-	O
C5	O
(	O
MW	O
approximately	O
210	O
,	O
000	O
)	O
,	O
of	O
the	O
two	O
-	O
chain	O
(	O
alpha	O
chain	O
,	O
125	O
,	O
000	O
and	O
beta	O
chain	O
83	O
,	O
000	O
MW	O
)	O
C5	O
protein6	O
.	O

Radiolabelled	O
precursor	O
C5	O
was	O
contained	O
within	O
the	O
cells	O
and	O
was	O
secreted	O
into	O
the	O
tissue	O
culture	O
media	O
.	O

Using	O
similar	O
methods	O
,	O
we	O
now	O
find	O
that	O
C5	B
deficiency	I
in	O
each	O
of	O
five	O
different	O
mouse	O
strains	O
(	O
AKR	O
,	O
SWR	O
,	O
DBA	O
/	O
2J8	O
A	O
/	O
HeJ	O
and	O
B10	O
.	O

D2	O
/	O
old	O
line	O
)	O
is	O
due	O
to	O
a	O
failure	O
in	O
secretion	O
of	O
C5	O
protein	O
and	O
not	O
to	O
a	O
failure	O
in	O
biosynthesis	O
of	O
pro	O
-	O
C5	O

Deficiency	B
of	I
the	I
fifth	I
component	I
of	I
complement	I
in	O
human	O
subjects	O
.	O

Clinical	O
,	O
genetic	O
and	O
immunologic	O
studies	O
in	O
a	O
large	O
kindred	O
.	O

The	O
discovery	O
of	O
a	O
large	O
kindred	O
with	O
a	O
heritable	O
deficiency	B
of	I
the	I
fifth	I
component	I
of	I
complement	I
(	O
C5	O
)	O
has	O
permitted	O
the	O
accumulation	O
of	O
new	O
clinical	O
,	O
genetic	O
and	O
immunologic	O
data	O
concerning	O
the	O
role	O
of	O
C5	O
in	O
human	O
subjects	O
.	O

The	O
proband	O
,	O
who	O
has	O
had	O
nine	O
episodes	O
of	O
disseminated	O
gonococcal	B
infection	I
,	O
has	O
a	O
hemolytic	O
C5	O
level	O
of	O
approximately	O
0	O
.	O
5	O
per	O
cent	O
of	O
normal	O
.	O

No	O
C5	O
protein	O
was	O
detectable	O
,	O
but	O
low	O
levels	O
of	O
functional	O
C5	O
activity	O
could	O
be	O
found	O
using	O
a	O
sensitive	O
bactericidal	O
assay	O
.	O

The	O
probands	O
twin	O
as	O
well	O
as	O
another	O
sister	O
also	O
had	O
extremely	O
low	O
levels	O
of	O
hemolytic	O
C5	O
(	O
approximately	O
0	O
.	O
5	O
per	O
cent	O
normal	O
)	O
,	O
but	O
both	O
these	O
subjects	O
have	O
been	O
healthy	O
.	O

Hemolytic	O
complement	O
and	O
bacteriolytic	O
activity	O
could	O
be	O
restored	O
by	O
the	O
addition	O
of	O
purified	O
C5	O
.	O

No	O
chemotactic	O
activity	O
for	O
polymorphonuclear	O
leukocytes	O
could	O
be	O
generated	O
in	O
the	O
C5-deficient	B
serums	O
upon	O
activation	O
of	O
either	O
the	O
classic	O
or	O
alternative	O
pathways	O
,	O
again	O
demonstrating	O
the	O
importance	O
of	O
C5	O
in	O
human	O
subjects	O
for	O
the	O
production	O
of	O
chemotactic	O
factors	O
.	O

The	O
chemotactic	O
responsiveness	O
of	O
the	O
patients	O
polymorphonuclear	O
leukocytes	O
and	O
monocytes	O
to	O
preformed	O
chemotactic	O
factors	O
was	O
not	O
depressed	O
.	O

Twenty	O
-	O
two	O
of	O
32	O
other	O
family	O
members	O
from	O
three	O
generations	O
had	O
depressed	O
whole	O
hemolytic	O
complement	O
levels	O
.	O

In	O
19	O
of	O
30	O
family	O
members	O
,	O
levels	O
of	O
hemolytic	O
C5	O
ranged	O
from	O
13	O
to	O
64	O
per	O
cent	O
of	O
normal	O
.	O

No	O
linkage	O
for	O
C5	B
deficiency	I
and	O
the	O
A	O
or	O
B	O
loci	O
of	O
the	O
major	O
histocompatibility	O
complex	O
could	O
be	O
found	O
.	O

These	O
data	O
suggest	O
an	O
autosomal	O
codominant	O
mode	O
of	O
inheritance	O
of	O
C5	B
deficiency	I
.	O

Deficiency	B
of	I
C5	I
is	O
compatible	O
with	O
good	O
health	O
,	O
but	O
it	O
can	O
be	O
associated	O
with	O
repeated	O
disseminated	O
gonococcal	B
infection	I

Utilization	O
of	O
purines	O
by	O
an	O
HPRT	O
variant	O
in	O
an	O
intelligent	O
,	O
nonmutilative	O
patient	O
with	O
features	O
of	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

The	O
patient	O
,	O
H.	O
Chr	O
.	O

B.	O
,	O
was	O
among	O
the	O
first	O
reported	O
with	O
hyperuricemia	B
and	O
central	B
nervous	I
system	I
symptoms	I
.	O

He	O
has	O
been	O
found	O
to	O
have	O
a	O
variant	O
of	O
hypoxanthine	O
guanine	O
phosphoribosyl	O
transferase	O
(	O
HPRT	O
;	O
E.	O
C.	O
2	O
.	O
4	O
.	O
2	O
.	O

8)	O
distinct	O
from	O
the	O
enzyme	O
present	O
in	O
patients	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
.	O

The	O
patient	O
had	O
chroeoathetosis	B
,	O
spasticity	B
,	O
dysarthric	B
speech	I
,	O
and	O
hyperuricemia	B
.	O

However	O
,	O
his	O
intelligence	O
was	O
normal	O
and	O
he	O
had	O
no	O
evidence	O
of	O
self	O
-	O
mutilation	O
.	O

There	O
was	O
no	O
activity	O
of	O
HPRT	O
in	O
the	O
lysates	O
of	O
erythrocytes	O
and	O
cultured	O
fibroblasts	O
when	O
analyzed	O
in	O
the	O
usual	O
manner	O
.	O

Using	O
a	O
newly	O
developed	O
method	O
for	O
the	O
study	O
of	O
purine	O
metabolism	O
in	O
intact	O
cultured	O
cells	O
,	O
this	O
patient	O
was	O
found	O
to	O
metabolize	O
some	O
9	O
%	O
of	O
8	O
-	O
14C	O
-	O
hypoxanthine	O
,	O
and	O
90	O
%	O
of	O
the	O
isotope	O
utilized	O
was	O
converted	O
to	O
adenine	O
and	O
guanine	O
nucleotides	O
.	O

In	O
contrast	O
,	O
cells	O
from	O
patients	O
with	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I
were	O
virtually	O
completely	O
unable	O
to	O
convert	O
hypoxanthine	O
to	O
nucleotides	O
.	O

The	O
patients	O
fibroblasts	O
were	O
even	O
more	O
efficient	O
in	O
the	O
metabolism	O
of	O
8	O
-	O
14C	O
-	O
guanine	O
,	O
which	O
was	O
utilized	O
to	O
the	O
extent	O
of	O
27	O
%	O
,	O
over	O
80	O
%	O
of	O
which	O
was	O
converted	O
to	O
guanine	O
and	O
adenine	O
nucleotides	O
.	O

The	O
growth	O
of	O
the	O
cultured	O
fibroblasts	O
of	O
this	O
patient	O
was	O
intermediate	O
in	O
media	O
containing	O
hypoxanthine	O
aminopterin	O
thymidine	O
(	O
HAT	O
)	O
,	O
whereas	O
the	O
growth	O
of	O
Lesch	B
-	I
Nyhan	I
cells	O
was	O
inhibited	O
and	O
normal	O
cells	O
grew	O
normally	O
.	O

Similarly	O
in	O
8-azaguanine	O
,	O
6-thioguanine	O
,	O
and	O
8-azahypoxanthine	O
,	O
the	O
growth	O
of	O
the	O
patients	O
cells	O
was	O
intermediate	O
between	O
normal	O
and	O
Lesch	B
-	I
Nyhan	I
cells	O
.	O

These	O
observations	O
provide	O
further	O
evidence	O
for	O
genetic	O
heterogeneity	O
among	O
patients	O
with	O
disorders	O
in	O
purine	O
metabolism	O
involving	O
the	O
HPRT	O
gene	O
.	O

They	O
document	O
that	O
this	O
famous	O
patient	O
did	O
not	O
have	O
the	O
Lesch	B
-	I
Nyhan	I
syndrome	I

Allelic	O
exclusion	O
of	O
glucose-6-phosphate	O
dehydrogenase	O
in	O
platelets	O
and	O
T	O
lymphocytes	O
from	O
a	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
carrier	O
.	O

An	O
obligate	O
carrier	O
of	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
(	O
WAS	B
)	O
who	O
was	O
also	O
heterozygous	O
for	O
the	O
A	O
and	O
B	O
types	O
of	O
X	O
-	O
linked	O
glucose-6-phosphate	O
dehydrogenase	O
was	O
found	O
.	O

With	O
her	O
it	O
became	O
possible	O
to	O
determine	O
whether	O
allelic	O
exclusion	O
occurs	O
in	O
particular	O
cell	O
-	O
types	O
of	O
the	O
WAS	B
carrier	O
.	O

If	O
so	O
,	O
the	O
remaining	O
cells	O
of	O
a	O
particular	O
cell	O
-	O
type	O
would	O
express	O
only	O
the	O
normal	O
X	O
chromosome	O
and	O
only	O
one	O
glucose-6-phosphate	O
dehydrogenase	O
isoenzyme	O
would	O
be	O
demonstrable	O
.	O

This	O
carrier	O
had	O
only	O
the	O
B	O
isoenzyme	O
of	O
glucose-6-phosphate	O
dehydrogenase	O
in	O
platelets	O
and	O
thymus	O
-	O
derived	O
T	O
lymphocytes	O
,	O
although	O
both	O
isoenzymes	O
A	O
and	O
B	O
were	O
present	O
in	O
erythrocytes	O
and	O
neutrophils	O
.	O

These	O
findings	O
suggest	O
that	O
selection	O
against	O
the	O
WAS	B
gene	O
occurs	O
in	O
platelets	O
and	O
thymus	O
-	O
derived	O
T	O
lymphocytes	O
and	O
that	O
the	O
defects	O
associated	O
with	O
WAS	B
expressed	O
in	O
these	O
cell	O
-	O
types	O
may	O
be	O
implicated	O
in	O
the	O
genesis	O
of	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
..	O

Heterogeneity	O
of	O
glucose-6-phosphate	B
dehydrogenase	I
deficiency	I
in	O
Algeria	O
.	O

Study	O
in	O
Northern	O
Algeria	O
with	O
description	O
of	O
five	O
new	O
variants	O
.	O

Glucose-6-phosphate	B
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
was	O
found	O
in	O
3	O
.	O
2	O
%	O
of	O
the	O
male	O
population	O
living	O
in	O
the	O
urban	O
area	O
of	O
Algiers	O
.	O

The	O
deficient	O
subjects	O
originated	O
from	O
multiple	O
geographic	O
regions	O
of	O
Northern	O
Algeria	O
,	O
with	O
prevalence	O
of	O
individuals	O
of	O
Berber	O
-	O
Kabyle	O
origin	O
.	O

Red	O
blood	O
cell	O
G6PD	O
was	O
partially	O
purified	O
and	O
characterized	O
in	O
deficient	O
males	O
from	O
17	O
families	O
,	O
and	O
six	O
different	O
variants	O
were	O
found	O
.	O

Among	O
them	O
,	O
only	O
one	O
,	O
the	O
Gd	O
(	O
-	O
)	O
Kabyle	O
variant	O
,	O
had	O
been	O
previously	O
described	O
.	O

It	O
was	O
detected	O
in	O
nine	O
families	O
.	O

The	O
other	O
five	O
variants	O
were	O
new	O
Gd	O
(	O
-	O
)	O
Laghouat	O
(	O
four	O
cases	O
)	O
,	O
Gd	O
(	O
-	O
)	O
Blida	O
(	O
one	O
case	O
)	O
,	O
Gd	O
(	O
-	O
)	O
Thenia	O
(	O
one	O
case	O
)	O
,	O
Gd	O
(	O
-	O
)	O
Titteri	O
(	O
one	O
case	O
)	O
,	O
and	O
Gd	O
(	O
-	O
)	O
Alger	O
(	O
two	O
brothers	O
)	O
.	O

Strikingly	O
,	O
the	O
common	O
Mediterranean	O
variant	O
was	O
not	O
found	O
.	O

G6PD	B
deficiency	I
is	O
heterogeneous	O
in	O
northern	O
Algeria	O
where	O
autochtonous	O
variants	O
seem	O
to	O
prevail	O
.	O

The	O
Kabyle	O
variant	O
may	O
be	O
common	O
in	O
this	O
country	O
.	O

Bone	O
marrow	O
transplant	O
in	O
adrenoleukodystrophy	B
.	O

An	O
allogeneic	O
bone	O
marrow	O
transplant	O
(	O
BMT	O
)	O
from	O
a	O
normal	O
HLA	O
identical	O
sibling	O
donor	O
was	O
performed	O
in	O
a	O
13-year	O
-	O
old	O
boy	O
with	O
rapidly	O
progressive	O
adrenoleukodystrophy	B
(	O
ALD	B
)	O
.	O

Engraftment	O
and	O
complete	O
hematologic	O
recovery	O
occurred	O
within	O
4	O
weeks	O
,	O
but	O
neurologic	B
deterioration	I
continued	O
.	O

The	O
patient	O
died	O
of	O
an	O
adenovirus	B
infection	I
141	O
days	O
after	O
BMT	O
.	O

ALD	B
is	O
characterized	O
by	O
abnormally	O
high	O
plasma	O
levels	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
(	O
VLCFA	O
)	O
as	O
a	O
result	O
of	O
impaired	O
capacity	O
to	O
degrade	O
them	O
.	O

Ten	O
days	O
after	O
BMT	O
,	O
the	O
white	O
blood	O
cell	O
VLCFA	O
levels	O
and	O
enzyme	O
activity	O
became	O
normal	O
;	O
after	O
3	O
months	O
,	O
there	O
was	O
progressive	O
reduction	O
of	O
plasma	O
VLCFA	O
to	O
levels	O
only	O
slightly	O
above	O
normal	O
..	O

Nephropathy	B
in	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
.	O

Nephropathy	B
was	O
detected	O
in	O
five	O
of	O
32	O
patients	O
with	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
who	O
were	O
participating	O
in	O
a	O
study	O
of	O
transfer	O
factor	O
(	O
TF	O
)	O
therapy	O
.	O

In	O
two	O
patients	O
,	O
nephropathy	B
was	O
present	O
before	O
TF	O
and	O
did	O
not	O
appear	O
changed	O
by	O
TF	O
therapy	O
.	O

One	O
of	O
these	O
patients	O
subsequently	O
developed	O
progressive	O
renal	B
failure	I
requiring	O
dialysis	O
beginning	O
5	O
1	O
/	O
2	O
years	O
after	O
TF	O
therapy	O
.	O

In	O
two	O
patients	O
,	O
decreased	O
renal	O
function	O
appeared	O
very	O
soon	O
after	O
the	O
administration	O
of	O
TF	O
.	O

One	O
patient	O
showed	O
gradually	O
decreasing	O
renal	O
function	O
beginning	O
after	O
two	O
years	O
of	O
TF	O
therapy	O
.	O

An	O
additional	O
patient	O
was	O
identified	O
who	O
died	O
with	O
renal	B
failure	I
without	O
having	O
received	O
TF	O
.	O

The	O
results	O
suggest	O
that	O
renal	B
failure	I
occurs	O
in	O
the	O
Wiskott	B
-	I
Aldrich	I
syndrome	I
more	O
frequently	O
than	O
generally	O
recognized	O
and	O
that	O
administration	O
of	O
TF	O
may	O
precipitate	O
or	O
accelerate	O
the	O
renal	B
disease	I
in	O
patients	O
with	O
this	O
syndrome	O
..	O

Increased	O
incidence	O
of	O
cataracts	B
in	O
male	O
subjects	O
deficient	B
in	I
glucose-6-phosphate	I
dehydrogenase	I
.	O

Glucose-6-phosphate	B
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
in	O
RBCs	O
was	O
found	O
significantly	O
more	O
frequently	O
in	O
210	O
male	O
cataractous	B
patients	O
than	O
in	O
672	O
control	O
subjects	O
of	O
Sardinian	O
origin	O
.	O

The	O
frequency	O
of	O
the	O
deficiency	O
was	O
increasingly	O
higher	O
in	O
presenile	O
cataracts	B
.	O

In	O
the	O
G6PD	B
-	I
deficient	I
group	O
,	O
the	O
incidence	O
of	O
cortical	B
and	I
total	I
cataracts	I
was	O
also	O
increased	O
.	O

It	O
is	O
suggested	O
that	O
decrease	O
of	O
the	O
G6PD	O
activity	O
in	O
the	O
lens	O
,	O
which	O
accompanies	O
its	O
deficiency	O
in	O
the	O
erythrocyte	O
,	O
might	O
play	O
a	O
role	O
in	O
the	O
cataracto	O
-	O
genesis	O
of	O
these	O
patients	O
.	O

Moreover	O
,	O
G6PD	B
deficiency	I
should	O
be	O
added	O
to	O
other	O
conditions	O
,	O
such	O
as	O
the	O
galactosemic	B
states	O
and	O
riboflavin	B
deficiency	I
,	O
where	O
cataracts	B
represent	O
a	O
sensitive	O
indicator	O
of	O
metabolic	B
abnormalities	I
of	O
the	O
RBC	O
..	O

Molecular	O
characterization	O
of	O
galactosemia	B
(	O
type	O
1	O
)	O
mutations	O
in	O
Japanese	O
.	O

We	O
characterized	O
two	O
novel	O
mutations	O
of	O
the	O
galactose-1-phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
gene	O
in	O
two	O
Japanese	O
patients	O
with	O
GALT	B
deficiency	I
and	O
identified	O
N314D	O
and	O
R333W	O
mutations	O
,	O
previously	O
found	O
in	O
Caucasians	O
.	O

One	O
novel	O
missense	O
mutation	O
was	O
an	O
G	O
-	O
to	O
-	O
A	O
transition	O
in	O
exon	O
8	O
,	O
resulting	O
in	O
the	O
substitution	O
of	O
arginine	O
by	O
histidine	O
at	O
the	O
codon	O
231	O
(	O
R231H	O
)	O
.	O

GALT	O
activity	O
of	O
the	O
R231H	O
mutant	O
construct	O
was	O
reduced	O
to	O
15	O
%	O
of	O
normal	O
controls	O
in	O
a	O
COS	O
cell	O
expression	O
system	O
.	O

The	O
other	O
was	O
a	O
splicing	O
mutation	O
,	O
an	O
A	O
-	O
to	O
-	O
G	O
transition	O
at	O
the	O
38th	O
nucleotide	O
in	O
exon	O
3	O
(	O
318A--	O
>	O
G	O
)	O
,	O
resulting	O
in	O
a	O
38-bp	O
deletion	O
in	O
the	O
GALT	O
cDNA	O
by	O
activating	O
a	O
cryptic	O
splice	O
acceptor	O
site	O
.	O

In	O
seven	O
Japanese	O
families	O
(	O
14	O
alleles	O
for	O
classic	O
form	O
and	O
one	O
allele	O
for	O
Duarte	O
variant	O
)	O
with	O
GALT	B
deficiency	I
,	O
the	O
R231H	O
and	O
318A--	O
>	O
G	O
mutations	O
were	O
found	O
only	O
on	O
both	O
alleles	O
of	O
the	O
proband	O
.	O

The	O
N314D	O
and	O
R333W	O
mutations	O
were	O
found	O
on	O
one	O
allele	O
each	O
.	O

The	O
Q188R	O
was	O
prevalent	O
in	O
the	O
United	O
States	O
but	O
not	O
in	O
Japanese	O
patients	O
.	O

The	O
N314D	O
mutation	O
was	O
associated	O
with	O
the	O
Duarte	O
variant	O
in	O
Japanese	O
persons	O
,	O
as	O
well	O
as	O
in	O
the	O
United	O
States	O
.	O

We	O
speculate	O
that	O
classic	B
galactosemia	I
mutations	O
appear	O
to	O
differ	O
between	O
Japanese	O
and	O
Caucasian	O
patients	O
.	O

Our	O
limited	O
data	O
set	O
on	O
galactosemia	B
mutations	O
in	O
Japanese	O
suggests	O
that	O
the	O
N314D	O
GALT	O
mutation	O
encoding	O
the	O
Duarte	O
variant	O
arose	O
before	O
Asian	O
and	O
Caucasian	O
people	O
diverged	O
and	O
that	O
classic	B
galactosemia	I
mutations	O
arose	O
and/or	O
accumulated	O
after	O
the	O
divergence	O
of	O
Asian	O
and	O
Caucasian	O
populations	O
..	O

Three	O
novel	O
aniridia	B
mutations	O
in	O
the	O
human	O
PAX6	O
gene	O
.	O

Aniridia	B
(	O
iris	B
hypoplasia	I
)	O
is	O
an	O
autosomal	B
dominant	I
congenital	I
disorder	I
of	I
the	I
eye	I
.	O

Mutations	O
in	O
the	O
human	O
aniridia	B
(	O
PAX6	O
)	O
gene	O
have	O
now	O
been	O
identified	O
in	O
many	O
patients	O
from	O
various	O
ethnic	O
groups	O
.	O

In	O
the	O
study	O
reported	O
here	O
we	O
describe	O
PAX6	O
mutations	O
in	O
one	O
sporadic	O
and	O
five	O
familial	O
cases	O
with	O
aniridia	B
.	O

Of	O
the	O
four	O
different	O
mutations	O
identified	O
,	O
one	O
was	O
identical	O
to	O
a	O
previously	O
reported	O
mutation	O
(	O
C--	O
>	O
T	O
transition	O
at	O
codon	O
240	O
)	O
,	O
and	O
three	O
were	O
novel	O
two	O
in	O
the	O
glycine	O
-	O
rich	O
region	O
and	O
one	O
in	O
the	O
proline	O
/	O
serine	O
/	O
threonine	O
-	O
rich	O
(	O
PST	O
)	O
region	O
.	O

One	O
PAX6	O
mutation	O
found	O
in	O
the	O
PST	O
region	O
was	O
associated	O
with	O
cataracts	B
in	O
an	O
aniridia	B
family	O
.	O

Another	O
splice	O
mutation	O
in	O
the	O
PST	O
domain	O
occurred	O
in	O
an	O
aniridia	B
patient	O
with	O
anosmia	B
(	O
inability	O
to	O
smell	O
)	O
.	O

The	O
six	O
new	O
aniridia	B
cases	O
reported	O
here	O
have	O
mutations	O
predicted	O
to	O
generate	O
incomplete	O
PAX6	O
proteins	O
.	O

These	O
results	O
support	O
the	O
theory	O
that	O
human	O
aniridia	B
is	O
caused	O
by	O
haploinsufficiency	B
of	I
PAX6	I
..	O

Myotonia	B
levior	I
is	O
a	O
chloride	B
channel	I
disorder	I
.	O

The	O
group	O
of	O
dominant	B
non	I
-	I
dystrophic	I
myotonias	I
,	O
comprising	O
disorders	O
characterized	O
by	O
clinically	O
similar	O
forms	O
of	O
myogenic	O
muscle	O
stiffness	O
,	O
is	O
genetically	O
inhomogeneous	O
.	O

Dominant	B
myotonia	I
congenita	I
(	O
Thomsens	B
disease	I
)	O
is	O
linked	O
to	O
CLCN1	O
,	O
the	O
gene	O
encoding	O
the	O
major	O
muscle	O
chloride	O
channel	O
,	O
localized	O
on	O
chromosome	O
7q35	O
.	O

In	O
contrast	O
,	O
dominant	B
myotonias	I
sensitive	O
to	O
potassium	O
are	O
caused	O
by	O
point	O
mutations	O
in	O
SCN4A	O
on	O
chromosome	O
17q	O
,	O
the	O
gene	O
for	O
the	O
alpha	O
subunit	O
of	O
the	O
adult	O
skeletal	O
muscle	O
sodium	O
channel	O
.	O

No	O
linkage	O
or	O
molecular	O
genetic	O
data	O
are	O
as	O
yet	O
available	O
on	O
myotonia	B
levior	I
characterized	O
by	O
milder	O
symptoms	O
and	O
later	O
onset	O
of	O
myotonia	B
than	O
in	O
Thomsens	B
disease	I
,	O
and	O
absence	O
of	O
muscle	B
hypertrophy	I
.	O

We	O
report	O
a	O
CLCN1	O
Gln-552-Arg	O
substitution	O
for	O
a	O
family	O
with	O
dominant	O
inheritance	O
previously	O
diagnosed	O
to	O
have	O
myotonia	B
levior	I
.	O

Thus	O
,	O
this	O
disorder	O
appears	O
as	O
a	O
variant	O
of	O
Thomsens	B
disease	I
due	O
to	O
mutations	O
leading	O
to	O
low	O
clinical	O
expressivity	O
.	O

In	O
addition	O
,	O
we	O
report	O
a	O
novel	O
Ile-290-Met	O
CLCN1	O
mutation	O
for	O
a	O
typical	O
Thomsen	O
pedigree	O
.	O

In	O
another	O
family	O
previously	O
diagnosed	O
as	O
having	O
Thomsens	B
disease	I
,	O
we	O
unexpectedly	O
found	O
a	O
CLCN1	O
14	O
bp	O
deletion	O
known	O
to	O
cause	O
recessive	B
myotonia	I
,	O
and	O
a	O
rare	O
Trp-118-Gly	O
polymorphism	O
..	O

Natural	O
selection	O
of	O
hemi-	O
and	O
heterozygotes	O
for	O
G6PD	B
deficiency	I
in	O
Africa	O
by	O
resistance	O
to	O
severe	O
malaria	B
.	O

Glucose-6-phosphate	B
dehydrogenase	I
(	I
G6PD	I
)	I
deficiency	I
,	O
the	O
most	O
common	O
enzymopathy	B
of	O
humans	O
,	O
affects	O
over	O
400	O
million	O
people	O
.	O

The	O
geographical	O
correlation	O
of	O
its	O
distribution	O
with	O
the	O
historical	O
endemicity	O
of	O
malaria	B
suggests	O
that	O
this	O
disorder	O
has	O
risen	O
in	O
frequency	O
through	O
natural	O
selection	O
by	O
malaria	B
.	O

However	O
,	O
attempts	O
to	O
confirm	O
that	O
G6PD	B
deficiency	I
is	O
protective	O
in	O
case	O
-	O
control	O
studies	O
of	O
malaria	B
have	O
yielded	O
conflicting	O
results	O
.	O

Hence	O
,	O
for	O
this	O
X	B
-	I
linked	I
disorder	I
,	O
it	O
is	O
unclear	O
whether	O
both	O
male	O
hemizygotes	O
and	O
female	O
heterozygotes	O
are	O
protected	O
or	O
,	O
as	O
frequently	O
suggested	O
,	O
only	O
females	O
.	O

Furthermore	O
,	O
how	O
much	O
protection	O
may	O
be	O
afforded	O
is	O
unknown	O
.	O

Here	O
we	O
report	O
that	O
,	O
in	O
two	O
large	O
case	O
-	O
control	O
studies	O
of	O
over	O
2	O
,	O
000	O
African	O
children	O
,	O
the	O
common	O
African	O
form	O
of	O
G6PD	B
deficiency	I
(	O
G6PD	B
A-	I
)	O
is	O
associated	O
with	O
a	O
46	O
-	O
58	O
%	O
reduction	O
in	O
risk	O
of	O
severe	O
malaria	B
for	O
both	O
female	O
heterozygotes	O
and	O
male	O
hemizygotes	O
.	O

A	O
mathematical	O
model	O
incorporating	O
the	O
measured	O
selective	O
advantage	O
against	O
malaria	B
suggests	O
that	O
a	O
counterbalancing	O
selective	O
disadvantage	O
,	O
associated	O
with	O
this	O
enzyme	B
deficiency	I
,	O
has	O
retarded	O
its	O
rise	O
in	O
frequency	O
in	O
malaria	B
-	O
endemic	O
regions	O
.	O

Although	O
G6PD	B
deficiency	I
is	O
now	O
regarded	O
as	O
a	O
generally	O
benign	O
disorder	O
,	O
in	O
earlier	O
environmental	O
conditions	O
it	O
could	O
have	O
been	O
significantly	O
disadvantageous	O
..	O

Structural	O
analysis	O
of	O
the	O
5	O
'	O
region	O
of	O
mouse	O
and	O
human	O
Huntington	B
disease	I
genes	O
reveals	O
conservation	O
of	O
putative	O
promoter	O
region	O
and	O
di-	O
and	O
trinucleotide	O
polymorphisms	O
.	O

We	O
have	O
previously	O
cloned	O
and	O
characterized	O
the	O
murine	O
homologue	O
of	O
the	O
Huntington	B
disease	I
(	O
HD	B
)	O
gene	O
and	O
shown	O
that	O
it	O
maps	O
to	O
mouse	O
chromosome	O
5	O
within	O
a	O
region	O
of	O
conserved	O
synteny	O
with	O
human	O
chromosome	O
4p16	O
.	O

3	O
3	O
.	O

Here	O
we	O
present	O
a	O
detailed	O
comparison	O
of	O
the	O
sequence	O
of	O
the	O
putative	O
promoter	O
and	O
the	O
organization	O
of	O
the	O
5	O
genomic	O
region	O
of	O
the	O
murine	O
(	O
Hdh	O
)	O
and	O
human	O
HD	B
genes	O
encompassing	O
the	O
first	O
five	O
exons	O
.	O

We	O
show	O
that	O
in	O
this	O
region	O
these	O
two	O
genes	O
share	O
identical	O
exon	O
boundaries	O
,	O
but	O
have	O
different	O
-	O
size	O
introns	O
.	O

Two	O
dinucleotide	O
(	O
CT	O
)	O
and	O
one	O
trinucleotide	O
intronic	O
polymorphism	O
in	O
Hdh	O
and	O
an	O
intronic	O
CA	O
polymorphism	O
in	O
the	O
HD	B
gene	O
were	O
identified	O
.	O

Comparison	O
of	O
940-bp	O
sequence	O
5	O
to	O
the	O
putative	O
translation	O
start	O
site	O
reveals	O
a	O
highly	O
conserved	O
region	O
(	O
78	O
.	O
8	O
%	O
nucleotide	O
identity	O
)	O
between	O
Hdh	O
and	O
the	O
HD	B
gene	O
from	O
nucleotide	O
-56	O
to	O
-206	O
(	O
of	O
Hdh	O
)	O
.	O

Neither	O
Hdh	O
nor	O
the	O
HD	B
gene	O
have	O
typical	O
TATA	O
or	O
CCAAT	O
elements	O
,	O
but	O
both	O
show	O
one	O
putative	O
AP2	O
binding	O
site	O
and	O
numerous	O
potential	O
Sp1	O
binding	O
sites	O
.	O

The	O
high	O
sequence	O
identity	O
between	O
Hdh	O
and	O
the	O
HD	B
gene	O
for	O
approximately	O
200	O
bp	O
5	O
to	O
the	O
putative	O
translation	O
start	O
site	O
indicates	O
that	O
these	O
sequences	O
may	O
play	O
a	O
role	O
in	O
regulating	O
expression	O
of	O
the	O
Huntington	B
disease	I
gene	O

Somatic	O
mutations	O
in	O
the	O
BRCA1	O
gene	O
in	O
sporadic	B
ovarian	I
tumours	I
.	O

The	O
BRCA1	O
gene	O
on	O
chromosome	O
17q21	O
is	O
responsible	O
for	O
an	O
autosomal	B
dominant	I
syndrome	I
of	O
increased	O
susceptibility	O
to	O
breast	B
and	I
ovarian	I
cancer	I
but	O
no	O
somatic	O
mutations	O
in	O
tumours	B
have	O
yet	O
been	O
described	O
.	O

To	O
study	O
the	O
potential	O
role	O
of	O
BRCA1	O
in	O
sporadic	O
carcinogenesis	O
,	O
we	O
analysed	O
the	O
genomic	O
DNA	O
of	O
tumour	B
and	O
normal	O
fractions	O
of	O
47	O
ovarian	B
cancers	I
for	O
mutations	O
in	O
BRCA1	O
using	O
the	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
technique	O
.	O

We	O
now	O
describe	O
somatic	O
mutations	O
in	O
the	O
DNA	O
of	O
four	O
tumours	B
which	O
also	O
had	O
loss	O
of	O
heterozygosity	O
(	O
LOH	O
)	O
at	O
a	O
BRCA1	O
intragenic	O
marker	O
.	O

Our	O
data	O
support	O
a	O
tumour	B
suppressor	O
mechanism	O
for	O
BRCA1	O
;	O
somatic	O
mutations	O
and	O
LOH	O
may	O
result	O
in	O
inactivation	O
of	O
BRCA1	O
in	O
at	O
least	O
a	O
small	O
number	O
of	O
ovarian	B
cancers	I
..	O

Decreased	O
expression	O
of	O
BRCA1	O
accelerates	O
growth	O
and	O
is	O
often	O
present	O
during	O
sporadic	B
breast	I
cancer	I
progression	O
.	O

We	O
have	O
characterized	O
expression	O
of	O
the	O
familial	B
breast	I
and	I
ovarian	I
cancer	I
gene	O
,	O
BRCA1	O
,	O
in	O
cases	O
of	O
non	B
-	I
hereditary	I
(	I
sporadic	I
)	I
breast	I
cancer	I
and	O
analyzed	O
the	O
effect	O
of	O
antisense	O
inhibition	O
of	O
BRCA1	O
on	O
the	O
proliferative	O
rate	O
of	O
mammary	O
epithelial	O
cells	O
.	O

BRCA1	O
mRNA	O
levels	O
are	O
markedly	O
decreased	O
during	O
the	O
transition	O
from	O
carcinoma	B
in	I
situ	I
to	O
invasive	B
cancer	I
.	O

Experimental	O
inhibition	O
of	O
BRCA1	O
expression	O
with	O
antisense	O
oligonucleotides	O
produced	O
accelerated	O
growth	O
of	O
normal	O
and	O
malignant	O
mammary	O
cells	O
,	O
but	O
had	O
no	O
effect	O
on	O
non	O
-	O
mammary	O
epithelial	O
cells	O
.	O

These	O
studies	O
suggest	O
that	O
BRCA1	O
may	O
normally	O
serve	O
as	O
a	O
negative	O
regulator	O
of	O
mammary	O
epithelial	O
cell	O
growth	O
whose	O
function	O
is	O
compromised	O
in	O
breast	B
cancer	I
either	O
by	O
direct	O
mutation	O
or	O
alterations	O
in	O
gene	O
expression	O
..	O

Mutations	O
in	O
the	O
BRCA1	O
gene	O
in	O
families	O
with	O
early	O
-	O
onset	O
breast	B
and	I
ovarian	I
cancer	I
.	O

We	O
analysed	O
50	O
probands	O
with	O
a	O
family	O
history	O
of	O
breast	B
and/or	I
ovarian	I
cancer	I
for	O
germline	O
mutations	O
in	O
the	O
coding	O
region	O
of	O
the	O
BRCA1	O
candidate	O
gene	O
,	O
using	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
(	O
SSCP	O
)	O
analysis	O
on	O
PCR	O
-	O
amplified	O
genomic	O
DNA	O
.	O

A	O
total	O
of	O
eight	O
putative	O
disease	O
-	O
causing	O
alterations	O
were	O
identified	O
four	O
of	O
these	O
are	O
frameshifts	O
and	O
two	O
are	O
nonsense	O
mutations	O
.	O

In	O
addition	O
,	O
we	O
found	O
two	O
missense	O
mutations	O
,	O
one	O
of	O
which	O
changes	O
the	O
final	O
cysteine	O
of	O
the	O
BRCA1	O
zinc	O
finger	O
motif	O
to	O
glycine	O
.	O

These	O
data	O
are	O
consistent	O
with	O
a	O
tumour	B
suppressor	O
model	O
,	O
and	O
support	O
the	O
notion	O
that	O
this	O
candidate	O
gene	O
is	O
in	O
fact	O
BRCA1	O
.	O

The	O
heterogeneity	O
of	O
mutations	O
,	O
coupled	O
with	O
the	O
large	O
size	O
of	O
the	O
gene	O
,	O
indicates	O
that	O
clinical	O
application	O
of	O
BRCA1	O
mutation	O
testing	O
will	O
be	O
technically	O
challenging	O
..	O

Confirmation	O
of	O
BRCA1	O
by	O
analysis	O
of	O
germline	O
mutations	O
linked	O
to	O
breast	B
and	I
ovarian	I
cancer	I
in	O
ten	O
families	O
.	O

We	O
provide	O
genetic	O
evidence	O
supporting	O
the	O
identity	O
of	O
the	O
candidate	O
gene	O
for	O
BRCA1	O
through	O
the	O
characterization	O
of	O
germline	O
mutations	O
in	O
63	O
breast	B
cancer	I
patients	O
and	O
10	O
ovarian	B
cancer	I
patients	O
in	O
ten	O
families	O
with	O
cancer	B
linked	O
to	O
chromosome	O
17q21	O
.	O

Nine	O
different	O
mutations	O
were	O
detected	O
by	O
screening	O
BRCA1	O
DNA	O
and	O
RNA	O
by	O
single	O
-	O
strand	O
conformation	O
polymorphism	O
analysis	O
and	O
direct	O
sequencing	O
.	O

Seven	O
mutations	O
lead	O
to	O
protein	O
truncations	O
at	O
sites	O
throughout	O
the	O
gene	O
.	O

One	O
missense	O
mutation	O
(	O
which	O
occurred	O
independently	O
in	O
two	O
families	O
)	O
leads	O
to	O
loss	O
of	O
a	O
cysteine	O
in	O
the	O
zinc	O
binding	O
domain	O
.	O

An	O
intronic	O
single	O
basepair	O
substitution	O
destroys	O
an	O
acceptor	O
site	O
and	O
activates	O
a	O
cryptic	O
splice	O
site	O
,	O
leading	O
to	O
a	O
59	O
basepair	O
insertion	O
and	O
chain	O
termination	O
.	O

The	O
four	O
families	O
with	O
both	O
breast	B
and	I
ovarian	I
cancer	I
had	O
chain	O
termination	O
mutations	O
in	O
the	O
N	O
-	O
terminal	O
half	O
of	O
the	O
protein	O
..	O

High	O
resolution	O
genetic	O
analysis	O
suggests	O
one	O
ancestral	O
predisposing	O
haplotype	O
for	O
the	O
origin	O
of	O
the	O
myotonic	B
dystrophy	I
mutation	O
.	O

The	O
mutation	O
causing	O
myotonic	B
dystrophy	I
(	O
DM	B
)	O
has	O
been	O
identified	O
as	O
an	O
amplification	O
of	O
an	O
unstable	O
trinucleotide	O
(	O
CTG	O
)	O
n	O
repeat	O
in	O
over	O
99	O
%	O
of	O
the	O
global	O
DM	B
population	O
.	O

It	O
is	O
in	O
complete	O
linkage	O
disequilibrium	O
with	O
an	O
Alu	O
element	O
polymorphism	O
within	O
the	O
DM	B
kinase	O
gene	O
,	O
suggesting	O
that	O
DM	B
is	O
a	O
consequence	O
of	O
one	O
or	O
few	O
ancestral	O
mutations	O
.	O

A	O
recent	O
analysis	O
utilizing	O
this	O
polymorphism	O
as	O
well	O
as	O
a	O
flanking	O
dinucleotide	O
marker	O
,	O
suggested	O
that	O
similar	O
to	O
Fragile	B
X	I
syndrome	I
,	O
DM	B
exhibited	O
a	O
founder	O
effect	O
(	O
Imbert	O
et	O
al.	O
,	O
1993	O
Nature	O
Genet	O
.	O

4	O
,	O
72	O
-	O
76	O
)	O
.	O

In	O
contrast	O
,	O
the	O
low	O
reproductive	O
fitness	O
of	O
individuals	O
with	O
congenital	O
DM	B
(	O
the	O
endpoint	O
of	O
genetic	O
anticipation	O
in	O
myotonic	B
dystrophy	I
)	O
suggests	O
a	O
higher	O
rate	O
of	O
new	O
mutations	O
.	O

We	O
present	O
a	O
high	O
resolution	O
genetic	O
analysis	O
of	O
the	O
DM	B
locus	O
using	O
PCR	O
based	O
assays	O
of	O
nine	O
polymorphisms	O
,	O
spanning	O
a	O
physical	O
distance	O
of	O
30	O
kb	O
,	O
within	O
and	O
immediately	O
flanking	O
the	O
DM	B
kinase	O
gene	O
.	O

The	O
persistent	O
complete	O
allelic	O
association	O
of	O
the	O
DM	B
mutation	O
with	O
all	O
these	O
polymorphisms	O
provides	O
further	O
support	O
to	O
previous	O
observations	O
and	O
suggests	O
more	O
strongly	O
that	O
the	O
DM	B
mutation	O
occurred	O
on	O
the	O
background	O
of	O
a	O
particular	O
haplotype	O
in	O
which	O
the	O
(	O
CTG	O
)	O
n	O
repeat	O
became	O
inherently	O
unstable	O
and	O
therefore	O
predisposed	O
to	O
amplification	O
.	O

Genomic	O
organization	O
of	O
the	O
adrenoleukodystrophy	B
gene	O
.	O

Adrenoleukodystrophy	B
(	O
ALD	B
)	O
,	O
the	O
most	O
frequent	O
peroxisomal	B
disorder	I
,	O
is	O
a	O
severe	O
neurodegenerative	B
disease	I
associated	O
with	O
an	O
impairment	B
of	I
very	I
long	I
chain	I
fatty	I
acids	I
beta	I
-	I
oxidation	I
.	O

We	O
have	O
recently	O
identified	O
by	O
positional	O
cloning	O
the	O
gene	O
responsible	O
for	O
ALD	B
,	O
located	O
in	O
Xq28	O
.	O

It	O
encodes	O
a	O
new	O
member	O
of	O
the	O
""""	O
ABC	O
""""	O
superfamily	O
of	O
membrane	O
-	O
associated	O
transporters	O
that	O
shows	O
,	O
in	O
particular	O
,	O
significant	O
homology	O
to	O
the	O
70-kDa	O
peroxisomal	O
membrane	O
protein	O
(	O
PMP70	O
)	O
.	O

We	O
report	O
here	O
a	O
detailed	O
characterization	O
of	O
the	O
ALD	B
gene	O
structure	O
.	O

It	O
extends	O
over	O
21	O
kb	O
and	O
consists	O
of	O
10	O
exons	O
.	O

To	O
facilitate	O
the	O
detection	O
of	O
mutations	O
in	O
ALD	B
patients	O
,	O
we	O
have	O
determined	O
the	O
intronic	O
sequences	O
flanking	O
the	O
exons	O
as	O
well	O
as	O
the	O
sequence	O
of	O
the	O
3	O
untranslated	O
region	O
and	O
of	O
the	O
immediate	O
5	O
promoter	O
region	O
.	O

Sequences	O
present	O
in	O
distal	O
exons	O
cross	O
-	O
hybridize	O
strongly	O
to	O
additional	O
sequences	O
in	O
the	O
human	O
genome	O
.	O

The	O
ALD	B
gene	O
has	O
been	O
positioned	O
on	O
a	O
pulsed	O
-	O
field	O
map	O
between	O
DXS15	O
and	O
the	O
L1CAM	O
gene	O
,	O
about	O
650	O
kb	O
upstream	O
from	O
the	O
color	O
pigment	O
genes	O
.	O

The	O
frequent	O
occurrence	O
of	O
color	O
vision	O
anomalies	O
observed	O
in	O
patients	O
with	O
adrenomyeloneuropathy	B
(	O
the	O
adult	O
onset	O
form	O
of	O
ALD	B
)	O
thus	O
does	O
not	O
represent	O
a	O
contiguous	B
gene	I
syndrome	I
but	O
a	O
secondary	O
manifestation	O
of	O
ALD	B
..	O

Predominance	O
of	O
the	O
adrenomyeloneuropathy	B
phenotype	O
of	O
X	B
-	I
linked	I
adrenoleukodystrophy	I
in	O
The	O
Netherlands	O
:	O
a	O
survey	O
of	O
30	O
kindreds	O
.	O

X	B
-	I
linked	I
adrenoleukodystrophy	I
(	O
X	B
-	I
ALD	I
)	O
is	O
an	O
inherited	B
disorder	I
of	O
peroxisomal	O
beta	O
-	O
oxidation	O
associated	O
with	O
accumulation	O
of	O
saturated	O
very	O
long	O
-	O
chain	O
fatty	O
acids	O
,	O
which	O
results	O
in	O
central	O
and	O
peripheral	O
demyelination	B
and	O
in	O
impaired	B
function	I
of	I
adrenal	I
cortex	I
and	I
testes	I
.	O

The	O
phenotypic	O
expression	O
is	O
highly	O
variable	O
,	O
childhood	B
cerebral	I
ALD	I
(	O
CCALD	B
)	O
and	O
adrenomyeloneuropathy	B
(	O
AMN	B
)	O
being	O
the	O
main	O
variants	O
.	O

We	O
explored	O
the	O
30	O
Dutch	O
kindreds	O
well	O
known	O
to	O
the	O
Dutch	O
X	B
-	I
ALD	I
/	O
AMN	B
Study	O
Group	O
and	O
phenotyped	O
77	O
male	O
patients	O
35	O
(	O
46	O
%	O
)	O
had	O
AMN	B
and	O
24	O
(	O
31	O
%	O
)	O
CCALD	B
or	O
adolescent	B
cerebral	I
ALD	I
(	O
AdolCALD	B
)	O
.	O

These	O
percentages	O
differ	O
significantly	O
from	O
previous	O
reports	O
,	O
in	O
which	O
25	O
to	O
28	O
%	O
of	O
the	O
patients	O
developed	O
AMN	B
and	O
53	O
to	O
57	O
%	O
CCALD	B
or	O
AdolCALD	B
.	O

Our	O
findings	O
indicate	O
that	O
--	O
at	O
least	O
in	O
the	O
Netherlands	O
--	O
AMN	B
may	O
be	O
the	O
most	O
frequent	O
phenotype	O
of	O
X	B
-	I
ALD	I
..	O

Structure	O
of	O
the	O
human	O
Na+	O
/	O
glucose	O
cotransporter	O
gene	O
SGLT1	O
.	O

Intestinal	O
uptake	O
of	O
dietary	O
glucose	O
and	O
galactose	O
is	O
mediated	O
by	O
the	O
SGLT1	O
Na	O
+	O
/glucose	O
cotransporter	O
of	O
the	O
brush	O
border	O
.	O

An	O
SGLT1	O
missense	O
mutation	O
underlies	O
hereditary	B
glucose	I
/	I
galactose	I
malabsorption	I
,	O
characterized	O
by	O
potentially	O
fatal	O
diarrhea	B
;	O
conversely	O
,	O
oral	O
rehydration	O
therapy	O
exploits	O
normal	O
transport	O
to	O
alleviate	O
life	O
-	O
threatening	O
diarrhea	B
of	O
infectious	O
origin	O
.	O

We	O
have	O
mapped	O
the	O
entire	O
human	O
SGLT1	O
Na	O
+	O
/glucose	O
cotransporter	O
gene	O
from	O
cosmid	O
and	O
lambda	O
phage	O
clones	O
representing	O
a	O
genomic	O
region	O
of	O
112	O
kilobases	O
.	O

Transcription	O
initiation	O
occurred	O
from	O
a	O
site	O
27	O
base	O
pairs	O
3	O
of	O
a	O
TATAA	O
sequence	O
.	O

All	O
exon	O
-	O
flanking	O
regions	O
were	O
sequenced	O
,	O
and	O
the	O
entire	O
112-kilobase	O
region	O
mapped	O
with	O
four	O
restriction	O
enzymes	O
.	O

SGLT1	O
is	O
comprised	O
of	O
15	O
exons	O
(	O
spanning	O
72	O
kilobases	O
)	O
;	O
a	O
possible	O
evolutionary	O
origin	O
from	O
a	O
six	O
-	O
membrane	O
-	O
span	O
ancestral	O
precursor	O
via	O
a	O
gene	O
duplication	O
event	O
is	O
suggested	O
from	O
comparison	O
of	O
exons	O
against	O
protein	O
secondary	O
structure	O
and	O
from	O
sequence	O
considerations	O
.	O

A	O
new	O
missense	O
mutation	O
in	O
exon	O
1	O
causing	O
glucose	B
/	I
galactose	I
malabsorption	I
is	O
also	O
described	O
.	O

This	O
is	O
the	O
first	O
Na	O
(	O
+	O
)	O
-dependent	O
cotransporter	O
gene	O
structure	O
reported	O
.	O

These	O
data	O
facilitate	O
the	O
search	O
for	O
new	O
glucose	B
/	I
galactose	I
malabsorption	I
-	O
related	O
mutations	O
in	O
this	O
important	O
gene	O
and	O
provide	O
a	O
basis	O
for	O
future	O
evolutionary	O
comparisons	O
with	O
other	O
Na	O
(	O
+	O
)	O
-dependent	O
cotransporters	O
..	O

Association	O
of	O
the	O
APC	B
tumor	I
suppressor	O
protein	O
with	O
catenins	O
.	O

Mutations	O
of	O
APC	O
appear	O
to	O
initiate	O
sporadic	O
and	O
inherited	O
forms	O
of	O
human	O
colorectal	B
cancer	I
.	O

Although	O
these	O
mutations	O
have	O
been	O
well	O
characterized	O
,	O
little	O
is	O
known	O
about	O
the	O
function	O
of	O
the	O
APC	B
gene	O
product	O
.	O

Two	O
cellular	O
proteins	O
that	O
associate	O
with	O
APC	B
were	O
identified	O
by	O
nucleotide	O
sequence	O
analysis	O
and	O
peptide	O
mapping	O
as	O
the	O
E	O
-	O
cadherin	O
-	O
associated	O
proteins	O
alpha-	O
and	O
beta	O
-	O
catenin	O
.	O

A	O
27-residue	O
fragment	O
of	O
APC	O
containing	O
a	O
15-amino	O
acid	O
repeat	O
was	O
sufficient	O
for	O
the	O
interaction	O
with	O
the	O
catenins	O
.	O

These	O
results	O
suggest	O
an	O
important	O
link	O
between	O
tumor	B
initiation	O
and	O
cell	O
adhesion	O
..	O

Anonymous	O
marker	O
loci	O
within	O
400	O
kb	O
of	O
HLA	O
-	O
A	O
generate	O
haplotypes	O
in	O
linkage	O
disequilibrium	O
with	O
the	O
hemochromatosis	B
gene	O
(	O
HFE	O
)	O
The	O
hemochromatosis	B
gene	O
(	O
HFE	O
)	O
maps	O
to	O
6p21	O
.	O

3	O
and	O
is	O
less	O
than	O
1	O
cM	O
from	O
the	O
HLA	O
class	O
I	O
genes	O
;	O
however	O
,	O
the	O
precise	O
physical	O
location	O
of	O
the	O
gene	O
has	O
remained	O
elusive	O
and	O
controversial	O
.	O

The	O
unambiguous	O
identification	O
of	O
a	O
crossover	O
event	O
within	O
hemochromatosis	B
families	O
is	O
very	O
difficult	O
;	O
it	O
is	O
particularly	O
hampered	O
by	O
the	O
variability	O
of	O
the	O
phenotypic	O
expression	O
as	O
well	O
as	O
by	O
the	O
sex-	O
and	O
age	O
-	O
related	O
penetrance	O
of	O
the	O
disease	O
.	O

For	O
these	O
practical	O
considerations	O
,	O
traditional	O
linkage	O
analysis	O
could	O
prove	O
of	O
limited	O
value	O
in	O
further	O
refining	O
the	O
extrapolated	O
physical	O
position	O
of	O
HFE	O
.	O

We	O
therefore	O
embarked	O
upon	O
a	O
linkage	O
-	O
disequilibrium	O
analysis	O
of	O
HFE	O
and	O
normal	O
chromosomes	O
from	O
the	O
Brittany	O
population	O
.	O

In	O
the	O
present	O
report	O
,	O
66	O
hemochromatosis	B
families	O
yielding	O
151	O
hemochromatosis	B
chromosomes	O
and	O
182	O
normal	O
chromosomes	O
were	O
RFLP	O
-	O
typed	O
with	O
a	O
battery	O
of	O
probes	O
,	O
including	O
two	O
newly	O
derived	O
polymorphic	O
markers	O
from	O
the	O
6	O
.	O

7	O
and	O
HLA	O
-	O
F	O
loci	O
located	O
150	O
and	O
250	O
kb	O
telomeric	O
to	O
HLA	O
-	O
A	O
,	O
respectively	O
.	O

The	O
results	O
suggest	O
a	O
strong	O
peak	O
of	O
existing	O
linkage	O
disequilibrium	O
focused	O
within	O
the	O
i82-to-6	O
.	O

7	O
interval	O
(	O
approximately	O
250	O
kb	O
)	O
.	O

The	O
zone	O
of	O
linkage	O
disequilibrium	O
is	O
flanked	O
by	O
the	O
i97	O
locus	O
,	O
positioned	O
30	O
kb	O
proximal	O
to	O
i82	O
,	O
and	O
the	O
HLA	O
-	O
F	O
gene	O
,	O
found	O
250	O
kb	O
distal	O
to	O
HLA	O
-	O
A	O
,	O
markers	O
of	O
which	O
display	O
no	O
significant	O
association	O
with	O
HFE	O
.	O

These	O
data	O
support	O
the	O
possibility	O
that	O
HFE	O
resides	O
within	O
the	O
400-kb	O
expanse	O
of	O
DNA	O
between	O
i97	O
and	O
HLA	O
-	O
F.	O
Alternatively	O
,	O
the	O
very	O
tight	O
association	O
of	O
HLA	O
-	O
A3	O
and	O
allele	O
1	O
of	O
the	O
6	O
.	O

7	O
locus	O
,	O
both	O
of	O
which	O
are	O
comprised	O
by	O
the	O
major	O
ancestral	O
or	O
founder	O
HFE	O
haplotype	O
in	O
Brittany	O
,	O
supports	O
the	O
possibility	O
that	O
the	O
disease	O
gene	O
may	O
reside	O
immediately	O
telomeric	O
to	O
the	O
6	O
.	O

7	O
locus	O
within	O
the	O
linkage	O
-	O
disequilibrium	O
zone	O
.	O

Additionally	O
,	O
hemochromatosis	B
haplotypes	O
possessing	O
HLA	O
-	O
A11	O
and	O
the	O
low	O
-	O
frequency	O
HLA	O
-	O
F	O
polymorphism	O
(	O
allele	O
2	O
)	O
are	O
supportive	O
of	O
a	O
separate	O
founder	O
chromosome	O
containing	O
a	O
second	O
,	O
independently	O
arising	O
mutant	O
allele	O
.	O

Overall	O
,	O
the	O
establishment	O
of	O
a	O
likely	O
""""	O
hemochromatosis	B
critical	O
region	O
""""	O
centromeric	O
boundary	O
and	O
the	O
identification	O
of	O
a	O
linkage	O
-	O
disequilibrium	O
zone	O
both	O
significantly	O
contribute	O
to	O
a	O
reduction	O
in	O
the	O
amount	O
of	O
DNA	O
required	O
to	O
be	O
searched	O
for	O
novel	O
coding	O
sequences	O
constituting	O
the	O
HFE	B
defect	I

Further	O
investigation	O
of	O
the	O
HEXA	O
gene	O
intron	O
9	O
donor	O
splice	O
site	O
mutation	O
frequently	O
found	O
in	O
non	O
-	O
Jewish	O
Tay	B
-	I
Sachs	I
disease	I
patients	O
from	O
the	O
British	O
Isles	O
.	O

In	O
a	O
previous	O
study	O
we	O
found	O
that	O
a	O
Tay	B
-	I
Sachs	I
disease	I
(	O
TSD	B
)	O
causing	O
mutation	O
in	O
the	O
intron	O
9	O
donor	O
splice	O
site	O
of	O
the	O
HEXA	O
gene	O
occurs	O
at	O
high	O
frequency	O
in	O
non	O
-	O
Jewish	O
patients	O
and	O
carriers	O
from	O
the	O
British	O
Isles	O
.	O

It	O
was	O
found	O
more	O
frequently	O
in	O
subjects	O
of	O
Irish	O
,	O
Scottish	O
,	O
and	O
Welsh	O
origin	O
compared	O
with	O
English	O
origin	O
(	O
63	O
%	O
and	O
31	O
%	O
respectively	O
)	O
.	O

We	O
have	O
now	O
tested	O
,	O
in	O
a	O
blind	O
study	O
,	O
26	O
American	O
TSD	B
carriers	O
and	O
28	O
non	O
-	O
carriers	O
who	O
have	O
British	O
ancestry	O
for	O
the	O
intron	O
9	O
splice	O
site	O
mutation	O
.	O

Six	O
of	O
the	O
carriers	O
and	O
none	O
of	O
the	O
controls	O
were	O
positive	O
for	O
the	O
mutation	O
.	O

All	O
six	O
had	O
Irish	O
ancestry	O
,	O
compared	O
with	O
nine	O
of	O
the	O
20	O
other	O
(	O
intron	O
9	O
mutation	O
negative	O
)	O
TSD	B
carriers	O
(	O
p	O
<	O
0	O
.	O
05	O
)	O
.	O

These	O
results	O
confirm	O
the	O
previously	O
found	O
high	O
frequency	O
of	O
the	O
intron	O
9	O
mutation	O
in	O
non	O
-	O
Jewish	O
TSD	B
families	O
of	O
British	O
Isles	O
,	O
particularly	O
Irish	O
,	O
origin	O
,	O
and	O
reinforce	O
the	O
need	O
to	O
screen	O
such	O
families	O
for	O
this	O
mutation	O
.	O

Familial	B
Mediterranean	I
fever	I
in	O
the	O
colchicine	O
era	O
:	O
the	O
fate	O
of	O
one	O
family	O
.	O

In	O
order	O
to	O
demonstrate	O
the	O
effect	O
of	O
prophylactic	O
colchicine	O
treatment	O
on	O
the	O
natural	O
history	O
of	O
familial	B
Mediterranean	I
fever	I
(	O
FMF	B
)	O
,	O
a	O
family	O
is	O
presented	O
with	O
6	O
out	O
of	O
9	O
siblings	O
affected	O
by	O
FMF	B
.	O

Each	O
patient	O
represents	O
a	O
different	O
stage	O
of	O
the	O
amyloidotic	B
kidney	I
disease	I
of	O
FMF	B
and	O
the	O
effect	O
of	O
continuous	O
colchicine	O
treatment	O
on	O
its	O
course	O
.	O

Considered	O
together	O
,	O
the	O
members	O
of	O
this	O
family	O
present	O
an	O
almost	O
complete	O
clinical	O
,	O
genetic	O
,	O
and	O
behavioral	O
picture	O
of	O
the	O
disease	O
..	O

A	O
prevalent	O
mutation	O
for	O
galactosemia	B
among	O
black	O
Americans	O
.	O

OBJECTIVE	O
To	O
define	O
the	O
mutation	O
causing	O
galactosemia	B
in	O
patients	O
of	O
black	O
American	O
origin	O
who	O
have	O
no	O
galactose-1-phosphate	O
uridyltransferase	O
(	O
GALT	O
)	O
activity	O
in	O
erythrocytes	O
but	O
good	O
clinical	O
outcome	O
.	O

METHODS	O
We	O
discovered	O
a	O
mutation	O
caused	O
by	O
a	O
C--	O
>	O
T	O
transition	O
at	O
base	O
-	O
pair	O
1158	O
of	O
the	O
GALT	O
gene	O
that	O
results	O
in	O
a	O
serine	O
-	O
to	O
-	O
leucine	O
substitution	O
at	O
codon	O
135	O
(	O
S135L	O
)	O
.	O

We	O
developed	O
a	O
method	O
with	O
which	O
to	O
screen	O
populations	O
for	O
its	O
prevalence	O
.	O

We	O
compared	O
galactose-1-phosphate	O
uridyltransferase	O
among	O
erythrocytes	O
,	O
leukocytes	O
,	O
and	O
transformed	O
lymphoblasts	O
,	O
as	O
well	O
as	O
total	O
body	O
oxidation	O
of	O
D-	O
(	O
13C	O
)	O
-galactose	O
to	O
13CO2	O
among	O
three	O
genotypes	O
for	O
GALT	O
(	O
S135L	O
/	O
S135L	O
,	O
Q188R	O
/	O
Q188R	O
,	O
and	O
Normal	O
/	O
Normal	O
)	O
.	O

RESULTS	O
We	O
found	O
a	O
48	O
%	O
prevalence	O
of	O
the	O
S135L	O
mutation	O
among	O
17	O
black	O
American	O
patients	O
with	O
classic	B
galactosemia	I
and	O
a	O
1	O
%	O
prevalence	O
in	O
a	O
population	O
of	O
50	O
black	O
Americans	O
without	O
galactosemia	B
.	O

The	O
S135L	O
mutation	O
was	O
not	O
found	O
in	O
84	O
white	O
patients	O
with	O
G	O
/	O
G	O
galactosemia	B
nor	O
in	O
87	O
white	O
control	O
subjects	O
without	O
galactosemia	B
.	O

We	O
found	O
normal	O
whole	O
body	O
oxidation	O
of	O
D-	O
(	O
13C	O
)	O
-galactose	O
by	O
the	O
patient	O
homozygous	O
for	O
S135L	O
and	O
various	O
degrees	O
of	O
enzyme	O
impairment	O
among	O
different	O
tissues	O
.	O

CONCLUSIONS	O
The	O
S135L	O
mutation	O
in	O
the	O
GALT	O
gene	O
is	O
a	O
prevalent	O
cause	O
of	O
galactosemia	B
among	O
black	O
patients	O
.	O

Because	O
GALT	O
activity	O
varies	O
in	O
different	O
tissues	O
of	O
patients	O
homozygous	O
for	O
S135L	O
,	O
they	O
may	O
have	O
a	O
better	O
clinical	O
outcome	O
than	O
patients	O
who	O
are	O
homozygous	O
for	O
Q188R	O
when	O
both	O
are	O
treated	O
from	O
infancy	O
..	O

Isolation	O
of	O
the	O
mouse	O
homologue	O
of	O
BRCA1	O
and	O
genetic	O
mapping	O
to	O
mouse	O
chromosome	O
11	O
.	O

The	O
BRCA1	O
gene	O
is	O
in	O
large	O
part	O
responsible	O
for	O
hereditary	B
human	I
breast	I
and	I
ovarian	I
cancer	I
.	O

Here	O
we	O
report	O
the	O
isolation	O
of	O
the	O
murine	O
Brca1	O
homologue	O
cDNA	O
clones	O
.	O

In	O
addition	O
,	O
we	O
identified	O
genomic	O
P1	O
clones	O
that	O
contain	O
most	O
,	O
if	O
not	O
all	O
,	O
of	O
the	O
mouse	O
Brca1	O
locus	O
.	O

DNA	O
sequence	O
analysis	O
revealed	O
that	O
the	O
mouse	O
and	O
human	O
coding	O
regions	O
are	O
75	O
%	O
identical	O
at	O
the	O
nucleotide	O
level	O
while	O
the	O
predicted	O
amino	O
acid	O
identity	O
is	O
only	O
58	O
%	O
.	O

A	O
DNA	O
sequence	O
variant	O
in	O
the	O
Brca1	O
locus	O
was	O
identified	O
and	O
used	O
to	O
map	O
this	O
gene	O
on	O
a	O
(	O
Mus	O
m.	O
musculus	O
Czech	O
II	O
x	O
C57BL	O
/	O
KsJ	O
)	O
F1	O
x	O
C57BL	O
/	O
KsJ	O
intersubspecific	O
backcross	O
to	O
distal	O
mouse	O
chromosome	O
11	O
.	O

The	O
mapping	O
of	O
this	O
gene	O
to	O
a	O
region	O
highly	O
syntenic	O
with	O
human	O
chromosome	O
17	O
,	O
coupled	O
with	O
Southern	O
and	O
Northern	O
analyses	O
,	O
confirms	O
that	O
we	O
isolated	O
the	O
murine	O
Brca1	O
homologue	O
rather	O
than	O
a	O
related	O
RING	O
finger	O
gene	O
.	O

The	O
isolation	O
of	O
the	O
mouse	O
Brca1	O
homologue	O
will	O
facilitate	O
the	O
creation	O
of	O
mouse	O
models	O
for	O
germline	O
BRCA1	B
defects	I
..	O

Nutritional	O
supplements	O
with	O
oral	O
amino	O
acid	O
mixtures	O
increases	O
whole	O
-	O
body	O
lean	O
mass	O
and	O
insulin	O
sensitivity	O
in	O
elderly	O
subjects	O
with	O
sarcopenia	B
.	O

Decreases	O
in	O
whole	O
-	O
body	O
lean	O
mass	O
can	O
cause	O
sarcopenia	B
,	O
a	O
disease	O
frequently	O
found	O
in	O
the	O
elderly	O
.	O

This	O
condition	O
is	O
frequently	O
associated	O
with	O
frailty	B
and	O
disability	B
in	I
aging	I
as	O
well	O
as	O
the	O
onset	O
and	O
progression	O
of	O
several	O
geriatric	B
syndromes	I
.	O

Sarcopenia	B
therefore	O
must	O
be	O
managed	O
with	O
multidimensional	O
approaches	O
that	O
include	O
physical	O
training	O
,	O
nutritional	O
support	O
,	O
and	O
metabolic	O
and	O
anabolic	O
treatment	O
.	O

The	O
purpose	O
of	O
our	O
study	O
was	O
to	O
assess	O
the	O
effect	O
of	O
an	O
orally	O
administered	O
special	O
mixture	O
of	O
amino	O
acids	O
(	O
AAs	O
)	O
in	O
elderly	O
subjects	O
with	O
reduced	O
lean	O
body	O
mass	O
and	O
sarcopenia	B
.	O

A	O
randomized	O
,	O
open	O
-	O
label	O
,	O
crossover	O
study	O
was	O
conducted	O
in	O
41	O
elderly	O
subjects	O
(	O
age	O
range	O
:	O
66	O
-	O
84	O
years	O
)	O
with	O
sarcopenia	B
,	O
assigned	O
to	O
2	O
distinct	O
treatments	O
(	O
AAs	O
and	O
placebo	O
)	O
.	O

All	O
subjects	O
had	O
normal	O
body	O
weight	O
(	O
body	O
mass	O
index	O
within	O
19	O
-	O
23	O
)	O
.	O

The	O
AA	O
treatment	O
consisted	O
of	O
70.6	O
kcal	O
/	O
day	O
(	O
1	O
kcal	O
=	O
4.2	O
kJ	O
)	O
of	O
8	O
g	O
of	O
essential	O
AA	O
snacks	O
,	O
given	O
at	O
10	O
:	O
00	O
am	O
and	O
5	O
:	O
00	O
pm	O
.	O

Lean	O
mass	O
was	O
measured	O
with	O
dual	O
-	O
energy	O
x	O
-	O
ray	O
absorptiometry	O
in	O
leg	O
,	O
arm	O
,	O
and	O
trunk	O
tissues	O
.	O

Significant	O
increases	O
in	O
whole	O
-	O
body	O
lean	O
mass	O
in	O
all	O
areas	O
were	O
seen	O
after	O
6	O
months	O
and	O
more	O
consistently	O
after	O
18	O
months	O
of	O
oral	O
nutritional	O
supplementation	O
with	O
AAs	O
.	O

Fasting	O
blood	O
glucose	O
,	O
serum	O
insulin	O
,	O
and	O
homeostatic	O
model	O
assessment	O
of	O
insulin	B
resistance	I
(	O
an	O
index	O
of	O
insulin	B
resistance	I
)	O
significantly	O
decreased	O
during	O
AA	O
treatment	O
.	O

Furthermore	O
,	O
a	O
significant	O
reduction	O
in	O
serum	O
tumor	O
necrosis	O
factor	O
-	O
alpha	O
(	O
TNF	O
-	O
alpha	O
)	O
and	O
a	O
significant	O
increase	O
in	O
both	O
insulin	O
-	O
like	O
growth	O
factor	O
-	O
1	O
(	O
IGF	O
-	O
1	O
)	O
serum	O
concentrations	O
and	O
in	O
the	O
IGF	O
-	O
1	O
/	O
TNF	O
-	O
alpha	O
ratio	O
were	O
also	O
found	O
.	O

No	O
significant	O
adverse	O
effects	O
were	O
observed	O
during	O
AA	O
treatment	O
.	O

These	O
preliminary	O
data	O
indicate	O
that	O
nutritional	O
supplements	O
with	O
the	O
oral	O
AA	O
mixture	O
significantly	O
increased	O
whole	O
-	O
body	O
lean	O
mass	O
in	O
elderly	O
subjects	O
with	O
sarcopenia	B
.	O

The	O
improvement	O
in	O
the	O
amount	O
of	O
whole	O
-	O
body	O
lean	O
mass	O
could	O
be	O
linked	O
to	O
increased	O
insulin	O
sensitivity	O
and	O
anabolic	O
conditions	O
related	O
to	O
IGF	O
-	O
1	O
availability	O
.	O

Variable	O
response	O
to	O
opioid	O
treatment	O
:	O
any	O
genetic	O
predictors	O
within	O
sight	O
?	O

The	O
aim	O
of	O
this	O
literature	O
review	O
is	O
to	O
summarize	O
and	O
discuss	O
the	O
available	O
evidence	O
for	O
a	O
relationship	O
between	O
polymorphisms	O
in	O
human	O
genes	O
and	O
variability	O
in	O
opioid	O
analgesia	O
and	O
side	O
effects	O
among	O
patients	O
treated	O
for	O
moderate	O
or	O
severe	O
pain	B
.	O

The	O
evidence	O
supporting	O
a	O
role	O
of	O
certain	O
alleles	O
,	O
genotypes	O
or	O
haplotypes	O
in	O
modulation	O
of	O
opioid	O
analgesia	O
is	O
derived	O
from	O
a	O
limited	O
number	O
of	O
studies	O
,	O
a	O
limited	O
number	O
of	O
genes	O
and	O
a	O
limited	O
number	O
of	O
opioids	O
.	O

Although	O
several	O
interesting	O
candidates	O
have	O
emerged	O
as	O
potentially	O
relevant	O
factors	O
,	O
only	O
for	O
one	O
polymorphism	O
,	O
the	O
prevalent	O
118A	O
>	O
G	O
of	O
the	O
micro	O
-	O
opioid	O
receptor	O
,	O
the	O
accumulated	O
evidence	O
is	O
sufficient	O
to	O
suggest	O
a	O
clinically	O
relevant	O
effect	O
for	O
an	O
opioid	O
used	O
for	O
moderate	O
or	O
severe	O
pain	B
.	O

Still	O
the	O
data	O
are	O
valid	O
only	O
at	O
the	O
group	O
level	O
and	O
can	O
not	O
be	O
used	O
to	O
predict	O
treatment	O
outcome	O
in	O
individual	O
patients	O
.	O

Only	O
a	O
few	O
of	O
the	O
symptoms	O
often	O
seen	O
as	O
opioid	O
adverse	O
effects	O
in	O
palliative	O
care	O
,	O
such	O
as	O
nausea	B
,	O
vomiting	B
,	O
constipation	B
and	O
sedation	B
,	O
have	O
been	O
associated	O
with	O
genetic	O
variants	O
in	O
various	O
genes	O
,	O
but	O
the	O
results	O
have	O
been	O
based	O
on	O
case	O
reports	O
,	O
healthy	O
volunteers	O
or	O
post	O
-	O
operative	O
patients	O
.	O

So	O
far	O
,	O
there	O
is	O
no	O
clear	O
evidence	O
that	O
genetic	O
markers	O
can	O
be	O
used	O
to	O
predict	O
opioid	O
efficacy	O
or	O
adverse	O
effects	O
in	O
palliative	O
care	O
patients	O
.	O

This	O
reflects	O
the	O
general	O
lack	O
of	O
studies	O
performed	O
in	O
the	O
context	O
of	O
palliative	O
care	O
,	O
the	O
lack	O
of	O
sufficiently	O
scaled	O
studies	O
and	O
the	O
lack	O
of	O
international	O
standards	O
for	O
the	O
assessment	O
of	O
subjective	O
symptoms	O
.	O

Design	O
of	O
potent	O
,	O
non	O
-	O
toxic	O
antimicrobial	O
agents	O
based	O
upon	O
the	O
naturally	O
occurring	O
frog	O
skin	O
peptides	O
,	O
ascaphin	O
-	O
8	O
and	O
peptide	O
XT	O
-	O
7	O
.	O

The	O
frog	O
skin	O
peptides	O
,	O
ascaphin	O
-	O
8	O
(	O
GFKDLLKGAAKALVKTVLF	O
.	O

NH	O
(	O
2	O
)	O
)	O
and	O
XT	O
-	O
7	O
(	O
GLLGPLLKIAAKVGSNLL	O
.	O

NH	O
(	O
2	O
)	O
)	O
,	O
show	O
broad	O
-	O
spectrum	O
antimicrobial	O
activity	O
but	O
their	O
therapeutic	O
potential	O
is	O
limited	O
by	O
toxicity	O
against	O
mammalian	O
cells	O
.	O

Circular	O
dichroism	O
spectra	O
demonstrate	O
that	O
the	O
peptides	O
adopt	O
an	O
amphipathic	O
alpha	O
-	O
helical	O
conformation	O
in	O
a	O
membrane	O
-	O
mimetic	O
solvent	O
.	O

This	O
study	O
has	O
investigated	O
the	O
cytolytic	O
properties	O
of	O
analogs	O
containing	O
selected	O
amino	O
acid	O
substitutions	O
that	O
increase	O
cationicity	O
while	O
maintaining	O
amphipathicity	O
.	O

Substitutions	O
at	O
Ala	O
(	O
10	O
)	O
,	O
Val	O
(	O
14	O
)	O
,	O
and	O
Leu	O
(	O
18	O
)	O
in	O
ascaphin	O
-	O
8	O
by	O
either	O
L	O
-	O
Lys	O
or	O
D	O
-	O
Lys	O
produced	O
peptides	O
that	O
retained	O
antimicrobial	O
activity	O
against	O
the	O
bacteria	O
Escherichia	O
coli	O
and	O
Staphylococcus	O
aureus	O
and	O
the	O
opportunistic	O
yeast	O
pathogen	O
,	O
Candida	O
albicans	O
but	O
showed	O
appreciably	O
reduced	O
toxicities	O
(	O
>	O
10	O
-	O
fold	O
)	O
against	O
human	O
erythrocytes	O
,	O
HepG2	O
hepatoma	O
-	O
derived	O
cells	O
,	O
and	O
L929	O
fibroblasts	O
.	O

The	O
improved	O
therapeutic	O
index	O
of	O
the	O
L	O
-	O
Lys	O
(	O
18	O
)	O
and	O
D	O
-	O
Lys	O
(	O
18	O
)	O
analogs	O
correlated	O
with	O
a	O
decrease	O
in	O
%	O
helicity	O
and	O
in	O
effective	O
hydrophobicity	O
.	O

Substitution	O
of	O
Gly	O
(	O
4	O
)	O
by	O
L	O
-	O
Lys	O
in	O
XT	O
-	O
7	O
produced	O
an	O
analog	O
with	O
high	O
potency	O
against	O
micro	O
-	O
organisms	O
(	O
MIC	O
<	O
or	O
=	O
25	O
microM	O
)	O
but	O
low	O
cytolytic	O
activity	O
against	O
erythrocytes	O
(	O
LD	O
(	O
50	O
)	O
>	O
500	O
microM	O
)	O
and	O
this	O
increase	O
in	O
therapeutic	O
index	O
also	O
correlated	O
with	O
decreased	O
helicity	O
and	O
hydrophobicity	O
.	O

Analogs	O
of	O
XT	O
-	O
7	O
with	O
increased	O
cationicity	O
,	O
containing	O
multiple	O
substitutions	O
by	O
L	O
-	O
Lys	O
,	O
not	O
only	O
displayed	O
increased	O
antimicrobial	O
potencies	O
,	O
particularly	O
against	O
Candida	O
albicans	O
(	O
MIC	O
<	O
or	O
=	O
6	O
microM	O
)	O
,	O
but	O
also	O
increased	O
hemolytic	O
activities	O
.	O

The	O
role	O
of	O
placental	O
breast	O
cancer	O
resistance	O
protein	O
in	O
the	O
efflux	O
of	O
glyburide	O
across	O
the	O
human	O
placenta	O
.	O

Gestational	B
diabetes	I
mellitus	I
is	O
a	O
common	O
medical	O
complication	O
in	O
pregnancy	O
.	O

Recent	O
findings	O
demonstrate	O
that	O
glyburide	O
is	O
effluxed	O
against	O
a	O
concentration	O
gradient	O
from	O
the	O
fetal	O
to	O
the	O
maternal	O
circulation	O
.	O

However	O
,	O
the	O
transport	O
systems	O
involved	O
in	O
the	O
active	O
efflux	O
of	O
glyburide	O
in	O
the	O
human	O
placenta	O
have	O
not	O
yet	O
been	O
identified	O
.	O

The	O
ATP	O
-	O
binding	O
cassette	O
transporter	O
,	O
breast	O
cancer	O
resistance	O
protein	O
(	O
BCRP	O
)	O
,	O
is	O
highly	O
expressed	O
in	O
placental	O
syncytiotrophoblast	O
suggesting	O
it	O
may	O
play	O
a	O
role	O
in	O
protecting	O
the	O
fetus	O
from	O
drug	B
toxicity	I
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
whether	O
BCRP	O
participates	O
in	O
the	O
transport	O
of	O
glyburide	O
across	O
the	O
human	O
placenta	O
.	O

The	O
placental	O
transfer	O
of	O
glyburide	O
in	O
the	O
presence	O
of	O
specific	O
BCRP	O
inhibitor	O
,	O
nicardipine	O
,	O
was	O
investigated	O
using	O
the	O
ex	O
vivo	O
dual	O
perfusion	O
system	O
of	O
isolated	O
human	O
placental	O
lobules	O
.	O

In	O
a	O
closed	O
experiment	O
,	O
glyburide	O
was	O
added	O
(	O
200	O
ng	O
/	O
mL	O
)	O
to	O
the	O
maternal	O
and	O
fetal	O
circulations	O
and	O
the	O
BCRP	O
inhibitor	O
(	O
20	O
microM	O
)	O
was	O
added	O
to	O
the	O
maternal	O
circulation	O
.	O

Samples	O
were	O
taken	O
during	O
pre	O
-	O
control	O
,	O
experimental	O
,	O
and	O
post	O
-	O
control	O
periods	O
for	O
measurement	O
of	O
glyburide	O
and	O
markers	O
of	O
tissue	O
viability	O
.	O

Results	O
obtained	O
from	O
perfusions	O
(	O
n	O
=	O
4	O
)	O
in	O
the	O
presence	O
of	O
the	O
BCRP	O
inhibitor	O
show	O
a	O
significant	O
increase	O
in	O
the	O
mean	O
fetal	O
-	O
to	O
-	O
maternal	O
concentration	O
ratio	O
of	O
glyburide	O
determined	O
at	O
180	O
min	O
,	O
0.56	O
+	O
/	O
-	O
0.06	O
,	O
when	O
compared	O
to	O
the	O
mean	O
ratio	O
obtained	O
in	O
the	O
absence	O
of	O
inhibitor	O
,	O
0.32	O
+	O
/	O
-	O
0.06	O
(	O
p	O
=	O
0.04	O
)	O
.	O

These	O
data	O
indicate	O
that	O
nicardipine	O
partially	O
blocked	O
the	O
transfer	O
of	O
glyburide	O
across	O
the	O
whole	O
placenta	O
through	O
its	O
inhibition	O
of	O
BCRP	O
.	O

This	O
is	O
the	O
first	O
ex	O
vivo	O
evidence	O
that	O
BCRP	O
actively	O
transports	O
glyburide	O
.	O

The	O
efficacy	O
of	O
Femal	O
in	O
women	O
with	O
premenstrual	B
syndrome	I
:	O
a	O
randomised	O
,	O
double	O
-	O
blind	O
,	O
parallel	O
-	O
group	O
,	O
placebo	O
-	O
controlled	O
,	O
multicentre	O
study	O
.	O

INTRODUCTION	O
:	O
A	O
double	O
-	O
blind	O
,	O
placebo	O
-	O
controlled	O
,	O
randomised	O
,	O
parallel	O
-	O
group	O
,	O
multicentre	O
study	O
was	O
conducted	O
to	O
evaluate	O
the	O
effect	O
of	O
a	O
pollen	O
-	O
based	O
herbal	O
medicinal	O
product	O
,	O
Femal	O
(	O
Sea	O
-	O
Band	O
Ltd	O
,	O
Leicestershire	O
,	O
UK	O
)	O
,	O
on	O
premenstrual	B
sleep	I
disturbances	I
(	O
PSD	B
)	O
in	O
women	O
with	O
premenstrual	B
syndrome	I
(	O
PMS	B
)	O
.	O

METHODS	O
:	O
Femal	O
,	O
160	O
mg	O
twice	O
-	O
daily	O
,	O
was	O
given	O
for	O
four	O
menstrual	O
cycles	O
to	O
50	O
women	O
,	O
and	O
placebo	O
to	O
51	O
women	O
.	O

PSD	B
were	O
evaluated	O
on	O
a	O
visual	O
analogue	O
scale	O
prior	O
to	O
and	O
after	O
the	O
four	O
cycles	O
.	O

The	O
effect	O
on	O
overall	O
PMS	B
symptoms	I
was	O
assessed	O
with	O
the	O
Steiner	O
premenstrual	B
tension	I
syndrome	I
(	O
PMTS	B
)	O
self	O
-	O
rating	O
questionnaire	O
.	O

The	O
results	O
were	O
analysed	O
statistically	O
based	O
on	O
intention	O
to	O
treat	O
.	O

RESULTS	O
:	O
Femal	O
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
in	O
PSD	B
(	O
P	O
<	O
0.05	O
)	O
whereas	O
placebo	O
had	O
no	O
significant	O
effect	O
(	O
P	O
>	O
0.05	O
)	O
.	O

In	O
a	O
subgroup	O
analysis	O
of	O
women	O
with	O
irritability	B
as	O
their	O
main	O
PMS	B
symptom	I
cluster	O
,	O
the	O
reduction	O
of	O
PSD	B
was	O
even	O
more	O
pronounced	O
(	O
P	O
<	O
0.001	O
)	O
.	O

There	O
was	O
no	O
significant	O
difference	O
in	O
overall	O
degree	O
of	O
PMS	B
symptom	I
reduction	O
between	O
Femal	O
and	O
placebo	O
when	O
all	O
participating	O
women	O
were	O
evaluated	O
(	O
P	O
>	O
0.05	O
)	O
.	O

However	O
,	O
in	O
women	O
with	O
irritability	B
as	O
their	O
main	O
PMS	B
symptom	I
cluster	O
,	O
Femal	O
treatment	O
resulted	O
in	O
a	O
significant	O
reduction	O
of	O
the	O
Steiner	O
score	O
(	O
P	O
<	O
0.05	O
)	O
.	O

The	O
frequency	O
of	O
adverse	O
events	O
was	O
not	O
significantly	O
different	O
in	O
women	O
on	O
Femal	O
compared	O
to	O
women	O
on	O
placebo	O
(	O
P	O
>	O
0.05	O
)	O
.	O

No	O
serious	O
adverse	O
events	O
were	O
recorded	O
.	O

CONCLUSION	O
:	O
Femal	O
treatment	O
reduced	O
PSD	B
to	O
a	O
significant	O
degree	O
,	O
particularly	O
in	O
women	O
with	O
irritability	B
as	O
their	O
main	O
PMS	B
symptom	I
.	O

Femal	O
treatment	O
also	O
reduced	O
overall	O
PMS	B
symptoms	I
in	O
women	O
with	O
irritability	B
(	O
but	O
not	O
dysphoria	B
)	O
as	O
their	O
main	O
PMS	B
symptom	I
.	O

The	O
safety	O
of	O
Femal	O
and	O
its	O
efficacy	O
in	O
PSD	B
and	O
other	O
symptoms	O
in	O
women	O
with	O
irritability	B
as	O
the	O
main	O
symptom	O
cluster	O
makes	O
this	O
herbal	O
medicinal	O
product	O
a	O
promising	O
addition	O
to	O
the	O
therapeutic	O
arsenal	O
for	O
women	O
with	O
PMS	B
.	O

A	O
novel	O
polyherbal	O
microbicide	O
with	O
inhibitory	O
effect	O
on	O
bacterial	O
,	O
fungal	O
and	O
viral	O
genital	O
pathogens	O
.	O

A	O
polyherbal	O
cream	O
(	O
Basant	O
)	O
has	O
been	O
formulated	O
using	O
diferuloylmethane	O
(	O
curcumin	O
)	O
,	O
purified	O
extracts	O
of	O
Emblica	O
officinalis	O
(	O
Amla	O
)	O
,	O
purified	O
saponins	O
from	O
Sapindus	O
mukorossi	O
,	O
Aloe	O
vera	O
and	O
rose	O
water	O
along	O
with	O
pharmacopoeially	O
approved	O
excipients	O
and	O
preservatives	O
.	O

Basant	O
inhibits	O
the	O
growth	O
of	O
WHO	O
strains	O
and	O
clinical	O
isolates	O
of	O
Neisseria	O
gonorrhoeae	O
,	O
including	O
those	O
resistant	O
to	O
penicillin	O
,	O
tetracycline	O
,	O
nalidixic	O
acid	O
and	O
ciprofloxacin	O
.	O

It	O
has	O
pronounced	O
inhibitory	O
action	O
against	O
Candida	O
glabrata	O
,	O
Candida	O
albicans	O
and	O
Candida	O
tropicalis	O
isolated	O
from	O
women	O
with	O
vulvovaginal	B
candidiasis	I
,	O
including	O
three	O
isolates	O
resistant	O
to	O
azole	O
drugs	O
and	O
amphotericin	O
B	O
.	O

Basant	O
displayed	O
a	O
high	O
virucidal	O
action	O
against	O
human	O
immunodeficiency	O
virus	O
HIV	O
-	O
1NL4	O
.3	O
in	O
CEM	O
-	O
GFP	O
reporter	O
T	O
and	O
P4	O
(	O
Hela	O
-	O
CD4	O
-	O
LTR	O
-	O
betaGal	O
)	O
cell	O
lines	O
with	O
a	O
50	O
%	O
effective	O
concentration	O
(	O
EC50	O
)	O
of	O
1	O
:	O
20000	O
dilution	O
and	O
nearly	O
complete	O
(	O
98	O
-	O
99	O
%	O
)	O
inhibition	O
at	O
1	O
:	O
1000	O
dilution	O
.	O

It	O
also	O
prevented	O
the	O
entry	O
of	O
HIV	O
-	O
1	O
(	O
IIIB	O
)	O
virus	O
into	O
P4	O
-	O
CCR5	O
cells	O
(	O
EC50	O
approximately	O
1	O
:	O
2492	O
)	O
.	O

Two	O
ingredients	O
,	O
Aloe	O
and	O
Amla	O
,	O
inhibited	O
the	O
transduction	O
of	O
human	O
papillomavirus	O
type	O
16	O
(	O
HPV	O
-	O
16	O
)	O
pseudovirus	O
in	O
HeLa	O
cells	O
at	O
concentrations	O
far	O
below	O
those	O
that	O
are	O
cytotoxic	O
and	O
those	O
used	O
in	O
the	O
formulation	O
.	O

Basant	O
was	O
found	O
to	O
be	O
totally	O
safe	O
according	O
to	O
pre	O
-	O
clinical	O
toxicology	O
carried	O
out	O
on	O
rabbit	O
vagina	O
after	O
application	O
for	O
7	O
consecutive	O
days	O
or	O
twice	O
daily	O
for	O
3	O
weeks	O
.	O

Basant	O
has	O
the	O
potential	O
of	O
regressing	O
vulvovaginal	B
candidiasis	I
and	O
preventing	O
N	O
.	O

gonorrhoeae	O
,	O
HIV	O
and	O
HPV	B
infections	I
.	O

Neuroprotection	O
by	O
Spirulina	O
platensis	O
protean	O
extract	O
and	O
phycocyanin	O
against	O
iron	O
-	O
induced	O
toxicity	O
in	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cells	O
.	O

We	O
investigated	O
the	O
effect	O
of	O
Spirulina	O
platensis	O
protean	O
extract	O
and	O
the	O
biliprotein	O
phycocyanin	O
isolated	O
from	O
this	O
microalga	O
,	O
on	O
the	O
activities	O
of	O
the	O
antioxidant	O
enzymes	O
SOD	O
,	O
CAT	O
,	O
GPx	O
,	O
and	O
GR	O
,	O
lipid	O
peroxidation	O
inhibitory	O
activity	O
and	O
glutathione	O
levels	O
after	O
the	O
iron	O
induced	O
oxidative	O
stress	O
in	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cells	O
.	O

Iron	O
is	O
one	O
of	O
the	O
most	O
important	O
agents	O
that	O
produce	O
oxidative	O
stress	O
and	O
decline	O
of	O
neuronal	O
functions	O
.	O

S	O
.	O

platensis	O
protean	O
extract	O
and	O
phycocyanin	O
exert	O
the	O
antioxidant	O
activity	O
by	O
protecting	O
the	O
activity	O
of	O
the	O
cellular	O
antioxidant	O
enzymes	O
total	O
GPx	O
,	O
GPx	O
-	O
Se	O
and	O
GR	O
and	O
by	O
increasing	O
reduced	O
glutathione	O
in	O
cells	O
against	O
oxidative	O
stress	O
induced	O
by	O
iron	O
.	O

These	O
results	O
suggested	O
that	O
S	O
.	O

platensis	O
protean	O
extract	O
is	O
a	O
powerful	O
antioxidant	O
through	O
a	O
mechanism	O
related	O
to	O
antioxidant	O
activity	O
,	O
capable	O
of	O
interfering	O
with	O
radical	O
-	O
mediated	O
cell	O
death	O
.	O

S	O
.	O

platensis	O
may	O
be	O
useful	O
in	O
diseases	O
known	O
to	O
be	O
aggravated	O
by	O
reactive	O
oxygen	O
species	O
and	O
in	O
the	O
development	O
of	O
novel	O
treatments	O
for	O
neurodegenerative	B
disorders	I
as	O
long	O
as	O
iron	O
has	O
been	O
implicated	O
in	O
the	O
neuropathology	O
of	O
several	O
neurodegenerative	B
disorders	I
such	O
as	O
Alzheimer	O
's	O
or	O
Parkinson	B
diseases	I
.	O

Safety	O
and	O
pharmacodynamics	O
of	O
lansoprazole	O
in	O
patients	O
with	O
gastroesophageal	B
reflux	I
disease	I
aged	O
<	O
1	O
year	O
.	O

BACKGROUND	O
:	O
The	O
use	O
of	O
proton	O
pump	O
inhibitors	O
(	O
PPIs	O
)	O
for	O
the	O
treatment	O
of	O
gastroesophageal	B
reflux	I
disease	I
(	O
GERD	B
)	O
in	O
pediatric	O
patients	O
<	O
1	O
year	O
of	O
age	O
is	O
increasing	O
.	O

However	O
,	O
few	O
studies	O
with	O
PPIs	O
have	O
been	O
reported	O
in	O
such	O
patients	O
.	O

OBJECTIVES	O
:	O
To	O
assess	O
the	O
effect	O
of	O
once	O
-	O
daily	O
lansoprazole	O
on	O
safety	O
and	O
to	O
characterize	O
the	O
pharmacodynamic	O
profile	O
of	O
lansoprazole	O
in	O
a	O
subset	O
of	O
subjects	O
<	O
1	O
year	O
of	O
age	O
.	O

The	O
effect	O
of	O
lansoprazole	O
on	O
predefined	O
GERD	B
-	I
associated	I
symptoms	I
was	O
also	O
assessed	O
.	O

METHODS	O
:	O
Two	O
phase	O
I	O
,	O
single	O
-	O
and	O
repeated	O
-	O
dose	O
,	O
randomized	O
,	O
parallel	O
-	O
group	O
,	O
open	O
-	O
label	O
,	O
multicenter	O
studies	O
were	O
performed	O
.	O

Both	O
studies	O
involved	O
either	O
a	O
7	O
-	O
or	O
14	O
-	O
day	O
pre	O
-	O
treatment	O
period	O
,	O
with	O
a	O
dose	O
administration	O
period	O
of	O
5	O
days	O
,	O
and	O
a	O
follow	O
-	O
up	O
period	O
of	O
30	O
days	O
for	O
adverse	O
events	O
collection	O
.	O

A	O
total	O
of	O
six	O
investigative	O
sites	O
were	O
involved	O
:	O
four	O
university	O
hospital	O
/	O
medical	O
centers	O
(	O
three	O
in	O
Poland	O
,	O
one	O
in	O
the	O
US	O
)	O
,	O
one	O
large	O
regional	O
medical	O
center	O
(	O
Poland	O
)	O
,	O
and	O
one	O
private	O
practice	O
(	O
US	O
)	O
.	O

The	O
studies	O
involved	O
24	O
neonates	O
(	O
<	O
or	O
=	O
28	O
days	O
of	O
age	O
)	O
and	O
24	O
infants	O
(	O
>	O
28	O
days	O
but	O
<	O
1	O
year	O
of	O
age	O
)	O
with	O
GERD	O
-	O
associated	O
symptoms	O
diagnosed	O
by	O
medical	O
history	O
and	O
the	O
clinical	O
judgment	O
of	O
the	O
treating	O
physician	O
.	O

Eligible	O
subjects	O
were	O
randomized	O
to	O
receive	O
either	O
lansoprazole	O
0.5	O
or	O
1.0	O
mg	O
/	O
kg	O
/	O
day	O
(	O
neonates	O
)	O
,	O
or	O
1.0	O
or	O
2.0	O
mg	O
/	O
kg	O
/	O
day	O
(	O
infants	O
)	O
,	O
for	O
5	O
days	O
.	O

Safety	O
and	O
pharmacodynamic	O
parameters	O
were	O
the	O
primary	O
outcome	O
measures	O
.	O

Safety	O
and	O
GERD	B
symptoms	I
were	O
assessed	O
in	O
all	O
participants	O
.	O

Intragastric	O
/	O
intraesophageal	O
pH	O
monitoring	O
was	O
performed	O
in	O
a	O
subset	O
of	O
six	O
neonates	O
and	O
six	O
infants	O
at	O
baseline	O
and	O
on	O
dose	O
administration	O
days	O
1	O
and	O
5	O
.	O

RESULTS	O
:	O
Over	O
5	O
days	O
of	O
daily	O
dose	O
administration	O
,	O
lansoprazole	O
was	O
well	O
tolerated	O
in	O
neonates	O
and	O
infants	O
.	O

Four	O
neonates	O
and	O
one	O
infant	O
experienced	O
mild	O
to	O
moderate	O
treatment	O
-	O
related	O
adverse	O
events	O
during	O
the	O
dose	O
administration	O
period	O
.	O

One	O
neonate	O
experienced	O
a	O
serious	O
adverse	O
event	O
that	O
was	O
unrelated	O
to	O
treatment	O
.	O

Lansoprazole	O
increased	O
the	O
percentage	O
of	O
time	O
that	O
intragastric	O
pH	O
was	O
above	O
3	O
,	O
4	O
,	O
5	O
,	O
and	O
6	O
over	O
the	O
24	O
-	O
hour	O
post	O
-	O
dose	O
period	O
on	O
days	O
1	O
and	O
5	O
when	O
compared	O
with	O
baseline	O
.	O

Mean	O
24	O
-	O
hour	O
integrated	O
gastric	O
acidity	O
decreased	O
from	O
baseline	O
to	O
day	O
5	O
in	O
both	O
populations	O
.	O

The	O
daily	O
number	O
of	O
episodes	O
of	O
regurgitation	B
/	O
vomiting	B
was	O
lower	O
than	O
at	O
baseline	O
among	O
neonates	O
after	O
5	O
days	O
of	O
lansoprazole	O
treatment	O
;	O
among	O
infants	O
,	O
both	O
the	O
prevalence	O
and	O
the	O
average	O
daily	O
number	O
of	O
episodes	O
of	O
several	O
individual	O
GERD	B
-	I
associated	I
symptoms	I
were	O
lower	O
than	O
at	O
baseline	O
.	O

CONCLUSIONS	O
:	O
After	O
5	O
days	O
of	O
open	O
-	O
label	O
administration	O
,	O
lansoprazole	O
was	O
well	O
tolerated	O
and	O
increased	O
intragastric	O
pH	O
in	O
pediatric	O
subjects	O
<	O
1	O
year	O
of	O
age	O
.	O

A	O
decrease	O
in	O
the	O
frequency	O
of	O
GERD	B
symptoms	I
was	O
also	O
observed	O
.	O

Low	O
-	O
dose	O
interleukin	O
-	O
2	O
immunotherapy	O
does	O
not	O
improve	O
outcome	O
of	O
patients	O
age	O
60	O
years	O
and	O
older	O
with	O
acute	B
myeloid	I
leukemia	I
in	O
first	O
complete	O
remission	O
:	O
Cancer	B
and	O
Leukemia	B
Group	O
B	O
Study	O
9720	O
.	O

PURPOSE	O
:	O
Cancer	B
and	O
Leukemia	B
Group	O
B	O
(	O
CALGB	O
)	O
9720	O
evaluated	O
subcutaneous	O
low	O
-	O
dose	O
recombinant	O
interleukin	O
-	O
2	O
(	O
rIL	O
-	O
2	O
)	O
maintenance	O
immunotherapy	O
as	O
a	O
strategy	O
for	O
prolonging	O
remission	O
in	O
older	O
patients	O
with	O
acute	B
myeloid	I
leukemia	I
(	O
AML	B
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
AML	B
patients	O
age	O
60	O
years	O
and	O
older	O
in	O
first	O
complete	O
remission	O
after	O
induction	O
and	O
consolidation	O
chemotherapy	O
were	O
randomly	O
assigned	O
to	O
no	O
further	O
therapy	O
or	O
a	O
90	O
-	O
day	O
regimen	O
of	O
14	O
-	O
day	O
cycles	O
of	O
low	O
-	O
dose	O
rIL	O
-	O
2	O
,	O
aimed	O
at	O
expanding	O
natural	O
killer	O
(	O
NK	O
)	O
cells	O
,	O
followed	O
by	O
3	O
-	O
day	O
higher	O
doses	O
aimed	O
at	O
activating	O
cytotoxicity	O
of	O
expanded	O
NK	O
cells	O
to	O
lyse	O
residual	O
AML	O
cells	O
.	O

All	O
randomly	O
assigned	O
patients	O
were	O
included	O
in	O
an	O
intention	O
-	O
to	O
-	O
treat	O
analysis	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
163	O
(	O
64	O
%	O
)	O
of	O
254	O
patients	O
who	O
completed	O
induction	O
and	O
consolidation	O
chemotherapy	O
on	O
CALGB	O
9720	O
were	O
randomly	O
assigned	O
to	O
rIL	O
-	O
2	O
(	O
n	O
=	O
81	O
)	O
or	O
no	O
further	O
therapy	O
(	O
n	O
=	O
82	O
)	O
;	O
the	O
most	O
common	O
reasons	O
for	O
lack	O
of	O
random	O
assignment	O
were	O
patient	O
refusal	O
and	O
relapse	O
.	O

Fifteen	O
patients	O
randomly	O
assigned	O
to	O
rIL	O
-	O
2	O
never	O
initiated	O
it	O
because	O
of	O
refusal	O
,	O
intercurrent	O
medical	O
problems	O
,	O
or	O
relapse	O
,	O
and	O
24	O
patients	O
initiated	O
rIL	O
-	O
2	O
but	O
stopped	O
early	O
because	O
of	O
toxicity	O
or	O
relapse	O
.	O

Grade	O
4	O
toxicities	O
during	O
rIL	O
-	O
2	O
therapy	O
included	O
thrombocytopenia	B
(	O
65	O
%	O
)	O
and	O
neutropenia	B
(	O
64	O
%	O
)	O
,	O
and	O
grade	O
3	O
toxicities	O
included	O
anemia	B
(	O
33	O
%	O
)	O
,	O
infection	B
(	O
24	O
%	O
)	O
and	O
malaise	B
/	O
fatigue	B
(	O
14	O
%	O
)	O
.	O

Forty	O
-	O
two	O
patients	O
(	O
52	O
%	O
)	O
randomly	O
assigned	O
to	O
rIL	O
-	O
2	O
completed	O
the	O
full	O
90	O
-	O
day	O
course	O
.	O

Patients	O
in	O
both	O
arms	O
had	O
similar	O
distributions	O
of	O
both	O
disease	O
-	O
free	O
(	O
combined	O
median	O
=	O
6.1	O
months	O
;	O
P	O
=	O
.47	O
)	O
and	O
overall	O
survival	O
(	O
combined	O
median	O
=	O
14.7	O
months	O
;	O
P	O
=	O
.61	O
)	O
after	O
random	O
assignment	O
.	O

Moreover	O
,	O
the	O
42	O
patients	O
who	O
completed	O
all	O
planned	O
therapy	O
did	O
not	O
show	O
prolongation	O
of	O
disease	O
-	O
free	O
or	O
overall	O
survival	O
.	O

CONCLUSION	O
:	O
Low	O
-	O
dose	O
rIL	O
-	O
2	O
maintenance	O
immunotherapy	O
is	O
not	O
a	O
successful	O
strategy	O
in	O
older	O
AML	B
patients	O
.	O

Prostaglandin	O
receptor	O
EP2	O
protects	O
dopaminergic	O
neurons	O
against	O
6	O
-	O
OHDA	O
-	O
mediated	O
low	O
oxidative	O
stress	O
.	O

Dopaminergic	O
neurons	O
in	O
the	O
substantia	O
nigra	O
(	O
SN	O
)	O
selectively	O
die	O
in	O
Parkinson	B
's	I
disease	I
(	O
PD	B
)	O
,	O
but	O
it	O
is	O
unclear	O
how	O
and	O
why	O
this	O
occurs	O
.	O

Recent	O
findings	O
implicate	O
prostaglandin	O
E	O
(	O
2	O
)	O
(	O
PGE	O
(	O
2	O
)	O
)	O
and	O
two	O
of	O
its	O
four	O
receptors	O
,	O
namely	O
EP1	O
and	O
EP2	O
,	O
as	O
mediators	O
of	O
degenerative	O
and	O
protective	O
events	O
in	O
situations	O
of	O
acute	O
and	O
chronic	B
neuronal	I
death	I
.	O

EP1	O
activation	O
can	O
exacerbate	O
excitotoxic	O
damage	O
in	O
stroke	B
models	O
and	O
our	O
recent	O
study	O
showed	O
that	O
EP1	O
activation	O
may	O
explain	O
the	O
selective	O
sensitivity	O
of	O
dopaminergic	O
neurons	O
to	O
oxidative	O
stress	O
.	O

Conversely	O
,	O
EP2	O
activation	O
may	O
be	O
neuroprotective	O
,	O
although	O
toxic	O
effects	O
have	O
also	O
been	O
demonstrated	O
.	O

Here	O
we	O
investigated	O
if	O
and	O
how	O
EP2	O
activation	O
might	O
alter	O
the	O
survival	O
of	O
dopaminergic	O
neurons	O
following	O
selective	O
low	O
-	O
level	O
oxidative	O
injury	O
evoked	O
by	O
the	O
neurotoxin	O
6	O
-	O
hydroxydopamine	O
(	O
6	O
-	O
OHDA	O
)	O
in	O
primary	O
neuronal	O
cultures	O
prepared	O
from	O
embryonic	O
rat	O
midbrain	O
.	O

We	O
found	O
that	O
cultured	O
dopaminergic	O
neurons	O
displayed	O
EP2	O
receptors	O
.	O

Butaprost	O
,	O
a	O
selective	O
EP2	O
agonist	O
,	O
significantly	O
reduced	O
6	O
-	O
OHDA	O
neurotoxicity	B
.	O

EP2	O
receptors	O
are	O
coupled	O
to	O
stimulatory	O
G	O
-	O
proteins	O
(	O
Gs	O
)	O
,	O
which	O
activate	O
adenylate	O
cyclase	O
,	O
increasing	O
cAMP	O
synthesis	O
,	O
which	O
then	O
activates	O
protein	O
kinase	O
A	O
(	O
PKA	O
)	O
.	O

Both	O
dibutyryl	O
cAMP	O
and	O
forskolin	O
reduced	O
dopaminergic	O
cell	O
loss	O
after	O
6	O
-	O
OHDA	O
exposure	O
.	O

Conversely	O
,	O
KT5720	O
and	O
H	O
-	O
89	O
,	O
two	O
structurally	O
distinct	O
high	O
-	O
affinity	O
PKA	O
inhibitors	O
,	O
abolished	O
the	O
protective	O
effect	O
of	O
butaprost	O
,	O
implicating	O
cAMP	O
-	O
dependent	O
PKA	O
activity	O
in	O
the	O
neuroprotection	O
by	O
EP2	O
activation	O
.	O

Finally	O
,	O
we	O
show	O
that	O
melanized	O
dopaminergic	O
neurons	O
in	O
the	O
human	O
SN	O
express	O
EP2	O
.	O

This	O
pathway	O
warrants	O
consideration	O
as	O
a	O
neuroprotective	O
strategy	O
for	O
PD	B
.	O

Utility	O
of	O
published	O
guidelines	O
on	O
the	O
use	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
in	O
the	O
elderly	O
.	O

Canadian	O
Consensus	O
guidelines	O
regarding	O
appropriate	O
use	O
of	O
nonsteroidal	O
anti	O
-	O
inflammatory	O
drugs	O
(	O
NSAID	O
)	O
were	O
recently	O
published	O
.	O

This	O
study	O
was	O
done	O
to	O
evaluate	O
the	O
application	O
of	O
these	O
guidelines	O
on	O
NSAID	O
practice	O
patterns	O
in	O
frail	O
elderly	O
patients	O
referred	O
to	O
a	O
specialist	O
Geriatric	O
Assessment	O
Clinic	O
.	O

A	O
retrospective	O
chart	O
review	O
was	O
undertaken	O
of	O
referrals	O
who	O
were	O
currently	O
prescribed	O
NSAIDs	O
.	O

Data	O
were	O
captured	O
on	O
age	O
,	O
sex	O
,	O
weight	O
,	O
diagnoses	O
,	O
medications	O
and	O
dosages	O
,	O
indication	O
for	O
NSAID	O
treatment	O
,	O
lying	O
BP	O
(	O
as	O
assessed	O
in	O
the	O
clinic	O
)	O
and	O
recent	O
serum	O
creatinine	O
result	O
.	O

Creatinine	O
clearance	O
was	O
subsequently	O
calculated	O
use	O
the	O
Cockcroft	O
-	O
Gault	O
equation	O
.	O

Complete	O
data	O
were	O
available	O
on	O
107	O
patients	O
(	O
68	O
%	O
women	O
,	O
average	O
age	O
80.6	O
years	O
)	O
.	O

Thirty	O
percent	O
were	O
on	O
a	O
traditional	O
NSAID	O
,	O
the	O
remainder	O
were	O
on	O
a	O
Coxib	O
.	O

Concomitant	O
aspirin	O
was	O
prescribed	O
in	O
37	O
%	O
.	O

Cytoprotection	O
was	O
being	O
used	O
in	O
38	O
%	O
and	O
did	O
not	O
increase	O
appreciably	O
in	O
patients	O
with	O
additional	O
risk	O
factors	O
for	O
GI	B
toxicity	I
,	O
i.e.	O
,	O
concomitant	O
aspirin	O
usage	O
(	O
35	O
%	O
)	O
,	O
and	O
history	O
of	O
GI	B
toxicity	I
(	O
48	O
%	O
)	O
.	O

Sixty	O
-	O
seven	O
were	O
taking	O
anti	O
-	O
hypertensive	O
medications	O
,	O
although	O
more	O
than	O
two	O
thirds	O
of	O
these	O
patients	O
were	O
uncontrolled	O
.	O

Newly	O
diagnosed	O
hypertension	B
was	O
present	O
in	O
19.6	O
%	O
.	O

Calculated	O
creatinine	O
clearance	O
revealed	O
moderate	O
to	O
severe	O
renal	B
impairment	I
in	O
79	O
%	O
of	O
subjects	O
,	O
although	O
serum	O
creatinine	O
was	O
only	O
elevated	O
in	O
18	O
%	O
.	O

In	O
total	O
,	O
70	O
%	O
of	O
subjects	O
were	O
found	O
to	O
have	O
relative	O
or	O
absolute	O
risk	O
factors	O
for	O
NSAID	O
therapy	O
.	O

Given	O
the	O
high	O
prevalence	O
of	O
potential	O
contraindications	O
to	O
anti	O
-	O
inflammatory	O
drug	O
usage	O
in	O
this	O
study	O
,	O
we	O
advocate	O
the	O
dissemination	O
and	O
application	O
of	O
these	O
guidelines	O
in	O
geriatric	O
patients	O
in	O
an	O
attempt	O
to	O
reduce	O
potential	O
morbidity	O
and	O
mortality	O
.	O

Practical	O
model	O
-	O
based	O
dose	O
finding	O
in	O
early	O
-	O
phase	O
clinical	O
trials	O
:	O
optimizing	O
tissue	O
plasminogen	O
activator	O
dose	O
for	O
treatment	O
of	O
ischemic	B
stroke	I
in	O
children	O
.	O

BACKGROUND	O
AND	O
PURPOSE	O
:	O
A	O
safe	O
and	O
effective	O
tissue	O
plasminogen	O
activator	O
(	O
tPA	O
)	O
dose	O
for	O
childhood	O
stroke	B
has	O
not	O
been	O
established	O
.	O

This	O
article	O
describes	O
a	O
Bayesian	O
outcome	O
-	O
adaptive	O
method	O
for	O
determining	O
the	O
best	O
dose	O
of	O
an	O
experimental	O
agent	O
and	O
explains	O
how	O
this	O
method	O
was	O
used	O
to	O
design	O
a	O
dose	O
-	O
finding	O
trial	O
for	O
tPA	O
in	O
childhood	O
.	O

METHODS	O
:	O
The	O
method	O
assigns	O
doses	O
to	O
successive	O
cohorts	O
of	O
patients	O
on	O
the	O
basis	O
of	O
each	O
dose	O
's	O
desirability	O
,	O
quantified	O
in	O
terms	O
of	O
the	O
tradeoff	O
between	O
efficacy	O
and	O
toxicity	O
.	O

The	O
tradeoff	O
function	O
is	O
constructed	O
from	O
several	O
pairs	O
of	O
equally	O
desirable	O
(	O
efficacy	O
,	O
toxicity	O
)	O
probabilities	O
specified	O
by	O
the	O
physicians	O
planning	O
the	O
trial	O
.	O

Each	O
cohort	O
's	O
dose	O
is	O
chosen	O
adaptively	O
,	O
based	O
on	O
dose	O
-	O
outcome	O
data	O
from	O
the	O
patients	O
treated	O
previously	O
in	O
the	O
trial	O
,	O
to	O
optimize	O
the	O
efficacy	O
-	O
toxicity	O
tradeoff	O
.	O

Application	O
of	O
the	O
method	O
to	O
design	O
the	O
tPA	O
trial	O
is	O
described	O
,	O
including	O
a	O
computer	O
simulation	O
study	O
to	O
establish	O
design	O
properties	O
.	O

A	O
hypothetical	O
cohort	O
-	O
by	O
-	O
cohort	O
example	O
is	O
given	O
to	O
illustrate	O
how	O
the	O
method	O
works	O
during	O
trial	O
conduct	O
.	O

RESULTS	O
:	O
Because	O
only	O
a	O
dose	O
that	O
is	O
both	O
safe	O
and	O
efficacious	O
may	O
be	O
selected	O
and	O
the	O
method	O
combines	O
phase	O
I	O
and	O
phase	O
II	O
by	O
integrating	O
efficacy	O
and	O
toxicity	O
to	O
choose	O
doses	O
,	O
it	O
avoids	O
the	O
more	O
time	O
-	O
consuming	O
and	O
expensive	O
conventional	O
approach	O
of	O
conducting	O
a	O
phase	O
I	O
trial	O
based	O
on	O
toxicity	O
alone	O
followed	O
by	O
a	O
phase	O
II	O
trial	O
based	O
on	O
efficacy	O
alone	O
.	O

This	O
is	O
especially	O
useful	O
in	O
settings	O
with	O
low	O
accrual	O
rates	O
,	O
such	O
as	O
trials	O
of	O
tPA	O
for	O
pediatric	O
acute	B
ischemic	I
stroke	I
.	O

Pre	O
-	O
clinical	O
evidence	O
for	O
altered	O
absorption	O
and	O
biliary	O
excretion	O
of	O
irinotecan	O
(	O
CPT	O
-	O
11	O
)	O
in	O
combination	O
with	O
quercetin	O
:	O
possible	O
contribution	O
of	O
P	O
-	O
glycoprotein	O
.	O

P	O
-	O
glycoprotein	O
(	O
P	O
-	O
gp	O
)	O
is	O
found	O
to	O
play	O
a	O
very	O
significant	O
role	O
in	O
intestinal	O
and	O
biliary	O
transport	O
of	O
irinotecan	O
and	O
its	O
active	O
metabolite	O
,	O
SN	O
-	O
38	O
.	O

This	O
makes	O
P	O
-	O
gp	O
inhibition	O
a	O
logical	O
strategy	O
for	O
improving	O
irinotecan	O
's	O
oral	O
efficacy	O
and	O
reducing	O
its	O
toxicity	O
.	O

The	O
objective	O
of	O
the	O
present	O
study	O
was	O
to	O
identify	O
the	O
most	O
suitable	O
P	O
-	O
gp	O
inhibitor	O
,	O
amongst	O
various	O
commonly	O
used	O
herbal	O
components	O
via	O
in	O
vitro	O
screening	O
;	O
followed	O
by	O
determination	O
of	O
in	O
vivo	O
effects	O
in	O
rats	O
.	O

Caco	O
-	O
2	O
cell	O
monolayers	O
were	O
used	O
to	O
investigate	O
the	O
influence	O
of	O
various	O
components	O
(	O
quercetin	O
,	O
hesperitin	O
,	O
piperine	O
,	O
curcumin	O
and	O
naringenin	O
)	O
on	O
the	O
transport	O
of	O
irinotecan	O
.	O

The	O
secretory	O
transport	O
(	O
basolateral	O
-	O
to	O
-	O
apical	O
)	O
was	O
significantly	O
decreased	O
by	O
all	O
components	O
(	O
p	O
<	O
0.05	O
)	O
except	O
piperine	O
.	O

In	O
the	O
apical	O
-	O
to	O
-	O
basolateral	O
transport	O
,	O
quercetin	O
showed	O
the	O
highest	O
absorptive	O
permeability	O
enhancement	O
and	O
P	O
-	O
gp	O
interaction	O
potential	O
making	O
it	O
an	O
appropriate	O
candidate	O
for	O
further	O
in	O
vivo	O
studies	O
in	O
female	O
Wistar	O
rats	O
.	O

Quercetin	O
pre	O
-	O
treatment	O
resulted	O
in	O
increased	O
irinotecan	O
C	O
(	O
max	O
)	O
and	O
area	O
under	O
curve	O
(	O
AUC	O
)	O
with	O
a	O
concomitant	O
decrease	O
in	O
t	O
(	O
max	O
)	O
,	O
plasma	O
clearance	O
and	O
volume	O
of	O
distribution	O
(	O
p	O
<	O
0.05	O
)	O
.	O

The	O
absolute	O
bioavailability	O
(	O
F	O
)	O
of	O
irinotecan	O
control	O
was	O
33	O
%	O
,	O
which	O
was	O
increased	O
to	O
43	O
%	O
(	O
1.3	O
fold	O
)	O
by	O
quercetin	O
administration	O
.	O

The	O
amounts	O
of	O
irinotecan	O
and	O
SN	O
-	O
38	O
eliminated	O
in	O
bile	O
in	O
control	O
rats	O
,	O
is	O
reduced	O
to	O
almost	O
half	O
when	O
treated	O
with	O
quercetin	O
.	O

Our	O
studies	O
not	O
only	O
propose	O
a	O
safe	O
approach	O
for	O
bioavailability	O
enhancement	O
and	O
reducing	O
toxicity	O
of	O
irinotecan	O
by	O
P	O
-	O
gp	O
inhibition	O
but	O
in	O
another	O
way	O
also	O
reiterate	O
the	O
significance	O
of	O
elucidating	O
herb	O
-	O
drug	O
interactions	O
for	O
future	O
insights	O
.	O

Fragrance	O
material	O
review	O
on	O
geraniol	O
.	O

A	O
toxicologic	O
and	O
dermatologic	O
review	O
of	O
geraniol	O
when	O
used	O
as	O
a	O
fragrance	O
ingredient	O
is	O
presented	O
.	O

A	O
phase	O
II	O
trial	O
of	O
tetrathiomolybdate	O
after	O
surgery	O
for	O
malignant	B
mesothelioma	I
:	O
final	O
results	O
.	O

BACKGROUND	O
:	O
Tetrathiomolybdate	O
(	O
TM	O
)	O
is	O
an	O
oral	O
copper	O
-	O
depleting	O
agent	O
that	O
has	O
been	O
shown	O
to	O
inhibit	O
angiogenesis	O
,	O
and	O
angiogenesis	O
is	O
a	O
predictor	O
of	O
poor	O
prognosis	O
in	O
malignant	B
pleural	I
mesothelioma	I
.	O

We	O
hypothesized	O
that	O
cytoreduction	O
of	O
malignant	B
pleural	I
mesothelioma	I
followed	O
by	O
TM	O
will	O
delay	O
time	O
to	O
progression	O
.	O

METHODS	O
:	O
Between	O
November	O
2000	O
and	O
August	O
2003	O
,	O
30	O
patients	O
with	O
malignant	B
pleural	I
mesothelioma	I
received	O
postoperative	O
TM	O
beginning	O
4	O
to	O
6	O
weeks	O
after	O
surgery	O
at	O
a	O
dose	O
adjusted	O
to	O
keep	O
ceruloplasmin	O
between	O
5	O
and	O
15	O
mg	O
/	O
dL	O
)	O
.	O

Time	O
to	O
progression	O
was	O
compared	O
with	O
the	O
55	O
stage	O
I	O
and	O
II	O
patients	O
and	O
109	O
stage	O
III	O
patients	O
previously	O
treated	O
with	O
cytoreduction	O
by	O
one	O
of	O
us	O
(	O
H	O
.	O

P	O
.	O
)	O
.	O

RESULTS	O
:	O
The	O
30	O
patients	O
(	O
25	O
men	O
,	O
5	O
women	O
;	O
13	O
stage	O
I	O
and	O
II	O
,	O
17	O
stage	O
III	O
)	O
,	O
median	O
age	O
67	O
years	O
(	O
range	O
,	O
49	O
-	O
81	O
years	O
)	O
,	O
remained	O
on	O
TM	O
a	O
median	O
of	O
14.9	O
months	O
(	O
range	O
,	O
2	O
to	O
57	O
months	O
)	O
.	O

All	O
patients	O
reached	O
target	O
ceruloplasmin	O
levels	O
at	O
a	O
mean	O
of	O
34	O
+	O
/	O
-	O
2	O
days	O
(	O
95	O
%	O
confidence	O
interval	O
,	O
30	O
to	O
39	O
days	O
)	O
,	O
and	O
vascular	O
endothelial	O
growth	O
factor	O
levels	O
at	O
baseline	O
(	O
ceruloplasmin	O
=	O
45.2	O
+	O
/	O
-	O
2	O
mg	O
/	O
dL	O
)	O
decreased	O
from	O
2,086	O
+	O
/	O
-	O
390	O
pg	O
/	O
mL	O
to	O
1,250	O
+	O
/	O
-	O
712	O
pg	O
/	O
mL	O
(	O
p	O
<	O
0.002	O
)	O
at	O
target	O
ceruloplasmin	O
(	O
13	O
+	O
/	O
-	O
2	O
mg	O
/	O
dL	O
;	O
p	O
<	O
0.0001	O
from	O
baseline	O
)	O
.	O

The	O
time	O
to	O
progression	O
for	O
all	O
stage	O
I	O
or	O
II	O
TM	O
patients	O
was	O
20	O
months	O
whereas	O
that	O
of	O
55	O
stage	O
I	O
or	O
II	O
non	O
-	O
TM	O
-	O
treated	O
patients	O
was	O
10	O
months	O
(	O
p	O
=	O
0.046	O
versus	O
TM	O
)	O
.	O

No	O
differences	O
in	O
time	O
to	O
progression	O
for	O
the	O
stage	O
III	O
TM	O
patents	O
from	O
surgery	O
were	O
seen	O
(	O
7	O
months	O
)	O
.	O

CONCLUSIONS	O
:	O
Tetrathiomolybdate	O
has	O
antiangiogenic	O
effects	O
in	O
malignant	B
pleural	I
mesothelioma	I
patients	O
after	O
resection	O
of	O
gross	B
disease	I
,	O
and	O
exhibits	O
minimal	O
toxicity	O
and	O
comparable	O
efficacy	O
to	O
previous	O
multimodality	O
trials	O
.	O

Tetrathiomolybdate	O
should	O
be	O
evaluated	O
for	O
efficacy	O
in	O
combination	O
with	O
standard	O
malignant	B
pleural	I
mesothelioma	I
regimens	O
,	O
as	O
well	O
as	O
for	O
postsurgical	O
maintenance	O
therapy	O
.	O

Role	O
of	O
physical	O
chemical	O
properties	O
in	O
drug	O
relay	O
into	O
skin	O
compartments	O
.	O

The	O
ability	O
of	O
a	O
drug	O
to	O
reach	O
the	O
interstitial	O
fluid	O
is	O
an	O
important	O
aspect	O
of	O
drug	O
efficacy	O
-	O
as	O
a	O
possible	O
indicator	O
of	O
skin	O
and	O
cell	O
compartment	O
concentration	O
.	O

This	O
overview	O
addresses	O
the	O
relationship	O
of	O
the	O
physical	O
properties	O
of	O
several	O
antibiotics	O
to	O
their	O
ability	O
to	O
enter	O
the	O
interstitial	O
fluid	O
utilizing	O
a	O
cantharidin	O
blister	O
model	O
.	O

By	O
collecting	O
pharmacokinetic	O
data	O
for	O
12	O
antibiotics	O
administered	O
orally	O
and	O
11	O
intravenously	O
,	O
we	O
compared	O
the	O
fraction	O
of	O
drug	O
that	O
reaches	O
the	O
interstitial	O
fluid	O
(	O
AUC	O
(	O
blister	O
)	O
/	O
AUC	O
(	O
serum	O
)	O
)	O
to	O
partition	O
coefficients	O
.	O

Following	O
data	O
analysis	O
,	O
we	O
found	O
no	O
correlation	O
(	O
p	O
=	O
0.98	O
and	O
0.09	O
,	O
respectively	O
)	O
between	O
hydrophobicity	O
and	O
the	O
ability	O
to	O
reach	O
the	O
interstitium	O
.	O

Both	O
orally	O
and	O
intravenously	O
administered	O
antibiotics	O
display	O
a	O
strong	O
linear	O
correlation	O
(	O
p	O
<	O
0.001	O
and	O
p	O
=	O
0.006	O
,	O
respectively	O
)	O
in	O
the	O
total	O
concentration	O
found	O
in	O
the	O
serum	O
and	O
interstitial	O
fluid	O
indicating	O
that	O
serum	O
concentration	O
may	O
be	O
an	O
important	O
factor	O
in	O
dictating	O
interstitial	O
fluid	O
concentration	O
.	O

This	O
correlation	O
may	O
prove	O
useful	O
in	O
clinical	O
application	O
as	O
a	O
means	O
of	O
determining	O
interstitial	O
fluid	O
concentration	O
by	O
measuring	O
only	O
serum	O
levels	O
.	O

Systemic	O
therapy	O
for	O
unresectable	O
and	O
metastatic	B
transitional	I
cell	I
carcinoma	I
of	I
the	I
urothelium	I
:	O
first	O
-	O
line	O
and	O
beyond	O
.	O

PURPOSE	O
OF	O
REVIEW	O
:	O
The	O
review	O
aims	O
to	O
provide	O
an	O
overview	O
of	O
recent	O
advances	O
and	O
future	O
research	O
direction	O
in	O
the	O
management	O
of	O
patients	O
with	O
advanced	O
transitional	B
cell	I
carcinoma	I
.	O

RECENT	O
FINDINGS	O
:	O
Early	O
data	O
of	O
the	O
randomized	O
phase	O
III	O
study	O
comparing	O
paclitaxel	O
,	O
cisplatin	O
,	O
and	O
gemcitabine	O
with	O
gemcitabine	O
plus	O
cisplatin	O
for	O
advanced	O
urothelial	B
cancer	I
detected	O
no	O
survival	O
difference	O
.	O

A	O
phase	O
II	O
study	O
investigated	O
the	O
safety	O
and	O
efficacy	O
of	O
trastuzumab	O
,	O
carboplatin	O
,	O
gemcitabine	O
,	O
and	O
paclitaxel	O
in	O
human	O
epidermal	O
growth	O
factor	O
receptor	O
-	O
2	O
/	O
neu	O
-	O
positive	O
advanced	O
urothelial	B
carcinoma	I
and	O
reported	O
promising	O
results	O
.	O

Renal	O
-	O
sparing	O
regimens	O
are	O
under	O
active	O
development	O
.	O

A	O
nonrandomized	O
comparison	O
of	O
the	O
3	O
-	O
week	O
with	O
the	O
4	O
-	O
week	O
schedule	O
for	O
gemcitabine	O
and	O
cisplatin	O
showed	O
that	O
the	O
3	O
-	O
week	O
schedule	O
had	O
less	O
hematological	B
toxicity	I
and	O
better	O
dose	O
intensity	O
.	O

Potential	O
molecular	O
markers	O
such	O
as	O
excision	O
repair	O
cross	O
-	O
complementation	O
group	O
1	O
,	O
emmprin	O
,	O
and	O
survivin	O
for	O
survival	O
and	O
/	O
or	O
platinum	O
resistance	O
in	O
patients	O
with	O
transitional	B
cell	I
carcinoma	I
showed	O
promise	O
.	O

SUMMARY	O
:	O
Recent	O
data	O
do	O
not	O
support	O
change	O
in	O
the	O
current	O
standard	O
of	O
care	O
for	O
advanced	O
transitional	B
cell	I
carcinoma	I
.	O

Clinical	O
testing	O
of	O
emerging	O
anticancer	O
therapies	O
using	O
new	O
agents	O
,	O
new	O
combinations	O
,	O
and	O
new	O
approaches	O
is	O
under	O
active	O
investigation	O
.	O

Rational	O
combination	O
and	O
new	O
strategy	O
in	O
clinical	O
trial	O
design	O
are	O
critical	O
for	O
new	O
drug	O
development	O
for	O
transitional	B
cell	I
carcinoma	I
.	O

Catalase	O
ameliorates	O
polychlorinated	O
biphenyl	O
-	O
induced	O
cytotoxicity	B
in	O
nonmalignant	O
human	O
breast	O
epithelial	O
cells	O
.	O

Polychlorinated	O
biphenyls	O
(	O
PCBs	O
)	O
are	O
environmental	O
chemical	O
contaminants	O
believed	O
to	O
adversely	O
affect	O
cellular	O
processes	O
.	O

We	O
investigated	O
the	O
hypothesis	O
that	O
PCB	O
-	O
induced	O
changes	O
in	O
the	O
levels	O
of	O
cellular	O
reactive	O
oxygen	O
species	O
(	O
ROS	O
)	O
induce	O
DNA	O
damage	O
resulting	O
in	O
cytotoxicity	B
.	O

Exponentially	O
growing	O
cultures	O
of	O
human	O
nonmalignant	O
breast	O
epithelial	O
cells	O
(	O
MCF10A	O
)	O
were	O
incubated	O
with	O
PCBs	O
for	O
3	O
days	O
and	O
assayed	O
for	O
cell	O
number	O
,	O
ROS	O
levels	O
,	O
DNA	O
damage	O
,	O
and	O
cytotoxicity	B
.	O

Exposure	O
to	O
2,2	O
'	O
,	O
4,4	O
'	O
,	O
5,5	O
'	O
-	O
hexachlorobiphenyl	O
(	O
PCB153	O
)	O
or	O
2	O
-	O
(	O
4	O
-	O
chlorophenyl	O
)	O
benzo	O
-	O
1,4	O
-	O
quinone	O
(	O
4	O
-	O
Cl	O
-	O
BQ	O
)	O
,	O
a	O
metabolite	O
of	O
4	O
-	O
chlorobiphenyl	O
(	O
PCB3	O
)	O
,	O
significantly	O
decreased	O
cell	O
number	O
and	O
MTS	O
reduction	O
and	O
increased	O
the	O
percentage	O
of	O
cells	O
with	O
sub	O
-	O
G1	O
DNA	O
content	O
.	O

Results	O
from	O
electron	O
paramagnetic	O
resonance	O
(	O
EPR	O
)	O
spectroscopy	O
showed	O
a	O
4	O
-	O
fold	O
increase	O
in	O
the	O
steady	O
-	O
state	O
levels	O
of	O
ROS	O
,	O
which	O
was	O
suppressed	O
in	O
cells	O
pretreated	O
with	O
catalase	O
.	O

EPR	O
measurements	O
in	O
cells	O
treated	O
with	O
4	O
-	O
Cl	O
-	O
BQ	O
detected	O
the	O
presence	O
of	O
a	O
semiquinone	O
radical	O
,	O
suggesting	O
that	O
the	O
increased	O
levels	O
of	O
ROS	O
could	O
be	O
due	O
to	O
the	O
redox	O
cycling	O
of	O
4	O
-	O
Cl	O
-	O
BQ	O
.	O

A	O
dose	O
-	O
dependent	O
increase	O
in	O
micronuclei	O
frequency	O
was	O
observed	O
in	O
PCB	O
-	O
treated	O
cells	O
,	O
consistent	O
with	O
an	O
increase	O
in	O
histone	O
2AX	O
phosphorylation	O
.	O

Treatment	O
of	O
cells	O
with	O
catalase	O
blunted	O
the	O
PCB	O
-	O
induced	O
increase	O
in	O
micronuclei	O
frequency	O
and	O
H2AX	O
phosphorylation	O
that	O
was	O
consistent	O
with	O
an	O
increase	O
in	O
cell	O
survival	O
.	O

Our	O
results	O
demonstrate	O
a	O
PCB	O
-	O
induced	O
increase	O
in	O
cellular	O
levels	O
of	O
ROS	O
causing	O
DNA	O
damage	O
,	O
resulting	O
in	O
cell	O
killing	O
.	O

Inhibition	O
of	O
class	O
I	O
histone	O
deacetylase	O
with	O
an	O
apicidin	O
derivative	O
prevents	O
cardiac	B
hypertrophy	I
and	O
failure	O
.	O

AIMS	O
:	O
Recent	O
studies	O
have	O
demonstrated	O
the	O
importance	O
of	O
chromatin	O
remodelling	O
via	O
histone	O
acetylation	O
/	O
deacetylation	O
for	O
the	O
control	O
of	O
cardiac	O
gene	O
expression	O
.	O

Specific	O
histone	O
deacetylases	O
(	O
HDACs	O
)	O
can	O
,	O
in	O
fact	O
,	O
play	O
a	O
positive	O
or	O
negative	O
role	O
in	O
determining	O
cardiac	O
myocyte	O
(	O
CM	O
)	O
size	O
.	O

Here	O
,	O
we	O
report	O
on	O
the	O
effect	O
on	O
hypertrophy	B
development	O
of	O
three	O
inhibitors	O
(	O
HDACi	O
)	O
of	O
class	O
I	O
HDACs	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
The	O
compounds	O
were	O
first	O
analysed	O
in	O
vitro	O
by	O
scoring	O
hypertrophy	B
,	O
expression	O
of	O
foetal	O
genes	O
,	O
and	O
apoptosis	O
of	O
neonatal	O
rat	O
CMs	O
stimulated	O
with	O
phenylephrine	O
,	O
an	O
alpha1	O
-	O
adrenergic	O
agonist	O
.	O

This	O
initial	O
screening	O
indicated	O
that	O
a	O
truncated	O
derivative	O
of	O
apicidin	O
with	O
class	O
I	O
HDAC	O
specificity	O
,	O
denoted	O
API	O
-	O
D	O
,	O
had	O
the	O
highest	O
efficacy	O
to	O
toxicity	O
ratio	O
,	O
and	O
was	O
thus	O
selected	O
for	O
further	O
analysis	O
in	O
vivo	O
.	O

Administration	O
of	O
this	O
drug	O
significantly	O
decreased	O
myocardial	B
hypertrophy	I
and	O
foetal	O
gene	O
expression	O
after	O
1	O
week	O
of	O
pressure	O
overload	O
induced	O
by	O
thoracic	O
aortic	O
constriction	O
(	O
TAC	O
)	O
in	O
mice	O
.	O

After	O
9	O
weeks	O
of	O
TAC	O
,	O
when	O
manifest	O
heart	B
failure	I
is	O
encountered	O
,	O
mice	O
treated	O
with	O
API	O
-	O
D	O
presented	O
with	O
significantly	O
improved	O
echocardiographic	O
and	O
haemodynamic	O
parameters	O
of	O
cardiac	O
function	O
when	O
compared	O
with	O
untreated	O
TAC	O
-	O
operated	O
mice	O
.	O

CONCLUSION	O
:	O
The	O
apicidin	O
derivative	O
,	O
API	O
-	O
D	O
,	O
is	O
capable	O
of	O
reducing	O
hypertrophy	B
and	O
,	O
consequently	O
,	O
the	O
transition	O
to	O
heart	B
failure	I
in	O
mice	O
subjected	O
to	O
TAC	O
.	O

Treatment	O
with	O
this	O
substance	O
,	O
therefore	O
,	O
holds	O
promise	O
as	O
an	O
important	O
therapeutic	O
option	O
for	O
heart	B
failure	I
.	O

Application	O
of	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
in	O
metabolism	O
and	O
in	O
metabolism	B
-	I
mediated	I
toxicity	I
studies	O
.	O

Stable	O
isotope	O
-	O
labeled	O
compounds	O
have	O
been	O
synthesized	O
and	O
utilized	O
by	O
scientists	O
from	O
various	O
areas	O
of	O
biomedical	O
research	O
during	O
the	O
last	O
several	O
decades	O
.	O

Compounds	O
labeled	O
with	O
stable	O
isotopes	O
,	O
such	O
as	O
deuterium	O
and	O
carbon	O
-	O
13	O
,	O
have	O
been	O
used	O
effectively	O
by	O
drug	O
metabolism	O
scientists	O
and	O
toxicologists	O
to	O
gain	O
better	O
understanding	O
of	O
drugs	O
'	O
disposition	O
and	O
their	O
potential	O
role	O
in	O
target	B
organ	I
toxicities	I
.	O

The	O
combination	O
of	O
stable	O
isotope	O
-	O
labeling	O
techniques	O
with	O
mass	O
spectrometry	O
and	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
spectroscopy	O
,	O
which	O
allows	O
rapid	O
acquisition	O
and	O
interpretation	O
of	O
data	O
,	O
has	O
promoted	O
greater	O
use	O
of	O
these	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
in	O
absorption	O
,	O
distribution	O
,	O
metabolism	O
,	O
and	O
excretion	O
(	O
ADME	O
)	O
studies	O
.	O

Examples	O
of	O
the	O
use	O
of	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
in	O
elucidating	O
structures	O
of	O
metabolites	O
and	O
delineating	O
complex	O
metabolic	O
pathways	O
are	O
presented	O
in	O
this	O
review	O
.	O

The	O
application	O
of	O
labeled	O
compounds	O
in	O
mechanistic	O
toxicity	O
studies	O
will	O
be	O
discussed	O
by	O
providing	O
an	O
example	O
of	O
how	O
strategic	O
placement	O
of	O
a	O
deuterium	O
atom	O
in	O
a	O
drug	O
molecule	O
mitigated	O
specific	O
-	O
specific	O
renal	B
toxicity	I
.	O

Other	O
examples	O
from	O
the	O
literature	O
demonstrating	O
the	O
application	O
of	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
in	O
understanding	O
metabolism	B
-	I
mediated	I
toxicities	I
are	O
presented	O
.	O

Furthermore	O
,	O
an	O
example	O
of	O
how	O
a	O
stable	O
isotope	O
-	O
labeled	O
compound	O
was	O
utilized	O
to	O
better	O
understand	O
some	O
of	O
the	O
gene	O
changes	O
in	O
toxicogenomic	O
studies	O
is	O
discussed	O
.	O

The	O
interpretation	O
of	O
large	O
sets	O
of	O
data	O
produced	O
from	O
toxicogenomics	O
studies	O
can	O
be	O
a	O
challenge	O
.	O

One	O
approach	O
that	O
could	O
be	O
used	O
to	O
simplify	O
interpretation	O
of	O
the	O
data	O
,	O
especially	O
from	O
studies	O
designed	O
to	O
link	O
gene	O
changes	O
with	O
the	O
formation	O
of	O
reactive	O
metabolites	O
thought	O
to	O
be	O
responsible	O
for	O
toxicities	O
,	O
is	O
through	O
the	O
use	O
of	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
.	O

This	O
is	O
a	O
relatively	O
unexplored	O
territory	O
and	O
needs	O
to	O
be	O
further	O
investigated	O
.	O

The	O
employment	O
of	O
analytical	O
techniques	O
,	O
especially	O
mass	O
spectrometry	O
and	O
NMR	O
,	O
used	O
in	O
conjunction	O
with	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
to	O
establish	O
and	O
understand	O
mechanistic	O
link	O
between	O
reactive	O
metabolite	O
formation	O
,	O
genomic	O
,	O
and	O
proteomic	O
changes	O
and	O
onset	O
of	O
toxicity	O
is	O
proposed	O
.	O

The	O
use	O
of	O
stable	O
isotope	O
-	O
labeled	O
compounds	O
in	O
early	O
human	O
ADME	O
studies	O
as	O
a	O
way	O
of	O
identifying	O
and	O
possibly	O
quantifying	O
all	O
drug	O
-	O
related	O
components	O
present	O
in	O
systemic	O
circulation	O
is	O
suggested	O
.	O

Delayed	O
initiation	O
of	O
breast	O
development	O
in	O
girls	O
with	O
higher	O
prenatal	O
dioxin	O
exposure	O
;	O
a	O
longitudinal	O
cohort	O
study	O
.	O

OBJECTIVES	O
:	O
While	O
many	O
studies	O
have	O
assessed	O
the	O
health	O
impacts	O
of	O
PCDD	O
/	O
Fs	O
and	O
PCBs	O
on	O
animals	O
and	O
humans	O
,	O
long	O
-	O
term	O
consequences	O
for	O
especially	O
adolescents	O
,	O
have	O
not	O
(	O
yet	O
)	O
been	O
well	O
documented	O
.	O

This	O
is	O
certainly	O
also	O
true	O
for	O
the	O
effects	O
of	O
PBDE	O
exposure	O
.	O

As	O
part	O
of	O
a	O
longitudinal	O
cohort	O
study	O
,	O
now	O
well	O
into	O
its	O
second	O
decade	O
,	O
effects	O
of	O
perinatal	O
and	O
current	O
PCDD	O
/	O
F	O
exposure	O
,	O
as	O
well	O
as	O
current	O
dl	O
-	O
PCB	O
and	O
PBDE	O
exposures	O
,	O
on	O
puberty	O
,	O
were	O
assessed	O
.	O

STUDY	O
DESIGN	O
:	O
Prenatal	O
,	O
lactational	O
and	O
current	O
PCDD	O
/	O
F	O
,	O
dl	O
-	O
PCB	O
and	O
PBDE	O
concentrations	O
were	O
determined	O
using	O
GC	O
-	O
MS	O
.	O

Pubertal	O
development	O
and	O
growth	O
were	O
assessed	O
by	O
means	O
of	O
physical	O
examination	O
and	O
the	O
Tanner	O
scale	O
.	O

33	O
Children	O
(	O
born	O
between	O
1986	O
and	O
1991	O
)	O
consented	O
to	O
the	O
current	O
follow	O
-	O
up	O
study	O
.	O

Outcomes	O
were	O
evaluated	O
using	O
linear	O
regression	O
or	O
the	O
non	O
parametric	O
Spearman	O
's	O
correlation	O
coefficient	O
.	O

RESULTS	O
:	O
A	O
delay	O
in	O
initiation	O
of	O
breast	O
development	O
was	O
found	O
in	O
girls	O
(	O
n	O
=	O
18	O
)	O
with	O
higher	O
prenatal	O
(	O
p	O
=	O
0.023	O
)	O
and	O
lactational	O
PCDD	O
/	O
F	O
exposure	O
(	O
p	O
=	O
0.048	O
)	O
.	O

The	O
males	O
revealed	O
a	O
negative	O
trend	O
with	O
age	O
at	O
first	O
ejaculation	O
.	O

For	O
other	O
endpoints	O
on	O
puberty	O
and	O
growth	O
(	O
pubic	O
hair	O
,	O
axillary	O
hair	O
,	O
genital	O
stage	O
,	O
length	O
,	O
BMI	O
,	O
testicular	O
volume	O
,	O
menarche	O
)	O
no	O
significant	O
relation	O
was	O
found	O
with	O
any	O
of	O
the	O
measured	O
compounds	O
.	O

DISCUSSION	O
AND	O
CONCLUSION	O
:	O
A	O
relation	O
between	O
prenatal	O
PCDD	O
/	O
F	O
exposure	O
and	O
later	O
initiation	O
of	O
breast	O
development	O
was	O
seen	O
.	O

A	O
Belgian	O
study	O
found	O
a	O
delay	O
in	O
breast	O
development	O
with	O
higher	O
current	O
serum	O
concentrations	O
of	O
dioxin	O
-	O
like	O
compounds	O
.	O

The	O
initiation	O
of	O
puberty	O
is	O
a	O
complex	O
process	O
and	O
it	O
is	O
yet	O
not	O
clear	O
how	O
dioxin	O
-	O
like	O
compounds	O
precisely	O
affect	O
this	O
process	O
prenatally	O
.	O

Further	O
follow	O
-	O
up	O
into	O
adulthood	O
is	O
warranted	O
,	O
in	O
order	O
to	O
detect	O
the	O
possibility	O
of	O
developing	O
malignancies	B
and	O
fertility	O
problems	O
.	O

Preparation	O
of	O
BMP	O
-	O
2	O
containing	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
nanoparticles	O
stabilized	O
by	O
polymer	O
coating	O
.	O

PURPOSE	O
:	O
The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
investigate	O
the	O
preparation	O
process	O
of	O
bone	O
morphogenetic	O
protein	O
-	O
2	O
(	O
BMP	O
-	O
2	O
)	O
containing	O
bovine	O
serum	O
albumin	O
(	O
BSA	O
)	O
nanoparticles	O
(	O
NPs	O
)	O
,	O
and	O
to	O
assess	O
the	O
bioactivity	O
of	O
BMP	O
-	O
2	O
encapsulated	O
in	O
such	O
NPs	O
.	O

METHODS	O
:	O
The	O
NPs	O
were	O
prepared	O
by	O
a	O
coacervation	O
method	O
,	O
and	O
the	O
effects	O
of	O
process	O
parameters	O
on	O
NP	O
size	O
and	O
polydispersity	O
were	O
examined	O
.	O

Polymer	O
coated	O
NPs	O
were	O
characterized	O
with	O
respect	O
to	O
amount	O
of	O
adsorbed	O
polymer	O
,	O
particle	O
size	O
and	O
zeta	O
potential	O
.	O

Using	O
bone	O
marrow	O
stromal	O
cells	O
(	O
BMSC	O
)	O
,	O
biocompatibility	O
of	O
the	O
NPs	O
was	O
investigated	O
by	O
the	O
3	O
-	O
(	O
4,5	O
-	O
dimethylthiazol	O
-	O
2	O
-	O
yl	O
)	O
-	O
2,5	O
-	O
diphenyl	O
-	O
tetrazolium	O
bromide	O
(	O
MTT	O
)	O
Assay	O
,	O
and	O
bioactivity	O
of	O
the	O
encapsulated	O
BMP	O
-	O
2	O
was	O
investigated	O
by	O
alkaline	O
phosphatase	O
(	O
ALP	O
)	O
induction	O
and	O
calcification	O
.	O

RESULTS	O
:	O
The	O
size	O
of	O
NPs	O
could	O
be	O
controlled	O
in	O
the	O
50	O
-	O
400	O
nm	O
range	O
by	O
process	O
parameters	O
including	O
BSA	O
concentration	O
,	O
non	O
-	O
solvent	O
:	O
solvent	O
ratio	O
and	O
pH	O
value	O
.	O

After	O
coating	O
with	O
cationic	O
polymers	O
,	O
the	O
particle	O
size	O
and	O
zeta	O
potential	O
were	O
significantly	O
increased	O
.	O

MTT	O
assay	O
indicated	O
no	O
toxicity	O
of	O
both	O
the	O
uncoated	O
and	O
coated	O
NPs	O
on	O
BMSC	O
.	O

Based	O
on	O
ALP	O
induction	O
and	O
calcification	O
,	O
full	O
retention	O
of	O
BMP	O
-	O
2	O
bioactivity	O
was	O
retained	O
in	O
the	O
polymer	O
-	O
coated	O
NPs	O
.	O

CONCLUSIONS	O
:	O
This	O
study	O
described	O
a	O
preparation	O
procedure	O
for	O
BSA	O
NPs	O
with	O
controllable	O
particle	O
size	O
,	O
and	O
such	O
polymer	O
-	O
coated	O
BSA	O
NPs	O
are	O
promising	O
delivery	O
agents	O
for	O
local	O
and	O
systemic	O
administration	O
of	O
BMP	O
-	O
2	O
in	O
bone	O
regeneration	O
.	O

Effect	O
of	O
cement	O
dust	O
exposure	O
on	O
phagocytic	O
function	O
of	O
polymorphonuclear	O
neutrophils	O
in	O
cement	O
mill	O
workers	O
.	O

OBJECTIVES	O
:	O
Exposure	O
to	O
cement	O
dust	O
can	O
cause	O
various	O
occupational	O
health	O
problems	O
due	O
to	O
its	O
increasing	O
incidence	O
and	O
long	O
-	O
term	O
complications	O
.	O

However	O
,	O
the	O
influence	O
of	O
cement	O
dust	O
on	O
phagocytic	O
function	O
of	O
polymorphonuclear	O
neutrophils	O
(	O
PMNs	O
)	O
,	O
has	O
not	O
as	O
yet	O
been	O
investigated	O
.	O

Therefore	O
,	O
the	O
aim	O
of	O
the	O
study	O
was	O
to	O
measure	O
the	O
phagocytic	O
activity	O
of	O
PMNs	O
by	O
assessing	O
chemilumiscence	O
(	O
CL	O
)	O
response	O
in	O
cement	O
mill	O
workers	O
and	O
controls	O
.	O

MATERIAL	O
AND	O
METHODS	O
:	O
In	O
this	O
study	O
,	O
50	O
volunteer	O
males	O
,	O
aged	O
25	O
-	O
60	O
years	O
,	O
apparently	O
healthy	O
and	O
nonsmoking	O
,	O
were	O
randomly	O
selected	O
from	O
among	O
cement	O
mill	O
workers	O
.	O

These	O
workers	O
were	O
further	O
classified	O
into	O
subgroups	O
based	O
on	O
exposure	O
duration	O
of	O
less	O
than	O
10	O
,	O
10	O
-	O
20	O
,	O
and	O
more	O
than	O
20	O
years	O
.	O

The	O
controls	O
were	O
50	O
healthy	O
,	O
nonsmoking	O
,	O
males	O
who	O
matched	O
the	O
study	O
group	O
with	O
respect	O
to	O
age	O
,	O
height	O
,	O
weight	O
,	O
and	O
socioeconomic	O
status	O
.	O

The	O
phagocytic	O
function	O
of	O
PMNs	O
,	O
stimulated	O
with	O
opsonized	O
zymosan	O
,	O
was	O
determined	O
by	O
measuring	O
CL	O
response	O
.	O

RESULTS	O
:	O
The	O
findings	O
show	O
a	O
significant	O
decrease	O
in	O
phagocytic	O
activity	O
of	O
PMNs	O
[	O
PMNs	O
OPZ	O
p	O
<	O
0.005	O
]	O
in	O
cement	O
mill	O
workers	O
compared	O
to	O
controls	O
.	O

CONCLUSION	O
:	O
It	O
is	O
concluded	O
that	O
exposure	O
to	O
cement	O
dust	O
can	O
impair	O
the	O
phagocytic	O
function	O
of	O
PMNs	O
which	O
is	O
reflected	O
in	O
decreased	O
chemiluminescence	O
response	O
.	O

Tadalafil	O
administered	O
once	O
daily	O
for	O
lower	O
urinary	B
tract	I
symptoms	I
secondary	O
to	O
benign	B
prostatic	I
hyperplasia	I
:	O
a	O
dose	O
finding	O
study	O
.	O

PURPOSE	O
:	O
Phosphodiesterase	O
type	O
5	O
inhibitors	O
are	O
widely	O
used	O
to	O
treat	O
erectile	B
dysfunction	I
.	O

Preliminary	O
data	O
have	O
suggested	O
phosphodiesterase	O
type	O
5	O
inhibitor	O
efficacy	O
in	O
men	O
with	O
lower	O
urinary	B
tract	I
symptoms	I
associated	O
with	O
clinical	O
benign	B
prostatic	I
hyperplasia	I
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
After	O
a	O
4	O
-	O
week	O
placebo	O
run	O
-	O
in	O
period	O
1,058	O
men	O
with	O
benign	B
prostatic	I
hyperplasia	I
lower	I
urinary	I
tract	I
symptoms	I
were	O
randomly	O
allocated	O
to	O
receive	O
12	O
-	O
week	O
,	O
once	O
daily	O
treatment	O
with	O
placebo	O
or	O
tadalafil	O
(	O
2.5	O
,	O
5	O
,	O
10	O
or	O
20	O
mg	O
)	O
.	O

RESULTS	O
:	O
The	O
International	O
Prostate	O
Symptom	O
Score	O
least	O
squares	O
mean	O
change	O
from	O
baseline	O
to	O
end	O
point	O
was	O
significantly	O
improved	O
for	O
2.5	O
(	O
-	O
3.9	O
,	O
p	O
=	O
0.015	O
)	O
,	O
5	O
(	O
-	O
4.9	O
,	O
p	O
<	O
0.001	O
)	O
,	O
10	O
(	O
-	O
5.2	O
,	O
p	O
<	O
0.001	O
)	O
and	O
20	O
mg	O
(	O
-	O
5.2	O
,	O
p	O
<	O
0.001	O
)	O
tadalafil	O
compared	O
to	O
placebo	O
(	O
-	O
2.3	O
)	O
.	O

International	O
Prostate	O
Symptom	O
Score	O
improvements	O
at	O
4	O
,	O
8	O
and	O
12	O
weeks	O
were	O
significant	O
for	O
all	O
tadalafil	O
doses	O
and	O
they	O
demonstrated	O
a	O
dose	O
-	O
response	O
relationship	O
.	O

Tadalafil	O
(	O
2.5	O
mg	O
)	O
significantly	O
improved	O
the	O
International	O
Prostate	O
Symptom	O
Score	O
obstructive	O
subscore	O
and	O
the	O
International	O
Index	O
of	O
Erectile	O
Function	O
-	O
Erectile	O
Function	O
domain	O
,	O
the	O
latter	O
in	O
sexually	O
active	O
men	O
with	O
a	O
history	O
of	O
erectile	B
dysfunction	I
.	O

Statistically	O
significant	O
improvements	O
were	O
noted	O
for	O
5	O
,	O
10	O
and	O
20	O
mg	O
tadalafil	O
compared	O
to	O
placebo	O
,	O
as	O
assessed	O
by	O
the	O
International	O
Prostate	O
Symptom	O
Score	O
irritative	O
and	O
obstructive	O
subscores	O
,	O
International	O
Prostate	O
Symptom	O
Score	O
Quality	O
of	O
Life	O
,	O
Benign	B
Prostatic	I
Hyperplasia	I
Impact	O
Index	O
(	O
nonsignificant	O
for	O
10	O
mg	O
)	O
,	O
Global	O
Assessment	O
Question	O
and	O
International	O
Index	O
of	O
Erectile	O
Function	O
-	O
Erectile	O
Function	O
domain	O
.	O

No	O
statistically	O
significant	O
effect	O
of	O
treatment	O
compared	O
to	O
placebo	O
was	O
noted	O
for	O
peak	O
flow	O
at	O
any	O
tadalafil	O
dose	O
.	O

Treatment	O
emergent	O
adverse	O
events	O
were	O
infrequent	O
in	O
all	O
tadalafil	O
groups	O
.	O

CONCLUSIONS	O
:	O
Once	O
daily	O
tadalafil	O
demonstrated	O
clinically	O
meaningful	O
and	O
statistically	O
significant	O
efficacy	O
and	O
it	O
was	O
well	O
tolerated	O
in	O
men	O
with	O
benign	B
prostatic	I
hyperplasia	I
lower	I
urinary	I
tract	I
symptoms	I
.	O

Of	O
the	O
doses	O
studied	O
5	O
mg	O
tadalafil	O
appeared	O
to	O
provide	O
a	O
positive	O
risk	O
-	O
benefit	O
profile	O
.	O

Mitochondrial	O
dysfunction	O
and	O
delayed	O
hepatotoxicity	B
:	O
another	O
lesson	O
from	O
troglitazone	O
.	O

AIMS	O
/	O
HYPOTHESIS	O
:	O
Troglitazone	O
was	O
approved	O
for	O
treatment	O
of	O
type	B
2	I
diabetes	I
mellitus	I
,	O
but	O
by	O
2000	O
it	O
had	O
been	O
removed	O
from	O
all	O
world	O
markets	O
due	O
to	O
severe	O
drug	O
-	O
induced	O
liver	B
injury	I
.	O

Even	O
today	O
,	O
we	O
still	O
do	O
not	O
know	O
how	O
many	O
patients	O
sustained	O
a	O
long	O
-	O
term	O
liver	B
injury	I
.	O

No	O
system	O
is	O
in	O
place	O
to	O
acquire	O
that	O
knowledge	O
.	O

Regarding	O
toxicity	O
mechanisms	O
,	O
controversy	O
persists	O
as	O
to	O
which	O
ones	O
are	O
class	O
effects	O
of	O
thiazolidinediones	O
(	O
TZDs	O
)	O
and	O
which	O
are	O
unique	O
to	O
troglitazone	O
.	O

This	O
study	O
aims	O
to	O
provide	O
long	O
-	O
term	O
outcome	O
data	O
and	O
new	O
insights	O
on	O
mechanisms	O
of	O
troglitazone	O
-	O
induced	O
liver	B
injury	I
.	O

METHODS	O
:	O
This	O
case	O
series	O
reports	O
the	O
liver	O
injuries	O
sustained	O
by	O
eleven	O
type	O
2	O
diabetic	O
patients	O
treated	O
with	O
troglitazone	O
between	O
1997	O
and	O
2000	O
.	O

Exhaustive	O
review	O
of	O
medical	O
records	O
was	O
performed	O
for	O
all	O
patients	O
.	O

Long	O
-	O
term	O
outcomes	O
were	O
available	O
for	O
all	O
the	O
non	O
-	O
fatal	O
cases	O
.	O

A	O
comprehensive	O
literature	O
review	O
was	O
also	O
performed	O
.	O

RESULTS	O
:	O
Long	O
-	O
term	O
liver	B
injury	I
progressing	O
to	O
cirrhosis	B
was	O
identified	O
in	O
seven	O
patients	O
.	O

All	O
eleven	O
cases	O
had	O
liver	B
injury	I
patterns	O
consistent	O
with	O
troglitazone	O
toxicity	O
.	O

Analysis	O
of	O
these	O
cases	O
and	O
of	O
the	O
experimental	O
troglitazone	O
toxicity	O
data	O
points	O
to	O
mitochondrial	B
toxicity	I
as	O
a	O
central	O
factor	O
.	O

The	O
general	O
clinical	O
patterns	O
of	O
mitochondrial	B
hepatotoxic	I
events	I
are	O
reviewed	O
,	O
as	O
are	O
the	O
implications	O
for	O
other	O
members	O
of	O
the	O
TZD	O
family	O
.	O

CONCLUSIONS	O
/	O
INTERPRETATION	O
:	O
This	O
analysis	O
enables	O
the	O
liver	B
injury	I
induced	O
by	O
troglitazone	O
to	O
be	O
better	O
understood	O
.	O

In	O
future	O
cases	O
of	O
delayed	O
drug	O
-	O
induced	O
liver	B
injury	I
that	O
progresses	O
after	O
discontinuation	O
,	O
the	O
possibility	O
of	O
mitochondrial	B
toxicity	I
should	O
be	O
considered	O
.	O

When	O
appropriate	O
,	O
this	O
can	O
then	O
be	O
evaluated	O
experimentally	O
.	O

Such	O
proactive	O
investigation	O
may	O
anticipate	O
clinical	O
risk	O
before	O
a	O
large	O
-	O
scale	O
therapeutic	O
misadventure	O
occurs	O
.	O

Drug	O
-	O
induced	O
liver	B
injury	I
due	O
to	O
mitochondrial	O
hepatotoxins	O
may	O
be	O
less	O
unpredictable	O
than	O
has	O
previously	O
been	O
surmised	O
.	O

Understanding	O
the	O
genetic	O
causes	O
of	O
inter	O
-	O
patient	O
variability	O
.	O

Clinical	O
relevance	O
with	O
focus	O
on	O
cardiovascular	O
drugs	O
.	O

There	O
is	O
a	O
large	O
inter	O
-	O
patient	O
variability	O
concerning	O
the	O
response	O
to	O
drug	O
therapy	O
and	O
a	O
great	O
interest	O
for	O
determining	O
the	O
causes	O
of	O
this	O
variability	O
.	O

This	O
review	O
takes	O
into	O
discussion	O
some	O
aspects	O
of	O
cardiovascular	O
drugs	O
metabolism	O
and	O
transport	O
,	O
pointing	O
out	O
the	O
effects	O
of	O
genetic	O
variation	O
.	O

Isoenyzmes	O
belonging	O
to	O
the	O
Cytochrome	O
P450	O
super	O
family	O
have	O
an	O
important	O
role	O
in	O
cardiovascular	O
drug	O
metabolism	O
,	O
namely	O
CYP	O
1A2	O
;	O
CYP	O
3A	O
;	O
CYP	O
2C19	O
;	O
CYP2C9	O
;	O
CYP	O
2D6	O
,	O
involved	O
in	O
the	O
oxidative	O
phase	O
and	O
also	O
N	O
-	O
acetyltransferase	O
2	O
,	O
involved	O
in	O
the	O
conjungative	O
phase	O
of	O
the	O
metabolism	O
.	O

P	O
-	O
glycoprotein	O
is	O
implied	O
in	O
cardiovascular	O
drug	O
transport	O
.	O

Polymorphisms	O
of	O
those	O
enzymes	O
and	O
transport	O
protein	O
result	O
in	O
different	O
phenotypes	O
,	O
that	O
is	O
the	O
case	O
of	O
CYP	O
isoenyzmes	O
with	O
abolished	O
,	O
low	O
or	O
increased	O
activity	O
and	O
in	O
the	O
case	O
of	O
N	O
-	O
acetyltransferase	O
2	O
,	O
slow	O
,	O
intermediate	O
and	O
rapid	O
acetylator	O
phenotypes	O
.	O

There	O
is	O
hope	O
that	O
,	O
in	O
the	O
future	O
,	O
a	O
more	O
individualized	O
treatment	O
of	O
a	O
certain	O
disease	O
,	O
with	O
minimum	O
adverse	O
effects	O
and	O
a	O
maximum	O
therapeutic	O
effect	O
,	O
will	O
be	O
available	O
,	O
by	O
means	O
of	O
genetic	O
testing	O
.	O

The	O
islet	O
beta	O
-	O
cell	O
:	O
fuel	O
responsive	O
and	O
vulnerable	O
.	O

The	O
pancreatic	O
beta	O
-	O
cell	O
senses	O
blood	O
nutrient	O
levels	O
and	O
is	O
modulated	O
by	O
neurohormonal	O
signals	O
so	O
that	O
it	O
secretes	O
insulin	O
according	O
to	O
the	O
need	O
of	O
the	O
organism	O
.	O

Nutrient	O
sensing	O
involves	O
marked	O
metabolic	O
activation	O
,	O
resulting	O
in	O
the	O
production	O
of	O
coupling	O
signals	O
that	O
promote	O
insulin	O
biosynthesis	O
and	O
secretion	O
.	O

The	O
beta	O
-	O
cell	O
's	O
high	O
capacity	O
for	O
nutrient	O
sensing	O
,	O
however	O
,	O
necessitates	O
reduced	O
protection	O
to	O
nutrient	B
toxicity	I
.	O

This	O
potentially	O
explains	O
why	O
in	O
susceptible	O
individuals	O
,	O
chronic	O
fuel	O
surfeit	O
results	O
in	O
beta	O
-	O
cell	O
failure	O
and	O
type	B
2	I
diabetes	I
.	O

Here	O
we	O
discuss	O
recent	O
insights	O
into	O
first	O
,	O
the	O
biochemical	O
basis	O
of	O
beta	O
-	O
cell	O
signaling	O
in	O
response	O
to	O
glucose	O
,	O
amino	O
acids	O
and	O
fatty	O
acids	O
,	O
and	O
second	O
,	O
beta	O
-	O
cell	O
nutrient	O
detoxification	O
.	O

We	O
emphasize	O
the	O
emerging	O
role	O
of	O
glycerolipid	O
/	O
fatty	O
acid	O
cycling	O
in	O
these	O
processes	O
.	O

Recurrent	O
seizures	B
in	O
patients	O
with	O
dementia	B
:	O
frequency	O
,	O
seizure	B
types	O
,	O
and	O
treatment	O
outcome	O
.	O

OBJECTIVE	O
:	O
Patients	O
with	O
a	O
primary	O
neurodegenerative	B
disorder	I
associated	O
with	O
cognitive	B
impairment	I
are	O
at	O
increased	O
risk	O
for	O
epilepsy	B
.	O

The	O
goal	O
of	O
the	O
present	O
study	O
was	O
to	O
characterize	O
seizure	B
type	O
(	O
s	O
)	O
,	O
etiological	O
diagnosis	O
of	O
dementia	B
,	O
electroencephalogram	O
(	O
EEG	O
)	O
and	O
imaging	O
findings	O
,	O
and	O
response	O
to	O
antiepileptic	O
drug	O
(	O
AED	O
)	O
therapy	O
in	O
these	O
individuals	O
.	O

METHODS	O
:	O
A	O
retrospective	O
study	O
was	O
performed	O
identifying	O
patients	O
in	O
the	O
Mayo	O
Alzheimer	B
Disease	I
Patient	O
Registry	O
(	O
ADPR	O
)	O
and	O
Alzheimer	B
Disease	I
Research	O
Center	O
(	O
ADRC	O
)	O
who	O
were	O
classified	O
as	O
having	O
dementia	B
and	O
epilepsy	B
from	O
1986	O
to	O
2006	O
.	O

Multiple	O
clinical	O
parameters	O
were	O
extracted	O
from	O
patient	O
charts	O
and	O
evaluated	O
to	O
characterize	O
the	O
primary	O
neurodegenerative	B
disorder	I
and	O
seizure	B
outcomes	O
.	O

RESULTS	O
:	O
Sixty	O
-	O
three	O
of	O
the	O
1738	O
ADPR	O
and	O
ADRC	O
patients	O
(	O
3.6	O
%	O
)	O
had	O
epilepsy	B
.	O

Twenty	O
-	O
four	O
of	O
the	O
63	O
patients	O
were	O
excluded	O
because	O
of	O
insufficient	O
information	O
regarding	O
their	O
epilepsy	B
.	O

The	O
remaining	O
39	O
patients	O
were	O
analyzed	O
.	O

Twenty	O
-	O
eight	O
of	O
the	O
63	O
patients	O
(	O
72	O
%	O
)	O
experienced	O
complex	B
partial	I
seizures	I
.	O

Head	O
MRI	O
was	O
performed	O
in	O
35	O
patients	O
(	O
90	O
%	O
)	O
.	O

Fourteen	O
patients	O
(	O
36	O
%	O
)	O
had	O
MRI	O
-	O
identified	O
structural	O
lesions	O
that	O
included	O
remote	O
stroke	B
and	O
prior	O
intracerebral	B
hemorrhage	I
.	O

EEGs	O
were	O
obtained	O
in	O
29	O
patients	O
(	O
74	O
%	O
)	O
.	O

Fifteen	O
patients	O
(	O
38	O
%	O
)	O
had	O
epileptiform	O
discharges	O
.	O

Overall	O
,	O
it	O
was	O
found	O
that	O
79	O
%	O
had	O
an	O
excellent	O
response	O
to	O
AED	O
therapy	O
.	O

Approximately	O
one	O
-	O
third	O
of	O
the	O
patients	O
had	O
dose	B
-	I
related	I
side	I
effects	I
from	O
an	O
AED	O
.	O

CONCLUSION	O
:	O
The	O
present	O
study	O
indicated	O
that	O
most	O
individuals	O
with	O
the	O
comorbidity	O
of	O
epilepsy	B
and	O
dementia	B
have	O
complex	B
partial	I
seizures	I
that	O
may	O
be	O
adequately	O
controlled	O
on	O
AED	O
therapy	O
.	O

The	O
long	O
-	O
term	O
effect	O
of	O
seizure	B
activity	O
on	O
the	O
neurodegenerative	B
disorder	I
is	O
unknown	O
.	O

Pharmacokinetic	O
-	O
directed	O
dosing	O
of	O
vandetanib	O
and	O
docetaxel	O
in	O
a	O
mouse	O
model	O
of	O
human	O
squamous	B
cell	I
carcinoma	I
.	O

Docetaxel	O
,	O
usually	O
administered	O
according	O
to	O
maximum	O
tolerated	O
dose	O
(	O
MTD	O
)	O
,	O
can	O
inhibit	O
endothelial	O
cell	O
proliferation	O
at	O
low	O
nanomolar	O
concentrations	O
.	O

Docetaxel	O
may	O
exert	O
antiangiogenic	O
effects	O
if	O
dosed	O
so	O
plasma	O
levels	O
are	O
maintained	O
at	O
low	O
nanomolar	O
concentrations	O
over	O
a	O
prolonged	O
time	O
.	O

We	O
evaluated	O
metronomic	O
and	O
MTD	O
-	O
based	O
dosing	O
of	O
docetaxel	O
with	O
and	O
without	O
vandetanib	O
,	O
a	O
vascular	O
endothelial	O
growth	O
factor	O
receptor	O
-	O
2	O
and	O
epidermal	O
growth	O
factor	O
receptor	O
tyrosine	O
kinase	O
inhibitor	O
with	O
antiangiogenic	O
and	O
antitumor	O
activity	O
,	O
in	O
a	O
head	O
and	O
neck	O
xenograft	O
model	O
.	O

A	O
murine	O
physiologically	O
based	O
pharmacokinetic	O
model	O
was	O
modified	O
to	O
predict	O
docetaxel	O
distribution	O
following	O
i	O
.	O

p	O
.	O

administration	O
to	O
design	O
dosing	O
regimens	O
that	O
target	O
prespecified	O
plasma	O
concentrations	O
,	O
for	O
antiendothelial	O
effects	O
(	O
metronomic	O
)	O
,	O
or	O
exposure	O
,	O
to	O
mimic	O
30	O
mg	O
/	O
m2	O
(	O
weekly	O
/	O
MTD	O
)	O
docetaxel	O
in	O
humans	O
.	O

Animals	O
were	O
treated	O
for	O
28	O
days	O
with	O
1	O
mg	O
/	O
kg	O
/	O
d	O
(	O
DTX1	O
)	O
or	O
6	O
mg	O
/	O
kg	O
q4d	O
(	O
DTX6	O
)	O
docetaxel	O
with	O
or	O
without	O
vandetanib	O
(	O
15	O
mg	O
/	O
kg	O
/	O
d	O
p	O
.	O

o	O
.	O
)	O
in	O
mice	O
bearing	O
UMSCC2	O
tumor	B
xenografts	O
.	O

The	O
DTX1	O
dosing	O
scheme	O
was	O
adjusted	O
to	O
treatment	O
for	O
10	O
days	O
followed	O
by	O
9	O
days	O
off	O
due	O
to	O
severe	O
gastrointestinal	B
toxicity	I
.	O

All	O
treatment	O
groups	O
significantly	O
reduced	O
tumor	B
volume	O
,	O
tumor	B
proliferation	O
(	O
Ki	O
-	O
67	O
)	O
,	O
and	O
tumor	O
endothelial	O
cell	O
proliferation	O
(	O
Ki	O
-	O
67	O
/	O
von	O
Willebrand	O
factor	O
)	O
compared	O
with	O
control	O
.	O

Addition	O
of	O
vandetanib	O
to	O
docetaxel	O
treatment	O
significantly	O
enhanced	O
tumor	B
growth	O
inhibition	O
over	O
single	O
-	O
agent	O
therapy	O
.	O

A	O
positive	O
correlation	O
of	O
tumor	O
endothelial	O
cell	O
proliferation	O
with	O
tumor	B
growth	O
rates	O
demonstrates	O
vandetanib	O
and	O
docetaxel	O
antiangiogenic	O
effects	O
.	O

Due	O
to	O
the	O
morbidity	O
observed	O
with	O
DTX1	O
treatment	O
,	O
it	O
is	O
difficult	O
to	O
clearly	O
ascertain	O
if	O
metronomic	O
schedules	O
will	O
be	O
effective	O
for	O
treatment	O
.	O

Docetaxel	O
with	O
vandetanib	O
is	O
effective	O
in	O
treating	O
UMSCC2	O
xenografts	O
at	O
concentrations	O
relevant	O
to	O
exposures	O
in	O
humans	O
.	O

Prospective	O
evaluation	O
of	O
sexual	O
function	O
in	O
patients	O
receiving	O
cryosurgery	O
as	O
a	O
primary	O
radical	O
treatment	O
for	O
localized	O
prostate	B
cancer	I
.	O

OBJECTIVE	O
:	O
To	O
evaluate	O
prospectively	O
the	O
sexual	O
function	O
of	O
patients	O
undergoing	O
cryosurgery	O
as	O
a	O
primary	O
radical	O
treatment	O
for	O
localized	O
prostate	B
cancer	I
,	O
as	O
the	O
development	O
of	O
17	O
G	O
cryotherapy	O
probes	O
has	O
improved	O
the	O
delivery	O
of	O
this	O
treatment	O
,	O
but	O
one	O
of	O
the	O
side	O
-	O
effects	O
of	O
cryosurgery	O
is	O
the	O
development	O
of	O
erectile	B
dysfunction	I
(	O
ED	B
)	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
Between	O
July	O
2003	O
and	O
May	O
2008	O
,	O
53	O
patients	O
were	O
treated	O
using	O
an	O
argon	O
-	O
based	O
third	O
-	O
generation	O
cryotherapy	O
system	O
(	O
Oncura	O
,	O
Arlington	O
Heights	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Prospective	O
data	O
were	O
collected	O
at	O
6	O
weeks	O
,	O
3	O
months	O
,	O
then	O
3	O
-	O
monthly	O
up	O
to	O
1	O
year	O
and	O
subsequently	O
6	O
-	O
monthly	O
.	O

Patients	O
were	O
followed	O
up	O
for	O
up	O
to	O
54	O
months	O
,	O
with	O
a	O
median	O
(	O
mean	O
)	O
follow	O
-	O
up	O
36	O
(	O
30.5	O
)	O
months	O
.	O

RESULTS	O
:	O
All	O
53	O
patients	O
were	O
followed	O
after	O
receiving	O
cryosurgery	O
as	O
primary	O
treatment	O
for	O
prostate	B
cancer	I
;	O
51	O
(	O
96.3	O
%	O
)	O
had	O
ED	O
at	O
6	O
weeks	O
while	O
two	O
(	O
3.7	O
%	O
)	O
were	O
experiencing	O
partial	O
erections	O
.	O

By	O
9	O
months	O
one	O
(	O
2.4	O
%	O
)	O
of	O
42	O
patients	O
was	O
fully	O
potent	O
using	O
phosphodiesterase	O
type	O
-	O
5	O
inhibitors	O
,	O
and	O
six	O
(	O
14.3	O
%	O
)	O
were	O
experiencing	O
partial	O
erections	O
.	O

By	O
18	O
months	O
eight	O
(	O
21	O
%	O
)	O
of	O
39	O
patients	O
followed	O
up	O
had	O
regained	O
full	O
potency	O
and	O
by	O
24	O
months	O
eight	O
(	O
24	O
%	O
)	O
of	O
33	O
patients	O
were	O
fully	O
potent	O
and	O
three	O
(	O
9	O
%	O
)	O
experienced	O
partial	O
erections	O
.	O

CONCLUSION	O
:	O
While	O
ED	B
is	O
a	O
significant	O
side	O
-	O
effect	O
of	O
cryotherapy	O
,	O
a	O
considerable	O
proportion	O
of	O
patients	O
who	O
have	O
no	O
ED	B
before	O
treatment	O
(	O
39	O
%	O
)	O
recover	O
full	O
sexual	O
function	O
afterward	O
.	O

Focal	O
nerve	O
-	O
sparing	O
cryosurgery	O
might	O
be	O
the	O
way	O
forward	O
in	O
an	O
attempt	O
to	O
preserve	O
erectile	O
function	O
in	O
men	O
who	O
had	O
no	O
ED	B
before	O
treatment	O
.	O

Erectile	O
aids	O
should	O
be	O
made	O
available	O
for	O
those	O
patients	O
for	O
whom	O
sexual	B
dysfunction	I
compromises	O
the	O
quality	O
of	O
their	O
life	O
and	O
relationships	O
.	O

A	O
single	O
dose	O
of	O
anti	O
-	O
D	O
immunoglobulin	O
raises	O
platelet	O
count	O
as	O
efficiently	O
as	O
intravenous	O
immunoglobulin	O
in	O
newly	O
diagnosed	O
immune	B
thrombocytopenic	I
purpura	I
in	O
Korean	O
children	O
.	O

OBJECTIVE	O
:	O
The	O
aim	O
of	O
this	O
study	O
is	O
to	O
compare	O
the	O
efficacy	O
and	O
safety	O
of	O
a	O
single	O
dose	O
of	O
anti	O
-	O
D	O
immunoglobulin	O
(	O
anti	O
-	O
D	O
)	O
at	O
50	O
mug	O
/	O
kg	O
to	O
intravenous	O
immunoglobulin	O
(	O
IVIG	O
)	O
in	O
Korean	O
children	O
with	O
acute	B
immune	I
thrombocytopenic	I
purpura	I
(	O
ITP	B
)	O
.	O

METHODS	O
:	O
We	O
performed	O
this	O
study	O
prospectively	O
by	O
randomly	O
administering	O
2	O
consecutive	O
doses	O
of	O
IVIG	O
at	O
a	O
dose	O
of	O
1.0	O
g	O
/	O
kg	O
/	O
dor	O
a	O
single	O
dose	O
of	O
anti	O
-	O
D	O
at	O
50	O
microg	O
/	O
kg	O
to	O
children	O
upon	O
initial	O
diagnosis	O
of	O
acute	B
ITP	I
.	O

The	O
platelet	O
count	O
and	O
adverse	O
events	O
,	O
including	O
hemoglobin	O
concentration	O
,	O
were	O
then	O
serially	O
evaluated	O
,	O
and	O
the	O
responses	O
were	O
compared	O
.	O

RESULTS	O
:	O
The	O
likelihood	O
of	O
having	O
a	O
platelet	O
count	O
greater	O
than	O
20x10	O
/	O
mm	O
after	O
3	O
days	O
of	O
treatment	O
in	O
the	O
IVIG	O
and	O
anti	O
-	O
D	O
group	O
was	O
93	O
%	O
and	O
92	O
%	O
,	O
respectively	O
.	O

In	O
addition	O
,	O
hemoglobin	O
concentration	O
in	O
the	O
anti	O
-	O
D	O
group	O
had	O
declined	O
more	O
than	O
that	O
of	O
the	O
IVIG	O
group	O
(	O
1.49	O
g	O
/	O
dL	O
vs.	O
0.80	O
g	O
/	O
dL	O
,	O
P	O
=	O
0.014	O
)	O
3	O
days	O
after	O
treatment	O
.	O

Fever	B
,	O
chills	B
,	O
and	O
headache	B
occurred	O
less	O
frequently	O
in	O
the	O
anti	O
-	O
D	O
group	O
than	O
the	O
IVIG	O
group	O
,	O
however	O
,	O
this	O
difference	O
was	O
not	O
statistically	O
significant	O
(	O
25	O
%	O
vs.	O
45	O
%	O
,	O
P	O
=	O
0.494	O
)	O
.	O

CONCLUSIONS	O
:	O
A	O
single	O
dose	O
of	O
50	O
microg	O
/	O
kg	O
of	O
anti	O
-	O
D	O
raised	O
platelet	O
count	O
as	O
efficiently	O
as	O
IVIG	O
in	O
newly	O
diagnosed	O
cases	O
of	O
ITP	B
in	O
Korean	O
children	O
.	O

Although	O
50	O
microg	O
/	O
kg	O
of	O
anti	O
-	O
D	O
had	O
a	O
greater	O
effect	O
on	O
the	O
hemoglobin	O
concentration	O
than	O
IVIG	O
,	O
the	O
adverse	O
effects	O
were	O
found	O
to	O
be	O
acceptable	O
,	O
and	O
no	O
serious	O
events	O
were	O
observed	O
.	O

Right	O
-	O
sided	O
vagus	O
nerve	O
stimulation	O
in	O
humans	O
:	O
an	O
effective	O
therapy	O
?	O

Vagus	O
nerve	O
stimulation	O
(	O
VNS	O
)	O
is	O
an	O
additive	O
treatment	O
option	O
for	O
refractory	B
epilepsy	I
.	O

The	O
electrode	O
is	O
placed	O
on	O
the	O
cervical	O
trunk	O
of	O
the	O
left	O
vagus	O
nerve	O
.	O

In	O
patients	O
who	O
are	O
not	O
suitable	O
for	O
left	O
-	O
sided	O
vagus	O
nerve	O
stimulation	O
(	O
L	O
-	O
VNS	O
)	O
right	O
-	O
sided	O
vagus	O
nerve	O
stimulation	O
(	O
R	O
-	O
VNS	O
)	O
may	O
be	O
as	O
effective	O
.	O

In	O
animal	O
models	O
epilepsy	B
is	O
sufficiently	O
suppressed	O
by	O
R	O
-	O
VNS	O
.	O

In	O
a	O
16	O
years	O
old	O
boy	O
suffering	O
from	O
medically	O
refractory	B
psychomotoric	I
seizures	I
with	O
secondary	O
generalisation	O
,	O
L	O
-	O
VNS	O
reduced	O
the	O
frequency	O
of	O
generalized	O
seizures	B
.	O

A	O
deep	O
wound	B
infection	I
required	O
the	O
removal	O
of	O
the	O
system	O
eight	O
weeks	O
later	O
.	O

Cicatrisation	O
did	O
not	O
allow	O
preparation	O
of	O
the	O
left	O
vagus	O
nerve	O
,	O
therefore	O
we	O
implanted	O
R	O
-	O
VNS	O
with	O
sufficient	O
seizure	B
suppression	O
.	O

However	O
,	O
compared	O
to	O
L	O
-	O
VNS	O
,	O
the	O
effect	O
occurred	O
months	O
later	O
and	O
cardiac	B
symptoms	I
were	O
induced	O
by	O
stimulation	O
of	O
the	O
right	O
vagus	O
nerve	O
.	O

R	O
-	O
VNS	O
seems	O
to	O
be	O
an	O
effective	O
and	O
alternative	O
therapy	O
in	O
selected	O
patients	O
responding	O
to	O
L	O
-	O
VNS	O
where	O
a	O
left	O
-	O
sided	O
reimplantation	O
is	O
not	O
possible	O
.	O

Placement	O
and	O
adjustment	O
of	O
the	O
device	O
should	O
be	O
performed	O
under	O
ECG	O
control	O
.	O

Further	O
studies	O
are	O
necessary	O
to	O
compare	O
the	O
efficacy	O
of	O
L	O
-	O
VNS	O
and	O
R	O
-	O
VNS	O
.	O

Astaxanthin	O
,	O
canthaxanthin	O
and	O
beta	O
-	O
carotene	O
differently	O
affect	O
UVA	O
-	O
induced	O
oxidative	O
damage	O
and	O
expression	O
of	O
oxidative	O
stress	O
-	O
responsive	O
enzymes	O
.	O

Carotenoids	O
are	O
used	O
for	O
systemic	O
photoprotection	O
in	O
humans	O
.	O

Regarding	O
mechanisms	O
underlying	O
photoprotective	O
effects	O
of	O
carotenoids	O
,	O
here	O
we	O
compared	O
the	O
modulation	O
of	O
UVA	O
-	O
related	O
injury	O
by	O
carotenoids	O
.	O

Human	O
dermal	O
fibroblasts	O
(	O
HDF	O
)	O
were	O
exposed	O
to	O
moderate	O
doses	O
of	O
UVA	O
,	O
which	O
stimulated	O
apoptosis	O
,	O
increased	O
levels	O
of	O
reactive	O
oxygen	O
species	O
and	O
thiobarbituric	O
acid	O
reactive	O
substances	O
,	O
decreased	O
antioxidant	O
enzymes	O
activities	O
,	O
promoted	O
membrane	O
perturbation	O
,	O
and	O
induced	O
the	O
expression	O
of	O
heme	O
oxygenase	O
-	O
1	O
(	O
HO	O
-	O
1	O
)	O
.	O

The	O
carotenoids	O
astaxanthin	O
(	O
AX	O
)	O
,	O
canthaxanthin	O
(	O
CX	O
)	O
and	O
beta	O
-	O
carotene	O
(	O
betaC	O
)	O
were	O
delivered	O
to	O
HDF	O
24	O
h	O
before	O
exposure	O
to	O
UVA	O
.	O

Astaxanthin	O
exhibited	O
a	O
pronounced	O
photoprotective	O
effect	O
and	O
counteracted	O
all	O
of	O
the	O
above	O
-	O
mentioned	O
UVA	O
-	O
induced	O
alterations	O
to	O
a	O
significant	O
extent	O
.	O

beta	O
-	O
Carotene	O
only	O
partially	O
prevented	O
the	O
UVA	O
-	O
induced	O
decline	O
of	O
catalase	O
and	O
superoxide	O
dismutase	O
activities	O
,	O
but	O
it	O
increased	O
membrane	O
damage	O
and	O
stimulated	O
HO	O
-	O
1	O
expression	O
.	O

Moreover	O
,	O
betaC	O
dose	O
-	O
dependently	O
induced	O
caspase	O
-	O
3	O
activity	O
following	O
UVA	O
exposure	O
.	O

In	O
contrast	O
,	O
CX	O
had	O
no	O
effect	O
on	O
oxidative	O
damage	O
,	O
except	O
for	O
HO	O
-	O
1	O
expression	O
,	O
which	O
was	O
augmented	O
.	O

Uptake	O
of	O
AX	O
by	O
fibroblasts	O
was	O
higher	O
than	O
that	O
of	O
the	O
other	O
two	O
carotenoids	O
.	O

The	O
photostability	O
of	O
the	O
three	O
compounds	O
in	O
fibroblasts	O
was	O
AX	O
>	O
CX	O
>	O
>	O
betaC	O
.	O

The	O
data	O
indicate	O
that	O
the	O
oxo	O
-	O
carotenoid	O
AX	O
has	O
a	O
superior	O
preventive	O
effect	O
towards	O
photo	O
-	O
oxidative	O
changes	O
in	O
cell	O
culture	O
.	O

Protective	O
effect	O
of	O
Pycnogenol	O
in	O
human	O
neuroblastoma	O
SH	O
-	O
SY5Y	O
cells	O
following	O
acrolein	O
-	O
induced	O
cytotoxicity	B
.	O

Oxidative	O
stress	O
is	O
one	O
of	O
the	O
hypotheses	O
involved	O
in	O
the	O
etiology	O
of	O
Alzheimer	B
's	I
disease	I
(	O
AD	B
)	O
.	O

Considerable	O
attention	O
has	O
been	O
focused	O
on	O
increasing	O
the	O
intracellular	O
glutathione	O
(	O
GSH	O
)	O
levels	O
in	O
many	O
neurodegenerative	B
diseases	I
,	O
including	O
AD	B
.	O

Pycnogenol	O
(	O
PYC	O
)	O
has	O
antioxidant	O
properties	O
and	O
stabilizes	O
intracellular	O
antioxidant	O
defense	O
systems	O
including	O
glutathione	O
levels	O
.	O

The	O
present	O
study	O
investigated	O
the	O
protective	O
effects	O
of	O
PYC	O
on	O
acrolein	O
-	O
induced	O
oxidative	B
cell	I
toxicity	I
in	O
cultured	O
SH	O
-	O
SY5Y	O
neuroblastoma	O
cells	O
.	O

Decreased	O
cell	O
survival	O
in	O
SH	O
-	O
SY5Y	O
cultures	O
treated	O
with	O
acrolein	O
correlated	O
with	O
oxidative	O
stress	O
,	O
increased	O
NADPH	O
oxidase	O
activity	O
,	O
free	O
radical	O
production	O
,	O
protein	O
oxidation	O
/	O
nitration	O
(	O
protein	O
carbonyl	O
,	O
3	O
-	O
nitrotyrosine	O
)	O
,	O
and	O
lipid	O
peroxidation	O
(	O
4	O
-	O
hydroxy	O
-	O
2	O
-	O
nonenal	O
)	O
.	O

Pretreatment	O
with	O
PYC	O
significantly	O
attenuated	O
acrolein	O
-	O
induced	O
cytotoxicity	B
,	O
protein	O
damage	O
,	O
lipid	O
peroxidation	O
,	O
and	O
cell	O
death	O
.	O

A	O
dose	O
-	O
response	O
study	O
suggested	O
that	O
PYC	O
showed	O
protective	O
effects	O
against	O
acrolein	B
toxicity	I
by	O
modulating	O
oxidative	O
stress	O
and	O
increasing	O
GSH	O
.	O

These	O
findings	O
provide	O
support	O
that	O
PYC	O
may	O
provide	O
a	O
promising	O
approach	O
for	O
the	O
treatment	O
of	O
oxidative	O
stress	O
-	O
related	O
neurodegenerative	B
diseases	I
such	O
as	O
AD	B
.	O

Lipid	O
nanoparticles	O
for	O
parenteral	O
delivery	O
of	O
actives	O
.	O

The	O
present	O
review	O
compiles	O
the	O
applications	O
of	O
lipid	O
nanoparticles	O
mainly	O
solid	O
lipid	O
nanoparticles	O
(	O
SLN	O
)	O
,	O
nanostructured	O
lipid	O
carriers	O
(	O
NLC	O
)	O
and	O
lipid	O
drug	O
conjugates	O
(	O
LDC	O
)	O
in	O
parenteral	O
delivery	O
of	O
pharmaceutical	O
actives	O
.	O

The	O
attempts	O
to	O
incorporate	O
anticancer	O
agents	O
,	O
imaging	O
agents	O
,	O
antiparasitics	O
,	O
antiarthritics	O
,	O
genes	O
for	O
transfection	O
,	O
agents	O
for	O
liver	O
,	O
cardiovascular	O
and	O
central	O
nervous	O
system	O
targeting	O
have	O
been	O
summarized	O
.	O

The	O
utility	O
of	O
lipid	O
nanoparticles	O
as	O
adjuvant	O
has	O
been	O
discussed	O
separately	O
.	O

A	O
special	O
focus	O
of	O
this	O
review	O
is	O
on	O
toxicity	O
caused	O
by	O
these	O
kinds	O
of	O
lipid	O
nanoparticles	O
with	O
a	O
glance	O
on	O
the	O
fate	O
of	O
lipid	O
nanoparticles	O
after	O
their	O
parenteral	O
delivery	O
in	O
vivo	O
viz	O
the	O
protein	O
adsorption	O
patterns	O
.	O

Orally	O
administrated	O
Juzen	O
-	O
taiho	O
-	O
to	O
/	O
TJ	O
-	O
48	O
ameliorates	O
erythropoietin	B
(	I
rHuEPO	I
)	I
-	I
resistant	I
anemia	I
in	O
patients	O
on	O
hemodialysis	O
.	O

Maintenance	O
of	O
the	O
red	O
blood	O
cell	O
volume	O
is	O
a	O
fundamental	O
aspect	O
of	O
ensuring	O
oxygen	O
supply	O
to	O
the	O
tissue	O
.	O

Recombinant	O
human	O
erythropoietin	O
(	O
rHuEPO	O
)	O
was	O
approved	O
for	O
marketing	O
in	O
Japan	O
in	O
1990	O
for	O
the	O
treatment	O
of	O
anemia	B
in	O
patients	O
on	O
dialysis	O
.	O

Recombinant	O
human	O
erythropoietin	O
caused	O
a	O
significant	O
increase	O
in	O
hemoglobin	O
(	O
Hb	O
)	O
levels	O
in	O
patients	O
on	O
dialysis	O
.	O

However	O
,	O
not	O
all	O
have	O
a	O
good	O
response	O
to	O
rHuEPO	O
therapy	O
;	O
the	O
causes	O
of	O
rHuEPO	O
failure	O
include	O
iron	B
deficiency	I
,	O
infection	B
,	O
uremia	B
,	O
and	O
interaction	O
of	O
some	O
drugs	O
.	O

Juzen	O
-	O
taiho	O
-	O
to	O
(	O
TJ	O
-	O
48	O
)	O
,	O
a	O
mixture	O
of	O
extracts	O
from	O
10	O
medicinal	O
herbs	O
,	O
has	O
been	O
used	O
traditionally	O
to	O
treat	O
patients	O
with	O
anemia	B
,	O
anorexia	B
,	O
or	O
fatigue	B
.	O

To	O
clarify	O
the	O
effect	O
of	O
TJ	O
-	O
48	O
on	O
erythropoietin	B
-	I
resistant	I
anemia	I
,	O
we	O
studied	O
the	O
effect	O
of	O
TJ	O
-	O
48	O
in	O
patients	O
on	O
hemodialysis	O
with	O
erythropoietin	B
-	I
resistant	I
anemia	I
.	O

We	O
divided	O
42	O
end	O
-	O
stage	O
renal	B
disease	I
patients	O
on	O
hemodialysis	O
with	O
erythropoietin	B
-	I
resistant	I
anemia	I
(	O
Hb	O
<	O
10.0	O
g	O
/	O
dL	O
with	O
rHuEPO	O
9000	O
U	O
/	O
wk	O
or	O
15	O
U	O
/	O
kg	O
/	O
wk	O
treatment	O
)	O
into	O
2	O
groups	O
as	O
follows	O
:	O
a	O
TJ	O
-	O
48	O
-	O
treated	O
group	O
(	O
TJ	O
-	O
48	O
group	O
,	O
7.5	O
g	O
/	O
d	O
,	O
n	O
=	O
22	O
)	O
and	O
a	O
TJ	O
-	O
48	O
nontreated	O
(	O
control	O
group	O
,	O
n	O
=	O
20	O
)	O
.	O

At	O
the	O
beginning	O
of	O
this	O
study	O
,	O
there	O
was	O
no	O
significant	O
difference	O
between	O
the	O
groups	O
in	O
age	O
,	O
sex	O
,	O
serum	O
creatinine	O
,	O
blood	O
urea	O
nitrogen	O
,	O
serum	O
iron	O
,	O
and	O
ferritin	O
.	O

After	O
12	O
weeks	O
of	O
treatment	O
,	O
the	O
Hb	O
level	O
had	O
significantly	O
increased	O
from	O
8.4	O
+	O
/	O
-	O
1.1	O
to	O
9.5	O
+	O
/	O
-	O
1.3	O
g	O
/	O
dL	O
(	O
P	O
=	O
0.0272	O
)	O
in	O
the	O
TJ	O
-	O
48	O
group	O
.	O

C	O
-	O
reactive	O
protein	O
(	O
CRP	O
)	O
had	O
significantly	O
decreased	O
from	O
1.4	O
+	O
/	O
-	O
1.7	O
to	O
0.6	O
+	O
/	O
-	O
0.8	O
mg	O
/	O
dL	O
(	O
P	O
=	O
0.0438	O
)	O
.	O

There	O
was	O
a	O
significant	O
negative	O
correlation	O
between	O
Hb	O
and	O
CRP	O
in	O
the	O
TJ	O
-	O
48	O
group	O
(	O
r	O
(	O
2	O
)	O
=	O
0.121	O
,	O
P	O
=	O
0.0066	O
)	O
.	O

In	O
contrast	O
,	O
in	O
the	O
control	O
group	O
,	O
Hb	O
and	O
CRP	O
showed	O
no	O
significant	O
changes	O
throughout	O
this	O
study	O
.	O

Nor	O
was	O
there	O
a	O
significant	O
correlation	O
between	O
Hb	O
and	O
CRP	O
in	O
the	O
control	O
group	O
.	O

In	O
conclusion	O
,	O
TJ	O
-	O
48	O
was	O
effective	O
in	O
improving	O
erythropoietin	B
-	I
resistant	I
anemia	I
in	O
end	O
-	O
stage	O
renal	B
disease	I
patients	O
.	O

This	O
effect	O
was	O
,	O
at	O
least	O
in	O
part	O
,	O
due	O
to	O
the	O
anti	O
-	O
inflammatory	O
effect	O
of	O
TJ	O
-	O
48	O
in	O
patients	O
on	O
hemodialysis	O
.	O

Fragrance	O
material	O
review	O
on	O
1	O
-	O
ethynylcyclohexyl	O
acetate	O
.	O

A	O
toxicologic	O
and	O
dermatologic	O
review	O
of	O
1	O
-	O
ethynylcyclohexyl	O
acetate	O
when	O
used	O
as	O
a	O
fragrance	O
ingredient	O
is	O
presented	O
.	O

Vitamin	O
K	O
supplementation	O
in	O
postmenopausal	O
women	O
with	O
osteopenia	B
(	O
ECKO	O
trial	O
)	O
:	O
a	O
randomized	O
controlled	O
trial	O
.	O

BACKGROUND	O
:	O
Vitamin	O
K	O
has	O
been	O
widely	O
promoted	O
as	O
a	O
supplement	O
for	O
decreasing	O
bone	B
loss	I
in	O
postmenopausal	O
women	O
,	O
but	O
the	O
long	O
-	O
term	O
benefits	O
and	O
potential	O
harms	O
are	O
unknown	O
.	O

This	O
study	O
was	O
conducted	O
to	O
determine	O
whether	O
daily	O
high	O
-	O
dose	O
vitamin	O
K1	O
supplementation	O
safely	O
reduces	O
bone	B
loss	I
,	O
bone	O
turnover	O
,	O
and	O
fractures	O
.	O

METHODS	O
AND	O
FINDINGS	O
:	O
This	O
single	O
-	O
center	O
study	O
was	O
designed	O
as	O
a	O
2	O
-	O
y	O
randomized	O
,	O
placebo	O
-	O
controlled	O
,	O
double	O
-	O
blind	O
trial	O
,	O
extended	O
for	O
earlier	O
participants	O
for	O
up	O
to	O
an	O
additional	O
2	O
y	O
because	O
of	O
interest	O
in	O
long	O
-	O
term	O
safety	O
and	O
fractures	O
.	O

A	O
total	O
of	O
440	O
postmenopausal	O
women	O
with	O
osteopenia	B
were	O
randomized	O
to	O
either	O
5	O
mg	O
of	O
vitamin	O
K1	O
or	O
placebo	O
daily	O
.	O

Primary	O
outcomes	O
were	O
changes	O
in	O
BMD	O
at	O
the	O
lumbar	O
spine	O
and	O
total	O
hip	O
at	O
2	O
y	O
.	O

Secondary	O
outcomes	O
included	O
changes	O
in	O
BMD	O
at	O
other	O
sites	O
and	O
other	O
time	O
points	O
,	O
bone	O
turnover	O
markers	O
,	O
height	O
,	O
fractures	O
,	O
adverse	O
effects	O
,	O
and	O
health	O
-	O
related	O
quality	O
of	O
life	O
.	O

This	O
study	O
has	O
a	O
power	O
of	O
90	O
%	O
to	O
detect	O
3	O
%	O
differences	O
in	O
BMD	O
between	O
the	O
two	O
groups	O
.	O

The	O
women	O
in	O
this	O
study	O
were	O
vitamin	O
D	O
replete	O
,	O
with	O
a	O
mean	O
serum	O
25	O
-	O
hydroxyvitamin	O
D	O
level	O
of	O
77	O
nmol	O
/	O
l	O
at	O
baseline	O
.	O

Over	O
2	O
y	O
,	O
BMD	O
decreased	O
by	O
-	O
1.28	O
%	O
and	O
-	O
1.22	O
%	O
(	O
p	O
=	O
0.84	O
)	O
(	O
difference	O
of	O
-	O
0.06	O
%	O
;	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
-	O
0.67	O
%	O
to	O
0.54	O
%	O
)	O
at	O
the	O
lumbar	O
spine	O
and	O
-	O
0.69	O
%	O
and	O
-	O
0.88	O
%	O
(	O
p	O
=	O
0.51	O
)	O
(	O
difference	O
of	O
0.19	O
%	O
;	O
95	O
%	O
CI	O
-	O
0.37	O
%	O
to	O
0.75	O
%	O
)	O
at	O
the	O
total	O
hip	O
in	O
the	O
vitamin	O
K	O
and	O
placebo	O
groups	O
,	O
respectively	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
changes	O
in	O
BMD	O
at	O
any	O
site	O
between	O
the	O
two	O
groups	O
over	O
the	O
2	O
-	O
to	O
4	O
-	O
y	O
period	O
.	O

Daily	O
vitamin	O
K1	O
supplementation	O
increased	O
serum	O
vitamin	O
K1	O
levels	O
by	O
10	O
-	O
fold	O
,	O
and	O
decreased	O
the	O
percentage	O
of	O
undercarboxylated	O
osteocalcin	O
and	O
total	O
osteocalcin	O
levels	O
(	O
bone	O
formation	O
marker	O
)	O
.	O

However	O
,	O
C	O
-	O
telopeptide	O
levels	O
(	O
bone	O
resorption	O
marker	O
)	O
were	O
not	O
significantly	O
different	O
between	O
the	O
two	O
groups	O
.	O

Fewer	O
women	O
in	O
the	O
vitamin	O
K	O
group	O
had	O
clinical	O
fractures	O
(	O
nine	O
versus	O
20	O
,	O
p	O
=	O
0.04	O
)	O
and	O
fewer	O
had	O
cancers	O
(	O
three	O
versus	O
12	O
,	O
p	O
=	O
0.02	O
)	O
.	O

Vitamin	O
K	O
supplements	O
were	O
well	O
-	O
tolerated	O
over	O
the	O
4	O
-	O
y	O
period	O
.	O

There	O
were	O
no	O
significant	O
differences	O
in	O
adverse	O
effects	O
or	O
health	O
-	O
related	O
quality	O
of	O
life	O
between	O
the	O
two	O
groups	O
.	O

The	O
study	O
was	O
not	O
powered	O
to	O
examine	O
fractures	O
or	O
cancers	O
,	O
and	O
their	O
numbers	O
were	O
small	O
.	O

CONCLUSIONS	O
:	O
Daily	O
5	O
mg	O
of	O
vitamin	O
K1	O
supplementation	O
for	O
2	O
to	O
4	O
y	O
does	O
not	O
protect	O
against	O
age	O
-	O
related	O
decline	O
in	O
BMD	O
,	O
but	O
may	O
protect	O
against	O
fractures	O
and	O
cancers	O
in	O
postmenopausal	O
women	O
with	O
osteopenia	B
.	O

More	O
studies	O
are	O
needed	O
to	O
further	O
examine	O
the	O
effect	O
of	O
vitamin	O
K	O
on	O
fractures	O
and	O
cancers	O
.	O

Trial	O
registration	O
:	O
ClinicalTrials	O
.	O

gov	O
(	O
#	O
NCT00150969	O
)	O
and	O
Current	O
Controlled	O
Trials	O
(	O
#	O
ISRCTN61708241	O
)	O
.	O

Peptide	O
-	O
mediated	O
cellular	O
uptake	O
of	O
cryptophane	O
.	O

Cryptophane	O
-	O
A	O
has	O
generated	O
considerable	O
interest	O
based	O
on	O
its	O
high	O
affinity	O
for	O
xenon	O
and	O
potential	O
for	O
creating	O
biosensors	O
for	O
(	O
129	O
)	O
Xe	O
nuclear	O
magnetic	O
resonance	O
(	O
NMR	O
)	O
spectroscopy	O
.	O

Here	O
,	O
we	O
report	O
the	O
cellular	O
delivery	O
of	O
three	O
peptide	O
-	O
functionalized	O
cryptophane	O
biosensors	O
.	O

Cryptophanes	O
were	O
delivered	O
using	O
two	O
cationic	O
cell	O
penetrating	O
peptides	O
into	O
several	O
human	O
cancer	B
and	O
normal	O
cell	O
lines	O
.	O

An	O
RGD	O
peptide	O
targeting	O
alpha	O
(	O
v	O
)	O
beta	O
(	O
3	O
)	O
integrin	O
receptor	O
was	O
shown	O
to	O
increase	O
specificity	O
of	O
cryptophane	O
cell	O
uptake	O
.	O

Labeling	O
the	O
peptides	O
with	O
Cy3	O
made	O
it	O
possible	O
to	O
monitor	O
cellular	O
delivery	O
using	O
confocal	O
laser	O
scanning	O
microscopy	O
.	O

The	O
peptido	O
-	O
cryptophanes	O
were	O
determined	O
to	O
be	O
relatively	O
nontoxic	O
by	O
MTT	O
assay	O
at	O
the	O
micromolar	O
cryptophane	O
concentrations	O
that	O
are	O
required	O
for	O
(	O
129	O
)	O
Xe	O
NMR	O
biosensing	O
experiments	O
.	O

Effectiveness	O
and	O
tolerability	O
of	O
open	O
label	O
olanzapine	O
in	O
children	O
and	O
adolescents	O
with	O
Tourette	B
syndrome	I
.	O

OBJECTIVES	O
:	O
The	O
primary	O
aim	O
of	O
the	O
study	O
was	O
to	O
evaluate	O
the	O
effectiveness	O
and	O
tolerability	O
of	O
open	O
-	O
label	O
olanzapine	O
on	O
motor	O
and	O
vocal	O
tics	O
in	O
children	O
and	O
adolescents	O
with	O
Tourette	B
syndrome	I
(	O
TS	B
)	O
.	O

Secondary	O
aims	O
included	O
assessing	O
the	O
response	O
of	O
TS	O
-	O
associated	O
disruptive	B
behaviors	I
to	O
olanzapine	O
exposure	O
.	O

METHOD	O
:	O
Twelve	O
children	O
and	O
adolescents	O
(	O
mean	O
age	O
11.3	O
+	O
/	O
-	O
2.4	O
years	O
,	O
range	O
7	O
-	O
14	O
years	O
)	O
with	O
Diagnostic	O
and	O
Statistical	O
Manual	O
of	O
Mental	B
Disorders	I
,	O
4th	O
edition	O
(	O
DSM	O
-	O
IV	O
)	O
TS	B
were	O
enrolled	O
in	O
a	O
single	O
-	O
site	O
,	O
6	O
-	O
week	O
,	O
open	O
-	O
label	O
,	O
prospective	O
,	O
flexible	O
-	O
dose	O
design	O
in	O
outpatients	O
receiving	O
monotherapy	O
with	O
olanzapine	O
.	O

Standardized	O
ratings	O
of	O
tic	B
symptoms	I
,	O
disruptive	B
behaviors	I
,	O
and	O
aggression	B
were	O
obtained	O
,	O
along	O
with	O
adverse	O
events	O
and	O
safety	O
data	O
.	O

RESULTS	O
:	O
Over	O
the	O
6	O
-	O
week	O
trial	O
,	O
olanzapine	O
administration	O
was	O
associated	O
with	O
a	O
significant	O
decrease	O
in	O
total	O
tic	B
severity	O
as	O
measured	O
by	O
the	O
Yale	O
Global	O
Tic	B
Severity	O
Scale	O
(	O
30	O
%	O
reduction	O
by	O
week	O
6	O
;	O
effect	O
size	O
0.49	O
)	O
.	O

A	O
significant	O
majority	O
of	O
subjects	O
were	O
rated	O
as	O
""""	O
much	O
improved	O
""""	O
or	O
""""	O
very	O
much	O
improved	O
""""	O
on	O
the	O
Clinical	O
Global	O
Impressions	O
-	O
Improvement	O
Scale	O
(	O
GCI	O
-	O
I	O
)	O
by	O
both	O
clinicians	O
(	O
67	O
%	O
;	O
8	O
/	O
12	O
)	O
and	O
parents	O
(	O
64	O
%	O
;	O
7	O
/	O
11	O
)	O
.	O

Attention	B
-	I
deficit	I
/	I
hyperactivity	I
disorder	I
(	O
ADHD	B
)	O
symptoms	O
showed	O
significant	O
improvements	O
from	O
baseline	O
for	O
both	O
inattention	O
(	O
33	O
%	O
decrease	O
)	O
and	O
hyperactive	O
/	O
impulsivity	O
(	O
50	O
%	O
decrease	O
)	O
scores	O
(	O
effect	O
sizes	O
0.44	O
and	O
0.43	O
,	O
respectively	O
)	O
.	O

Aggression	B
was	O
also	O
decreased	O
as	O
assessed	O
by	O
fewer	O
numbers	O
of	O
aggressive	O
episodes	O
on	O
the	O
Overt	O
Aggression	B
Scale	O
(	O
OAS	O
)	O
.	O

Little	O
change	O
in	O
anxiety	B
symptoms	O
was	O
noted	O
.	O

The	O
most	O
widely	O
reported	O
side	O
effects	O
were	O
drowsiness	B
/	O
sedation	B
and	O
weight	O
gain	O
;	O
adverse	O
events	O
were	O
generally	O
well	O
tolerated	O
.	O

Mean	O
weight	O
gain	O
of	O
4.1	O
+	O
/	O
-	O
2.0	O
kg	O
was	O
observed	O
over	O
the	O
6	O
-	O
week	O
trial	O
,	O
a	O
mean	O
percent	O
change	O
of	O
8.4	O
+	O
/	O
-	O
4.4	O
(	O
p	O
<	O
0.001	O
)	O
.	O

CONCLUSIONS	O
:	O
Additional	O
studies	O
of	O
the	O
benefits	O
of	O
olanzapine	O
treatment	O
for	O
tic	B
control	O
as	O
well	O
as	O
the	O
commonly	O
associated	O
co	O
-	O
morbid	O
features	O
of	O
TS	B
are	O
indicated	O
,	O
especially	O
if	O
approaches	O
to	O
predict	O
or	O
minimize	O
weight	O
gain	O
can	O
be	O
determined	O
.	O

Statistical	O
methods	O
We	O
analyzed	O
correlations	O
between	O
categorical	O
variables	O
using	O
the	O
2	O
or	O
Fisher	O
's	O
exact	O
test	O
.	O

We	O
used	O
analysis	O
of	O
variance	O
to	O
study	O
correlations	O
between	O
continuous	O
and	O
categorical	O
variables	O
,	O
and	O
simple	O
regression	O
to	O
analyze	O
correlations	O
between	O
continuous	O
variables	O
.	O

p53	O
mutation	O
is	O
strongly	O
associated	O
with	O
Type	B
A	I
MSI	I
in	O
human	O
colorectal	B
cancer	I
One	O
view	O
of	O
the	O
involvement	O
of	O
MMR	O
defects	O
in	O
cancer	B
development	O
is	O
that	O
the	O
'	O
microsatellite	O
mutator	O
phenotype	O
(	O
MMP	O
)	O
'	O
(	O
29,30	O
)	O
in	O
mismatch	O
repair	O
-	O
defective	O
cells	O
offers	O
an	O
alternative	O
to	O
chromosomal	O
instability	O
as	O
a	O
mechanism	O
for	O
genetic	O
instability	O
in	O
cancer	B
(	O
31	O
)	O
.	O

On	O
this	O
model	O
,	O
MSI	O
and	O
chromosomal	O
instability	O
represent	O
mutually	O
exclusive	O
pathways	O
of	O
tumour	B
development	O
.	O

This	O
reasoning	O
is	O
based	O
partly	O
in	O
the	O
observation	O
that	O
p53	O
mutations	O
,	O
commonly	O
associated	O
with	O
chromosomal	O
instability	O
,	O
are	O
infrequent	O
among	O
MSI+	B
tumours	B
(	O
2,3234	O
)	O
.	O

To	O
examine	O
the	O
relationship	O
between	O
Type	O
A	O
/	O
B	O
instability	O
and	O
p53	O
mutation	O
,	O
we	O
sequenced	O
the	O
p53	O
gene	O
in	O
our	O
panel	O
of	O
79	O
colorectal	O
tumours	B
.	O

p53	O
mutations	O
resulting	O
in	O
an	O
amino	O
acid	O
substitution	O
were	O
detected	O
in	O
23	O
tumours	B
(	O
29.1	O
%	O
)	O
.	O

The	O
mutations	O
were	O
predominantly	O
transitions	O
in	O
acknowledged	O
hot	O
spots	O
;	O
codons	O
175	O
,	O
248	O
and	O
273	O
(	O
Table	O
2	O
)	O
.	O

Of	O
the	O
p53	O
mutations	O
that	O
were	O
found	O
in	O
MSI+	O
tumours	B
,	O
all	O
were	O
associated	O
with	O
Type	B
A	I
MSI	I
(	O
Tables	O
2	O
and	O
3	O
)	O
.	O

No	O
p53	O
mutations	O
were	O
detected	O
among	O
the	O
14	O
Type	O
B	O
tumours	B
.	O

Among	O
Type	O
A	O
tumours	B
,	O
the	O
frequency	O
of	O
p53	O
mutation	O
approached	O
50	O
%	O
(	O
12	O
/	O
25	O
)	O
.	O

These	O
findings	O
confirm	O
that	O
p53	O
mutations	O
are	O
rare	O
in	O
tumours	B
with	O
Type	B
B	I
MSI	I
.	O

More	O
importantly	O
,	O
they	O
suggest	O
that	O
,	O
in	O
contrast	O
to	O
prevailing	O
opinion	O
,	O
defective	O
MMR	O
is	O
significantly	O
associated	O
with	O
p53	O
mutation	O
,	O
at	O
least	O
in	O
human	O
colorectal	B
cancer	I
.	O

Discussion	O
The	O
exact	O
identities	O
and	O
numbers	O
of	O
mutations	O
required	O
for	O
transformation	O
are	O
uncertain	O
.	O

With	O
simple	O
multistage	O
models	O
[	O
3	O
-	O
6,11	O
]	O
,	O
all	O
cancers	B
of	O
a	O
given	O
type	O
require	O
the	O
same	O
number	O
of	O
oncogenic	O
mutations	O
,	O
but	O
stochastic	O
differences	O
in	O
the	O
times	O
to	O
accumulate	O
these	O
mutations	O
allow	O
individual	O
cancers	B
to	O
appear	O
at	O
different	O
ages	O
.	O

Precisely	O
when	O
and	O
how	O
quickly	O
mutations	O
accumulate	O
are	O
unknown	O
,	O
but	O
a	O
basic	O
premise	O
is	O
that	O
cancer	B
types	O
requiring	O
more	O
mutations	O
will	O
tend	O
to	O
appear	O
later	O
in	O
life	O
.	O

Therefore	O
,	O
numbers	O
of	O
mutations	O
may	O
be	O
estimated	O
from	O
cancer	B
epidemiology	O
.	O

Colorectal	B
cancer	I
frequencies	O
increase	O
with	O
age	O
,	O
and	O
the	O
pattern	O
of	O
this	O
increase	O
is	O
consistent	O
with	O
approximately	O
five	O
to	O
seven	O
oncogenic	O
mutations	O
[	O
3	O
-	O
6	O
]	O
.	O

In	O
this	O
study	O
numbers	O
of	O
mutations	O
were	O
estimated	O
for	O
well	O
-	O
defined	O
subgroups	O
of	O
colorectal	B
cancers	I
because	O
biological	O
heterogeneity	O
may	O
confound	O
this	O
type	O
of	O
quantitative	O
analysis	O
.	O

Such	O
estimates	O
should	O
be	O
considered	O
rough	O
guides	O
rather	O
than	O
absolute	O
values	O
because	O
our	O
model	O
does	O
not	O
account	O
for	O
all	O
factors	O
.	O

Cancers	B
were	O
classified	O
as	O
MSI+	B
or	O
MSI-	B
,	O
and	O
MSI+	B
cancers	B
were	O
further	O
sub	O
-	O
classified	O
as	O
either	O
hereditary	O
(	O
HNPCC	B
)	O
or	O
sporadic	O
.	O

As	O
expected	O
because	O
one	O
MMR	O
mutation	O
is	O
inherited	O
,	O
estimated	O
numbers	O
of	O
critical	O
mutations	O
were	O
less	O
for	O
MSI+	B
HNPCC	B
cancers	B
compared	O
to	O
sporadic	O
MSI+	B
cancers	B
.	O

However	O
,	O
sporadic	O
MSI+	B
cancers	B
required	O
more	O
than	O
one	O
additional	O
somatic	O
mutation	O
compared	O
to	O
HNPCC	B
cancers	B
.	O

Of	O
interest	O
,	O
a	O
difference	O
of	O
more	O
than	O
a	O
single	O
mutation	O
has	O
also	O
been	O
inferred	O
between	O
sporadic	O
and	O
FAP	B
cancers	B
,	O
with	O
estimates	O
of	O
three	O
to	O
four	O
mutations	O
for	O
FAP	B
cancers	B
versus	O
six	O
for	O
sporadic	O
cancers	B
[	O
6,13	O
]	O
,	O
although	O
another	O
analysis	O
was	O
consistent	O
with	O
a	O
difference	O
of	O
only	O
a	O
single	O
mutation	O
[	O
14	O
]	O
.	O

Therefore	O
,	O
germline	O
mutations	O
(	O
APC	O
and	O
MMR	O
loci	O
)	O
in	O
both	O
common	O
colorectal	O
familial	O
cancer	B
syndromes	O
(	O
FAP	B
and	O
HNPCC	B
)	O
appear	O
to	O
advance	O
progression	O
by	O
more	O
than	O
a	O
single	O
mutation	O
relative	O
to	O
their	O
sporadic	O
counterparts	O
.	O

An	O
epigenetic	O
mechanism	O
may	O
help	O
explain	O
why	O
sporadic	O
MSI+	B
cancers	B
require	O
more	O
than	O
one	O
additional	O
somatic	O
alteration	O
relative	O
to	O
HNPCC	B
cancers	B
.	O

Inactivation	O
of	O
the	O
normal	O
MMR	O
allele	O
occurs	O
through	O
mutation	O
(	O
usually	O
LOH	O
[	O
15	O
]	O
)	O
in	O
HNPCC	B
whereas	O
MMR	O
loss	O
in	O
sporadic	O
MSI+	B
cancers	B
is	O
associated	O
with	O
MLH1	O
promoter	O
methylation	O
[	O
16,17	O
]	O
.	O

CpG	O
islands	O
may	O
be	O
""""	O
protected	O
""""	O
from	O
methylation	O
because	O
most	O
are	O
unmethylated	O
at	O
birth	O
and	O
usually	O
remain	O
unmethylated	O
throughout	O
life	O
[	O
18	O
]	O
.	O

Epigenetic	O
MLH1	O
inactivation	O
may	O
require	O
at	O
least	O
two	O
cis	O
acting	O
somatic	O
alterations	O
---	O
loss	O
of	O
a	O
mechanism	O
that	O
normally	O
prevents	O
methylation	O
,	O
followed	O
by	O
the	O
accumulation	O
of	O
methylation	O
at	O
sufficient	O
numbers	O
of	O
CpG	O
sites	O
to	O
silence	O
expression	O
.	O

In	O
agreement	O
with	O
prior	O
studies	O
,	O
there	O
were	O
seven	O
mutations	O
estimated	O
for	O
sporadic	O
MSI-	B
Finnish	O
cancers	B
[	O
4	O
]	O
,	O
and	O
seven	O
or	O
eight	O
mutations	O
for	O
MSI+	B
cancers	B
.	O

A	O
requirement	O
for	O
more	O
alterations	O
before	O
tranformation	O
for	O
sporadic	O
MSI+	B
compared	O
to	O
sporadic	O
MSI-	B
cancers	B
may	O
help	O
explain	O
why	O
sporadic	O
MSI+	B
cancers	B
are	O
a	O
minority	O
of	O
all	O
colorectal	B
cancers	I
and	O
occur	O
in	O
slightly	O
older	O
patients	O
[	O
19,20	O
]	O
.	O

Although	O
numbers	O
of	O
oncogenic	O
mutations	O
before	O
transformation	O
are	O
similar	O
between	O
sporadic	O
MSI+	B
and	O
MSI-	B
cancers	B
,	O
their	O
identities	O
likely	O
differ	O
[	O
7,8	O
]	O
.	O

Discussion	O
In	O
this	O
study	O
,	O
the	O
occurrence	O
of	O
mutations	O
in	O
the	O
APC	O
,	O
CTNNB1	O
and	O
K	O
-	O
ras	O
genes	O
as	O
well	O
as	O
expression	O
of	O
the	O
hMLH1	O
protein	O
in	O
tumour	B
tissue	O
of	O
656	O
sporadic	O
colorectal	B
cancer	I
cases	O
were	O
investigated	O
.	O

The	O
occurrence	O
of	O
mutations	O
in	O
the	O
CTNNB1	O
gene	O
,	O
which	O
codes	O
for	O
	O
-	O
catenin	O
,	O
was	O
rare	O
:	O
only	O
five	O
of	O
464	O
tumours	B
analysed	O
were	O
found	O
to	O
have	O
a	O
mutation	O
at	O
one	O
of	O
the	O
phosphorylation	O
sites	O
in	O
exon	O
3	O
.	O

Truncating	O
mutations	O
in	O
APC	O
and	O
activating	O
mutations	O
in	O
K	O
-	O
ras	O
appeared	O
to	O
occur	O
at	O
similar	O
frequencies	O
.	O

Although	O
tumours	B
harbouring	O
both	O
mutations	O
were	O
relatively	O
rare	O
,	O
mutations	O
in	O
APC	O
and	O
K	O
-	O
ras	O
seemed	O
to	O
occur	O
co	O
-	O
dependently	O
.	O

Nine	O
percent	O
of	O
all	O
tumours	B
(	O
58	O
/	O
656	O
)	O
lacked	O
hMLH1	O
expression	O
,	O
and	O
in	O
these	O
tumours	B
almost	O
no	O
APC	O
or	O
K	O
-	O
ras	O
mutations	O
was	O
detected	O
.	O

Patients	O
harbouring	O
a	O
tumour	B
with	O
absent	O
hMLH1	O
expression	O
were	O
older	O
,	O
more	O
often	O
women	O
,	O
more	O
often	O
had	O
proximal	O
colon	O
tumours	B
that	O
showed	O
poorer	O
differentiation	O
when	O
compared	O
to	O
patients	O
who	O
harboured	O
a	O
tumour	B
with	O
an	O
APC	O
and/or	O
K	O
-	O
ras	O
mutation	O
.	O

The	O
selection	O
of	O
patients	O
included	O
in	O
this	O
study	O
was	O
based	O
on	O
the	O
completeness	O
of	O
analyses	O
of	O
both	O
APC	O
and	O
K	O
-	O
ras	O
genes	O
as	O
well	O
as	O
hMLH1	O
expression	O
and	O
this	O
led	O
to	O
a	O
considerable	O
reduction	O
in	O
the	O
number	O
of	O
cases	O
that	O
could	O
be	O
included	O
in	O
the	O
analyses	O
presented	O
in	O
this	O
study	O
.	O

The	O
largest	O
reduction	O
(	O
72	O
cases	O
)	O
was	O
due	O
to	O
incompleteness	O
of	O
the	O
analysis	O
of	O
all	O
fragments	O
comprising	O
the	O
APC	O
mutation	O
cluster	O
region	O
.	O

Tumour	B
DNA	O
was	O
derived	O
from	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tumour	B
tissue	O
blocks	O
.	O

Depending	O
on	O
the	O
conditions	O
of	O
fixation	O
and	O
storage	O
,	O
the	O
extracted	O
DNA	O
is	O
more	O
or	O
less	O
fragmented	O
,	O
which	O
may	O
have	O
impaired	O
the	O
analysis	O
of	O
mutations	O
in	O
the	O
APC	O
gene	O
more	O
than	O
in	O
the	O
K	O
-	O
ras	O
gene	O
,	O
since	O
the	O
analysis	O
of	O
the	O
latter	O
is	O
based	O
on	O
the	O
amplification	O
of	O
a	O
smaller	O
gene	O
fragment	O
.	O

It	O
should	O
be	O
emphasized	O
that	O
characteristics	O
of	O
patients	O
(	O
age	O
,	O
sex	O
,	O
family	O
history	O
of	O
colorectal	B
cancer	I
)	O
and	O
tumours	B
(	O
sub	O
-	O
localisation	O
,	O
Dukes	O
'	O
stage	O
and	O
differentiation	O
)	O
of	O
the	O
group	O
under	O
study	O
are	O
similar	O
to	O
the	O
737	O
patients	O
for	O
whom	O
tumour	B
material	O
was	O
available	O
and	O
to	O
all	O
819	O
patients	O
initially	O
recognized	O
within	O
the	O
cohort	O
(	O
data	O
not	O
shown	O
)	O
.	O

Moreover	O
,	O
the	O
K	O
-	O
ras	O
and	O
hMLH1data	O
presented	O
here	O
are	O
similar	O
to	O
the	O
data	O
for	O
K	O
-	O
ras	O
and	O
hMLH1	O
based	O
on	O
the	O
complete	O
groups	O
(	O
737	O
and	O
724	O
cases	O
,	O
respectively	O
)	O
(	O
data	O
not	O
shown	O
)	O
.	O

Mutations	O
in	O
exon	O
3	O
of	O
the	O
CTNNB1	O
gene	O
leading	O
to	O
loss	O
of	O
one	O
of	O
the	O
phosphorylation	O
sites	O
were	O
rare	O
.	O

Strikingly	O
,	O
all	O
five	O
of	O
these	O
mutations	O
occurred	O
in	O
the	O
proximal	O
colon	O
and	O
three	O
of	O
these	O
also	O
had	O
absent	O
hMLH1	O
expression	O
.	O

This	O
may	O
indicate	O
that	O
these	O
proximal	O
colon	O
tumours	B
,	O
which	O
often	O
also	O
show	O
mismatch	O
repair	O
deficiency	O
,	O
are	O
more	O
likely	O
to	O
harbour	O
CTNNB1	O
mutations	O
.	O

This	O
was	O
also	O
found	O
in	O
a	O
study	O
of	O
microsatellite	B
instable	I
colorectal	O
tumours	B
[	O
26	O
]	O
.	O

The	O
WAVE	O
screening	O
technique	O
has	O
not	O
been	O
used	O
previously	O
for	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
tissue	O
,	O
and	O
therefore	O
it	O
seems	O
plausible	O
that	O
samples	O
harbouring	O
a	O
CTNNB1	O
mutation	O
have	O
escaped	O
detection	O
.	O

However	O
,	O
all	O
58	O
hMLH1	B
deficient	I
samples	O
were	O
analysed	O
by	O
direct	O
sequencing	O
without	O
a	O
prior	O
screening	O
step	O
,	O
and	O
only	O
three	O
of	O
these	O
samples	O
harboured	O
a	O
CTNNB1	O
mutation	O
,	O
indicating	O
the	O
low	O
frequency	O
of	O
such	O
mutations	O
.	O

Background	O
Hereditary	B
non	I
-	I
polyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
is	O
an	O
inherited	O
syndrome	O
predisposing	O
to	O
the	O
early	B
development	I
of	O
cancers	B
of	O
colon	O
,	O
rectum	O
,	O
endometrium	O
,	O
ovarium	O
,	O
small	O
bowel	O
,	O
stomach	O
and	O
urinary	O
tract	O
[	O
1,2	O
]	O
.	O

Since	O
there	O
are	O
no	O
premonitory	O
signs	O
of	O
susceptibility	O
to	O
HNPCC	B
,	O
family	O
history	O
has	O
been	O
the	O
primary	O
method	O
for	O
identifying	O
patients	O
at	O
risk	O
.	O

Defined	O
by	O
the	O
International	O
Collaborative	O
group	O
on	O
HNPCC	B
,	O
the	O
typical	O
HNPCC	B
family	O
fulfill	O
the	O
following	O
criteria	O
(	O
referred	O
to	O
as	O
the	O
Amsterdam	O
-	O
I	O
criteria	O
[	O
3	O
]	O
)	O
:	O
1	O
.	O

Three	O
or	O
more	O
relatives	O
with	O
histologically	O
verified	O
colorectal	B
cancer	I
,	O
one	O
of	O
whom	O
is	O
a	O
first	O
-	O
degree	O
relative	O
of	O
the	O
other	O
two	O
;	O
2	O
.	O

Colorectal	B
cancer	I
affecting	O
at	O
least	O
2	O
successive	O
generations	O
;	O
and	O
3	O
.	O

At	O
least	O
one	O
relative	O
diagnosed	O
with	O
colorectal	B
cancer	I
under	O
the	O
age	O
of	O
50	O
.	O

The	O
fulfillment	O
of	O
these	O
criteria	O
prompted	O
further	O
genetics	O
investigations	O
.	O

More	O
recently	O
it	O
has	O
been	O
revised	O
to	O
take	O
into	O
account	O
the	O
prevalence	O
of	O
extracolonic	B
cancer	I
in	O
certain	O
HNPCC	B
families	O
[	O
4	O
]	O
.	O

This	O
autosomal	O
dominantly	O
inherited	O
disorder	O
is	O
caused	O
by	O
germline	O
mutations	O
in	O
genes	O
coding	O
proteins	O
responsible	O
for	O
the	O
repair	O
of	O
DNA	O
replication	O
errors	O
,	O
which	O
are	O
referred	O
to	O
as	O
DNA	O
mismatch	O
repair	O
(	O
MMR	O
)	O
genes	O
[	O
5	O
]	O
.	O

DNA	O
mismatch	O
repair	O
machinery	O
plays	O
a	O
critical	O
role	O
in	O
genomic	O
stability	O
,	O
including	O
correction	O
of	O
mispaired	O
bases	O
associated	O
with	O
DNA	O
replication	O
and	O
recombination	O
.	O

Germline	O
mutations	O
in	O
one	O
allele	O
of	O
any	O
of	O
these	O
genes	O
followed	O
by	O
the	O
somatic	O
loss	O
or	O
inactivation	O
of	O
the	O
wild	O
-	O
type	O
allele	O
leads	O
to	O
a	O
defective	O
mismatch	O
repair	O
mechanism	O
.	O

The	O
current	O
""""	O
gold	O
standard	O
""""	O
for	O
assessing	O
tumor	O
DNA	O
MMR	O
activity	O
is	O
molecular	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
testing	O
.	O

In	O
most	O
cases	O
,	O
it	O
involves	O
extracting	O
DNA	O
from	O
both	O
tumor	O
and	O
normal	O
tissue	O
.	O

The	O
DNA	O
is	O
subjected	O
to	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
amplification	O
of	O
five	O
or	O
more	O
different	O
chromosomal	O
loci	O
that	O
compare	O
""""	O
microsatellites	O
""""	O
,	O
running	O
the	O
PCR	O
products	O
through	O
a	O
gel	O
to	O
separate	O
DNA	O
fragments	O
by	O
size	O
,	O
comparing	O
the	O
tumor	O
-	O
normal	O
pairs	O
,	O
and	O
scoring	O
for	O
differences	O
between	O
the	O
two	O
.	O

Instability	O
at	O
two	O
or	O
more	O
out	O
of	O
five	O
markers	O
defines	O
a	O
tumor	B
as	O
MSI	B
-	I
H	I
and	O
prompts	O
further	O
analysis	O
,	O
as	O
sequencing	O
of	O
DNA	O
MMR	O
genes	O
.	O

A	O
number	O
of	O
them	O
have	O
been	O
associated	O
with	O
HNPCC	B
,	O
including	O
hMSH2	O
,	O
hMLH1	O
,	O
hPMS1	O
,	O
hPMS2	O
,	O
hMSH3	O
,	O
and	O
hMSH6	O
.	O

Most	O
of	O
the	O
HNPCC	B
families	O
in	O
which	O
mutations	O
have	O
been	O
identified	O
involved	O
hMSH2	O
and	O
hMLH1	O
genes	O
[	O
6	O
]	O
.	O

A	O
much	O
less	O
labor	O
-	O
intensive	O
alternative	O
method	O
used	O
to	O
prescreen	O
high	O
-	O
risk	O
individuals	O
for	O
further	O
germline	O
mutation	O
analysis	O
is	O
immunohistochemistry	O
(	O
IHC	O
)	O
testing	O
for	O
MLH1	O
and	O
MSH2	O
expression	O
.	O

IHC	O
testing	O
may	O
identify	O
which	O
gene	O
to	O
target	O
for	O
analysis	O
.	O

We	O
describe	O
MSI	O
testing	O
in	O
the	O
absence	O
of	O
proband	O
non	O
-	O
tumor	O
tissue	O
using	O
the	O
Bethesda	O
consensus	O
panel	O
(	O
mononucleotide	O
repeats	O
BAT25	O
and	O
BAT26	O
,	O
and	O
dinucleotide	O
repeats	O
D2S123	O
,	O
D5S346	O
,	O
and	O
D17S250	O
)	O
and	O
we	O
report	O
a	O
novel	O
hMSH2	O
germline	O
mutation	O
found	O
in	O
the	O
family	O
.	O

Microsatellite	O
instability	O
.	O

Three	O
of	O
five	O
microsatellite	O
markers	O
(	O
BAT-25	O
,	O
BAT-26	O
and	O
D5S346	O
)	O
presented	O
different	O
alleles	O
(	O
*	O
)	O
in	O
the	O
proband	O
's	O
primary	O
tumor	B
(	O
T	O
'	O
)	O
and	O
its	O
metastasis	O
(	O
T	O
""""	O
)	O
of	O
those	O
inherited	O
from	O
his	O
biological	O
mother	O
(	O
BM	O
)	O
and	O
father	O
(	O
BF	O
)	O
.	O

DNA	O
sequencing	O
of	O
hMSH2	O
and	O
hMLH1	O
genes	O
A	O
second	O
blood	O
sample	O
was	O
obtained	O
from	O
the	O
proband	O
's	O
mother	O
and	O
forwarded	O
to	O
the	O
Department	O
of	O
Clinical	O
Cancer	O
Genetics	O
(	O
City	O
of	O
Hope	O
Cancer	O
Center	O
,	O
Duarte	O
,	O
California	O
,	O
USA	O
)	O
to	O
full	O
mutation	O
analysis	O
of	O
the	O
hMSH2	O
and	O
hMLH1	O
genes	O
.	O

The	O
sample	O
was	O
amplified	O
followed	O
by	O
direct	O
sequencing	O
to	O
screen	O
the	O
coding	O
regions	O
of	O
both	O
the	O
hMSH2	O
and	O
the	O
hMLH1	O
genes	O
for	O
germline	O
mutation	O
in	O
the	O
DNA	O
.	O

After	O
establishing	O
the	O
familial	O
mutation	O
in	O
the	O
proband	O
's	O
mother	O
,	O
located	O
in	O
the	O
exon	O
12	O
of	O
hMSH2	O
gene	O
,	O
it	O
was	O
searched	O
in	O
the	O
proband	O
's	O
sisters	O
by	O
direct	O
sequencing	O
using	O
a	O
manual	O
Sequenase	O
PCR	O
products	O
kit	O
(	O
Amersham	O
Biosciences	O
)	O
.	O

Mutation	O
screening	O
was	O
done	O
in	O
both	O
sisters	O
to	O
assign	O
their	O
risk	O
to	O
develop	O
HNPCC	B
and	O
other	O
related	O
cancers	B
.	O

We	O
found	O
the	O
mutation	O
in	O
one	O
of	O
them	O
and	O
opportune	O
recommendations	O
for	O
surveillance	O
and	O
prophylaxis	O
were	O
given	O
.	O

Two	O
years	O
after	O
that	O
,	O
the	O
proband	O
's	O
mother	O
,	O
unaffected	B
during	O
this	O
study	O
,	O
developed	O
an	O
endometrial	O
adenocarcinoma	B
.	O

Methods	O
Patients	O
25	O
colorectal	B
cancer	I
patients	O
undergoing	O
elective	O
standard	O
oncological	O
resection	O
at	O
the	O
department	O
of	O
surgery	O
,	O
Charit	O
,	O
Campus	O
Benjamin	O
Franklin	O
,	O
Berlin	O
,	O
Germany	O
were	O
prospectively	O
recruited	O
for	O
this	O
study	O
.	O

The	O
study	O
was	O
approved	O
by	O
the	O
local	O
ethical	O
committee	O
and	O
informed	O
consent	O
was	O
obtained	O
from	O
all	O
patients	O
.	O

Rectal	B
cancer	I
patients	O
receiving	O
neo	O
-	O
adjuvant	O
radiochemotherapy	O
were	O
excluded	O
from	O
this	O
study	O
.	O

Tissue	O
samples	O
and	O
UV	O
-	O
laser	O
microdissection	O
Transmural	O
cancer	B
specimens	O
were	O
snap	O
frozen	O
(	O
liquid	O
nitrogen	O
)	O
within	O
20	O
minutes	O
following	O
excision	O
and	O
stored	O
at	O
-80	O
	O
C	O
.	O

All	O
tissue	O
samples	O
were	O
evaluated	O
by	O
a	O
pathologist	O
before	O
and	O
during	O
laser	O
micro	O
-	O
dissection	O
to	O
ensure	O
an	O
enrichment	O
of	O
vital	O
tumor	B
cells	O
.	O

Six	O
-	O
micron	O
serial	O
frozen	O
sections	O
were	O
cut	O
on	O
a	O
standard	O
cryostat	O
and	O
mounted	O
on	O
RNase	O
-	O
free	O
foil	O
(	O
2,5	O
m	O
)	O
coated	O
on	O
glass	O
slides	O
followed	O
by	O
immediate	O
fixation	O
(	O
70	O
%	O
ethanol	O
for	O
30s	O
)	O
,	O
H&E	O
staining	O
,	O
and	O
ethanol	O
dehydration	O
(	O
70	O
%	O
,	O
95	O
%	O
and	O
finally	O
100	O
%	O
ethanol	O
)	O
.	O

After	O
vacuum	O
drying	O
the	O
membranes	O
carrying	O
the	O
sections	O
were	O
manually	O
turned	O
and	O
coated	O
on	O
new	O
RNase	O
free	O
glass	O
slides	O
.	O

Optically	O
transparent	O
CapSure	O
LCM	O
caps	O
(	O
ARCTURUS	O
,	O
CA	O
)	O
were	O
placed	O
on	O
the	O
foil	O
over	O
a	O
selected	O
field	O
of	O
cells	O
.	O

Vital	O
colorectal	O
epithelial	O
carcinoma	O
cells	O
(	O
>	O
90	O
%	O
proportion	O
)	O
from	O
the	O
invasion	O
front	O
were	O
isolated	O
using	O
UV	O
-	O
LCM	O
Systems	O
from	O
PALM	O
(	O
Microlaser	O
Technologie	O
,	O
Germany	O
)	O
and	O
SL	O
(	O
Microtest	O
GmbH	O
,	O
Germany	O
)	O
.	O

After	O
visual	O
control	O
of	O
completeness	O
of	O
dissection	O
the	O
captured	O
cells	O
were	O
immersed	O
in	O
denaturation	O
buffer	O
(	O
GTC	O
Extraction	O
Buffer	O
,	O
2	O
%	O
beta	O
-	O
mercaptoethanol	O
,	O
Promega	O
,	O
WI	O
)	O
and	O
stored	O
at	O
-80	O
	O
C	O
.	O

mRNA	O
-	O
extraction	O
,	O
cRNA	O
-	O
preparation	O
and	O
-amplification	O
Poly	O
(	O
A	O
)	O
+	O
RNAs	O
were	O
isolated	O
using	O
PolyATtract	O
1000	O
kit	O
(	O
Promega	O
,	O
Heidelberg	O
,	O
Germany	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
recommendations	O
.	O

For	O
each	O
sample	O
the	O
cDNA	O
synthesis	O
and	O
repetitive	O
in	O
vitro	O
transcription	O
were	O
performed	O
three	O
times	O
,	O
as	O
described	O
previously	O
[	O
38	O
-	O
40	O
]	O
.	O

In	O
brief	O
,	O
the	O
total	O
amount	O
of	O
prepared	O
mRNA	O
from	O
one	O
sample	O
was	O
used	O
.	O

First	O
strand	O
cDNA	O
synthesis	O
was	O
initiated	O
using	O
the	O
Affymetrix	O
T7-oligo	O
-	O
dT	O
promoter	O
-	O
primer	O
combination	O
.	O

The	O
second	O
strand	O
cDNA	O
was	O
synthesized	O
by	O
internal	O
priming	O
.	O

In	O
vitro	O
transcription	O
was	O
performed	O
using	O
Ambion	O
's	O
Megascript	O
kit	O
(	O
Ambion	O
,	O
Huntington	O
,	O
UK	O
)	O
as	O
recommended	O
by	O
the	O
manufacturer	O
.	O

From	O
the	O
generated	O
cRNA	O
a	O
new	O
first	O
strand	O
synthesis	O
was	O
initiated	O
using	O
0.025	O
mM	O
of	O
a	O
random	O
hexamer	O
as	O
primer	O
.	O

After	O
completion	O
,	O
the	O
second	O
strand	O
synthesis	O
was	O
primed	O
using	O
the	O
Affymetrix	O
T7-oligo	O
-	O
dT	O
promoter	O
-	O
primer	O
combination	O
at	O
a	O
concentration	O
of	O
0.1	O
mM.	O
A	O
second	O
in	O
vitro	O
transcription	O
was	O
performed	O
and	O
then	O
the	O
procedure	O
was	O
repeated	O
one	O
additional	O
time	O
.	O

During	O
the	O
third	O
in	O
vitro	O
transcription	O
biotin	O
-	O
labeled	O
nucleotides	O
were	O
incorporated	O
into	O
the	O
cRNA	O
as	O
recommended	O
by	O
the	O
Affymetrix	O
protocol	O
.	O

Microarray	O
hybridization	O
BIO+cRNAs	O
were	O
hybridized	O
on	O
Affymetrix	O
Human	O
Genome	O
U133A	O
and	O
U133B	O
GeneChips	O
,	O
that	O
consist	O
of	O
44.928	O
probe	O
sets	O
(	O
Affymetrix	O
,	O
Santa	O
Clara	O
,	O
CA	O
)	O
.	O

Fragmentation	O
,	O
preparation	O
of	O
hybridization	O
cocktails	O
,	O
hybridization	O
,	O
washing	O
,	O
staining	O
and	O
scanning	O
of	O
Affymetrix	O
GeneChip	O
were	O
performed	O
according	O
to	O
the	O
manufacturer	O
's	O
protocols	O
.	O

Introduction	O

The	O
traditional	O
view	O
of	O
epithelial	O
polyps	B
of	O
the	O
colorectum	O
envisages	O
a	O
larger	O
non	B
-	I
neoplastic	I
category	O
of	O
hyperplastic	B
polyps	B
(	O
HPs	B
)	O
that	O
can	O
be	O
safely	O
ignored	O
and	O
a	O
smaller	O
category	O
of	O
neoplastic	B
polyps	B
or	O
adenomas	B
that	O
are	O
precancerous.1	O
With	O
respect	O
to	O
adenomas	B
,	O
it	O
is	O
clear	O
that	O
the	O
majority	O
will	O
not	O
progress	O
to	O
colorectal	B
cancer	I
(	O
CRC	B
)	O
.2	O
The	O
risk	O
of	O
cancer	B
developing	O
within	O
an	O
adenoma	B
increases	O
with	O
size	O
,	O
grade	O
of	O
dysplasia	O
(	O
synonymous	O
with	O
intraepithelial	O
neoplasia	O
)	O
and	O
villosity.3	O
These	O
features	O
,	O
together	O
with	O
polyp	B
numbers	O
,	O
are	O
also	O
predictive	O
of	O
metachronous	O
neoplasia	B
and	O
may	O
therefore	O
influence	O
the	O
decision	O
to	O
offer	O
follow	O
-	O
up	O
endoscopic	O
surveillance.4	O
However	O
,	O
the	O
grading	O
of	O
dysplasia	O
and	O
estimation	O
of	O
the	O
extent	O
of	O
villous	O
change	O
may	O
not	O
be	O
fully	O
reproducible	O
and	O
it	O
may	O
be	O
difficult	O
to	O
distinguish	O
new	O
from	O
recurrent	O
adenomas	B
.	O

Establishing	O
a	O
risk	O
profile	O
on	O
the	O
basis	O
of	O
the	O
traditional	O
features	O
of	O
adenoma	B
is	O
therefore	O
not	O
always	O
straightforward	O
.	O

The	O
addition	O
of	O
molecular	O
profiling	O
to	O
polyp	B
description	O
offers	O
hope	O
of	O
a	O
more	O
objective	O
and	O
therefore	O
reproducible	O
approach	O
to	O
the	O
classification	O
of	O
colorectal	O
adenomas	B
.	O

The	O
genetic	O
evolutionary	O
paradigm	O
envisages	O
a	O
linear	O
sequence	O
of	O
changes	O
beginning	O
with	O
bi	O
-	O
allelic	O
inactivation	O
of	O
APC	O
,	O
followed	O
by	O
oncogenic	O
KRAS	O
mutation	O
and	O
culminating	O
in	O
inactivation	O
of	O
TP53	O
at	O
the	O
transition	O
from	O
adenoma	B
to	O
carcinoma.5	B
While	O
there	O
is	O
good	O
evidence	O
that	O
KRAS	O
mutation	O
is	O
associated	O
with	O
advanced	O
adenoma	B
features6	O
and	O
could	O
therefore	O
be	O
used	O
as	O
objective	O
evidence	O
of	O
aggression	O
,	O
this	O
approach	O
has	O
a	O
number	O
of	O
limitations	O
.	O

First	O
,	O
KRAS	O
mutation	O
also	O
occurs	O
frequently	O
in	O
dysplastic	B
aberrant	I
crypt	I
foci	I
(	O
microadenomas	B
)	O
and	O
in	O
some	O
small	O
tubular	O
adenomas	B
,	O
suggesting	O
that	O
KRAS	O
mutation	O
may	O
initiate	O
a	O
subset	O
of	O
small	O
adenomas	B
with	O
limited	O
potential	O
for	O
progression.6,7	O
Second	O
,	O
around	O
70	O
%	O
of	O
CRCs	B
lack	O
mutation	O
of	O
KRAS.8	O
From	O
this	O
it	O
follows	O
that	O
most	O
of	O
the	O
precancerous	O
lesions	B
that	O
eventually	O
become	O
cancers	B
do	O
not	O
in	O
fact	O
have	O
KRAS	O
mutation	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
CRC	B
evolves	O
through	O
a	O
number	O
of	O
pathways	O
and	O
the	O
traditional	O
adenoma	B
	O
carcinoma	B
sequence	O
,	O
with	O
its	O
accompanying	O
genetic	O
steps	O
,	O
provides	O
a	O
surprisingly	O
narrow	O
window	O
of	O
understanding	O
of	O
this	O
multipathway	O
reality.9	O
In	O
recent	O
years	O
,	O
the	O
fundamental	O
division	O
of	O
colorectal	O
polyps	B
into	O
precancerous	O
adenomas	B
and	O
innocent	O
HPs	B
has	O
begun	O
to	O
erode	O
and	O
the	O
concept	O
of	O
an	O
alternative	O
serrated	O
pathway	O
has	O
gained	O
support	O
.	O

This	O
revision	O
began	O
with	O
the	O
description	O
of	O
an	O
intermediate	O
lesion	B
described	O
as	O
serrated	O
adenoma	B
(	O
SA	B
)	O
.10	O
Initially	O
,	O
however	O
,	O
SA	B
was	O
not	O
conceived	O
as	O
an	O
intermediate	O
category	O
of	O
polyp	B
but	O
essentially	O
as	O
an	O
adenoma	B
with	O
a	O
superimposed	B
serrated	I
architecture	I
that	O
conferred	O
only	O
a	O
superficial	O
likeness	O
to	O
a	O
HP.10	B
Additionally	O
,	O
the	O
mixed	O
polyp	B
(	O
MP	B
)	O
was	O
perceived	O
as	O
a	O
chance	O
collision	O
between	O
a	O
HP	B
and	O
an	O
adenoma	B
,	O
giving	O
a	O
combined	O
polyp	B
.	O

These	O
preliminary	O
interpretations	O
did	O
not	O
represent	O
a	O
major	O
departure	O
from	O
the	O
traditional	O
classification	O
of	O
colorectal	O
polyps	B
but	O
preserved	O
the	O
fundamental	O
distinction	O
of	O
neoplastic	B
adenomas	B
versus	O
non	B
-	I
neoplastic	I
HPs	B
.	O

Statistics	O
Data	O
were	O
analysed	O
by	O
2	O
test	O
,	O
Fisher	O
's	O
exact	O
test	O
or	O
T	O
-	O
test	O
,	O
as	O
appropriate	O
,	O
using	O
SAS	O
software	O
,	O
version	O
8.2	O
(	O
Cary	O
,	O
NC	O
,	O
USA	O
)	O
.	O

P	O
-	O
values	O
<	O
0.05	O
were	O
interpreted	O
as	O
significant	O
.	O

Results	O
KRAS	O
and	O
BRAF	O
mutation	O
DNA	O
failed	O
to	O
amplify	O
in	O
the	O
KRAS	O
assay	O
for	O
one	O
SSA	B
and	O
one	O
TA	B
<	O
10	O
mm	O
.	O

Overall	O
,	O
34	O
of	O
188	O
polyps	B
(	O
18	O
%	O
)	O
had	O
mutation	O
of	O
KRAS	O
.	O

Twenty	O
-	O
eight	O
mutations	O
were	O
in	O
codon	O
12	O
(	O
20	O
GA	O
,	O
seven	O
GT	O
and	O
one	O
GC	O
)	O
and	O
six	O
mutations	O
were	O
in	O
codon	O
13	O
(	O
all	O
GA	O
)	O
.	O

One	O
serrated	O
adenoma	B
had	O
two	O
KRAS	O
mutations	O
in	O
codon	O
12	O
(	O
GT	O
at	O
position	O
35	O
and	O
TG	O
at	O
position	O
36	O
)	O
.	O

BRAF	O
mutation	O
at	O
V600E	O
could	O
be	O
assessed	O
in	O
all	O
polyps	B
except	O
for	O
a	O
single	O
TA	B
<	O
10	O
mm	O
.	O

BRAF	O
mutation	O
was	O
found	O
in	O
82	O
of	O
189	O
polyps	B
(	O
43	O
%	O
)	O
.	O

BRAF	O
and	O
KRAS	O
mutations	O
were	O
negatively	O
correlated	O
,	O
with	O
only	O
four	O
polyps	B
having	O
both	O
mutations	O
(	O
two	O
TAs	B
,	O
one	O
TVA	B
and	O
one	O
SSA	B
)	O
.	O

The	O
three	O
conventional	O
adenomas	B
with	O
mutations	O
of	O
both	O
BRAF	O
and	O
KRAS	O
were	O
among	O
only	O
four	O
adenomas	B
that	O
had	O
any	O
BRAF	O
mutations	O
at	O
all	O
.	O

Mutation	O
frequencies	O
for	O
both	O
KRAS	O
and	O
BRAF	O
were	O
distributed	O
differently	O
across	O
the	O
seven	O
polyp	B
groups	O
(	O
Table	O
1	O
)	O
.	O

Frequency	O
of	O
KRAS	O
and	O
BRAF	O
mutation	O
and	O
loss	O
of	O
expression	O
of	O
O-6-methylguanine	O
DNA	O
methyltransferase	O
(	O
MGMT	O
)	O
by	O
polyp	B
type	O
Mutation	O
frequencies	O
for	O
both	O
KRAS	O
(	O
P	O
<	O
0.0001	O
)	O
and	O
BRAF	O
(	O
P	O
<	O
0.0001	O
)	O
are	O
distributed	O
differently	O
across	O
the	O
seven	O
classes	O
of	O
polyp	B
(	O
see	O
Results	O
for	O
individual	O
comparisons	O
)	O
.	O

Distribution	O
of	O
MGMT	O
loss	O
differs	O
across	O
the	O
seven	O
classes	O
of	O
polyp	B
(	O
P	O
<	O
0.001	O
)	O
.	O

Note	O
:	O
no	O
result	O
for	O
KRAS	O
in	O
one	O
sessile	O
serrated	O
adenoma	B
(	O
SSA	B
)	O
and	O
one	O
tubular	O
adenoma	B
(	O
TA	B
)	O
or	O
for	O
BRAF	O
in	O
one	O
TA	B
.	O

MGMT	O
immunstaining	O
not	O
performed	O
in	O
15	O
polyps	B
(	O
seven	O
HPs	B
,	O
one	O
SSA	B
,	O
one	O
MP	B
and	O
six	O
TAs	B
)	O
.	O

KRAS	O
mutation	O
occurred	O
in	O
26.5	O
%	O
and	O
BRAF	O
mutation	O
in	O
4.8	O
%	O
of	O
adenomas	B
(	O
all	O
types	O
)	O
(	O
Table	O
1	O
)	O
(	O
P	O
<	O
0.0001	O
)	O
.	O

TVAs	B
/	O
VAs	B
were	O
more	O
likely	O
to	O
have	O
KRAS	O
mutation	O
(	O
50	O
%	O
)	O
than	O
TAs	B
<	O
10	O
mm	O
(	O
18	O
%	O
)	O
(	O
P	O
<	O
0.004	O
)	O
or	O
TAS	B
>	O
10	O
mm	O
in	O
diameter	O
(	O
17	O
%	O
)	O
(	O
P	O
<	O
0.02	O
)	O
.	O

In	O
the	O
case	O
of	O
TAs	B
there	O
was	O
a	O
trend	O
for	O
KRAS	O
mutation	O
to	O
occur	O
more	O
frequently	O
in	O
polyps	B
from	O
the	O
proximal	O
colon	O
(	O
P	O
=	O
0.08	O
)	O
and	O
in	O
females	O
(	O
P	O
=	O
0.07	O
)	O
.	O

SSAs	B
were	O
more	O
likely	O
to	O
have	O
BRAF	O
mutation	O
(	O
81	O
%	O
)	O
than	O
either	O
SAs	B
(	O
33	O
%	O
)	O
(	O
P	O
<	O
0.001	O
)	O
or	O
MPs	B
(	O
40	O
%	O
)	O
(	O
P	O
<	O
0.02	O
)	O
.	O

KRAS	O
mutation	O
was	O
infrequent	O
among	O
both	O
SSAs	B
(	O
3	O
%	O
)	O
and	O
HPs	B
(	O
4	O
%	O
)	O
(	O
Table	O
1	O
)	O
.	O

Patient	O
age	O
,	O
gender	O
and	O
anatomical	O
location	O
were	O
not	O
predictors	O
of	O
BRAF	O
mutation	O
in	O
either	O
SSAs	B
or	O
HPs	B
.	O

The	O
mean	O
age	O
of	O
subjects	O
with	O
SSAs	B
(	O
64	O
years	O
)	O
differed	O
from	O
that	O
of	O
subjects	O
with	O
HPs	B
(	O
55	O
years	O
)	O
(	O
P	O
<	O
0.001	O
)	O
.	O

Background	O
Colorectal	B
cancer	I
(	O
CRC	B
)	O
is	O
the	O
one	O
of	O
the	O
most	O
common	O
malignancies	B
in	O
the	O
Western	O
world	O
.	O

Already	O
in	O
1913	O
,	O
familial	O
aggregation	O
of	O
CRC	B
was	O
described	O
by	O
Warthin	O
[	O
1	O
]	O
and	O
later	O
Lynch	O
et	O
al.	O
described	O
an	O
additional	O
family	O
with	O
clustering	O
of	O
colorectal	O
and	O
endometrial	O
cancer	B
[	O
2	O
]	O
.	O

Clinical	O
definition	O
of	O
Lynch	B
syndrome	I
,	O
or	O
HNPCC	B
,	O
in	O
1991	O
[	O
3,4	O
]	O
was	O
instrumental	O
for	O
linkage	O
analysis	O
,	O
and	O
ultimately	O
for	O
the	O
identification	O
of	O
the	O
underlying	O
gene	O
defects	O
in	O
HNPCC	B
families	O
.	O

The	O
first	O
HNPCC	B
loci	O
were	O
mapped	O
to	O
chromosomes	O
2	O
and	O
3	O
using	O
microsatellite	O
markers	O
[	O
5,6	O
]	O
.	O

This	O
eventually	O
led	O
to	O
the	O
identification	O
of	O
germ	O
line	O
mutations	O
in	O
MSH2	O
[	O
7	O
]	O
and	O
MLH1	O
[	O
8	O
]	O
,	O
respectively	O
.	O

Later	O
,	O
PMS2	O
[	O
9	O
]	O
,	O
MSH6	O
[	O
10,11	O
]	O
and	O
recently	O
MutYH	O
[	O
12	O
]	O
were	O
identified	O
as	O
CRC	B
susceptibility	O
genes	O
.	O

However	O
,	O
the	O
so	O
far	O
identified	O
CRC	B
susceptibility	O
genes	O
can	O
only	O
explain	O
up	O
to	O
5	O
%	O
of	O
all	O
cases	O
[	O
13	O
]	O
,	O
while	O
in	O
~35	O
%	O
of	O
all	O
colorectal	B
cancer	I
cases	O
familial	O
clustering	O
is	O
seen	O
[	O
14	O
]	O
.	O

Furthermore	O
,	O
it	O
is	O
shown	O
that	O
first	O
degree	O
relatives	O
of	O
patients	O
with	O
colorectal	B
cancer	I
have	O
a	O
relative	O
risk	O
of	O
2.3	O
to	O
develop	O
the	O
disease	B
[	O
15	O
]	O
.	O

This	O
indicates	O
that	O
still	O
some	O
genes	O
with	O
strong	O
or	O
moderate	O
effect	O
on	O
CRC	B
development	O
remain	O
to	O
be	O
identified	O
.	O

In	O
order	O
to	O
identify	O
these	O
genes	O
,	O
linkage	O
analysis	O
in	O
families	O
could	O
point	O
to	O
the	O
loci	O
where	O
unknown	O
susceptibility	O
genes	O
may	O
reside	O
.	O

Indeed	O
,	O
different	O
linkage	O
analysis	O
studies	O
revealed	O
potentially	O
interesting	O
regions	O
on	O
chromosomes	O
3q	O
,	O
9q	O
,	O
11q	O
,	O
14q	O
,	O
15q	O
and	O
22q	O
[	O
16	O
-	O
20	O
]	O
.	O

Families	O
with	O
a	O
clustering	O
of	O
colorectal	B
cancer	I
but	O
without	O
germ	O
line	O
mutations	O
in	O
CRC	B
genes	O
have	O
been	O
under	O
surveillance	O
in	O
Leiden	O
since	O
the	O
1980s	O
.	O

Due	O
to	O
the	O
long	O
period	O
of	O
follow	O
-	O
up	O
,	O
with	O
three	O
to	O
four	O
affected	B
generations	O
,	O
these	O
Dutch	O
HNPCC	B
-	I
like	I
families	O
have	O
become	O
informative	O
for	O
linkage	O
analysis	O
.	O

Traditionally	O
,	O
linkage	O
analysis	O
is	O
performed	O
with	O
multi	O
-	O
allelic	O
microsatellite	O
markers	O
.	O

Recently	O
,	O
however	O
,	O
the	O
more	O
advanced	O
single	O
nucleotide	O
polymorphism	O
(	O
SNP	O
)	O
arrays	O
were	O
brought	O
into	O
use	O
for	O
linkage	O
analysis	O
.	O

It	O
was	O
shown	O
that	O
the	O
information	O
content	O
of	O
a	O
dense	O
SNP	O
map	O
is	O
significantly	O
and	O
uniformly	O
higher	O
than	O
that	O
of	O
a	O
genome	O
wide	O
microsatellite	O
marker	O
map	O
[	O
21	O
]	O
.	O

Several	O
studies	O
conducting	O
linkage	O
analysis	O
on	O
genotype	O
data	O
from	O
SNP	O
arrays	O
appeared	O
in	O
recent	O
years	O
[	O
22	O
-	O
24	O
]	O
.	O

In	O
these	O
studies	O
non	O
-	O
parametric	O
as	O
well	O
as	O
parametric	O
linkage	O
analysis	O
was	O
performed	O
in	O
sib	O
pairs	O
or	O
in	O
small	O
to	O
moderate	O
size	O
pedigrees	O
.	O

However	O
,	O
to	O
date	O
,	O
no	O
studies	O
have	O
been	O
published	O
on	O
linkage	O
analysis	O
using	O
SNPs	O
in	O
large	O
pedigrees	O
(	O
e.g.	O
>	O
3540	O
bits	O
)	O
.	O

Studying	O
large	O
families	O
with	O
thousands	O
of	O
SNPs	O
results	O
in	O
a	O
computational	O
complex	O
analysis	O
that	O
is	O
challenging	O
for	O
existing	O
statistical	O
packages	O
and	O
that	O
may	O
even	O
exceed	O
their	O
capacity	O
.	O

Current	O
linkage	O
analysis	O
programs	O
can	O
handle	O
either	O
large	O
pedigrees	O
or	O
large	O
numbers	O
of	O
markers	O
,	O
depending	O
on	O
the	O
underlying	O
algorithm	O
.	O

In	O
order	O
to	O
perform	O
linkage	O
analysis	O
in	O
large	O
pedigrees	O
using	O
SNP	O
arrays	O
,	O
we	O
explored	O
the	O
possibilities	O
of	O
currently	O
available	O
linkage	O
analysis	O
software	O
.	O

Most	O
currently	O
available	O
programs	O
are	O
based	O
on	O
the	O
Lander	O
-	O
Green	O
or	O
the	O
Elston	O
-	O
Stewart	O
algorithm	O
or	O
both	O
.	O

The	O
computation	O
time	O
of	O
the	O
former	O
algorithm	O
increases	O
exponentially	O
with	O
the	O
number	O
of	O
bits	O
(	O
2n	O
-	O
f	O
,	O
where	O
'	O
n	O
'	O
is	O
the	O
number	O
of	O
non	O
-	O
founders	O
and	O
'	O
f	O
'	O
the	O
number	O
of	O
founders	O
)	O
in	O
a	O
pedigree	O
,	O
whereas	O
the	O
latter	O
scales	O
exponentially	O
with	O
the	O
number	O
of	O
markers	O
.	O

To	O
perform	O
multipoint	O
linkage	O
analysis	O
in	O
a	O
large	O
family	O
with	O
SNP	O
arrays	O
in	O
one	O
run	O
would	O
probably	O
take	O
several	O
months	O
computation	O
time	O
,	O
if	O
at	O
all	O
possible	O
.	O

Statistics	O
Significance	O
values	O
were	O
calculated	O
using	O
the	O
software	O
package	O
SPSS	O
10.0.7	O
(	O
SPSS	O
Inc.	O
,	O
Chicago	O
,	O
IL	O
,	O
USA	O
)	O
.	O

Methods	O
Colorectal	B
cancer	I
samples	O
Samples	O
of	O
colorectal	B
cancer	I
tissue	O
and	O
matched	O
normal	B
colonic	O
mucosa	O
were	O
obtained	O
from	O
fresh	O
surgical	O
specimens	O
,	O
frozen	O
in	O
liquid	O
nitrogen	O
,	O
and	O
stored	O
at	O
-80	O
	O
C	O
.	O

Thirty	O
nine	O
carcinomas	B
,	O
23	O
microsatellite	B
stable	I
(	O
MSS	O
)	O
and	O
16	O
with	O
high	B
-	I
frequency	I
MSI	I
(	O
MSI	O
-	O
H	O
)	O
were	O
analyzed	O
in	O
the	O
course	O
of	O
the	O
study	O
.	O

The	O
clinico	O
-	O
pathological	O
features	O
of	O
the	O
tumors	B
are	O
detailed	O
in	O
Table	O
1	O
.	O

MSI	O
status	O
was	O
determined	O
with	O
a	O
fluorescence	O
-	O
based	O
PCR	O
method	O
,	O
using	O
the	O
five	O
markers	O
of	O
the	O
panel	O
of	O
Bethesda	O
(	O
BAT25	O
,	O
BAT26	O
,	O
D2S123	O
,	O
D5S346	O
,	O
and	O
D17S250	O
)	O
[	O
42	O
]	O
.	O

PCR	O
products	O
were	O
run	O
in	O
an	O
ABI	O
PRISM	O
377	O
DNA	O
sequencer	O
(	O
Perkin	O
-	O
Elmer	O
Applied	O
Biosystems	O
Division	O
,	O
Foster	O
City	O
,	O
CA	O
)	O
and	O
analyzed	O
by	O
the	O
GeneScan	O
3.1	O
version	O
software	O
(	O
Perkin	O
-	O
Elmer	O
)	O
[	O
43	O
]	O
.	O

According	O
to	O
the	O
guidelines	O
of	O
the	O
Workshop	O
of	O
Bethesda	O
[	O
42	O
]	O
,	O
tumors	B
showing	O
instability	O
at	O
two	O
or	O
more	O
loci	O
were	O
classified	O
as	O
MSI	B
-	I
H	I
and	O
tumors	B
without	O
instability	O
at	O
any	O
locus	O
as	O
MSS	B
.	O

None	O
of	O
the	O
tumors	B
included	O
in	O
this	O
study	O
exhibited	O
instability	O
at	O
a	O
single	O
locus	O
(	O
low	O
-	O
frequency	O
MSI	O
or	O
MSI	O
-	O
L	O
)	O
.	O

All	O
MSI	B
-	I
H	I
carcinomas	B
displayed	O
instability	O
at	O
mononucleotide	O
DNA	O
sequences	O
(	O
BAT25	O
and	O
BAT26	O
markers	O
)	O
.	O

Tumors	B
were	O
also	O
examined	O
for	O
expression	O
of	O
the	O
DNA	O
mismatch	O
repair	O
proteins	O
MLH1	O
and	O
MSH2	O
,	O
using	O
the	O
immunohistochemical	O
analytic	O
procedure	O
previously	O
described	O
[	O
43	O
]	O
.	O

Carcinomas	B
showing	O
complete	O
loss	O
of	O
nuclear	O
MLH1	O
or	O
MSH2	O
expression	O
were	O
classified	O
as	O
MLH1	B
or	I
MSH2	I
negative	I
,	O
whereas	O
cancers	B
with	O
normal	O
expression	O
of	O
MLH1	O
and	O
MSH2	O
gene	O
products	O
were	O
classified	O
as	O
MLH1	O
and	O
MSH2	O
positive	O
.	O

As	O
reported	O
in	O
Table	O
1	O
,	O
all	O
MSS	B
carcinomas	B
demonstrated	O
normal	O
nuclear	O
expression	O
of	O
both	O
MLH1	O
and	O
MSH2	O
proteins	O
(	O
MLH1	B
/	I
MSH2	I
positive	I
)	O
.	O

By	O
contrast	O
,	O
of	O
the	O
16	O
MSI	B
-	I
H	I
tumors	B
15	O
were	O
MLH1	B
negative	I
and	O
one	O
was	O
MSH2	O
negative	O
.	O

As	O
expected	O
,	O
MSI	B
-	I
H	I
carcinomas	B
were	O
more	O
frequently	O
located	O
in	O
the	O
proximal	O
colon	O
(	O
P	O
<	O
0.001	O
)	O
and	O
poorly	O
differentiated	O
(	O
P	O
<	O
0.001	O
)	O
and	O
more	O
often	O
contained	O
a	O
mucinous	O
component	O
(	O
P	O
<	O
0.001	O
)	O
with	O
respect	O
to	O
MSS	B
tumors	B
(	O
Table	O
1	O
)	O
.	O

Total	O
RNA	O
was	O
isolated	O
using	O
Trizol	O
(	O
Invitrogen	O
)	O
following	O
manufacturer	O
's	O
indications	O
.	O

RNA	O
integrity	O
was	O
assessed	O
on	O
a	O
2100	O
Agilent	O
Bioanalyzer	O
.	O

Only	O
samples	O
with	O
intact	O
RNA	O
were	O
used	O
for	O
the	O
gene	O
expression	O
analysis	O
.	O

RNA	O
labeling	O
and	O
microarray	O
hybridization	O
RNA	O
labeling	O
and	O
hybridization	O
on	O
microRNA	O
microarray	O
chips	O
was	O
performed	O
as	O
previously	O
described	O
.	O

[	O
21,22	O
]	O
Briefly	O
,	O
5	O
g	O
of	O
total	O
RNA	O
from	O
each	O
sample	O
was	O
biotin	O
-	O
labeled	O
by	O
reverse	O
transcription	O
using	O
5	O
'	O
biotin	O
end	O
labeled	O
random	O
examers	O
oligo	O
primer	O
.	O

Hybridization	O
of	O
biotin	O
-	O
labeled	O
cDNA	O
was	O
carried	O
out	O
on	O
our	O
miRNA	O
microarray	O
chip	O
(	O
ArrayExpress	O
accession	O
number	O
:	O
A	O
-	O
MEXP-86	O
)	O
,	O
which	O
contains	O
230	O
human	O
microRNA	O
probes	O
,	O
in	O
triplicate	O
.	O

Hybridization	O
signals	O
were	O
detected	O
by	O
biotin	O
binding	O
of	O
a	O
Streptavidin	O
	O
Alexa	O
647	O
conjugate	O
using	O
Axon	O
Scanner	O
4000B	O
(	O
Axon	O
Instrument	O
Inc.	O
CA	O
)	O
.	O

Introduction	O
The	O
immune	O
system	O
is	O
thought	O
to	O
have	O
an	O
important	O
function	O
in	O
controlling	O
tumor	B
growth	O
and	O
eliminating	O
metastasizing	B
tumor	B
cells	O
.	O

The	O
expression	O
of	O
human	O
leukocyte	O
antigen	O
(	O
HLA	O
)	O
class	O
I	O
,	O
presenting	O
tumor	B
-	O
associated	O
antigens	O
on	O
the	O
tumor	B
cell	O
surface	O
,	O
is	O
considered	O
as	O
a	O
prerequisite	O
for	O
an	O
effective	O
T	O
cell	O
immune	O
response	O
[	O
34	O
]	O
.	O

As	O
a	O
consequence	O
,	O
tumor	B
cells	O
with	O
down	O
-	O
regulated	O
HLA	O
class	O
I	O
expression	O
might	O
escape	O
this	O
immune	O
response	O
,	O
resulting	O
in	O
a	O
selective	O
outgrowth	O
of	O
these	O
tumor	B
cells	O
.	O

Many	O
studies	O
described	O
HLA	O
class	O
I	O
expression	O
in	O
cancer	B
[	O
10	O
,	O
17	O
,	O
22	O
,	O
33	O
]	O
.	O

Only	O
limited	O
studies	O
have	O
reported	O
on	O
the	O
clinical	O
impact	O
of	O
HLA	O
class	O
I	O
expression	O
in	O
colorectal	B
cancer	I
with	O
contrasting	O
results	O
.	O

Some	O
studies	O
found	O
no	O
significant	O
correlation	O
between	O
staining	O
intensity	O
and	O
survival	O
[	O
1	O
,	O
19	O
,	O
20	O
]	O
,	O
while	O
others	O
found	O
a	O
prognostic	O
correlation	O
between	O
HLA	O
expression	O
and	O
survival	O
[	O
18	O
,	O
35	O
]	O
.	O

The	O
latter	O
two	O
studies	O
had	O
in	O
common	O
that	O
total	O
absence	O
of	O
HLA	O
class	O
I	O
resulted	O
in	O
a	O
favorable	O
prognosis	O
as	O
compared	O
to	O
patients	O
with	O
down	O
-	O
regulated	O
expression	O
of	O
HLA	O
class	O
I	O
of	O
tumor	B
cells	O
.	O

The	O
discrepancy	O
between	O
these	O
two	O
studies	O
is	O
,	O
whereas	O
the	O
one	O
described	O
high	O
expression	O
of	O
HLA	O
class	O
I	O
in	O
tumor	B
cells	O
that	O
resulted	O
in	O
a	O
better	O
prognosis	O
as	O
compared	O
to	O
the	O
partial	O
down	O
-	O
regulation	O
of	O
HLA	O
class	O
I	O
[	O
35	O
]	O
,	O
the	O
other	O
found	O
the	O
opposite	O
[	O
18	O
]	O
.	O

These	O
studies	O
both	O
analyzed	O
a	O
mixed	O
population	O
of	O
colon	O
and	O
rectal	B
cancer	I
patients	O
.	O

For	O
rectal	B
cancer	I
patients	O
,	O
the	O
clinical	O
impact	O
of	O
HLA	O
class	O
I	O
expression	O
is	O
still	O
unknown	O
.	O

Since	O
HLA	O
class	O
I	O
expression	O
is	O
often	O
absent	O
in	O
microsatellite	B
instable	I
(	O
MSI	B
)	O
tumors	B
[	O
9	O
,	O
16	O
]	O
and	O
MSI	B
is	O
more	O
frequently	O
observed	O
in	O
right	O
-	O
sided	O
colon	O
tumors	B
than	O
in	O
rectal	O
tumors	B
[	O
30	O
]	O
,	O
therefore	O
the	O
results	O
obtained	O
from	O
a	O
mixed	O
population	O
of	O
colon	O
and	O
rectal	B
cancer	I
patients	O
might	O
not	O
hold	O
true	O
for	O
rectal	B
cancer	I
patients	O
.	O

The	O
purpose	O
of	O
this	O
study	O
was	O
to	O
analyze	O
the	O
clinical	O
relevance	O
of	O
HLA	O
class	O
I	O
expression	O
for	O
rectal	B
cancer	I
patients	O
.	O

In	O
addition	O
to	O
determining	O
the	O
impact	O
of	O
MSI	O
on	O
HLA	O
class	O
I	O
expression	O
,	O
the	O
tumors	B
most	O
at	O
risk	O
for	O
MSI	O
i.e.	O
HLA	B
-	I
negative	I
tumors	B
were	O
examined	O
for	O
MSI	O
by	O
determining	O
the	O
expression	O
of	O
the	O
mismatch	O
repair	O
proteins	O
,	O
mismatch	O
mutL	O
homolog	O
1	O
(	O
MLH1	O
)	O
and	O
postmeiotic	O
segregation	O
increased	O
2	O
(	O
PMS2	O
)	O
,	O
that	O
are	O
most	O
absent	O
in	O
sporadic	O
MSI	B
tumors	B
[	O
7	O
,	O
36	O
]	O
.	O

Radiotherapy	O
has	O
been	O
described	O
recently	O
to	O
increase	O
cell	O
surface	O
expression	O
of	O
major	O
histocompatibility	O
complex	O
(	O
MHC	O
)	O
class	O
I	O
molecules	O
in	O
a	O
murine	O
colon	O
adenocarcinoma	B
cell	O
line	O
[	O
26	O
]	O
.	O

Therefore	O
,	O
our	O
study	O
also	O
evaluated	O
the	O
effect	O
of	O
radiotherapy	O
on	O
HLA	O
class	O
I	O
expression	O
in	O
rectal	B
cancer	I
patients	O
.	O

For	O
these	O
purposes	O
,	O
HLA	O
class	O
I	O
expression	O
was	O
evaluated	O
in	O
a	O
set	O
of	O
1,135	O
formalin	O
-	O
fixed	O
paraffin	O
-	O
embedded	O
rectal	B
cancer	I
specimens	O
.	O

The	O
tumors	B
studied	O
were	O
obtained	O
at	O
the	O
time	O
of	O
surgery	O
from	O
patients	O
of	O
a	O
prospective	O
multicenter	O
trial	O
,	O
who	O
were	O
randomized	O
between	O
standardized	O
preoperative	O
radiotherapy	O
treatment	O
followed	O
by	O
surgery	O
or	O
surgery	O
alone	O
[	O
15	O
]	O
.	O

Expression	O
of	O
HLA	O
class	O
I	O
in	O
rectal	B
cancer	I
using	O
HCA2	O
and	O
HC10	O
antibodies	O
Expression	O
of	O
results	O
of	O
HCA2	O
and	O
HC10	O
staining	O
in	O
a	O
cross	O
table	O
for	O
numbers	O
(	O
N	O
)	O
of	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
;	O
expression	O
of	O
HCA2	O
and	O
HC10	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
low	O
)	O
is	O
shown	O
.	O

A	O
significant	O
correlation	O
was	O
noted	O
between	O
HCA2	O
and	O
HC10	O
staining	O
for	O
both	O
irradiated	O
(	O
2	O
=	O
53.947	O
,	O
P	O
<	O
0.001	O
)	O
and	O
non	O
-	O
irradiated	O
patients	O
(	O
2	O
=	O
61.257	O
,	O
P	O
<	O
0.001	O
)	O
.	O

The	O
right	O
side	O
of	O
the	O
table	O
displays	O
HLA	O
class	O
I	O
expression	O
estimated	O
on	O
HCA2	O
and	O
HC10	O
expression	O
.	O

A	O
total	O
of	O
406	O
(	O
85	O
%	O
)	O
irradiated	O
and	O
445	O
(	O
84	O
%	O
)	O
non	O
-	O
irradiated	O
tumors	B
exhibited	O
expression	O
of	O
at	O
least	O
one	O
of	O
the	O
two	O
markers	O
showing	O
>	O
50	O
%	O
positive	O
staining	O
of	O
all	O
tumor	B
cells	O
.	O

A	O
total	O
of	O
70	O
(	O
15	O
%	O
)	O
irradiated	O
and	O
88	O
(	O
16	O
%	O
)	O
non	O
-	O
irradiated	O
tumors	B
showed	O
reduced	O
numbers	O
(	O
50	O
%	O
)	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	B
cells	O
.	O

The	O
number	O
of	O
patients	O
in	O
the	O
group	O
of	O
the	O
HLA	O
class	O
I	O
high	O
expression	O
group	O
and	O
the	O
HLA	O
class	O
I	O
low	O
expression	O
group	O
was	O
equally	O
distributed	O
between	O
irradiated	O
and	O
non	O
-	O
irradiated	O
tumors	B
(	O
2	O
=	O
0.519	O
,	O
P	O
=	O
0.471	O
)	O
HLA	B
class	I
I	I
negative	I
cells	O
and	O
microsatellite	O
instability	O
It	O
has	O
been	O
described	O
that	O
a	O
majority	O
of	O
MSI	B
colorectal	O
tumors	B
do	O
not	O
express	O
HLA	O
class	O
I	O
,	O
while	O
only	O
a	O
minority	O
of	O
MSS	B
tumors	B
do	O
not	O
express	O
HLA	O
class	O
I	O
[	O
8	O
,	O
16	O
]	O
.	O

Therefore	O
,	O
HLA	B
class	I
I	I
negative	I
rectal	O
tumors	B
are	O
the	O
most	O
at	O
risk	O
to	O
be	O
MSI	B
tumors	B
.	O

To	O
evaluate	O
the	O
numbers	O
of	O
sporadic	O
MSI	B
tumors	B
in	O
our	O
study	O
,	O
HCA2	B
or	I
HC10	I
negative	I
tumors	B
were	O
analyzed	O
for	O
the	O
expression	O
of	O
PMS2	O
and	O
MLH1	O
.	O

PMS2	O
and	O
MLH1	O
are	O
mismatch	O
repairs	O
proteins	O
that	O
are	O
most	O
frequently	O
absent	O
in	O
MSI	B
sporadic	O
tumors	B
[	O
6	O
]	O
.	O

Of	O
the	O
HLA	B
class	I
I	I
negative	I
tumors	B
only	O
1	O
out	O
of	O
11	O
tumors	B
did	O
not	O
express	O
PMS2	O
and	O
MLH1	O
.	O

In	O
the	O
tumor	B
group	O
negative	O
for	O
only	O
1	O
of	O
the	O
2	O
HLA	O
class	O
I	O
markers	O
,	O
2	O
of	O
81	O
tumors	B
displayed	O
no	O
PMS2	O
and	O
MLH1	O
staining	O
.	O

These	O
results	O
indicate	O
that	O
HLA	O
class	O
I	O
down	O
-	O
regulation	O
is	O
not	O
associated	O
with	O
MSI	O
in	O
rectal	B
cancer	I
and	O
are	O
in	O
accordance	O
with	O
the	O
previous	O
findings	O
that	O
only	O
a	O
very	O
small	O
minority	O
of	O
rectal	O
tumors	B
are	O
MSI	B
[	O
4	O
,	O
25	O
]	O
.	O

HLA	O
class	O
I	O
expression	O
and	O
clinicopathological	O
parameters	O
The	O
relationship	O
between	O
HLA	O
class	O
I	O
expression	O
and	O
patient	O
/	O
tumor	B
characteristics	O
was	O
assessed	O
(	O
Table	O
3	O
)	O
.	O

The	O
HLA	O
class	O
I	O
expression	O
levels	O
were	O
distributed	O
equally	O
in	O
non	O
-	O
irradiated	O
and	O
irradiated	O
patients	O
with	O
regard	O
to	O
most	O
clinical	O
and	O
pathological	O
parameters	O
.	O

Three	O
significant	O
differences	O
were	O
observed	O
.	O

For	O
the	O
non	O
-	O
irradiated	O
patients	O
,	O
significantly	O
more	O
men	O
appeared	O
in	O
the	O
HLA	O
class	O
I	O
low	O
-	O
expression	O
group	O
(	O
P	O
=	O
0.03	O
)	O
.	O

The	O
group	O
of	O
irradiated	O
tumors	B
with	O
HLA	O
class	O
I	O
low	O
expression	O
contained	O
significantly	O
more	O
stage	O
III	O
and	O
IV	O
tumors	B
(	O
P	O
=	O
0.01	O
)	O
and	O
also	O
more	O
patients	O
with	O
a	O
tumor	O
-	O
positive	O
circumferential	O
resection	O
margin	O
(	O
P	O
=	O
0.02	O
)	O
when	O
compared	O
with	O
tumors	B
with	O
high	O
HLA	O
class	O
I	O
expression	O
.	O

Table	O
3Clinicopathological	O
characteristics	O
of	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
with	O
high	O
or	O
low	O
numbers	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	B
cells	O
Non	O
-	O
irradiated	O
patientsIrradiated	O
patientsHigh	O
N	O
=	O
445Low	O
N	O
=	O
87P	O
valueHigh	O
N	O
=	O
406Low	O
N	O
=	O
70P	O
valueGender	O
Male	O
(	O
%	O
)	O
63750.0365660.90Age	O
Median	O
years65680.3265650.99TNM	O
stage	O
(	O
%	O
)	O
I31240.5233240.01	O
II27303021	O
III36383240	O
IV58514Circumferential	O
margin	O
Negative	O
(	O
%	O
)	O
83770.2886740.02Distant	O
from	O
anal	O
verge	O
(	O
%	O
)	O
10	O
cm28330.1727320.30	O
510	O
cm41314636	O
<	O
5	O
cm31362732Operation	O
type	O
(	O
%	O
)	O
Low	O
anterior	O
resection66610.7765660.89	O
Abdomino	O
-	O
perineal	O
resection29332930	O
Hartmann5664Number	O
(	O
N	O
)	O
of	O
patients	O
with	O
expression	O
of	O
total	O
HLA	O
class	O
I	O
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
high	O
)	O
and	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
low	O
)	O

*	O
Statistical	O
significant	O
P	O
values	O
are	O
in	O
bold	O

Clinicopathological	O
characteristics	O
of	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
with	O
high	O
or	O
low	O
numbers	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	B
cells	O
Number	O
(	O
N	O
)	O
of	O
patients	O
with	O
expression	O
of	O
total	O
HLA	O
class	O
I	O
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
high	O
)	O
and	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
low	O
)	O
*	O
Statistical	O
significant	O
P	O
values	O
are	O
in	O
bold	O
Expression	O
of	O
HLA	O
class	O
I	O
and	O
clinical	O
prognosis	O
Because	O
radiotherapy	O
might	O
influence	O
local	O
tumor	B
recurrences	O
[	O
15	O
]	O
,	O
irradiated	O
and	O
non	O
-	O
irradiated	O
tumors	B
were	O
analyzed	O
separately	O
in	O
order	O
to	O
evaluate	O
the	O
impact	O
of	O
HLA	O
class	O
I	O
expression	O
on	O
tumor	B
recurrence	O
and	O
patient	O
survival	O
.	O

The	O
HLA	O
class	O
I	O
expression	O
was	O
not	O
related	O
with	O
distant	O
or	O
local	O
recurrence	O
rates	O
.	O

The	O
patients	O
with	O
low	O
expression	O
of	O
HLA	O
class	O
I	O
had	O
a	O
worse	O
overall	O
survival	O
and	O
disease	O
-	O
free	O
survival	O
when	O
compared	O
to	O
patients	O
with	O
HLA	O
class	O
I	O
high	O
expression	O
,	O
irrespective	O
of	O
treatment	O
(	O
Fig.	O
2	O
;	O
overall	O
survival	O
:	O
P	O
=	O
0.008	O
and	O
P	O
=	O
0.01	O
;	O
disease	B
free	O
survival	O
:	O
P	O
=	O
0.01	O
,	O
P	O
=	O
0.006	O
in	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
,	O
respectively	O
)	O
.	O

Irradiated	O
patients	O
with	O
low	O
HLA	O
class	O
I	O
expression	O
also	O
had	O
a	O
worse	O
cancer	B
-	O
specific	O
survival	O
(	O
P	O
=	O
0.003	O
)	O
.	O

For	O
non	O
-	O
irradiated	O
patients	O
,	O
HLA	O
class	O
I	O
expression	O
had	O
no	O
significant	O
effect	O
on	O
cancer	B
-	O
specific	O
survival	O
(	O
Fig.	O
2	O
)	O
.	O

All	O
results	O
of	O
univariate	O
analysis	O
are	O
shown	O
in	O
Table	O
4	O
.	O

Univariate	O
analysis	O
showed	O
a	O
better	O
outcome	O
for	O
overall	O
survival	O
and	O
disease	B
-	O
free	O
survival	O
in	O
patients	O
with	O
high	O
HLA	O
class	O
I	O
expression	O
.	O

Fig.	O
2Examples	O
of	O
Kaplan	O
	O
Meier	O
curves	O
showing	O
overall	O
survival	O
and	O
cancer	B
specific	O
survival	O
for	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
(	O
a	O
	O
d	O
)	O
.	O

Kaplan	O
	O
Meier	O
curves	O
for	O
overall	O
survival	O
(	O
a	O
,	O
b	O
)	O
and	O
cancer	B
specific	O
survival	O
(	O
c	O
,	O
d	O
)	O
;	O
curves	O
show	O
prognosis	O
for	O
non	O
-	O
irradiated	O
(	O
a	O
,	O
c	O
)	O
and	O
irradiated	O
patients	O
(	O
b	O
,	O
d	O
)	O
for	O
HLA	O
class	O
I	O
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
low	O
)	O
.	O

P	O
value	O
is	O
based	O
on	O
univariate	O
log	O
rank	O
analysesTable	O
4Both	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
with	O
high	O
expression	O
of	O
HLA	O
class	O
I	O
have	O
a	O
better	O
overall	O
,	O
and	O
disease	B
free	O
survivalNon	O
-	O
irradiated	O
patientsIrradiated	O
patientsHigh	O
(	O
%	O
)	O
Low	O
(	O
%	O
)	O
P	O
valueHigh	O
(	O
%	O
)	O
Low	O
(	O
%	O
)	O
P	O
valueOverall	O
survival65.558.50.01267.551.30.008Disease	O
free	O
survival62.253.50.01562.248.30.006Cancer	O
specific	O
survival74.371.40.4180.161.80.003Local	O
recurrence8.913.70.224.73.20.72Distant	O
recurrence26.728.70.8824.729.30.34Survival	O
and	O
recurrence	O
rates	O
indicated	O
in	O
percentages	O
after	O
5-years	O
of	O
follow	O
-	O
up	O
for	O
non	O
-	O
irradiated	O
and	O
irradiated	O
patients	O
for	O
HLA	O
class	O
I	O
expression	O
in	O
more	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
high	O
)	O
versus	O
expression	O
in	O
less	O
than	O
50	O
%	O
of	O
the	O
tumor	B
cells	O
(	O
low	O
)	O
.	O

P	O
value	O
is	O
based	O
on	O
univariate	O
log	O
rank	O
analyses	O
for	O
overall	O
survival	O
,	O
disease	B
free	O
survival	O
,	O
cancer	B
specific	O
survival	O
,	O
local	O
recurrence	O
and	O
distant	O
recurrence	O
*	O
Statistical	O
significant	O
P	O
values	O
are	O
in	O
bold	O

Discussion	O
We	O
showed	O
that	O
rectal	B
cancer	I
patients	O
from	O
the	O
HLA	O
class	O
I	O
low	O
expression	O
group	O
had	O
an	O
independent	O
worse	O
overall	O
and	O
disease	B
-	O
free	O
survival	O
when	O
compared	O
to	O
patients	O
from	O
the	O
HLA	O
class	O
I	O
high	O
-	O
expression	O
group	O
.	O

These	O
data	O
imply	O
that	O
the	O
expression	O
of	O
HLA	O
class	O
I	O
in	O
tumor	B
cells	O
predicts	O
survival	O
for	O
rectal	B
cancer	I
patients	O
.	O

Although	O
significant	O
better	O
cancer	B
-	O
specific	O
survival	O
for	O
irradiated	O
patients	O
with	O
high	O
HLA	O
class	O
I	O
was	O
found	O
in	O
univariate	O
analysis	O
,	O
the	O
predictive	O
value	O
was	O
lost	O
in	O
multivariate	O
analysis	O
.	O

This	O
observation	O
can	O
be	O
explained	O
by	O
the	O
fact	O
that	O
the	O
group	O
with	O
low	B
HLA	I
class	I
I	I
significantly	O
included	O
more	O
stage	O
III	O
/	O
IV	O
and	O
more	O
patients	O
with	O
a	O
positive	O
circumferential	O
margin	O
as	O
compared	O
to	O
the	O
group	O
of	O
patients	O
with	O
high	O
expression	O
of	O
HLA	O
class	O
I.	O
Also	O
no	O
predictive	O
value	O
of	O
HLA	O
class	O
I	O
expression	O
was	O
found	O
with	O
regard	O
to	O
recurrence	O
-	O
free	O
survival	O
of	O
these	O
patients	O
.	O

Therefore	O
,	O
we	O
have	O
no	O
indications	O
that	O
support	O
the	O
notion	O
that	O
better	O
survival	O
of	O
high	O
HLA	O
class	O
I	O
expression	O
is	O
due	O
to	O
the	O
better	O
antigen	O
presenting	O
function	O
of	O
these	O
tumor	B
cells	O
,	O
as	O
has	O
been	O
suggested	O
[	O
18	O
,	O
35	O
]	O
.	O

In	O
our	O
study	O
,	O
no	O
difference	O
was	O
found	O
between	O
irradiated	O
and	O
non	O
-	O
irradiated	O
patients	O
for	O
HLA	O
class	O
I	O
expression	O
in	O
tumor	B
cells	O
.	O

It	O
has	O
been	O
described	O
that	O
	O
-	O
irradiation	O
induces	O
enhanced	O
peptide	O
production	O
and	O
surface	O
expression	O
of	O
MHC	B
class	I
I	I
in	O
a	O
colorectal	O
mouse	O
tumor	B
cell	O
line	O
[	O
26	O
]	O
.	O

The	O
fact	O
that	O
we	O
could	O
not	O
find	O
more	O
HLA	O
class	O
I	O
expression	O
in	O
irradiated	O
tumors	B
than	O
in	O
non	O
-	O
irradiated	O
tumors	B
indicates	O
that	O
radiotherapy	O
does	O
not	O
induce	O
HLA	O
class	O
I	O
expression	O
in	O
vivo	O
.	O

Immunohistochemistry	O
,	O
however	O
,	O
is	O
less	O
suitable	O
to	O
measure	O
subtle	O
expression	O
changes	O
.	O

Therefore	O
,	O
additional	O
research	O
is	O
required	O
to	O
determine	O
the	O
impact	O
of	O
radiotherapy	O
on	O
expression	O
levels	O
of	O
HLA	O
class	O
I	O
in	O
human	O
tumors	B
.	O

In	O
our	O
study	O
,	O
more	O
tumors	B
showed	O
HLA	O
class	O
I	O
down	O
-	O
regulation	O
after	O
immunohistochemical	O
staining	O
using	O
HCA2	O
than	O
using	O
HC10	O
.	O

This	O
difference	O
might	O
be	O
due	O
to	O
differences	O
in	O
reactivity	O
spectrum	O
of	O
both	O
antibodies	O
(	O
see	O
Materials	O
and	O
methods	O
)	O
or	O
to	O
the	O
fact	O
that	O
HLA	O
alleles	O
are	O
differently	O
affected	O
in	O
colorectal	B
cancer	I
.	O

If	O
the	O
latter	O
is	O
the	O
case	O
,	O
our	O
results	O
suggest	O
that	O
HLA	O
A	O
alleles	O
preferentially	O
show	O
down	O
-	O
regulation	O
in	O
rectal	B
cancer	I
.	O

Previous	O
reports	O
evaluated	O
HLA	O
class	O
I	O
expression	O
in	O
mixed	O
patient	O
populations	O
of	O
colon	O
and	O
rectal	B
cancer	I
patients	O
[	O
18	O
,	O
35	O
]	O
.	O

Watson	O
et	O
al.	O
also	O
found	O
in	O
a	O
large	O
group	O
of	O
colorectal	B
cancer	I
patients	O
that	O
patients	O
with	O
low	O
expression	O
of	O
HLA	O
class	O
I	O
had	O
a	O
poor	O
prognosis	O
[	O
35	O
]	O
.	O

However	O
,	O
in	O
contrast	O
to	O
our	O
results	O
,	O
both	O
studies	O
described	O
a	O
substantial	O
population	O
of	O
patients	O
with	O
tumors	B
showing	O
absence	O
of	O
HLA	O
class	O
I.	O
In	O
addition	O
,	O
they	O
described	O
that	O
absence	O
of	O
HLA	O
class	O
I	O
was	O
associated	O
with	O
better	O
prognosis	O
as	O
compared	O
to	O
tumors	B
expressing	O
reduced	O
numbers	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	O
cells	O
.	O

A	O
relatively	O
low	O
number	O
(	O
1.1	O
%	O
)	O
of	O
HLA	B
class	I
I	I
negative	I
tumors	B
was	O
observed	O
in	O
our	O
cohort	O
of	O
rectal	B
cancer	I
patients	O
only	O
.	O

These	O
patients	O
showed	O
no	O
survival	O
advantage	O
when	O
compared	O
to	O
patients	O
with	O
reduced	O
numbers	O
of	O
HLA	O
class	O
I	O
positive	O
tumor	B
cells	O
.	O

There	O
are	O
several	O
explanations	O
for	O
the	O
discrepancy	O
in	O
the	O
number	O
of	O
HLA	B
class	I
I	I
negative	I
tumors	B
between	O
the	O
study	O
of	O
Watson	O
et	O
al.	O
and	O
ours	O
,	O
like	O
different	O
definition	O
of	O
HLA	O
class	O
I	O
expression	O
,	O
differences	O
in	O
staining	O
techniques	O
,	O
different	O
patient	O
cohort	O
and	O
number	O
of	O
MSI	B
tumors	B
.	O

Both	O
human	O
CRCs	B
and	O
mouse	O
colon	O
tumors	B
reactivate	O
an	O
embryonic	O
gene	O
signature	O
.	O

When	O
human	O
and	O
murine	O
tumors	B
are	O
compared	O
,	O
they	O
both	O
broadly	O
re	O
-	O
express	O
an	O
embryonic	O
gene	O
expression	O
pattern	O
.	O

Gene	O
expression	O
profiles	O
from	O
the	O
mouse	O
tumor	B
models	O
and	O
human	O
CRC	B
samples	O
were	O
combined	O
into	O
a	O
single	O
non	O
-	O
redundant	O
gene	O
ortholog	O
genome	O
table	O
structure	O
and	O
subjected	O
to	O
comparative	O
profile	O
analysis	O
.	O

Informative	O
probe	O
-	O
sets	O
from	O
human	O
and	O
mouse	O
platforms	O
were	O
selected	O
,	O
mapped	O
to	O
corresponding	O
ortholog	O
genes	O
,	O
and	O
used	O
to	O
populate	O
a	O
table	O
in	O
which	O
normalized	O
expression	O
for	O
each	O
gene	O
is	O
relative	O
to	O
normal	B
adult	O
colon	O
.	O

(	O
a	O
)	O
Heatmap	O
plot	O
for	O
all	O
cross	O
-	O
species	O
gene	O
orthologs	O
both	O
present	O
and	O
successfully	O
measured	O
on	O
both	O
the	O
Affymetrix	O
Hg	O
-	O
U133	O
and	O
Vanderbilt	O
Mouse	O
NIA	O
20	O
K	O
microarrays	O
(	O
n	O
=	O
8,621	O
features	O
)	O
.	O

This	O
representation	O
suggests	O
that	O
a	O
large	O
number	O
of	O
human	O
CRC	B
signatures	O
exhibit	O
similar	O
behaviors	O
in	O
the	O
mouse	O
tumors	B
and	O
during	O
embryonic	O
mouse	O
colon	O
development	O
(	O
sidebar	O
:	O
1,080	O
(	O
red	O
)	O
and	O
431	O
(	O
green	O
)	O
gene	O
lists	O
from	O
(	O
b	O
)	O
)	O
.	O

(	O
b	O
)	O
Based	O
on	O
results	O
in	O
(	O
a	O
)	O
,	O
four	O
separate	O
gene	O
lists	O
were	O
generated	O
with	O
criteria	O
of	O
over-	O
or	O
under	O
-	O
expression	O
in	O
development	O
or	O
over	O
-	O
expression	O
or	O
under	O
-	O
expression	O
in	O
human	O
CRCs	B
(	O
2,718	O
,	O
2,365	O
,	O
2,212	O
,	O
and	O
737	O
,	O
respectively	O
,	O
with	O
the	O
overlaps	O
shown	O
as	O
a	O
sidebar	O
in	O
(	O
a	O
)	O
;	O
red	O
,	O
1,080	O
transcripts	O
,	O
and	O
green	O
,	O
431	O
transcripts	O
)	O
.	O

Genes	O
over	O
-	O
expressed	O
and	O
under	O
-	O
expressed	O
in	O
embryonic	O
mouse	O
colon	O
and	O
human	O
CRCs	B
were	O
found	O
to	O
be	O
over	O
-	O
represented	O
as	O
determined	O
by	O
Fisher	O
's	O
exact	O
test	O
analysis	O
(	O
*	O
p	O
<	O
7	O
	O
10	O
-	O
88	O
,	O
*	O

*	O
p	O
<	O
1	O
	O
10	O
-	O
76	O
,	O

*	O

*	O
*	O
p	O
<	O
5	O
	O
10	O
-	O
4	O
,	O

*	O

*	O

*	O

*	O
p	O
<	O
1	O
	O
10	O
-	O
76	O
)	O
.	O

(	O
c	O
)	O
Heatmap	O
plot	O
of	O
all	O
genes	O
co	O
-	O
regulated	O
in	O
human	O
CRCs	B
and	O
during	O
early	O
(	O
ED	O
)	O
and	O
late	O
(	O
LD	O
)	O
mouse	O
embryonic	O
colon	O
development	O
(	O
n	O
=	O
2,216	O
features	O
)	O
.	O

Six	O
predominant	O
clusters	O
(	O
C18-C23	O
)	O
characterize	O
the	O
transcriptional	O
relationship	O
between	O
human	O
CRC	B
and	O
mouse	O
colon	O
tumor	B
models	O
and	O
embryonic	O
development	O
.	O

Two	O
clusters	O
(	O
C20	O
and	O
21	O
)	O
primarily	O
distinguish	O
human	O
CRCs	B
from	O
murine	O
tumors	B
(	O
A	O
,	O
M	O
,	O
S	O
and	O
T	O
)	O
.	O

For	O
example	O
,	O
CRC	B
up	O
-	O
regulated	O
transcripts	O
that	O
are	O
either	O
developmentally	O
up-	O
or	O
down	O
-	O
regulated	O
are	O
represented	O
by	O
cluster	O
C22	O
(	O
n	O
=	O
860	O
features	O
)	O
and	O
clusters	O
C21	O
/	O
C23	O
(	O
n	O
=	O
142	O
features	O
)	O
,	O
respectively	O
.	O

Conversely	O
,	O
CRC	B
down	O
-	O
regulated	O
transcripts	O
that	O
are	O
either	O
down-	O
or	O
up	O
-	O
regulated	O
during	O
development	O
are	O
shown	O
in	O
clusters	O
C18	O
/	O
C19	O
(	O
n	O
=	O
258	O
features	O
)	O
and	O
cluster	O
C20	O
(	O
n	O
=	O
42	O
features	O
)	O
,	O
respectively	O
.	O

Interestingly	O
,	O
while	O
approximately	O
80	O
%	O
and	O
approximately	O
60	O
%	O
of	O
genes	O
up-	O
and	O
down	O
-	O
regulated	O
in	O
both	O
human	O
CRCs	B
and	O
mouse	O
development	O
were	O
also	O
up-	O
and	O
down	O
-	O
regulated	O
in	O
tumors	B
from	O
the	O
various	O
mouse	O
models	O
,	O
several	O
clusters	O
provide	O
very	O
interesting	O
exceptions	O
:	O
cluster	O
C20	O
comprises	O
genes	O
down	O
-	O
regulated	O
in	O
human	O
CRCs	B
that	O
are	O
routinely	O
over	O
-	O
expressed	O
in	O
mouse	O
tumors	B
and	O
development	O
;	O
cluster	O
C21	O
comprises	O
genes	O
robustly	O
expressed	O
in	O
human	O
CRC	B
that	O
are	O
rarely	O
expressed	O
in	O
embryonic	O
colon	O
or	O
murine	O
tumors	B
.	O

Sample	O
groups	O
:	O
ED	O
,	O
early	O
development	O
(	O
E13.5-E15.5	O
)	O
;	O
LD	O
,	O
late	O
development	O
(	O
E16.5-E18.5	O
)	O
;	O
A	O
,	O
AOM	O
-	O
induced	O
;	O
M	O
,	O
ApcMin	O
/	O
+	O
;	O
T	O
,	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
;	O
S	O
,	O
Smad3-	O
/	O
-	O
.	O

Tissue	O
groups	O
:	O
AC	O
,	O
adult	O
colon	O
;	O
CRC	B
,	O
human	O
CRC	B
.	O

Staging	O
:	O
nAC	O
,	O
normal	B
colon	O
.	O

Detailed	O
cluster	O
analysis	O
:	O
differential	O
and	O
statistically	O
significant	O
biological	O
functions	O
in	O
clusters	O
C18-C23	O
A	O
,	O
AOM	O
-	O
induced	O
;	O
M	O
,	O
ApcMin	O
/	O
+	O
;	O
PS	O
,	O
ProbeSets	O
;	O
S	O
,	O
Smad3-	O
/	O
-	O
;	O
T	O
,	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
.	O

The	O
up	O
-	O
regulated	O
signature	O
in	O
tumors	B
from	O
ApcMin	O
/	O
+	O
(	O
M	O
)	O
and	O
AOM	O
(	O
A	O
)	O
models	O
(	O
cluster	O
C6	O
,	O
Figure	O
2	O
)	O
is	O
enriched	O
with	O
genes	O
associated	O
with	O
the	O
activation	O
of	O
the	O
canonical	O
WNT	O
signaling	O
pathway	O
,	O
as	O
determined	O
by	O
nuclear	B
	I
-	I
catenin	I
positivity	I
.	O

(	O
a	O
)	O
Schematic	O
diagram	O
of	O
the	O
canonical	O
WNT	O
signaling	O
pathway	O
showing	O
elements	O
present	O
in	O
cluster	O
C6	O
(	O
gene	O
symbols	O
with	O
gray	O
background	O
)	O
.	O

Key	O
elements	O
of	O
this	O
pathway	O
(	O
Ctnnb1	O
,	O
Lef1	O
,	O
Tcf	O
and	O
Myc	O
)	O
are	O
outlined	O
in	O
blue	O
.	O

(	O
b	O
)	O
Relative	O
gene	O
expression	O
for	O
MYC	O
and	O
SOX4	O
is	O
plotted	O
for	O
individual	O
murine	O
and	O
human	O
tumors	B
.	O

The	O
relative	O
expression	O
level	O
of	O
MYC	O
and	O
SOX4	O
is	O
normalized	O
to	O
adult	O
colon	O
.	O

Note	O
that	O
whereas	O
Sox4	O
,	O
a	O
canonical	O
WNT	O
target	O
gene	O
,	O
is	O
expressed	O
at	O
high	O
levels	O
in	O
all	O
human	O
CRCs	B
,	O
A	O
/	O
M	O
tumors	B
and	O
during	O
embryonic	O
mouse	O
colon	O
development	O
,	O
it	O
is	O
not	O
expressed	O
in	O
Smad3-	O
/	O
-	O
(	O
S	O
)	O
and	O
Tgfb1-	O
/	O
-	O
;	O
Rag2-	O
/	O
-	O
(	O
T	O
)	O
tumors	B
(	O
black	O
)	O
.	O

In	O
contrast	O
,	O
MYC	O
is	O
over	O
-	O
expressed	O
in	O
all	O
human	O
and	O
murine	O
tumors	B
and	O
during	O
colonic	O
embryonic	O
development	O
(	O
red	O
)	O
,	O
irrespective	O
of	O
the	O
activation	O
of	O
canonical	O
WNT	O
signaling	O
,	O
as	O
determined	O
by	O
nuclear	O
	O
-	O
catenin	O
positivity	O
(	O
Figure	O
2	O
)	O
.	O

Tissue	O
groups	O
:	O
as	O
above	O
and	O
:	O
nAC	O
-	O
m	O
,	O
normal	B
adult	O
mouse	O
colon	O
;	O
nAC	O
-	O
h	O
,	O
normal	B
adult	O
human	O
colon	O
;	O
Dev	O
,	O
developing	O
mouse	O
colon	O
.	O

Materials	O
and	O
methods	O
Individuals	O
and	O
study	O
samples	O
The	O
research	O
was	O
completed	O
in	O
compliance	O
with	O
the	O
Helsinki	O
Declaration	O
.	O

The	O
Ethics	O
of	O
Human	O
Research	O
Committee	O
of	O
Peter	O
MacCallum	O
Cancer	O
Centre	O
approved	O
the	O
study	O
(	O
approval	O
number	O
02	O
/	O
70	O
)	O
.	O

Individuals	O
used	O
in	O
the	O
study	O
were	O
enrolled	O
in	O
the	O
Kathleen	O
Cuningham	O
Consortium	O
for	O
Research	O
in	O
Familial	O
Breast	B
Cancer	I
(	O
kConFab	O
)	O
.	O

kConFab	O
identified	O
seven	O
breast	B
cancer	I
cases	O
(	O
KCF1	O
-	O
7	O
)	O
with	O
BRCA1-like	O
features	O
for	O
analysis	O
.	O

kConFab	O
provided	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
leukocytes	O
from	O
each	O
case	O
and	O
DNA	O
from	O
buccal	O
mucosa	O
of	O
patient	O
KCF3	O
.	O

Tumour	B
material	O
from	O
the	O
KCF1	O
,	O
KCF2	O
,	O
KCF3	O
,	O
KCF4	O
and	O
KCF6	O
cases	O
was	O
available	O
.	O

Four	O
unstained	O
,	O
formalin	O
-	O
fixed	O
,	O
paraffin	O
-	O
embedded	O
sections	O
from	O
each	O
tumour	B
were	O
provided	O
for	O
analysis	O
.	O

DNA	O
was	O
extracted	O
from	O
the	O
paraffin	O
sections	O
using	O
the	O
DNeasy	O
tissue	O
kit	O
(	O
Qiagen	O
,	O
Hilden	O
,	O
Germany	O
)	O
.	O

Normal	B
control	O
DNAs	O
were	O
provided	O
by	O
the	O
Peter	O
MacCallum	O
Cancer	O
Centre	O
tissue	O
bank	O
.	O

Methylation	O
analysis	O
CpGenome	O
Universal	O
Methylated	O
DNA	O
(	O
Chemicon	O
,	O
Millipore	O
,	O
Billerica	O
,	O
MA	O
,	O
USA	O
)	O
was	O
used	O
as	O
the	O
100	O
%	O
methylated	O
control	O
and	O
DNA	O
extracted	O
from	O
peripheral	O
blood	O
mononuclear	O
cells	O
of	O
normal	B
individuals	O
was	O
used	O
as	O
unmethylated	O
control	O
DNA	O
.	O

Bisulfite	O
modification	O
of	O
DNA	O
was	O
performed	O
with	O
the	O
MethylEasy	O
kit	O
(	O
Human	O
Genetic	O
Signatures	O
,	O
Sydney	O
,	O
Australia	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Methylation	O
standards	O
were	O
constructed	O
by	O
diluting	O
100	O
%	O
methylated	O
control	O
DNA	O
(	O
bisulfite	O
modified	O
)	O
in	O
a	O
pool	O
of	O
normal	B
DNA	O
(	O
bisulfite	O
modified	O
)	O
at	O
50	O
%	O
,	O
25	O
%	O
,	O
10	O
%	O
,	O
5	O
%	O
and	O
1	O
%	O
ratios	O
.	O

Methylation	O
of	O
the	O
BRCA1	O
promoter	O
was	O
assessed	O
using	O
real	O
-	O
time	O
methylation	O
specific	O
PCR	O
(	O
MethyLight	O
)	O
[	O
19	O
]	O
and	O
methylation	O
-	O
sensitive	O
high	O
resolution	O
melting	O
(	O
MS	O
-	O
HRM	O
)	O
[	O
20	O
]	O
.	O

All	O
samples	O
were	O
run	O
in	O
triplicate	O
for	O
each	O
assay	O
.	O

The	O
locations	O
of	O
the	O
MethyLight	O
and	O
MS	O
-	O
HRM	O
primers	O
and	O
probes	O
on	O
the	O
BRCA1	O
promoter	O
are	O
illustrated	O
in	O
Figure	O
1	O
.	O

The	O
MethyLight	O
assay	O
assessed	O
five	O
CpG	O
sites	O
and	O
the	O
MS	O
-	O
HRM	O
assay	O
assessed	O
four	O
sites	O
.	O

Careful	O
design	O
of	O
each	O
assay	O
was	O
required	O
to	O
avoid	O
amplification	O
from	O
the	O
BRCA1	O
pseudogene	O
.	O

The	O
HMBS	O
gene	O
was	O
used	O
as	O
a	O
control	O
for	O
the	O
BRCA1	O
MethyLight	O
assay	O
.	O

Primer	O
sequences	O
are	O
available	O
on	O
request	O
.	O

Map	O
of	O
the	O
BRCA1	O
promoter	O
region	O
studied	O
by	O
the	O
MethyLight	O
and	O
MS	O
-	O
HRM	O
assays	O
.	O

The	O
numbering	O
of	O
the	O
promoter	O
is	O
according	O
to	O
that	O
used	O
by	O
Rice	O
et	O
al.	O
[	O
24	O
]	O
.	O

TSS	O
denotes	O
the	O
transcription	O
start	O
site	O
.	O

The	O
positions	O
of	O
the	O
primers	O
flanking	O
the	O
MethyLight	O
and	O
MS	O
-	O
HRM	O
amplicons	O
are	O
indicated	O
as	O
well	O
as	O
the	O
position	O
of	O
the	O
MethyLight	O
probe	O
.	O

Experiments	O
were	O
performed	O
on	O
the	O
RotorGene	O
	O
3000	O
(	O
MethyLight	O
assays	O
)	O
and	O
RotorGene	O
	O
6000	O
(	O
MS	O
-	O
HRM	O
assays	O
)	O
instruments	O
(	O
Corbett	O
Research	O
,	O
Sydney	O
,	O
Australia	O
)	O
.	O

The	O
MethyLight	O
data	O
was	O
analysed	O
by	O
obtaining	O
the	O
take	O
-	O
off	O
(	O
Ct	O
)	O
and	O
amplification	O
efficiency	O
values	O
for	O
each	O
sample	O
for	O
BRCA1	O
and	O
HMBS	O
from	O
the	O
comparative	O
quantitation	O
tab	O
of	O
the	O
RotorGene	O
	O
analysis	O
software	O
and	O
comparing	O
them	O
to	O
the	O
values	O
for	O
the	O
100	O
%	O
methylated	O
DNA	O
according	O
to	O
the	O
Pfaffl	O
method	O
of	O
relative	O
quantification	O
[	O
21	O
]	O
.	O

Ingenuity	O
Pathway	O
Analysis	O
(	O
Ingenuity	O
Systems	O
,	O
www.ingenuity.com	O
)	O
was	O
used	O
for	O
biological	O
interpretation	O
of	O
gene	O
lists	O
.	O

Analysis	O
of	O
the	O
transcripts	O
found	O
to	O
be	O
up-	O
and	O
down	O
-	O
regulated	O
in	O
irradiated	O
LCLs	O
as	O
identified	O
for	O
the	O
different	O
mutation	O
categories	O
identified	O
those	O
biochemical	O
networks	O
most	O
likely	O
to	O
be	O
affected	B
by	O
a	O
BRCA1	O
and	O
BRCA2	O
truncating	O
and	O
missense	O
mutation	O
,	O
relative	O
to	O
BRCAX	O
.	O

Those	O
pathways	O
with	O
multiple	O
hits	O
or	O
a	O
significance	O
score	O
20	O
were	O
then	O
compared	O
.	O

Methods	O
Patients	O
Between	O
1957	O
and	O
31	O
December	O
2004	O
the	O
Swedish	O
Polyposis	B
Registry	O
included	O
data	O
on	O
196	O
families	O
with	O
verified	O
FAP	B
(	O
defined	O
as	O
more	O
than	O
100	O
colorectal	O
adenomas	B
or	O
if	O
less	O
with	O
a	O
family	O
history	O
of	O
FAP	B
)	O
.	O

Sixty	O
-	O
one	O
of	O
these	O
families	O
are	O
now	O
extinct	O
but	O
135	O
families	O
with	O
at	O
least	O
one	O
living	O
disease	B
-	O
affected	O
member	O
remain	O
.	O

Presently	O
,	O
315	O
disease	B
-	O
affected	O
living	O
patients	O
are	O
included	O
in	O
the	O
registry	O
.	O

The	O
geographical	O
catchment	O
area	O
comprises	O
the	O
whole	O
of	O
Sweden	O
.	O

Details	O
of	O
how	O
patients	O
have	O
been	O
eligible	O
for	O
accession	O
into	O
the	O
registry	O
are	O
given	O
in	O
[	O
30	O
]	O
.	O

In	O
this	O
study	O
we	O
have	O
analyzed	O
96	O
families	O
included	O
in	O
the	O
registry	O
for	O
mutations	O
in	O
the	O
APC	O
gene	O
.	O

Twenty	O
-	O
four	O
of	O
the	O
remaining	O
39	O
families	O
have	O
been	O
analyzed	O
for	O
APC	O
gene	O
mutations	O
at	O
other	O
genetic	O
laboratories	O
and	O
15	O
families	O
remain	O
to	O
be	O
tested	O
.	O

We	O
have	O
previously	O
reported	O
six	O
of	O
these	O
patients	O
who	O
carried	O
bi	O
-	O
allelic	O
MUTYH	O
mutations	O
[	O
31	O
]	O
.	O

Probands	O
were	O
defined	O
as	O
those	O
diagnosed	O
on	O
the	O
basis	O
of	O
the	O
occurrence	O
of	O
symptoms	O
and	O
irrespective	O
of	O
other	O
cases	O
in	O
the	O
family	O
and	O
call	O
-	O
up	O
patients	O
,	O
as	O
those	O
identified	O
as	O
subjects	O
at	O
risk	O
on	O
the	O
basis	O
of	O
studies	O
of	O
pedigrees	O
and	O
found	O
to	O
have	O
FAP	B
.	O

De	O
novo	O
mutations	O
were	O
defined	O
in	O
those	O
individuals	O
where	O
none	O
of	O
the	O
parents	O
carried	O
the	O
mutation	O
or	O
where	O
the	O
parents	O
had	O
a	O
negative	O
colonoscopy	O
after	O
the	O
age	O
of	O
50	O
or	O
died	O
of	O
a	O
non	O
-	O
FAP	B
related	O
cause	O
after	O
the	O
age	O
of	O
75	O
.	O

All	O
patients	O
have	O
given	O
their	O
consent	O
and	O
the	O
local	O
ethics	O
committees	O
have	O
approved	O
the	O
study	O
.	O

The	O
clinical	O
features	O
of	O
index	O
patients	O
of	O
each	O
of	O
the	O
families	O
analyzed	O
are	O
listed	O
in	O
Additional	O
file	O
1	O
and	O
Table	O
1	O
.	O

Patients	O
without	O
any	O
detected	O
mutation	O
in	O
APC	O
or	O
MUTYH	O
Age	O
,	O
age	O
at	O
diagnosis	O
;	O
DL	B
,	O
duodenal	O
lesion	B
;	O
dom	O
,	O
dominant	O
;	O
FGP	B
,	O
fundic	O
gland	O
polyps	B
;	O
NA	O
,	O
no	O
available	O
data	O
;	O
NI	O
,	O
no	O
inheritance	O
;	O
Number	O
of	O
polyps	B
,	O
number	O
of	O
polyps	B
at	O
diagnosis	O
;	O
rec	O
,	O
recessive	O
Patient	O
C896	O
,	O
with	O
only	O
five	O
adenomas	B
,	O
was	O
included	O
because	O
of	O
a	O
family	B
history	I
of	I
FAP	I
.	O

Patient	O
C107	O
underwent	O
her	O
first	O
colonoscopy	O
due	O
to	O
intestinal	B
bleeding	I
at	O
age	O
47	O
.	O

At	O
diagnosis	O
,	O
1020	O
small	O
(	O
less	O
than	O
10	O
mm	O
)	O
polyps	B
were	O
found	O
in	O
most	O
colorectal	O
parts	O
.	O

Tubular	O
and	O
tubulovillous	O
adenomas	B
were	O
removed	O
yearly	O
.	O

At	O
age	O
50	O
,	O
carcinoma	B
(	O
Dukes	O
A	O
)	O
was	O
diagnosed	O
4	O
cm	O
from	O
valvula	O
Bauhini	O
in	O
conjunction	O
with	O
several	O
new	O
adenomas	B
.	O

At	O
that	O
time	O
the	O
patient	O
underwent	O
total	O
colectomy	O
with	O
ileorectal	O
anastomosis	O
(	O
IRA	O
)	O
.	O

DNA	O
,	O
RNA	O
and	O
cDNA	O
preparation	O
Genomic	O
DNA	O
was	O
isolated	O
from	O
samples	O
of	O
venous	O
blood	O
,	O
anti	O
-	O
coagulated	O
in	O
ethylenediaminetetraacetic	O
acid	O
(	O
EDTA	O
)	O
.	O

DNA	O
purification	O
was	O
performed	O
using	O
the	O
PuregeneR	O
DNA	O
Isolation	O
Kit	O
(	O
Gentra	O
Systems	O
,	O
Minneapolis	O
,	O
MN	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
recommendations	O
.	O

DNA	O
was	O
extracted	O
from	O
paraffin	O
-	O
embedded	O
tissue	O
as	O
described	O
previously	O
[	O
32	O
]	O
.	O

Histopaque	O
(	O
Sigma	O
,	O
St	O
Louis	O
,	O
MO	O
)	O
or	O
Lymphoprep	O
(	O
Axis	O
-	O
Shield	O
PoC	O
AS	O
,	O
Oslo	O
,	O
Norway	O
)	O
was	O
used	O
for	O
purification	O
of	O
the	O
lymphocytes	O
,	O
and	O
total	O
RNA	O
was	O
extracted	O
using	O
RNA	O
-	O
Stat	O
60	O
(	O
Tel	O
-	O
Test	O
,	O
Friendswood	O
,	O
TX	O
)	O
.	O

cDNA	O
was	O
synthesized	O
as	O
described	O
previously	O
[	O
33	O
]	O
.	O

The	O
phenotype	O
of	O
the	O
patient	O
(	O
C157	O
)	O
,	O
carrying	O
the	O
c.70C	O
>	O
T	O
mutation	O
,	O
is	O
in	O
agreement	O
with	O
the	O
suggested	O
genotype	O
-	O
phenotype	O
correlation	O
where	O
a	O
milder	O
form	O
of	O
polyposis	B
is	O
proposed	O
to	O
be	O
caused	O
by	O
mutations	O
in	O
the	O
5	O
'	O
end	O
of	O
the	O
gene	O
.	O

A	O
model	O
for	O
the	O
attenuated	O
phenotype	O
in	O
patients	O
carrying	O
mutations	O
in	O
the	O
first	O
four	O
exons	O
of	O
APC	O
have	O
been	O
suggested	O
by	O
Heppner	O
Goss	O
et	O
al	O
[	O
42	O
]	O
,	O
in	O
which	O
the	O
internal	O
ATG	O
at	O
codon	O
184	O
could	O
be	O
used	O
as	O
an	O
alternative	O
translation	O
initiation	O
codon	O
in	O
the	O
allele	O
carrying	O
a	O
truncating	O
mutation	O
upstream	O
of	O
this	O
site	O
(	O
Figure	O
1	O
)	O
.	O

Such	O
an	O
alternative	O
start	O
of	O
translation	O
would	O
supply	O
the	O
cell	O
with	O
an	O
APC	O
protein	O
of	O
almost	O
full	O
length	O
,	O
thus	O
explaining	O
the	O
attenuated	O
phenotype	O
.	O

Patient	O
C159	O
,	O
with	O
the	O
most	O
3	O
'	O
localized	O
mutation	O
was	O
a	O
case	O
of	O
attenuated	O
FAP	B
(	O
1001000	O
polyps	B
,	O
46	O
years	O
of	O
age	O
at	O
diagnosis	O
)	O
.	O

In	O
family	O
1	O
(	O
reduced	O
expression	O
of	O
APC	O
)	O
,	O
patient	O
C152	O
displayed	O
a	O
classical	O
FAP	B
phenotype	O
including	O
a	O
large	B
number	I
of	I
polyps	I
,	O
duodenal	O
adenomas	B
,	O
and	O
fundic	O
gland	O
polyps	B
(	O
Additional	O
file	O
1	O
)	O
.	O

The	O
APC-	B
and	I
MUTYH	I
-	I
mutation	I
negative	I
patients	O
all	O
display	O
an	O
attenuated	O
form	O
of	O
disease	B
with	O
a	O
low	O
number	O
of	O
polyps	B
,	O
comparably	O
high	O
age	O
at	O
diagnosis	O
,	O
and	O
a	O
low	O
frequency	O
of	O
extracolonic	O
manifestations	O
.	O

Whether	O
these	O
patients	O
really	O
are	O
affected	O
by	O
APC	O
-	O
associated	O
FAP	B
can	O
(	O
of	O
course	O
)	O
be	O
called	O
into	O
question	O
.	O

However	O
,	O
among	O
attenuated	O
cases	O
of	O
FAP	B
in	O
these	O
study	O
we	O
have	O
found	O
very	O
subtle	O
mutations	O
such	O
as	O
the	O
mosaic	O
case	O
as	O
well	O
as	O
the	O
c.70C	O
>	O
T	O
mutation	O
and	O
splice	O
-	O
site	O
mutations	O
.	O

Considering	O
these	O
facts	O
,	O
at	O
least	O
some	O
of	O
the	O
cases	O
could	O
be	O
caused	O
by	O
mutations	O
in	O
APC	O
resulting	O
in	O
only	O
partially	O
inactivation	O
of	O
the	O
gene	O
function	O
.	O

Since	O
the	O
main	O
purpose	O
of	O
this	O
study	O
was	O
to	O
achieve	O
as	O
high	O
mutation	O
-	O
detection	O
rate	O
as	O
possible	O
in	O
families	O
with	O
colorectal	B
polyposis	I
syndromes	I
,	O
using	O
a	O
range	O
of	O
different	O
molecular	O
genetic	O
techniques	O
,	O
we	O
have	O
not	O
yet	O
performed	O
any	O
further	O
analyses	O
of	O
the	O
relatively	O
few	O
mutation	O
negative	O
cases	O
to	O
determine	O
if	O
they	O
belong	O
to	O
non	B
-	I
polyposis	I
CRC	I
syndromes	I
.	O

Large	O
deletions	O
of	O
the	O
APC	O
gene	O
The	O
fraction	O
of	O
large	O
deletions	O
of	O
all	O
APC	O
mutations	O
identified	O
in	O
the	O
Swedish	O
patients	O
was	O
9	O
%	O
,	O
which	O
is	O
higher	O
than	O
the	O
5	O
%	O
of	O
large	O
deletions	O
reported	O
in	O
[	O
38	O
]	O
.	O

The	O
relatively	O
large	O
number	O
of	O
gross	O
deletions	O
identified	O
could	O
be	O
a	O
result	O
of	O
the	O
thorough	O
analysis	O
applied	O
for	O
every	O
patient	O
,	O
including	O
the	O
use	O
of	O
the	O
MLPA	O
technique	O
.	O

It	O
is	O
noteworthy	O
that	O
no	O
deletion	O
of	O
APC	O
exon	O
4	O
in	O
patient	O
3765	O
was	O
detected	O
using	O
MLPA	O
although	O
it	O
had	O
been	O
identified	O
and	O
confirmed	O
by	O
other	O
methods	O
.	O

A	O
still	O
untested	O
possibility	O
is	O
that	O
exon	O
4	O
has	O
been	O
translocated	O
to	O
another	O
chromosomal	O
locus	O
and	O
thus	O
generates	O
the	O
positive	O
MLPA	O
result	O
.	O

RESULTS	O
MSH6	O
Good	O
quality	O
sequence	O
was	O
obtained	O
for	O
all	O
10	O
exons	O
of	O
MSH6	O
in	O
220	O
participants	O
,	O
115	O
from	O
HNPCC	B
cohort	O
,	O
and	O
105	O
from	O
endometrial	O
cohort	O
.	O

Results	O
with	O
exact	O
binomial	O
confidence	O
limits	O
for	O
a	O
proportion	O
are	O
shown	O
in	O
table	O
I.	O
Given	O
that	O
the	O
pathogenicity	O
of	O
the	O
missense	O
mutations	O
identified	O
has	O
yet	O
to	O
be	O
determined	O
,	O
arguably	O
the	O
proportion	O
of	O
the	O
truncating	O
mutations	O
is	O
more	O
relevant	O
.	O

All	O
sequences	O
were	O
viewed	O
with	O
reference	O
to	O
a	O
control	O
sample	O
(	O
with	O
a	O
known	O
mutation	O
in	O
MLH1	O
or	O
MSH2	O
)	O
,	O
and	O
reference	O
sequences	O
(	O
,	O
)	O
.	O

All	O
variants	O
are	O
described	O
with	O
reference	O
to	O
den	O
Dunnen	O
et	O
al26	O
.	O

All	O
truncating	O
and	O
missense	O
variants	O
identified	O
are	O
shown	O
in	O
tables	O
II	O
and	O
III	O
(	O
example	O
figure	O
1	O
)	O
with	O
their	O
corresponding	O
cohort	O
and	O
family	O
classification	O
.	O

Participants	O
from	O
the	O
endometrial	O
cohort	O
with	O
a	O
variant	O
identified	O
were	O
also	O
classified	O
according	O
to	O
Amsterdam	O
I	O
,	O
II	O
,	O
'	O
HNPCC	B
like	O
'	O
,	O
or	O
,	O
a	O
family	O
history	O
that	O
was	O
not	O
in	O
keeping	O
with	O
HNPCC	B
.	O

All	O
missense	O
variants	O
were	O
subject	O
to	O
analysis	O
by	O
PolyPhen	O
(	O
)	O
,	O
a	O
tool	O
that	O
predicts	O
the	O
potential	O
impact	O
of	O
an	O
amino	O
acid	O
substitution	O
on	O
the	O
structure	O
and	O
function	O
of	O
a	O
human	O
protein	O
(	O
see	O
table	O
III	O
for	O
predictions	O
)	O
.	O

Further	O
population	O
,	O
family	O
and	O
functional	O
studies	O
were	O
not	O
carried	O
out	O
to	O
evaluate	O
the	O
missense	O
variants	O
but	O
further	O
work	O
is	O
planned	O
.	O

Sequencing	O
analysis	O
showing	O
a	O
truncating	O
mutation	O
c.755	O
C	O
>	O
G	O
(	O
p.	O

Ser252X	O
)	O
in	O
exon	O
4	O
of	O
MSH6	O
Truncating	O
mutations	O
identified	O
Missense	O
variants	O
identified	O
MLPA	O
All	O
samples	O
underwent	O
MLPA	O
analysis	O
.	O

Out	O
of	O
268	O
successful	O
MLPA	O
results	O
,	O
no	O
aberration	O
in	O
copy	O
number	O
was	O
identified	O
.	O

Methods	O
Cell	O
Culture	O
MCF7	O
,	O
MDA	O
-	O
MB-231	O
,	O
MDA	O
-	O
MB-468	O
,	O
T-47D	O
,	O
HT-29	O
,	O
Caco-2	O
,	O
Colo320	O
,	O
SW480	O
,	O
RKO	O
,	O
and	O
HCT116	O
cells	O
and	O
isogenic	O
DNA	O
methyltransferase	O
(	O
DNMT	O
)	O
1	O
/	O
3b	O
genetic	O
knockout	O
derivatives	O
were	O
maintained	O
in	O
culture	O
as	O
recommended	O
by	O
American	O
Type	O
Tissue	O
Culture	O
(	O
ATCC	O
)	O
.	O

All	O
HCC	O
series	O
lines	O
used	O
were	O
obtained	O
from	O
ATCC	O
.	O

For	O
drug	O
treatments	O
,	O
log	O
phase	O
cells	O
were	O
cultured	O
in	O
the	O
appropriate	O
media	O
(	O
Invitrogen	O
)	O
containing	O
10	O
%	O
FBS	O
and	O
1	O
	O
penicillin	O
/	O
streptomycin	O
with	O
5	O
M	O
5aza	O
-	O
deoxycytidine	O
(	O
DAC	O
)	O
(	O
Sigma	O
;	O
stock	O
solution	O
:	O
1	O
mM	O
in	O
PBS	O
)	O
for	O
96	O
h	O
,	O
replacing	O
media	O
and	O
DAC	O
every	O
24	O
h.	O
Cell	O
treatment	O
with	O
300	O
nM	O
Trichostatin	O
A	O
(	O
Sigma	O
;	O
stock	O
solution	O
:	O
1.5	O
mM	O
dissolved	O
in	O
ethanol	O
)	O
was	O
performed	O
for	O
18	O
h.	O
Control	O
cells	O
underwent	O
mock	O
treatment	O
in	O
parallel	O
with	O
addition	O
of	O
equal	O
volume	O
of	O
PBS	O
or	O
ethanol	O
without	O
drugs	O
.	O

Microarray	O
Analysis	O
Total	O
RNA	O
was	O
harvested	O
from	O
log	O
phase	O
cells	O
using	O
the	O
Qiagen	O
RNEasy	O
kit	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Sample	O
amplification	O
and	O
labeling	O
procedures	O
were	O
carried	O
out	O
using	O
the	O
Low	O
RNA	O
Input	O
Fluorescent	O
Linear	O
Amplification	O
kit	O
(	O
Agilent	O
Technologies	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Hybridization	O
was	O
carried	O
out	O
according	O
to	O
the	O
Agilent	O
microarray	O
protocol	O
.	O

Scanning	O
was	O
performed	O
with	O
the	O
Agilent	O
G2565BA	O
microarray	O
scanner	O
.	O

Data	O
Analysis	O
All	O
arrays	O
were	O
subject	O
to	O
quality	O
checks	O
recommended	O
by	O
the	O
manufacturer	O
.	O

All	O
calculations	O
were	O
performed	O
using	O
the	O
R	O
statistical	O
computing	O
platform	O
[	O
16	O
]	O
and	O
packages	O
from	O
Bioconductor	O
bioinformatics	O
software	O
project	O
[	O
17	O
]	O
.	O

The	O
log	O
ratio	O
of	O
red	O
signal	O
to	O
green	O
signal	O
was	O
calculated	O
after	O
background	O
-	O
subtraction	O
and	O
LoEss	O
normalization	O
as	O
implemented	O
in	O
the	O
limma	O
package	O
from	O
Bioconductor	O
[	O
18	O
]	O
.	O

Individual	O
arrays	O
were	O
scaled	O
to	O
have	O
the	O
same	O
interquartile	O
range	O
(	O
75th	O
percentile	O
to	O
25th	O
percentile	O
)	O
.	O

Patient	O
information	O
,	O
including	O
clinical	O
data	O
and	O
gene	O
expression	O
data	O
,	O
was	O
obtained	O
from	O
and	O
analyzed	O
using	O
Oncomine	O
(	O
http://www.oncomine.org	O
)	O
.	O

Our	O
analysis	O
included	O
microarray	O
databases	O
such	O
as	O
the	O
Netherlands	O
Cancer	O
Institute	O
breast	B
cancer	I
database	O
[	O
19	O
]	O
.	O

The	O
microarray	O
meta	O
-	O
analysis	O
algorithms	O
and	O
statistical	O
analysis	O
used	O
were	O
as	O
previously	O
described	O
[	O
20,21	O
]	O
.	O

p	O
-	O
Values	O
were	O
calculated	O
using	O
adjustment	O
for	O
multiple	O
testing	O
and	O
false	O
discovery	O
as	O
described	O
at	O
http://www.oncomine.org	O
[	O
21	O
]	O
.	O

Methylation	O
and	O
Gene	O
Expression	O
Analysis	O
RNA	O
was	O
isolated	O
with	O
TRIzol	O
Reagent	O
(	O
Invitrogen	O
)	O
according	O
to	O
the	O
manufacturer	O
's	O
instructions	O
.	O

For	O
reverse	O
transcription	O
-	O
PCR	O
(	O
RT	O
-	O
PCR	O
)	O
,	O
1	O
g	O
of	O
total	O
RNA	O
was	O
reverse	O
transcribed	O
by	O
using	O
Ready	O
-	O
To	O
-	O
Go	O
You	O
-	O
Prime	O
First	O
-	O
Strand	O
Beads	O
(	O
Amersham	O
Biosciences	O
)	O
with	O
addition	O
of	O
random	O
hexamers	O
(	O
0.2	O
g	O
per	O
reaction	O
)	O
.	O

Bisulfite	O
modification	O
of	O
genomic	O
DNA	O
was	O
carried	O
out	O
using	O
the	O
EZ	O
DNA	O
methylation	O
kit	O
(	O
Zymo	O
Research	O
)	O
.	O

Selection	O
of	O
primers	O
used	O
for	O
methylation	O
-	O
specific	O
PCR	O
(	O
MSP	O
)	O
and	O
determinants	O
for	O
CpG	O
island	O
localization	O
and	O
designation	O
was	O
accomplished	O
using	O
MSPPrimer	O
(	O
http://www.mspprimer.org	O
)	O
[	O
22	O
]	O
.	O

MSP	O
was	O
performed	O
as	O
previously	O
described	O
[	O
23	O
]	O
.	O

Primer	O
sequences	O
are	O
listed	O
in	O
Table	O
S3	O
.	O

Bisulfite	O
sequencing	O
and	O
RT	O
-	O
PCR	O
was	O
preformed	O
as	O
previously	O
described	O
[	O
24	O
]	O
.	O

Gene	O
expression	O
quantitation	O
was	O
performed	O
using	O
RT	O
-	O
PCR	O
and	O
the	O
1D	O
software	O
package	O
(	O
Kodak	O
)	O
.	O

For	O
Table	O
S1	O
,	O
decreased	O
expression	O
was	O
defined	O
as	O
expression	O
that	O
was	O
not	O
detectable	O
with	O
RT	O
-	O
PCR	O
or	O
decreased	O
by	O
two	O
-	O
thirds	O
compared	O
to	O
expression	O
levels	O
in	O
normal	B
tissue	O
measured	O
using	O
the	O
1D	O
software	O
to	O
quantitate	O
bands	O
.	O

Quantitative	O
PCR	O
was	O
performed	O
using	O
the	O
Invitrogen	O
SYBR	O
Green	O
qPCR	O
kit	O
according	O
the	O
manufacturer	O
's	O
instructions	O
.	O

Real	O
-	O
time	O
PCR	O
reactions	O
were	O
performed	O
using	O
the	O
Mastercycler	O
Realplex	O
machine	O
(	O
Eppendorf	O
)	O
.	O

Readings	O
were	O
normalized	O
using	O
GAPDH	O
.	O

Discussion	O
Overall	O
our	O
study	O
presents	O
an	O
extensive	O
search	O
for	O
the	O
presence	O
of	O
and	O
interactions	O
between	O
both	O
genetic	O
and	O
epigenetic	O
alterations	O
in	O
cancer	B
.	O

As	O
it	O
currently	O
stands	O
,	O
these	O
studies	O
do	O
have	O
several	O
limitations	O
.	O

First	O
,	O
our	O
data	O
do	O
not	O
address	O
the	O
biological	O
effects	O
of	O
the	O
individual	O
mutations	O
observed	O
in	O
the	O
CAN	O
genes	O
.	O

Second	O
,	O
the	O
data	O
draw	O
on	O
only	O
the	O
13,023	O
subset	O
of	O
CCDS	O
genes	O
that	O
were	O
previously	O
sequenced	O
,	O
and	O
additional	O
genes	O
have	O
now	O
been	O
sequenced	O
and	O
more	O
mutations	O
have	O
been	O
discovered	O
[	O
42	O
]	O
.	O

Despite	O
these	O
limitations	O
,	O
our	O
study	O
describes	O
a	O
valuable	O
approach	O
to	O
begin	O
to	O
understand	O
the	O
biological	O
significance	O
of	O
the	O
vast	O
amount	O
of	O
mutational	O
data	O
generated	O
by	O
cancer	B
resequencing	O
efforts	O
.	O

In	O
these	O
regards	O
,	O
our	O
findings	O
allow	O
several	O
important	O
conclusions	O
to	O
be	O
drawn	O
.	O

First	O
,	O
our	O
study	O
shows	O
that	O
large	O
-	O
scale	O
,	O
combined	O
genetic	O
and	O
epigenetic	O
analysis	O
is	O
feasible	O
and	O
useful	O
for	O
cancer	B
gene	O
discovery	O
.	O

Such	O
combined	O
analyses	O
can	O
markedly	O
enhance	O
links	O
made	O
between	O
gene	O
alterations	O
and	O
key	O
clinical	O
parameters	O
for	O
cancer	B
.	O

It	O
is	O
becoming	O
increasingly	O
clear	O
that	O
examination	O
and	O
interpretation	O
of	O
mutations	O
to	O
identify	O
cancer	B
genes	O
on	O
a	O
genome	O
-	O
wide	O
scale	O
can	O
be	O
significantly	O
complicated	O
by	O
passenger	O
mutations	O
[	O
43,44	O
]	O
.	O

Furthermore	O
,	O
as	O
we	O
mentioned	O
above	O
in	O
the	O
Results	O
,	O
it	O
is	O
very	O
unlikely	O
that	O
a	O
given	O
gene	O
that	O
in	O
breast	O
and/or	O
colon	B
cancer	I
has	O
evidence	O
for	O
mutations	O
,	O
promoter	O
hypermethylation	O
,	O
reduced	O
expression	O
,	O
and	O
is	O
localized	O
to	O
chromosome	O
regions	O
harboring	O
frequent	O
deletions	O
in	O
tumors	B
is	O
not	O
important	O
for	O
tumor	B
development	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
by	O
beginning	O
with	O
a	O
large	O
pool	O
of	O
genes	O
harboring	O
mostly	O
low	O
incidence	O
heterozygous	O
missense	O
mutations	O
and	O
then	O
characterizing	O
the	O
methylation	O
and	O
expression	O
status	O
of	O
these	O
genes	O
,	O
our	O
approach	O
allowed	O
us	O
to	O
identify	O
genes	O
that	O
possess	O
potentially	O
prognostic	O
value	O
.	O

Our	O
results	O
also	O
confirm	O
that	O
our	O
microarray	O
strategy	O
is	O
an	O
effective	O
approach	O
to	O
identify	O
genes	O
that	O
are	O
silenced	O
by	O
hypermethylation	O
in	O
colon	O
and	O
breast	B
cancer	I
.	O

Other	O
methods	O
have	O
been	O
developed	O
to	O
identify	O
hypermethylated	O
genes	O
in	O
cancer	B
,	O
including	O
restriction	O
landmark	O
genomic	O
scanning	O
,	O
promoter	O
CpG	O
island	O
microarrays	O
,	O
and	O
methylation	O
-	O
specific	O
digital	O
karyotyping	O
[	O
28,45	O
]	O
.	O

However	O
,	O
the	O
sensitivity	O
of	O
these	O
techniques	O
is	O
restricted	O
by	O
the	O
locations	O
of	O
methylation	O
-	O
sensitive	O
restriction	O
sites	O
in	O
the	O
genome	O
.	O

Several	O
of	O
the	O
common	O
target	O
genes	O
have	O
been	O
noted	O
to	O
undergo	O
methylation	O
-	O
associated	O
silencing	O
in	O
cancers	B
by	O
other	O
investigators	O
.	O

Lund	O
et	O
al.	O
noted	O
that	O
oncogenic	O
RAS	O
can	O
lead	O
to	O
the	O
hypermethylation	O
of	O
the	O
MMP2	O
gene	O
[	O
46	O
]	O
.	O

EVL	O
has	O
been	O
found	O
to	O
be	O
hypermethylated	O
in	O
colon	O
carcinoma	B
[	O
47	O
]	O
.	O

N	O
-	O
CAM	O
has	O
been	O
found	O
to	O
be	O
hypermethylated	O
in	O
lung	O
cancer	B
in	O
a	O
survey	O
of	O
methylated	O
genes	O
described	O
by	O
Shames	O
et	O
al.	O
[	O
48	O
]	O
.	O

The	O
presence	O
of	O
methylation	O
of	O
the	O
common	O
target	O
genes	O
in	O
other	O
tumor	B
types	O
suggests	O
that	O
these	O
genes	O
may	O
be	O
targets	O
of	O
inactivation	O
in	O
a	O
broader	O
range	O
of	O
cancers	B
,	O
a	O
hypothesis	O
that	O
warrants	O
future	O
investigation	O
.	O

In	O
particular	O
,	O
it	O
would	O
be	O
of	O
value	O
to	O
directly	O
compare	O
our	O
results	O
with	O
those	O
derived	O
by	O
other	O
strategies	O
for	O
analyzing	O
the	O
hypermethylome	O
from	O
the	O
same	O
as	O
well	O
as	O
from	O
other	O
types	O
of	O
malignancies	O
[	O
4851	O
]	O
.	O

Together	O
with	O
these	O
studies	O
,	O
our	O
data	O
strongly	O
suggest	O
that	O
a	O
compendium	O
of	O
epigenetic	O
changes	O
underlie	O
the	O
progression	O
of	O
human	O
cancers	B
.	O

Stabilizing	O
mutation	O
of	O
/beta	O
-	O
catenin	O
and	O
protein	O
accumulation	O
analyzed	O
in	O
a	O
large	O
series	O
of	O
parathyroid	O
tumors	B
of	O
Swedish	O
patients	O
Abstract	O
Background	O
Aberrant	O
accumulation	O
of	O
	O
-	O
catenin	O
plays	O
an	O
important	O
role	O
in	O
a	O
variety	O
of	O
human	O
neoplasms	B
.	O

We	O
recently	O
reported	O
accumulation	O
of	O
	O
-	O
catenin	O
in	O
parathyroid	O
adenomas	B
from	O
patients	O
with	O
primary	B
hyperparathyroidism	I
(	O
pHPT	B
)	O
.	O

In	O
CTNNB1	O
exon	O
3	O
,	O
we	O
detected	O
a	O
stabilizing	O
mutation	O
(	O
S37A	O
)	O
in	O
3	O
out	O
of	O
20	O
analyzed	O
adenomas	B
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
frequency	O
and	O
zygosity	O
of	O
mutations	O
in	O
CTNNB1	O
exon	O
3	O
,	O
and	O
	O
-	O
catenin	O
accumulation	O
in	O
a	O
large	O
series	O
of	O
parathyroid	O
adenomas	B
of	O
Swedish	O
patients	O
.	O

Results	O
The	O
mutation	O
S37A	O
(	O
TCT	O
>	O
GCT	O
)	O
was	O
detected	O
by	O
direct	O
DNA	O
sequencing	O
of	O
PCR	O
fragments	O
in	O
6	O
out	O
of	O
104	O
sporadic	O
parathyroid	O
adenomas	B
(	O
5.8	O
%	O
)	O
.	O

Taking	O
our	O
previous	O
study	O
into	O
account	O
,	O
a	O
total	O
of	O
9	O
out	O
of	O
124	O
(	O
7.3	O
%	O
)	O
adenomas	B
displayed	O
the	O
same	O
mutation	O
.	O

The	O
mutations	O
were	O
homozygous	O
by	O
DNA	O
sequencing	O
,	O
restriction	O
enzyme	O
cleavage	O
,	O
and	O
gene	O
copy	O
number	O
determination	O
using	O
the	O
GeneChip	O
500	O
K	O
Mapping	O
Array	O
Set	O
.	O

All	O
tumors	B
analyzed	O
by	O
immunohistochemistry	O
,	O
including	O
those	O
with	O
mutation	O
,	O
displayed	O
aberrant	O
	O
-	O
catenin	O
accumulation	O
.	O

Western	O
blotting	O
revealed	O
a	O
slightly	O
higher	O
expression	O
level	O
of	O
	O
-	O
catenin	O
and	O
nonphosphorylated	O
active	O
	O
-	O
catenin	O
in	O
tumors	B
with	O
mutation	O
compared	O
to	O
those	O
without	O
.	O

Presence	O
of	O
the	O
mutation	O
was	O
not	O
related	O
to	O
distinct	O
clinical	O
characteristics	O
.	O

Conclusion	O
Aberrant	O
accumulation	O
of	O
	O
-	O
catenin	O
is	O
very	O
common	O
in	O
parathyroid	O
tumors	B
,	O
and	O
is	O
caused	O
by	O
stabilizing	O
homozygous	O
mutation	O
in	O
7.3	O
%	O
of	O
Swedish	O
pHPT	B
patients	O
.	O

Hybridization	O
of	O
the	O
SBE	O
reaction	O
products	O
The	O
slides	O
printed	O
with	O
'	O
anti	O
-	O
tags	O
'	O
were	O
pre	O
-	O
heated	O
to	O
42	O
	O
C	O
in	O
a	O
custom	O
-	O
made	O
aluminium	O
reaction	O
rack	O
with	O
a	O
re	O
-	O
usable	O
silicon	O
rubber	O
grid	O
placed	O
on	O
the	O
slides	O
to	O
form	O
75	O
separate	O
reaction	O
chambers	O
on	O
each	O
slide	O
[	O
24	O
]	O
.	O

The	O
hybridization	O
mixtures	O
,	O
containing	O
the	O
SBE	O
reaction	O
products	O
in	O
6.5	O
	O
SSC	O
were	O
added	O
to	O
each	O
reaction	O
chamber	O
on	O
the	O
pre	O
-	O
heated	O
slide	O
.	O

The	O
hybridization	O
time	O
was	O
2.5	O
hours	O
at	O
42	O
	O
C	O
followed	O
by	O
a	O
brief	O
rinse	O
with	O
4	O
	O
SSC	O
at	O
room	O
temperature	O
.	O

Subsequently	O
,	O
the	O
slides	O
were	O
washed	O
twice	O
for	O
5	O
min	O
.	O

in	O
2	O
	O
SSC	O
,	O
0.1	O
%	O
SDS	O
(	O
42	O
	O
C	O
)	O
and	O
twice	O
for	O
1	O
min	O
.	O

in	O
0.2	O
	O
SSC	O
(	O
room	O
temperature	O
)	O
.	O

Finally	O
,	O
the	O
slides	O
were	O
spin	O
dried	O
for	O
3	O
min	O
.	O

at	O
800	O
rpm	O
.	O

Signal	O
detection	O
The	O
signal	O
detection	O
was	O
performed	O
mainly	O
as	O
described	O
by	O
Lindroos	O
et	O
al.	O
[	O
23	O
]	O
.	O

The	O
fluorescence	O
signals	O
were	O
detected	O
with	O
a	O
ScanArray	O
4000XL	O
instrument	O
and	O
the	O
ScanArray	O
Express	O
software	O
(	O
PerkinElmer	O
Life	O
and	O
Analytical	O
Sciences	O
,	O
Inc	O
,	O
Wellesley	O
,	O
Ma	O
)	O
.	O

The	O
four	O
excitation	O
lasers	O
were	O
:	O
blue	O
Argon	O
,	O
488	O
nm	O
;	O
Green	O
HeNe	O
,	O
543.8	O
nm	O
;	O
Yellow	O
HeNe	O
,	O
594	O
nm	O
and	O
Red	O
HeNe	O
632.8	O
nm	O
.	O

The	O
laser	O
power	O
was	O
kept	O
constant	O
at	O
90	O
%	O
,	O
whereas	O
the	O
photo	O
-	O
multiplier	O
tube	O
(	O
PMT	O
)	O
varied	O
between	O
fluorophores	O
.	O

A	O
typical	O
setting	O
for	O
the	O
PMT	O
gain	O
was	O
65	O
,	O
75	O
,	O
65	O
and	O
70	O
%	O
for	O
the	O
fluorophores	O
Cy5-ddCTP	O
,	O
TAMRA	O
-	O
ddUTP	O
,	O
Texas	O
Red	O
	O
-5-ddATP	O
and	O
R110-ddGTP	O
,	O
respectively	O
.	O

Statistics	O
Association	O
tests	O
A	O
Bonferroni	O
corrected	O
Fisher	O
exact	O
test	O
was	O
used	O
to	O
test	O
for	O
association	O
between	O
the	O
genotypes	O
of	O
each	O
SNP	O
and	O
the	O
familiar	O
CRC	B
cohort	O
and	O
the	O
cohort	O
of	O
sporadic	O
CRC	B
,	O
respectively	O
.	O

Fifteen	O
tests	O
were	O
made	O
for	O
single	O
marker	O
associations	O
,	O
in	O
the	O
cohort	O
of	O
familiar	O
CRC	B
,	O
yielding	O
a	O
Bonferroni	O
corrected	O
significance	O
level	O
of	O
0.05	O
/	O
15	O
=	O
0.0033	O
.	O

Likewise	O
the	O
Bonferroni	O
corrected	O
p	O
-	O
value	O
of	O
the	O
cohort	O
of	O
sporadic	O
cases	O
was	O
0.05	O
/	O
13	O
=	O
0.0038	O
.	O

A	O
Bonferroni	O
corrected	O
Monte	O
Carlo	O
(	O
MC	O
)	O
Fisher	O
exact	O
test	O
was	O
used	O
to	O
test	O
for	O
association	O
between	O
each	O
pair	O
of	O
SNPs	O
,	O
and	O
sporadic	O
or	O
familiar	O
CRC	B
.	O

One	O
hundred	O
thousand	O
permutations	O
were	O
used	O
for	O
each	O
test	O
.	O

Missing	O
data	O
were	O
handled	O
by	O
omitting	O
persons	O
with	O
missing	O
data	O
in	O
the	O
genotype	O
counts	O
;	O
e.g.	O
all	O
individuals	O
with	O
missing	O
data	O
in	O
either	O
variant	O
i	O
d	O
26	O
or	O
variant	O
i	O
d	O
27	O
were	O
omitted	O
when	O
calculating	O
the	O
genotype	O
frequencies	O
of	O
that	O
specific	O
SNP	O
-	O
pair	O
.	O

Power	O
calculations	O

The	O
power	O
was	O
calculated	O
by	O
applying	O
the	O
Fisher	O
exact	O
test	O
to	O
10000	O
independent	O
simulated	O
cases	O
with	O
the	O
given	O
odds	O
ratio	O
and	O
frequency	O
of	O
the	O
disease	B
causing	O
genotype	O
.	O

In	O
that	O
case	O
the	O
power	O
is	O
the	O
proportion	O
of	O
the	O
simulations	O
that	O
reach	O
a	O
p	O
-	O
value	O
lower	O
than	O
0.05	O
/	O
15	O
=	O
0.0033	O
.	O

Test	O
for	O
Hardy	O
-	O
Weinberg	O
proportions	O
Each	O
variant	O
was	O
tested	O
for	O
deviation	O
from	O
Hardy	O
-	O
Weinberg	O
proportions	O
in	O
the	O
sub	O
-	O
cohort	O
,	O
using	O
the	O
exact	O
test	O
described	O
by	O
Wigginton	O
et	O
al.	O
[	O
25	O
]	O
.	O

The	O
used	O
significance	O
level	O
was	O
0.01	O
.	O

Linkage	O
disequilibrium	O
Linkage	O
disequilibrium	O
(	O
LD	O
)	O
was	O
investigated	O
using	O
HaploView	O
(	O
v.	O
3.31	O
)	O
,	O
[	O
26	O
]	O
and	O
genome	O
build	O
NCBI35	O
for	O
information	O
track	O
.	O

In	O
silico	O
analysis	O
In	O
silico	O
prediction	O
of	O
the	O
functional	O
consequence	O
of	O
the	O
missense	O
variants	O
was	O
performed	O
using	O
SIFT	O
(	O
Sorting	O
Intolerant	O
From	O
Tolerant	O
)	O
[	O
27	O
]	O
,	O
Polyphen	O
[	O
28	O
]	O
and	O
PMUT	O
[	O
29	O
]	O
.	O

Mis	O
-	O
splicing	O
was	O
analysed	O
using	O
SNAP	O
(	O
SNP	O
Annotation	O
Platform	O
)	O
[	O
30	O
]	O
.	O

The	O
alignments	O
of	O
MSH2	O
or	O
MLH1	O
polypeptides	O
used	O
in	O
the	O
phylogenetic	O
analysis	O
of	O
the	O
missense	O
variants	O
was	O
performed	O
using	O
ClustalW	O
[	O
31	O
]	O
.	O

Thirteen	O
variants	O
were	O
polymorphic	O
in	O
the	O
present	O
study	O
.	O

The	O
majority	O
of	O
the	O
polymorphic	O
variants	O
(	O
i.e.	O
9	O
/	O
13	O
)	O
were	O
silent	O
or	O
present	O
in	O
non	O
-	O
coding	O
regions	O
.	O

This	O
corresponds	O
with	O
common	O
variants	O
being	O
more	O
abundant	O
in	O
introns	O
and	O
other	O
regions	O
than	O
in	O
coding	O
regions	O
[	O
38	O
]	O
.	O

Three	O
of	O
polymorphic	O
variants	O
i.e.	O
MLH1	O
p.	O

Val219Ile	O
,	O
p.	O

Ser406Asn	O
and	O
p.	O

Lys618Ala	O
changed	O
non	O
-	O
conserved	O
amino	O
acids	O
and	O
one	O
i.e.	O
MSH2	O
pGly322Asp	O
changed	O
a	O
conserved	O
amino	O
acid	O
.	O

Furthermore	O
,	O
two	O
polymorphic	O
variants	O
i.e.hMSH2	O
c.-118	O
T	O
>	O
C	O
and	O
hMLH1	O
c.1668	O
-	O
19	O
A	O
>	O
G	O
demonstrated	O
borderline	O
significant	O
p	O
-	O
values	O
i.e.	O
0.0037	O
(	O
significance	O
level	O
:	O
0.05	O
/	O
13	O
=	O
0.0038	O
)	O
and	O
0.0044	O
(	O
significance	O
level	O
:	O
0.05	O
/	O
15	O
=	O
0.0033	O
)	O
,	O
respectively	O
.	O

It	O
has	O
been	O
stated	O
that	O
the	O
conventional	O
threshold	O
for	O
declaration	O
of	O
statistical	O
evidence	O
of	O
association	O
(	O
i.e.	O
a	O
p	O
-	O
value	O
of	O
5	O
	O
10	O
-	O
2	O
)	O
is	O
not	O
sufficient	O
to	O
detect	O
gene	O
-	O
disease	B
interactions	O
.	O

Consequently	O
,	O
it	O
has	O
been	O
suggested	O
to	O
lower	O
the	O
threshold	O
to	O
5	O
	O
10	O
-	O
5	O
[	O
39	O
]	O
.	O

The	O
borderline	O
significant	O
p	O
-	O
values	O
and	O
the	O
previously	O
published	O
functional	O
analysis	O
of	O
one	O
of	O
the	O
variants	O
suggest	O
that	O
hMSH2	O
c.-118	O
T	O
>	O
C	O
and	O
hMLH1	O
c.1668	O
-	O
19	O
A	O
>	O
G	O
are	O
not	O
associated	O
with	O
increased	O
susceptibility	O
to	O
neither	O
sporadic	O
nor	O
familiar	O
CRC	B
in	O
the	O
Danish	O
population	O
.	O

The	O
remaining	O
polymorphic	O
variants	O
were	O
not	O
associated	O
with	O
CRC	B
in	O
the	O
analyzed	O
cohorts	O
,	O
neither	O
individually	O
nor	O
as	O
pairs	O
,	O
and	O
they	O
are	O
hence	O
neutral	O
variants	O
in	O
the	O
Danish	O
population	O
.	O

Some	O
of	O
these	O
variants	O
i.e.	O
hMLH1	O
c.655	O
A	O
>	O
G	O
(	O
p	O
.	O
Val219Ile	O
)	O
,	O
c.1217G	O
>	O
A	O
(	O
p.	O

Ser406Asn	O
)	O
,	O
c.1558	O
+	O
14	O
G	O
>	O
A	O
and	O
hMSH2	O
c.1959G	O
>	O
T	O
(	O
p.	O

Leu653Leu	O
)	O
have	O
been	O
characterized	O
as	O
neutral	O
variants	O
in	O
other	O
studies	O
as	O
well	O
[	O
40	O
-	O
42	O
]	O
.	O

In	O
vitro	O
functional	O
analysis	O
have	O
also	O
demonstrated	O
that	O
the	O
variants	O
MLH1	O
p.	O

Val219Ile	O
and	O
p.	O

Ser406Asn	O
exhibit	O
wild	O
-	O
type	O
activity	O
[	O
8,11,12	O
]	O
.	O

The	O
hMSH2	O
variant	O
c.965G	O
>	O
A	O
(	O
p.	O

Gly322Asp	O
)	O
has	O
previously	O
been	O
classified	O
as	O
a	O
neutral	O
variant	O
[	O
43	O
]	O
.	O

This	O
variant	O
changes	O
a	O
conserved	O
amino	O
acid	O
and	O
functional	O
analysis	O
in	O
yeast	O
has	O
shown	O
that	O
it	O
has	O
a	O
slightly	O
reduced	O
MMR	O
activity	O
[	O
8,44	O
]	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
frequency	O
of	O
the	O
c.965	O
G	O
>	O
A	O
variant	O
was	O
higher	O
in	O
the	O
cohort	O
of	O
individuals	O
with	O
familiar	O
CRC	B
compared	O
to	O
the	O
sub	O
-	O
cohort	O
although	O
this	O
was	O
not	O
statistically	O
significant	O
(	O
Tables	O
3	O
and	O
4	O
)	O
.	O

Results	O
regarding	O
the	O
MLH1	O
p.	O

Lys618Ala	O
variants	O
have	O
so	O
far	O
been	O
contradictory	O
.	O

Functional	O
analyses	O
have	O
identified	O
this	O
variant	O
both	O
as	O
a	O
pathogenic	O
mutation	O
and	O
as	O
a	O
neutral	O
variant	O
[	O
9,11,45	O
-	O
47	O
]	O
.	O

Raevaara	O
et	O
al.	O
used	O
four	O
different	O
assays	O
to	O
evaluate	O
the	O
pathogenic	O
status	O
[	O
9	O
]	O
.	O

In	O
all	O
four	O
assays	O
the	O
p.	O

Lys618Val	O
variant	O
functioned	O
like	O
wt	O
MLH1	O
.	O

In	O
addition	O
,	O
p.	O

Lys618Ala	O
has	O
been	O
identified	O
in	O
one	O
healthy	B
control	O
in	O
a	O
previous	O
study	O
[	O
48	O
]	O
.	O

The	O
identification	O
of	O
the	O
p.	O

Lys618Ala	O
variant	O
in	O
controls	O
in	O
the	O
present	O
study	O
further	O
support	O
,	O
that	O
this	O
variant	O
is	O
not	O
a	O
disease	B
causing	O
mutation	O
involved	O
in	O
HNPCC	B
or	O
HNPCC	B
-	O
related	O
cancers	B
.	O

In	O
addition	O
,	O
the	O
frequencies	O
of	O
the	O
variant	O
in	O
the	O
cohorts	O
analyzed	O
in	O
the	O
present	O
study	O
did	O
not	O
differ	O
significantly	O
and	O
therefore	O
p.	O

Lys618Ala	O
does	O
not	O
increase	O
susceptibility	O
to	O
sporadic	O
CRC	B
in	O
the	O
Danish	O
population	O
.	O

In	O
conclusion	O
none	O
of	O
the	O
polymorphic	O
variants	O
in	O
the	O
present	O
study	O
are	O
highly	O
associated	O
with	O
CRC	B
in	O
the	O
Danish	O
population	O
.	O

When	O
we	O
ran	O
null	O
simulations	O
in	O
the	O
presence	O
of	O
heterogeneity	O
of	O
marker	O
alleles	O
,	O
disease	B
alleles	O
,	O
or	O
both	O
,	O
we	O
observed	O
that	O
Zc	O
and	O
Zp	O
behaved	O
differently	O
depending	O
on	O
the	O
heterogeneity	O
model	O
we	O
simulated	O
.	O

Although	O
Zp	O
was	O
conservatively	O
biased	O
when	O
disease	B
allele	O
frequencies	O
differed	O
between	O
populations	O
,	O
regardless	O
of	O
whether	O
marker	O
allele	O
frequencies	O
differed	O
,	O
its	O
small	O
conservative	O
bias	O
was	O
not	O
significantly	O
different	O
from	O
that	O
observed	O
in	O
the	O
homogeneous	O
population	O
of	O
Table	O
2	O
.	O

In	O
contrast	O
,	O
Zc	O
exhibited	O
an	O
anticonservative	O
bias	O
when	O
marker	O
allele	O
frequencies	O
differed	O
between	O
populations	O
,	O
regardless	O
of	O
whether	O
disease	B
allele	O
frequencies	O
differed	O
.	O

Alternative	O
Model	O
Simulation	O
Results	O
A	O
subset	O
of	O
results	O
from	O
alternative	O
model	O
simulations	O
in	O
which	O
there	O
were	O
linkages	O
are	O
given	O
in	O
Table	O
4	O
,	O
based	O
on	O
20	O
replicate	O
simulations	O
for	O
each	O
combination	O
of	O
parameters	O
.	O

The	O
numbers	O
given	O
represent	O
mean	O
Z	O
statistics	O
,	O
their	O
ARE	O
values	O
,	O
and	O
sample	O
sizes	O
required	O
to	O
attain	O
80	O
%	O
power	O
.	O

The	O
results	O
displayed	O
were	O
chosen	O
to	O
highlight	O
the	O
effect	O
of	O
sampling	O
(	O
and	O
genotyping	O
)	O
varying	O
the	O
numbers	O
of	O
unaffected	B
sibs	O
and/or	O
parents	O
from	O
families	O
with	O
two	O
or	O
three	O
affected	B
sibs	O
and	O
two	O
unaffected	B
sibs	O
.	O

Full	O
results	O
are	O
available	O
online	O
[	O
64	O
]	O
.	O

On	O
average	O
,	O
the	O
concordant	O
test	O
was	O
always	O
more	O
efficient	O
on	O
a	O
per	O
-	O
genotype	O
basis	O
than	O
the	O
paired	O
test	O
,	O
although	O
the	O
power	O
of	O
the	O
paired	O
test	O
was	O
usually	O
greater	O
when	O
the	O
number	O
of	O
unaffected	B
sibs	O
tested	O
was	O
>	O
2	O
.	O

Alternative	O
Model	O
Simulation	O
Mean	O
Z	O
score	O
,	O
asymptotic	O
relative	O
efficiency	O
per	O
genotype	O
(	O
ARE	O
	O
see	O
text	O
)	O
,	O
and	O
sample	O
size	O
required	O
to	O
attain	O
80	O
%	O
power	O
for	O
two	O
-	O
point	O
linkage	O
(	O
	O
=	O
0.05	O
)	O
for	O
predisposition	O
to	O
colorectal	B
cancer	I
with	O
a	O
baseline	O
risk	O
of	O
0.018	O
,	O
a	O
relative	O
risk	O
to	O
carriers	O
of	O
20	O
,	O
allele	O
frequency	O
of	O
0.003	O
,	O
with	O
a	O
lifetime	O
penetrance	O
of	O
0.27	O
,	O
under	O
3	O
different	O
heterogeneity	O
models	O
:	O
A	O
)	O
no	O
heterogeneity	O
;	O
B	O
)	O
an	O
equally	O
penetrant	O
,	O
less	O
common	O
(	O
allele	O
frequency	O
0.001	O
)	O
unlinked	O
predisposing	O
locus	O
;	O
C	O
)	O
an	O
equally	O
penetrant	O
,	O
equally	O
common	O
unlinked	O
predisposing	O
locus	O
.	O

All	O
results	O
based	O
on	O
500	O
simulated	O
families	O
and	O
20	O
replicate	O
simulations	O
per	O
parameter	O
set	O
.	O

Zc	O
mean	O
concordant	O
test	O
;	O

Zp	O
mean	O
paired	O
test	O
;	O
ARE	O
(	O
Zc	O
)	O
asymptotic	O
relative	O
efficiency	O
concordant	O
test	O
;	O
ARE	O
(	O
Zp	O
)	O
asymptotic	O
relative	O
efficiency	O
paired	O
test	O
;	O
Nc	O
(	O
80	O
%	O
)	O
number	O
of	O
families	O
required	O
for	O
80	O
%	O
power	O
using	O
concordant	O
test	O
;	O
Np	O
(	O
80	O
%	O
)	O
number	O
of	O
families	O
required	O
for	O
80	O
%	O
power	O
using	O
paired	O
test	O
.	O

Regression	O
Models	O
Table	O
5	O
shows	O
the	O
effect	O
of	O
various	O
design	O
and	O
population	O
parameters	O
on	O
the	O
noncentrality	O
parameter	O
for	O
both	O
the	O
concordant	O
-	O
only	O
test	O
(	O
Zc	O
/	O
F	O
)	O
and	O
the	O
paired	O
test	O
(	O
Zp	O
/	O
F	O
)	O
.	O

The	O
only	O
change	O
in	O
parameterization	O
of	O
the	O
model	O
for	O
the	O
paired	O
test	O
vis	O
-	O
a	O
-	O
vis	O
the	O
concordant	O
test	O
involved	O
substituting	O
the	O
number	O
of	O
typed	O
unaffected	B
sibs	O
for	O
the	O
total	O
number	O
of	O
unaffected	B
sibs	O
.	O

The	O
AR	O
for	O
the	O
linked	O
locus	O
had	O
the	O
largest	O
positive	O
effect	O
on	O
power	O
of	O
the	O
concordant	O
test	O
,	O
followed	O
closely	O
by	O
the	O
negative	O
effect	O
on	O
power	O
of	O
increasing	O
AR	O
at	O
the	O
unlinked	O
locus	O
and	O
increasing	O
recombination	O
fraction	O
between	O
the	O
marker	O
and	O
trait	O
loci	O
.	O

Increasing	O
the	O
number	O
of	O
affected	B
sibs	O
per	O
family	O
and	O
increasing	O
the	O
number	O
of	O
affected	B
sibs	O
genotyped	O
per	O
family	O
both	O
substantially	O
improved	O
power	O
.	O

The	O
number	O
of	O
unaffected	B
sibs	O
present	O
in	O
sampled	O
families	O
had	O
little	O
or	O
no	O
effect	O
on	O
power	O
.	O

Increased	O
power	O
was	O
also	O
observed	O
for	O
increasing	O
numbers	O
of	O
available	O
parents	O
,	O
the	O
size	O
of	O
the	O
effect	O
on	O
Zc	O
/	O
F	O
being	O
about	O
15	O
%	O
of	O
the	O
effect	O
of	O
increasing	O
numbers	O
of	O
affected	B
sibs	O
.	O

Substituting	O
spouse	O
and	O
offspring	O
for	O
an	O
unavailable	O
affected	B
sib	O
reduced	O
power	O
substantially	O
,	O
but	O
genotyping	O
a	O
second	O
child	O
recovered	O
much	O
of	O
that	O
lost	O
power	O
.	O

Comparison	O
of	O
two	O
-	O
point	O
vs.	O
multipoint	O
linkage	O
scores	O
under	O
various	O
non	O
-	O
null	O
simulation	O
conditions	O
.	O

All	O
simulations	O
employed	O
20	O
replicates	O
of	O
500	O
families	O
with	O
2	O
affected	B
and	O
2	O
unaffected	B
sibs	O
,	O
all	O
sibs	O
typed	O
,	O
no	O
parents	O
or	O
children	O
typed	O
.	O

a	O
Baseline	O
risk	O
of	O
0.018	O
,	O
a	O
relative	O
risk	O
to	O
carriers	O
of	O
20	O
,	O
allele	O
frequency	O
of	O
0.003	O
,	O
with	O
a	O
lifetime	O
penetrance	O
of	O
0.27	O
,	O
no	O
genetic	O
heterogeneity	O
.	O

b	O
Baseline	O
risk	O
of	O
0.018	O
,	O
a	O
relative	O
risk	O
to	O
carriers	O
of	O
20	O
,	O
allele	O
frequency	O
of	O
0.003	O
,	O
with	O
a	O
lifetime	O
penetrance	O
of	O
0.27	O
,	O
and	O
a	O
less	O
common	O
(	O
allele	O
frequency	O
0.001	O
)	O
,	O
equally	O
penetrant	O
unlinked	O
predisposition	O
syndrome	O
.	O

c	O
Two	O
populations	O
modeled	O
in	O
an	O
80%	O
/	O
20	O
%	O
mixture	O
:	O
1	O
)	O
marker	O
allele	O
frequencies	O
for	O
all	O
markers	O
[	O
0.25,0.25,0.25,0.25	O
]	O
,	O
disease	B
allele	O
0.00325	O
;	O
2	O
)	O
marker	O
alleles	O
[	O
0.4,0.3,0.2,0.1	O
]	O
,	O
disease	B
allele	O
0.002	O
.	O

d	O
Two	O
populations	O
modeled	O
in	O
an	O
80%	O
/	O
20	O
%	O
mixture	O
:	O
1	O
)	O
marker	O
allele	O
frequencies	O
for	O
all	O
markers	O
[	O
0.25,0.25,0.25,0.25	O
]	O
,	O
disease	B
allele	O
0.0035	O
;	O
2	O
)	O
marker	O
alleles	O
[	O
0.4,0.3,0.2,0.1	O
]	O
,	O
disease	B
allele	O
0.001	O
.	O

Replacement	O
of	O
a	O
missing	O
affected	B
individual	O
by	O
a	O
spouse	O
and	O
offspring	O
is	O
not	O
generally	O
as	O
efficient	O
per	O
genotype	O
as	O
if	O
that	O
individual	O
had	O
been	O
available	O
,	O
although	O
the	O
efficiency	O
improves	O
with	O
each	O
additional	O
offspring	O
included	O
.	O

Figure	O
5	O
shows	O
the	O
effect	O
of	O
replacing	O
one	O
member	O
of	O
an	O
ASP	O
with	O
one	O
or	O
two	O
offspring	O
and	O
the	O
spouse	O
.	O

Figure	O
6	O
shows	O
the	O
effect	O
of	O
replacing	O
one	O
member	O
of	O
an	O
affected	B
sib	O
trio	O
with	O
one	O
or	O
two	O
offspring	O
and	O
the	O
spouse	O
.	O

Because	O
families	O
with	O
three	O
affected	B
sibs	O
are	O
more	O
likely	O
to	O
be	O
segregating	O
a	O
disease	B
-	O
predisposing	O
allele	O
than	O
families	O
with	O
two	O
affected	B
sibs	O
,	O
each	O
family	O
is	O
more	O
informative	O
for	O
linkage	O
,	O
even	O
if	O
DNA	O
is	O
available	O
for	O
only	O
two	O
sibs	O
.	O

Substituting	O
the	O
spouse	O
and	O
one	O
or	O
more	O
offspring	O
for	O
the	O
missing	O
sib	O
adds	O
additional	O
power	O
,	O
although	O
at	O
the	O
cost	O
of	O
additional	O
genotyping	O
.	O

Conclusion	O
We	O
have	O
shown	O
that	O
for	O
a	O
wide	O
variety	O
of	O
situations	O
relevant	O
to	O
sib	O
-	O
pair	O
studies	O
of	O
colon	B
cancer	I
and	O
similar	O
late	O
-	O
onset	O
complex	O
diseases	B
,	O
standard	O
concordant	O
-	O
pair	O
allele	O
-	O
sharing	O
statistics	O
based	O
on	O
identity	O
by	O
descent	O
probabilities	O
are	O
more	O
efficient	O
than	O
similarly	O
constructed	O
discordant	O
statistics	O
in	O
homogeneous	O
populations	O
,	O
but	O
may	O
be	O
biased	O
away	O
from	O
the	O
null	O
in	O
situations	O
where	O
subjects	O
are	O
chosen	O
from	O
multiple	O
populations	O
having	O
differing	O
marker	O
allele	O
frequencies	O
or	O
other	O
sources	O
of	O
bias	O
.	O

Where	O
heterogeneity	O
in	O
marker	O
allele	O
frequencies	O
is	O
anticipated	O
because	O
of	O
underlying	O
population	O
admixture	O
,	O
linkage	O
tests	O
based	O
on	O
comparison	O
of	O
concordant	O
vs.	O
discordant	O
allele	O
sharing	O
should	O
be	O
considered	O
.	O

Either	O
of	O
these	O
approaches	O
should	O
allow	O
studies	O
of	O
5001000	O
families	O
containing	O
an	O
ASP	O
to	O
achieve	O
reasonable	O
power	O
to	O
detect	O
linkage	O
under	O
conditions	O
including	O
genetic	O
and	O
population	O
heterogeneity	O
,	O
unavailable	O
parents	O
,	O
misspecified	O
allele	O
frequencies	O
,	O
and	O
other	O
afflictions	O
of	O
the	O
sib	O
-	O
pair	O
design	O
.	O

While	O
collecting	O
DNA	O
samples	O
from	O
unaffected	B
sibs	O
can	O
be	O
useful	O
for	O
a	O
wide	O
variety	O
of	O
purposes	O
	O
especially	O
if	O
multipoint	O
methods	O
are	O
used	O
	O
in	O
many	O
circumstances	O
it	O
should	O
be	O
unnecessary	O
to	O
genotype	O
these	O
samples	O
for	O
purposes	O
of	O
performing	O
a	O
genome	O
scan	O
.	O

If	O
adequate	O
allele	O
frequency	O
data	O
are	O
available	O
and	O
microsatellites	O
are	O
being	O
used	O
,	O
we	O
suggest	O
a	O
single	O
-	O
point	O
affecteds	O
-	O
only	O
analysis	O
for	O
a	O
initial	O
scan	O
,	O
followed	O
by	O
a	O
multipoint	O
analysis	O
of	O
affected	B
and	O
unaffected	B
members	O
of	O
all	O
available	O
sibships	O
with	O
additional	O
markers	O
around	O
initial	O
hits	O
.	O

For	O
dense	O
SNP	O
mapping	O
studies	O
,	O
analysis	O
using	O
individual	O
SNPs	O
will	O
not	O
be	O
sufficiently	O
informative	O
and	O
so	O
multipoint	O
analyses	O
will	O
be	O
required	O
,	O
but	O
unless	O
the	O
parents	O
are	O
all	O
available	O
,	O
analyses	O
should	O
be	O
restricted	O
to	O
markers	O
that	O
show	O
low	O
levels	O
of	O
linkage	O
disequilibrium	O
(	O
the	O
reference	O
here	O
would	O
be	O
to	O
a	O
paper	O
by	O
Bacanu	O
SA	O
.	O

Multipoint	O
linkage	O
analysis	O
for	O
a	O
very	O
dense	O
set	O
of	O
markers	O
Genet	O
Epidemiol	O
.	O

2005	O
Nov;29	O
(	O
3	O
)	O
:195203	O
.	O
)	O
or	O
estimate	O
haplotype	O
frequencies	O
(	O
Abecasis	O
and	O
Wigginton	O
,	O
Handling	O
marker	O
-	O
marker	O
linkage	O
disequilibrium	O
:	O
pedigree	O
analysis	O
with	O
clustered	O
markers	O
.	O

Am	O
J	O
Hum	O
Genet	O
.	O

2005	O
Nov;77	O
(	O
5	O
)	O
:75467	O
.	O

Epub	O
2005	O
Sep	O
20	O
.	O
)	O

If	O
the	O
parents	O
are	O
available	O
,	O
even	O
though	O
we	O
have	O
shown	O
that	O
genotyping	O
them	O
is	O
inefficient	O
,	O
an	O
argument	O
can	O
be	O
made	O
for	O
genotyping	O
them	O
because	O
their	O
inclusion	O
ameliorates	O
any	O
potential	O
effect	O
of	O
population	O
admixture	O
,	O
greatly	O
facilitates	O
the	O
identification	O
of	O
any	O
genotyping	O
errors	O
and	O
reduces	O
the	O
dependence	O
upon	O
correct	O
specification	O
of	O
haplotype	O
frequencies	O
when	O
multipoint	O
analyses	O
are	O
conducted	O
(	O
can	O
refer	O
to	O
Huang	O
et	O
al	O
,	O
2004	O
Ignoring	O
linkage	O
disequilibrium	O
among	O
tightly	O
linked	O
markers	O
induces	O
false	O
-	O
positive	O
evidence	O
of	O
linkage	O
for	O
affected	B
sib	O
pair	O
analysis	O
.	O

Am	O
J	O
Hum	O
Genet	O
.	O

2004	O
Dec;75	O
(	O
6	O
)	O
:1106	O
-	O
12	O
.	O

Epub	O
2004	O
Oct	O
18	O
.	O
)	O
.	O

The	O
choice	O
of	O
whether	O
or	O
not	O
to	O
genotype	O
unaffected	B
individuals	O
also	O
would	O
depend	O
upon	O
the	O
feasibility	O
and	O
cost	O
of	O
cherry	O
-	O
picking	O
for	O
regional	O
genotyping	O
of	O
regions	O
showing	O
evidence	O
for	O
linkage	O
,	O
but	O
we	O
have	O
not	O
studied	O
either	O
of	O
these	O
issues	O
in	O
this	O
paper	O
.	O

Admixture	O
is	O
more	O
likely	O
to	O
be	O
of	O
concern	O
when	O
studying	O
populations	O
that	O
are	O
known	O
to	O
have	O
been	O
founded	O
by	O
different	O
ethnic	O
groups	O
or	O
races	O
such	O
as	O
Hispanics	O
and	O
African	O
-	O
Americans	O
.	O

INTRODUCTION	O
Colorectal	B
cancer	I
arises	O
from	O
a	O
series	O
of	O
somatically	O
inherited	O
changes	O
,	O
including	O
mutations	O
and	O
transmissible	O
epigenetic	O
events	O
such	O
as	O
methylation	O
of	O
CpG	O
islands	O
(	O
1	O
)	O
,	O
some	O
or	O
all	O
of	O
which	O
produce	O
a	O
growth	O
advantage	O
relative	O
to	O
surrounding	O
cells	O
(	O
2	O
,	O
3	O
)	O
.	O

Among	O
the	O
epigenetic	O
events	O
involved	O
in	O
tumorigenesis	B
are	O
DNA	O
methylation	O
,	O
genomic	O
imprinting	O
,	O
and	O
histone	O
modification	O
(	O
4	O
)	O
.	O

Global	O
decreases	O
in	O
5-methylcytosine	O
content	O
have	O
been	O
associated	O
with	O
tumor	B
formation	O
,	O
including	O
that	O
of	O
colorectal	B
cancers	I
.	O

Another	O
molecular	O
defect	O
commonly	O
occurring	O
during	O
neoplasia	B
is	O
de	O
novo	O
CpG	O
island	O
methylation	O
(	O
4	O
-	O
6	O
)	O
.	O

Recently	O
,	O
a	O
distinct	O
pathway	O
of	O
colorectal	O
carcinogenesis	O
was	O
described	O
,	O
termed	O
the	O
CpG	O
island	O
methylation	O
phenotype	O
(	O
CIMP	O
)	O
(	O
7	O
)	O
.	O

This	O
pathway	O
was	O
uncovered	O
through	O
a	O
series	O
of	O
observations	O
that	O
included	O
association	O
between	O
microsatellite	O
instability	O
(	O
MSI	O
)	O
and	O
hypermethylation	O
of	O
multiple	O
genes	O
,	O
from	O
the	O
concordance	O
between	O
the	O
methylation	O
status	O
of	O
different	O
genes	O
unrelated	O
to	O
the	O
gene	O
function	O
or	O
chromosomal	O
location	O
,	O
and	O
from	O
the	O
bimodal	O
distribution	O
of	O
methylation	O
in	O
a	O
selected	O
subset	O
of	O
genes	O
.	O

Colorectal	B
cancer	I
is	O
the	O
third	O
leading	O
cause	O
of	O
cancer	B
-	O
related	O
deaths	O
worldwide	O
(	O
8)	O
.	O

Almost	O
70	O
%	O
of	O
all	O
colorectal	B
cancers	I
are	O
sporadic	O
.	O

Of	O
the	O
remaining	O
30	O
%	O
,	O
a	O
small	O
number	O
belong	O
to	O
the	O
familial	O
syndromes	O
of	O
hereditary	B
nonpolyposis	I
colorectal	I
cancer	I
(	O
HNPCC	B
)	O
and	O
familial	B
adenomatous	I
polyposis	I
(	O
FAP	B
)	O
,	O
whereas	O
the	O
vast	O
majority	O
show	O
non	O
-	O
syndromatic	O
familial	O
susceptibility	O
(	O
9	O
)	O
.	O

The	O
proportion	O
of	O
all	O
cases	O
considered	O
familial	O
depends	O
in	O
the	O
definition	O
.	O

Of	O
all	O
patients	O
with	O
colorectal	B
cancer	I
,	O
11	O
-	O
16	O
%	O
have	O
at	B
least	I
one	I
first	I
-	I
degree	I
relative	I
with	I
colorectal	I
cancer	I
(	O
10	O
,	O
11	O
)	O
,	O
but	O
the	O
proportion	O
is	O
much	O
higher	O
if	O
second-	O
or	O
third	O
-	O
degree	O
relatives	O
are	O
considered	O
.	O

In	O
one	O
study	O
,	O
53	O
%	O
of	O
colorectal	B
cancer	I
probands	O
had	O
a	O
first	B
-	I
degree	I
relative	I
with	I
cancer	I
(	O
11	O
)	O
.	O

In	O
fact	O
,	O
first	O
-	O
degree	O
relatives	O
of	O
patients	O
affected	O
by	O
colorectal	B
cancer	I
,	O
but	O
who	O
do	O
not	O
fulfill	O
the	O
criteria	O
for	O
FAP	B
and	O
HNPCC	B
,	O
have	O
a	O
more	O
than	O
2-fold	O
increased	O
risk	O
of	O
developing	O
tumors	B
of	O
the	O
large	O
intestine	O
(	O
12	O
)	O
.	O

HNPCC	B
is	O
caused	O
by	O
germline	O
mutations	O
in	O
the	O
mismatch	O
repair	O
(	O
MMR	O
)	O
genes	O
hMLH1	O
,	O
hMSH2	O
,	O
hMSH6	O
,	O
and	O
hPMS2	O
,	O
with	O
a	O
penetrance	O
of	O
approximately	O
80	O
%	O
for	O
colorectal	B
cancer	I
,	O
60	O
%	O
for	O
endometrial	B
cancer	I
,	O
and	O
below	O
20	O
%	O
for	O
other	O
cancers	B
(	O
13	O
)	O
.	O

HNPCC	B
is	O
characterized	O
by	O
early	O
onset	O
,	O
the	O
development	O
of	O
neoplastic	B
lesions	I
in	O
a	O
variety	O
of	O
tissues	O
,	O
and	O
MSI	B
.	O

The	O
Amsterdam	O
criteria	O
for	O
HNPCC	B
are	O
strictly	O
defined	O
and	O
exclude	O
most	O
tumors	B
suspected	O
of	O
being	O
hereditary	O
.	O

In	O
contrast	O
,	O
the	O
Bethesda	O
guidelines	O
broaden	O
the	O
disease	B
spectrum	O
by	O
including	O
colorectal	B
cancer	I
families	O
with	O
specific	O
accompanying	O
cancers	B
and	O
clinicopathologic	O
characteristics	O
(	O
13	O
,	O
14	O
)	O
.	O

These	O
latter	O
criteria	O
provide	O
important	O
clues	O
for	O
identifying	O
genetic	O
pathways	O
associated	O
with	O
atypical	O
phenotypes	O
of	O
hereditary	O
colorectal	B
cancer	I
.	O

Although	O
the	O
strict	O
Amsterdam	O
criteria	O
could	O
be	O
used	O
to	O
detect	O
underlying	O
molecular	O
events	O
in	O
hereditary	O
colorectal	B
cancers	I
,	O
only	O
50	O
%	O
(	O
range	O
,	O
30	O
-	O
80	O
%	O
)	O
of	O
cases	O
involve	O
a	O
detectable	O
germline	O
mutation	O
in	O
an	O
MMR	O
gene	O
(	O
15	O
)	O
.	O

Therefore	O
,	O
by	O
restricting	O
the	O
definition	O
of	O
HNPCC	B
to	O
tumors	B
containing	O
an	O
MMR	O
germline	O
mutation	O
,	O
only	O
about	O
2.5	O
%	O
of	O
colorectal	B
cancers	I
are	O
thought	O
to	O
be	O
caused	O
by	O
HNPCC	B
.	O

Thus	O
,	O
the	O
carcinogenesis	O
pathways	O
and	O
molecular	O
events	O
in	O
familial	O
cancers	B
with	O
no	O
detectable	O
germline	O
mutations	O
and/or	O
not	O
fulfilling	O
HNPCC	B
criteria	O
,	O
remain	O
to	O
be	O
determined	O
.	O

Grouping	O
of	O
adenomas	B
and	O
carcinomas	B
by	O
promoter	O
methylation	O
status	O
Tumors	B
were	O
classified	O
as	O
methylation	O
-	O
resistant	O
(	O
MR	O
)	O
if	O
fewer	O
than	O
two	O
loci	O
were	O
methylated	O
or	O
methylation	O
-	O
prone	O
(	O
MP	O
)	O
if	O
two	O
or	O
more	O
loci	O
were	O
methylated	O
.	O

Each	O
tumor	B
and	O
group	O
were	O
represented	O
by	O
a	O
methylation	O
index	O
(	O
number	O
of	O
loci	O
methylated	O
/	O
number	O
of	O
loci	O
evaluated	O
)	O
.	O

MSI	O
MSI	O
status	O
was	O
determined	O
by	O
PCR	O
using	O
primers	O
to	O
amplify	O
the	O
five	O
microsatellite	O
markers	O
recommended	O
by	O
the	O
National	O
Cancer	O
Institute	O
(	O
Bethesda	O
,	O
MD	O
.	O
,	O
U.S.A.	O
)	O
,	O
i.e.	O
,	O
BAT25	O
,	O
BAT26	O
,	O
D17S250	O
,	O
D5S346	O
,	O
and	O
D2S123	O
(	O
13	O
)	O
.	O

Denaturation	O
of	O
the	O
PCR	O
products	O
,	O
gel	O
electrophoresis	O
,	O
and	O
silver	O
staining	O
were	O
performed	O
as	O
described	O
.	O

MSI	O
was	O
scored	O
as	O
positive	O
when	O
there	O
was	O
a	O
definite	O
shift	O
of	O
PCR	O
product	O
in	O
tumor	B
DNA	O
compared	O
with	O
normal	B
mucosal	O
DNA	O
.	O

All	O
MSI	O
-	O
positive	O
loci	O
were	O
confirmed	O
on	O
duplicate	O
examinations	O
.	O

Tumors	B
with	O
MSI	B
in	I
at	I
least	I
two	I
loci	I
were	O
classified	O
as	O
high	B
-	I
frequency	I
MSI	I
(	O
MSI	O
-	O
H	O
)	O
,	O
tumors	B
with	O
MSI	B
at	I
one	I
locus	I
were	O
classified	O
as	O
low	B
frequency	I
MSI	I
(	O
MSI	O
-	O
L	O
)	O
,	O
and	O
tumors	B
with	O
MSI	B
at	I
no	I
locus	I
were	O
classified	O
as	O
microsatellite	B
stable	I
(	O
MSS	B
)	O
.	O

Statistical	O
analysis	O
The	O
interactions	O
between	O
methylation	O
and	O
clinicopathologic	O
parameters	O
in	O
two	O
groups	O
were	O
evaluated	O
with	O
chi	O
-	O
square	O
tests	O
and	O
Fisher	O
's	O
exact	O
tests	O
.	O

All	O
p	O
values	O
were	O
two	O
-	O
sided	O
,	O
and	O
a	O
p	O
value	O
less	O
than	O
0.05	O
was	O
considered	O
statistically	O
significant	O
.	O

Calculations	O
were	O
performed	O
using	O
the	O
SPSS	O
program	O
(	O
Version	O
12.0	O
,	O
Chicago	O
,	O
IL	O
,	O
U.S.A.	O
)	O
.	O

The	O
majority	O
of	O
tumors	B
were	O
found	O
to	O
be	O
moderately	O
differentiated	O
in	O
African	O
Americans	O
(	O
79	O
%	O
)	O
and	O
Omanis	O
(	O
82	O
%	O
;	O
Table	O
1	O
,	O
2	O
)	O
.	O

Iranian	O
tumors	B
were	O
mostly	O
well	O
differentiated	O
(	O
54	O
%	O
)	O
.	O

The	O
percentage	O
of	O
moderately	O
differentiated	O
tumors	B
was	O
86	O
%	O
in	O
the	O
MSI	B
-	I
H	I
Omani	O
group	O
compared	O
with	O
72	O
%	O
in	O
African	O
Americans	O
and	O
64	O
%	O
in	O
Iranians	O
(	O
Table	O
1	O
,	O
3	O
)	O
.	O

In	O
addition	O
,	O
seven	O
and	O
one	O
MSI	B
-	I
H	I
tumors	B
showed	O
poor	O
differentiation	O
in	O
African	O
Americans	O
and	O
Omanis	O
,	O
respectively	O
.	O

While	O
in	O
African	O
Americans	O
,	O
one	O
MSI	B
-	I
H	I
was	O
well	O
differentiated	O
,	O
no	O
patient	O
in	O
Iranian	O
non	B
-	I
MSI	I
-	I
H	I
cases	O
was	O
poorly	O
differentiated	O
(	O
Table	O
1	O
,	O
3	O
)	O
.	O

The	O
difference	O
was	O
insignificant	O
trend	O
in	O
African	O
Americans	O
and	O
Omanis	O
but	O
in	O
Iranian	O
patients	O
differentiation	O
was	O
significantly	O
correlated	O
with	O
MSI	O
-	O
H	O
occurrence	O
.	O

This	O
finding	O
was	O
not	O
sustained	O
in	O
multivariate	O
analysis	O
.	O

Most	O
of	O
the	O
patients	O
in	O
the	O
series	O
were	O
stage	O
II	O
or	O
higher	O
(	O
Table	O
1	O
,	O
2	O
,	O
3	O
)	O
,	O
with	O
45	O
%	O
[	O
13	O
]	O
of	O
African	O
American	O
,	O
62	O
%	O
[	O
5	O
]	O
of	O
Omani	O
,	O
and	O
14	O
%	O
[	O
2	O
]	O
of	O
Iranian	O
MSI	B
-	I
H	I
lesions	B
at	O
stage	O
II	O
.	O

Thirty	O
-	O
eight	O
percent	O
[	O
24	O
]	O
of	O
African	O
American	O
,	O
28	O
%	O
[	O
15	O
]	O
of	O
Omani	O
,	O
and	O
23	O
%	O
[	O
12	O
]	O
of	O
Iranian	O
of	O
the	O
non	B
-	I
MSI	I
-	I
H	I
lesions	B
were	O
at	O
stage	O
II	O
(	O
Table	O
3	O
)	O
.	O

Forty	O
-	O
one	O
percent	O
[	O
12	O
]	O
of	O
African	O
American	O
,	O
25	O
%	O
[	O
2	O
]	O
of	O
Omani	O
,	O
and	O
79	O
%	O
[	O
11	O
]	O
of	O
Iranian	O
of	O
the	O
MSI	B
-	I
H	I
lesions	B
were	O
at	O
stage	O
III	O
(	O
Table	O
1	O
,	O
2	O
,	O
3	O
)	O
.	O

Thirty	O
-	O
seven	O
percent	O
[	O
23	O
]	O
of	O
African	O
American	O
,	O
55	O
%	O
[	O
29	O
]	O
of	O
Omani	O
,	O
and	O
67	O
%	O
[	O
26	O
]	O
of	O
Iranian	O
of	O
the	O
non	B
-	I
MSI	I
-	I
H	I
lesions	B
were	O
at	O
stage	O
III	O
.	O

Fourteen	O
percent	O
[	O
9	O
]	O
of	O
African	O
American	O
,	O
15	O
%	O
[	O
8	O
]	O
of	O
Omani	O
,	O
and	O
7	O
%	O
[	O
3	O
]	O
of	O
Iranian	O
of	O
the	O
non	B
-	I
MSI	I
-	I
H	I
lesions	B
were	O
at	O
stage	O
IV	O
(	O
Table	O
1	O
,	O
2	O
,	O
3	O
)	O
.	O

There	O
was	O
insignificant	O
trend	O
in	O
the	O
stage	O
of	O
the	O
lesions	B
between	O
the	O
MSI	B
and	O
non	B
-	I
MSI	I
-	I
H	I
groups	O
.	O

Correlation	O
between	O
methylation	O
pattern	O
of	O
the	O
hMLH1	O
promoter	O
and	O
MSI	O
status	O
Among	O
MSI	O
-	O
H	O
samples	O
,	O
hMLH1	O
promoter	O
methylation	O
was	O
found	O
in	O
90	O
%	O
[	O
18	O
]	O
of	O
African	O
American	O
,	O
75	O
%	O
[	O
6	O
]	O
of	O
Omani	O
and	O
71	O
%	O
[	O
10	O
]	O
of	O
Iranian	O
tumors	B
,	O
confirming	O
a	O
previous	O
finding	O
of	O
predominant	O
methylation	O
of	O
these	O
genes	O
of	O
the	O
promoter	O
in	O
Africans	O
(	O
Table	O
1	O
,	O
2	O
,	O
3	O
)	O
[	O
3,4	O
]	O
.	O

Non	B
-	I
MSI	I
-	I
H	I
tumors	B
in	O
both	O
African	O
Americans	O
and	O
Omani	O
tumors	B
showed	O
methylation	O
of	O
the	O
hMLH1	O
promoter	O
as	O
well	O
(	O
>	O
80	O
%	O
)	O
.	O

In	O
Iranian	O
non	B
-	I
MSI	I
-	I
H	I
patients	O
,	O
the	O
frequency	O
of	O
hMLH1	O
methylation	O
was	O
3	O
%	O
[	O
1	O
]	O
.	O

The	O
methylation	O
status	O
of	O
hMLH1	O
does	O
not	O
seem	O
to	O
be	O
gender-	O
or	O
stage	O
-	O
specific	O
.	O

In	O
multivariate	O
analysis	O
,	O
including	O
the	O
interaction	O
terms	O
,	O
the	O
hMLH1	O
methylation	O
has	O
a	O
significant	O
effect	O
on	O
MSI	O
-	O
H	O
occurrence	O
(	O
OR	O
=	O
13.84	O
(	O
1.05182.72	O
)	O
;	O
p	O
=	O
0.046	O
)	O
(	O
Table	O
4	O
)	O
.	O

In	O
MSI	B
-	I
H	I
tumors	B
,	O
p16	O
methylation	O
occurred	O
in	O
33	O
%	O
[	O
7	O
]	O
of	O
African	O
American	O
,	O
12	O
%	O
[	O
1	O
]	O
of	O
Omani	O
and	O
50	O
%	O
[	O
7	O
]	O
of	O
Iranian	O
tumors	B
.	O

While	O
it	O
was	O
more	O
than	O
40	O
%	O
in	O
non	B
-	I
MSI	I
-	I
H	I
tumors	B
in	O
African	O
Americans	O
and	O
Omani	O
patient	O
populations	O
,	O
this	O
figure	O
was	O
3	O
%	O
[	O
1	O
]	O
in	O
Iranian	O
non	B
-	I
MSI	I
-	I
H	I
CRC	B
patients	O
.	O

Methods	O
We	O
analyzed	O
40	O
HNPCC	B
patients	O
(	O
25	O
males	O
and	O
15	O
females	O
)	O
with	O
histological	O
verified	O
colorectal	O
carcinoma	B
and	O
a	O
consecutive	O
series	O
of	O
573	O
(	O
312	O
males	O
and	O
261	O
females	O
)	O
sporadic	O
CRC	B
patients	O
with	O
no	B
familial	I
predisposition	I
,	O
observed	O
and	O
treated	O
at	O
the	O
Regina	O
Elena	O
Cancer	O
Institute	O
of	O
Rome	O
during	O
the	O
period	O
19701993	O
[	O
23	O
]	O
.	O

HNPCC	B
patients	O
were	O
selected	O
by	O
both	O
personal	O
and	O
familial	O
history	O
(	O
performing	O
complete	O
pedigree	O
including	O
first	O
and	O
second	O
-	O
degree	O
relatives	O
)	O
according	O
to	O
Amsterdam	O
I	O
criteria	O
.	O

In	O
15	O
patients	O
of	O
the	O
HNPCC	B
group	O
,	O
we	O
performed	O
mutational	O
analysis	O
for	O
microsatellite	O
instability	O
,	O
investigating	O
mutations	O
in	O
mismatch	O
repair	O
genes	O
as	O
hMLH1	O
and	O
hMSH2	O
correlated	O
with	O
disease	B
.	O

We	O
analyzed	O
seven	O
microsatellite	O
loci	O
:	O
D2S123	O
,	O
D3S1611	O
,	O
and	O
BAT-26	O
,	O
D9S145	O
,	O
D1S158	O
,	O
SCZD1	O
,	O
and	O
D11S905	O
[	O
5,14,24,25	O
]	O
.	O

All	O
cases	O
were	O
pathologically	O
staged	O
taking	O
into	O
account	O
a	O
total	O
number	O
of	O
lymphonodes	O
exceeding	O
7	O
(	O
range	O
7	O
to	O
31	O
,	O
mean	O
13.0	O
,	O
mode	O
11.9	O
,	O
standard	O
deviation	O
6.2	O
)	O
,	O
as	O
recommended	O
by	O
the	O
American	O
Joint	O
Committee	O
on	O
Cancer	O
/	O
International	O
Union	O
Against	O
Cancer	O
[	O
26	O
]	O
.	O

Histological	O
examination	O
was	O
performed	O
according	O
to	O
WHO	O
criteria	O
and	O
carcinomas	B
were	O
classified	O
according	O
to	O
the	O
Dukes	O
'	O
stage	O
.	O

Furthermore	O
,	O
we	O
defined	O
the	O
right	O
colon	O
as	O
the	O
tract	O
from	O
the	O
cecum	O
to	O
the	O
splenic	O
flexure	O
.	O

The	O
left	O
colon	O
included	O
the	O
descending	O
and	O
sigmoid	O
colon	O
.	O

The	O
rectum	O
was	O
defined	O
as	O
the	O
rectosigmoid	O
junction	O
and	O
rectum	O
.	O

From	O
1990	O
,	O
the	O
rectal	O
cancer	B
patients	O
clinically	O
staged	O
Dukes	O
'	O
B	O
and	O
C	O
were	O
addressed	O
to	O
high	O
-	O
dose	O
pelvic	O
radiotherapy	O
,	O
all	O
the	O
rectal	O
cancer	B
patients	O
underwent	O
a	O
total	O
mesorectal	O
excision	O
(	O
TME	O
)	O
surgery	O
.	O

Adjuvant	O
i.v	O
.	O

chemotherapy	O
was	O
administered	O
in	O
all	O
the	O
eligible	O
Dukes	O
'	O
C	O
colorectal	B
cancer	I
patients	O
,	O
those	O
staged	O
Dukes	O
'	O
D	O
underwent	O
chemotherapy	O
.	O

Patients	O
with	O
sporadic	O
CRC	B
were	O
submitted	O
to	O
a	O
yearly	O
colonoscopy	O
for	O
the	O
first	O
5	O
years	O
and	O
every	O
2	O
years	O
thereafter	O
[	O
23	O
]	O
,	O
HNPCC	B
patients	O
with	O
CRC	B
were	O
submitted	O
to	O
a	O
yearly	O
colonoscopy	O
.	O

Considering	O
the	O
increased	O
risk	O
of	O
extracolonic	O
manifestations	O
,	O
hereditary	O
colorectal	B
cancer	I
patients	O
were	O
also	O
submitted	O
to	O
periodical	O
instrumental	O
examinations	O
tailored	O
to	O
the	O
different	O
spectrum	O
of	O
the	O
disease	B
[	O
4,27	O
]	O
.	O

The	O
index	O
date	O
for	O
survival	O
calculation	O
was	O
defined	O
as	O
the	O
date	O
of	O
treatment	O
for	O
the	O
first	O
colorectal	B
cancer	I
.	O

Clinical	O
follow	O
-	O
up	O
procedures	O
provided	O
information	O
on	O
the	O
subject	O
's	O
status	O
.	O

Statistical	O
analysis	O
Survival	O
curves	O
were	O
estimated	O
using	O
the	O
Kaplan	O
-	O
Meier	O
method	O
and	O
stratified	O
according	O
to	O
various	O
clinical	O
and	O
pathological	O
variables	O
.	O

Differences	O
were	O
tested	O
using	O
the	O
log	O
-	O
rank	O
test	O
.	O

Multivariate	O
analysis	O
was	O
performed	O
using	O
the	O
Cox	O
regression	O
analysis	O
.	O

The	O
multivariate	O
analysis	O
of	O
the	O
HNPCC	B
versus	O
CRC	B
groups	O
,	O
Dukes	O
'	O
stage	O
,	O
tumor	B
site	O
showed	O
that	O
all	O
these	O
parameters	O
independently	O
affected	O
disease	O
-	O
specific	O
survival	O
(	O
p	O
<	O
0.0001	O
,	O
p	O
<	O
0.0001	O
and	O
p	O
=	O
0.03	O
respectively	O
)	O
.	O

Out	O
of	O
40	O
HNPCC	B
patients	O
,	O
15	O
were	O
investigated	O
for	O
microsatellite	B
instability	I
(	O
MSI	O
)	O
;	O
all	O
resulting	O
positive	O
.	O

Furthermore	O
,	O
the	O
HNPCC	B
patients	O
with	O
MSI	B
(	O
15	O
/	O
40	O
)	O
had	O
a	O
survival	O
of	O
100	O
%	O
.	O

Statistical	O
analysis	O
Mutation	O
rates	O
of	O
cell	O
lines	O
were	O
compared	O
by	O
T	O
-	O
test	O
or	O
one	O
-	O
way	O
ANOVA	O
.	O

